<?xml version="1.0" encoding="UTF-8" ?>
<!DOCTYPE PubmedArticleSet>
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35286247</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1744-5116</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>60</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Pharmaceutical biology</Title>
          <ISOAbbreviation>Pharm Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Banxia-Houpu decoction diminishes iron toxicity damage in heart induced by chronic intermittent hypoxia.</ArticleTitle>
        <Pagination>
          <StartPage>609</StartPage>
          <EndPage>620</EndPage>
          <MedlinePgn>609-620</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/13880209.2022.2043392</ELocationID>
        <Abstract>
          <AbstractText Label="CONTEXT" NlmCategory="UNASSIGNED">Obstructive sleep apnoea (OSA) causes chronic intermittent hypoxia (CIH), which results in mitochondrial dysfunction and generates reactive oxygen species (ROS) in the heart. Excessive free iron could accelerate oxidative damage, which may be involved in this process. Banxia-Houpu decoction (BHD) was reported to improve the apnoea hypopnoea index in OSA patients, but the specific mechanism was still unclear.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To investigate whether BHD could reduce CIH-induced heart damage by regulating iron metabolism and mitochondrial function.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">C57BL/6N mice were randomly divided into control, CIH and BHD groups. Mice were exposed to CIH (21&#x2009;-&#x2009;5% O2, 20 times/h, 8&#x2009;h/d) and administered BHD (3.51, 7.01 and 14.02&#x2009;g/kg, intragastrically) for 21 d. Cardiac and mitochondrial function, iron levels, apoptosis and mitophagy were determined.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">BHD (7.01&#x2009;g/kg) significantly improved cardiac dysfunction, pathological change and mitochondrial structure induced by CIH. BHD increased the Bcl-2/Bax ratio (1.4-fold) and inhibited caspase 3 cleavage in CIH mice (0.45-fold). BHD activated mitophagy by upregulating Parkin (1.94-fold) and PINK1 (1.26-fold), inhibiting the PI3K-AKT-mTOR pathway. BHD suppressed ROS generation by decreasing NOX2 (0.59-fold) and 4-HNE (0.83-fold). BHD reduced the total iron in myocardial cells (0.72-fold) and mitochondrial iron by downregulating Mfrn2 (0.81-fold) and MtFt (0.78-fold) proteins, and upregulating ABCB8 protein (1.33-fold). Rosmarinic acid, the main component of Perilla Leaf in BHD, was able to react with Fe[2+] and Fe[3+] in&#xa0;vitro.</AbstractText>
          <AbstractText Label="DISCUSSION AND CONCLUSIONS" NlmCategory="UNASSIGNED">These findings encourage the use of BHD to resist cardiovascular injury and provide the theoretical basis for clinical treatment in OSA patients.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Ji-Xian</ForeName>
            <Initials>JX</Initials>
            <Identifier Source="ORCID">0000-0002-4998-8553</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Institute of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Ya-Shuo</ForeName>
            <Initials>YS</Initials>
            <Identifier Source="ORCID">0000-0002-5793-5574</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Institute of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhen</LastName>
            <ForeName>Ya-Qin</ForeName>
            <Initials>YQ</Initials>
            <Identifier Source="ORCID">0000-0003-0092-3713</Identifier>
            <AffiliationInfo>
              <Affiliation>Experimental Center, Hebei University of Chinese Medicine, Shijiazhuang, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Xin-Yue</ForeName>
            <Initials>XY</Initials>
            <Identifier Source="ORCID">0000-0002-7277-7252</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Institute of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Qi</ForeName>
            <Initials>Q</Initials>
            <Identifier Source="ORCID">0000-0002-3756-7997</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Institute of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>An</LastName>
            <ForeName>Ji-Ren</ForeName>
            <Initials>JR</Initials>
            <Identifier Source="ORCID">0000-0001-5274-8289</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Institute of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang, PR China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ji</LastName>
            <ForeName>En-Sheng</ForeName>
            <Initials>ES</Initials>
            <Identifier Source="ORCID">0000-0002-5858-7567</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Institute of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Pharm Biol</MedlineTA>
        <NlmUniqueID>9812552</NlmUniqueID>
        <ISSNLinking>1388-0209</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C120141">Banxia Houpo Tang</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002934">Cinnamates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053630">Depsides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>MQE6XG29YI</RegistryNumber>
          <NameOfSubstance UI="C041376">rosmarinic acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002934" MajorTopicYN="N">Cinnamates</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053630" MajorTopicYN="N">Depsides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006335" MajorTopicYN="N">Heart Injuries</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020181" MajorTopicYN="N">Sleep Apnea, Obstructive</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Obstructive sleep apnoea</Keyword>
        <Keyword MajorTopicYN="N">cardiac damage</Keyword>
        <Keyword MajorTopicYN="N">mitochondrial disfunction</Keyword>
        <Keyword MajorTopicYN="N">rosmarinic acid</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>14</Day>
          <Hour>17</Hour>
          <Minute>17</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35286247</ArticleId>
        <ArticleId IdType="pmc">PMC8928803</ArticleId>
        <ArticleId IdType="doi">10.1080/13880209.2022.2043392</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>An JR, Zhao YS, Luo LF, Guan P, Tan M, Ji ES.. 2020. Huperzine A, reduces brain iron overload and alleviates cognitive deficit in mice exposed to chronic intermittent hypoxia. Life Sci. 250:117573&#x2013;10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32209423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson ER, Shah YM.. 2013. Iron homeostasis in the liver. Compr Physiol. 3(1):315&#x2013;330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3936199</ArticleId>
            <ArticleId IdType="pubmed">23720289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ban T, Ishihara T, Kohno H, Saita S, Ichimura A, Maenaka K, Oka T, Mihara K, Ishihara N.. 2017. Molecular basis of selective mitochondrial fusion by heterotypic action between OPA1 and cardiolipin. Nat Cell Biol. 19(7):856&#x2013;863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28628083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, Nunez CM, Patel SR, Penzel T, Pepin JL, et al. . 2019. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 7(8):687&#x2013;698.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7007763</ArticleId>
            <ArticleId IdType="pubmed">31300334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brentnall M, Rodriguez-Menocal L, De Guevara RL, Cepero E, Boise LH.. 2013. Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biol. 14:32&#x2013;39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3710246</ArticleId>
            <ArticleId IdType="pubmed">23834359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao XH, Zhao SS, Liu DY, Wang Z, Niu LL, Hou LH, Wang CL.. 2011. ROS-Ca2+ is associated with mitochondria permeability transition pore involved in surfactin-induced MCF-7 cells apoptosis. Chem Biol Interact. 190(1):16&#x2013;27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21241685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang HC, Wu R, Shang M, Sato T, Chen C, Shapiro JS, Liu T, Thakur A, Sawicki KT, Prasad SV, et al. . 2016. Reduction in mitochondrial iron alleviates cardiac damage during injury. EMBO Mol Med. 8(3):247&#x2013;267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4772952</ArticleId>
            <ArticleId IdType="pubmed">26896449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen YR, Zweier JL.. 2014. Cardiac mitochondria and reactive oxygen species generation. Circ Res. 114(3):524&#x2013;537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4118662</ArticleId>
            <ArticleId IdType="pubmed">24481843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen ZY, Xie DF, Liu ZY, Zhong YQ, Zeng JY, Chen Z, Chen XL.. 2020. Identification of the significant pathways of Banxia Houpu decoction in the treatment of depression based on network pharmacology. PLoS One. 15(9):e0239843&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7527207</ArticleId>
            <ArticleId IdType="pubmed">32997725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng J, Dong S, Yi L, Geng D, Liu Q.. 2018. Magnolol abrogates chronic mild stress-induced depressive-like behaviors by inhibiting neuroinflammation and oxidative stress in the prefrontal cortex of mice. Int Immunopharmacol. 59:61&#x2013;67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29627576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeMartino T, Ghoul RE, Wang L, Bena J, Hazen SL, Tracy R, Patel SR, Auckley D, Mehra R.. 2016. Oxidative stress and inflammation differentially elevated in objective versus habitual subjective reduced sleep duration in obstructive sleep apnea. Sleep. 39(7):1361&#x2013;1369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4909618</ArticleId>
            <ArticleId IdType="pubmed">27091532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doblado L, Lueck C, Rey C, Samhan-Arias AK, Prieto I, Stacchiotti A, Monsalve M.. 2021. Mitophagy in human diseases. Int J Mol Sci. 22(8):3903&#x2013;3951.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8069949</ArticleId>
            <ArticleId IdType="pubmed">33918863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dorn GW, Kitsis RN.. 2015. The mitochondrial dynamism-mitophagy-cell death interactome: multiple roles performed by members of a mitochondrial molecular ensemble. Circ Res. 116(1):167&#x2013;182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4282600</ArticleId>
            <ArticleId IdType="pubmed">25323859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Emran AA, Chinna Chowdary BR, Ahmed F, Hammerlindl H, Huefner A, Haass NK, Schuehly W, Schaider H.. 2019. Magnolol induces cell death through PI3K/Akt-mediated epigenetic modifications boosting treatment of BRAF- and NRAS-mutant melanoma. Cancer Med. 8(3):1186&#x2013;1196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6434221</ArticleId>
            <ArticleId IdType="pubmed">30793515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang F, Deng LW, Deng HW, Wang S, Xie JJ, Zhu XY.. 2018. Clinical research of the modified banxia houpo decoction in the treatment of obstructive sleep apnea hypopnea syndrome of the interaction of phlegm and qi. World J Integra Trad Western Med. 13:1715&#x2013;1718.</Citation>
        </Reference>
        <Reference>
          <Citation>Gao JY, Feng WJ, Lv W, Liu WH, Fu CH.. 2021. HIF-1/AKT signaling-activated PFKFB2 alleviates cardiac dysfunction and cardiomyocyte apoptosis in response to hypoxia. Int Heart J. 62(2):350&#x2013;358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33678793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerogianni PS, Chatziathanasiadou MV, Diamantis DA, Tzakos AG, Galaris D.. 2018. Lipophilic ester and amide derivatives of rosmarinic acid protect cells against H2O2-induced DNA damage and apoptosis: the potential role of intracellular accumulation and labile iron chelation. Redox Biol. 15:548&#x2013;556.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5975196</ArticleId>
            <ArticleId IdType="pubmed">29413966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gottlieb RA, Thomas A.. 2017. Mitophagy and mitochondrial quality control mechanisms in the heart. Curr Pathobiol Rep. 5(2):161&#x2013;169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5656254</ArticleId>
            <ArticleId IdType="pubmed">29082112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guan P, Sun ZM, Luo LF, Zhao YS, Yang SC, Yu FY, Wang N, Ji ES.. 2019. Hydrogen gas alleviates chronic intermittent hypoxia-induced renal injury through reducing iron overload. Molecules. 24(6):1184&#x2013;1114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6471060</ArticleId>
            <ArticleId IdType="pubmed">30917568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guan P, Sun ZM, Wang N, Zhou J, Luo LF, Zhao YS, Ji ES.. 2019. Resveratrol prevents chronic intermittent hypoxia-induced cardiac hypertrophy by targeting the PI3K/AKT/mTOR pathway. Life Sci. 233:116748&#x2013;116749.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31412263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jahng JWS, Alsaadi RM, Palanivel R, Song E, Hipolito VEB, Sung HK, Botelho RJ, Russell RC, Sweeney G.. 2019. Iron overload inhibits late stage autophagic flux leading to insulin resistance. EMBO Rep. 20(10):e47911&#x2013;18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6776927</ArticleId>
            <ArticleId IdType="pubmed">31441223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia KK, Zheng YJ, Zhang YX, Liu JH, Jiao RQ, Pan Y, Kong LD.. 2017. Banxia-Houpu decoction restores glucose intolerance in CUMS rats through improvement of insulin signaling and suppression of NLRP3 inflammasome activation in liver and brain. J Ethnopharmacol. 209:219&#x2013;229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28782622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang S, Jiao G, Chen Y, Han M, Wang X, Liu W.. 2020. Astragaloside IV attenuates chronic intermittent hypoxia-induced myocardial injury by modulating Ca2+ homeostasis. Cell Biochem Funct. 38(6):710&#x2013;720.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32306464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang ZY, Lian LL, Qian XQ, Liu XL, Zhu BY, Li BF, Tao HL.. 2021. Clinical study on the intervention of 30 patients with obstructive sleep apnea hypopnea syndrome in the acute exacerbation of chronic obstructive pulmonary disease by modified Banxia houpo decoction. Jiangsu Trad Chinese Med. 20:34&#x2013;37.</Citation>
        </Reference>
        <Reference>
          <Citation>Kagohashi K, Tamura T, Ohara G, Satoh H.. 2016. Effect of a traditional herbal medicine, hangekobokuto, on the sensation of a lump in the throat in patients with respiratory diseases. Biomed Rep. 4(3):384&#x2013;386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4774332</ArticleId>
            <ArticleId IdType="pubmed">26998281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalkavan H, Green DR.. 2018. MOMP, cell suicide as a BCL-2 family business. Cell Death Differ. 25(1):46&#x2013;55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5729535</ArticleId>
            <ArticleId IdType="pubmed">29053143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamerkar SC, Kraus F, Sharpe AJ, Pucadyil TJ, Ryan MT.. 2018. Dynamin-related protein 1 has membrane constricting and severing abilities sufficient for mitochondrial and peroxisomal fission. Nat Commun. 9(1):5239&#x2013;5215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6286342</ArticleId>
            <ArticleId IdType="pubmed">30531964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kell DB. 2009. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics. 2:2&#x2013;49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2672098</ArticleId>
            <ArticleId IdType="pubmed">19133145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim YS, Kwak JW, Lee KE, Cho HS, Lim SJ, Kim KS, Yang HS, Kim HJ.. 2014. Can mitochondrial dysfunction be a predictive factor for oxidative stress in patients with obstructive sleep apnea? Antioxid Redox Signal. 21(9):1285&#x2013;1288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4158965</ArticleId>
            <ArticleId IdType="pubmed">24926527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kvansakul M, Hinds MG.. 2015. The Bcl-2 family: structures, interactions and targets for drug discovery. Apoptosis. 20(2):136&#x2013;150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25398535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lacedonia D, Carpagnano GE, Crisetti E, Cotugno G, Palladino GP, Patricelli G, Sabato R, Foschino Barbaro MP.. 2015. Mitochondrial DNA alteration in obstructive sleep apnea. Respir Res. 47:1&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4392628</ArticleId>
            <ArticleId IdType="pubmed">25890226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lakhal-Littleton S. 2019. Mechanisms of cardiac iron homeostasis and their importance to heart function. Free Radic Biol Med. 133:234&#x2013;237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6375725</ArticleId>
            <ArticleId IdType="pubmed">30107217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lang F, Hoffmann EK.. 2012. Role of ion transport in control of apoptotic cell death. Compr Physiol. 2(3):2037&#x2013;2061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23723032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee H, Smith SB, Sheu SS, Yoon Y.. 2020. The short variant of optic atrophy 1 (OPA1) improves cell survival under oxidative stress. J Biol Chem. 295(19):6543&#x2013;6560.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7212625</ArticleId>
            <ArticleId IdType="pubmed">32245890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lesnefsky EJ, Chen Q, Hoppel CL.. 2016. Mitochondrial metabolism in aging heart. Circ Res. 118(10):1593&#x2013;1611.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5009371</ArticleId>
            <ArticleId IdType="pubmed">27174952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li B, Bai HH.. 2019. Effects of Banxia-Houpo Decoction on lung function and microscopic indexes in acute phase of phlegm-dampness obstructive pulmonary disease. Shanxi Trad Chinese Med. 40:466&#x2013;468.</Citation>
        </Reference>
        <Reference>
          <Citation>Lian LS, Jiang ZY, Liu XH, Zhu XJ, Li LL.. 2020. Effect of Banxia Houpu Decoction on inflammatory reaction, oxidative stress and vascular endothelial dysfunction in patients with obstructive sleep apnea-hypopnea syndrome. J Guangzhou Univ Trad Chinese Med. 37:1636&#x2013;1640.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu J, Kuang F, Kroemer G, Klionsky DJ, Kang R, Tang D.. 2020. Autophagy-dependent ferroptosis: machinery and regulation. Cell Chem Biol. 27(4):420&#x2013;435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7166192</ArticleId>
            <ArticleId IdType="pubmed">32160513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lo YC, Teng CM, Chen CF, Chen CC, Hong CY.. 1994. Magnolol and honokiol isolated from Magnolia officinalis protect rat heart mitochondria against lipid peroxidation. Biochem Pharmacol. 47(3):549&#x2013;553.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8117323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicholson SC, Squier M, Ferguson DJ, Nagy Z, Westaby S, Evans RD.. 1997. Effect of desferrioxamine cardioplegia on ischemia-reperfusion injury in isolated rat heart. Ann Thorac Surg. 63(4):1003&#x2013;1011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9124897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oikawa T, Ito G, Hoshino T, Koyama H, Hanawa T.. 2009. Hangekobokuto (Banxia-houpo-tang), a kampo medicine that treats functional dyspepsia. Evid Based Complement Alternat Med. 6(3):375&#x2013;378.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2722198</ArticleId>
            <ArticleId IdType="pubmed">18955239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oudit GY, Trivieri MG, Khaper N, Liu PP, Backx PH.. 2006. Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med (Berl). 84(5):349&#x2013;364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7095819</ArticleId>
            <ArticleId IdType="pubmed">16604332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paul BT, Manz DH, Torti FM, Torti SV.. 2017. Mitochondria and iron: current questions. Expert Rev Hematol. 10(1):65&#x2013;79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5538026</ArticleId>
            <ArticleId IdType="pubmed">27911100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahbardar MG, Eisvand F, Rameshrad M, Razavi BM, Hosseinzadeh H.. 2021. In vivo and in&#xa0;vitro protective effects of rosmarinic acid against doxorubicin-induced cardiotoxicity. Nutr Cancer. 4:1&#x2013;13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34085575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ravingerova T, Kindernay L, Bartekova M, Ferko M, Adameova A, Zohdi V, Bernatova I, Ferenczyova K, Lazou A.. 2020. The molecular mechanisms of iron metabolism and its role in cardiac dysfunction and cardioprotection. Int J Mol Sci. 21(21):7889&#x2013;7824.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7660609</ArticleId>
            <ArticleId IdType="pubmed">33114290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roche J, Rae D, Redman K, Knutson KL, von Schantz M, Gomez-Olive FX, Scheuermaier K.. 2021. Impact of obstructive sleep apnea on cardiometabolic health in a random sample of older adults in rural South Africa: building the case for the treatment of sleep disorders in under-resourced settings. J Clin Sleep Med. 17(7):1423&#x2013;1434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8314613</ArticleId>
            <ArticleId IdType="pubmed">33687325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sadidi M, Lentz SI, Feldman EL.. 2009. Hydrogen peroxide-induced Akt phosphorylation regulates Bax activation. Biochimie. 91(5):577&#x2013;585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2697849</ArticleId>
            <ArticleId IdType="pubmed">19278624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sciarretta S, Maejima Y, Zablocki D, Sadoshima J.. 2018. The role of autophagy in the heart. Annu Rev Physiol. 80:1&#x2013;26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29068766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song HK, Kim J, Lee JS, Nho KJ, Jeong HC, Kim J, Ahn Y, Park WJ, Kim DH.. 2015. Pik3ip1 modulates cardiac hypertrophy by inhibiting PI3K pathway. PLoS One. 10(3):e0122251&#x2013;18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4380398</ArticleId>
            <ArticleId IdType="pubmed">25826393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y, Yuan H, Zhao MQ, Wang Y, Xia M, Li YZ.. 2014. Cardiac structural and functional changes in old elderly patients with obstructive sleep apnoea-hypopnoea syndrome. J Int Med Res. 42(2):395&#x2013;404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24445697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang CY, Han HL, Liu ZW, Liu YX, Yin LJ, Cai J, He LY, Liu Y, Chen GC, Zhang ZH, et al. . 2019. Activation of BNIP3-mediated mitophagy protects against renal ischemia-reperfusion injury. Cell Death Dis. 10(9):677&#x2013;615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6742651</ArticleId>
            <ArticleId IdType="pubmed">31515472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vela D. 2020. Keeping heart homeostasis in check through the balance of iron metabolism. Acta Physiol (Oxf). 228(1):e13324&#x2013;18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31162883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu WY, Chang SY, Wu Q, Xu ZF, Wang PN, Li YR, Yu P, Gao GF, Shi ZH, Duan XL, et al. . 2016. Mitochondrial ferritin protects the murine myocardium from acute exhaustive exercise injury. Cell Death Dis. 7(11):e2475&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5260894</ArticleId>
            <ArticleId IdType="pubmed">27853170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao YS, An JR, Yang S, Guan P, Yu FY, Li W, Li JR, Guo Y, Sun ZM, Ji ES.. 2019. Hydrogen and oxygen mixture to improve cardiac dysfunction and myocardial pathological changes induced by intermittent hypoxia in rats. Oxid Med Cell Longev. 2019:7415212&#x2013;7415213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6431505</ArticleId>
            <ArticleId IdType="pubmed">30984338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhuang XD, Sun XT, Zhou HM, Zhang SZ, Zhong XB, Xu XF, Guo Y, Xiong ZY, Liu MH, Lin YF, et al. . 2021. Klotho attenuated doxorubicin-induced cardiomyopathy by alleviating dynamin-related protein 1-mediated mitochondrial dysfunction. Mech Ageing Dev. 195:111442&#x2013;111410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33539906</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34866381</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>31</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1520-6025</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>84</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of natural products</Title>
          <ISOAbbreviation>J Nat Prod</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Antitumor Effects of Scorpion Peptide Smp43 through Mitochondrial Dysfunction and Membrane Disruption on Hepatocellular Carcinoma.</ArticleTitle>
        <Pagination>
          <StartPage>3147</StartPage>
          <EndPage>3160</EndPage>
          <MedlinePgn>3147-3160</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jnatprod.1c00963</ELocationID>
        <Abstract>
          <AbstractText>Smp43, a cationic antimicrobial peptide identified from the venom gland of the Egyptian scorpion Scorpio maurus palmatus, shows cytotoxicity toward hepatoma cell line HepG2 by membrane disruption. However, its underlying detailed mechanisms still remain to be further clarified. In the present study, we evaluated the cellular internalization of Smp43 and explored its effects on cell viability, cell cycle, apoptosis, autophagy, necrosis, and factor expression related to these cellular processes in human HepG2. Smp43 was found to suppress the growth of HepG2, Huh7, and human primary hepatocellular carcinoma cells while showing low toxicity to normal LO2 cells. Furthermore, Smp43 could interact with the cell membrane and be internalized into HepG2 cells via endocytosis and pore formation, which caused a ROS production increase, mitochondrial membrane potential decline, cytoskeleton disorganization, dysregulation of cyclin expression, mitochondrial apoptotic pathway activation, and alteration of MAPK as well as PI3K/Akt/mTOR signaling pathways. Finally, Smp43 showed effective antitumor protection in the HepG2 xenograft mice model. Overall, these findings indicate that Smp43 significantly exerts antitumor effects via induction of apoptosis, autophagy, necrosis, and cell cycle arrest due to its induction of mitochondrial dysfunction and membrane disruption. This discovery will extend the antitumor mechanisms of antimicrobial peptides and contribute to the development of antitumor agents against hepatocellular carcinoma.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chai</LastName>
            <ForeName>Jinwei</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Wanren</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>General Surgery Center, Department of Hepatobiliary Surgery II, Guangdong Provincial Research Center for Artificial Organ and Tissue Engineering, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Yahua</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Ruiyin</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Qing</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>General Surgery Center, Department of Hepatobiliary Surgery II, Guangdong Provincial Research Center for Artificial Organ and Tissue Engineering, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abdel-Rahman</LastName>
            <ForeName>Mohamed A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Zoology Department, Faculty of Science, Suez Canal University, Ismailia 41522, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Xueqing</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0002-4525-5803</Identifier>
            <AffiliationInfo>
              <Affiliation>Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Nat Prod</MedlineTA>
        <NlmUniqueID>7906882</NlmUniqueID>
        <ISSNLinking>0163-3864</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012604">Scorpion Venoms</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008930" MajorTopicYN="N">Mitochondria, Liver</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051336" MajorTopicYN="N">Mitochondrial Membranes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012604" MajorTopicYN="N">Scorpion Venoms</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>6</Day>
          <Hour>8</Hour>
          <Minute>43</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34866381</ArticleId>
        <ArticleId IdType="doi">10.1021/acs.jnatprod.1c00963</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34610415</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-7980</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>523</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer letters</Title>
          <ISOAbbreviation>Cancer Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Mitochondrial stress adaptation promotes resistance to aromatase inhibitor in human breast cancer cells via ROS/calcium up-regulated amphiregulin-estrogen receptor loop signaling.</ArticleTitle>
        <Pagination>
          <StartPage>82</StartPage>
          <EndPage>99</EndPage>
          <MedlinePgn>82-99</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2021.09.043</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0304-3835(21)00504-8</ELocationID>
        <Abstract>
          <AbstractText>Many breast cancer patients harbor high estrogen receptor (ER) expression in tumors that can be treated with endocrine therapy, which includes aromatase inhibitors (AI); unfortunately, resistance often occurs. Mitochondrial dysfunction has been thought to contribute to progression and to be related to hormone receptor expression in breast tumors. Mitochondrial alterations in AI-resistant breast cancer have not yet been defined. In this study, we characterized mitochondrial alterations and their roles in AI resistance. MCF-7aro AI-resistant breast cancer cells were shown to have significant changes in mitochondria. Low expressions of mitochondrial genes and proteins could be poor prognostic factors for breast cancer patients. Long-term mitochondrial inhibitor treatments-mediated mitochondrial stress adaptation could induce letrozole resistance. ERα-amphiregulin (AREG) loop signaling was activated and contributed to mitochondrial stress adaptation-mediated letrozole resistance. The up-regulation of AREG-epidermal growth factor receptor (EGFR) crosstalk activated the PI3K/Akt/mTOR and ERK pathways and was responsible for ERα activation. Moreover, mitochondrial stress adaptation-increased intracellular levels of reactive oxygen species (ROS) and calcium were shown to induce AREG expression and secretion. In conclusion, our results support the claim that mitochondrial stress adaptation contributes to AI resistance via ROS/calcium-mediated AREG-ERα loop signaling and provide possible treatment targets for overcoming AI resistance.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Sheng-Fan</ForeName>
            <Initials>SF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Taipei Veterans General Hospital, Taipei, 112, Taiwan; Department of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei, 110, Taiwan; Department and Institute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chang</LastName>
            <ForeName>Yuh-Lih</ForeName>
            <Initials>YL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Taipei Veterans General Hospital, Taipei, 112, Taiwan; Department and Institute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan; Faculty of Pharmacy, School of Pharmaceutical Sciences, National Yang-Ming Chiao Tung University, Taipei, 112, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tzeng</LastName>
            <ForeName>Yen-Dun</ForeName>
            <Initials>YD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, 813, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Chun-Ling</ForeName>
            <Initials>CL</Initials>
            <AffiliationInfo>
              <Affiliation>Department and Institute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yuan-Zhong</ForeName>
            <Initials>YZ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cancer Biology, Beckman Research Institute of the City of Hope, CA, 91010, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tseng</LastName>
            <ForeName>Ling-Ming</ForeName>
            <Initials>LM</Initials>
            <AffiliationInfo>
              <Affiliation>Comprehensive Breast Health Center, Department of Surgery, Taipei Veterans General Hospital, Taipei, 112, Taiwan; Department of Surgery, School of Medicine, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan. Electronic address: lmtseng@vghtpe.gov.tw.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Shiuan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cancer Biology, Beckman Research Institute of the City of Hope, CA, 91010, USA. Electronic address: schen@coh.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Hsin-Chen</ForeName>
            <Initials>HC</Initials>
            <AffiliationInfo>
              <Affiliation>Department and Institute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan; Faculty of Pharmacy, School of Pharmaceutical Sciences, National Yang-Ming Chiao Tung University, Taipei, 112, Taiwan. Electronic address: hclee2@ncyu.edu.tw.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>Cancer Lett</MedlineTA>
        <NlmUniqueID>7600053</NlmUniqueID>
        <ISSNLinking>0304-3835</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C587848">AREG protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D066258">Amphiregulin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047072">Aromatase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7LKK855W8I</RegistryNumber>
          <NameOfSubstance UI="D000077289">Letrozole</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SY7Q814VUP</RegistryNumber>
          <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D066258" MajorTopicYN="N">Amphiregulin</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047072" MajorTopicYN="N">Aromatase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077289" MajorTopicYN="N">Letrozole</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Amphiregulin</Keyword>
        <Keyword MajorTopicYN="N">Aromatase inhibitor resistance</Keyword>
        <Keyword MajorTopicYN="N">Calcium</Keyword>
        <Keyword MajorTopicYN="N">Mitochondrial stress adaptation</Keyword>
        <Keyword MajorTopicYN="N">Reactive oxygen species</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>5</Day>
          <Hour>20</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34610415</ArticleId>
        <ArticleId IdType="doi">10.1016/j.canlet.2021.09.043</ArticleId>
        <ArticleId IdType="pii">S0304-3835(21)00504-8</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34362635</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1590-3729</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>31</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
              <Day>22</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nutrition, metabolism, and cardiovascular diseases : NMCD</Title>
          <ISOAbbreviation>Nutr Metab Cardiovasc Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Leucine induces cardioprotection in vitro by promoting mitochondrial function via mTOR and Opa-1 signaling.</ArticleTitle>
        <Pagination>
          <StartPage>2979</StartPage>
          <EndPage>2986</EndPage>
          <MedlinePgn>2979-2986</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.numecd.2021.06.025</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0939-4753(21)00322-7</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND AIMS">Coronary heart disease is a major global health concern. Further, severity of this condition is greatly influenced by myocardial ischemia/reperfusion (I/R) injury. Branched-chain amino acids (BCAAs) have cardioprotective effects against I/R via mammalian target of rapamycin (mTOR) activity, wherein Leu is considered to particularly regulate mTOR activation. However, the mechanism underlying cardioprotective effects of Leu via mTOR activity is not fully elucidated. Here, we aimed to study the signaling pathway of cardioprotection and mitochondrial function induced by Leu treatment.</AbstractText>
          <AbstractText Label="METHODS AND RESULTS">Cardiac myocytes isolated from adult male Wistar rats were incubated and exposed to simulated I/R (SI/R) injury by replacing the air content. Cardiac myocytes were treated with Leu and subsequently, their survival rate was calculated. To elucidate the signaling pathway and mitochondrial function, immunoblots and mitochondrial permeability transition pore were examined. Cell survival rate was decreased with SI/R but improved by 160&#xa0;&#x3bc;M Leu (38.5&#xa0;&#xb1;&#xa0;3.6% vs. 64.5&#xa0;&#xb1;&#xa0;4.2%, respectively, p&#xa0;&lt;&#xa0;0.001). Although rapamycin (mTOR inhibitor) prevented this cardioprotective effect induced by Leu, wortmannin (PI3K inhibitor) did not interfere with this effect. In addition, we indicated that overexpression of Opa-1 and mitochondrial function are ameliorated via Leu-induced mitochondrial biogenesis. In contrast, knockdown of Opa-1 suppressed Leu-induced cardioprotection.</AbstractText>
          <AbstractText Label="CONCLUSION">Leu treatment is critical in rendering a cardioprotective effect exhibited by BCAAs via mTOR signaling. Furthermore, Leu improved mitochondrial function.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Morio</LastName>
            <ForeName>Atsushi</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology and Critical Care, Hiroshima University, Hiroshima, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsutsumi</LastName>
            <ForeName>Rie</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nutrition and Metabolism, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kondo</LastName>
            <ForeName>Takashi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology and Critical Care, Hiroshima University, Hiroshima, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miyoshi</LastName>
            <ForeName>Hirotsugu</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology and Critical Care, Hiroshima University, Hiroshima, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kato</LastName>
            <ForeName>Takahiro</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology and Critical Care, Hiroshima University, Hiroshima, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Narasaki</LastName>
            <ForeName>Soshi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology and Critical Care, Hiroshima University, Hiroshima, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Satomi</LastName>
            <ForeName>Shiho</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology and Critical Care, Hiroshima University, Hiroshima, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakaya</LastName>
            <ForeName>Erika</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nutrition and Metabolism, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kuroda</LastName>
            <ForeName>Masashi</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nutrition and Metabolism, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sakaue</LastName>
            <ForeName>Hiroshi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nutrition and Metabolism, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kitamura</LastName>
            <ForeName>Tadahiro</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Metabolic Signal, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsutsumi</LastName>
            <ForeName>Yasuo M</ForeName>
            <Initials>YM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology and Critical Care, Hiroshima University, Hiroshima, Japan. Electronic address: yasuo223@hiroshima-u.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>07</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Nutr Metab Cardiovasc Dis</MedlineTA>
        <NlmUniqueID>9111474</NlmUniqueID>
        <ISSNLinking>0939-4753</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546845">mTOR protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.1.-</RegistryNumber>
          <NameOfSubstance UI="D020558">GTP Phosphohydrolases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.1.-</RegistryNumber>
          <NameOfSubstance UI="C498811">Opa1 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GMW67QNF9C</RegistryNumber>
          <NameOfSubstance UI="D007930">Leucine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020558" MajorTopicYN="N">GTP Phosphohydrolases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007930" MajorTopicYN="N">Leucine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008929" MajorTopicYN="N">Mitochondria, Heart</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063154" MajorTopicYN="N">Mitochondrial Dynamics</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015428" MajorTopicYN="N">Myocardial Reperfusion Injury</DescriptorName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032383" MajorTopicYN="N">Myocytes, Cardiac</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001678" MajorTopicYN="N">Organelle Biogenesis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">BCAAs</Keyword>
        <Keyword MajorTopicYN="N">Ischemia-reperfusion</Keyword>
        <Keyword MajorTopicYN="N">Leucine</Keyword>
        <Keyword MajorTopicYN="N">Mitochondrial function</Keyword>
        <Keyword MajorTopicYN="N">Opa-1</Keyword>
        <Keyword MajorTopicYN="N">mTOR</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of competing interest The authors have nothing to disclose.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>7</Day>
          <Hour>5</Hour>
          <Minute>37</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34362635</ArticleId>
        <ArticleId IdType="doi">10.1016/j.numecd.2021.06.025</ArticleId>
        <ArticleId IdType="pii">S0939-4753(21)00322-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34285767</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1942-0994</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>2021</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Oxidative medicine and cellular longevity</Title>
          <ISOAbbreviation>Oxid Med Cell Longev</ISOAbbreviation>
        </Journal>
        <ArticleTitle>PIN1 Protects Hair Cells and Auditory HEI-OC1 Cells against Senescence by Inhibiting the PI3K/Akt/mTOR Pathway.</ArticleTitle>
        <Pagination>
          <StartPage>9980444</StartPage>
          <MedlinePgn>9980444</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">9980444</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1155/2021/9980444</ELocationID>
        <Abstract>
          <AbstractText>A growing amount of evidence has confirmed the crucial role of the prolyl isomerase PIN1 in aging and age-related diseases. However, the mechanism of PIN1 in age-related hearing loss (ARHL) remains unclear. Pathologically, ARHL is primarily due to the loss and dysfunction of hair cells (HCs) and spiral ganglion cells (SGCs) in the cochlea. Therefore, in this study, we aimed to investigate the role of PIN1 in protecting hair cells and auditory HEI-OC1 cells from senescence. Enzyme-linked immunosorbent assays, immunohistochemistry, and immunofluorescence were used to detect the PIN1 protein level in the serum of ARHL patients and C57BL/6 mice in different groups, and in the SGCs and HCs of young and aged C57BL/6 mice. In addition, a model of HEI-OC1 cell senescence induced by H2O2 was used. Adult C57BL/6 mice were treated with juglone, or juglone and NAC, for 4 weeks. Interestingly, we found that the PIN1 protein expression decreased in the serum of patients with ARHL, in senescent HEI-OC1 cells, and in the cochlea of aged mice. Moreover, under H2O2 and juglone treatment, a large amount of ROS was produced, and phosphorylation of p53 was induced. Importantly, PIN1 expression was significantly increased by treatment with the p53 inhibitor pifithrin-α. Overexpression of PIN1 reversed the increased level of p-p53 and rescued HEI-OC1 cells from senescence. Furthermore, PIN1 mediated cellular senescence by the PI3K/Akt/mTOR signaling pathway. In vivo data from C57BL/6 mice showed that treatment with juglone led to hearing loss. Taken together, these findings demonstrated that PIN1 may act as a vital modulator in hair cell and HEI-OC1 cell senescence.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Yanzhuo Zhang et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yanzhuo</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-3663-8319</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology, The Second Hospital of Hebei Medical University, No. 215 West Heping Road, Shijiazhuang 050000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lv</LastName>
            <ForeName>Zhe</ForeName>
            <Initials>Z</Initials>
            <Identifier Source="ORCID">0000-0001-8660-7767</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology, The Second Hospital of Hebei Medical University, No. 215 West Heping Road, Shijiazhuang 050000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yudong</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-3615-965X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology, The Second Hospital of Hebei Medical University, No. 215 West Heping Road, Shijiazhuang 050000, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology, Hebei General Hospital, Shijiazhuang 050051, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cao</LastName>
            <ForeName>Huan</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0001-7454-1465</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology, The Second Hospital of Hebei Medical University, No. 215 West Heping Road, Shijiazhuang 050000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Jianwang</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-9125-7957</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology, The Second Hospital of Hebei Medical University, No. 215 West Heping Road, Shijiazhuang 050000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Baoshan</ForeName>
            <Initials>B</Initials>
            <Identifier Source="ORCID">0000-0002-2455-8338</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology, The Second Hospital of Hebei Medical University, No. 215 West Heping Road, Shijiazhuang 050000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Oxid Med Cell Longev</MedlineTA>
        <NlmUniqueID>101479826</NlmUniqueID>
        <ISSNLinking>1942-0994</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000072340">NIMA-Interacting Peptidylprolyl Isomerase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BBX060AN9V</RegistryNumber>
          <NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 5.2.1.8</RegistryNumber>
          <NameOfSubstance UI="C000606846">PIN1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 5.2.1.8</RegistryNumber>
          <NameOfSubstance UI="C000606850">Pin1 protein, mouse</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016922" MajorTopicYN="N">Cellular Senescence</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006198" MajorTopicYN="N">Hair Cells, Auditory</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072340" MajorTopicYN="N">NIMA-Interacting Peptidylprolyl Isomerase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>All authors declare that they have no conflicts of financial interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>34</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34285767</ArticleId>
        <ArticleId IdType="pmc">PMC8273041</ArticleId>
        <ArticleId IdType="doi">10.1155/2021/9980444</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>He Z. H., Zou S. Y., Li M., et al. The nuclear transcription factor FoxG1 affects the sensitivity of mimetic aging hair cells to inflammation by regulating autophagy pathways. Redox Biology. 2020;28, article 101364 doi: 10.1016/j.redox.2019.101364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.redox.2019.101364</ArticleId>
            <ArticleId IdType="pmc">PMC6920089</ArticleId>
            <ArticleId IdType="pubmed">31731101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu X., Sun X., Zhang L., et al. Tuberous sclerosis complex-mediated mTORC1 overactivation promotes age-related hearing loss. Journal of Clinical Investigation. 2018;128(11):4938&#x2013;4955. doi: 10.1172/JCI98058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI98058</ArticleId>
            <ArticleId IdType="pmc">PMC6205401</ArticleId>
            <ArticleId IdType="pubmed">30247156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>WHO. Addressing the Rising Prevalence of Hearing Loss. Geneva, Switzerland: World Health Organization; 2018.</Citation>
        </Reference>
        <Reference>
          <Citation>Sha S. H., Kanicki A., Dootz G., et al. Age-related auditory pathology in the CBA/J mouse. Hearing Research. 2008;243(1&#x2013;2):87&#x2013;94. doi: 10.1016/j.heares.2008.06.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.heares.2008.06.001</ArticleId>
            <ArticleId IdType="pmc">PMC2577824</ArticleId>
            <ArticleId IdType="pubmed">18573325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>La Montagna R., Caligiuri I., Giordano A., Rizzolio F. Pin1 and nuclear receptors: a new language? Journal of Cellular Physiology. 2013;228(9):1799&#x2013;1801. doi: 10.1002/jcp.24316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.24316</ArticleId>
            <ArticleId IdType="pubmed">23280577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toko H., Hariharan N., Konstandin M. H., et al. Differential Regulation of Cellular Senescence and Differentiation by Prolyl Isomerase Pin1 in Cardiac Progenitor Cells. The Journal of Biological Chemistry. 2014;289(9):5348&#x2013;5356. doi: 10.1074/jbc.M113.526442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M113.526442</ArticleId>
            <ArticleId IdType="pmc">PMC3937613</ArticleId>
            <ArticleId IdType="pubmed">24375406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee T. H., Pastorino L., Lu K. P. Peptidyl-prolyl cis-trans isomerase Pin1 in ageing, cancer and Alzheimer disease. Expert Reviews in Molecular Medicine. 2011;13, article e21 doi: 10.1017/S1462399411001906.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S1462399411001906</ArticleId>
            <ArticleId IdType="pubmed">21682951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wheaton K., Muir J., Ma W., Benchimol S. BTG2 antagonizes Pin1 in response to mitogens and telomere disruption during replicative senescence. Aging Cell. 2010;9(5):747&#x2013;760. doi: 10.1111/j.1474-9726.2010.00601.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1474-9726.2010.00601.x</ArticleId>
            <ArticleId IdType="pubmed">20569234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee T. H., Tun-Kyi A., Shi R., et al. Essential role of Pin1 in the regulation of TRF1 stability and telomere maintenance. Nature Cell Biology. 2009;11(1):97&#x2013;105. doi: 10.1038/ncb1818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb1818</ArticleId>
            <ArticleId IdType="pmc">PMC2699942</ArticleId>
            <ArticleId IdType="pubmed">19060891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toko H., Konstandin M. H., Doroudgar S., et al. Regulation of cardiac hypertrophic signaling by prolyl isomerase Pin1. Circulation Research. 2013;112(9):1244&#x2013;1252. doi: 10.1161/CIRCRESAHA.113.301084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCRESAHA.113.301084</ArticleId>
            <ArticleId IdType="pmc">PMC3742109</ArticleId>
            <ArticleId IdType="pubmed">23487407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W., Xu L., Wang X., et al. PRDX1 activates autophagy via the PTEN-AKT signaling pathway to protect against cisplatin-induced spiral ganglion neuron damage. Autophagy. 2021;12:1&#x2013;23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33749526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang S., Zhang Y., Dong Y., et al. Knock-down of Foxg1 in supporting cells increases the trans-differentiation of supporting cells into hair cells in the neonatal mouse cochlea. Cellular and Molecular Life Sciences. 2020;77(7, article 3291):1401&#x2013;1419. doi: 10.1007/s00018-019-03291-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-019-03291-2</ArticleId>
            <ArticleId IdType="pmc">PMC7113235</ArticleId>
            <ArticleId IdType="pubmed">31485717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou H., Qian X., Xu N., et al. Disruption of Atg7-dependent autophagy causes electromotility disturbances, outer hair cell loss, and deafness in mice. Cell Death &amp; Disease. 2020;11(10, article 3110):p. 913. doi: 10.1038/s41419-020-03110-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-020-03110-8</ArticleId>
            <ArticleId IdType="pmc">PMC7585579</ArticleId>
            <ArticleId IdType="pubmed">33099575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Z., Guo L., Shu Y., et al. Autophagy protects auditory hair cells against neomycin-induced damage. Autophagy. 2017;13(11):1884&#x2013;1904. doi: 10.1080/15548627.2017.1359449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15548627.2017.1359449</ArticleId>
            <ArticleId IdType="pmc">PMC5788479</ArticleId>
            <ArticleId IdType="pubmed">28968134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang B., Xiao H. Rapamycin alleviates cisplatin-induced ototoxicity in vivo. Biochemical and Biophysical Research Communications. 2014;448(4):443&#x2013;447. doi: 10.1016/j.bbrc.2014.04.123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2014.04.123</ArticleId>
            <ArticleId IdType="pubmed">24796670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan W. J. T., Song L., Graham M., et al. Novel role of the mitochondrial protein Fus1 in protection from premature hearing loss via regulation of oxidative stress and nutrient and energy sensing pathways in the inner ear. Antioxidants &amp; Redox Signaling. 2017;27(8):489&#x2013;509. doi: 10.1089/ars.2016.6851.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2016.6851</ArticleId>
            <ArticleId IdType="pmc">PMC5564041</ArticleId>
            <ArticleId IdType="pubmed">28135838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong Z., Fu X., Li H., et al. Citicoline protects auditory hair cells against neomycin-induced damage. Frontiers in Cell and Developmental Biology. 2020;8:p. 712. doi: 10.3389/fcell.2020.00712.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2020.00712</ArticleId>
            <ArticleId IdType="pmc">PMC7487320</ArticleId>
            <ArticleId IdType="pubmed">32984303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao S., Cheng C., Wang M., et al. Blebbistatin inhibits neomycin-induced apoptosis in hair cell-like HEI-OC-1 cells and in cochlear hair cells. Frontiers in Cellular Neuroscience. 2020;13:p. 590. doi: 10.3389/fncel.2019.00590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fncel.2019.00590</ArticleId>
            <ArticleId IdType="pmc">PMC7025583</ArticleId>
            <ArticleId IdType="pubmed">32116554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Z. H., Li M., Fang Q. J., et al. FOXG1 promotes aging inner ear hair cell survival through activation of the autophagy pathway. Autophagy. 2021;19:1&#x2013;22. doi: 10.1016/j.neuropharm.2018.10.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2018.10.021</ArticleId>
            <ArticleId IdType="pubmed">34006186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y., Li W., He Z., et al. Pre-treatment with Fasudil prevents neomycin-induced hair cell damage by reducing the accumulation of reactive oxygen species. Frontiers in Molecular Neuroscience. 2019;12:p. 264. doi: 10.3389/fnmol.2019.00264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnmol.2019.00264</ArticleId>
            <ArticleId IdType="pmc">PMC6851027</ArticleId>
            <ArticleId IdType="pubmed">31780893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li A., You D., Li W., et al. Novel compounds protect auditory hair cells against gentamycin-induced apoptosis by maintaining the expression level of H3K4me2. Drug Delivery. 2018;25(1):1033&#x2013;1043. doi: 10.1080/10717544.2018.1461277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/10717544.2018.1461277</ArticleId>
            <ArticleId IdType="pmc">PMC6058728</ArticleId>
            <ArticleId IdType="pubmed">30799660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mesalam A. A., el-Sheikh M., Joo M. D., et al. Induction of oxidative stress and mitochondrial dysfunction by juglone affects the development of bovine oocytes. International Journal of Molecular Sciences. 2020;22(1):168&#x2013;214. doi: 10.3390/ijms22010168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms22010168</ArticleId>
            <ArticleId IdType="pmc">PMC7794829</ArticleId>
            <ArticleId IdType="pubmed">33375280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W., Xu X., Fan Z., et al. Wnt signaling activates TP53-Induced Glycolysis and Apoptosis Regulator and protects against cisplatin-induced spiral ganglion neuron damage in the mouse cochlea. Antioxidants &amp; Redox Signaling. 2019;30(11):1389&#x2013;1410. doi: 10.1089/ars.2017.7288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2017.7288</ArticleId>
            <ArticleId IdType="pubmed">29587485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qi J., Liu Y., Chu C., et al. A cytoskeleton structure revealed by super-resolution fluorescence imaging in inner ear hair cells. Cell Discovery. 2019;5(1):p. 12. doi: 10.1038/s41421-018-0076-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41421-018-0076-4</ArticleId>
            <ArticleId IdType="pmc">PMC6379372</ArticleId>
            <ArticleId IdType="pubmed">30792888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng C., Wang Y., Guo L., et al. Age-related transcriptome changes in Sox2+ supporting cells in the mouse cochlea. Stem Cell Research &amp; Therapy. 2019;10(1, article 1437):p. 365. doi: 10.1186/s13287-019-1437-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13287-019-1437-0</ArticleId>
            <ArticleId IdType="pmc">PMC6889721</ArticleId>
            <ArticleId IdType="pubmed">31791390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu L., Chen Y., Qi J., et al. Wnt activation protects against neomycin-induced hair cell damage in the mouse cochlea. Cell Death &amp; Disease. 2016;7(3, article e2136) doi: 10.1038/cddis.2016.35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2016.35</ArticleId>
            <ArticleId IdType="pmc">PMC4823936</ArticleId>
            <ArticleId IdType="pubmed">26962686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo R., Xiao M., Zhao W., et al. 2D Ti3C2TxMXene couples electrical stimulation to promote proliferation and neural differentiation of neural stem cells. Acta Biomaterialia. 2020;S1742-7061(20):30749&#x2013;30752. doi: 10.1016/j.actbio.2020.12.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.actbio.2020.12.035</ArticleId>
            <ArticleId IdType="pubmed">33348061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo R., Zhang S., Xiao M., et al. Accelerating bioelectric functional development of neural stem cells by graphene coupling: implications for neural interfacing with conductive materials. Biomaterials. 2016;106:193&#x2013;204. doi: 10.1016/j.biomaterials.2016.08.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biomaterials.2016.08.019</ArticleId>
            <ArticleId IdType="pubmed">27566868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan F., Chu C., Qi J., et al. AAV-ie enables safe and efficient gene transfer to inner ear cells. Nature Communications. 2019;10(1, article 11687):p. 3733. doi: 10.1038/s41467-019-11687-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-11687-8</ArticleId>
            <ArticleId IdType="pmc">PMC6700137</ArticleId>
            <ArticleId IdType="pubmed">31427575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y., Qi J., Chen X., et al. Critical role of spectrin in hearing development and deafness. Science Advances. 2019;5(4, article eaav7803) doi: 10.1126/sciadv.aav7803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciadv.aav7803</ArticleId>
            <ArticleId IdType="pmc">PMC6469942</ArticleId>
            <ArticleId IdType="pubmed">31001589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lv J., Fu X., Li Y., et al. Deletion of Kcnj16 in mice does not alter auditory function. Frontiers in Cell and Developmental Biology. 2021;9, article 630361 doi: 10.3389/fcell.2021.630361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2021.630361</ArticleId>
            <ArticleId IdType="pmc">PMC7937937</ArticleId>
            <ArticleId IdType="pubmed">33693002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qian F., Wang X., Yin Z., et al. The slc4a2b gene is required for hair cell development in zebrafish. Aging. 2020;12(19, article 103840):18804&#x2013;18821. doi: 10.18632/aging.103840.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/aging.103840</ArticleId>
            <ArticleId IdType="pmc">PMC7732325</ArticleId>
            <ArticleId IdType="pubmed">33044947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Z., Fang Q., Li H., et al. The role of FOXG1 in the postnatal development and survival of mouse cochlear hair cells. Neuropharmacology. 2019;144:43&#x2013;57. doi: 10.1016/j.neuropharm.2018.10.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2018.10.021</ArticleId>
            <ArticleId IdType="pubmed">30336149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu K. P., Zhou X. Z. The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nature Reviews. Molecular Cell Biology. 2007;8(11):904&#x2013;916. doi: 10.1038/nrm2261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm2261</ArticleId>
            <ArticleId IdType="pubmed">17878917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fagiani F., Govoni S., Racchi M., Lanni C. The peptidyl-prolyl isomerase Pin1 in neuronal signaling: from neurodevelopment to neurodegeneration. Molecular Neurobiology. 2021;58(3, article 2179):1062&#x2013;1073. doi: 10.1007/s12035-020-02179-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12035-020-02179-8</ArticleId>
            <ArticleId IdType="pmc">PMC7878263</ArticleId>
            <ArticleId IdType="pubmed">33083964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liou Y. C., Ryo A., Huang H. K., et al. Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes. Proceedings of the National Academy of Sciences. 2002;99(3):1335&#x2013;1340. doi: 10.1073/pnas.032404099.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.032404099</ArticleId>
            <ArticleId IdType="pmc">PMC122191</ArticleId>
            <ArticleId IdType="pubmed">11805292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pastorino L., Sun A., Lu P. J., et al. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-&#x3b2; production. Nature. 2006;440(7083):528&#x2013;534. doi: 10.1038/nature04543.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature04543</ArticleId>
            <ArticleId IdType="pubmed">16554819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Driver J. A., Zhou X. Z., Lu K. P. Pin1 dysregulation helps to explain the inverse association between cancer and Alzheimer&#x2019;s disease. Biochimica et Biophysica Acta. 2015;1850(10):2069&#x2013;2076. doi: 10.1016/j.bbagen.2014.12.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbagen.2014.12.025</ArticleId>
            <ArticleId IdType="pmc">PMC4499009</ArticleId>
            <ArticleId IdType="pubmed">25583562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atchison F. W., Capel B., Means A. R. Pin1 regulates the timing of mammalian primordial germ cell proliferation. Development. 2003;130(15):3579&#x2013;3586. doi: 10.1242/dev.00584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/dev.00584</ArticleId>
            <ArticleId IdType="pubmed">12810604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lv L., Ye M., Duan R., et al. Downregulation of Pin1 in human atherosclerosis and its association with vascular smooth muscle cell senescence. Journal of Vascular Surgery. 2018;68(3):873&#x2013;883.e5. doi: 10.1016/j.jvs.2017.09.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jvs.2017.09.006</ArticleId>
            <ArticleId IdType="pubmed">28986099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Astle M. V., Hannan K. M., Ng P. Y., et al. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. Oncogene. 2012;31(15):1949&#x2013;1962. doi: 10.1038/onc.2011.394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2011.394</ArticleId>
            <ArticleId IdType="pmc">PMC3325598</ArticleId>
            <ArticleId IdType="pubmed">21909130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes &amp; Development. 2004;18(16):1926&#x2013;1945. doi: 10.1101/gad.1212704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1212704</ArticleId>
            <ArticleId IdType="pubmed">15314020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung C. L., Lawrence I., Hoffman M., et al. Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial. Geroscience. 2019;41(6):861&#x2013;869. doi: 10.1007/s11357-019-00113-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11357-019-00113-y</ArticleId>
            <ArticleId IdType="pmc">PMC6925069</ArticleId>
            <ArticleId IdType="pubmed">31761958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang N., Luo Z., Jin M., et al. Exploration of age-related mitochondrial dysfunction and the anti-aging effects of resveratrol in zebrafish retina. Aging (Albany NY) 2019;11(10, article 101966):3117&#x2013;3137. doi: 10.18632/aging.101966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/aging.101966</ArticleId>
            <ArticleId IdType="pmc">PMC6555466</ArticleId>
            <ArticleId IdType="pubmed">31105084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heinrich U. R., Strieth S., Schmidtmann I., Helling K., Li H. Gentamicin alters Akt-expression and its activation in the guinea pig cochlea. Neuroscience. 2015;311:490&#x2013;498. doi: 10.1016/j.neuroscience.2015.10.050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuroscience.2015.10.050</ArticleId>
            <ArticleId IdType="pubmed">26528886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ebnoether E., Ramseier A., Cortada M., Levano-Huaman S., Bodmer D. Sesn2 gene ablation enhances susceptibility to gentamicin-induced hair cell death via modulation of AMPK/mTOR signaling. Cell Death Discovery. 2017;3(1, article 17024) doi: 10.1038/cddiscovery.2017.24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddiscovery.2017.24</ArticleId>
            <ArticleId IdType="pmc">PMC5447131</ArticleId>
            <ArticleId IdType="pubmed">28580173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J., Yuan H., Talaska A. E., Sha S. H., Hill K. Increased sensitivity to noise-induced hearing loss by blockade of endogenous PI3K/Akt signaling. Journal of the Association for Research in Otolaryngology. 2015;16(3):347&#x2013;356. doi: 10.1007/s10162-015-0508-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10162-015-0508-x</ArticleId>
            <ArticleId IdType="pmc">PMC4417093</ArticleId>
            <ArticleId IdType="pubmed">25790950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu W. Y., Jin X., Ma Y. C., Liu Z. B. MIF protects against oxygen-glucose deprivation-induced ototoxicity in HEI-OC1 cochlear cells by enhancement of Akt-Nrf2-HO-1 pathway. Biochemical and Biophysical Research Communications. 2018;503(2):665&#x2013;670. doi: 10.1016/j.bbrc.2018.06.058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2018.06.058</ArticleId>
            <ArticleId IdType="pubmed">29908183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leitmeyer K., Glutz A., Radojevic V., et al. Inhibition of mTOR by rapamycin results in auditory hair cell damage and decreased spiral ganglion neuron outgrowth and neurite formation in vitro. BioMed research international. 2015;2015:10. doi: 10.1155/2015/925890.925890</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2015/925890</ArticleId>
            <ArticleId IdType="pmc">PMC4395993</ArticleId>
            <ArticleId IdType="pubmed">25918725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Breitschopf K., Zeiher A. M., Dimmeler S. Pro-atherogenic factors induce telomerase inactivation in endothelial cells through an Akt-dependent mechanism. FEBS Letters. 2001;493(1):21&#x2013;25. doi: 10.1016/S0014-5793(01)02272-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0014-5793(01)02272-4</ArticleId>
            <ArticleId IdType="pubmed">11277998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Courtois-Cox S., Genther Williams S. M., Johnson B. W., et al. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell. 2006;10(6):459&#x2013;472. doi: 10.1016/j.ccr.2006.10.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2006.10.003</ArticleId>
            <ArticleId IdType="pmc">PMC2692661</ArticleId>
            <ArticleId IdType="pubmed">17157787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park K. H., Cho E. H., Bae W. J., et al. Role of PIN1 on in vivo periodontal tissue and in vitro cells. Journal of Periodontal Research. 2017;52(3):617&#x2013;627. doi: 10.1111/jre.12430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jre.12430</ArticleId>
            <ArticleId IdType="pubmed">28198538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demir &#xd6;., Barros E. P., Offutt T. L., Amaro R. E., Rosenfeld M. An integrated view of p53 dynamics, function, and reactivation. Current Opinion in Structural Biology. 2021;67:187&#x2013;194. doi: 10.1016/j.sbi.2020.11.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.sbi.2020.11.005</ArticleId>
            <ArticleId IdType="pubmed">33401096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeong K., Kim S. J., Oh Y., et al. p53 negatively regulates Pin1 expression under ER stress. Biochemical and Biophysical Research Communications. 2014;454(4):518&#x2013;523. doi: 10.1016/j.bbrc.2014.10.101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2014.10.101</ArticleId>
            <ArticleId IdType="pubmed">25451271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saxena S., Vekaria H., Sullivan P. G., Seifert A. W. Connective tissue fibroblasts from highly regenerative mammals are refractory to ROS-induced cellular senescence. Nature Communications. 2019;10(1, article 12398):p. 4400. doi: 10.1038/s41467-019-12398-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-12398-w</ArticleId>
            <ArticleId IdType="pmc">PMC6764955</ArticleId>
            <ArticleId IdType="pubmed">31562333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marazita M. C., Dugour A., Marquioni-Ramella M. D., Suburo A. M., Figueroa J. M. Oxidative stress-induced premature senescence dysregulates VEGF and CFH expression in retinal pigment epithelial cells: implications for age-related macular degeneration. Redox Biology. 2016;7:78&#x2013;87. doi: 10.1016/j.redox.2015.11.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.redox.2015.11.011</ArticleId>
            <ArticleId IdType="pmc">PMC4683426</ArticleId>
            <ArticleId IdType="pubmed">26654980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xue D. F., Pan S. T., Huang G., Qiu J. X. ROS enhances the cytotoxicity of cisplatin by inducing apoptosis and autophagy in tongue squamous cell carcinoma cells. The International Journal of Biochemistry &amp; Cell Biology. 2020;122, article 105732 doi: 10.1016/j.biocel.2020.105732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biocel.2020.105732</ArticleId>
            <ArticleId IdType="pubmed">32097729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang C., Shi S., Liu M., et al. PIN1 maintains redox balance via the c-Myc/NRF2 axis to counteract Kras-induced mitochondrial respiratory injury in pancreatic cancer cells. Cancer research. 2019;79(1):133&#x2013;145. doi: 10.1158/0008-5472.CAN-18-1968.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-18-1968</ArticleId>
            <ArticleId IdType="pubmed">30355620</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34031618</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1529-2916</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nature immunology</Title>
          <ISOAbbreviation>Nat Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Metabolic reprogramming of terminally exhausted CD8[+] T cells by IL-10 enhances anti-tumor immunity.</ArticleTitle>
        <Pagination>
          <StartPage>746</StartPage>
          <EndPage>756</EndPage>
          <MedlinePgn>746-756</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41590-021-00940-2</ELocationID>
        <Abstract>
          <AbstractText>T cell exhaustion presents one of the major hurdles to cancer immunotherapy. Among exhausted CD8[+] tumor-infiltrating lymphocytes, the terminally exhausted subset contributes directly to tumor cell killing owing to its cytotoxic effector function. However, this subset does not respond to immune checkpoint blockades and is difficult to be reinvigorated with restored proliferative capacity. Here, we show that a half-life-extended interleukin-10-Fc fusion protein directly and potently enhanced expansion and effector function of terminally exhausted CD8[+] tumor-infiltrating lymphocytes by promoting oxidative phosphorylation, a process that was independent of the progenitor exhausted T cells. Interleukin-10-Fc was a safe and highly efficient metabolic intervention that synergized with adoptive T cell transfer immunotherapy, leading to eradication of established solid tumors and durable cures in the majority of treated mice. These findings show that metabolic reprogramming by upregulating mitochondrial pyruvate carrier-dependent oxidative phosphorylation can revitalize terminally exhausted T cells and enhance the response to cancer immunotherapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Guo</LastName>
            <ForeName>Yugang</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0003-4499-8274</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Materials Science &amp; Engineering, EPFL, Lausanne, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Xie</LastName>
            <ForeName>Yu-Qing</ForeName>
            <Initials>YQ</Initials>
            <Identifier Source="ORCID">0000-0003-3996-2234</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Min</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-2106-0267</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Franco</LastName>
            <ForeName>Fabien</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, University of Lausanne, Epalinges, Switzerland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wenes</LastName>
            <ForeName>Mathias</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, University of Lausanne, Epalinges, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Siddiqui</LastName>
            <ForeName>Imran</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, University of Lausanne, Epalinges, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bevilacqua</LastName>
            <ForeName>Alessio</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0001-7009-4362</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, University of Lausanne, Epalinges, Switzerland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Haiping</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, University of Lausanne, Epalinges, Switzerland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Hanshuo</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Bing</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Materials Science &amp; Engineering, EPFL, Lausanne, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0002-6784-4860</Identifier>
            <AffiliationInfo>
              <Affiliation>Center for Genomics and Systems Biology, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sabatel</LastName>
            <ForeName>Catherine M</ForeName>
            <Initials>CM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, University of Lausanne, Epalinges, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tschumi</LastName>
            <ForeName>Benjamin</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, University of Lausanne, Epalinges, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chaiboonchoe</LastName>
            <ForeName>Amphun</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-0009-0806</Identifier>
            <AffiliationInfo>
              <Affiliation>Siriraj Center of Research Excellence for Systems Pharmacology, Department of Pharmacology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yuxi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, West China Medical School/West China Hospital, Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Weimin</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, West China Medical School/West China Hospital, Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Weihua</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology of the First Affiliated Hospital, Division of Life Sciences and Medicine, The CAS Key Laboratory of Innate Immunity and Chronic Disease, Hefei National Laboratory for Physical Sciences at Microscale, University of Science and Technology of China, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Held</LastName>
            <ForeName>Werner</ForeName>
            <Initials>W</Initials>
            <Identifier Source="ORCID">0000-0003-3292-1536</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, University of Lausanne, Epalinges, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Romero</LastName>
            <ForeName>Pedro</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0002-9688-2882</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, University of Lausanne, Epalinges, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ho</LastName>
            <ForeName>Ping-Chih</ForeName>
            <Initials>PC</Initials>
            <Identifier Source="ORCID">0000-0003-3078-3774</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, University of Lausanne, Epalinges, Switzerland. ping-chih.ho@unil.ch.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland. ping-chih.ho@unil.ch.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0002-6393-982X</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. li.tang@epfl.ch.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Materials Science &amp; Engineering, EPFL, Lausanne, Switzerland. li.tang@epfl.ch.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>173243</GrantID>
            <Acronym>SNSF_</Acronym>
            <Agency>Swiss National Science Foundation</Agency>
            <Country>Switzerland</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>05</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Nat Immunol</MedlineTA>
        <NlmUniqueID>100941354</NlmUniqueID>
        <ISSNLinking>1529-2908</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027321">Anion Transport Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C508609">IL10 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007141">Immunoglobulin Fc Fragments</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000595573">MPC1 pyruvate carrier protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D033681">Mitochondrial Membrane Transport Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D027501">Monocarboxylic Acid Transporters</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000076962">Receptors, Chimeric Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053701">Receptors, Interleukin-10</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>130068-27-8</RegistryNumber>
          <NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D027321" MajorTopicYN="N">Anion Transport Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006207" MajorTopicYN="N">Half-Life</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007141" MajorTopicYN="N">Immunoglobulin Fc Fragments</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016219" MajorTopicYN="N">Immunotherapy, Adoptive</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D033681" MajorTopicYN="N">Mitochondrial Membrane Transport Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D027501" MajorTopicYN="N">Monocarboxylic Acid Transporters</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010085" MajorTopicYN="N">Oxidative Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000076962" MajorTopicYN="N">Receptors, Chimeric Antigen</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053701" MajorTopicYN="N">Receptors, Interleukin-10</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Competing interests
. Y.G., L.T., and Y.-Q.X. are inventors on patents (International Publication Number WO 2021053134) related to the technology described in this manuscript. The remaining authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34031618</ArticleId>
        <ArticleId IdType="mid">EMS123191</ArticleId>
        <ArticleId IdType="pmc">PMC7610876</ArticleId>
        <ArticleId IdType="doi">10.1038/s41590-021-00940-2</ArticleId>
        <ArticleId IdType="pii">10.1038/s41590-021-00940-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Chen DS, Mellman I. Elements of cancer immunity and the cancer&#x2013;immune set point. Nature. 2017;541:321&#x2013;330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28102259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robert C, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521&#x2013;2532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25891173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune Modulation in Cancer with Antibodies. Annu Rev Med. 2014;65:185&#x2013;202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24188664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017;168:707&#x2013;723.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5391692</ArticleId>
            <ArticleId IdType="pubmed">28187290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Annu Rev Immunol. 2019;37:457&#x2013;495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30676822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thommen DS, Schumacher TN. T Cell Dysfunction in Cancer. Cancer Cell. 2018;33:547&#x2013;562.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7116508</ArticleId>
            <ArticleId IdType="pubmed">29634943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J, et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019;567:530&#x2013;534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6546093</ArticleId>
            <ArticleId IdType="pubmed">30814732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller BC, et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019;20:326&#x2013;336.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6673650</ArticleId>
            <ArticleId IdType="pubmed">30778252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siddiqui I, et al. Intratumoral Tcf1+ PD-1+ CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. Immunity. 2019;50:195&#x2013;211.:e10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30635237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurtulus S, et al. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1- CD8+ Tumor-Infiltrating T Cells. Immunity. 2019;50:181&#x2013;194.:e6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6336113</ArticleId>
            <ArticleId IdType="pubmed">30635236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LaFleur MW, et al. PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity. Nat Immunol. 2019;20:1335&#x2013;1347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6754306</ArticleId>
            <ArticleId IdType="pubmed">31527834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paley MA, et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science. 2012;338:1220&#x2013;1225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3653769</ArticleId>
            <ArticleId IdType="pubmed">23197535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He R, et al. Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection. Nature. 2016;537:412&#x2013;416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27501245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Im SJ, et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016;537:417&#x2013;421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5297183</ArticleId>
            <ArticleId IdType="pubmed">27501248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franco F, Jaccard A, Romero P, Yu YR, Ho PC. Metabolic and epigenetic regulation of T-cell exhaustion. Nat Metab. 2020;2:1001&#x2013;1012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32958939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Romero P. Metabolic Control of CD8+ T Cell Fate Decisions and Antitumor Immunity. Trends Mol Med. 2018;24:30&#x2013;48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29246759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bengsch B, et al. Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8+ T Cell Exhaustion. Immunity. 2016;45:358&#x2013;373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4988919</ArticleId>
            <ArticleId IdType="pubmed">27496729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scharping NE, et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol. 2021;22:205&#x2013;215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7971090</ArticleId>
            <ArticleId IdType="pubmed">33398183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu YR, et al. Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion. Nat Immunol. 2020;21:1540&#x2013;1551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33020660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vardhana SA, et al. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nat Immunol. 2020;21:1022&#x2013;1033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7442749</ArticleId>
            <ArticleId IdType="pubmed">32661364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujii SI, Shimizu K, Shimizu T, Lotze MT. Interleukin-10 promotes the maintenance of antitumor CD8+ T-cell effector function in situ. Blood. 2001;98:2143&#x2013;2151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11568001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mumm JB, et al. IL-10 Elicits IFN&#x3b3;-dependent tumor immune surveillance. Cancer Cell. 2011;20:781&#x2013;796.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22172723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanikawa T, et al. Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res. 2012;72:420&#x2013;429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3261323</ArticleId>
            <ArticleId IdType="pubmed">22123924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naing A, et al. PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. Cancer Cell. 2018;34:775&#x2013;791.:e3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8098754</ArticleId>
            <ArticleId IdType="pubmed">30423297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ip WKE, Hoshi N, Shouval DS, Snapper S, Medzhitov R. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science. 2017;356:513&#x2013;519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6260791</ArticleId>
            <ArticleId IdType="pubmed">28473584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan JC, Indelicato SR, Narula SK, Zavodny PJ, Chou CC. Characterization of interleukin-10 receptors on human and mouse cells. J Biol Chem. 1993;268:21053&#x2013;21059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8407942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, Saffold S, Krauss J, Chen W, Cao X. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol. 1998;161:5516&#x2013;5524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9820528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lechner MG, et al. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother. 2013;36:477&#x2013;489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3910494</ArticleId>
            <ArticleId IdType="pubmed">24145359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alfei F, et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature. 2019;571:265&#x2013;269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31207605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moynihan KD, et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med. 2016;22:1402&#x2013;1410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5209798</ArticleId>
            <ArticleId IdType="pubmed">27775706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pai CCS, et al. Clonal Deletion of Tumor-Specific T Cells by Interferon-&#x3b3; Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. Immunity. 2019;50:477&#x2013;492.:e8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6886475</ArticleId>
            <ArticleId IdType="pubmed">30737146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>June CH, O&#x2019;Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361&#x2013;1365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29567707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santos JM, et al. Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy. Mol Ther. 2018;26:2243&#x2013;2254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6127851</ArticleId>
            <ArticleId IdType="pubmed">30017877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klapper JA, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: A retrospective analysis of response and survival in patients treated in the Surgery Branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008;113:293&#x2013;301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3486432</ArticleId>
            <ArticleId IdType="pubmed">18457330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Floros T, Tarhini AA. Anticancer Cytokines: Biology and Clinical Effects of Interferon-&#x3b1;2, Interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol. 2015;42:539&#x2013;548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4557618</ArticleId>
            <ArticleId IdType="pubmed">26320059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buck MDD, et al. Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming. Cell. 2016;166:63&#x2013;76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4974356</ArticleId>
            <ArticleId IdType="pubmed">27293185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herzig S, et al. Identification and functional expression of the mitochondrial pyruvate carrier. Science. 2012;336:93&#x2013;96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22628554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gray LR, et al. Hepatic mitochondrial pyruvate carrier 1 is required for efficient regulation of gluconeogenesis and whole-body glucose homeostasis. Cell Metab. 2015;22:669&#x2013;681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4754674</ArticleId>
            <ArticleId IdType="pubmed">26344103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grenell A, et al. Loss of MPC1 reprograms retinal metabolism to impair visual function. Proc Natl Acad Sci U S A. 2019;116:3530&#x2013;3535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6397593</ArticleId>
            <ArticleId IdType="pubmed">30808746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wegrzyn J, et al. Function of mitochondrial Stat3 in cellular respiration. Science. 2009;323:793&#x2013;797.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2758306</ArticleId>
            <ArticleId IdType="pubmed">19131594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamaidi I, et al. Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells. Cell Metab. 2020;32:420&#x2013;436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7484212</ArticleId>
            <ArticleId IdType="pubmed">32768387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim AR, Rathmell WK, Rathmell JC. The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. Elife. 2020;9:1&#x2013;13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7200151</ArticleId>
            <ArticleId IdType="pubmed">32367803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, et al. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. Nat Rev Clin Oncol. 2019;16:425&#x2013;441.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30914826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chapman NM, Boothby MR, Chi H. Metabolic coordination of T cell quiescence and activation. Nat Rev Immunol. 2020;20:55&#x2013;70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31406325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiao J, et al. Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis. Cancer Cell. 2019;35:901&#x2013;915.:e4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31185213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naing A, et al. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 2019;20:1544&#x2013;1555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8436252</ArticleId>
            <ArticleId IdType="pubmed">31563517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Platt RJ, et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell. 2014;159:440&#x2013;455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4265475</ArticleId>
            <ArticleId IdType="pubmed">25263330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vanderperre B, et al. Embryonic Lethality of Mitochondrial Pyruvate Carrier 1 Deficient Mouse Can Be Rescued by a Ketogenic Diet. PLoS Genet. 2016;12:1&#x2013;20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4866774</ArticleId>
            <ArticleId IdType="pubmed">27176894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng WC, et al. Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle. Nat Immunol. 2019;20:206&#x2013;217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30664764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tschumi BO, et al. CART cells are prone to Fas- and DR5-mediated cell death. J Immunother Cancer. 2018;6:1&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6045821</ArticleId>
            <ArticleId IdType="pubmed">30005714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo Y, et al. Purification and characterization of human IL-10/Fc fusion protein expressed in Pichia pastoris. Protein Expr Purif. 2012;83:152&#x2013;156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22484198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Armour KL, Clark MR, Hadley AG, Williamson LM. Recombinant human IgG molecules lacking Fc&#x3b3; receptor I binding and monocyte triggering activities. Eur J Immunol. 1999;29:2613&#x2013;2624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10458776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steele AW, Nickerson PW, Steurer W, Steiger J, Strom TB. Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J Immunol. 1995;154:5590&#x2013;5600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7730658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doench JG, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016;34:184&#x2013;191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4744125</ArticleId>
            <ArticleId IdType="pubmed">26780180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma L, et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science. 2019;365:162&#x2013;168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6800571</ArticleId>
            <ArticleId IdType="pubmed">31296767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michelet X, et al. Metabolic reprogramming of natural killer cells in obesity limits antitumor responses. Nat Immunol. 2018;19:1330&#x2013;1340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30420624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Picelli S, et al. Full-length RNA-seq from single cells using Smart-seq2. Nat Protoc. 2014;9:171&#x2013;181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24385147</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33984457</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-7573</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>276</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Aug</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of ethnopharmacology</Title>
          <ISOAbbreviation>J Ethnopharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Chinese herbal medicine Feiyanning cooperates with cisplatin to enhance cytotoxicity to non-small-cell lung cancer by inhibiting protective autophagy.</ArticleTitle>
        <Pagination>
          <StartPage>114196</StartPage>
          <MedlinePgn>114196</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jep.2021.114196</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0378-8741(21)00423-2</ELocationID>
        <Abstract>
          <AbstractText Label="ETHNOPHARMACOLOGICAL RELEVANCE" NlmCategory="BACKGROUND">Feiyanning (FYN), the Chinese herbal medicine (CHM), has been used to manage non-small cell lung cancer (NSCLC) for the past 23 years. Chemotherapeutic drugs can induce autophagy in cancer cells to protect themselves from death. However, FYN can inhibit the protective autophagy in cancer cells. We investigated the biological mechanisms on the synergistic effects of FYN combined with chemotherapy in lung cancer cells.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We analyzed the effective chemical components for the quality control of FYN using the UPLC-Q-TOF-MS.The cell proliferation ability was detected by the cell counting kit-8 (CCK-8) and colony formation. The cell apoptosis was determined with Flow cytometry. Expression of important differential proteins were detected by western blot. Autophagy structure was observed by TEM (Tansmission electron microscopy). Tandem mCherry-EGFP-LC3B immunofluorescence was used to measure autophagic flux.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Both FYN and cisplatin significantly induced apoptosis and inhibited cell proliferation in A549&#xa0;cells. FYN reduced cell viability and increased apoptotic cell populations less effectively than cisplatin. FYN cooperated with cisplatin suppressed the cell viability, colony formation, as well as increased the cell apoptosis rate, and the expression of cleaved caspase-3 and PARP. FYN inhibited autophagy in A549&#xa0;cells, which characterized by the decrease of autophagosome formation, lysosomal fusion, LC3B-II accumulation and SQSTM1 degradation, down-regulation of ATG5 and ATG7. Protective autophagy in A549&#xa0;cells was induced by cisplatin. Suppression of the autophagic response using chloroquine (CQ) which is autophagy inhibitor improved the ability of cisplatin to kill cancer cells, as did FYN combined with cisplatin.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In summary, we revealed that the synergistic mechanism of FYN and cisplatin is that FYN inhibited the protective autophagy induced by cisplatin in A549&#xa0;cells.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Zhan</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, PR China. Electronic address: zhengzhan@shutcm.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Yue</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, PR China. Electronic address: 1336759760@qq.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Lifang</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, PR China. Electronic address: 13816927507@139.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>Haibin</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, PR China. Electronic address: 13661578200@139.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zhongqi</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, PR China. Electronic address: wangzhongqi2003@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jianwen</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, PR China. Electronic address: 854035476@qq.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Zhenye</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, PR China. Electronic address: xuzhenye1947@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>05</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>J Ethnopharmacol</MedlineTA>
        <NlmUniqueID>7903310</NlmUniqueID>
        <ISSNLinking>0378-8741</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>886U3H6UFF</RegistryNumber>
          <NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q20Q21Q62J</RegistryNumber>
          <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000072283" MajorTopicYN="N">A549 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Autophagy</Keyword>
        <Keyword MajorTopicYN="N">Chinese herbal medicine</Keyword>
        <Keyword MajorTopicYN="N">Cisplatin</Keyword>
        <Keyword MajorTopicYN="N">Feiyanning</Keyword>
        <Keyword MajorTopicYN="N">Non-small cell lung cancer</Keyword>
        <Keyword MajorTopicYN="N">Synergistic effect</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>13</Day>
          <Hour>20</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33984457</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jep.2021.114196</ArticleId>
        <ArticleId IdType="pii">S0378-8741(21)00423-2</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33950949</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>01</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1536-5964</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>100</Volume>
            <Issue>18</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>May</Month>
              <Day>07</Day>
            </PubDate>
          </JournalIssue>
          <Title>Medicine</Title>
          <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Comprehensive TCM treatments combined with chemotherapy for advanced non-small cell lung cancer: A randomized, controlled trial.</ArticleTitle>
        <Pagination>
          <StartPage>e25690</StartPage>
          <MedlinePgn>e25690</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e25690</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000025690</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We conducted this study to evaluate the efficacy and safety of traditional Chinese medicine (TCM) in advanced non-small cell lung cancer (NSCLC) patients who underwent chemotherapy.</AbstractText>
          <AbstractText Label="DESIGN" NlmCategory="METHODS">This was a prospective, open-label, randomized controlled trial. NSCLC patients at stage IIIA, IIIB, or IV were randomly assigned to either TCM plus chemotherapy or chemotherapy alone. The comprehensive TCM treatment consisted of Kang Ai injection, herbal decoction, and Zhenqifuzheng capsules. The primary endpoint was quality of life (QOL) measured by the Functional Assessment of Cancer Therapy-Lung version 4.0. The secondary endpoints were chemotherapy completion rate, tumor response, and adverse events. All assessments were done at baseline, the third week, and the sixth week.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-nine participants were randomly assigned to the treatment group and 36 to the control group. The QOL scores were significantly improved in the treatment group compared with those of the control group in social well-being (cycle 1, P&#x200a;=&#x200a;.048; cycle 2, P&#x200a;=&#x200a;.015), emotional well-being (cycle 1, P&#x200a;=&#x200a;.047; cycle 2, P&#x200a;=&#x200a;4.29E-05), and functional well-being (cycle 1, P&#x200a;=&#x200a;.030; cycle 2, P&#x200a;=&#x200a;.003), while the QOL scores in the above 3 domains declined in the control group (P&#x200a;&lt;&#x200a;.05). Both groups had a decline in the physical well-being score (cycle 1, P&#x200a;=&#x200a;.042; cycle 2, P&#x200a;=&#x200a;.017) and lung cancer symptom score (cycle 1, P&#x200a;=&#x200a;.001; cycle 2, P&#x200a;=&#x200a;.001) after 2 courses of intervention. The deterioration in physical well-being and lung cancer symptoms was noticeably smaller in the treatment group (P&#x200a;&lt;&#x200a;.05). There were significant differences between the 2 groups in social well-being, emotional well-being, functional well-being, lung cancer symptom domain, and the total score (P&#x200a;&lt;&#x200a;.05). Patients in the treatment group had a significantly lower incidence of platelet reduction than the control group (P&#x200a;=&#x200a;.028) after 2 cycles of treatment. No significant difference in nonhematological adverse events (AEs) was observed.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study illustrated that comprehensive TCM treatment could promote the QOL of NSCLC patients, alleviate symptoms, and reduce the AEs caused by chemotherapy, verifying the synergistic and attenuating effects of TCM in NSCLC patients undergoing chemotherapy.</AbstractText>
          <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Chinese Clinical Trial Registry (www.chictr.org.cn): ChiCTR-TRC-13003637.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Zhiwei</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Oncology Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Zhiqiang</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Guangzhou University of Chinese Medicine.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Rui</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Oncology Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Liming</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Research Center, South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Zeyun</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Guangzhou University of Chinese Medicine.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Jietao</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Oncology Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Leihao</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Guangzhou University of Chinese Medicine.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Xuewu</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Oncology Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Lizhu</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0003-4707-291</Identifier>
            <AffiliationInfo>
              <Affiliation>Oncology Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>2013EC087-01</GrantID>
            <Agency>the ethical committee of Guang'anmen Hospital, China Academy of Chinese Medical Sciences</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Medicine (Baltimore)</MedlineTA>
        <NlmUniqueID>2985248R</NlmUniqueID>
        <ISSNLinking>0025-7974</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010976" MajorTopicYN="N">Platelet Count</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013921" MajorTopicYN="N">Thrombocytopenia</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>5</Day>
          <Hour>17</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33950949</ArticleId>
        <ArticleId IdType="pmc">PMC8104195</ArticleId>
        <ArticleId IdType="doi">10.1097/MD.0000000000025690</ArticleId>
        <ArticleId IdType="pii">00005792-202105070-00037</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:07&#x2013;34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30620402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc 2019;94:1623&#x2013;40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31378236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pujol JL, Paz-Ares L, de Marinis F, et al. . Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2014;15:418&#x2013;25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25104617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D&#x2019;Addario G, Pintilie M, Leighl NB, et al. . Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005;23:2926&#x2013;36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15728229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hellmann MD, Li BT, Chaft JE, et al. . Chemotherapy remains an essential element of personalized care for persons with lung cancers. Ann Oncol 2016;27:1829&#x2013;35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5035786</ArticleId>
            <ArticleId IdType="pubmed">27456296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenzweig KE, Gomez JE. Concurrent chemotherapy and radiation therapy for inoperable locally advanced non-small-cell lung cancer. J Clin Oncol 2017;35:06&#x2013;10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27870565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ai D, Guan Y, Liu XJ, et al. . Clinical comparative investigation of efficacy and toxicity of cisplatin plus gemcitabine or plus Abraxane as first-line chemotherapy for stage III/IV non-small-cell lung cancer. Onco Targets Ther 2016;9:5693&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5033500</ArticleId>
            <ArticleId IdType="pubmed">27695347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li SG, Chen HY, Ou-Yang CS, et al. . The efficacy of Chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 2013;8:e57604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3585199</ArticleId>
            <ArticleId IdType="pubmed">23469033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye L, Jia Y, Ji KE, et al. . Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis. Oncol Lett 2015;10:1240&#x2013;50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4533180</ArticleId>
            <ArticleId IdType="pubmed">26622657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun L, Yim WS, Fahey P, et al. . Investigation on advanced non-small-cell lung cancer among elderly patients treated with Chinese herbal medicine versus chemotherapy: a pooled analysis of individual data. Evid Based Complement Alternat Med 2019;2019:1898345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6334362</ArticleId>
            <ArticleId IdType="pubmed">30719055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin LZ, Zhou DH, Zheng XT, et al. . Effect of traditional Chinese medicine in improving quality of life of patients with non-small cell lung cancer in late stage. Chin J Integr Traditional Western Med 2006;26:389&#x2013;93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16883901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chao J, Dai Y, Verpoorte R, et al. . Major achievements of evidence-based traditional Chinese medicine in treating major diseases. Biochem Pharmacol 2017;139:94&#x2013;104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28636884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lam W, Bussom S, Guan F, et al. . The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med 2010;2:45ra59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20720216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao J, Chen Z, Zhu Y, et al. . Huangqi-Honghua combination and its main components ameliorate cerebral infarction with Qi deficiency and blood stasis syndrome by antioxidant action in rats. J Ethnopharmacol 2014;155:1053&#x2013;60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24960183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huangfu YR, Peng W, Guo BJ, et al. . Effects of acupuncture in treating insomnia due to spleen-stomach disharmony syndrome and its influence on intestinal microbiome: study protocol for a randomized controlled trial. J Integr Med 2019;17:161&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30819614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang Y, Liu LS, Shen LP, et al. . Traditional Chinese Medicine treatment as adjuvant therapy in completely resected Stage IB-IIIA non-small-cell lung cancer: study protocol for a multicenter, double-blind, randomized, placebo-controlled trial. Clin Lung Cancer 2019;20:e541&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31230892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhai Y, Xu J, Feng L, et al. . Broad range metabolomics coupled with network analysis for explaining possible mechanisms of Er-Zhi-Wan in treating liver-kidney Yin deficiency syndrome of Traditional Chinese medicine. J Ethnopharmacol 2019;234:57&#x2013;66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30690072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vijayananthan A, Nawawi O. The importance of Good Clinical Practice guidelines and its role in clinical trials. Biomed Imaging Interv J 2008;4:e5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3097692</ArticleId>
            <ArticleId IdType="pubmed">21614316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471&#x2013;4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20180029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eisenhauer EA, Therasse P, Bogaerts J, et al. . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228&#x2013;47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19097774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cella DF, Bonomi AE, Lloyd SR, et al. . Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995;12:199&#x2013;220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7655830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wan C, Zhang C, Cai L, et al. . Psychometric properties of the Chinese version of the FACT-L for measuring quality of life in patients with lung cancer. Lung Cancer 2007;56:415&#x2013;21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17316887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montazeri A, Milroy R, Hole D, et al. . Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer 2001;31:233&#x2013;40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11165402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xue NZ, Fang RM, Lin LZ. Application of response evaluation criteria of traditional Chinese medicine for solid tumor in advanced non-small cell lung cancer. Chin J Integr Med 2014;20:910&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25428339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong J, Su SY, Wang MY, et al. . Shenqi fuzheng, an injection concocted from Chinese medicinal herbs, combined with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review. J Exp Clin Cancer Res 2010;29:137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2972256</ArticleId>
            <ArticleId IdType="pubmed">20969765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang Y, Liu LS, Shen LP, et al. . Traditional Chinese Medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: a randomized controlled trial. Complement Ther Med 2016;24:55&#x2013;62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26860802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lam W, Jiang Z, Guan F, et al. . PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment. Sci Rep 2015;5:9384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4377583</ArticleId>
            <ArticleId IdType="pubmed">25819872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saif MW, Li J, Lamb L, et al. . First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 2014;73:373&#x2013;80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4123311</ArticleId>
            <ArticleId IdType="pubmed">24297682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang S, Peng W, Mao D, et al. . Kangai Injection, a traditional Chinese medicine, improves efficacy and reduces toxicity of chemotherapy in advanced colorectal cancer patients: a systematic review and meta-analysis. Evid Based Complement Alternat Med 2019;2019:8423037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6662435</ArticleId>
            <ArticleId IdType="pubmed">31379968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu Q, Li CL. Therapeutic efficacy and safety of Kang-ai injection combined with platinum-based doublet chemotherapy in advanced NSCLC: a meta-analysis. Life Sci 2018;210:09&#x2013;19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30145153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xue JX, Zhu ZY, Bian WH, et al. . The traditional Chinese medicine Kangai injection as an adjuvant method in combination with chemotherapy for the treatment of breast cancer in Chinese patients: a meta-analysis. Evid Based Complement Alternat Med 2018;2018:6305645.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5932437</ArticleId>
            <ArticleId IdType="pubmed">29849714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang D, Wu J, Liu S, et al. . Network meta-analysis of Chinese herbal injections combined with the chemotherapy for the treatment of pancreatic cancer. Medicine (Baltimore) 2017;96:e7005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5457895</ArticleId>
            <ArticleId IdType="pubmed">28538415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang T, Fu X, Wang Z. Danshen formulae for cancer: a systematic review and meta-analysis of high-quality randomized controlled trials. Evid Based Complement Alternat Med 2019;2019:2310639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6466905</ArticleId>
            <ArticleId IdType="pubmed">31061667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu J, Chu Y, Liao B, et al. . Panax ginseng genome examination for ginsenoside biosynthesis. Gigascience 2017;6:01&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5710592</ArticleId>
            <ArticleId IdType="pubmed">29048480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chian S, Zhao Y, Xu M, et al. . Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway. Anticancer Drugs 2019;30:838&#x2013;45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31415285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin Y, Yang Q, Liang L, et al. . Compound kushen injection suppresses human acute myeloid leukaemia by regulating the Prdxs/ROS/Trx1 signalling pathway. J Exp Clin Cancer Res 2018;37:277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6245615</ArticleId>
            <ArticleId IdType="pubmed">30454068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu W, Lin H, Zhang Y, et al. . Compound Kushen Injection suppresses human breast cancer stem-like cells by down-regulating the canonical Wnt/&#x3b2;-catenin pathway. J Exp Clin Cancer Res 2011;30:103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3219673</ArticleId>
            <ArticleId IdType="pubmed">22032476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Z, Fan H, Higgins T, et al. . Fufang Kushen injection inhibits sarcoma growth and tumor-induced hyperalgesia via TRPV1 signaling pathways. Cancer Lett 2014;355:232&#x2013;41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4253542</ArticleId>
            <ArticleId IdType="pubmed">25242356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Z, Liao H, Ju Y. Effect of compound Kushen injection on T-cell subgroups and natural killer cells in patients with locally advanced non-small-cell lung cancer treated with concomitant radiochemotherapy. J Tradit Chin Med 2016;36:14&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26946613</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33826903</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2211-1247</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>35</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Apr</Month>
              <Day>06</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell reports</Title>
          <ISOAbbreviation>Cell Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors.</ArticleTitle>
        <Pagination>
          <StartPage>108944</StartPage>
          <MedlinePgn>108944</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2021.108944</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S2211-1247(21)00258-8</ELocationID>
        <Abstract>
          <AbstractText>Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6i) delay progression of metastatic breast cancer. However, complete responses are uncommon and tumors eventually relapse. Here, we show that CDK4/6i can enhance efficacy of T cell-based therapies, such as adoptive T cell transfer or T cell-activating antibodies anti-OX40/anti-4-1BB, in murine breast cancer models. This effect is driven by the induction of chemokines CCL5, CXCL9, and CXCL10 in CDK4/6i-treated tumor cells facilitating recruitment of activated CD8[+] T cells, but not Tregs, into the tumor. Mechanistically, chemokine induction is associated with metabolic stress that CDK4/6i treatment induces in breast cancer cells. Despite the cell cycle arrest, CDK4/6i-treated cells retain high metabolic activity driven by deregulated PI3K/mTOR pathway. This causes cell hypertrophy and increases mitochondrial content/activity associated with oxidative stress and inflammatory stress response. Our findings uncover a link between tumor metabolic vulnerabilities and anti-tumor immunity and support further development of CDK4/6i and immunotherapy combinations.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021. Published by Elsevier Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Uzhachenko</LastName>
            <ForeName>Roman V</ForeName>
            <Initials>RV</Initials>
            <AffiliationInfo>
              <Affiliation>Comprehensive Cancer Center - James, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA; Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bharti</LastName>
            <ForeName>Vijaya</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Comprehensive Cancer Center - James, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA; Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ouyang</LastName>
            <ForeName>Zhufeng</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Comprehensive Cancer Center - James, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA; Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Blevins</LastName>
            <ForeName>Ashlyn</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37212, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mont</LastName>
            <ForeName>Stacey</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37212, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saleh</LastName>
            <ForeName>Nabil</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37212, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lawrence</LastName>
            <ForeName>Hunter A</ForeName>
            <Initials>HA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37212, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Chengli</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Comprehensive Cancer Center - James, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Sheau-Chiann</ForeName>
            <Initials>SC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37212, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ayers</LastName>
            <ForeName>Gregory D</ForeName>
            <Initials>GD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37212, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>DeNardo</LastName>
            <ForeName>David G</ForeName>
            <Initials>DG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Washington University St. Louis, School of Medicine, St. Louis, MO 63110, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arteaga</LastName>
            <ForeName>Carlos</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Richmond</LastName>
            <ForeName>Ann</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37212, USA; Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN 37212, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vilgelm</LastName>
            <ForeName>Anna E</ForeName>
            <Initials>AE</Initials>
            <AffiliationInfo>
              <Affiliation>Comprehensive Cancer Center - James, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA; Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA. Electronic address: anna.vilgelm@osumc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 CA016672</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>IK6 BX005225</GrantID>
            <Acronym>BX</Acronym>
            <Agency>BLRD VA</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA243326</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P50 CA098131</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>I01 BX000196</GrantID>
            <Acronym>BX</Acronym>
            <Agency>BLRD VA</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>PEC 16-001</GrantID>
            <Acronym>VA</Acronym>
            <Agency>VA</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA068485</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA116021</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R37 CA233770</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cell Rep</MedlineTA>
        <NlmUniqueID>101573691</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018925">Chemokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019707">Receptors, Chemokine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.22</RegistryNumber>
          <NameOfSubstance UI="D051358">Cyclin-Dependent Kinase 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.22</RegistryNumber>
          <NameOfSubstance UI="D051361">Cyclin-Dependent Kinase 6</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>Cell Rep. 2021 Jun 22;35(12):109271</RefSource>
          <PMID Version="1">34161761</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051358" MajorTopicYN="N">Cyclin-Dependent Kinase 4</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051361" MajorTopicYN="N">Cyclin-Dependent Kinase 6</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006984" MajorTopicYN="N">Hypertrophy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015674" MajorTopicYN="N">Mammary Neoplasms, Animal</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019707" MajorTopicYN="N">Receptors, Chemokine</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CCL5</Keyword>
        <Keyword MajorTopicYN="N">CDK4/6 inhibitors</Keyword>
        <Keyword MajorTopicYN="N">ROS</Keyword>
        <Keyword MajorTopicYN="N">adoptive cell transfer</Keyword>
        <Keyword MajorTopicYN="N">anti-tumor immunity</Keyword>
        <Keyword MajorTopicYN="N">cancer metabolism</Keyword>
        <Keyword MajorTopicYN="N">chemokines</Keyword>
        <Keyword MajorTopicYN="N">metabolic stress</Keyword>
        <Keyword MajorTopicYN="N">palbociclib</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>7</Day>
          <Hour>20</Hour>
          <Minute>7</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33826903</ArticleId>
        <ArticleId IdType="mid">NIHMS1718900</ArticleId>
        <ArticleId IdType="pmc">PMC8383195</ArticleId>
        <ArticleId IdType="doi">10.1016/j.celrep.2021.108944</ArticleId>
        <ArticleId IdType="pii">S2211-1247(21)00258-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Alvarez-Fernandez M, and Malumbres M. (2020). Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition. Cancer Cell 37, 514&#x2013;529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32289274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, et al. (2017). IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127, 2930&#x2013;2940.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5531419</ArticleId>
            <ArticleId IdType="pubmed">28650338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bottcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, Rogers NC, Sahai E, Zelenay S, and Sousa CRE (2018). NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control. Cell 172, 1022-+.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5847168</ArticleId>
            <ArticleId IdType="pubmed">29429633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. (2012). The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2, 401&#x2013;404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3956037</ArticleId>
            <ArticleId IdType="pubmed">22588877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen YX, Zhou ZY, and Min W. (2018). Mitochondria, Oxidative Stress and Innate Immunity. Front Physiol 9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6200916</ArticleId>
            <ArticleId IdType="pubmed">30405440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chow MT, and Luster AD (2014). Chemokines in cancer. Cancer Immunol Res 2, 1125&#x2013;1131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4258879</ArticleId>
            <ArticleId IdType="pubmed">25480554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cretella D, Ravelli A, Fumarola C, La Monica S, Digiacomo G, Cavazzoni A, Alfieri R, Biondi A, Generali D, Bonelli M, et al. (2018). The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells . J Exp Clin Canc Res 37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5872523</ArticleId>
            <ArticleId IdType="pubmed">29587820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, et al. (2018). Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6718162</ArticleId>
            <ArticleId IdType="pubmed">30309915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, et al. (2016). Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17, 425&#x2013;439.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26947331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA, Lanitis E, Duraiswamy J, Tanyi JL, Benencia F, et al. (2019). Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. Cancer Cell 35, 885&#x2013;900 e810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6961655</ArticleId>
            <ArticleId IdType="pubmed">31185212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeNardo GL, Mirick GR, Hok S, DeNardo SJ, Beckett LA, Adamson GN, and Balhorn RL (2009). Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia. Int J Oncol 34, 511&#x2013;516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19148487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng JH, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu HY, Aref AR, et al. (2018). CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov 8, 216&#x2013;233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5809273</ArticleId>
            <ArticleId IdType="pubmed">29101163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dushyanthen S, Beavis PA, Savas P, Teo ZL, Zhou C, Mansour M, Darcy PK, and Loi S. (2015). Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med 13, 202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4547422</ArticleId>
            <ArticleId IdType="pubmed">26300242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Escola JM, Kuenzi G, Gaertner H, Foti M, and Hartley O. (2010). CC chemokine receptor 5 (CCR5) desensitization: cycling receptors accumulate in the trans-Golgi network. J Biol Chem 285, 41772&#x2013;41780.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3009905</ArticleId>
            <ArticleId IdType="pubmed">21041313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, et al. (2009). PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 11, R77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2790859</ArticleId>
            <ArticleId IdType="pubmed">19874578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forrester SJ, Kikuchi DS, Hernandes MS, Xu Q, and Griendling KK (2018). Reactive Oxygen Species in Metabolic and Inflammatory Signaling. Circ Res 122, 877-+.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5926825</ArticleId>
            <ArticleId IdType="pubmed">29700084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franco J, Balaji U, Freinkman E, Witkiewicz AK, and Knudsen ES (2016). Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities. Cell Rep 14, 979&#x2013;990.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4757440</ArticleId>
            <ArticleId IdType="pubmed">26804906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie SZ, Metzger-Filho O, et al. (2017). CDK4/6 inhibition triggers anti-tumour immunity. Nature 548, 471-+.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5570667</ArticleId>
            <ArticleId IdType="pubmed">28813415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, Ramm S, Palmer AC, Yuzugullu H, Varadan V, et al. (2016). Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell 29, 255&#x2013;269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4794996</ArticleId>
            <ArticleId IdType="pubmed">26977878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gogvadze V, Orrenius S, and Zhivotovsky B. (2008). Mitochondria in cancer cells: what is so special about them? Trends Cell Biol 18, 165&#x2013;173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18296052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griffith JW, Sokol CL, and Luster AD (2014). Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol 32, 659&#x2013;702.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24655300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guy CT, Cardiff RD, and Muller WJ (1992). Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12, 954&#x2013;961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC369527</ArticleId>
            <ArticleId IdType="pubmed">1312220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harlin H, Meng Y, Peterson AC, Zha YY, Tretiakova M, Slingluff C, McKee M, and Gajewski TF (2009). Chemokine Expression in Melanoma Metastases Associated with CD8(+) T-Cell Recruitment. Cancer Research 69, 3077&#x2013;3085.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3886718</ArticleId>
            <ArticleId IdType="pubmed">19293190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hurvitz SA, Martin M, Press MF, Chan D, Fernandez-Abad M, Petru E, Rostorfer R, Guarneri V, Huang CS, Barriga S, et al. (2020). Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR(+)/HER2(&#x2212;) Breast Cancer. Clin Cancer Res 26, 566&#x2013;580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7498177</ArticleId>
            <ArticleId IdType="pubmed">31615937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin J, and Zhao Q. (2020). Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration. Theranostics 10, 6231&#x2013;6244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7255024</ArticleId>
            <ArticleId IdType="pubmed">32483450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein ME, Kovatcheva M, Davis LE, Tap WD, and Koff A. (2018). CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. Cancer Cell 34, 9&#x2013;20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6039233</ArticleId>
            <ArticleId IdType="pubmed">29731395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knudsen ES, and Witkiewicz AK (2017). The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. Trends Cancer 3, 39&#x2013;55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5347397</ArticleId>
            <ArticleId IdType="pubmed">28303264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kohchi C, Inagawa H, Nishizawa T, and Soma GI (2009). ROS and Innate Immunity. Anticancer Res 29, 817&#x2013;821.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19414314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laplante M, and Sabatini DM (2012). mTOR Signaling. Cold Spring Harb Perspect Biol 4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3281571</ArticleId>
            <ArticleId IdType="pubmed">22129599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, and Liu XS (2020). TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res 48, W509&#x2013;W514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7319575</ArticleId>
            <ArticleId IdType="pubmed">32442275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, and Pollard JW (2003). Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163, 2113&#x2013;2126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1892434</ArticleId>
            <ArticleId IdType="pubmed">14578209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin HY, Chang KT, Hung CC, Kuo CH, Hwang SJ, Chen HC, Hung CH, and Lin SF (2014). Effects of the mTOR inhibitor rapamycin on monocyte-secreted chemokines. BMC Immunol 15, 37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4189728</ArticleId>
            <ArticleId IdType="pubmed">25257976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu GY, and Sabatini DM (2020). mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol 21, 183&#x2013;203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7102936</ArticleId>
            <ArticleId IdType="pubmed">31937935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lugrin J, Rosenblatt-Velin N, Parapanov R, and Liaudet L. (2014). The role of oxidative stress during inflammatory processes. Biol Chem 395, 203&#x2013;230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24127541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morita M, Gravel SP, Chenard V, Sikstrom K, Zheng L, Alain T, Gandin V, Avizonis D, Arguello M, Zakaria C, et al. (2013). mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab 18, 698&#x2013;711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24206664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagarsheth N, Wicha MS, and Zou WP (2017). Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol 17, 559&#x2013;572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5731833</ArticleId>
            <ArticleId IdType="pubmed">28555670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, and Alizadeh AA (2015). Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12, 453&#x2013;457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4739640</ArticleId>
            <ArticleId IdType="pubmed">25822800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O&#x2019;Brien NA, McDermott MSJ, Conklin D, Luo T, Ayala R, Salgar S, Chau K, DiTomaso E, Babbar N, Su F, et al. (2020). Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer. Breast Cancer Res 22, 89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7427086</ArticleId>
            <ArticleId IdType="pubmed">32795346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petroni G, Formenti SC, Chen-Kiang S, and Galluzzi L. (2020). Immunomodulation by anticancer cell cycle inhibitors. Nat Rev Immunol 20, 669&#x2013;679.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7584736</ArticleId>
            <ArticleId IdType="pubmed">32346095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabatini DM (2017). Twenty-five years of mTOR: Uncovering the link from nutrients to growth. Proc Natl Acad Sci U S A 114, 11818&#x2013;11825.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5692607</ArticleId>
            <ArticleId IdType="pubmed">29078414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saxton RA, and Sabatini DM (2017). mTOR Signaling in Growth, Metabolism, and Disease. Cell 169, 361&#x2013;371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28388417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schaer DA, Beckmann RP, Dempsey JA, Huber L, Forest A, Amaladas N, Li YX, Wang YC, Rasmussen ER, Chin D, et al. (2018). The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade. Cell Rep 22, 2978&#x2013;2994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29539425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scialo F, Fernandez-Ayala DJ, and Sanz A. (2017). Role of Mitochondrial Reverse Electron Transport in ROS Signaling: Potential Roles in Health and Disease. Front Physiol 8, 428.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5486155</ArticleId>
            <ArticleId IdType="pubmed">28701960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sozzani S, Bosisio D, Mantovani A, and Ghezzi P. (2005). Linking stress, oxidation and the chemokine system. Eur J Immunol 35, 3095&#x2013;3098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16276481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spranger S, Dai D, Horton B, and Gajewski TF (2017). Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell 31, 711-+.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5650691</ArticleId>
            <ArticleId IdType="pubmed">28486109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stoll G, Pol J, Soumelis V, Zitvogel L, and Kroemer G. (2018). Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts. Oncoimmunology 7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6169589</ArticleId>
            <ArticleId IdType="pubmed">30288345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tarrado-Castellarnau M, de Atauri P, Tarrago-Celada J, Perarnau J, Yuneva M, Thomson TM, and Cascante M. (2017). De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition. Mol Syst Biol 13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5658703</ArticleId>
            <ArticleId IdType="pubmed">28978620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teh JLF, and Aplin AE (2019). Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment. Clinical Cancer Research 25, 921&#x2013;927.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6359975</ArticleId>
            <ArticleId IdType="pubmed">30287548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, et al. (2018). In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms (vol 8, pg 568, 2018). Cancer Discov 8, 1654&#x2013;1654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30510016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. (2014). PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568&#x2013;571.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4246418</ArticleId>
            <ArticleId IdType="pubmed">25428505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, et al. (2018). Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. New Engl J Med 379, 1926&#x2013;1936.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30345905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valcourt JR, Lemons JM, Haley EM, Kojima M, Demuren OO, and Coller HA (2012). Staying alive: metabolic adaptations to quiescence. Cell Cycle 11, 1680&#x2013;1696.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3372394</ArticleId>
            <ArticleId IdType="pubmed">22510571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vilgelm AE, Cobb P, Malikayil K, Flaherty D, Andrew Johnson C, Raman D, Saleh N, Higgins B, Vara BA, Johnston JN, et al. (2017). MDM2 Antagonists Counteract Drug-Induced DNA Damage. EBioMedicine 24, 43&#x2013;55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5652019</ArticleId>
            <ArticleId IdType="pubmed">29030058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vilgelm AE, Johnson CA, Prasad N, Yang JM, Chen SC, Ayers GD, Pawlikowski JS, Raman D, Sosman JA, Kelley M, et al. (2016a). Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment. Jnci-J Natl Cancer I 108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4849355</ArticleId>
            <ArticleId IdType="pubmed">26719346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vilgelm AE, Johnson DB, and Richmond A. (2016b). Combinatorial approach to cancer immunotherapy: strength in numbers. J Leukoc Biol 100, 275&#x2013;290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6608090</ArticleId>
            <ArticleId IdType="pubmed">27256570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, et al. (2015). Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Cancer Res 75, 181&#x2013;193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4286469</ArticleId>
            <ArticleId IdType="pubmed">25398437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vilgelm AE, and Richmond A. (2019). Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy. Front Immunol 10, 333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6400988</ArticleId>
            <ArticleId IdType="pubmed">30873179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vilgelm AE, Saleh N, Shattuck-Brandt R, Riemenschneider K, Slesur L, Chen SC, Johnson CA, Yang J, Blevins A, Yan C, et al. (2019). MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21. Sci Transl Med 11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7584132</ArticleId>
            <ArticleId IdType="pubmed">31413145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warth B, Palermo A, Rattray NJW, Lee NV, Zhu Z, Hoang LT, Cai Y, Mazurek A, Dann S, VanArsdale T, et al. (2019). Palbociclib and Fulvestrant Act in Synergy to Modulate Central Carbon Metabolism in Breast Cancer Cells. Metabolites 9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6359333</ArticleId>
            <ArticleId IdType="pubmed">30609717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warth B, Raffeiner P, Granados A, Huan T, Fang M, Forsberg EM, Benton HP, Goetz L, Johnson CH, and Siuzdak G. (2018). Metabolomics Reveals that Dietary Xenoestrogens Alter Cellular Metabolism Induced by Palbociclib/Letrozole Combination Cancer Therapy. Cell Chem Biol 25, 291&#x2013;300 e293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5856613</ArticleId>
            <ArticleId IdType="pubmed">29337187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weichhart T, Hengstschlager M, and Linke M. (2015). Regulation of innate immune cell function by mTOR. Nat Rev Immunol 15, 599&#x2013;614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6095456</ArticleId>
            <ArticleId IdType="pubmed">26403194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wellen KE, and Thompson CB (2010). Cellular Metabolic Stress: Considering How Cells Respond to Nutrient Excess. Mol Cell 40, 323&#x2013;332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3190402</ArticleId>
            <ArticleId IdType="pubmed">20965425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wellenstein MD, and de Visser KE (2018). Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape. Immunity 48, 399&#x2013;416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29562192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>William M, Leroux LP, Chaparro V, Graber TE, Alain T, and Jaramillo M. (2019). Translational repression of Ccl5 and Cxcl10 by 4E-BP1 and 4E-BP2 restrains the ability of mouse macrophages to induce migration of activated T cells. Eur J Immunol 49, 1200&#x2013;1212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31032899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yarosz EL, and Chang CH (2018). The Role of Reactive Oxygen Species in Regulating T Cell-mediated Immunity and Disease. Immune Netw 18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5833121</ArticleId>
            <ArticleId IdType="pubmed">29503744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshida A, Bu Y, Qie S, Wrangle J, Camp ER, Hazard ES, Hardiman G, de Leeuw R, Knudsen KE, and Diehl JA (2019). SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors. Sci Adv 5, eaax6352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6750908</ArticleId>
            <ArticleId IdType="pubmed">31555743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanuy M, Ramos-Montoya A, Villacanas O, Canela N, Miranda A, Aguilar E, Agell N, Bachs O, Rubio-Martinez J, Pujol MD, et al. (2012). Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle. Metabolomics 8, 454&#x2013;464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3361763</ArticleId>
            <ArticleId IdType="pubmed">22661920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang JF, Bu X, Wang HZ, Zhu YS, Geng Y, Nihira NT, Tan YY, Ci YP, Wu F, Dai XP, et al. (2018). Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 553, 91-+.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5754234</ArticleId>
            <ArticleId IdType="pubmed">29160310</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33802158</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2072-6651</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Toxins</Title>
          <ISOAbbreviation>Toxins (Basel)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Zearalenone Induces Apoptosis and Cytoprotective Autophagy in Chicken Granulosa Cells by PI3K-AKT-mTOR and MAPK Signaling Pathways.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">199</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/toxins13030199</ELocationID>
        <Abstract>
          <AbstractText>Zearalenone (ZEA) is a nonsteroidal estrogenic mycotoxin found in several food commodities worldwide. ZEA causes reproductive disorders, genotoxicity, and testicular toxicity in animals. However, little is known about the functions of apoptosis and autophagy after exposure to ZEA in granulosa cells. This study investigated the effects of ZEA on chicken granulosa cells. The results show that ZEA at different doses significantly inhibited the growth of chicken granulosa cells by inducing apoptosis. ZEA treatment up-regulated Bax and downregulated Bcl-2 expression, promoted cytochrome c release into the cytosol, and triggered mitochondria-mediated apoptosis. Consequently, caspase-9 and downstream effector caspase-3 were activated, resulting in chicken granulosa cells apoptosis. ZEA treatment also upregulated LC3-II and Beclin-1 expression, suggesting that ZEA induced a high level of autophagy. Pretreatment with chloroquine (an autophagy inhibitor) and rapamycin (an autophagy inducer) increased and decreased the rate of apoptosis, respectively, in contrast with other ZEA-treated groups. Autophagy delayed apoptosis in the ZEA-treated cells. Therefore, autophagy may prevent cells from undergoing apoptosis by reducing ZEA-induced cytotoxicity. In addition, our results further show that the autophagy was stimulated by ZEA through PI3K-AKT-mTOR and MAPK signaling pathways in chicken granulosa cells.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Yifeng</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Animal Nutrition, Key Laboratory for Animal Disease-Resistance Nutrition of China, Ministry of Education, Sichuan Agricultural University, Chengdu 611130, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Heng</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Farm Animal Genetic Resources Exploration and Innovation Key Laboratory of Sichuan Province, Sichuan Agricultural University, Chengdu 611130, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Jianping</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Animal Nutrition, Key Laboratory for Animal Disease-Resistance Nutrition of China, Ministry of Education, Sichuan Agricultural University, Chengdu 611130, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Shunshun</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Farm Animal Genetic Resources Exploration and Innovation Key Laboratory of Sichuan Province, Sichuan Agricultural University, Chengdu 611130, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yao</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Farm Animal Genetic Resources Exploration and Innovation Key Laboratory of Sichuan Province, Sichuan Agricultural University, Chengdu 611130, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Menggen</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-1855-7064</Identifier>
            <AffiliationInfo>
              <Affiliation>College of Resources, Sichuan Agricultural University, Chengdu 611130, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Qing</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Farm Animal Genetic Resources Exploration and Innovation Key Laboratory of Sichuan Province, Sichuan Agricultural University, Chengdu 611130, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Keying</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Animal Nutrition, Key Laboratory for Animal Disease-Resistance Nutrition of China, Ministry of Education, Sichuan Agricultural University, Chengdu 611130, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yin</LastName>
            <ForeName>Huadong</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0001-9132-3603</Identifier>
            <AffiliationInfo>
              <Affiliation>Farm Animal Genetic Resources Exploration and Innovation Key Laboratory of Sichuan Province, Sichuan Agricultural University, Chengdu 611130, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>2020NZZJ021 and 2019NZZJ0011</GrantID>
            <Agency>Sichuan Science and Technology Program</Agency>
          </Grant>
          <Grant>
            <GrantID>2019-YF05-02309-SN</GrantID>
            <Agency>Chengdu Science and Technology Program</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>03</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Toxins (Basel)</MedlineTA>
        <NlmUniqueID>101530765</NlmUniqueID>
        <ISSNLinking>2072-6651</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071183">Autophagy-Related Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5W827M159J</RegistryNumber>
          <NameOfSubstance UI="D015025">Zearalenone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071183" MajorTopicYN="N">Autophagy-Related Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002645" MajorTopicYN="N">Chickens</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006107" MajorTopicYN="N">Granulosa Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020928" MajorTopicYN="N">Mitogen-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015025" MajorTopicYN="N">Zearalenone</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">MAPK</Keyword>
        <Keyword MajorTopicYN="N">PI3K-AKT-mTOR</Keyword>
        <Keyword MajorTopicYN="N">apoptosis</Keyword>
        <Keyword MajorTopicYN="N">autophagy</Keyword>
        <Keyword MajorTopicYN="N">chicken</Keyword>
        <Keyword MajorTopicYN="N">granulosa cells</Keyword>
        <Keyword MajorTopicYN="N">zearalenone</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>3</Day>
          <Hour>1</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33802158</ArticleId>
        <ArticleId IdType="pmc">PMC7999718</ArticleId>
        <ArticleId IdType="doi">10.3390/toxins13030199</ArticleId>
        <ArticleId IdType="pii">toxins13030199</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Zheng W., Wang B., Si M., Zou H., Song R., Gu J., Yuan Y., Liu X., Zhu G., Bai J. Zearalenone altered the cytoskeletal structure via ER stress- autophagy- oxidative stress pathway in mouse TM4 Sertoli cells. Sci. Rep. 2018;8:3320. doi: 10.1038/s41598-018-21567-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-21567-8</ArticleId>
            <ArticleId IdType="pmc">PMC5820275</ArticleId>
            <ArticleId IdType="pubmed">29463855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y., Zheng W., Bian X., Yuan Y., Gu J., Liu X., Liu Z., Bian J. Zearalenone induces apoptosis and cytoprotective autophagy in primary Leydig cells. Toxicol. Lett. 2014;226:182&#x2013;191. doi: 10.1016/j.toxlet.2014.02.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxlet.2014.02.003</ArticleId>
            <ArticleId IdType="pubmed">24530352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han J., Wang T., Fu L., Shi L.Y., Zhu C.C., Liu J., Zhang Y., Cui X.S., Kim N.H., Sun S.C. Altered oxidative stress, apoptosis/autophagy, and epigenetic modifications in Zearalenone-treated porcine oocytes. Toxicol. Res. 2015;4:1184&#x2013;1194. doi: 10.1039/C5TX00070J.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/C5TX00070J</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eppig J.J. Intercommunication between mammalian oocytes and companion somatic cells. Bioessays New Rev. Mol. Cell. Dev. Biol. 1991;13:569&#x2013;574. doi: 10.1002/bies.950131105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/bies.950131105</ArticleId>
            <ArticleId IdType="pubmed">1772412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eppig J.J. Maintenance of meiotic arrest and the induction of oocyte maturation in mouse oocyte-granulosa cell complexes developed in vitro from preantral follicles. Biol. Reprod. 1991;45:824&#x2013;830. doi: 10.1095/biolreprod45.6.824.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1095/biolreprod45.6.824</ArticleId>
            <ArticleId IdType="pubmed">1666849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan S.Y., Hong S.S., Zheng B.H., Wei L.I., Ming J.L., Jing H.T. Apoptosis in Granulosa cells during follicular atresia: relationship with steroids and insulin-like growth factors. Cell Res. 2004;14:341&#x2013;346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15353131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kolesarova A., Capcarova M., Medvedova M., Sirotkin A.V., Kovacik J. In vitro assessment of iron effect on porcine ovarian granulosa cells: Secretory activity, markers of proliferation and apoptosis. Physiol. Res. 2011;60:503&#x2013;510. doi: 10.33549/physiolres.931969.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.33549/physiolres.931969</ArticleId>
            <ArticleId IdType="pubmed">21401293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>EFSA Panel on Contaminants in the Food Chain Scientific Opinion on the risks for animal and public health related to the presence of phomopsins in feed and food. Efsa J. 2019;17:e05860.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7008800</ArticleId>
            <ArticleId IdType="pubmed">32626161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Streit E., Schatzmayr G., Tassis P., Tzika E., Marin D., Taranu I., Tabuc C., Nicolau A., Aprodu I., Puel O. Current Situation of Mycotoxin Contamination and Co-occurrence in Animal Feed&#x2014;Focus on Europe. Toxins. 2012;4:788&#x2013;809. doi: 10.3390/toxins4100788.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins4100788</ArticleId>
            <ArticleId IdType="pmc">PMC3496989</ArticleId>
            <ArticleId IdType="pubmed">23162698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reddy K., Salleh B., Saad B., Abbas H.K., Abel C.A., Shier W.T. An overview of mycotoxin contamination in foods and its implications for human health. Toxin Rev. 2010;29:3&#x2013;26. doi: 10.3109/15569541003598553.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/15569541003598553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ben S.I., Boussabbeh M., Pires D.S.J., Guilbert A., Bacha H., Abidessefi S., Lemaire C. SIRT1 protects cardiac cells against apoptosis induced by zearalenone or its metabolites &#x3b1;- and &#x3b2;-zearalenol through an autophagy-dependent pathway. Toxicol. Appl. Pharmacol. 2016;314</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27889531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>M&#x2019;Baye M., Hua G., Khan H.A., Yang L. RNAi-mediated knockdown of INHBB increases apoptosis and inhibits steroidogenesis in mouse granulosacells. J. Reprod. Dev. 2015;61:391. doi: 10.1262/jrd.2014-158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1262/jrd.2014-158</ArticleId>
            <ArticleId IdType="pmc">PMC4623144</ArticleId>
            <ArticleId IdType="pubmed">26063610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu L., Yuan H., Guo C., Lu Y., Deng S., Yang Y., Wei Q., Wen L., He Z. Zearalenone induces apoptosis and necrosis in porcine granulosa cells via a caspase-3- and caspase-9-dependent mitochondrial signaling pathway. J. Cell. Physiol. 2012;227:1814&#x2013;1820. doi: 10.1002/jcp.22906.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.22906</ArticleId>
            <ArticleId IdType="pubmed">21732350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin X., Cao M., Lai F., Yang F., Ge W., Zhang X., Cheng S., Sun X., Qin G., Shen W. Oxidative Stress Induced by Zearalenone in Porcine Granulosa Cells and Its Rescue by Curcumin In Vitro. PLoS ONE. 2015;10:e0127551. doi: 10.1371/journal.pone.0127551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0127551</ArticleId>
            <ArticleId IdType="pmc">PMC4452521</ArticleId>
            <ArticleId IdType="pubmed">26030649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cortiella J., Niles J., Cantu A., Brettler A., Pham A., Vargas G., Winston S., Wang J., Walls S., Nichols J.E. Influence of acellular natural lung matrix on murine embryonic stem cell differentiation and tissue formation. Tissue Eng. Part A. 2010;16:2565&#x2013;2580. doi: 10.1089/ten.tea.2009.0730.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ten.tea.2009.0730</ArticleId>
            <ArticleId IdType="pubmed">20408765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim I.H., Son H.Y., Cho S.W., Ha C.S., Kang B.H. Zearalenone induces male germ cell apoptosis in rats. Toxicol. Lett. 2003;138:185&#x2013;192. doi: 10.1016/S0378-4274(02)00405-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0378-4274(02)00405-8</ArticleId>
            <ArticleId IdType="pubmed">12565195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banjerdpongchai R., Kongtawelert P., Khantamat O., Srisomsap C., Chokchaichamnankit D., Subhasitanont P., Svasti J. Mitochondrial and endoplasmic reticulum stress pathways cooperate in zearalenone-induced apoptosis of human leukemic cells. J. Hematol. Oncol. 2010;3:50. doi: 10.1186/1756-8722-3-50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1756-8722-3-50</ArticleId>
            <ArticleId IdType="pmc">PMC3018374</ArticleId>
            <ArticleId IdType="pubmed">21190589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamaji T., Nakamura S., Takematsu H., Kawasaki T., Kozutsumi Y. Apoptosis of CTLL-2 cells induced by an immunosuppressant, ISP-I, is caspase-3-like protease-independent. J. Biochem. 2001;129:521&#x2013;527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11275550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng W.L., Wang B.J., Wang L., Shan Y.P., Zou H., Song R.L., Wang T., Gu J.H., Yuan Y., Liu X.Z. ROS-Mediated Cell Cycle Arrest and Apoptosis Induced by Zearalenone in Mouse Sertoli Cells via ER Stress and the ATP/AMPK Pathway. Toxins. 2018;10:24. doi: 10.3390/toxins10010024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins10010024</ArticleId>
            <ArticleId IdType="pmc">PMC5793111</ArticleId>
            <ArticleId IdType="pubmed">29301253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sambuu R., Takagi M., Namula Z., Otoi T., Shiga S., Rodrigues D.S.R., Finkgremmels J. Effects of exposure to zearalenone on porcine oocytes and sperm during maturation and fertilization in vitro. J. Reprod. Dev. 2011;57:547. doi: 10.1262/jrd.11-026H.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1262/jrd.11-026H</ArticleId>
            <ArticleId IdType="pubmed">21606630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomaszewski J., Miturski R., Semczuk A., Kotarski J., Jakowicki J. Tissue zearalenone concentration in normal, hyperplastic and neoplastic human endometrium. Ginekologia Polska. 1998;69:363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9695344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayed-Boussema I., Bouaziz C., Rjiba K., Valenti K., Laporte F., Bacha H., Hassen W. The mycotoxin Zearalenone induces apoptosis in human hepatocytes (HepG2) via p53-dependent mitochondrial signaling pathway. Toxicol. In Vitro. 2008;22:1671&#x2013;1680. doi: 10.1016/j.tiv.2008.06.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tiv.2008.06.016</ArticleId>
            <ArticleId IdType="pubmed">18662769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skommer J. Brittain, T. Raychaudhuri, S. Bcl-2 inhibits apoptosis by increasing the time-to-death and intrinsic cell-to-cell variations in the mitochondrial pathway of cell death. Apoptosis. 2010;15:1223&#x2013;1233. doi: 10.1007/s10495-010-0515-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10495-010-0515-7</ArticleId>
            <ArticleId IdType="pmc">PMC2948171</ArticleId>
            <ArticleId IdType="pubmed">20563668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bras M., Queenan B., Susin S.A. Programmed cell death via mitochondria: Different modes of dying. Biochem. Biokhimiia. 2005;70:231&#x2013;239. doi: 10.1007/s10541-005-0105-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10541-005-0105-4</ArticleId>
            <ArticleId IdType="pubmed">15807663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee M.G., Lee K.T., Chi S.G., Park J.H. Costunolide induces apoptosis by ROS-mediated mitochondrial permeability transition and cytochrome C release. Biol. Pharm. Bull. 2002;24:303&#x2013;306. doi: 10.1248/bpb.24.303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1248/bpb.24.303</ArticleId>
            <ArticleId IdType="pubmed">11256490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Estaquier J., Vallette F., Vayssiere J.L., Mignotte B. The mitochondrial pathways of apoptosis. J. Beijing Med Univ. 2002;942:157.</Citation>
        </Reference>
        <Reference>
          <Citation>Li G.Y., Xie P., Li H.Y., Hao L., Xiong Q., Qiu T. Involment of p53, Bax, and Bcl-2 pathway in microcystins-induced apoptosis in rat testis. Environ. Toxicol. 2011;26:111&#x2013;117. doi: 10.1002/tox.20532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/tox.20532</ArticleId>
            <ArticleId IdType="pubmed">19760617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu J.Y., Zheng Z.H., Son Y.O., Shi X., Jang Y.O., Lee J.C. Mycotoxin zearalenone induces AIF- and ROS-mediated cell death through p53- and MAPK-dependent signaling pathways in RAW264.7 macrophages. Toxicol. In Vitro. 2011;25:1654&#x2013;1663. doi: 10.1016/j.tiv.2011.07.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tiv.2011.07.002</ArticleId>
            <ArticleId IdType="pubmed">21767629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan W., Shen T., Ding Q., Lv Y., Li L., Huang K., Yan L., Song S. Zearalenone induces ROS-mediated mitochondrial damage in porcine IPEC-J2 cells. J. Biochem. Mol. Toxicol. 2017;31:e21944. doi: 10.1002/jbt.21944.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jbt.21944</ArticleId>
            <ArticleId IdType="pubmed">28608607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klionsky D.J., Emr S.D. Autophagy as a regulated pathway of cellular degradation. Science. 2000;290:1717&#x2013;1721. doi: 10.1126/science.290.5497.1717.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.290.5497.1717</ArticleId>
            <ArticleId IdType="pmc">PMC2732363</ArticleId>
            <ArticleId IdType="pubmed">11099404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takagi H., Matsui Y., Sadoshima J. The role of autophagy in mediating cell survival and death during ischemia and reperfusion in the heart. Antioxid. Redox Signal. 2007;9:1373&#x2013;1381. doi: 10.1089/ars.2007.1689.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2007.1689</ArticleId>
            <ArticleId IdType="pubmed">17627477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han R., Liang H., Qin Z.H., Liu C.Y. Crotoxin induces apoptosis and autophagy in human lung carcinoma cells in vitro via activation of the p38MAPK signaling pathway. Acta Pharmacol Sin. 2014;35:1323&#x2013;1332. doi: 10.1038/aps.2014.62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/aps.2014.62</ArticleId>
            <ArticleId IdType="pmc">PMC4186982</ArticleId>
            <ArticleId IdType="pubmed">25132339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moscat J., Diaz-Meco M.T. p62 at the Crossroads of Autophagy, Apoptosis, and Cancer. Cell. 2009;137:1001&#x2013;1004. doi: 10.1016/j.cell.2009.05.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2009.05.023</ArticleId>
            <ArticleId IdType="pmc">PMC3971861</ArticleId>
            <ArticleId IdType="pubmed">19524504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maiuri M.C., Zalckvar E., Kimchi A., Kroemer G. Self-eating and self-killing: Crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 2007;8:741&#x2013;752. doi: 10.1038/nrm2239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm2239</ArticleId>
            <ArticleId IdType="pubmed">17717517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao R., Chen M., Jiang Z., Zhao F., Xi B., Xu Z., Fu H., Zhou K. Platycodin-D Induced Autophagy in Non-Small Cell Lung Cancer Cells via PI3K/Akt/mTOR and MAPK Signaling Pathways. J. Cancer. 2015;6:623&#x2013;631. doi: 10.7150/jca.11291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/jca.11291</ArticleId>
            <ArticleId IdType="pmc">PMC4466411</ArticleId>
            <ArticleId IdType="pubmed">26078792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirota Y., Yamashita S., Kurihara Y., Jin X., Aihara M., Saigusa T., Kang D., Kanki T. Mitophagy is primarily due to alternative autophagy and requires the MAPK1 and MAPK14 signaling pathways. Autophagy. 2015;11:332&#x2013;343. doi: 10.1080/15548627.2015.1023047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15548627.2015.1023047</ArticleId>
            <ArticleId IdType="pmc">PMC4502654</ArticleId>
            <ArticleId IdType="pubmed">25831013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herassandoval D., P&#xe9;rezrojas J.M., Hern&#xe1;ndezdami&#xe1;n J., Pedrazachaverri J. The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. Cell. Signal. 2014;26:2694&#x2013;2701. doi: 10.1016/j.cellsig.2014.08.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellsig.2014.08.019</ArticleId>
            <ArticleId IdType="pubmed">25173700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>So M., Sha S., Antoniou M., Wu S., Tanun K. Mycotoxin Zearalenone induced apoptosis in BEAS-2B cells through generation of ROS and activation of JNK and p38 MAPKs signalling pathways. BMC Genet. 2012;6:231&#x2013;240.</Citation>
        </Reference>
        <Reference>
          <Citation>Gilbert A.B., Evans A.J., Perry M.M., Davidson M.H. A method for separating the granulosa cells, the basal lamina and the theca of the preovulatory ovarian follicle of the domestic fowl (Gallus domesticus) J. Reprod. Fertil. 1977;50:179&#x2013;181. doi: 10.1530/jrf.0.0500179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/jrf.0.0500179</ArticleId>
            <ArticleId IdType="pubmed">864645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahumada-Sol&#xf3;rzano S.M., Carranza M.E., Pedernera E., Rodr&#xed;guez-M&#xe9;ndez A.J., Luna M., Ar&#xe1;mburo C. Local expression and distribution of growth hormone and growth hormone receptor in the chicken ovary: Effects of GH on steroidogenesis in cultured follicular granulosa cells. Gen. Comp. Endocrinol. 2012;175:297&#x2013;310. doi: 10.1016/j.ygcen.2011.11.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygcen.2011.11.027</ArticleId>
            <ArticleId IdType="pubmed">22142535</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33715980</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1878-1705</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>94</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>International immunopharmacology</Title>
          <ISOAbbreviation>Int Immunopharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Isovitexin potentiated the antitumor activity of cisplatin by inhibiting the glucose metabolism of lung cancer cells and reduced cisplatin-induced immunotoxicity in mice.</ArticleTitle>
        <Pagination>
          <StartPage>107357</StartPage>
          <MedlinePgn>107357</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.intimp.2020.107357</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1567-5769(20)33825-X</ELocationID>
        <Abstract>
          <AbstractText>The increased resistance and toxicity have become the main causes of chemotherapy failure for treating lung cancer. The combination of chemotherapeutic drugs with other agents has been recognized as a promising strategy to overcome these difficulties. Isovitexin (IVT) is a well-known flavone C-glycoside found in many plants and has attracted wide attention due to its obvious antitumor and antioxidant effects. In this study, we investigated the synergistic effects of IVX and cisplatin (DDP) in non-small cell lung cancer (NSCLC) A549 and H1975 cells. The results showed that the combined treatment with IVT and DDP markedly inhibited proliferation and induced apoptosis of the two NSCLC cells. Using a mouse model of A549 xenograft, IVT potentiated the inhibition of DDP on tumor growth, but reduced DDP-induced hepatotoxicity and nephrotoxicity in mice. Remarkedly, IVT promoted lipopolysaccharide (LPS)- and lectin- stimulated splenocyte proliferation, and enhance cytotoxic T lymphocyte (CTL) and natural killer (NK) cell activities as well as the production of IL-2 and TNF-α. Furthermore, IVT significantly reduced glucose uptake, lactate production, and ATP production, and downregulated the protein expressions of pyruvate kinase M2 (PKM2)-mediated pathway in both A549 and H1975 cells. After the over-expression of PKM2 in the NSCLC cells, the synergistic antitumor effect of IVT and DDP was markedly weakened. Therefore, IVT not only inhibited cell proliferation and glucose metabolism via downregulating the expression of PKM2 to enhance the antitumor activity of DDP against lung cancer cells, and improved DDP-induced immunotoxicity in mice. It also presented a novel strategy to enhance the anti-tumor effect of platinum-based chemotherapy against NSCLC.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Rui-Lin</ForeName>
            <Initials>RL</Initials>
            <AffiliationInfo>
              <Affiliation>The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, China; The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou 310053, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zhen</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Ping</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310005, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Cai-Hua</ForeName>
            <Initials>CH</Initials>
            <AffiliationInfo>
              <Affiliation>The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Wen-Ying</ForeName>
            <Initials>WY</Initials>
            <AffiliationInfo>
              <Affiliation>Zhejiang Key Laboratory of Experimental Animal and Safety Evaluation, Zhejiang Academy of Medical Sciences (Hangzhou Medical College), Hangzhou 310013, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Huan-Huan</ForeName>
            <Initials>HH</Initials>
            <AffiliationInfo>
              <Affiliation>Zhejiang Key Laboratory of Experimental Animal and Safety Evaluation, Zhejiang Academy of Medical Sciences (Hangzhou Medical College), Hangzhou 310013, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Chen-Huan</ForeName>
            <Initials>CH</Initials>
            <AffiliationInfo>
              <Affiliation>Zhejiang Key Laboratory of Experimental Animal and Safety Evaluation, Zhejiang Academy of Medical Sciences (Hangzhou Medical College), Hangzhou 310013, China; Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Hangzhou 310018, China. Electronic address: yuchenhuan2002@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Jia-Qi</ForeName>
            <Initials>JQ</Initials>
            <AffiliationInfo>
              <Affiliation>The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, China. Electronic address: hejiaqi7788@sina.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>03</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Int Immunopharmacol</MedlineTA>
        <NlmUniqueID>100965259</NlmUniqueID>
        <ISSNLinking>1567-5769</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013963">Thyroid Hormones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C053648">thyroid hormone-binding proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>33X04XA5AT</RegistryNumber>
          <NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7V515PI7F6</RegistryNumber>
          <NameOfSubstance UI="D047310">Apigenin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8L70Q75FXE</RegistryNumber>
          <NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IY9XDZ35W2</RegistryNumber>
          <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>KTQ9R9MS0Q</RegistryNumber>
          <NameOfSubstance UI="C049772">isovitexin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q20Q21Q62J</RegistryNumber>
          <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047310" MajorTopicYN="N">Apigenin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019344" MajorTopicYN="N">Lactic Acid</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013963" MajorTopicYN="N">Thyroid Hormones</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">Flavone</Keyword>
        <Keyword MajorTopicYN="N">Glucose metabolism</Keyword>
        <Keyword MajorTopicYN="N">PKM2</Keyword>
        <Keyword MajorTopicYN="N">Synergistic effect</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>4</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33715980</ArticleId>
        <ArticleId IdType="doi">10.1016/j.intimp.2020.107357</ArticleId>
        <ArticleId IdType="pii">S1567-5769(20)33825-X</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33475857</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-1327</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>26</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry</Title>
          <ISOAbbreviation>J Biol Inorg Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Studies of anticancer activity in vivo and in vitro behaviors of liposomes encapsulated iridium(III) complex.</ArticleTitle>
        <Pagination>
          <StartPage>109</StartPage>
          <EndPage>122</EndPage>
          <MedlinePgn>109-122</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00775-020-01841-9</ELocationID>
        <Abstract>
          <AbstractText>Iridium(III) complexes have gained great attention in cancer treatment in recent years. In this paper, we designed and synthesized a new iridium(III) complex [Ir(piq)2(DQTT)](PF6) Ir1 (piq = 1-phenylisoquinoline, DQTT = 12-(1,4-dihydroquinoxalin-6-yl)-4,5,9,14-tetraazabenzo[b]triphenylene). The Ir1-loaded PEGylated liposomes (Lipo-Ir1) were prepared using the ethanol injection method. The anticancer activity of the complex and Lipo-Ir1 against SGC-7901 (human gastric adenocarcinoma), A549 (human lung carcinoma), HeLa (human cervical carcinoma), HepG2 (human hepatocellular carcinoma), BEL-7402 (human hepatocellular carcinoma), and normal NIH3T3 (mouse embryonic fibroblasts) was tested by the MTT method. The complex Ir1 shows moderate or low cytotoxicity against the selected cancer cells, whereas the Lipo-Ir1 exhibits high anticancer activity toward the same cancer cells. The apoptosis induced by Lipo-Ir1 was assayed by flow cytometry and Lipo-Ir1 induced apoptosis through increasing intracellular reactive-oxygen species levels, decreasing mitochondrial membrane potential, further promoting cytochrome c release and causing the increase of level of intracellular Ca[2+]. Western blot was used to detect the changes in Bcl-2 family protein and PI3K/AKT pathway proteins. The cloning experiments demonstrated that the Lipo-Ir1 can effectively inhibit cell proliferation. In vivo experiments, Lipo-Ir1 inhibited tumor growth in xenograft nude mice, and the percentage of tumor growth inhibition in vivo was 75.70%. Overall, the liposomes Lipo-Ir1 exhibits higher anticancer activity than Ir1 under the same conditions. These results indicated that Lipo-Ir1 may be a valuable resource for cancer therapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gu</LastName>
            <ForeName>Yiying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wen</LastName>
            <ForeName>Haoyu</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yuanyuan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bai</LastName>
            <ForeName>Lan</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Yi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Huiwen</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hao</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yunjun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, People's Republic of China. lyjche@gdpu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>01</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>J Biol Inorg Chem</MedlineTA>
        <NlmUniqueID>9616326</NlmUniqueID>
        <ISSNLinking>0949-8257</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D056831">Coordination Complexes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008081">Liposomes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>44448S9773</RegistryNumber>
          <NameOfSubstance UI="D007495">Iridium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SY7Q814VUP</RegistryNumber>
          <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056831" MajorTopicYN="N">Coordination Complexes</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065546" MajorTopicYN="N">Drug Liberation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006461" MajorTopicYN="N">Hemolysis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007495" MajorTopicYN="N">Iridium</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D041681" MajorTopicYN="N">NIH 3T3 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">AKT/mTOR</Keyword>
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">Iridium(III) complex</Keyword>
        <Keyword MajorTopicYN="N">Liposomes</Keyword>
        <Keyword MajorTopicYN="N">Mitochondria</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>21</Day>
          <Hour>12</Hour>
          <Minute>19</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33475857</ArticleId>
        <ArticleId IdType="doi">10.1007/s00775-020-01841-9</ArticleId>
        <ArticleId IdType="pii">10.1007/s00775-020-01841-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Jiao Y, Yin J, He H, Peng X, Gao Q (2018) J Am Chem Soc 140:5882&#x2013;5885</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29595259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah N, Mohammad AS, Saralkar P, Sprowls SA, Vickers SD, John D, Tallman RM, Lucke-Wold BP, Jarrell KE, Pinti M, Nolan RL, Lockman PR (2018) Pharmacol Res 132:47&#x2013;68</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29604436</ArticleId>
            <ArticleId IdType="pmc">5997530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng W, Ding Y, Zong W, Ju S (2019) Clin Chim Acta 496:125&#x2013;133</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31276633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen W, Zheng R, Zhang S, Zeng H, Xia C, Zuo T, Yang Z, Zou X, He J (2013) Cancer Lett 401:63&#x2013;71</Citation>
        </Reference>
        <Reference>
          <Citation>Suhail Y, Cain MP, Vanaja K, Kurywchak PA, Levchenko Kalluri A, Kshitiz R (2019) Cell Syst 9:109&#x2013;127</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31465728</ArticleId>
            <ArticleId IdType="pmc">6716621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Babu E, Bhuvaneswari J, Mareeswaran PM, Thanasekaran P, Lee HM, Coord S (2019) Chem Rev 380:519&#x2013;549</Citation>
        </Reference>
        <Reference>
          <Citation>Du F, Bai L, He M, Zhang WY, Gu YY, Yin H, Liu YJ (2019) J Inorg Biochem 201:110822</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31536949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He M, Yi QY, Zhang WY, Bai L, Du F, Gu YY, Liu YJ, Wei P (2019) New J Chem 43:8566&#x2013;8579</Citation>
        </Reference>
        <Reference>
          <Citation>Yi QY, Zhang WY, He M, Du F, Wang XZ, Wang YJ, Gu YY, Bai L, Liu YJ (2019) J Biol Inorg Chem 24:151&#x2013;169</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30564887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang LX, Gu YY, Wang YJ, Bai L, Du F, Zhang WY, He M, Liu YJ, Chen YZ (2019) Molecules 24:3129</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">6749586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bond R, Biver T, Via LD, Guarra F, Hyeraci M, Sissi C, Labella L, Marchetti F, Samaritani S (2020) J Inorg Biochem 202:110874</Citation>
        </Reference>
        <Reference>
          <Citation>Correa RS, Bomfim LM, Oliveira KM, Moreira DRM, Soares MBP, Ellena J, Bezerra DP, Batista AA (2019) J Inorg Biochem 198:110751</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31220757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen JC, Zhang Y, Li GD, Peng F, Jie XM, She J, Dongye GZ, Zou ZL, Rong SW, Chen LM (2018) J Biol Inorg Chem 23:261&#x2013;275</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29260327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Casells I, Stringer T, Hutton AT, Prince S, Smith GS (2018) J Biol Inorg Chem 23:763&#x2013;774</Citation>
        </Reference>
        <Reference>
          <Citation>Meksawangwong S, Gohil B, Punyain W, Pal R, Kielar F (2019) Inorg Chim Acta 497:119066</Citation>
        </Reference>
        <Reference>
          <Citation>Caporale C, Massi M (2018) Coord Chem Rev 363:71&#x2013;91</Citation>
        </Reference>
        <Reference>
          <Citation>Gupta G, Kumari P, Ryu JY, Lee J, Mobin SM, Lee CY (2019) Inorg Chem 58:8587&#x2013;8595</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31117633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta G, Cherukommu S, Srinivas G, Lee SW, Mum SH, Jung J, Nagesh N, Lee CY (2018) J Inorg Biochem 189:17&#x2013;29</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30153544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Z, Sadler PJ (2014) Acc Chem Res 47:1174&#x2013;1185</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24555658</ArticleId>
            <ArticleId IdType="pmc">3994614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu ZS, Zhang YJ, Zhang SM, Jia XL, Zhong GS, Yang YL, Du Q, Li JJ, Liu Z (2019) Cancer Lett 447:75&#x2013;85</Citation>
        </Reference>
        <Reference>
          <Citation>Li JJ, Guo LH, Tian ZZ, Zhang SM, Xu ZS, Han YL, Li RX, Li Y, Liu Z (2018) Inorg Chem 57:13552&#x2013;13563</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30289251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang YJ, Guo LH, Ge XX, Zhu T, Chen WJ, Zhou HX, Zhao LP, Liu Z (2020) Inorg Chem 59:748&#x2013;758</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31808678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang WZ, Zhang FY, Wang YL, Song B, Zhang R, Yuan JL (2017) Inorg Chem 56:1309&#x2013;1318</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28098984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Wang KN, He L, Ji LN, Mao ZW (2020) J Inorg Biochem 205:110976</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31926377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naito K, Yokoi K, Balachandran C, Hisamatsu Y, Aoki S (2019) J Inorg Biochem 199:110785</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31419676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C, Lai SH, Yang HH, Xing DG, Zeng CC, Tang B, Wan D, Liu YJ (2017) RSC Adv 7:17752&#x2013;17762</Citation>
        </Reference>
        <Reference>
          <Citation>Bai L, Fei WD, Gu YY, He M, Du F, Zhang WY, Yang LL, Liu YJ (2020) J Inorg Biochem 205:111014</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32044395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rubio AR, Fidalgo J, Martin-Vargas J, P&#xe9;rez-Arneiz C, Alonso-Torre SR, Biver T, Espino G, Busto N, Carc&#xed;a B (2020) J Inorg Biochem 203:110885</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31731049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang WY, Wang YJ, Du F, He M, Gu YY, Bai L, Yang LL, Liu YJ (2019) Eur J Med Chem 178:401&#x2013;416</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31202128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wan D, Tang B, Wang YJ, Guo BH, Yin H, Yi QY, Liu YJ (2017) Eur J Med Chem 139:180&#x2013;190</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28800456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang B, Wan D, Wang YJ, Yi QY, Guo BH, Liu YJ (2018) Eur J Med Chem 145:302&#x2013;314</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29331753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sriraman SK, Salzano G, Sarisozen C, Torchilin V (2016) Eur J Pharm Biopharm 105:40&#x2013;49</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27264717</ArticleId>
            <ArticleId IdType="pmc">4931959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kolate A, Baradia D, Patil S, Vhora I, Kore G, Misra A, Cont J (2014) Release 192:67&#x2013;81</Citation>
        </Reference>
        <Reference>
          <Citation>Poh S, Chelvam V, Kelderhouse LE, Ayala-Lopez W, Vaitilingam B, Putt KS, Low PS (2007) Nanomedicine 12:2441&#x2013;2451</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang WY, Du F, He M, Bai L, Gu YY, Yang LL, Liu YJ (2019) Eur J Med Chem 178:390&#x2013;400</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31202127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao CC, Xu DQ, Liu XH, Fang YQ, Yi J, Li XF, Guo BH (2018) Int J Nanomedicine 13:4417&#x2013;4431</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30104875</ArticleId>
            <ArticleId IdType="pmc">6071621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C, Han BJ, Zeng CC, Lai SH, Li W, Tang B, Wan D, Jiang GB, Liu YJ (2016) J Inorg Biochem 157:62&#x2013;72</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26828285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bilakhiya AK, Tyagi B, Paul P, Natarajan P (2002) Inorg Chem 41:3830&#x2013;3842</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12132906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaafar-Maalej C, Diab R, Andrieu V, Elaissari A, Fessi H (2010) J Lipo Res 20:228&#x2013;243</Citation>
        </Reference>
        <Reference>
          <Citation>Xiong H, Du S, Ni J, Zhou J, Yao J (2016) Biomaterials 94:70&#x2013;83</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27105438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mosmann T (1983) J Immunol Methods 65:55&#x2013;63</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6606682</ArticleId>
            <ArticleId IdType="pmc">6606682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang FX, Chen MH, Lin YN, Zhang H, Tan CP, Ji LN, Mao ZW, Appl ACS (2017) Mater Int 9:42471&#x2013;42481</Citation>
        </Reference>
        <Reference>
          <Citation>Wang C, Jiang L, Wang S, Shi H, Wang J, Wang R, Li Y, Dou Y, Liu Y, Hou G, Ke Y, Liu H (2015) PLoS ONE 10:6</Citation>
        </Reference>
        <Reference>
          <Citation>Lu LP, Suo FZ, Feng YL, Song LL, Li Y, Li YJ, Wang KT (2019) Eur J Med Chem 176:1&#x2013;10</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31082759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kannan K, Jain SK (2000) Pathophysiology 7:153&#x2013;163</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10996508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han X, Peng B, Xiao BB, Cao SL, Yang CR, Wang WZ, Wang FC, Li HY, Yuan XL, Shi RF, Liao J, Wang HL, Li J, Xu XZ (2019) Eur J Med Chem 162:586&#x2013;601</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30472605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodic S, Vincent MD (2018) Int J Cancer 142:440&#x2013;448</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28940517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lanna A, Gomes DC, Muller-Durovic B, McDonnell T, Escors D, Gilroy DW, Lee JH, Karin M, Akbar AN (2017) Nat Immunol 18:354&#x2013;363</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28114291</ArticleId>
            <ArticleId IdType="pmc">5321575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y, Liu WZ, Liu T, Feng X, Yang N, Zhou HF (2015) J Recept Sig Transd 35:600&#x2013;604</Citation>
        </Reference>
        <Reference>
          <Citation>Wei C, Wang X, Chen M, Ouyang K, Song LS, Cheng H (2008) Nature 457:901&#x2013;905</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19118385</ArticleId>
            <ArticleId IdType="pmc">3505761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo Y, Li H, Shi W, Zhang J, Feng J, Yang X, Wang K, Zhang H, Yang L (2017) J Colloid Interf Sci 502:59&#x2013;66</Citation>
        </Reference>
        <Reference>
          <Citation>Guo BH, Liao CC, Fang YQ, Li SQ, Li XF, Lu ZF, Chen YZ (2018) Nanomedicine 13:2851&#x2013;2866</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30457036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jing Z, Sui X, Yao J, Xie J, Jiang L, Zhou Y, Pan H, Han W (2016) Cancer Lett 372:226&#x2013;238</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26803057</ArticleId>
            <ArticleId IdType="pmc">5240807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mukhopadhyay P, Rajesh M, Hasko G, Hawkins BJ, Madesh M, Pacher P (2007) Nat Protoc 2:2295&#x2013;2301</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17853886</ArticleId>
            <ArticleId IdType="pmc">2225540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ly JD, Grubb DR, Lawen A (2013) Apoptosis 8:115&#x2013;128</Citation>
        </Reference>
        <Reference>
          <Citation>Chen Z, Tao S, Li X, Zeng X, Zhang M, Yao Q (2019) Artif Cell Nanomed B 47:2213&#x2013;2220</Citation>
        </Reference>
        <Reference>
          <Citation>Hwang JY, Park JH, Kim MJ, Kim WJ, Ha KT, Choi BT, Lee SY, Shin HK (2019) Cancer Lett 443:25&#x2013;33</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30503550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo R, Li G (2018) Hell J Cardiol 59:323&#x2013;328</Citation>
        </Reference>
        <Reference>
          <Citation>Chong SJF, Lai IXH, Qu J, Hirpara J, Kang J, Swaminathan K, Loh T, Kumar A, Vali S, Abbasi T, Pervaiz S (2019) Cancer Lett 457:151&#x2013;167</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31103719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yap TA, Garrett MD, Walton ML, Raynaud F, De Bono JS, Workman P (2008) Curr Opin Pharmacol 8:393&#x2013;412</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18721898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yi QY, Wan D, Tang B, Wang YJ, Zhang WY, Du F, He M, Liu YJ (2018) Eur J Med Chem 2018(145):338&#x2013;349</Citation>
        </Reference>
        <Reference>
          <Citation>Murugan AK, Munirajan AK, Tsuchida N (2012) Oral Oncol 48:383&#x2013;392</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22240207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho FM, Lin WW, Chen BC, Chao CM, Yang CR, Lin LY, Lai CC, Liu SH, Lian CS (2006) Cell Signal 18:391&#x2013;399</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15970429</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33408172</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Electronic-Print">
        <Journal>
          <ISSN IssnType="Electronic">1098-5514</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>95</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of virology</Title>
          <ISOAbbreviation>J Virol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Human Parainfluenza Virus Type 2 V Protein Modulates Iron Homeostasis.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e01861-20</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01861-20</ELocationID>
        <Abstract>
          <AbstractText>Intracellular iron concentration is tightly controlled for cell viability. It is known to affect the growth of several viruses, but the molecular mechanisms are not well understood. We found that iron chelators inhibit growth of human parainfluenza virus type 2 (hPIV-2). Furthermore, infection with hPIV-2 alters ferritin localization from granules to a homogenous distribution within cytoplasm of iron-stimulated cells. The V protein of hPIV-2 interacts with ferritin heavy chain 1 (FTH1), a ferritin subunit. It also binds to nuclear receptor coactivator 4 (NCOA4), which mediates autophagic degradation of ferritin, so-called ferritinophagy. V protein consequently interferes with interaction between FTH1 and NCOA4. hPIV-2 growth is inhibited in FTH1 knockdown cell line where severe hPIV-2-induced apoptosis is shown. In contrast, NCOA4 knockdown results in the promotion of hPIV-2 growth and limited apoptosis. Our data collectively suggest that hPIV-2 V protein inhibits FTH1-NCOA4 interaction and subsequent ferritinophagy. This iron homeostasis modulation allows infected cells to avoid apoptotic cell death, resulting in effective growth of hPIV-2.IMPORTANCE hPIV-2 V protein interferes with interaction between FTH1 and NCOA4 and inhibits NCOA4-mediated ferritin degradation, leading to the inhibition of iron release to the cytoplasm. This iron homeostasis modulation allows infected cells to avoid apoptotic cell death, resulting in effective growth of hPIV-2.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2021 American Society for Microbiology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ohta</LastName>
            <ForeName>Keisuke</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0003-4317-7407</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology, School of Medicine, Wakayama Medical University.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saka</LastName>
            <ForeName>Naoki</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology, School of Medicine, Wakayama Medical University.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nishio</LastName>
            <ForeName>Machiko</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-5311-5798</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology, School of Medicine, Wakayama Medical University mnishio@wakayama-med.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>02</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Virol</MedlineTA>
        <NlmUniqueID>0113724</NlmUniqueID>
        <ISSNLinking>0022-538X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C111382">NCOA4 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D056918">Nuclear Receptor Coactivators</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015678">Viral Structural Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-73-2</RegistryNumber>
          <NameOfSubstance UI="D005293">Ferritins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.-</RegistryNumber>
          <NameOfSubstance UI="C454461">FTH1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.-</RegistryNumber>
          <NameOfSubstance UI="D010088">Oxidoreductases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005293" MajorTopicYN="N">Ferritins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006706" MajorTopicYN="Y">Homeostasis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056918" MajorTopicYN="N">Nuclear Receptor Coactivators</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010088" MajorTopicYN="N">Oxidoreductases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010223" MajorTopicYN="N">Parainfluenza Virus 2, Human</DescriptorName>
          <QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015678" MajorTopicYN="N">Viral Structural Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">FTH1</Keyword>
        <Keyword MajorTopicYN="N">NCOA4</Keyword>
        <Keyword MajorTopicYN="N">V protein</Keyword>
        <Keyword MajorTopicYN="N">apoptosis</Keyword>
        <Keyword MajorTopicYN="N">human parainfluenza virus type 2</Keyword>
        <Keyword MajorTopicYN="N">iron homeostasis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33408172</ArticleId>
        <ArticleId IdType="pmc">PMC8094939</ArticleId>
        <ArticleId IdType="doi">10.1128/JVI.01861-20</ArticleId>
        <ArticleId IdType="pii">JVI.01861-20</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Pantopoulos K, Porwal SK, Tartakoff A, Devireddy L. 2012. Mechanisms of mammalian iron homeostasis. Biochemistry 51:5705&#x2013;5724. doi:10.1021/bi300752r.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi300752r</ArticleId>
            <ArticleId IdType="pmc">PMC3572738</ArticleId>
            <ArticleId IdType="pubmed">22703180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muckenthaler MU, Rivella S, Hentze MW, Galy B. 2017. A red carpet for iron metabolism. Cell 168:344&#x2013;361. doi:10.1016/j.cell.2016.12.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2016.12.034</ArticleId>
            <ArticleId IdType="pmc">PMC5706455</ArticleId>
            <ArticleId IdType="pubmed">28129536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sadrzadeh SM, Graf E, Panter SS, Hallaway PE, Eaton JW. 1984. Hemoglobin. A biologic fenton reagent. J Biol Chem 259:14354&#x2013;14356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6094553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torti FM, Torti SV. 2002. Regulation of ferritin genes and protein. Blood 99:3505&#x2013;3516. doi:10.1182/blood.v99.10.3505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.v99.10.3505</ArticleId>
            <ArticleId IdType="pubmed">11986201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arosio P, Ingrassia R, Cavadini P. 2009. Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta 1790:589&#x2013;599. doi:10.1016/j.bbagen.2008.09.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbagen.2008.09.004</ArticleId>
            <ArticleId IdType="pubmed">18929623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mancias JD, Wang X, Gygi SP, Harper JW, Kimmelman AC. 2014. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature 509:105&#x2013;109. doi:10.1038/nature13148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13148</ArticleId>
            <ArticleId IdType="pmc">PMC4180099</ArticleId>
            <ArticleId IdType="pubmed">24695223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mancias JD, Vaites LP, Nissim S, Biancur DE, Kim AJ, Wang X, Liu Y, Goessling W, Kimmelman AC, Harper JW. 2015. Ferritinophagy via NCOA4 is required for erythropoiesis and is regulated by iron dependent HERC2-mediated proteolysis. Elife 4:e10308. doi:10.7554/eLife.10308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.10308</ArticleId>
            <ArticleId IdType="pmc">PMC4592949</ArticleId>
            <ArticleId IdType="pubmed">26436293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartolomei G, Cevik RE, Marcello A. 2011. Modulation of hepatitis C virus replication by iron and hepcidin in Huh7 hepatocytes. J Gen Virol 92:2072&#x2013;2081. doi:10.1099/vir.0.032706-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1099/vir.0.032706-0</ArticleId>
            <ArticleId IdType="pubmed">21593278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terpi&#x142;owska S, Siwicki AK. 2017. Chromium(III) and iron(III) inhibits replication of DNA and RNA viruses. Biometals 30:565&#x2013;574. doi:10.1007/s10534-017-0027-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10534-017-0027-9</ArticleId>
            <ArticleId IdType="pmc">PMC5514213</ArticleId>
            <ArticleId IdType="pubmed">28612172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Georgiou NA, van der Bruggen T, Oudshoorn M, Nottet HS, Marx JJ, van Asbeck BS. 2000. Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin. J Infect Dis 181:484&#x2013;490. doi:10.1086/315223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/315223</ArticleId>
            <ArticleId IdType="pubmed">10669330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duchemin JB, Paradkar PN. 2017. Iron availability affects West Nile virus infection in its mosquito vector. Virol J 14:103. doi:10.1186/s12985-017-0770-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12985-017-0770-0</ArticleId>
            <ArticleId IdType="pmc">PMC5460528</ArticleId>
            <ArticleId IdType="pubmed">28583206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y, Bao Q, Xuan B, Xu W, Pan D, Li Q, Qian Z. 2018. Human cytomegalovirus protein pUL38 prevents premature cell death by binding to ubiquitin-specific protease 24 and regulating iron metabolism. J Virol 92:e00191-18. doi:10.1128/JVI.00191-18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.00191-18</ArticleId>
            <ArticleId IdType="pmc">PMC6002719</ArticleId>
            <ArticleId IdType="pubmed">29695420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamb RA, Parks GD. 2013. Paramyxoviridae: the viruses and their replication, p 957&#x2013;995. Knipe DM, Howley PM, Cohen JI, Griffin DE, Lamb RA, Martin MA, Racaniello VR, Roizman B(ed), Fields virology, 6th ed, vol 1. Lippincott Williams &amp; Wilkins, Philadelphia, PA.</Citation>
        </Reference>
        <Reference>
          <Citation>Ohgimoto S, Bando H, Kawano M, Okamoto K, Kondo K, Tsurudome M, Nishio M, Ito Y. 1990. Sequence analysis of P gene of human parainfluenza type 2 virus: P and cysteine-rich proteins are translated by two mRNAs that differ by two nontemplated G residues. Virology 177:116&#x2013;123. doi:10.1016/0042-6822(90)90465-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0042-6822(90)90465-4</ArticleId>
            <ArticleId IdType="pubmed">2162103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrejeva J, Childs KS, Young DF, Carlos TS, Stock N, Goodbourn S, Randall RE. 2004. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc Natl Acad Sci U S A 101:17264&#x2013;17269. doi:10.1073/pnas.0407639101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0407639101</ArticleId>
            <ArticleId IdType="pmc">PMC535396</ArticleId>
            <ArticleId IdType="pubmed">15563593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishio M, Tsurudome M, Ito M, Garcin D, Kolakofsky D, Ito Y. 2005. Identification of paramyxovirus V protein residues essential for STAT protein degradation and promotion of virus replication. J Virol 79:8591&#x2013;8601. doi:10.1128/JVI.79.13.8591-8601.2005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.79.13.8591-8601.2005</ArticleId>
            <ArticleId IdType="pmc">PMC1143765</ArticleId>
            <ArticleId IdType="pubmed">15956600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishio M, Tsurudome M, Ishihara H, Ito M, Ito Y. 2007. The conserved carboxyl terminus of human parainfluenza virus type 2 V protein plays an important role in virus growth. Virology 362:85&#x2013;98. doi:10.1016/j.virol.2006.12.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.virol.2006.12.017</ArticleId>
            <ArticleId IdType="pubmed">17250865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Childs K, Randall R, Goodbourn S. 2012. Paramyxovirus V proteins interact with the RNA Helicase LGP2 to inhibit RIG-I-dependent interferon induction. J Virol 86:3411&#x2013;3421. doi:10.1128/JVI.06405-11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.06405-11</ArticleId>
            <ArticleId IdType="pmc">PMC3302505</ArticleId>
            <ArticleId IdType="pubmed">22301134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitagawa Y, Yamaguchi M, Zhou M, Nishio M, Itoh M, Gotoh B. 2013. Human parainfluenza virus type 2 V protein inhibits TRAF6-mediated ubiquitination of IRF7 to prevent TLR7- and TLR9-dependent interferon induction. J Virol 87:7966&#x2013;7976. doi:10.1128/JVI.03525-12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.03525-12</ArticleId>
            <ArticleId IdType="pmc">PMC3700191</ArticleId>
            <ArticleId IdType="pubmed">23678181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohta K, Goto H, Yumine N, Nishio M. 2016. Human parainfluenza virus type 2 V protein inhibits and antagonizes tetherin. J Gen Virol 97:561&#x2013;570. doi:10.1099/jgv.0.000373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1099/jgv.0.000373</ArticleId>
            <ArticleId IdType="pubmed">26675672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohta K, Goto H, Matsumoto Y, Yumine N, Tsurudome M, Nishio M. 2016. Graf1 controls the growth of human parainfluenza virus type 2 through inactivation of RhoA signaling. J Virol 90:9394&#x2013;9405. doi:10.1128/JVI.01471-16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.01471-16</ArticleId>
            <ArticleId IdType="pmc">PMC5044827</ArticleId>
            <ArticleId IdType="pubmed">27512058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohta K, Matsumoto Y, Nishio M. 2018. Human parainfluenza virus type 2 V protein inhibits caspase-1. J Gen Virol 99:501&#x2013;511. doi:10.1099/jgv.0.001037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1099/jgv.0.001037</ArticleId>
            <ArticleId IdType="pubmed">29485395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohta K, Matsumoto Y, Yumine N, Nishio M. 2018. The V protein of human parainfluenza virus type 2 promotes RhoA-induced filamentous actin formation. Virology 524:90&#x2013;96. doi:10.1016/j.virol.2018.08.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.virol.2018.08.015</ArticleId>
            <ArticleId IdType="pubmed">30165310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohta K, Matsumoto Y, Nishio M. 2019. Profilin2 is required for filamentous actin formation induced by human parainfluenza virus type 2. Virology 533:108&#x2013;114. doi:10.1016/j.virol.2019.05.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.virol.2019.05.013</ArticleId>
            <ArticleId IdType="pubmed">31150988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohta K, Matsumoto Y, Nishio M. 2020. Inhibition of cavin3 degradation by the human parainfluenza virus type 2 V protein is important for efficient viral growth. Front Microbiol 11:803. doi:10.3389/fmicb.2020.00803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmicb.2020.00803</ArticleId>
            <ArticleId IdType="pmc">PMC7203785</ArticleId>
            <ArticleId IdType="pubmed">32425917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishio M, Garcin D, Simonet V, Kolakofsky D. 2002. The carboxyl segment of the mumps virus V protein associates with Stat proteins in vitro via a tryptophan-rich motif. Virology 300:92&#x2013;99. doi:10.1006/viro.2002.1509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/viro.2002.1509</ArticleId>
            <ArticleId IdType="pubmed">12202209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simon HU, Haj-Yehia A, Levi-Schaffer F. 2000. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 5:415&#x2013;418. doi:10.1023/a:1009616228304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/a:1009616228304</ArticleId>
            <ArticleId IdType="pubmed">11256882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li M, Li J, Zeng R, Yang J, Liu J, Zhang Z, Song X, Yao Z, Ma C, Li W, Wang K, Wei L. 2018. Respiratory syncytial virus replication is promoted by autophagy-mediated inhibition of apoptosis. J Virol 92:e02193-17. doi:10.1128/JVI.02193-17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.02193-17</ArticleId>
            <ArticleId IdType="pmc">PMC5874425</ArticleId>
            <ArticleId IdType="pubmed">29386287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ronaldson PT, Bendayan R. 2008. HIV-1 viral envelope glycoprotein gp120 produces oxidative stress and regulates the functional expression of multidrug resistance protein-1 (Mrp1) in glial cells. J Neurochem 106:1298&#x2013;1313. doi:10.1111/j.1471-4159.2008.05479.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1471-4159.2008.05479.x</ArticleId>
            <ArticleId IdType="pubmed">18485102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin W, Tsai WL, Shao RX, Wu G, Peng LF, Barlow LL, Chung WJ, Zhang L, Zhao H, Jang JY, Chung RT. 2010. Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology 138:2509&#x2013;2518. doi:10.1053/j.gastro.2010.03.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2010.03.008</ArticleId>
            <ArticleId IdType="pmc">PMC2883661</ArticleId>
            <ArticleId IdType="pubmed">20230822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishio M, Tsurudome M, Ito M, Watanabe N, Kawano M, Komada H, Ito Y. 1997. Human parainfluenza virus type 2 phosphoprotein: mapping of monoclonal antibody epitopes and location of the multimerization domain. J Gen Virol 78:1303&#x2013;1308. doi:10.1099/0022-1317-78-6-1303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1099/0022-1317-78-6-1303</ArticleId>
            <ArticleId IdType="pubmed">9191922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishio M, Tsurudome M, Kawano M, Watanabe N, Ohgimoto S, Ito M, Komada H, Ito Y. 1996. Interaction between nucleocapsid protein (NP) and phosphoprotein (P) of human parainfluenza virus type 2: one of the two NP binding sites on P is essential for granule formation. J Gen Virol 77:2457&#x2013;2463. doi:10.1099/0022-1317-77-10-2457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1099/0022-1317-77-10-2457</ArticleId>
            <ArticleId IdType="pubmed">8887478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohta K, Matsumoto Y, Nishio M. 2018. Rab27a facilitates human parainfluenza virus type 2 growth by promoting cell surface transport of envelope proteins. Med Microbiol Immunol 207:141&#x2013;150. doi:10.1007/s00430-018-0536-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00430-018-0536-3</ArticleId>
            <ArticleId IdType="pubmed">29374787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takei D, Ishihara H, Yamaguchi S, Yamada T, Tamura A, Katagiri H, Maruyama Y, Oka Y. 2006. WFS1 protein modulates the free Ca(2+) concentration in the endoplasmic reticulum. FEBS Lett 580:5635&#x2013;5640. doi:10.1016/j.febslet.2006.09.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2006.09.007</ArticleId>
            <ArticleId IdType="pubmed">16989814</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33383488</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1532-3072</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>69</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Tissue &amp; cell</Title>
          <ISOAbbreviation>Tissue Cell</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Rapamycin alleviates cognitive impairment in murine vascular dementia: The enhancement of mitophagy by PI3K/AKT/mTOR axis.</ArticleTitle>
        <Pagination>
          <StartPage>101481</StartPage>
          <MedlinePgn>101481</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tice.2020.101481</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0040-8166(20)30639-X</ELocationID>
        <Abstract>
          <AbstractText>There are no approved symptomatic treatments for vascular dementia (VaD). Rapamycin (RAPA) improves cognitive deficits in Alzheimer's disease rats. To explore whether RAPA improves cognitive impairment after VaD and its possible molecular mechanisms. Thirty Sprague Dawley rats were randomly divided into three groups: sham (received sham-operation), VaD model (received permanent ligation of bilateral carotid arteries) and RAPA (7.5 mg/kg) treatment. Cognitive function was evaluated by Morris water maze test. Neuronal apoptosis was evaluated by TUNEL staining. Mitophagy was assessed by mitochondrial DNA (mtDNA), ATP level, transmission electron microscope and mitophagy-associated proteins. Proteins were quantified by Western blot and immunofluorescence. BV2 cells were exposed to RAPA or/and MHY1485 (mTOR activator) to verify in vivo results. Compared to VaD rats, the escape latency of RAPA-treated rats was significantly decreased, and time spent in target quadrant was longer. Pathologic changes, mitochondrial dysfunction, increase of neuronal apoptosis and related proteins in VaD rats were remarkably alleviated by RAPA. After RAPA treatment, an increase in number of autophagosomes was observed, along with up-regulation of mitophagy-related proteins. Overexpression of PI3K, AKT and mTOR were suppressed by RAPA treatment. In vitro experiments confirmed effects of RAPA, and demonstrated that MHY1485 addition reversed the RAPA-caused apoptosis inhibition and mitophagy enhancement. Overall, RAPA improved the cognitive impairment of VaD rats, alleviated neuronal injury and mitochondrial dysfunction. We proposed a potential mechanism that RAPA may play improving role by inhibiting neuronal apoptosis and enhancing mitophagy through PI3K/AKT/mTOR pathway. Findings provided an exciting possibility for novel treatment strategy of VaD.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Guimin</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Hebei Medical University, China; Department of Rheumatology and Immunology, HeBei General Hospital, China. Electronic address: 13091093566@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Lei</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Imaging, HeBei General Hospital, China. Electronic address: 13653218019@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xiuqin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Geriatric Medicine, HeBei General Hospital, China. Electronic address: xiuqinli2019@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Niu</LastName>
            <ForeName>Xiaoli</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, HeBei General Hospital, China. Electronic address: niuxl0327@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Guodong</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurointerventional Surgery, HeBei General Hospital, China. Electronic address: xgd0606@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lv</LastName>
            <ForeName>Peiyuan</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Hebei Medical University, China; Department of Neurology, HeBei General Hospital, China. Electronic address: lvpeiyuanoffice@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Scotland</Country>
        <MedlineTA>Tissue Cell</MedlineTA>
        <NlmUniqueID>0214745</NlmUniqueID>
        <ISSNLinking>0040-8166</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>W36ZG6FT64</RegistryNumber>
          <NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063306" MajorTopicYN="Y">Mitophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Autophagy</Keyword>
        <Keyword MajorTopicYN="N">Cognitive impairment</Keyword>
        <Keyword MajorTopicYN="N">Mitophagy</Keyword>
        <Keyword MajorTopicYN="N">Rapamycin</Keyword>
        <Keyword MajorTopicYN="N">Vascular dementia</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>31</Day>
          <Hour>20</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33383488</ArticleId>
        <ArticleId IdType="doi">10.1016/j.tice.2020.101481</ArticleId>
        <ArticleId IdType="pii">S0040-8166(20)30639-X</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33354908</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1742-7843</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>128</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Basic &amp; clinical pharmacology &amp; toxicology</Title>
          <ISOAbbreviation>Basic Clin Pharmacol Toxicol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Curcumin attenuates renal interstitial fibrosis by regulating autophagy and retaining mitochondrial function in unilateral ureteral obstruction rats.</ArticleTitle>
        <Pagination>
          <StartPage>594</StartPage>
          <EndPage>604</EndPage>
          <MedlinePgn>594-604</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/bcpt.13550</ELocationID>
        <Abstract>
          <AbstractText>Renal interstitial fibrosis (RIF) is the leading cause of end-stage renal disease, partly because of the lack of effective treatments. Curcumin, the primary active ingredient in turmeric, reportedly exerts potent antifibrotic effects. This study investigated the effects of curcumin on RIF in unilateral ureteral obstruction (UUO) rats and characterized the underlying action mechanism. UUO rats were treated with curcumin for 7 and 14 d. Renal fibrosis was evaluated through haematoxylin-eosin staining, Masson staining, and type I and III collagen expression. Autophagy and mitochondria were observed through scanning electron microscopy. NLRP3 inflammasomes, mitochondria, and autophagy-related proteins were detected through Western blotting. Mitochondrial respiratory enzyme activity was assessed spectrophotometrically. Compared with UUO rats, renal fibrosis was attenuated and NLRP3 inflammasome activation was inhibited in curcumin-treated rats. Furthermore, mitochondrial dysfunction was ameliorated and the LC3B/LC3A ratio and Beclin-1 expression were increased in curcumin-treated rats. Additionally, curcumin inhibited the PI3K/AKT/mTOR pathway. These results indicate that curcumin is a promising treatment agent for RIF, and its antifibrotic effects may be mediated by the inhibition of NLRP3 inflammasome activity through the regulation of autophagy and protection of mitochondrial function in UUO rats.</AbstractText>
          <CopyrightInformation>&#xa9; 2020 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Miaomiao</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-6431-0057</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Hang</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiotherapy, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Wenlin</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xuemei</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Lili</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Hongli</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>81700625</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>20170520273</GrantID>
            <Agency>Doctoral Start-up Foundation of Liaoning Province</Agency>
          </Grant>
          <Grant>
            <GrantID>JYTJCZR2020060</GrantID>
            <Agency>Department of Education of Liaoning Province</Agency>
          </Grant>
          <Grant>
            <GrantID>JYTQN2020041</GrantID>
            <Agency>Department of Education of Liaoning Province</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>01</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Basic Clin Pharmacol Toxicol</MedlineTA>
        <NlmUniqueID>101208422</NlmUniqueID>
        <ISSNLinking>1742-7835</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071199">NLR Family, Pyrin Domain-Containing 3 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C573346">Nlrp3 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IT942ZTH98</RegistryNumber>
          <NameOfSubstance UI="D003474">Curcumin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003474" MajorTopicYN="N">Curcumin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005355" MajorTopicYN="N">Fibrosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058847" MajorTopicYN="N">Inflammasomes</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007676" MajorTopicYN="N">Kidney Failure, Chronic</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007684" MajorTopicYN="N">Kidney Tubules</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071199" MajorTopicYN="N">NLR Family, Pyrin Domain-Containing 3 Protein</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014517" MajorTopicYN="N">Ureteral Obstruction</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">autophagy</Keyword>
        <Keyword MajorTopicYN="N">curcumin</Keyword>
        <Keyword MajorTopicYN="N">mitochondria</Keyword>
        <Keyword MajorTopicYN="N">renal interstitial fibrosis</Keyword>
        <Keyword MajorTopicYN="N">unilateral ureteral obstruction</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>23</Day>
          <Hour>5</Hour>
          <Minute>54</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33354908</ArticleId>
        <ArticleId IdType="doi">10.1111/bcpt.13550</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Forbes MS, Thornhill BA, Chevalier RL. Proximal tubular injury and rapid formation of atubular glomeruli in mice with unilateral ureteral obstruction: a new look at an old model. Am J Physiol Renal Physiol. 2011;301(1):F110-F117.</Citation>
        </Reference>
        <Reference>
          <Citation>Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol. 2010;21(11):1819-1834.</Citation>
        </Reference>
        <Reference>
          <Citation>Pulskens WP, Rampanelli E, Teske GJ, et al. TLR4 promotes fibrosis but attenuates tubular damage in progressive renal injury. J Am Soc Nephrol. 2010;21(8):1299-1308.</Citation>
        </Reference>
        <Reference>
          <Citation>Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. Nature. 2012;481(7381):278-286.</Citation>
        </Reference>
        <Reference>
          <Citation>Lorenz G, Darisipudi MN, Anders HJ. Canonical and non-canonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis. Nephrol Dial Transplant. 2014;29(1):41-48.</Citation>
        </Reference>
        <Reference>
          <Citation>Vilaysane A, Chun J, Seamone ME, et al. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol. 2010;21(10):1732-1744.</Citation>
        </Reference>
        <Reference>
          <Citation>Artlett CM, Thacker JD. Molecular activation of the NLRP3 Inflammasome in fibrosis: common threads linking divergent fibrogenic diseases. Antioxid Redox Signal. 2015;22(13):1162-1175.</Citation>
        </Reference>
        <Reference>
          <Citation>Bugyei-Twum A, Abadeh A, Thai K, et al. Suppression of NLRP3 Inflammasome Activation Ameliorates Chronic Kidney Disease-Induced Cardiac Fibrosis and Diastolic Dysfunction. Sci Rep. 2016;6:39551.</Citation>
        </Reference>
        <Reference>
          <Citation>Dostert C, Petrilli V, Van Bruggen R, et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008;320(5876):674-677.</Citation>
        </Reference>
        <Reference>
          <Citation>Lambert AJ, Brand MD. Reactive oxygen species production by mitochondria. Methods Mol Biol. 2009;554:165-181.</Citation>
        </Reference>
        <Reference>
          <Citation>Granata S, Zaza G, Simone S, et al. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genom. 2009;10:388.</Citation>
        </Reference>
        <Reference>
          <Citation>Casalena G, Daehn I, Bottinger E. Transforming growth factor-beta, bioenergetics, and mitochondria in renal disease. Semin Nephrol. 2012;32(3):295-303.</Citation>
        </Reference>
        <Reference>
          <Citation>Brezniceanu ML, Liu F, Wei CC, et al. Attenuation of interstitial fibrosis and tubular apoptosis in db/db transgenic mice overexpressing catalase in renal proximal tubular cells. Diabetes. 2008;57(2):451-459.</Citation>
        </Reference>
        <Reference>
          <Citation>Kim SI, Na HJ, Ding Y, et al. Autophagy promotes intracellular degradation of type I collagen induced by transforming growth factor (TGF)-beta1. J Biol Chem. 2012;287(15):11677-11688.</Citation>
        </Reference>
        <Reference>
          <Citation>Kim WY, Nam SA, Song HC, et al. The role of autophagy in unilateral ureteral obstruction rat model. Nephrology. 2012;17(2):148-159.</Citation>
        </Reference>
        <Reference>
          <Citation>Yin H, Guo Q, Li X, et al. Curcumin Suppresses IL-1beta Secretion and Prevents Inflammation through Inhibition of the NLRP3 Inflammasome. J Immunol. 2018;200(8):2835-2846.</Citation>
        </Reference>
        <Reference>
          <Citation>Lu M, Yin N, Liu W, et al. Curcumin Ameliorates Diabetic Nephropathy by Suppressing NLRP3 Inflammasome Signaling. Biomed Res Int. 2017;2017:1516985.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Z, Chen Z, Li B, et al. Curcumin attenuates renal interstitial fibrosis of obstructive nephropathy by suppressing epithelial-mesenchymal transition through inhibition of the TLR4/NF-small ka, CyrillicB and PI3K/AKT signalling pathways. Pharm Biol. 2020;58(1):828-837.</Citation>
        </Reference>
        <Reference>
          <Citation>Tveden-Nyborg P, Bergmann TK, Lykkesfeldt J. Basic &amp; Clinical Pharmacology &amp; Toxicology Policy for Experimental and Clinical studies. Basic Clin Pharmacol Toxicol. 2018;123(3):233-235.</Citation>
        </Reference>
        <Reference>
          <Citation>Zheng L, Zhang J, Yuan X, et al. Fluorofenidone attenuates interleukin-1beta production by interacting with NLRP3 inflammasome in unilateral ureteral obstruction. Nephrology. 2018;23(6):573-584.</Citation>
        </Reference>
        <Reference>
          <Citation>Buyuklu M, Kandemir FM, Ozkaraca M, et al. Protective effect of curcumin against contrast induced nephropathy in rat kidney: what is happening to oxidative stress, inflammation, autophagy and apoptosis? Eur Rev Med Pharmaco. 2014;18(4):461-470.</Citation>
        </Reference>
        <Reference>
          <Citation>Lin SL, Chen RH, Chen YM, et al. Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol. 2005;16(9):2702-2713.</Citation>
        </Reference>
        <Reference>
          <Citation>Swanlund MJ, Kregel KC, Oberley TD. Investigating autophagy: Quantitative morphometric analysis using electron microscopy. Autophagy. 2010;6(2):270-277.</Citation>
        </Reference>
        <Reference>
          <Citation>Tong T, Liu Z, Zhang H, et al. Age-dependent expression of the vitamin D receptor and the protective effect of vitamin D receptor activation on H2O2-induced apoptosis in rat intervertebral disc cells. J Steroid Biochem Mol Biol. 2019;190:126-138.</Citation>
        </Reference>
        <Reference>
          <Citation>Decleves AE, Sharma K. Novel targets of antifibrotic and anti-inflammatory treatment in CKD. Nat Rev Nephrol. 2014;10(5):257-267.</Citation>
        </Reference>
        <Reference>
          <Citation>Gong Z, Zhou J, Li H, et al. Curcumin suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock. Mol Nutr Food Res. 2015;59(11):2132-2142.</Citation>
        </Reference>
        <Reference>
          <Citation>Sorbara MT, Girardin SE. Mitochondrial ROS fuel the inflammasome. Cell Res. 2011;21(4):558-560.</Citation>
        </Reference>
        <Reference>
          <Citation>Gurung P, Lukens JR, Kanneganti TD. Mitochondria: diversity in the regulation of the NLRP3 inflammasome. Trends Mol Med. 2015;21(3):193-201.</Citation>
        </Reference>
        <Reference>
          <Citation>Shimada K, Crother TR, Karlin J, et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity. 2012;36(3):401-414.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469(7329):221-225.</Citation>
        </Reference>
        <Reference>
          <Citation>Baroja-Mazo A, Martin-Sanchez F, Gomez AI, et al. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol. 2014;15(8):738-748.</Citation>
        </Reference>
        <Reference>
          <Citation>Subramanian N, Natarajan K, Clatworthy MR, Wang Z, Germain RN. The adaptor MAVS promotes NLRP3 mitochondrial localization and inflammasome activation. Cell. 2013;153(2):348-361.</Citation>
        </Reference>
        <Reference>
          <Citation>Colombini M. VDAC: the channel at the interface between mitochondria and the cytosol. Mol Cell Biochem. 2004;256-257(1-2):107-115.</Citation>
        </Reference>
        <Reference>
          <Citation>Lee GS, Subramanian N, Kim AI, et al. The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature. 2012;492(7427):123-127.</Citation>
        </Reference>
        <Reference>
          <Citation>Streeter A, Menzies FM, Rubinsztein DC. LC3-II Tagging and Western Blotting for Monitoring Autophagic Activity in Mammalian Cells. Methods Mol Biol. 2016;1303:161-170.</Citation>
        </Reference>
        <Reference>
          <Citation>He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. 2009;43:67-93.</Citation>
        </Reference>
        <Reference>
          <Citation>Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274-293.</Citation>
        </Reference>
        <Reference>
          <Citation>Nakahira K, Haspel JA, Rathinam VA, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol. 2011;12(3):222-230.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33227289</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1096-0384</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>697</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Jan</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Archives of biochemistry and biophysics</Title>
          <ISOAbbreviation>Arch Biochem Biophys</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Coptisine induces autophagic cell death through down-regulation of PI3K/Akt/mTOR signaling pathway and up-regulation of ROS-mediated mitochondrial dysfunction in hepatocellular carcinoma Hep3B cells.</ArticleTitle>
        <Pagination>
          <StartPage>108688</StartPage>
          <MedlinePgn>108688</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.abb.2020.108688</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0003-9861(20)30697-4</ELocationID>
        <Abstract>
          <AbstractText>Coptisine is isoquinoline alkaloid derived from Coptidis Rhizoma and is known to have potential anti-cancer activity toward various carcinomas. Targeting autophagy is one of the main approaches for cancer therapy, but whether the anti-cancer efficacy of coptisine involves autophagy is still unclear. Therefore, this study investigated the effect of coptisine on autophagy in hepatocellular carcinoma (HCC) Hep3B cells, and identified the underlying mechanism. Our results showed that coptisine increased cytotoxicity and autophagic vacuoles in a concentration-dependent manner. Furthermore, the expressions of light chain 3 (LC3)-I/II, Beclin-1 and autophagy genes were markedly increased by coptisine, while the expression of p62 decreased. In addition, we found that pretreatment with bafilomycin A1, an inhibitor of autophagosome-lysosome fusion, markedly reduced coptisine-mediated autophagic cell death, but 3-methyladenine, an inhibitor for autophagosome formation did not. Moreover, our results showed that although coptisine up-regulated AMP-activated protein kinase (AMPK) that partially induced LC3-I/II, coptisine-mediated AMPK signaling did not directly regulate autophagic cell death. Additionally, we found that coptisine suppressed the phosphorylation of phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR), and this effect was notably enhanced by PI3K inhibitor LY294002. Meanwhile, coptisine significantly increased both the production of mitochondrial reactive oxygen species (ROS) and the recruitment of mitophagy-regulated proteins to mitochondria. Furthermore, N-acetylcysteine, a potential ROS scavenger, substantially suppressed the expression of mitophagy-regulated proteins and LC3 puncta by coptisine. Overall, our results demonstrate that coptisine-mediated autophagic cell death was regulated by PI3K/Akt/mTOR signaling and mitochondrial ROS production associated with mitochondrial dysfunction. Taken together, these findings suggest that coptisine exerts its anti-cancer effects through induction of autophagy in HCC Hep3B cells.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2020. Published by Elsevier Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>So Young</ForeName>
            <Initials>SY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, Dong-eui University College of Korean Medicine and Anti-Aging Research Center, Dong-eui University, Busan, 47227, Republic of Korea; Department of Molecular Biology, College of Natural Sciences, Pusan National University, Busan, 46241, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hwangbo</LastName>
            <ForeName>Hyun</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, Dong-eui University College of Korean Medicine and Anti-Aging Research Center, Dong-eui University, Busan, 47227, Republic of Korea; Department of Molecular Biology, College of Natural Sciences, Pusan National University, Busan, 46241, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Min Yeong</ForeName>
            <Initials>MY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, Dong-eui University College of Korean Medicine and Anti-Aging Research Center, Dong-eui University, Busan, 47227, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ji</LastName>
            <ForeName>Seon Yeong</ForeName>
            <Initials>SY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, Dong-eui University College of Korean Medicine and Anti-Aging Research Center, Dong-eui University, Busan, 47227, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Hyesook</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, Dong-eui University College of Korean Medicine and Anti-Aging Research Center, Dong-eui University, Busan, 47227, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Gi-Young</ForeName>
            <Initials>GY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Marine Life Sciences, School of Marine Biomedical Sciences, Jeju National University, Jeju, 63243, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kwon</LastName>
            <ForeName>Chan-Young</ForeName>
            <Initials>CY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oriental Neuropsychiatry, Dong-eui University College of Korean Medicine, Busan, 47227, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leem</LastName>
            <ForeName>Sun-Hee</ForeName>
            <Initials>SH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biological Science, College of Natural Science, Dong-A University, Busan, 49315, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hong</LastName>
            <ForeName>Su Hyun</ForeName>
            <Initials>SH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, Dong-eui University College of Korean Medicine and Anti-Aging Research Center, Dong-eui University, Busan, 47227, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheong</LastName>
            <ForeName>JaeHun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Biology, College of Natural Sciences, Pusan National University, Busan, 46241, Republic of Korea. Electronic address: molecule85@pusan.ac.kr.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Yung Hyun</ForeName>
            <Initials>YH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, Dong-eui University College of Korean Medicine and Anti-Aging Research Center, Dong-eui University, Busan, 47227, Republic of Korea. Electronic address: choiyh@deu.ac.kr.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Arch Biochem Biophys</MedlineTA>
        <NlmUniqueID>0372430</NlmUniqueID>
        <ISSNLinking>0003-9861</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0GCL71VN14</RegistryNumber>
          <NameOfSubstance UI="C034384">coptisine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0I8Y3P32UF</RegistryNumber>
          <NameOfSubstance UI="D001599">Berberine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001599" MajorTopicYN="N">Berberine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Autophagy</Keyword>
        <Keyword MajorTopicYN="N">Coptisine</Keyword>
        <Keyword MajorTopicYN="N">Hepatocellular carcinoma</Keyword>
        <Keyword MajorTopicYN="N">PI3K/Akt/mTOR pathway</Keyword>
        <Keyword MajorTopicYN="N">ROS</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>23</Day>
          <Hour>20</Hour>
          <Minute>9</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33227289</ArticleId>
        <ArticleId IdType="doi">10.1016/j.abb.2020.108688</ArticleId>
        <ArticleId IdType="pii">S0003-9861(20)30697-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32791301</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-3177</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>68</Volume>
            <PubDate>
              <Year>2020</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Toxicology in vitro : an international journal published in association with BIBRA</Title>
          <ISOAbbreviation>Toxicol In Vitro</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Chelerythrine hydrochloride inhibits proliferation and induces mitochondrial apoptosis in cervical cancer cells via PI3K/BAD signaling pathway.</ArticleTitle>
        <Pagination>
          <StartPage>104965</StartPage>
          <MedlinePgn>104965</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tiv.2020.104965</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0887-2333(20)30515-4</ELocationID>
        <Abstract>
          <AbstractText>Cervical cancer is the fourth most common female cancer worldwide, and drug targeted therapy plays a crucial role in delaying the progression of cervical carcinoma. Chelerythrine hydrochloride (CHE) is a natural alkaloid, which is a focal point in anti-tumor research. In this study, we investigated the effect of CHE on HeLa cells by using MTT assay, RTCA, and colony formation assay. In addition, the flow cytometric analysis, immunofluorescence staining assay and western blot analysis were performed to study the mechanism of CHE. The results showed that CHE exhibited a significant inhibitory effect in HeLa cells, and it could suppress the expression of PI3K subunits in a dose-dependent manner. Moreover, we found that the treatment of CHE further restrained the downstream AKT/mTOR and PKCα signaling. In addition, CHE induced mitochondrial apoptosis of HeLa cells by regulating the BCL-2 family member's expression. Immunofluorescence staining assay indicated that AIF and Cytochrome C were translocated from mitochondria to cytoplasm or nucleus, and notable changes in mitochondrial morphology of HeLa cells were also observed. Finally, the aberrant expression of CHE led to the mitochondrial apoptosis by upregulating the expression of APAF1, Cleaved-Caspase9, Cleaved-Caspase3, and Cleaved-PARP. In summary, CHE suppresses the proliferation of HeLa cells by trigging the mitochondrial apoptosis through the PI3K/BAD signaling pathway.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Tianfeng</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, PR China; State Key Laboratory of Shaanxi for Natural Medicines Research and Engineering, Xi'an 710061, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Rui</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, PR China; State Key Laboratory of Shaanxi for Natural Medicines Research and Engineering, Xi'an 710061, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Su</LastName>
            <ForeName>Qi</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, PR China; State Key Laboratory of Shaanxi for Natural Medicines Research and Engineering, Xi'an 710061, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Hongying</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, PR China; State Key Laboratory of Shaanxi for Natural Medicines Research and Engineering, Xi'an 710061, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Feng</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Shaanxi Institute of International Trade &amp; Commence, Xianyang 712046, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dai</LastName>
            <ForeName>Bingling</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, PR China; State Key Laboratory of Shaanxi for Natural Medicines Research and Engineering, Xi'an 710061, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Bo</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, PR China; State Key Laboratory of Shaanxi for Natural Medicines Research and Engineering, Xi'an 710061, PR China. Electronic address: bobwang@xjtu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yanmin</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, PR China; State Key Laboratory of Shaanxi for Natural Medicines Research and Engineering, Xi'an 710061, PR China. Electronic address: zhang2008@mail.xjtu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>08</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Toxicol In Vitro</MedlineTA>
        <NlmUniqueID>8712158</NlmUniqueID>
        <ISSNLinking>0887-2333</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C494819">BAD protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053119">Benzophenanthridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051025">bcl-Associated Death Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E3B045W6X0</RegistryNumber>
          <NameOfSubstance UI="C016299">chelerythrine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053119" MajorTopicYN="N">Benzophenanthridines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051025" MajorTopicYN="N">bcl-Associated Death Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cervical cancer</Keyword>
        <Keyword MajorTopicYN="N">Chelerythrine hydrochloride</Keyword>
        <Keyword MajorTopicYN="N">Mitochondrial apoptosis</Keyword>
        <Keyword MajorTopicYN="N">PI3K/AKT/mTOR</Keyword>
        <Keyword MajorTopicYN="N">Targeted therapy</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32791301</ArticleId>
        <ArticleId IdType="doi">10.1016/j.tiv.2020.104965</ArticleId>
        <ArticleId IdType="pii">S0887-2333(20)30515-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32708306</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>21</Volume>
            <Issue>14</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jul</Month>
              <Day>21</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">5165</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms21145165</ELocationID>
        <Abstract>
          <AbstractText>Background: Malignant pleural mesothelioma (MPM) is an aggressive malignancy associated to asbestos exposure. One of the most frequent genetic alteration in MPM patients is CDKN2A/ARF loss, leading to aberrant activation of the Rb pathway. In MPM cells, we previously demonstrated the therapeutic efficacy of targeting this signaling with the CDK4/6 inhibitor palbociclib in combination with PI3K/mTOR inhibitors. Here, we investigated whether such combination may have an impact on cell energy metabolism. Methods: The study was performed in MPM cells of different histotypes; metabolic analyses were conducted by measuring GLUT-1 expression and glucose uptake/consumption, and by SeaHorse technologies. Results: MPM cell models differed for their ability to adapt to metabolic stress conditions, such as glucose starvation and hypoxia. Independently of these differences, combined treatments with palbociclib and PI3K/mTOR inhibitors inhibited cell proliferation more efficaciously than single agents. The drugs alone reduced glucose uptake/consumption as well as glycolysis, and their combination further enhanced these effects under both normoxic and hypoxic conditions. Moreover, the drug combinations significantly impaired mitochondrial respiration as compared with individual treatments. These metabolic effects were mediated by the concomitant inhibition of Rb/E2F/c-myc and PI3K/AKT/mTOR signaling. Conclusions: Dual blockade of glycolysis and respiration contributes to the anti-tumor efficacy of palbociclib-PI3K/mTOR inhibitors combination.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bonelli</LastName>
            <ForeName>Mara</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Terenziani</LastName>
            <ForeName>Rita</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zoppi</LastName>
            <ForeName>Silvia</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-8357-1073</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fumarola</LastName>
            <ForeName>Claudia</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0002-3291-6668</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>La Monica</LastName>
            <ForeName>Silvia</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cretella</LastName>
            <ForeName>Daniele</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alfieri</LastName>
            <ForeName>Roberta</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0003-0601-7244</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cavazzoni</LastName>
            <ForeName>Andrea</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-3752-1868</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Digiacomo</LastName>
            <ForeName>Graziana</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Galetti</LastName>
            <ForeName>Maricla</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-8061-8649</Identifier>
            <AffiliationInfo>
              <Affiliation>INAIL Research, Department of Occupational and Environmental Medicine, Epidemiology and Hygiene, 00078 Monte Porzio Catone (Rome), Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Petronini</LastName>
            <ForeName>Pier Giorgio</ForeName>
            <Initials>PG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>N/A</GrantID>
            <Agency>Associazione Augusto per la Vita (Novellara, RE)</Agency>
          </Grant>
          <Grant>
            <GrantID>N/A</GrantID>
            <Agency>CHIESI Farmaceutici S.p.A. (Parma)</Agency>
          </Grant>
          <Grant>
            <GrantID>N/A</GrantID>
            <Agency>Transfer Oil S.p.A. (Colorno, PR)</Agency>
          </Grant>
          <Grant>
            <GrantID>N/A</GrantID>
            <Agency>Famiglia Gigetto Furlotti (Parma)</Agency>
          </Grant>
          <Grant>
            <GrantID>N/A</GrantID>
            <Agency>A.VO.PRO.RI.T. (Parma)</Agency>
          </Grant>
          <Grant>
            <GrantID>N/A</GrantID>
            <Agency>Ing. Marco Nocivelli, EPTA S.p.A (Milano)</Agency>
          </Grant>
          <Grant>
            <GrantID>2018.0184</GrantID>
            <Agency>Fondazione CARIPARMA</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>07</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.22</RegistryNumber>
          <NameOfSubstance UI="C495900">CDK4 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.22</RegistryNumber>
          <NameOfSubstance UI="C495911">CDK6 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.22</RegistryNumber>
          <NameOfSubstance UI="D051358">Cyclin-Dependent Kinase 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.22</RegistryNumber>
          <NameOfSubstance UI="D051361">Cyclin-Dependent Kinase 6</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>G9ZF61LE7G</RegistryNumber>
          <NameOfSubstance UI="C500026">palbociclib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051358" MajorTopicYN="N">Cyclin-Dependent Kinase 4</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051361" MajorTopicYN="N">Cyclin-Dependent Kinase 6</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006019" MajorTopicYN="N">Glycolysis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086002" MajorTopicYN="N">Mesothelioma, Malignant</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081082" MajorTopicYN="N">Phosphoinositide-3 Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010997" MajorTopicYN="N">Pleural Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CDK4/6 inhibition</Keyword>
        <Keyword MajorTopicYN="N">PI3K/mTOR inhibitors</Keyword>
        <Keyword MajorTopicYN="N">Palbociclib</Keyword>
        <Keyword MajorTopicYN="N">malignant pleural mesothelioma</Keyword>
        <Keyword MajorTopicYN="N">metabolism</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32708306</ArticleId>
        <ArticleId IdType="pmc">PMC7403976</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms21145165</ArticleId>
        <ArticleId IdType="pii">ijms21145165</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Patel S.C., Dowell J.E. Modern management of malignant pleural mesothelioma. Lung Cancer. 2016;7:63&#x2013;72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5310692</ArticleId>
            <ArticleId IdType="pubmed">28210162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicolini F., Bocchini M., Bronte G., Delmonte A., Guidoboni M., Crino L., Mazza M. Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future. Front. Oncol. 2019;9:1519. doi: 10.3389/fonc.2019.01519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2019.01519</ArticleId>
            <ArticleId IdType="pmc">PMC6992646</ArticleId>
            <ArticleId IdType="pubmed">32039010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hmeljak J., Sanchez-Vega F., Hoadley K.A., Shih J., Stewart C., Heiman D., Tarpey P., Danilova L., Drill E., Gibb E.A., et al. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov. 2018;8:1548&#x2013;1565. doi: 10.1158/2159-8290.CD-18-0804.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-18-0804</ArticleId>
            <ArticleId IdType="pmc">PMC6310008</ArticleId>
            <ArticleId IdType="pubmed">30322867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bueno R., Stawiski E.W., Goldstein L.D., Durinck S., De Rienzo A., Modrusan Z., Gnad F., Nguyen T.T., Jaiswal B.S., Chirieac L.R., et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 2016;48:407&#x2013;416. doi: 10.1038/ng.3520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.3520</ArticleId>
            <ArticleId IdType="pubmed">26928227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis. 2013;34:1413&#x2013;1419. doi: 10.1093/carcin/bgt166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgt166</ArticleId>
            <ArticleId IdType="pubmed">23677068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J., Xu K., Liu P., Geng Y., Wang B., Gan W., Guo J., Wu F., Chin Y.R., Berrios C., et al. Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt. Mol. Cell. 2016;62:929&#x2013;942. doi: 10.1016/j.molcel.2016.04.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2016.04.023</ArticleId>
            <ArticleId IdType="pmc">PMC4912424</ArticleId>
            <ArticleId IdType="pubmed">27237051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonelli M.A., Digiacomo G., Fumarola C., Alfieri R., Quaini F., Falco A., Madeddu D., La Monica S., Cretella D., Ravelli A., et al. Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. Neoplasia. 2017;19:637&#x2013;648. doi: 10.1016/j.neo.2017.05.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neo.2017.05.003</ArticleId>
            <ArticleId IdType="pmc">PMC5508477</ArticleId>
            <ArticleId IdType="pubmed">28704762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonelli M., La Monica S., Fumarola C., Alfieri R. Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation. Biochem. Pharmacol. 2019;170:113676. doi: 10.1016/j.bcp.2019.113676.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2019.113676</ArticleId>
            <ArticleId IdType="pubmed">31647925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fajas L. Re-thinking cell cycle regulators: The cross-talk with metabolism. Front. Oncol. 2013;3:4. doi: 10.3389/fonc.2013.00004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2013.00004</ArticleId>
            <ArticleId IdType="pmc">PMC3555080</ArticleId>
            <ArticleId IdType="pubmed">23355973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solaki M., Ewald J.C. Fueling the Cycle: CDKs in Carbon and Energy Metabolism. Front. Cell Dev. Biol. 2018;6:93. doi: 10.3389/fcell.2018.00093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2018.00093</ArticleId>
            <ArticleId IdType="pmc">PMC6107797</ArticleId>
            <ArticleId IdType="pubmed">30175098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elstrom R.L., Bauer D.E., Buzzai M., Karnauskas R., Harris M.H., Plas D.R., Zhuang H., Cinalli R.M., Alavi A., Rudin C.M., et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64:3892&#x2013;3899. doi: 10.1158/0008-5472.CAN-03-2904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-03-2904</ArticleId>
            <ArticleId IdType="pubmed">15172999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer. 2011;11:85&#x2013;95. doi: 10.1038/nrc2981.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2981</ArticleId>
            <ArticleId IdType="pubmed">21258394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoxhaj G., Manning B.D. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat. Rev. Cancer. 2020;20:74&#x2013;88. doi: 10.1038/s41568-019-0216-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41568-019-0216-7</ArticleId>
            <ArticleId IdType="pmc">PMC7314312</ArticleId>
            <ArticleId IdType="pubmed">31686003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan Y., Dickman K.G., Zong W.X. Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. J. Biol. Chem. 2010;285:7324&#x2013;7333. doi: 10.1074/jbc.M109.035584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M109.035584</ArticleId>
            <ArticleId IdType="pmc">PMC2844180</ArticleId>
            <ArticleId IdType="pubmed">20018866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marques M., Tranchant R., Risa-Ebri B., Suarez-Solis M.L., Fernandez L.C., Carrillo-de-Santa-Pau E., Del Pozo N., Martinez de Villarreal J., Meiller C., Allory Y., et al. Combined MEK and PI3K/p110beta Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features. Cancer Res. 2020;80:843&#x2013;856. doi: 10.1158/0008-5472.CAN-19-1633.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-19-1633</ArticleId>
            <ArticleId IdType="pubmed">31911549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de la Cruz Lopez K.G., Toledo Guzman M.E., Sanchez E.O., Garcia Carranca A. mTORC1 as a Regulator of Mitochondrial Functions and a Therapeutic Target in Cancer. Front. Oncol. 2019;9:1373. doi: 10.3389/fonc.2019.01373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2019.01373</ArticleId>
            <ArticleId IdType="pmc">PMC6923780</ArticleId>
            <ArticleId IdType="pubmed">31921637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goetzman E.S., Prochownik E.V. The Role for Myc in Coordinating Glycolysis, Oxidative Phosphorylation, Glutaminolysis, and Fatty Acid Metabolism in Normal and Neoplastic Tissues. Front. Endocrinol. 2018;9:129. doi: 10.3389/fendo.2018.00129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fendo.2018.00129</ArticleId>
            <ArticleId IdType="pmc">PMC5907532</ArticleId>
            <ArticleId IdType="pubmed">29706933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Francis R.J., Byrne M.J., van der Schaaf A.A., Boucek J.A., Nowak A.K., Phillips M., Price R., Patrikeos A.P., Musk A.W., Millward M.J. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J. Nucl. Med. 2007;48:1449&#x2013;1458. doi: 10.2967/jnumed.107.042333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2967/jnumed.107.042333</ArticleId>
            <ArticleId IdType="pubmed">17704250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ceresoli G.L., Chiti A., Zucali P.A., Rodari M., Lutman R.F., Salamina S., Incarbone M., Alloisio M., Santoro A. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J. Clin. Oncol. 2006;24:4587&#x2013;4593. doi: 10.1200/JCO.2006.06.8999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2006.06.8999</ArticleId>
            <ArticleId IdType="pubmed">17008700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urso L., Cavallari I., Sharova E., Ciccarese F., Pasello G., Ciminale V. Metabolic rewiring and redox alterations in malignant pleural mesothelioma. Br. J. Cancer. 2020;122:52&#x2013;61. doi: 10.1038/s41416-019-0661-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41416-019-0661-9</ArticleId>
            <ArticleId IdType="pmc">PMC6964675</ArticleId>
            <ArticleId IdType="pubmed">31819191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hylebos M., Van Camp G., van Meerbeeck J.P., Op de Beeck K. The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing. J. Thorac. Oncol. 2016;11:1615&#x2013;1626. doi: 10.1016/j.jtho.2016.05.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2016.05.020</ArticleId>
            <ArticleId IdType="pubmed">27282309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lo Iacono M., Monica V., Righi L., Grosso F., Libener R., Vatrano S., Bironzo P., Novello S., Musmeci L., Volante M., et al. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: A retrospective study. J. Thorac. Oncol. 2015;10:492&#x2013;499. doi: 10.1097/JTO.0000000000000436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/JTO.0000000000000436</ArticleId>
            <ArticleId IdType="pubmed">25514803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooper J., Xu Q., Zhou L., Pavlovic M., Ojeda V., Moulick K., de Stanchina E., Poirier J.T., Zauderer M., Rudin C.M., et al. Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis. Mol. Cancer Ther. 2017;16:1693&#x2013;1704. doi: 10.1158/1535-7163.MCT-16-0821.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-16-0821</ArticleId>
            <ArticleId IdType="pmc">PMC5929164</ArticleId>
            <ArticleId IdType="pubmed">28468780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sekido Y., Pass H.I., Bader S., Mew D.J., Christman M.F., Gazdar A.F., Minna J.D. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 1995;55:1227&#x2013;1231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7882313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kato S., Tomson B.N., Buys T.P., Elkin S.K., Carter J.L., Kurzrock R. Genomic Landscape of Malignant Mesotheliomas. Mol. Cancer Ther. 2016;15:2498&#x2013;2507. doi: 10.1158/1535-7163.MCT-16-0229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-16-0229</ArticleId>
            <ArticleId IdType="pubmed">27507853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller D.M., Thomas S.D., Islam A., Muench D., Sedoris K. c-Myc and cancer metabolism. Clin. Cancer Res. 2012;18:5546&#x2013;5553. doi: 10.1158/1078-0432.CCR-12-0977.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-12-0977</ArticleId>
            <ArticleId IdType="pmc">PMC3505847</ArticleId>
            <ArticleId IdType="pubmed">23071356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stine Z.E., Walton Z.E., Altman B.J., Hsieh A.L., Dang C.V. MYC, Metabolism, and Cancer. Cancer Discov. 2015;5:1024&#x2013;1039. doi: 10.1158/2159-8290.CD-15-0507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-15-0507</ArticleId>
            <ArticleId IdType="pmc">PMC4592441</ArticleId>
            <ArticleId IdType="pubmed">26382145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cretella D., Ravelli A., Fumarola C., La Monica S., Digiacomo G., Cavazzoni A., Alfieri R., Biondi A., Generali D., Bonelli M., et al. The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells. J. Exp. Clin. Cancer Res. 2018;37:72. doi: 10.1186/s13046-018-0741-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-018-0741-3</ArticleId>
            <ArticleId IdType="pmc">PMC5872523</ArticleId>
            <ArticleId IdType="pubmed">29587820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cretella D., Fumarola C., Bonelli M., Alfieri R., La Monica S., Digiacomo G., Cavazzoni A., Galetti M., Generali D., Petronini P.G. Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells. Sci. Rep. 2019;9:13014. doi: 10.1038/s41598-019-49484-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-019-49484-4</ArticleId>
            <ArticleId IdType="pmc">PMC6736958</ArticleId>
            <ArticleId IdType="pubmed">31506466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J., Zhou L., Zhao S., Dicker D.T., El-Deiry W.S. The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia. Cell Cycle. 2017;16:1193&#x2013;1200. doi: 10.1080/15384101.2017.1320005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15384101.2017.1320005</ArticleId>
            <ArticleId IdType="pmc">PMC5499912</ArticleId>
            <ArticleId IdType="pubmed">28486050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J.W., Gao P., Liu Y.C., Semenza G.L., Dang C.V. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol. Cell Biol. 2007;27:7381&#x2013;7393. doi: 10.1128/MCB.00440-07.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.00440-07</ArticleId>
            <ArticleId IdType="pmc">PMC2169056</ArticleId>
            <ArticleId IdType="pubmed">17785433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaira K., Serizawa M., Koh Y., Takahashi T., Hanaoka H., Oriuchi N., Endo M., Kondo H., Nakajima T., Yamamoto N. Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. Eur. J. Cancer. 2012;48:1244&#x2013;1254. doi: 10.1016/j.ejca.2012.01.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2012.01.016</ArticleId>
            <ArticleId IdType="pubmed">22330319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morrish F., Hockenbery D. MYC and mitochondrial biogenesis. Cold Spring Harb. Perspect Med. 2014;4:a014225. doi: 10.1101/cshperspect.a014225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a014225</ArticleId>
            <ArticleId IdType="pmc">PMC3996374</ArticleId>
            <ArticleId IdType="pubmed">24789872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morita M., Gravel S.P., Hulea L., Larsson O., Pollak M., St-Pierre J., Topisirovic I. mTOR coordinates protein synthesis, mitochondrial activity and proliferation. Cell Cycle. 2015;14:473&#x2013;480. doi: 10.4161/15384101.2014.991572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/15384101.2014.991572</ArticleId>
            <ArticleId IdType="pmc">PMC4615141</ArticleId>
            <ArticleId IdType="pubmed">25590164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morita M., Gravel S.P., Chenard V., Sikstrom K., Zheng L., Alain T., Gandin V., Avizonis D., Arguello M., Zakaria C., et al. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab. 2013;18:698&#x2013;711. doi: 10.1016/j.cmet.2013.10.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2013.10.001</ArticleId>
            <ArticleId IdType="pubmed">24206664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGuirk S., Audet-Delage Y., St-Pierre J. Metabolic Fitness and Plasticity in Cancer Progression. Trends Cancer. 2020;6:49&#x2013;61. doi: 10.1016/j.trecan.2019.11.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trecan.2019.11.009</ArticleId>
            <ArticleId IdType="pubmed">31952781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cavazzoni A., Bonelli M.A., Fumarola C., La Monica S., Airoud K., Bertoni R., Alfieri R.R., Galetti M., Tramonti S., Galvani E., et al. Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Lett. 2012;323:77&#x2013;87. doi: 10.1016/j.canlet.2012.03.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2012.03.034</ArticleId>
            <ArticleId IdType="pubmed">22484466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>La Monica S., Cretella D., Bonelli M., Fumarola C., Cavazzoni A., Digiacomo G., Flammini L., Barocelli E., Minari R., Naldi N., et al. Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines. J. Exp. Clin. Cancer Res. 2017;36:174. doi: 10.1186/s13046-017-0653-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-017-0653-7</ArticleId>
            <ArticleId IdType="pmc">PMC5716361</ArticleId>
            <ArticleId IdType="pubmed">29202823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cavazzoni A., Alfieri R.R., Carmi C., Zuliani V., Galetti M., Fumarola C., Frazzi R., Bonelli M., Bordi F., Lodola A., et al. Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines. Mol. Cancer Ther. 2008;7:361&#x2013;370. doi: 10.1158/1535-7163.MCT-07-0477.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-07-0477</ArticleId>
            <ArticleId IdType="pubmed">18281519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fumarola C., Caffarra C., La Monica S., Galetti M., Alfieri R.R., Cavazzoni A., Galvani E., Generali D., Petronini P.G., Bonelli M.A. Effects of sorafenib on energy metabolism in breast cancer cells: Role of AMPK-mTORC1 signaling. Breast Cancer Res. Treat. 2013;141:67&#x2013;78. doi: 10.1007/s10549-013-2668-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-013-2668-x</ArticleId>
            <ArticleId IdType="pubmed">23963659</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32687921</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0712</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>883</Volume>
            <PubDate>
              <Year>2020</Year>
              <Month>Sep</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>European journal of pharmacology</Title>
          <ISOAbbreviation>Eur J Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>α-Cyperone inhibits the proliferation of human cervical cancer HeLa cells via ROS-mediated PI3K/Akt/mTOR signaling pathway.</ArticleTitle>
        <Pagination>
          <StartPage>173355</StartPage>
          <MedlinePgn>173355</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejphar.2020.173355</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0014-2999(20)30447-7</ELocationID>
        <Abstract>
          <AbstractText>Cervical cancer is the fourth leading killer of female cancer patients worldwide. Each year more than half a million women are diagnosed with cervical cancer and the disease results in over 300, 000 deaths. α-Cyperone is known as the principal active ingredient in the Cyperus rotundus (Family: Cyperaceae). However, the effects of α-Cyperone on cancers, especially on cervical cancer, are yet to be explored. In the present study, the underlying mechanism of the anti-tumor activity of α-Cyperone against HeLa cells was investigated. The results showed that α-Cyperone inhibited proliferation and induced apoptosis in HeLa cells. Mechanistically, α-Cyperone promoted HeLa cells apoptosis via a mitochondrial apoptotic pathway, which was proved by increased level of intracellular reactive oxygen species (ROS) and upregulated expression of cytochrome c, cleaved caspase-3, PARP, and Bax. Further RNA-sequencing revealed α-Cyperone inhibited the activation of PI3K/Akt/mTOR signaling pathway in HeLa cells, which confirmed by PI3K inhibitor and agonist. The PI3K inhibitor (LY294002) synergized with α-Cyperone in arresting the growth of HeLa cells, whereas the PI3K agonist (IGF-1) abrogated such an effect. Interestingly, the expression of PD-L1 was attenuated by both α-Cyperone and LY294002, while the supplement of IGF-1 rescued the low expression of PD-L1. In conclusion, our results reveal that the inhibitory effect of α-Cyperone on HeLa cell growth is triggered via the ROS-mediated PI3K/Akt/mTOR signaling pathway and closely related to a decline in the PD-L1 expression.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2020 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pei</LastName>
            <ForeName>Xiao-Dong</ForeName>
            <Initials>XD</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou, 563100, PR China; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, PR China; College of Light Industry and Food Engineering, Guangxi University, Nanning, Guangxi, 530004, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yao</LastName>
            <ForeName>Hong-Liang</ForeName>
            <Initials>HL</Initials>
            <AffiliationInfo>
              <Affiliation>Guangdong Key Laboratory of Animal Conservation and Resource Utilization, Guangdong Public Laboratory of Wild Animal Conservation and Utilization, Drug Synthesis and Evaluation Center, Guangdong Institute of Applied Biological Resources, Guangdong, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Li-Qun</ForeName>
            <Initials>LQ</Initials>
            <AffiliationInfo>
              <Affiliation>Guangxi Key Laboratory of Chemistry and Engineering of Forest Products, Guangxi University for Nationalities, Nanning, 530006, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Guilin Medical University, Guilin, Guangxi, 541000, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Lan</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Sichuan Industrial Institute of Antibiotics, Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Chengdu University, 610106, Chengdu, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Jun-Song</ForeName>
            <Initials>JS</Initials>
            <AffiliationInfo>
              <Affiliation>Beijing Higher Institution Engineering Research Center of Food Additives and Ingredients, Beijing Technology and Business University-BTBU, Beijing, 100048, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xin-Yu</ForeName>
            <Initials>XY</Initials>
            <AffiliationInfo>
              <Affiliation>College of Light Industry and Food Engineering, Guangxi University, Nanning, Guangxi, 530004, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Zhi-Long</ForeName>
            <Initials>ZL</Initials>
            <AffiliationInfo>
              <Affiliation>College of Light Industry and Food Engineering, Guangxi University, Nanning, Guangxi, 530004, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Li-He</ForeName>
            <Initials>LH</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou, 563100, PR China; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, PR China; College of Light Industry and Food Engineering, Guangxi University, Nanning, Guangxi, 530004, PR China; Medical College, Guangxi University, Nanning, 530004, PR China; School of Basic Medical Science, YouJiang Medical University for Nationaties, No. 98 Chengxiang Road, Baise, Guangxi, 533000, PR China. Electronic address: jianglihe@gxu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>07</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Eur J Pharmacol</MedlineTA>
        <NlmUniqueID>1254354</NlmUniqueID>
        <ISSNLinking>0014-2999</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C423236">CD274 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009281">Naphthalenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.137</RegistryNumber>
          <NameOfSubstance UI="D058539">Phosphatidylinositol 3-Kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>ZL24SG1C2D</RegistryNumber>
          <NameOfSubstance UI="C583938">alpha-cyperone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059585" MajorTopicYN="N">G1 Phase Cell Cycle Checkpoints</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009281" MajorTopicYN="N">Naphthalenes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058539" MajorTopicYN="N">Phosphatidylinositol 3-Kinase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">HeLa cells</Keyword>
        <Keyword MajorTopicYN="N">PD-L1</Keyword>
        <Keyword MajorTopicYN="N">PI3K/Akt/mTOR signaling pathway</Keyword>
        <Keyword MajorTopicYN="N">&#x3b1;-Cyperone</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32687921</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ejphar.2020.173355</ArticleId>
        <ArticleId IdType="pii">S0014-2999(20)30447-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32668192</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1535-4989</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>63</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>American journal of respiratory cell and molecular biology</Title>
          <ISOAbbreviation>Am J Respir Cell Mol Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>TGF-β Promotes Metabolic Reprogramming in Lung Fibroblasts via mTORC1-dependent ATF4 Activation.</ArticleTitle>
        <Pagination>
          <StartPage>601</StartPage>
          <EndPage>612</EndPage>
          <MedlinePgn>601-612</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1165/rcmb.2020-0143OC</ELocationID>
        <Abstract>
          <AbstractText>Idiopathic pulmonary fibrosis is a fatal interstitial lung disease characterized by the TGF-β (transforming growth factor-β)-dependent differentiation of lung fibroblasts into myofibroblasts, which leads to excessive deposition of collagen proteins and progressive scarring. We have previously shown that synthesis of collagen by myofibroblasts requires de novo synthesis of glycine, the most abundant amino acid found in collagen protein. TGF-β upregulates the expression of the enzymes of the de novo serine-glycine synthesis pathway in lung fibroblasts; however, the transcriptional and signaling regulators of this pathway remain incompletely understood. Here, we demonstrate that TGF-β promotes accumulation of ATF4 (activating transcription factor 4), which is required for increased expression of the serine-glycine synthesis pathway enzymes in response to TGF-β. We found that induction of the integrated stress response (ISR) contributes to TGF-β-induced ATF4 activity; however, the primary driver of ATF4 downstream of TGF-β is activation of mTORC1 (mTOR Complex 1). TGF-β activates the PI3K-Akt-mTOR pathway, and inhibition of PI3K prevents activation of downstream signaling and induction of ATF4. Using a panel of mTOR inhibitors, we found that ATF4 activation is dependent on mTORC1, independent of mTORC2. Rapamycin, which incompletely and allosterically inhibits mTORC1, had no effect on TGF-β-mediated induction of ATF4; however, Rapalink-1, which specifically targets the kinase domain of mTORC1, completely inhibited ATF4 induction and metabolic reprogramming downstream of TGF-β. Our results provide insight into the mechanisms of metabolic reprogramming in myofibroblasts and clarify contradictory published findings on the role of mTOR inhibition in myofibroblast differentiation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>O'Leary</LastName>
            <ForeName>Erin M</ForeName>
            <Initials>EM</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Pulmonary and Critical Care Medicine, Department of Medicine, The University of Chicago, Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Yufeng</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Pulmonary and Critical Care Medicine, Department of Medicine, The University of Chicago, Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nigdelioglu</LastName>
            <ForeName>Recep</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Loyola University Medical Center, Maywood, Illinois; and.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Witt</LastName>
            <ForeName>Leah J</ForeName>
            <Initials>LJ</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Geriatrics and Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, Department of Medicine, The University of California San Francisco, San Francisco, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cetin-Atalay</LastName>
            <ForeName>Rengul</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Pulmonary and Critical Care Medicine, Department of Medicine, The University of Chicago, Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meliton</LastName>
            <ForeName>Angelo Y</ForeName>
            <Initials>AY</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Pulmonary and Critical Care Medicine, Department of Medicine, The University of Chicago, Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Woods</LastName>
            <ForeName>Parker S</ForeName>
            <Initials>PS</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Pulmonary and Critical Care Medicine, Department of Medicine, The University of Chicago, Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kimmig</LastName>
            <ForeName>Lucas M</ForeName>
            <Initials>LM</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Pulmonary and Critical Care Medicine, Department of Medicine, The University of Chicago, Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Kaitlyn A</ForeName>
            <Initials>KA</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Pulmonary and Critical Care Medicine, Department of Medicine, The University of Chicago, Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gökalp</LastName>
            <ForeName>Gizem A</ForeName>
            <Initials>GA</Initials>
            <AffiliationInfo>
              <Affiliation>Section of Pulmonary and Critical Care Medicine, Department of Medicine, The University of Chicago, Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mutlu</LastName>
            <ForeName>Gökhan M</ForeName>
            <Initials>GM</Initials>
            <Identifier Source="ORCID">0000-0002-2056-612X</Identifier>
            <AffiliationInfo>
              <Affiliation>Section of Pulmonary and Critical Care Medicine, Department of Medicine, The University of Chicago, Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hamanaka</LastName>
            <ForeName>Robert B</ForeName>
            <Initials>RB</Initials>
            <Identifier Source="ORCID">0000-0002-8909-356X</Identifier>
            <AffiliationInfo>
              <Affiliation>Section of Pulmonary and Critical Care Medicine, Department of Medicine, The University of Chicago, Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P01 HL144454</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL151680</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 HL007605</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U01 ES026718</GrantID>
            <Acronym>ES</Acronym>
            <Agency>NIEHS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Respir Cell Mol Biol</MedlineTA>
        <NlmUniqueID>8917225</NlmUniqueID>
        <ISSNLinking>1044-1549</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>145891-90-3</RegistryNumber>
          <NameOfSubstance UI="D051701">Activating Transcription Factor 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>452VLY9402</RegistryNumber>
          <NameOfSubstance UI="D012694">Serine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-34-5</RegistryNumber>
          <NameOfSubstance UI="D003094">Collagen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D000076222">Mechanistic Target of Rapamycin Complex 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>TE7660XO1C</RegistryNumber>
          <NameOfSubstance UI="D005998">Glycine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D051701" MajorTopicYN="N">Activating Transcription Factor 4</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003094" MajorTopicYN="N">Collagen</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005998" MajorTopicYN="N">Glycine</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006019" MajorTopicYN="N">Glycolysis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000076222" MajorTopicYN="N">Mechanistic Target of Rapamycin Complex 1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010101" MajorTopicYN="N">Oxygen Consumption</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012694" MajorTopicYN="N">Serine</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013312" MajorTopicYN="N">Stress, Physiological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">fibrosis</Keyword>
        <Keyword MajorTopicYN="N">glycolysis</Keyword>
        <Keyword MajorTopicYN="N">metabolism</Keyword>
        <Keyword MajorTopicYN="N">mitochondria</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32668192</ArticleId>
        <ArticleId IdType="pmc">PMC7605163</ArticleId>
        <ArticleId IdType="doi">10.1165/rcmb.2020-0143OC</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174:810&#x2013;816.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16809633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev. 2012;21:355&#x2013;361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23204124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18:1028&#x2013;1040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3405917</ArticleId>
            <ArticleId IdType="pubmed">22772564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol. 2014;9:157&#x2013;179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4116429</ArticleId>
            <ArticleId IdType="pubmed">24050627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheppard D. Transforming growth factor beta: a central modulator of pulmonary and airway inflammation and fibrosis. Proc Am Thorac Soc. 2006;3:413&#x2013;417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2658705</ArticleId>
            <ArticleId IdType="pubmed">16799084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest. 2007;132:1311&#x2013;1321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17934117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernard K, Logsdon NJ, Ravi S, Xie N, Persons BP, Rangarajan S, et al. Metabolic reprogramming is required for myofibroblast contractility and differentiation. J Biol Chem. 2015;290:25427&#x2013;25438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4646190</ArticleId>
            <ArticleId IdType="pubmed">26318453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie N, Tan Z, Banerjee S, Cui H, Ge J, Liu RM, et al. Glycolytic reprogramming in myofibroblast differentiation and lung fibrosis. Am J Respir Crit Care Med. 2015;192:1462&#x2013;1474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4731722</ArticleId>
            <ArticleId IdType="pubmed">26284610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nigdelioglu R, Hamanaka RB, Meliton AY, O&#x2019;Leary E, Witt LJ, Cho T, et al. Transforming growth factor (TGF)-&#x3b2; promotes de novo serine synthesis for collagen production. J Biol Chem. 2016;291:27239&#x2013;27251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5207151</ArticleId>
            <ArticleId IdType="pubmed">27836973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamanaka RB, Nigdelioglu R, Meliton AY, Tian Y, Witt LJ, O&#x2019;Leary E, et al. Inhibition of phosphoglycerate dehydrogenase attenuates bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2018;58:585&#x2013;593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5946329</ArticleId>
            <ArticleId IdType="pubmed">29019702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamanaka RB, O&#x2019;Leary EM, Witt LJ, Tian Y, G&#xf6;kalp GA, Meliton AY, et al. Glutamine metabolism is required for collagen protein synthesis in lung fibroblasts. Am J Respir Cell Mol Biol. 2019;61:597&#x2013;606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6827066</ArticleId>
            <ArticleId IdType="pubmed">30973753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amelio I, Cutruzzol&#xe1; F, Antonov A, Agostini M, Melino G. Serine and glycine metabolism in cancer. Trends Biochem Sci. 2014;39:191&#x2013;198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3989988</ArticleId>
            <ArticleId IdType="pubmed">24657017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Locasale JW. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer. 2013;13:572&#x2013;583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3806315</ArticleId>
            <ArticleId IdType="pubmed">23822983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wortel IMN, van der Meer LT, Kilberg MS, van Leeuwen FN. Surviving stress: modulation of ATF4-mediated stress responses in normal and malignant cells. Trends Endocrinol Metab. 2017;28:794&#x2013;806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5951684</ArticleId>
            <ArticleId IdType="pubmed">28797581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M, et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell. 2003;11:619&#x2013;633.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12667446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye J, Mancuso A, Tong X, Ward PS, Fan J, Rabinowitz JD, et al. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc Natl Acad Sci USA. 2012;109:6904&#x2013;6909.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3345000</ArticleId>
            <ArticleId IdType="pubmed">22509023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeNicola GM, Chen PH, Mullarky E, Sudderth JA, Hu Z, Wu D, et al. NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat Genet. 2015;47:1475&#x2013;1481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4721512</ArticleId>
            <ArticleId IdType="pubmed">26482881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park Y, Reyna-Neyra A, Philippe L, Thoreen CC. mTORC1 balances cellular amino acid supply with demand for protein synthesis through post-transcriptional control of ATF4. Cell Rep. 2017;19:1083&#x2013;1090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5811220</ArticleId>
            <ArticleId IdType="pubmed">28494858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ben-Sahra I, Hoxhaj G, Ricoult SJH, Asara JM, Manning BD. mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. Science. 2016;351:728&#x2013;733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4786372</ArticleId>
            <ArticleId IdType="pubmed">26912861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selvarajah B, Azuelos I, Plat&#xe9; M, Guillotin D, Forty EJ, Contento G, et al. mTORC1 amplifies the ATF4-dependent de novo serine-glycine pathway to supply glycine during TGF-&#x3b2;1-induced collagen biosynthesis. Sci Signal. 2019;12:eaav3048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6584619</ArticleId>
            <ArticleId IdType="pubmed">31113850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reina-Campos M, Linares JF, Duran A, Cordes T, L&#x2019;Hermitte A, Badur MG, et al. Increased serine and one-carbon pathway metabolism by PKC&#x3bb;/&#x3b9; deficiency promotes neuroendocrine prostate cancer. Cancer Cell. 2019;35:385&#x2013;400, e9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6424636</ArticleId>
            <ArticleId IdType="pubmed">30827887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamanaka RB, Mutlu GM. PFKFB3, a direct target of p63, is required for proliferation and inhibits differentiation in epidermal keratinocytes. J Invest Dermatol. 2017;137:1267&#x2013;1276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5441935</ArticleId>
            <ArticleId IdType="pubmed">28108301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun KA, Li Y, Meliton AY, Woods PS, Kimmig LM, Cetin-Atalay R, et al. Endogenous itaconate is not required for particulate matter-induced NRF2 expression or inflammatory response. Elife. 2020;9:e54877.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7185992</ArticleId>
            <ArticleId IdType="pubmed">32255424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woods PS, Kimmig LM, Meliton AY, Sun KA, Tian Y, O&#x2019;Leary EM, et al. Tissue-resident alveolar macrophages do not rely on glycolysis for LPS-induced inflammation. Am J Respir Cell Mol Biol. 2020;62:243&#x2013;255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6993551</ArticleId>
            <ArticleId IdType="pubmed">31469581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schw&#xf6;rer S, Berisa M, Violante S, Qin W, Zhu J, Hendrickson RC, et al. Proline biosynthesis is a vent for TGF&#x3b2;-induced mitochondrial redox stress. EMBO J. 2020;39:e103334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7156964</ArticleId>
            <ArticleId IdType="pubmed">32134147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D&#x2019;Aniello C, Fico A, Casalino L, Guardiola O, Di Napoli G, Cermola F, et al. A novel autoregulatory loop between the Gcn2-Atf4 pathway and (L)-Proline [corrected] metabolism controls stem cell identity. Cell Death Differ. 2015;22:1094&#x2013;1105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4572871</ArticleId>
            <ArticleId IdType="pubmed">25857264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adams CM. Role of the transcription factor ATF4 in the anabolic actions of insulin and the anti-anabolic actions of glucocorticoids. J Biol Chem. 2007;282:16744&#x2013;16753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17430894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han J, Back SH, Hur J, Lin YH, Gildersleeve R, Shan J, et al. ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death. Nat Cell Biol. 2013;15:481&#x2013;490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3692270</ArticleId>
            <ArticleId IdType="pubmed">23624402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korfei M, Ruppert C, Mahavadi P, Henneke I, Markart P, Koch M, et al. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;178:838&#x2013;846.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2566794</ArticleId>
            <ArticleId IdType="pubmed">18635891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lawson WE, Crossno PF, Polosukhin VV, Roldan J, Cheng DS, Lane KB, et al. Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. Am J Physiol Lung Cell Mol Physiol. 2008;294:L1119&#x2013;L1126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18390830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsai JC, Miller-Vedam LE, Anand AA, Jaishankar P, Nguyen HC, Renslo AR, et al. Structure of the nucleotide exchange factor eIF2B reveals mechanism of memory-enhancing molecule. Science. 2018;359:eaaq0939.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6120582</ArticleId>
            <ArticleId IdType="pubmed">29599213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derynck R, Budi EH. Specificity, versatility, and control of TGF-&#x3b2; family signaling. Sci Signal. 2019;12:eaav5183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6800142</ArticleId>
            <ArticleId IdType="pubmed">30808818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res. 2009;19:128&#x2013;139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2635127</ArticleId>
            <ArticleId IdType="pubmed">19114990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howell JJ, Ricoult SJ, Ben-Sahra I, Manning BD. A growing role for mTOR in promoting anabolic metabolism. Biochem Soc Trans. 2013;41:906&#x2013;912.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23863154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yecies JL, Manning BD. Transcriptional control of cellular metabolism by mTOR signaling. Cancer Res. 2011;71:2815&#x2013;2820.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3693464</ArticleId>
            <ArticleId IdType="pubmed">21487041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168:960&#x2013;976.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5394987</ArticleId>
            <ArticleId IdType="pubmed">28283069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choo AY, Blenis J. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle. 2009;8:567&#x2013;572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19197153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA. 2008;105:17414&#x2013;17419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2582304</ArticleId>
            <ArticleId IdType="pubmed">18955708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang SA, Pacold ME, Cervantes CL, Lim D, Lou HJ, Ottina K, et al. mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science. 2013;341:1236566.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3771538</ArticleId>
            <ArticleId IdType="pubmed">23888043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem. 2009;284:8023&#x2013;8032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2658096</ArticleId>
            <ArticleId IdType="pubmed">19150980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009;7:e38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2637922</ArticleId>
            <ArticleId IdType="pubmed">19209957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan Q, Aksoy O, Wong RA, Ilkhanizadeh S, Novotny CJ, Gustafson WC, et al. A kinase inhibitor targeted to mTORC1 drives regression in glioblastoma. Cancer Cell. 2017;31:424&#x2013;435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5386178</ArticleId>
            <ArticleId IdType="pubmed">28292440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodrik-Outmezguine VS, Okaniwa M, Yao Z, Novotny CJ, McWhirter C, Banaji A, et al. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature. 2016;534:272&#x2013;276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4902179</ArticleId>
            <ArticleId IdType="pubmed">27279227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lawson WE, Cheng DS, Degryse AL, Tanjore H, Polosukhin VV, Xu XC, et al. Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs. Proc Natl Acad Sci USA. 2011;108:10562&#x2013;10567.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3127925</ArticleId>
            <ArticleId IdType="pubmed">21670280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Wang Y, Pandupuspitasari NS, Wu G, Xiang X, Gong Q, et al. Endoplasmic reticulum stress, a new wrestler, in the pathogenesis of idiopathic pulmonary fibrosis. Am J Transl Res. 2017;9:722&#x2013;735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5340708</ArticleId>
            <ArticleId IdType="pubmed">28337301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burman A, Tanjore H, Blackwell TS. Endoplasmic reticulum stress in pulmonary fibrosis. Matrix Biol. 2018;68-69:355&#x2013;365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6392005</ArticleId>
            <ArticleId IdType="pubmed">29567124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woodcock HV, Maher TM. The treatment of idiopathic pulmonary fibrosis. F1000Prime Rep. 2014;6:16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3944742</ArticleId>
            <ArticleId IdType="pubmed">24669297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang W, Wei K, Ho L, Berry GJ, Jacobs SS, Chang CH, et al. A critical role for the mTORC2 pathway in lung fibrosis. PLoS One. 2014;9:e106155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4146613</ArticleId>
            <ArticleId IdType="pubmed">25162417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malouf MA, Hopkins P, Snell G, Glanville AR Everolimus in IPF Study Investigators. An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis. Respirology. 2011;16:776&#x2013;783.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21362103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D&#xfc;vel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell. 2010;39:171&#x2013;183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2946786</ArticleId>
            <ArticleId IdType="pubmed">20670887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 2008;8:224&#x2013;236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2593919</ArticleId>
            <ArticleId IdType="pubmed">18762023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng SC, Quintin J, Cramer RA, Shepardson KM, Saeed S, Kumar V, et al. mTOR- and HIF-1&#x3b1;-mediated aerobic glycolysis as metabolic basis for trained immunity. Science. 2014;345:1250684. [Published erratum appears in Science 346:aaa1503.]</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4226238</ArticleId>
            <ArticleId IdType="pubmed">25258083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol. 2002;22:7004&#x2013;7014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC139825</ArticleId>
            <ArticleId IdType="pubmed">12242281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature. 2007;450:736&#x2013;740.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18046414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parker MW, Rossi D, Peterson M, Smith K, Sikstr&#xf6;m K, White ES, et al. Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest. 2014;124:1622&#x2013;1635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3971953</ArticleId>
            <ArticleId IdType="pubmed">24590289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu F, Mih JD, Shea BS, Kho AT, Sharif AS, Tager AM, et al. Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J Cell Biol. 2010;190:693&#x2013;706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2928007</ArticleId>
            <ArticleId IdType="pubmed">20733059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marinkovi&#x107; A, Liu F, Tschumperlin DJ. Matrices of physiologic stiffness potently inactivate idiopathic pulmonary fibrosis fibroblasts. Am J Respir Cell Mol Biol. 2013;48:422&#x2013;430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3653602</ArticleId>
            <ArticleId IdType="pubmed">23258227</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32603819</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>08</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0631</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>256</Volume>
            <PubDate>
              <Year>2020</Year>
              <Month>Sep</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Life sciences</Title>
          <ISOAbbreviation>Life Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>3-Bromopyruvate ameliorates pulmonary arterial hypertension by improving mitochondrial metabolism.</ArticleTitle>
        <Pagination>
          <StartPage>118009</StartPage>
          <MedlinePgn>118009</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lfs.2020.118009</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0024-3205(20)30759-1</ELocationID>
        <Abstract>
          <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Abnormal mitochondrial metabolism is an essential factor for excessive proliferation of pulmonary artery smooth muscle cells (PASMCs), which drives the pathological process of pulmonary arterial hypertension (PAH). 3-Bromopyruvate (3-BrPA) is an effective glycolytic inhibitor that improves mitochondrial metabolism, thereby repressing anomalous cell proliferation.</AbstractText>
          <AbstractText Label="MAIN METHODS" NlmCategory="METHODS">An experimental PAH model was established by injection of monocrotaline (MCT) in male Sprague Dawley rats, following which rats were assigned to three groups: control, MCT, and 3-BrPA groups. Three days post injection of MCT, rats were treated with 3-BrPA or vehicle for 4&#xa0;weeks. At the end of the study, hemodynamic data were measured to confirm PAH condition. Indicators of pulmonary arterial and right ventricular (RV) remodeling as well as the proliferative ability of PASMCs were assayed. Additionally, mitochondrial morphology and function, and antiglycolytic and antiproliferative pathways and genes were analyzed.</AbstractText>
          <AbstractText Label="KEY FINDINGS" NlmCategory="RESULTS">Treatment with 3-BrPA effectively improved pulmonary vascular remodeling and right ventricular function, inhibited PASMC proliferation, and preserved mitochondrial morphology and function. Besides, 3-BrPA treatment inhibited the PI3K/AKT/mTOR pathway and regulated the expression of antiproliferative genes in PASMCs. However, bloody ascites, bloating, and cirrhosis of organs were observed in some 3-BrPA treated rats.</AbstractText>
          <AbstractText Label="SIGNIFICANCE" NlmCategory="CONCLUSIONS">3-BrPA acts as an important glycolytic inhibitor to improve energy metabolism and reverse the course of PAH. However, 3-BrPA is associated with side effects in MCT-induced rats, indicating that it should be caution in drug delivery dosage, and further studies are needed to evaluate this toxicological mechanism.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2020 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Yuan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Medicine, The Affiliated Zhuzhou Hospital Xiangya Medical College, Central South University, Zhuzhou, Hunan 412000, China. Electronic address: guoyuan8141@csu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Xiangyang</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Medicine, The Affiliated Zhuzhou Hospital Xiangya Medical College, Central South University, Zhuzhou, Hunan 412000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yibo</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ultrasound, The Affiliated Zhuzhou Hospital Xiangya Medical College, Central South University, Zhuzhou, Hunan 412000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qiu</LastName>
            <ForeName>Haihua</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Medicine, The Affiliated Zhuzhou Hospital Xiangya Medical College, Central South University, Zhuzhou, Hunan 412000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ouyang</LastName>
            <ForeName>Fan</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Medicine, The Affiliated Zhuzhou Hospital Xiangya Medical College, Central South University, Zhuzhou, Hunan 412000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Yi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Medicine, The Affiliated Zhuzhou Hospital Xiangya Medical College, Central South University, Zhuzhou, Hunan 412000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>06</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Life Sci</MedlineTA>
        <NlmUniqueID>0375521</NlmUniqueID>
        <ISSNLinking>0024-3205</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011773">Pyruvates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>63JMV04GRK</RegistryNumber>
          <NameOfSubstance UI="C017092">bromopyruvate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>73077K8HYV</RegistryNumber>
          <NameOfSubstance UI="D016686">Monocrotaline</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546845">mTOR protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.137</RegistryNumber>
          <NameOfSubstance UI="D058539">Phosphatidylinositol 3-Kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016686" MajorTopicYN="N">Monocrotaline</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032389" MajorTopicYN="N">Myocytes, Smooth Muscle</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058539" MajorTopicYN="N">Phosphatidylinositol 3-Kinase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081029" MajorTopicYN="N">Pulmonary Arterial Hypertension</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011651" MajorTopicYN="N">Pulmonary Artery</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011773" MajorTopicYN="N">Pyruvates</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">3-Bromopyruvate</Keyword>
        <Keyword MajorTopicYN="N">Mitochondrial metabolism</Keyword>
        <Keyword MajorTopicYN="N">Pulmonary arterial hypertension</Keyword>
        <Keyword MajorTopicYN="N">Pulmonary artery smooth muscle cells</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32603819</ArticleId>
        <ArticleId IdType="doi">10.1016/j.lfs.2020.118009</ArticleId>
        <ArticleId IdType="pii">S0024-3205(20)30759-1</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32503622</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>11</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1465-542X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jun</Month>
              <Day>05</Day>
            </PubDate>
          </JournalIssue>
          <Title>Breast cancer research : BCR</Title>
          <ISOAbbreviation>Breast Cancer Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Enhanced mitochondrial fission suppresses signaling and metastasis in triple-negative breast cancer.</ArticleTitle>
        <Pagination>
          <StartPage>60</StartPage>
          <MedlinePgn>60</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">60</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13058-020-01301-x</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Mitochondrial dynamics underlies malignant transformation, cancer progression, and response to treatment. Current research presents conflicting evidence for functions of mitochondrial fission and fusion in tumor progression. Here, we investigated how mitochondrial fission and fusion states regulate underlying processes of cancer progression and metastasis in triple-negative breast cancer (TNBC).</AbstractText>
          <AbstractText Label="METHODS">We enforced mitochondrial fission and fusion states through chemical or genetic approaches and measured migration and invasion of TNBC cells in 2D and 3D in vitro models. We also utilized kinase translocation reporters (KTRs) to identify single cell effects of mitochondrial state on signaling cascades, PI3K/Akt/mTOR and Ras/Raf/MEK/ERK, commonly activated in TNBC. Furthermore, we determined effects of fission and fusion states on metastasis, bone destruction, and signaling in mouse models of breast cancer.</AbstractText>
          <AbstractText Label="RESULTS">Enforcing mitochondrial fission through chemical or genetic approaches inhibited migration, invasion, and metastasis in TNBC. Breast cancer cells with predominantly fissioned mitochondria exhibited reduced activation of Akt and ERK both in vitro and in mouse models of breast cancer. Treatment with leflunomide, a potent activator of mitochondrial fusion proteins, overcame inhibitory effects of fission on migration, signaling, and metastasis. Mining existing datasets for breast cancer revealed that increased expression of genes associated with mitochondrial fission correlated with improved survival in human breast cancer.</AbstractText>
          <AbstractText Label="CONCLUSIONS">In TNBC, mitochondrial fission inhibits cellular processes and signaling pathways associated with cancer progression and metastasis. These data suggest that therapies driving mitochondrial fission may benefit patients with breast cancer.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Humphries</LastName>
            <ForeName>Brock A</ForeName>
            <Initials>BA</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Molecular Imaging, Department of Radiology, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cutter</LastName>
            <ForeName>Alyssa C</ForeName>
            <Initials>AC</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Molecular Imaging, Department of Radiology, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Buschhaus</LastName>
            <ForeName>Johanna M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Molecular Imaging, Department of Radiology, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Yu-Chih</ForeName>
            <Initials>YC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Electrical Engineering and Computer Science, University of Michigan, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Forbes Institute for Cancer Discovery, University of Michigan, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qyli</LastName>
            <ForeName>Tonela</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Molecular Imaging, Department of Radiology, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Palagama</LastName>
            <ForeName>Dilrukshika S W</ForeName>
            <Initials>DSW</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Molecular Imaging, Department of Radiology, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eckley</LastName>
            <ForeName>Samantha</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Unit for Laboratory Medicine, University of Michigan, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Robison</LastName>
            <ForeName>Tanner H</ForeName>
            <Initials>TH</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Molecular Imaging, Department of Radiology, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bevoor</LastName>
            <ForeName>Avinash</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Molecular Imaging, Department of Radiology, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chiang</LastName>
            <ForeName>Benjamin</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Molecular Imaging, Department of Radiology, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Haley</LastName>
            <ForeName>Henry R</ForeName>
            <Initials>HR</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Molecular Imaging, Department of Radiology, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sahoo</LastName>
            <ForeName>Saswat</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Electrical Engineering and Computer Science, University of Michigan, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Spinosa</LastName>
            <ForeName>Phillip C</ForeName>
            <Initials>PC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Neale</LastName>
            <ForeName>Dylan B</ForeName>
            <Initials>DB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boppisetti</LastName>
            <ForeName>Jagadish</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Molecular Imaging, Department of Radiology, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sahoo</LastName>
            <ForeName>Debashis</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Department of Computer Science and Engineering, Jacob's School of Engineering, Rebecca and John Moore Comprehensive Cancer Center, University of California San Diego, La Jolla, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ghosh</LastName>
            <ForeName>Pradipta</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Department of Cellular and Molecular Medicine, Rebecca and John Moore Comprehensive Cancer Center, Veterans Affairs Medical Center, University of California San Diego, La Jolla, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lahann</LastName>
            <ForeName>Joerg</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Biointerfaces Institute, Departments of Chemical Engineering, Materials Science and Engineering, Biomedical Engineering, and Macromolecular Science and Engineering, University of Michigan, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ross</LastName>
            <ForeName>Brian D</ForeName>
            <Initials>BD</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Molecular Imaging, Department of Radiology, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yoon</LastName>
            <ForeName>Eusik</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Electrical Engineering and Computer Science, University of Michigan, Ann Arbor, MI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luker</LastName>
            <ForeName>Kathryn E</ForeName>
            <Initials>KE</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Molecular Imaging, Department of Radiology, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luker</LastName>
            <ForeName>Gary D</ForeName>
            <Initials>GD</Initials>
            <Identifier Source="ORCID">0000-0001-6832-2581</Identifier>
            <AffiliationInfo>
              <Affiliation>Center for Molecular Imaging, Department of Radiology, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA. gluker@med.umich.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Engineering, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA. gluker@med.umich.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA. gluker@med.umich.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>PF-18-236-01-CCG</GrantID>
            <Agency>American Cancer Society</Agency>
            <Country>International</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA238042</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA238023</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U01 CA210152</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA196018</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>DGE 1256260</GrantID>
            <Agency>National Science Foundation</Agency>
            <Country>International</Country>
          </Grant>
          <Grant>
            <GrantID>R37 CA222563</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R33 CA225549</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R50 CA221807</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>06</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Breast Cancer Res</MedlineTA>
        <NlmUniqueID>100927353</NlmUniqueID>
        <ISSNLinking>1465-5411</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 4.1.1.-</RegistryNumber>
          <NameOfSubstance UI="D002262">Carboxy-Lyases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 4.1.1.65</RegistryNumber>
          <NameOfSubstance UI="C022353">phosphatidylserine decarboxylase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>G162GK9U4W</RegistryNumber>
          <NameOfSubstance UI="D000077339">Leflunomide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001859" MajorTopicYN="N">Bone Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002262" MajorTopicYN="N">Carboxy-Lyases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002471" MajorTopicYN="N">Cell Transformation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077339" MajorTopicYN="N">Leflunomide</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016688" MajorTopicYN="N">Mice, Inbred NOD</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063154" MajorTopicYN="N">Mitochondrial Dynamics</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Akt</Keyword>
        <Keyword MajorTopicYN="N">ERK</Keyword>
        <Keyword MajorTopicYN="N">Fluorescence microscopy</Keyword>
        <Keyword MajorTopicYN="N">Metastasis</Keyword>
        <Keyword MajorTopicYN="N">Mitochondrial fission</Keyword>
        <Keyword MajorTopicYN="N">Mitochondrial fusion</Keyword>
        <Keyword MajorTopicYN="N">Triple-negative breast cancer</Keyword>
      </KeywordList>
      <CoiStatement>G.D.L. serves as a consultant and receives research funding from Polyphor. All other authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32503622</ArticleId>
        <ArticleId IdType="pmc">PMC7275541</ArticleId>
        <ArticleId IdType="doi">10.1186/s13058-020-01301-x</ArticleId>
        <ArticleId IdType="pii">10.1186/s13058-020-01301-x</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Vyas S, Zaganjor E, Haigis MC. Mitochondria and cancer. Cell. 2016;166(3):555&#x2013;566.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5036969</ArticleId>
            <ArticleId IdType="pubmed">27471965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zong WX, Rabinowitz JD, White E. Mitochondria and cancer. Mol Cell. 2016;61(5):667&#x2013;676.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4779192</ArticleId>
            <ArticleId IdType="pubmed">26942671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. Science. 2012;337:1062&#x2013;1065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4762028</ArticleId>
            <ArticleId IdType="pubmed">22936770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Westermann B. Bioenergetic role of mitochondrial fusion and fission. Biochim Biophys Acta. 2012;1817(10):1833&#x2013;1838.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22409868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liesa M, Shirihai OS. Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. Cell Metab. 2013;17(4):491&#x2013;506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5967396</ArticleId>
            <ArticleId IdType="pubmed">23562075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Westermann B. Mitochondrial fusion and fission in cell life and death. Nat Rev Mol Cell Biol. 2010;11:872&#x2013;884.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21102612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soubannier V, McBride HM. Positioning mitochondrial plasticity within cellular signaling cascades. Biochim Biophys Acta. 2009;1793(1):154&#x2013;170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18694785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kharbanda S, Saxena S, Yosida K, Pandey P, Kaneki M, Wang Q, et al. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-xL in response to DNA damage. J Biol Chem. 2000;275:322&#x2013;327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10617621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baines CP, Zhang J, Wang G-W, Zheng Y-T, Xiu JX, Cardwell EM, et al. Mitochondrial PKC&#x3b5; and MAPK form signaling modules in the murine heart. Circ Res. 2002;90(4):390&#x2013;397.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11884367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rasola A, Sciacovelli M, Chiara F, Pantic B, Brusilow WS, Bernardi P. Activation of mitochondrial ERK protects cancer cells from death through inhibition of the permeability transition. Proc Natl Acad Sci U S A. 2010;107(2):726&#x2013;731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2818893</ArticleId>
            <ArticleId IdType="pubmed">20080742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bijur GN, Jope RS. Rapid accumulation of Akt in mitochondria following phosphatidylinositol 3-kinase activation. J Neurochem. 2003;87:1427&#x2013;1435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2040497</ArticleId>
            <ArticleId IdType="pubmed">14713298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chae YC, Vaira V, Caino MC, Tang HY, Seo JH, Kossenkov AV, et al. Mitochondrial Akt regulation of hypoxic tumor reprogramming. Cancer Cell. 2016;30(2):257&#x2013;272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5131882</ArticleId>
            <ArticleId IdType="pubmed">27505672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Picard M, Burelle Y. Mitochondria: starving to reach quorum?: insight into the physiological purpose of mitochondrial fusion. Bioessays. 2012;34(4):272&#x2013;274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22290641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallace DC, Fan W. Energetics, epigenetics, mitochondrial genetics. Mitochondrion. 2010;10(1):12&#x2013;31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3245717</ArticleId>
            <ArticleId IdType="pubmed">19796712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen YC, Humphries B, Brien R, Gibbons AE, Chen YT, Qyli T, et al. Functional isolation of tumor-initiating cells using microfluidic-based migration identifies phosphatidylserine decarboxylase as a key regulator. Sci Rep. 2018;8(1):244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5762897</ArticleId>
            <ArticleId IdType="pubmed">29321615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitay BM, McCormack R, Wang Y, Tsoulfas P, Zhai RG. Mislocalization of neuronal mitochondria reveals regulation of Wallerian degeneration and NMNAT/WLD(S)-mediated axon protection independent of axonal mitochondria. Hum Mol Genet. 2013;22(8):1601&#x2013;1614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3657477</ArticleId>
            <ArticleId IdType="pubmed">23314018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Humphries BA, Buschhaus JM, Chen YC, Haley HR, Qyli T, Chiang B, et al. Plasminogen activator inhibitor 1 (PAI1) promotes actin cytoskeleton reorganization and glycolytic metabolism in triple-negative breast cancer. Mol Cancer Res. 2019;17:1142&#x2013;1154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6497540</ArticleId>
            <ArticleId IdType="pubmed">30718260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spinosa PC, Humphries BA, Lewin Mejia D, Buschhaus JM, Linderman JJ, Luker GD, et al. Short-term cellular memory tunes the signaling responses of the chemokine receptor CXCR4. Sci Signal. 2019;12:eaaw4204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7059217</ArticleId>
            <ArticleId IdType="pubmed">31289212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frank S, Gaume B, Bergmann-Leitner ES, Leitner WW, Robert EG, Catez F, et al. The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. Dev Cell. 2001;1:515&#x2013;525.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11703942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 2004;64:8604&#x2013;8612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15574767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cavnar SP, Rickelmann AD, Meguiar KF, Xiao A, Dosch J, Leung BM, et al. Modeling selective elimination of quiescent cancer cells from bone marrow. Neoplasia. 2015;17(8):625&#x2013;633.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4674483</ArticleId>
            <ArticleId IdType="pubmed">26408255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luker KE, Mihalko LA, Schmidt BT, Lewin SA, Ray P, Shcherbo D, et al. In vivo imaging of ligand receptor binding with Gaussia luciferase complementation. Nat Med. 2011;18(1):172&#x2013;177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3253890</ArticleId>
            <ArticleId IdType="pubmed">22138753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park KS, Lee HY, Lee SY, Kim MK, Kim SD, Kim JM, et al. Lysophosphatidylethanolamine stimulates chemotactic migration and cellular invasion in SK-OV3 human ovarian cancer cells: involvement of pertussis toxin-sensitive G-protein coupled receptor. FEBS Lett. 2007;581(23):4411&#x2013;4416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17719584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jordahl S, Solorio L, Neale DB, McDermott S, Jordahl JH, Fox A, et al. Engineered fibrillar fibronectin networks as three-dimensional tissue scaffolds. Adv Mater. 2019;31(46):e1904580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6851443</ArticleId>
            <ArticleId IdType="pubmed">31565823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911&#x2013;917.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13671378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao H, Ma L, Zhou J, Mao Z, Gao C, Shen J. Fabrication and physical and biological properties of fibrin gel derived from human plasma. Biomed Mater. 2008;3(1):015001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18458488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Regot S, Hughey JJ, Bajar BT, Carrasco S, Covert MW. High-sensitivity measurements of multiple kinase activities in live single cells. Cell. 2014;157:1724&#x2013;1734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4097317</ArticleId>
            <ArticleId IdType="pubmed">24949979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maryu G, Matsuda M, Aoki K. Multiplexed fluorescence imaging of ERK and Akt activities and cell-cycle progression. Cell Struct Funct. 2016;41:81&#x2013;92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27247077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ling H, Okada K. An efficient Earth Mover&#x2019;s Distance algorithm for robust histogram comparison. IEEE Trans Pattern Anal Mach Intell. 2007;29(5):840&#x2013;853.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17356203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orlova DY, Zimmerman N, Meehan S, Meehan C, Waters J, Ghosn EE, et al. Earth mover&#x2019;s distance (EMD): a true metric for comparing biomarker expression levels in cell populations. PLoS One. 2016;11(3):e0151859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4805242</ArticleId>
            <ArticleId IdType="pubmed">27008164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Owen DM, Rentero C, Magenau A, Abu-Siniyeh A, Gaus K. Quantitative imaging of membrane lipid order in cells and organisms. Nat Protoc. 2011;7(1):24&#x2013;35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22157973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bi J, Ichu TA, Zanca C, Yang H, Zhang W, Gu Y, et al. Oncogene amplification in growth factor signaling pathways renders cancers dependent on membrane lipid remodeling. Cell Metab. 2019;30(3):525&#x2013;538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6742496</ArticleId>
            <ArticleId IdType="pubmed">31303424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stacer AC, Fenner J, Cavnar SP, Xiao A, Zhao S, Chang SL, et al. Endothelial CXCR7 regulates breast cancer metastasis. Oncogene. 2016;35(13):1716&#x2013;1724.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4486335</ArticleId>
            <ArticleId IdType="pubmed">26119946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ray P, Stacer AC, Fenner J, Cavnar SP, Meguiar K, Brown M, et al. CXCL12-&#x3b3; in primary tumors drives breast cancer metastasis. Oncogene. 2014;34(16):2043&#x2013;2051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4261050</ArticleId>
            <ArticleId IdType="pubmed">24909174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haley HR, Shen N, Qyli T, Buschhaus JM, Pirone M, Luker KE, et al. Enhanced bone metastases in skeletally immature mice. Tomography. 2018;4(2):84&#x2013;93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6035009</ArticleId>
            <ArticleId IdType="pubmed">29984313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brisset JC, Hoff BA, Chenevert TL, Jacobson JA, Boes JL, Galban S, et al. Integrated multimodal imaging of dynamic bone-tumor alterations associated with metastatic prostate cancer. PLoS One. 2015;10(4):e0123877.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4393258</ArticleId>
            <ArticleId IdType="pubmed">25859981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng YH, Chen YC, Lin E, Brien R, Jung S, Chen YT, et al. Hydro-Seq enables contamination-free high-throughput single-cell RNA-sequencing for circulating tumor cells. Nat Commun. 2019;10(1):2163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6520360</ArticleId>
            <ArticleId IdType="pubmed">31092822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature. 2009;459(7249):1005&#x2013;1009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2698953</ArticleId>
            <ArticleId IdType="pubmed">19421193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer to lung. Nature. 2005;436:518&#x2013;524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1283098</ArticleId>
            <ArticleId IdType="pubmed">16049480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Klijn JGM, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365(9460):671&#x2013;679.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15721472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sahoo D, Dill DL, Tibshirani R, Plevritis SK. Extracting binary signals from microarray time-course data. Nucleic Acids Res. 2007;35(11):3705&#x2013;3712.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1920252</ArticleId>
            <ArticleId IdType="pubmed">17517782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zimmerberg J, Kozlov MM. How proteins produce cellular membrane curvature. Nat Rev Mol Cell Biol. 2006;7(1):9&#x2013;19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16365634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tasseva G, Bai HD, Davidescu M, Haromy A, Michelakis E, Vance JE. Phosphatidylethanolamine deficiency in mammalian mitochondria impairs oxidative phosphorylation and alters mitochondrial morphology. J Biol Chem. 2013;288(6):4158&#x2013;4173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3567666</ArticleId>
            <ArticleId IdType="pubmed">23250747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flis VV, Daum G. Lipid transport between the endoplasmic reticulum and mitochondria. Cold Spring Harb Perspect Biol. 2013;5(6):a013235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3660828</ArticleId>
            <ArticleId IdType="pubmed">23732475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miret-Casals L, Sebastian D, Brea J, Rico-Leo EM, Palacin M, Fernandez-Salguero PM, et al. Identification of new activators of mitochondrial fusion reveals a link between mitochondrial morphology and pyrimidine metabolism. Cell Chem Biol. 2018;25(3):268&#x2013;278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29290623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu M, Nguyen ND, Huang Y, Lin D, Fujimoto TN, Molkentine JM, et al. Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. JCI Insight. 2019;5(16):e126915.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6777817</ArticleId>
            <ArticleId IdType="pubmed">31335325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kashatus JA, Nascimento A, Myers LJ, Sher A, Byrne FL, Hoehn KL, et al. Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth. Mol Cell. 2015;57(3):537&#x2013;551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4393013</ArticleId>
            <ArticleId IdType="pubmed">25658205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prieto J, Leon M, Ponsoda X, Sendra R, Bort R, Ferrer-Lorente R, et al. Early ERK1/2 activation promotes DRP1-dependent mitochondrial fission necessary for cell reprogramming. Nat Commun. 2016;7:11124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4821885</ArticleId>
            <ArticleId IdType="pubmed">27030341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim DI, Lee KH, Gabr AA, Choi GE, Kim JS, Ko SH, et al. Abeta-induced Drp1 phosphorylation through Akt activation promotes excessive mitochondrial fission leading to neuronal apoptosis. Biochim Biophys Acta. 2016;1863(11):2820&#x2013;2834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27599716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pike LJ. Lipid rafts: bringing order to chaos. J Lipid Res. 2003;44(4):655&#x2013;667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12562849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;45(10):1113&#x2013;1120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3919969</ArticleId>
            <ArticleId IdType="pubmed">24071849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Emoto K, Kobayashi T, Yamaji A, Aizawa H, Yahara I, Inoue K, et al. Redistribution of phosphatidylethanolamine at the cleavage furrow of dividing cells during cytokinesis. Proc Natl Acad Sci U S A. 1996;93:12867&#x2013;12872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC24012</ArticleId>
            <ArticleId IdType="pubmed">8917511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Emoto K, Umeda M. An essential role for a membrane lipid in cytokinesis. Regulation of contractile ring disassembly by redistribution of phosphatidylethanolamine. J Cell Biol. 2000;149(6):1215&#x2013;1224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2175113</ArticleId>
            <ArticleId IdType="pubmed">10851019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chinni SR, Yamamoto H, Dong Z, Sabbota A, Bonfil RD, Cher ML. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res. 2008;6(3):446&#x2013;457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3842603</ArticleId>
            <ArticleId IdType="pubmed">18337451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irwin ME, Mueller KL, Bohin N, Ge Y, Boerner JL. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol. 2011;226(9):2316&#x2013;2328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3103760</ArticleId>
            <ArticleId IdType="pubmed">21660955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vance JE. Phospholipid synthesis and transport in mammalian cells. Traffic. 2015;16(1):1&#x2013;18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25243850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu L, Zhu Y, Lin X, Li Y, Cui K, Prochownik EV, et al. Amplification of glyceronephosphate O-acyltransferase and recruitment of USP30 stabilize DRP1 to promote hepatocarcinogenesis. Cancer Res. 2018;78(20):5808&#x2013;5819.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30143522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagdas S, Kashatus JA, Nascimento A, Hussain SS, Trainor RE, Pollock SR, et al. Drp1 promotes KRas-driven metabolic changes to drive pancreatic tumor growth. Cell Rep. 2019;28(7):1845&#x2013;1859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6711191</ArticleId>
            <ArticleId IdType="pubmed">31412251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung KP, Hsu CL, Fan LC, Huang Z, Bhatia D, Chen YJ, et al. Mitofusins regulate lipid metabolism to mediate the development of lung fibrosis. Nat Commun. 2019;10(1):3390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6662701</ArticleId>
            <ArticleId IdType="pubmed">31358769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao J, Zhang J, Yu M, Xie Y, Huang Y, Wolff DW, et al. Mitochondrial dynamics regulates migration and invasion of breast cancer cells. Oncogene. 2013;32(40):4814&#x2013;4824.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3911914</ArticleId>
            <ArticleId IdType="pubmed">23128392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Q, Wu Q, Horbinski CM, Flavahan WA, Yang K, Zhou W, et al. Mitochondrial control by DRP1 in brain tumor initiating cells. Nat Neurosci. 2015;18(4):501&#x2013;510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4376639</ArticleId>
            <ArticleId IdType="pubmed">25730670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu MJ, Chen YS, Kim MR, Chang CC, Gampala S, Zhang Y, et al. Epithelial-mesenchymal transition directs stem cell polarity via regulation of mitofusin. Cell Metab. 2019;29(4):993&#x2013;1002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30527740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caino MC, Ghosh JC, Chae YC, Vaira V, Rivadeneira DB, Faversani A, et al. PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion. Proc Natl Acad Sci U S A. 2015;112(28):8638&#x2013;8643.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4507184</ArticleId>
            <ArticleId IdType="pubmed">26124089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rivadeneira DB, Caino MC, Seo JH, Angelin A, Wallace DC, Languino LR, et al. Survivin promotes oxidative phosphorylation, subcellular mitochondrial repositioning, and tumor cell invasion. Sci Signal. 2015;8:ra80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4539531</ArticleId>
            <ArticleId IdType="pubmed">26268608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luchsinger LL, de Almeida MJ, Corrigan DJ, Mumau M, Snoeck HW. Mitofusin 2 maintains haematopoietic stem cells with extensive lymphoid potential. Nature. 2016;529(7587):528&#x2013;531.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5106870</ArticleId>
            <ArticleId IdType="pubmed">26789249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong X, Cui P, Cai Y, Wang L, He X, Long P, et al. Mitochondrial dynamics is critical for the full pluripotency and embryonic developmental potential of pluripotent stem cells. Cell Metab. 2019;29(4):979&#x2013;992.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30527743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LeBleu VS, O'Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC, et al. PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 2014;16(10):992&#x2013;1003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4369153</ArticleId>
            <ArticleId IdType="pubmed">25241037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serasinghe MN, Wieder SY, Renault TT, Elkholi R, Asciolla JJ, Yao JL, et al. Mitochondrial division is requisite to RAS-induced transformation and targeted by oncogenic MAPK pathway inhibitors. Mol Cell. 2015;57(3):521&#x2013;536.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4320323</ArticleId>
            <ArticleId IdType="pubmed">25658204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pyakurel A, Savoia C, Hess D, Scorrano L. Extracellular regulated kinase phosphorylates mitofusin 1 to control mitochondrial morphology and apoptosis. Mol Cell. 2015;58(2):244&#x2013;254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4405354</ArticleId>
            <ArticleId IdType="pubmed">25801171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graves JA, Wang Y, Sims-Lucas S, Cherok E, Rothermund K, Branca MF, et al. Mitochondrial structure, function and dynamics are temporally controlled by c-Myc. PLoS One. 2012;7(5):e37699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3357432</ArticleId>
            <ArticleId IdType="pubmed">22629444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>von Eyss B, Jaenicke LA, Kortlever RM, Royla N, Wiese KE, Letschert S, et al. A MYC-driven change in mitochondrial dynamics limits YAP/TAZ function in mammary epithelial cells and breast cancer. Cancer Cell. 2015;28(6):743&#x2013;757.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26678338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773(8):1263&#x2013;1284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2696318</ArticleId>
            <ArticleId IdType="pubmed">17126425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017;169(3):381&#x2013;405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5546324</ArticleId>
            <ArticleId IdType="pubmed">28431241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Betz C, Stracka D, Prescianotto-Baschong C, Frieden M, Demaurex N, Hall MN. Feature article: mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology. Proc Natl Acad Sci U S A. 2013;110(31):12526&#x2013;12534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3732980</ArticleId>
            <ArticleId IdType="pubmed">23852728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Betz C, Hall MN. Where is mTOR and what is it doing there? J Cell Biol. 2013;203(4):563&#x2013;574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3840941</ArticleId>
            <ArticleId IdType="pubmed">24385483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Brito OM, Scorrano L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature. 2008;456(7222):605&#x2013;610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19052620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naon D, Zaninello M, Giacomello M, Varanita T, Grespi F, Lakshminaranayan S, et al. Critical reappraisal confirms that Mitofusin 2 is an endoplasmic reticulum-mitochondria tether. Proc Natl Acad Sci U S A. 2016;113(40):11249&#x2013;11254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5056088</ArticleId>
            <ArticleId IdType="pubmed">27647893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merkwirth C, Langer T. Mitofusin 2 builds a bridge between ER and mitochondria. Cell. 2008;135(7):1165&#x2013;1167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19109886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galli S, Jahn O, Hitt R, Hesse D, Opitz L, Plessmann U, et al. A new paradigm for MAPK: structural interactions of hERK1 with mitochondria in HeLa cells. PLoS One. 2009;4(10):e7541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2760858</ArticleId>
            <ArticleId IdType="pubmed">19847302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Helfenberger KE, Villalba NM, Buchholz B, Boveris A, Poderoso JJ, Gelpi RJ, et al. Subcellular distribution of ERK phosphorylation in tyrosine and threonine depends on redox status in murine lung cells. PLoS One. 2018;13(2):e0193022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5831038</ArticleId>
            <ArticleId IdType="pubmed">29489891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Casar B, Pinto A, Crespo P. Essential role of ERK dimers in the activation of cytoplasmic but not nuclear substrates by ERK-scaffold complexes. Mol Cell. 2008;31(5):708&#x2013;721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18775330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Good MC, Zalatan JG, Lim WA. Scaffold proteins: hubs for controlling the flow of cellular information. Science. 2011;332:680&#x2013;686.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3117218</ArticleId>
            <ArticleId IdType="pubmed">21551057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol. 2005;6(11):827&#x2013;837.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16227978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallace DC. The epigenome and the mitochondrion: bioenergetics and the environment [corrected] Genes Dev. 2010;24(15):1571&#x2013;1573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2912552</ArticleId>
            <ArticleId IdType="pubmed">20679390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye C, Sutter BM, Wang Y, Kuang Z, Tu BP. A metabolic function for phospholipid and histone methylation. Mol Cell. 2017;66(2):180&#x2013;193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5482412</ArticleId>
            <ArticleId IdType="pubmed">28366644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sotgia F, Whitaker-Menezes D, Martinez-Outschoorn UE, Flomenberg N, Birbe RC, Witkiewicz AK, et al. Mitochondrial metabolism in cancer metastasis: visualizing tumor cell mitochondria and the &#x201c;reverse Warburg effect&#x201d; in positive lymph node tissue. Cell Cycle. 2012;11(7):1445&#x2013;1454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3350881</ArticleId>
            <ArticleId IdType="pubmed">22395432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whitaker-Menezes D, Martinez-Outschoorn UE, Flomenberg N, Birbe RC, Witkiewicz AK, Howell A, et al. Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. Cell Cycle. 2011;10(23):4047&#x2013;4064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3272287</ArticleId>
            <ArticleId IdType="pubmed">22134189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee K-m, Giltnane JM, Balko JM, Schwarz LJ, Guerrero-Zotano AL, Hutchinson KE, et al. MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metab. 2017;26(4):633&#x2013;47.e7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5650077</ArticleId>
            <ArticleId IdType="pubmed">28978427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Senyilmaz-Tiebe D, Pfaff DH, Virtue S, Schwarz KV, Fleming T, Altamura S, et al. Dietary stearic acid regulates mitochondria in vivo in humans. Nat Commun. 2018;9(1):3129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6081440</ArticleId>
            <ArticleId IdType="pubmed">30087348</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32446927</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-7573</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>259</Volume>
            <PubDate>
              <Year>2020</Year>
              <Month>Sep</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of ethnopharmacology</Title>
          <ISOAbbreviation>J Ethnopharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Anti-breast cancer and toxicity studies of total secondary saponin from Anemone raddeana Rhizome on MCF-7 cells via ROS generation and PI3K/AKT/mTOR inactivation.</ArticleTitle>
        <Pagination>
          <StartPage>112984</StartPage>
          <MedlinePgn>112984</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jep.2020.112984</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0378-8741(20)31138-7</ELocationID>
        <Abstract>
          <AbstractText Label="ETHNOPHARMACOLOGICAL RELEVANCE" NlmCategory="BACKGROUND">The rhizome of Anemone raddeana Regel (A. raddeana) is a famous traditional Chinese medicine (TCM) recorded in Chinese Pharmacopoeia for the treatment of carbuncle and swelling. Carbuncle swollen is an explanation of tumor in the theory of TCM and softening and resolving hard mass effects are one of the important pharmacological activities of A. raddeana.</AbstractText>
          <AbstractText Label="AIM OF THE STUDY" NlmCategory="OBJECTIVE">We investigated the potential anti-breast cancer effect and toxicological properties of alkali-ethanol extract from A. raddeana, namely total secondary saponin (TSS).</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Anti-proliferative effect of total saponin of A. raddeana (ATS) and TSS were tested using MTT assay. Hoechst staining, flow cytometry analysis, DCFH-DA fluorescence microscopy and western blot were carried out to evaluate the mechanisms of action of TSS. The potential anti-breast cancer activity and toxicological properties of TSS were tested in vivo.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">ATS and TSS could inhibit the proliferation of A549, HepG2, MCF-7, MDA-MB-231 and SKBr-3&#xa0;cells, especially for MCF-7&#xa0;cells. Flow cytometry analysis revealed that TSS (10, 12 and 15&#xa0;&#x3bc;g/ml) could induce cell cycle arrest on G0/G1 phase and promote apoptosis of MCF-7&#xa0;cells. TSS could increase Bax/Bcl-2 ratio, elevate cytochrome c levels in cytosol and activate caspase-3/9. In addition, TSS also induced ROS generation and inactivated PI3K/AKT/mTOR pathway which may involved in the mitochondrial dysfunction of MCF-7&#xa0;cells. TSS showed slight toxic at the dosage of 100 and 200&#xa0;mg/kg by oral administration without any toxic potential for 28 days. TSS (50, 100 and 200&#xa0;mg/kg) showed significant inhibitory effect on growth of transplanted tumor in mice. At last, twenty-three C-3 monosaccharide oleanane-type triterpene saponins were tentatively identified, which may contributed to the anti-cancer activity of TSS.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study demonstrated that TSS exhibited anti-proliferative and pro-apoptosis activities on MCF-7&#xa0;cells via ROS-mediated activation of mitochondrial apoptosis pathway. TSS might be used as chemotherapeutic agent for the treatment of breast cancer with relatively low toxicity.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2020 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Dandan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110006, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Qiao</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Research Center for Clinical Pharmacy, First Affiliated Hospital, College of Medicine, Zhejiang University, 79# Qingchun Road, Hangzhou, 310003, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Yunliang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Research Center for Clinical Pharmacy, First Affiliated Hospital, College of Medicine, Zhejiang University, 79# Qingchun Road, Hangzhou, 310003, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Jincai</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110006, PR China; Liaoning Provincial Key Laboratory of TCM Resources Conservation and Development, Shenyang Pharmaceutical University, Shenyang 110006, PR China. Electronic address: jincailu@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>05</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>J Ethnopharmacol</MedlineTA>
        <NlmUniqueID>7903310</NlmUniqueID>
        <ISSNLinking>0378-8741</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012503">Saponins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.137</RegistryNumber>
          <NameOfSubstance UI="D058539">Phosphatidylinositol 3-Kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000072283" MajorTopicYN="N">A549 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D031883" MajorTopicYN="Y">Anemone</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059447" MajorTopicYN="N">Cell Cycle Checkpoints</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056945" MajorTopicYN="N">Hep G2 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058539" MajorTopicYN="N">Phosphatidylinositol 3-Kinase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D027343" MajorTopicYN="Y">Rhizome</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012503" MajorTopicYN="N">Saponins</DescriptorName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Anemone raddeana</Keyword>
        <Keyword MajorTopicYN="N">HPLC-Q/TOF-MS</Keyword>
        <Keyword MajorTopicYN="N">Hederacolchiside A1 (PubChem CID:11622076)</Keyword>
        <Keyword MajorTopicYN="N">MCF-7</Keyword>
        <Keyword MajorTopicYN="N">Scabioside C (PubChem CID:11556805)</Keyword>
        <Keyword MajorTopicYN="N">Total secondary saponin</Keyword>
        <Keyword MajorTopicYN="N">Toxicity</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32446927</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jep.2020.112984</ArticleId>
        <ArticleId IdType="pii">S0378-8741(20)31138-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32304741</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-260X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>1866</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Aug</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biochimica et biophysica acta. Molecular basis of disease</Title>
          <ISOAbbreviation>Biochim Biophys Acta Mol Basis Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Regulation of the cerebrovascular smooth muscle cell phenotype by mitochondrial oxidative injury and endoplasmic reticulum stress in simulated microgravity rats via the PERK-eIF2α-ATF4-CHOP pathway.</ArticleTitle>
        <Pagination>
          <StartPage>165799</StartPage>
          <MedlinePgn>165799</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbadis.2020.165799</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0925-4439(20)30144-7</ELocationID>
        <Abstract>
          <AbstractText>Microgravity exposure results in vascular remodeling and cardiovascular dysfunction. Here, the effects of mitochondrial oxidative stress on vascular smooth muscle cells (VSMCs) in rat cerebral arteries under microgravity simulated by hindlimb unweighting (HU) was studied. Endoplasmic reticulum (ER)-resident transmembrane sensor proteins and phenotypic markers of rat cerebral VSMCs were examined. In HU rats, CHOP expression was increased gradually, and the upregulation of the PERK-eIF2α-ATF4 pathway was the most pronounced in cerebral arteries. Furthermore, PERK/p-PERK signaling, CHOP, GRP78 and reactive oxygen species were augmented by PERK overexpression but attenuated by the mitochondria-targeting antioxidant MitoTEMPO. Meanwhile, p-PI3K, p-Akt and p-mTOR protein levels in VSMCs were increased in HU rat cerebral arteries. Compared with the control, HU rats exhibited lower α-SMA, calponin, SM-MHC and caldesmon protein levels but higher OPN and elastin levels in cerebral VSMCs. The cerebral VSMC phenotype transition from a contractile to synthetic phenotype in HU rats was augmented by PERK overexpression and 740Y-P but reversed by MitoTEMPO and the ER stress inhibitors tauroursodeoxycholic acid (TUDCA) and 4-phenylbutyric acid (4-PBA). In summary, mitochondrial oxidative stress and ER stress induced by simulated microgravity contribute to phenotype transition of cerebral VSMCs through the PERK-eIF2a-ATF4-CHOP pathway in a rat model.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2020 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Ran</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology &amp; National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Min</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology &amp; National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jibin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology &amp; National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qiu</LastName>
            <ForeName>Ya</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology &amp; National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Danyang</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology &amp; National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Sulei</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology &amp; National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Junsong</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology &amp; National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Chuanbin</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology &amp; National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fang</LastName>
            <ForeName>Zhiyi</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology &amp; National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cao</LastName>
            <ForeName>Feng</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology &amp; National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China. Electronic address: fengcao8828@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>04</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Biochim Biophys Acta Mol Basis Dis</MedlineTA>
        <NlmUniqueID>101731730</NlmUniqueID>
        <ISSNLinking>0925-4439</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C497110">Atf4 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C497251">Ddit3 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015852">Eukaryotic Initiation Factor-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C051684">GRP78 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C555916">MitoTEMPO</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009943">Organophosphorus Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010654">Phenylbutyrates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010880">Piperidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>145891-90-3</RegistryNumber>
          <NameOfSubstance UI="D051701">Activating Transcription Factor 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>147336-12-7</RegistryNumber>
          <NameOfSubstance UI="D051742">Transcription Factor CHOP</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>516-35-8</RegistryNumber>
          <NameOfSubstance UI="D013655">Taurochenodeoxycholic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>60EUX8MN5X</RegistryNumber>
          <NameOfSubstance UI="C031655">ursodoxicoltaurine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7WY7YBI87E</RegistryNumber>
          <NameOfSubstance UI="C075773">4-phenylbutyric acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546845">mTOR protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="C117035">PERK kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D019892">eIF-2 Kinase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D051701" MajorTopicYN="N">Activating Transcription Factor 4</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002536" MajorTopicYN="N">Cerebral Arteries</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015852" MajorTopicYN="N">Eukaryotic Initiation Factor-2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006360" MajorTopicYN="N">Heat-Shock Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019417" MajorTopicYN="N">Hindlimb Suspension</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009131" MajorTopicYN="N">Muscle, Smooth, Vascular</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032389" MajorTopicYN="N">Myocytes, Smooth Muscle</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009943" MajorTopicYN="N">Organophosphorus Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010654" MajorTopicYN="N">Phenylbutyrates</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013655" MajorTopicYN="N">Taurochenodeoxycholic Acid</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051742" MajorTopicYN="N">Transcription Factor CHOP</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019892" MajorTopicYN="N">eIF-2 Kinase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Endoplasmic reticulum stress</Keyword>
        <Keyword MajorTopicYN="N">Hindlimb unweighting</Keyword>
        <Keyword MajorTopicYN="N">Mitochondria</Keyword>
        <Keyword MajorTopicYN="N">Oxidative stress</Keyword>
        <Keyword MajorTopicYN="N">Phenotype of vascular smooth muscle cells</Keyword>
        <Keyword MajorTopicYN="N">Vascular remodeling</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32304741</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bbadis.2020.165799</ArticleId>
        <ArticleId IdType="pii">S0925-4439(20)30144-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32164676</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>09</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>09</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2662-7671</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Mar</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>BMC complementary medicine and therapies</Title>
          <ISOAbbreviation>BMC Complement Med Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Total flavones of Dracocephalum moldavica L. protect astrocytes against H2O2-induced apoptosis through a mitochondria-dependent pathway.</ArticleTitle>
        <Pagination>
          <StartPage>78</StartPage>
          <MedlinePgn>78</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">78</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12906-020-2846-4</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The active components of Dracocephalum moldavica L. (TFDM) can inhibit myocardial ischemia by inhibiting oxidative stress. However, the effects of TFDM on astrocytes have not been investigated in vitro. The current study aimed to explore whether TFDM protects astrocytes against H2O2-induced apoptosis through a mitochondria-dependent pathway.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">The human glioma cell line U87 was used to investigate the ability of TFDM to protect astrocytes against H2O2-induced apoptosis. The cell counting kit-8 assay and flow cytometry were used to detect cell viability, apoptosis, MMP, Ca[2+] influx and reactive oxygen species (ROS). Lactate dehydrogenase (LDH) and malonic dialdehyde (MDA) levels were measured by ELISA. In addition, protein and mRNA expression changes were detected by Western blotting and qRT-PCR.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">TFDM (0.78~200&#x2009;&#x3bc;g/ml) had limited cytotoxic effects on the viability of U87 cells. Compared with the model group (treated with H2O2 only), cells treated with medium- and high-dose TFDM exhibited reduced MDA concentrations (P&#x2009;&lt;&#x2009;0.05) and ROS production (P&#x2009;&lt;&#x2009;0.05) and decreased MMP (P&#x2009;&lt;&#x2009;0.05) and reduced apoptosis (P&#x2009;&lt;&#x2009;0.05). The percentage of annexin V-FITC-stained cells was markedly suppressed by TFDM, confirming its anti-apoptotic properties. WB results showed that protein expression of Bcl-2-associated X protein (BAX), Caspase-3, Caspase-9, Caspase-12, and B-cell leukemia/lymphoma 2 (Bcl2) was reduced in the TFDM group compared with that in the model group (P&#x2009;&lt;&#x2009;0.05) and that expression of these proteins was normalized by TFDM treatment in a dose-dependent manner. According to RT-qPCR results, TFDM pretreatment resulted in reduced mRNA expression of BAX, Caspase-9, Caspase-12, p38MAPK, and CaMKII and increased mRNA expression of mTOR compared with the model group.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The current study revealed the protective effects of TFDM on U87 cells under oxidative stress conditions through the inhibition of a mitochondria-dependent pathway that is associated with the CaMKII/P38MAPK/ERK1/2 and PI3K/AKT/mTOR pathways.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Rui-Fang</ForeName>
            <Initials>RF</Initials>
            <AffiliationInfo>
              <Affiliation>Xinjiang Key Laboratory of Uighur Medicines, Xinjiang Institute of Materia Medica, 140 Xinhua South Road, Urumchi, 830004, Xinjiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Du</LastName>
            <ForeName>Yan-Wen</ForeName>
            <Initials>YW</Initials>
            <AffiliationInfo>
              <Affiliation>Xinjiang Medical University, Urumchi, 830000, Xinjiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Xinjiang Key Laboratory of Uighur Medicines, Xinjiang Institute of Materia Medica, 140 Xinhua South Road, Urumchi, 830004, Xinjiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zeng</LastName>
            <ForeName>Cheng</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Xinjiang Medical University, Urumchi, 830000, Xinjiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Xinjiang Key Laboratory of Uighur Medicines, Xinjiang Institute of Materia Medica, 140 Xinhua South Road, Urumchi, 830004, Xinjiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Hui-Fang</ForeName>
            <Initials>HF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Pharmacy, China Pharmaceutical University, 24 Tong jia Lane, P.O. Box 076, Nanjing, 210009, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xing</LastName>
            <ForeName>Jian-Guo</ForeName>
            <Initials>JG</Initials>
            <AffiliationInfo>
              <Affiliation>Xinjiang Key Laboratory of Uighur Medicines, Xinjiang Institute of Materia Medica, 140 Xinhua South Road, Urumchi, 830004, Xinjiang, China. xjguodd@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Ming</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Pharmacy, China Pharmaceutical University, 24 Tong jia Lane, P.O. Box 076, Nanjing, 210009, China. 2059974605@qq.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>No. PT1901</GrantID>
            <Agency>Resource Sharing Platform of Xinjiang Uygur Autonomous Region</Agency>
          </Grant>
          <Grant>
            <GrantID>No. 2017XS10</GrantID>
            <Agency>Reserve candidates for the Ten Thousands Plan of the Autonomous Region of Xinjiang Uygur Autonomous Region</Agency>
          </Grant>
          <Grant>
            <GrantID>No. ky2019099</GrantID>
            <Agency>Scientific Research Business Expenses of Xinjiang Uygur Autonomous Region</Agency>
          </Grant>
          <Grant>
            <GrantID>No.2019D01A80</GrantID>
            <Agency>Natural Fund of Xinjiang Uygur Autonomous Region</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>03</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>BMC Complement Med Ther</MedlineTA>
        <NlmUniqueID>101761232</NlmUniqueID>
        <ISSNLinking>2662-7671</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047309">Flavones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BBX060AN9V</RegistryNumber>
          <NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047309" MajorTopicYN="N">Flavones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019686" MajorTopicYN="N">Lamiaceae</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008516" MajorTopicYN="N">Medicine, Chinese Traditional</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32164676</ArticleId>
        <ArticleId IdType="pmc">PMC7076740</ArticleId>
        <ArticleId IdType="doi">10.1186/s12906-020-2846-4</ArticleId>
        <ArticleId IdType="pii">10.1186/s12906-020-2846-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet. 2008;371(9624):1612&#x2013;1623. doi: 10.1016/S0140-6736(08)60694-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(08)60694-7</ArticleId>
            <ArticleId IdType="pubmed">18468545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liapunova PN, Salo ND, Sergienko TA. Anatomical study of the Moldavian dragon's head herb (Dracocephalum moldavica L) Farmatsiia. 1975;24(5):15&#x2013;20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1225628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan ME, He CH, Jiang W, Zeng C, Yu N, Huang W, Gao ZG, Xing JG. Development of solid lipid nanoparticles containing total flavonoid extract from Dracocephalum moldavica L. and their therapeutic effect against myocardial ischemia-reperfusion injury in rats. Int J Nanomedicine. 2017;12:3253&#x2013;3265. doi: 10.2147/IJN.S131893.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/IJN.S131893</ArticleId>
            <ArticleId IdType="pmc">PMC5402922</ArticleId>
            <ArticleId IdType="pubmed">28458544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma L, Zeng C, Zheng R, Jiang W, He C, Xing J. Protective Effects of Tilianin on Brain Tissue in Cerebral Ischemia-reperfusion Injury Model Rats [J] China Pharm. 2018;29(20):2805&#x2013;2810.</Citation>
        </Reference>
        <Reference>
          <Citation>Jiang H, Fang J, Xing J, Wang L, Wang Q, Wang Y, Li Z, Liu R. Tilianin mediates neuroprotection against ischemic injury by attenuating CaMKII-dependent mitochondrion-mediated apoptosis and MAPK/NF-&#x3ba;B signaling. Life Sci. 2019;216:233&#x2013;245. doi: 10.1016/j.lfs.2018.11.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2018.11.035</ArticleId>
            <ArticleId IdType="pubmed">30472297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maimaiti TG, Setiwalidi A. Clinical Drug Use of Vanilla Fragrans in the Treatment of Cardiovascular Diseases in Uygur [J] Digest World Latest Med Inf. 2017;17(25):205&#x2013;209.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang N, et al. Insights into the importance of dietary chrysanthemum flower (Chrysanthemum morifolium cv. Hangju)-wolfberry (Lycium barbarum fruit) combination in antioxidant and anti-inflammatory properties. Food Res Int. 2019;116:810&#x2013;818. doi: 10.1016/j.foodres.2018.09.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.foodres.2018.09.015</ArticleId>
            <ArticleId IdType="pubmed">30717012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung HA, et al. Protective effects of flavonoids isolated from Korean milk thistle Cirsium japonicum var. maackii (Maxim.) Matsum on tert-butyl hydroperoxide-induced hepatotoxicity in HepG2 cells. J Ethnopharmacol. 2017;209:62&#x2013;72. doi: 10.1016/j.jep.2017.07.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jep.2017.07.027</ArticleId>
            <ArticleId IdType="pubmed">28735729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du Q, et al. Antioxidant constituents in the fruits of Luffa cylindrica (L.) Roem. J Agric Food Chem. 2006;54(12):4186&#x2013;4190. doi: 10.1021/jf0604790.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jf0604790</ArticleId>
            <ArticleId IdType="pubmed">16756345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian L, et al. Pretreatment with Tilianin improves mitochondrial energy metabolism and oxidative stress in rats with myocardial ischemia/reperfusion injury via AMPK/SIRT1/PGC-1 alpha signaling pathway. J Pharmacol Sci. 2019;139(4):352&#x2013;360. doi: 10.1016/j.jphs.2019.02.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jphs.2019.02.008</ArticleId>
            <ArticleId IdType="pubmed">30910451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu N, et al. Simultaneous Determination of Six Active Compounds in Yixin Badiranjibuya Granules, a Traditional Chinese Medicine, by RP-HPLC-UV Method. J Anal Methods Chem. 2015;2015:974039. doi: 10.1155/2015/974039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2015/974039</ArticleId>
            <ArticleId IdType="pmc">PMC4637494</ArticleId>
            <ArticleId IdType="pubmed">26587308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiang L. Study on Pharmacokinetic Characteristics and Metabolic Mechanism of Flavonoids in Pandan. South Med Univ. 2015;03:1&#x2013;145.</Citation>
        </Reference>
        <Reference>
          <Citation>Grassi D, Aggio A, Onori L, Croce G, Tiberti S, Ferri C, Ferri L, Desideri G. Tea flavonoids, and nitric oxide-mediated vascular reactivity. J Nutr. 2018;138(8):1554&#x2013;1560. doi: 10.1093/jn/138.8.1554S.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jn/138.8.1554S</ArticleId>
            <ArticleId IdType="pubmed">18641206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grassi D, Desideri G, Croce G, Tiberti S, Aggio A, Ferri C. Flavonoids vascular function and cardiovascular protection. Curr Pharm Design. 2009;15(10):1072&#x2013;1084. doi: 10.2174/138161209787846982.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/138161209787846982</ArticleId>
            <ArticleId IdType="pubmed">19355949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vauzour D, Vafeiadou K, Rodriguez-Mateos A, Rendeiro C, Spencer JP. The neuroprotective potential of flavonoids: a multiplicity of effects. Genes Nutr. 2008;3(3-4):115&#x2013;126. doi: 10.1007/s12263-008-0091-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12263-008-0091-4</ArticleId>
            <ArticleId IdType="pmc">PMC2593006</ArticleId>
            <ArticleId IdType="pubmed">18937002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang H, Fang J, Xing J, Wang L, Wang Q, Wang Y, Li Z, Liu R. Tilianin mediates neuroprotection against ischemic injury by attenuating CaMKII-dependent mitochondrion-mediated apoptosis and MAPK/NF-kappaB signaling. Life Sci. 2019;216:233&#x2013;245. doi: 10.1016/j.lfs.2018.11.035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2018.11.035</ArticleId>
            <ArticleId IdType="pubmed">30472297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan ME, He CH, Jiang W, Zeng C, Yu N, Huang W, Gao ZG, Xing JG. Development of solid lipid nanoparticles containing total flavonoid extract from Dracocephalum moldavica L. and their therapeutic effect against myocardial ischemia-reperfusion injury in rats. Int J Nanomedicine. 2017;12:3253&#x2013;3265. doi: 10.2147/IJN.S131893.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/IJN.S131893</ArticleId>
            <ArticleId IdType="pmc">PMC5402922</ArticleId>
            <ArticleId IdType="pubmed">28458544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng C, Jiang W, Yang X, He C, Wang W, Xing J. Pretreatment with Total Flavonoid Extract from Dracocephalum Moldavica L. Attenuates Ischemia Reperfusion-induced Apoptosis. Sci Rep. 2018;8(1):17491. doi: 10.1038/s41598-018-35726-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-35726-4</ArticleId>
            <ArticleId IdType="pmc">PMC6269513</ArticleId>
            <ArticleId IdType="pubmed">30504832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng C, Jiang W, Tan M, Xing J, He C. Improved Oral Bioavailability of Total Flavonoids of Dracocephalum moldavica via Composite Phospholipid Liposomes: Preparation, in-vitro Drug Release and Pharmacokinetics in Rats. Pharmacogn Mag. 2016;12(48):313&#x2013;318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5096279</ArticleId>
            <ArticleId IdType="pubmed">27867275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang J, Yuan X, Wang T, Chen H, Zhao H, Yan X, Wang Z, Sun X, Zheng Q. Antioxidative and cardioprotective effects of total flavonoids extracted from Dracocephalum moldavica L. against acute ischemia/reperfusion-induced myocardial injury in isolated rat heart. Cardiovasc Toxicol. 2014;14(1):74&#x2013;82. doi: 10.1007/s12012-013-9221-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12012-013-9221-3</ArticleId>
            <ArticleId IdType="pubmed">24395711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernandez-Fernandez S, Almeida A, Bolanos JP. Antioxidant and bioenergetic coupling between neurons and astrocytes. Biochem J. 2012;443(1):3&#x2013;11. doi: 10.1042/BJ20111943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BJ20111943</ArticleId>
            <ArticleId IdType="pubmed">22417747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li L, Lundkvist A, Andersson D, Wilhelmsson U, Nagai N, Pardo AC, et al. Protective role of reactive astrocytes in brain ischemia. J Cereb Blood Flow Metab. 2008;28(3):468&#x2013;481. doi: 10.1038/sj.jcbfm.9600546.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.jcbfm.9600546</ArticleId>
            <ArticleId IdType="pubmed">17726492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takano T, Oberheim N, Cotrina ML, Nedergaard M. Astrocytes and ischemic injury. Stroke. 2009;40:8&#x2013;12. doi: 10.1161/STROKEAHA.108.533166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/STROKEAHA.108.533166</ArticleId>
            <ArticleId IdType="pmc">PMC2653262</ArticleId>
            <ArticleId IdType="pubmed">19064795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nedergaard M, Dirnagl U. Role of glial cells in cerebral ischemia. Glia. 2005;50(4):281&#x2013;286. doi: 10.1002/glia.20205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/glia.20205</ArticleId>
            <ArticleId IdType="pubmed">15846807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poulletier de Gannes F, Haro E, Hurtier A. Effect of exposure to the edge signal on oxidative stress in brain cell models. Radiat Res. 2011;175(2):225&#x2013;230. doi: 10.1667/RR2320.1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1667/RR2320.1</ArticleId>
            <ArticleId IdType="pubmed">21268716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Erondu NE, Kennedy MB. Regional distribution of type II Ca2+/calmodulin-dependent protein kinase in rat brain. J Neurosci. 1985;5(12):3270&#x2013;3277. doi: 10.1523/JNEUROSCI.05-12-03270.1985.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.05-12-03270.1985</ArticleId>
            <ArticleId IdType="pmc">PMC6565219</ArticleId>
            <ArticleId IdType="pubmed">4078628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu M, Zhang HL. Death and survival of neuronal and astrocytic cells in ischemic brain injury: a role of autophagy. Acta Pharmacol Sin. 2011;32(9):1089&#x2013;1099. doi: 10.1038/aps.2011.50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/aps.2011.50</ArticleId>
            <ArticleId IdType="pmc">PMC4003297</ArticleId>
            <ArticleId IdType="pubmed">21804578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y, Rempe DA. Targeting astrocytes for stroke therapy. Neurotherapeutics. 2010;7(4):439&#x2013;451. doi: 10.1016/j.nurt.2010.07.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nurt.2010.07.004</ArticleId>
            <ArticleId IdType="pmc">PMC5084305</ArticleId>
            <ArticleId IdType="pubmed">20880507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Budd SL, Lipton SA. Calcium tsunamis: do astrocytes transmit cell death messages via gap junctions during ischemia? Nat Neurosci. 1998;1(6):431&#x2013;432. doi: 10.1038/2147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/2147</ArticleId>
            <ArticleId IdType="pubmed">10196536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin JH, Weigel H, Cotrina ML, Liu S, Bueno E, Hansen AJ, Hansen TW, Goldman S, Nedergaard M. Gap-junction-mediated propagation and amplification of cell injury. Nat Neurosci. 1998;1(6):494&#x2013;500. doi: 10.1038/2210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/2210</ArticleId>
            <ArticleId IdType="pubmed">10196547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim YK, Yoon HH, Lee YD, Youn DY, Ha TJ, Kim HS, Lee JH. Anthocyanin Extracts from Black Soybean (Glycine max L.) Protect Human Glial Cells Against Oxygen-Glucose Deprivation by Promoting Autophagy. Biomol Ther. 2012;20(1):68&#x2013;74. doi: 10.4062/biomolther.2012.20.1.068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4062/biomolther.2012.20.1.068</ArticleId>
            <ArticleId IdType="pmc">PMC3792204</ArticleId>
            <ArticleId IdType="pubmed">24116277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacobson J, Duchen MR. Interplay between mitochondria and cellular calcium signaling. Mol Cell Biochem. 2004;256-257(1-2):209&#x2013;218. doi: 10.1023/B:MCBI.0000009869.29827.df.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/B:MCBI.0000009869.29827.df</ArticleId>
            <ArticleId IdType="pubmed">14977182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicholls DG. Mitochondrial dysfunction and glutamate excitotoxicity studied in primary neuronal cultures. Curr Mol Med. 2004;4(2):149&#x2013;177. doi: 10.2174/1566524043479239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1566524043479239</ArticleId>
            <ArticleId IdType="pubmed">15032711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shih EK, Robinson MB. Role of Astrocytic Mitochondria in Limiting Ischemic Brain Injury? Physiology (Bethesda) 2018;33(2):99&#x2013;112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5899237</ArticleId>
            <ArticleId IdType="pubmed">29412059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toussaint F, Charbel C, Allen BG. Vascular CaMKII: heart and brain in your arteries. Am J Phys Cell Physiol. 2016;311(3):462&#x2013;478. doi: 10.1152/ajpcell.00341.2015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpcell.00341.2015</ArticleId>
            <ArticleId IdType="pmc">PMC5129758</ArticleId>
            <ArticleId IdType="pubmed">27306369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicholls DG, Johnson-Cadwell L, Vesce S, Jekabsons M, Yadava N. Bioenergetics of mitochondria in cultured neurons and their role in glutamate excitotoxicity. J Neurosci Res. 2007;85(15):3206&#x2013;3212. doi: 10.1002/jnr.21290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jnr.21290</ArticleId>
            <ArticleId IdType="pubmed">17455297</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32125033</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1095-8355</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>44</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cell biology international</Title>
          <ISOAbbreviation>Cell Biol Int</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Penehyclidine hydrochloride protects against anoxia/reoxygenation injury in cardiomyocytes through ATP-sensitive potassium channels, and the Akt/GSK-3β and Akt/mTOR signaling pathways.</ArticleTitle>
        <Pagination>
          <StartPage>1353</StartPage>
          <EndPage>1362</EndPage>
          <MedlinePgn>1353-1362</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/cbin.11329</ELocationID>
        <Abstract>
          <AbstractText>Penehyclidine hydrochloride (PHC) can protect against myocardial ischemia/reperfusion (I/R) injury. However, the possible mechanisms of PHC in anoxia/reoxygenation (A/R)-induced injury in H9c2 cells remain unclear. In the present study, H9c2 cells were pretreated with PI3K/Akt inhibitor LY294002, ATP-sensitive K[+] (KATP) channel blocker 5-hydroxydecanoate (5-HD), PHC, or KATP channel opener diazoxide (DZ) before subjecting to A/R injury. Cell viability and cell apoptosis were determined by cell counting kit-8 assay and annexin V/PI assay, respectively. Myocardial injury was evaluated by measuring creatine kinase (CK) and lactate dehydrogenase (LDH) activities. Intracellular Ca[2+] levels, reactive oxygen species (ROS) generation, mitochondrial membrane potential (ΔΨm), and mitochondrial permeability transition pore (mPTP) were measured. The levels of cytoplasmic/mitochondrial cytochrome c (Cyt-C), Bax, Bcl-2, cleaved caspase-3, KATP channel subunits (Kir6.2 and SUR2A), and the members of the Akt/GSK-3β and Akt/mTOR signaling pathways were determined by western blotting. We found that PHC preconditioning alleviated A/R-induced cell injury by increasing cell viability, reducing CK and LDH activities, and inhibiting cell apoptosis. In addition, PHC preconditioning ameliorated intracellular Ca[2+] overload and ROS production, accompanied by inhibition of both mPTP opening and Cyt-C release into cytoplasm, and maintenance of ΔΨm . Moreover, PHC preconditioning activated mitochondrial KATP channels, and modulated the Akt/GSK-3β and Akt/mTOR signaling pathways. Similar effects were observed upon treatment with DZ. Pretreatment with LY294002 or 5-HD blocked the beneficial effects of PHC. These results suggest that the protective effects of PHC preconditioning on A/R injury may be related to mitochondrial KATP channels, as well as the Akt/GSK-3β and Akt/mTOR signaling pathways.</AbstractText>
          <CopyrightInformation>&#xa9; 2020 International Federation for Cell Biology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zi</LastName>
            <ForeName>Congna</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology, Beijing Anzhen Hospital, Beijing Institute of Heart Lung and Blood Vessel Diseases, Capital Medical University, Beijing, 100029, PR China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, 075000, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Chunlei</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology, Beijing Anzhen Hospital, Beijing Institute of Heart Lung and Blood Vessel Diseases, Capital Medical University, Beijing, 100029, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Yanli</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology, Beijing Anzhen Hospital, Beijing Institute of Heart Lung and Blood Vessel Diseases, Capital Medical University, Beijing, 100029, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology, Beijing Anzhen Hospital, Beijing Institute of Heart Lung and Blood Vessel Diseases, Capital Medical University, Beijing, 100029, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>81871592</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>ZYLX201810</GrantID>
            <Agency>Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>03</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cell Biol Int</MedlineTA>
        <NlmUniqueID>9307129</NlmUniqueID>
        <ISSNLinking>1065-6995</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015221">Potassium Channels</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020011">Protective Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011812">Quinuclidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C117780">mitochondrial K(ATP) channel</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>353CX8CSHD</RegistryNumber>
          <NameOfSubstance UI="C486140">penehyclidine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015428" MajorTopicYN="N">Myocardial Reperfusion Injury</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032383" MajorTopicYN="N">Myocytes, Cardiac</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015221" MajorTopicYN="N">Potassium Channels</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020011" MajorTopicYN="N">Protective Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011812" MajorTopicYN="N">Quinuclidines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ATP-sensitive K+channel</Keyword>
        <Keyword MajorTopicYN="N">Akt/GSK-3&#x3b2; signaling</Keyword>
        <Keyword MajorTopicYN="N">Akt/mTOR signaling</Keyword>
        <Keyword MajorTopicYN="N">anoxia/reoxygenation injury</Keyword>
        <Keyword MajorTopicYN="N">penehyclidine hydrochloride</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32125033</ArticleId>
        <ArticleId IdType="doi">10.1002/cbin.11329</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Chang WT, Li J, Vanden Hoek MS, Zhu X, Li CQ, Huang HH, Shao ZH (2013) Baicalein preconditioning protects cardiomyocytes from ischemia-reperfusion injury via mitochondrial oxidant signaling. Am J Chin Med (Gard City N Y) 41(2): 315-31. https://doi.org/10.1142/S0192415X13500237</Citation>
        </Reference>
        <Reference>
          <Citation>Dudek M, Knutelska J, Bednarski M, Nowinski L, Zygmunt M, Bilska-Wilkosz A, Filipek B (2014) Alpha lipoic acid protects the heart against myocardial post ischemia-reperfusion arrhythmias via KATP channel activation in isolated rat hearts. Pharmacol Rep 66(3): 499-504. https://doi.org/10.1016/j.pharep.2013.11.001</Citation>
        </Reference>
        <Reference>
          <Citation>Halestrap AP (2009) Mitochondria and reperfusion injury of the heart-a holey death but not beyond salvation. J Bioenerg Biomembr 41(2): 113-21. https://doi.org/10.1007/s10863-009-9206-x</Citation>
        </Reference>
        <Reference>
          <Citation>Halestrap AP, Richardson AP (2015) The mitochondrial permeability transition: a current perspective on its identity and role in ischaemia/reperfusion injury. J Mol Cell Cardiol 78: 129-41. https://doi.org/10.1016/j.yjmcc.2014.08.018</Citation>
        </Reference>
        <Reference>
          <Citation>Horiba M, Kadomatsu K, Yasui K, Lee JK, Takenaka H, Sumida A, Kodama I (2006) Midkine plays a protective role against cardiac ischemia/reperfusion injury through a reduction of apoptotic reaction. Circulation 114(16): 1713-20. https://doi.org/10.1161/CIRCULATIONAHA.106.632273</Citation>
        </Reference>
        <Reference>
          <Citation>Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Widimsk&#xfd; P (2018) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39(2): 119-77. https://doi.org/10.1093/eurheartj/ehx393</Citation>
        </Reference>
        <Reference>
          <Citation>Jafari M, Ghadami E, Dadkhah T, Akhavan-Niaki H (2019) PI3k/AKT signaling pathway: erythropoiesis and beyond. J Cell Physiol 234(3): 2373-85. https://doi.org/10.1002/jcp.27262</Citation>
        </Reference>
        <Reference>
          <Citation>Kataoka Y, Shibata R, Ohashi K, Kambara T, Enomoto T, Uemura Y, Ouchi N (2014) Omentin prevents myocardial ischemic injury through AMP-activated protein kinase- and Akt-dependent mechanisms. J Am Coll Cardiol 63(24): 2722-33. https://doi.org/10.1016/j.jacc.2014.03.032</Citation>
        </Reference>
        <Reference>
          <Citation>Kristjansson RP, Oddsson A, Helgason H, Sveinbjornsson G, Arnadottir GA, Jensson BO, Stefansson K (2016) Common and rare variants associating with serum levels of creatine kinase and lactate dehydrogenase. Nat Commun 7: 10572. https://doi.org/10.1038/ncomms10572</Citation>
        </Reference>
        <Reference>
          <Citation>Lin D, Cui B, Ren J, Ma J (2018) Regulation of VDAC1 contributes to the cardioprotective effects of penehyclidine hydrochloride during myocardial ischemia/reperfusion. Exp Cell Res 367(2): 257-63. https://doi.org/10.1016/j.yexcr.2018.04.004</Citation>
        </Reference>
        <Reference>
          <Citation>Lin D, Ma J, Xue Y, Wang Z (2015) Penehyclidine hydrochloride preconditioning provides cardioprotection in a rat model of myocardial ischemia/reperfusion injury. PLoS One 10(12): e0138051. https://doi.org/10.1371/journal.pone.0138051</Citation>
        </Reference>
        <Reference>
          <Citation>Liu Z, Yang L, Huang J, Xu P, Zhang Z, Yin D, He M (2018) Luteoloside attenuates anoxia/reoxygenation-induced cardiomyocytes injury via mitochondrial pathway mediated by 14-3-3eta protein. Phytother Res 32(6): 1126-34. https://doi.org/10.1002/ptr.6053</Citation>
        </Reference>
        <Reference>
          <Citation>Meng LM, Ma HJ, Guo H, Kong QQ, Zhang Y (2016) The cardioprotective effect of naringenin against ischemia-reperfusion injury through activation of ATP-sensitive potassium channel in rat. Can J Physiol Pharmacol 94(9): 973-8. https://doi.org/10.1139/cjpp-2016-0008</Citation>
        </Reference>
        <Reference>
          <Citation>Nagata S (2018) Apoptosis and clearance of apoptotic cells. Annu Rev Immunol 36: 489-517. https://doi.org/10.1146/annurev-immunol-042617-053010</Citation>
        </Reference>
        <Reference>
          <Citation>Noma A (1983) ATP-regulated K+ channels in cardiac muscle. Nature 305(5930): 147-8. https://doi.org/10.1038/305147a0</Citation>
        </Reference>
        <Reference>
          <Citation>Pasupathy S, Homer-Vanniasinkam S (2005) Ischaemic preconditioning protects against ischaemia/reperfusion injury: emerging concepts. Eur J Vasc Endovasc Surg 29(2): 106-15. https://doi.org/10.1016/j.ejvs.2004.11.005</Citation>
        </Reference>
        <Reference>
          <Citation>Reed GW, Rossi JE, Cannon CP (2017) Acute myocardial infarction. Lancet 389(10065): 197-210. https://doi.org/10.1016/S0140-6736(16)30677-8</Citation>
        </Reference>
        <Reference>
          <Citation>Renault TT, Dejean LM, Manon S (2017) A brewing understanding of the regulation of Bax function by Bcl-xL and Bcl-2. Mech Ageing Dev 161(Pt B): 201-10. https://doi.org/10.1016/j.mad.2016.04.007</Citation>
        </Reference>
        <Reference>
          <Citation>Sanz-Rosa D, Garcia-Prieto J, Ibanez B (2012) The future: therapy of myocardial protection. Ann NY Acad Sci 1254: 90-8. https://doi.org/10.1111/j.1749-6632.2012.06501.x</Citation>
        </Reference>
        <Reference>
          <Citation>Song YJ, Zhong CB, Wang XB (2019) Heat shock protein 70: a promising therapeutic target for myocardial ischemia-reperfusion injury. J Cell Physiol 234(2): 1190-207. https://doi.org/10.1002/jcp.27110</Citation>
        </Reference>
        <Reference>
          <Citation>Sun YJ, Song DD, Diao YG, Zhou J, Zhang TZ (2013) Penehyclidine hydrochloride preserves the intestinal barrier function in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 146(1): 179-85. https://doi.org/10.1016/j.jtcvs.2013.01.042</Citation>
        </Reference>
        <Reference>
          <Citation>Tan H, Chen L, Ma J (2017) Penehyclidine hydrochloride post-conditioning reduces ischemia/reperfusion-induced cardiomyocyte apoptosis in rats. Exp Ther Med 14(5): 4272-8. https://doi.org/10.3892/etm.2017.5089</Citation>
        </Reference>
        <Reference>
          <Citation>Tratsiakovich Y, Yang J, Gonon AT, Sjoquist PO, Pernow J (2013) Arginase as a target for treatment of myocardial ischemia-reperfusion injury. Eur J Pharmacol 720(1-3): 121-3. https://doi.org/10.1016/j.ejphar.2013.10.040</Citation>
        </Reference>
        <Reference>
          <Citation>Wang D, Zhang X, Li D, Hao W, Meng F, Wang B, Zheng Q (2017a) Kaempferide protects against myocardial ischemia/reperfusion injury through activation of the PI3K/Akt/GSK-3beta pathway. Mediators Inflamm 2017: 5278218. https://doi.org/10.1155/2017/5278218</Citation>
        </Reference>
        <Reference>
          <Citation>Wang J, Ren Y, Zhu Y, Chen JW, Zhu MM, Xu YJ, Tan ZM (2013) Effect of penehyclidine hydrochloride on the incidence of intra-operative awareness in Chinese patients undergoing breast cancer surgery during general anaesthesia. Anaesthesia 68(2): 136-41. https://doi.org/10.1111/anae.12092</Citation>
        </Reference>
        <Reference>
          <Citation>Wang S, Li Y, Song X, Wang X, Zhao C, Chen A, Yang P (2015) Febuxostat pretreatment attenuates myocardial ischemia/reperfusion injury via mitochondrial apoptosis. J Transl Med 13: 209. https://doi.org/10.1186/s12967-015-0578-x</Citation>
        </Reference>
        <Reference>
          <Citation>Wang YA, Zhou WX, Li JX, Liu YQ, Yue YJ, Zheng JQ, Ruan JX (2005) Anticonvulsant effects of phencynonate hydrochloride and other anticholinergic drugs in soman poisoning: neurochemical mechanisms. Life Sci 78(2): 210-23. https://doi.org/10.1016/j.lfs.2005.04.071</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Z, Lin D, Zhang L, Liu W, Tan H, Ma J (2017b) Penehyclidine hydrochloride prevents anoxia/reoxygenation injury and induces H9c2 cardiomyocyte apoptosis via a mitochondrial pathway. Eur J Pharmacol 797: 115-23. https://doi.org/10.1016/j.ejphar.2017.01.012</Citation>
        </Reference>
        <Reference>
          <Citation>Wu QF, Qian C, Zhao N, Dong Q, Li J, Wang BB, Liao YH (2017) Activation of transient receptor potential vanilloid 4 involves in hypoxia/reoxygenation injury in cardiomyocytes. Cell Death Dis 8(5): e2828. https://doi.org/10.1038/cddis.2017.227</Citation>
        </Reference>
        <Reference>
          <Citation>Yandrapalli S, Nabors C, Goyal A, Aronow WS, Frishman WH (2019) Modifiable risk factors in young adults with first myocardial infarction. J Am Coll Cardiol 73(5): 573-84. https://doi.org/10.1016/j.jacc.2018.10.084</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang G, Wang Q, Wang W, Yu M, Zhang S, Xu N, Lai EY (2018) Tempol protects against acute renal injury by regulating PI3K/Akt/mTOR and GSK3beta signaling cascades and afferent arteriolar activity. Kidney Blood Pressure Res 43(3): 904-13. https://doi.org/10.1159/000490338</Citation>
        </Reference>
        <Reference>
          <Citation>Zheng Y, Bu J, Yu L, Chen J, Liu H (2017) Nobiletin improves propofol-induced neuroprotection via regulating Akt/mTOR and TLR 4/NF-kappaB signaling in ischemic brain injury in rats. Biomedicine. Pharmacotherapy 91: 494-503. https://doi.org/10.1016/j.biopha.2017.04.048</Citation>
        </Reference>
        <Reference>
          <Citation>Zhou M, Ren H, Han J, Wang W, Zheng Q, Wang D (2015) Protective effects of kaempferol against myocardial ischemia/reperfusion injury in isolated rat heart via antioxidant activity and inhibition of glycogen synthase kinase-3beta. Oxid Med Cell Longevity 2015: 481405. https://doi.org/10.1155/2015/481405</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32112876</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-3169</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>326</Volume>
            <PubDate>
              <Year>2020</Year>
              <Month>Jun</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Toxicology letters</Title>
          <ISOAbbreviation>Toxicol Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Arsenic-induced autophagic alterations and mitochondrial impairments in HPG-S axis of mature male mice offspring (F1-generation): A persistent toxicity study.</ArticleTitle>
        <Pagination>
          <StartPage>83</StartPage>
          <EndPage>98</EndPage>
          <MedlinePgn>83-98</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.toxlet.2020.02.013</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0378-4274(20)30062-X</ELocationID>
        <Abstract>
          <AbstractText>Arsenic (As) has been implicated in causing reproductive toxicity, but the precise cellular pathway through which the As toxicity in mature F1- male mice hypothalamic-pituitary- gonadal- sperm (HPG-S) axis is induced has not well been documented. Hence, parental mice were treated to As2O3 (0, 0.2, 2, and 20 ppm in deionized water) from five weeks before mating until weaning, and the male pups from weaning to maturity. Afterward, the markers of oxidative stress, mitochondrial impairment, and autophagy as fundamental mechanisms of cytotoxicity and organ injury were evaluated. Higher As2O3 doses (2 and 20 ppm) were a potent inducer of oxidative stress, mitochondrial dysfunction, and autophagy in HPG-S axis. Concomitant with a dose-dependent increase in the number of MDC-labeled autophagic vacuoles in the HPG axis, an adverse dose-dependent effect was observed on the mean body weight, litter size, organ coefficient, and spermatogenesis. Transmission electron microscopy also revealed more autophagosomes at high As2O3 dosage. Concomitant with a dose-dependent increment in gene expression of PI3K, Atg5, Atg12, as well as protein expression of Beclin1, LC3- I, II, P62 in HPG axis tissues and Atg12 in the pituitary; a dose-dependent decrease in mTOR gene expression was recorded in the HPG tissues of mature F1-males. These observations provide direct evidence that oxidative stress-induced mitochondrial impairments and autophagic cell death, through AMPK/TSC/mTOR and LC3 related pathways, are fundamental mechanisms for As2O3- induced toxicity on the reproductive system in mature male mice offspring.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2020. Published by Elsevier B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ommati</LastName>
            <ForeName>Mohammad Mehdi</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Shanxi Key Laboratory of Ecological Animal Science and Environmental Veterinary Medicine, Shanxi Agricultural University, Taigu, Shanxi, 030801, PR China; Department of Bioinformatics, College of Life Sciences, Shanxi Agricultural University, Taigu, Shanxi, Taigu, Shanxi, 030801, PR China. Electronic address: mehdi_ommati@outlook.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Manthari</LastName>
            <ForeName>Ram Kumar</ForeName>
            <Initials>RK</Initials>
            <AffiliationInfo>
              <Affiliation>Shanxi Key Laboratory of Ecological Animal Science and Environmental Veterinary Medicine, Shanxi Agricultural University, Taigu, Shanxi, 030801, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tikka</LastName>
            <ForeName>Chiranjeevi</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Shanxi Key Laboratory of Ecological Animal Science and Environmental Veterinary Medicine, Shanxi Agricultural University, Taigu, Shanxi, 030801, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Niu</LastName>
            <ForeName>Ruiyan</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Shanxi Key Laboratory of Ecological Animal Science and Environmental Veterinary Medicine, Shanxi Agricultural University, Taigu, Shanxi, 030801, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Zilong</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Shanxi Key Laboratory of Ecological Animal Science and Environmental Veterinary Medicine, Shanxi Agricultural University, Taigu, Shanxi, 030801, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sabouri</LastName>
            <ForeName>Samira</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Shanxi Key Laboratory of Ecological Animal Science and Environmental Veterinary Medicine, Shanxi Agricultural University, Taigu, Shanxi, 030801, PR China; Department of Bioinformatics, College of Life Sciences, Shanxi Agricultural University, Taigu, Shanxi, Taigu, Shanxi, 030801, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zamiri</LastName>
            <ForeName>Mohammad Javad</ForeName>
            <Initials>MJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Animal Science, College of Agriculture, Shiraz University, 71441-65186, Shiraz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ahmadi</LastName>
            <ForeName>Hasan Nategh</ForeName>
            <Initials>HN</Initials>
            <AffiliationInfo>
              <Affiliation>Shanxi Key Laboratory of Ecological Animal Science and Environmental Veterinary Medicine, Shanxi Agricultural University, Taigu, Shanxi, 030801, PR China; Department of Clinical Studies, School of Veterinary Medicine, Shiraz University, 71345, Shiraz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ghaffari</LastName>
            <ForeName>Hasti</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Veterinary Sciences, Urmia University, Urmia, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Heidari</LastName>
            <ForeName>Reza</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, 158371345, Shiraz, Iran. Electronic address: rezaheidari@hotmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Jundong</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Shanxi Key Laboratory of Ecological Animal Science and Environmental Veterinary Medicine, Shanxi Agricultural University, Taigu, Shanxi, 030801, PR China. Electronic address: wangjd53@outlook.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>02</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Toxicol Lett</MedlineTA>
        <NlmUniqueID>7709027</NlmUniqueID>
        <ISSNLinking>0378-4274</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>N712M78A8G</RegistryNumber>
          <NameOfSubstance UI="D001151">Arsenic</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001151" MajorTopicYN="N">Arsenic</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013091" MajorTopicYN="N">Spermatogenesis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Autophagy</Keyword>
        <Keyword MajorTopicYN="N">Infertility</Keyword>
        <Keyword MajorTopicYN="N">Mitochondria</Keyword>
        <Keyword MajorTopicYN="N">Oxidative stress</Keyword>
        <Keyword MajorTopicYN="N">Reproductive toxicity</Keyword>
        <Keyword MajorTopicYN="N">Spermatogenesis</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest The authors declare that they have no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32112876</ArticleId>
        <ArticleId IdType="doi">10.1016/j.toxlet.2020.02.013</ArticleId>
        <ArticleId IdType="pii">S0378-4274(20)30062-X</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32013230</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2072-6651</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jan</Month>
              <Day>29</Day>
            </PubDate>
          </JournalIssue>
          <Title>Toxins</Title>
          <ISOAbbreviation>Toxins (Basel)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>T-2 Toxin Induces Oxidative Stress, Apoptosis and Cytoprotective Autophagy in Chicken Hepatocytes.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">90</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/toxins12020090</ELocationID>
        <Abstract>
          <AbstractText>T-2 toxin is type A trichothecenes mycotoxin, which produced by fusarium species in cereal grains. T-2 toxin has been shown to induce a series of toxic effects on the health of human and animal, such as immunosuppression and carcinogenesis. Previous study has proven that T-2 toxin caused hepatotoxicity in chicken, but the regulatory mechanism is unclear. In the present study, we assessed the toxicological effect of T-2 toxin on apoptosis and autophagy in hepatocytes. The total of 120 1-day-old healthy broilers were allocated randomly into four groups and reared for 21 day with complete feed containing 0 mg/kg, 0.5 mg/kg, 1 mg/kg or 2 mg/kg T-2 toxin, respectively. The results showed that the apoptosis rate and pathological changes degree hepatocytes were aggravated with the increase of T-2 toxin. At the molecular mechanism level, T-2 toxin induced mitochondria-mediated apoptosis by producing reactive oxygen species, promoting cytochrome c translocation between the mitochondria and cytoplasm, and thus promoting apoptosomes formation. Meanwhile, the expression of the autophagy-related protein, ATG5, ATG7 and Beclin-1, and the LC3-II/LC3-I ratio were increased, while p62 was downregulated, suggesting T-2 toxin caused autophagy in hepatocytes. Further experiments demonstrated that the PI3K/AKT/mTOR signal may be participated in autophagy induced by T-2 toxin in chicken hepatocytes. These data suggest a possible underlying molecular mechanism for T-2 toxin that induces apoptosis and autophagy in chicken hepatocytes.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yin</LastName>
            <ForeName>Huadong</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Shunshun</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Yuqi</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Farm Animal Genetic Resources Exploration and Innovation Key Laboratory of Sichuan Province, Sichuan Agricultural University, Chengdu 611130, Sichuan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Diyan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Farm Animal Genetic Resources Exploration and Innovation Key Laboratory of Sichuan Province, Sichuan Agricultural University, Chengdu 611130, Sichuan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Qing</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Farm Animal Genetic Resources Exploration and Innovation Key Laboratory of Sichuan Province, Sichuan Agricultural University, Chengdu 611130, Sichuan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>CARS-40</GrantID>
            <Agency>China Agriculture Research System</Agency>
            <Country>International</Country>
          </Grant>
          <Grant>
            <GrantID>2016NYZ0050</GrantID>
            <Agency>Sichuan Science and Technology Program</Agency>
            <Country>International</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>01</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Toxins (Basel)</MedlineTA>
        <NlmUniqueID>101530765</NlmUniqueID>
        <ISSNLinking>2072-6651</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071183">Autophagy-Related Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I3FL5NM3MO</RegistryNumber>
          <NameOfSubstance UI="D013605">T-2 Toxin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071183" MajorTopicYN="N">Autophagy-Related Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002645" MajorTopicYN="N">Chickens</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022781" MajorTopicYN="N">Hepatocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013605" MajorTopicYN="N">T-2 Toxin</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">T-2 toxin</Keyword>
        <Keyword MajorTopicYN="N">apoptosis</Keyword>
        <Keyword MajorTopicYN="N">autophagy</Keyword>
        <Keyword MajorTopicYN="N">chicken</Keyword>
        <Keyword MajorTopicYN="N">hepatocyte</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32013230</ArticleId>
        <ArticleId IdType="pmc">PMC7076762</ArticleId>
        <ArticleId IdType="doi">10.3390/toxins12020090</ArticleId>
        <ArticleId IdType="pii">toxins12020090</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Chen F., Ma Y., Xue C., Ma J., Xie Q., Wang G., Bi Y., Cao Y. The combination of deoxynivalenol and zearalenone at permitted feed concentrations causes serious physiological effects in young pigs. J. Vet. Sci. 2008;9:39&#x2013;44. doi: 10.4142/jvs.2008.9.1.39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4142/jvs.2008.9.1.39</ArticleId>
            <ArticleId IdType="pmc">PMC2839111</ArticleId>
            <ArticleId IdType="pubmed">18296887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization . Selected Mycotoxins: Ochratoxins, Trichothecenes, Ergot-Environmental Health Criteria 105. World Health Organization; Geneva, Switzerland: 1990.</Citation>
        </Reference>
        <Reference>
          <Citation>Smith J.E., Solomons G., Lewis C., Anderson J.G. Role of mycotoxins in human and animal nutrition and health. Nat. Toxins. 1995;3:187&#x2013;192. doi: 10.1002/nt.2620030404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/nt.2620030404</ArticleId>
            <ArticleId IdType="pubmed">7582615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rocha O., Ansari K., Doohan F. Effects of trichothecene mycotoxins on eukaryotic cells: A review. Food Addit. Contam. 2005;22:369&#x2013;378. doi: 10.1080/02652030500058403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/02652030500058403</ArticleId>
            <ArticleId IdType="pubmed">16019807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shinozuka J., Suzuki M., Noguchi N., Sugimoto T., Uetsuka K., Nakayama H., Doi K. T-2 toxin-induced apoptosis in hematopoietic tissues of mice. Toxicol. Pathol. 1998;26:674&#x2013;681. doi: 10.1177/019262339802600512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/019262339802600512</ArticleId>
            <ArticleId IdType="pubmed">9789955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ihara T., Sugamata M., Sekijima M., Okumura H., Yoshino N., Ueno Y. Apoptotic cellular damage in mice after T-2 toxin-induced acute toxicosis. Nat. Toxins. 1997;5:141&#x2013;145. doi: 10.1002/19970504NT3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/19970504NT3</ArticleId>
            <ArticleId IdType="pubmed">9407556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li G., Shinozuka J., Uetsuka K., Nakayama H., Doi K. T-2 toxin-induced apoptosis in intestinal crypt epithelial cells of mice. Exp. Toxicol. Pathol. 1997;49:447&#x2013;450. doi: 10.1016/S0940-2993(97)80132-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0940-2993(97)80132-7</ArticleId>
            <ArticleId IdType="pubmed">9495644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boonchuvit B., Hamilton P., Burmeister H. Interaction of T-2 toxin with Salmonella infections of chickens. Poult. Sci. 1975;54:1693&#x2013;1696. doi: 10.3382/ps.0541693.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3382/ps.0541693</ArticleId>
            <ArticleId IdType="pubmed">1103111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L., Tu D., Zhao Z., Cui J. Cytotoxicity and apoptosis induced by mixed mycotoxins (T-2 and HT-2 toxin) on primary hepatocytes of broilers in vitro. Toxicon. 2017;129:1&#x2013;10. doi: 10.1016/j.toxicon.2017.01.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxicon.2017.01.001</ArticleId>
            <ArticleId IdType="pubmed">28093223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maiuri M.C., Zalckvar E., Kimchi A., Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 2007;8:741. doi: 10.1038/nrm2239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm2239</ArticleId>
            <ArticleId IdType="pubmed">17717517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galbenu-Morvay P.L., Alexandra T., Damiescu L., Simion G. T-2 Toxin Occurrence in Cereals and Cereal-Based Foods. Bull. Univ. Agric. Sci. Vet. Med. Cluj-Napoca. Agric. 2011;68:274&#x2013;280.</Citation>
        </Reference>
        <Reference>
          <Citation>Li Y., Wang Z., Beier R.C., Shen J., Smet D.D., De Saeger S., Zhang S. T-2 toxin, a trichothecene mycotoxin: Review of toxicity, metabolism, and analytical methods. J. Agric. Food Chem. 2011;59:3441&#x2013;3453. doi: 10.1021/jf200767q.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jf200767q</ArticleId>
            <ArticleId IdType="pubmed">21417259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chi M., Mirocha C., Kurtz H., Weaver G., Bates F., Shimoda W. Subacute toxicity of T-2 toxin in broiler chicks. Poult. Sci. 1977;56:306&#x2013;313. doi: 10.3382/ps.0560306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3382/ps.0560306</ArticleId>
            <ArticleId IdType="pubmed">605011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber M., Fodor J., Balogh K., Wagner L., Erdelyi M., M&#xe9;zes M. Effect of vitamin E supplementation on immunity against Newcastle disease virus in T-2 toxin challenged chickens. Acta Vet. Brno. 2008;77:45&#x2013;49. doi: 10.2754/avb200877010045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2754/avb200877010045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raju M., Devegowda G. Esterified-glucomannan in broiler chicken diets-contaminated with aflatoxin, ochratoxin and T-2 toxin: Evaluation of its binding ability (in vitro) and efficacy as immunomodulator. Asian-Australas. J. Anim. Sci. 2002;15:1051&#x2013;1056. doi: 10.5713/ajas.2002.1051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5713/ajas.2002.1051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen B., Li D., Li M., Li S., Peng K., Shi X., Zhou L., Zhang P., Xu Z., Yin H. Induction of mitochondria-mediated apoptosis and PI3K/Akt/mTOR-mediated autophagy by aflatoxin B2 in hepatocytes of broilers. Oncotarget. 2016;7:84989. doi: 10.18632/oncotarget.13356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.13356</ArticleId>
            <ArticleId IdType="pmc">PMC5356714</ArticleId>
            <ArticleId IdType="pubmed">27863407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y., Zhang J., Mao X., Wu Y., Liu G., Song L., Li Y., Yang J., You Y., Cao X. High-sensitivity chemiluminescent immunoassay investigation and application for the detection of T-2 toxin and major metabolite HT-2 toxin. J. Sci. Food Agric. 2017;97:818&#x2013;822. doi: 10.1002/jsfa.7801.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jsfa.7801</ArticleId>
            <ArticleId IdType="pubmed">27185279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rachitha P., Khanum F. T-2 Mycotoxin induced toxicity: A review. Int. J. Curr. Res. 2014;12:10798&#x2013;10806.</Citation>
        </Reference>
        <Reference>
          <Citation>Moosavi M., Rezaei M., Kalantari H., Behfar A., Varnaseri G. l-carnitine protects rat hepatocytes from oxidative stress induced by T-2 toxin. Drug Chem. Toxicol. 2016;39:445&#x2013;450. doi: 10.3109/01480545.2016.1141423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/01480545.2016.1141423</ArticleId>
            <ArticleId IdType="pubmed">26888052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L., Yu Z., Hou J., Deng Y., Zhou Z., Zhao Z., Cui J. Toxicity and oxidative stress induced by T-2 toxin and HT-2 toxin in broilers and broiler hepatocytes. Food Chem. Toxicol. 2016;87:128&#x2013;137. doi: 10.1016/j.fct.2015.12.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fct.2015.12.003</ArticleId>
            <ArticleId IdType="pubmed">26683309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albarenque S.M., Doi K. T-2 toxin-induced apoptosis in rat keratinocyte primary cultures. Exp. Mol. Pathol. 2005;78:144&#x2013;149. doi: 10.1016/j.yexmp.2004.07.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexmp.2004.07.005</ArticleId>
            <ArticleId IdType="pubmed">15713441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith T. Recent advances in the understanding of Fusarium trichothecene mycotoxicoses. J. Anim. Sci. 1992;70:3989&#x2013;3993. doi: 10.2527/1992.70123989x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2527/1992.70123989x</ArticleId>
            <ArticleId IdType="pubmed">1474035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guerre P., Eeckhoutte C., Burgat V., Galtier P. The effects of T-2 toxin exposure on liver drug metabolizing enzymes in rabbit. Food Addit. Contam. 2000;17:1019&#x2013;1026. doi: 10.1080/02652030050207819.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/02652030050207819</ArticleId>
            <ArticleId IdType="pubmed">11271836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meissonnier G., Laffitte J., Raymond I., Benoit E., Cossalter A.-M., Pinton P., Bertin G., Oswald I., Galtier P. Subclinical doses of T-2 toxin impair acquired immune response and liver cytochrome P450 in pigs. Toxicology. 2008;247:46&#x2013;54. doi: 10.1016/j.tox.2008.02.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tox.2008.02.003</ArticleId>
            <ArticleId IdType="pubmed">18355953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ok S., Yu J., Lee Y., Cho H., Shin I., Sohn J. Lipid emulsion attenuates apoptosis induced by a toxic dose of bupivacaine in H9c2 rat cardiomyoblast cells. Hum. Exp. Toxicol. 2016;35:929&#x2013;937. doi: 10.1177/0960327115608930.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0960327115608930</ArticleId>
            <ArticleId IdType="pubmed">26437793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong W.W.L., Puthalakath H. Bcl-2 family proteins: The sentinels of the mitochondrial apoptosis pathway. Iubmb Life. 2008;60:390&#x2013;397. doi: 10.1002/iub.51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/iub.51</ArticleId>
            <ArticleId IdType="pubmed">18425793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haddad J.J. The role of Bax/Bcl-2 and pro-caspase peptides in hypoxia/reperfusion-dependent regulation of MAPKERK: Discordant proteomic effect of MAPKp38. Protein Pept. Lett. 2007;14:361&#x2013;371. doi: 10.2174/092986607780363925.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/092986607780363925</ArticleId>
            <ArticleId IdType="pubmed">17504094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mu P., Xu M., Zhang L., Wu K., Wu J., Jiang J., Chen Q., Wang L., Tang X., Deng Y. Proteomic changes in chicken primary hepatocytes exposed to T-2 toxin are associated with oxidative stress and mitochondrial enhancement. Proteomics. 2013;13:3175&#x2013;3188. doi: 10.1002/pmic.201300015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pmic.201300015</ArticleId>
            <ArticleId IdType="pubmed">24030954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J., Jing L., Yuan H., Peng S.-Q. T-2 toxin induces apoptosis in ovarian granulosa cells of rats through reactive oxygen species-mediated mitochondrial pathway. Toxicol. Lett. 2011;202:168&#x2013;177. doi: 10.1016/j.toxlet.2011.01.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxlet.2011.01.029</ArticleId>
            <ArticleId IdType="pubmed">21296132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang H., Wu Y., Guo J., Rong J., Ma L., Zhao Z., Zuo D., Peng S. T-2 toxin induces apoptosis in differentiated murine embryonic stem cells through reactive oxygen species-mediated mitochondrial pathway. Apoptosis. 2012;17:895&#x2013;907. doi: 10.1007/s10495-012-0724-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10495-012-0724-3</ArticleId>
            <ArticleId IdType="pubmed">22614820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizushima N., Komatsu M. Autophagy: Renovation of cells and tissues. Cell. 2011;147:728&#x2013;741. doi: 10.1016/j.cell.2011.10.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2011.10.026</ArticleId>
            <ArticleId IdType="pubmed">22078875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shang Y., Lu X. The relationship between apoptosis and autophagy in tumor therapy. Prog. Mod. Biomed. 2010;10:766&#x2013;769.</Citation>
        </Reference>
        <Reference>
          <Citation>Marquez R.T., Xu L. Bcl-2: Beclin 1 complex: multiple, mechanisms regulating autophagy/apoptosis toggle switch. Am. J. Cancer Res. 2012;2:214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3304572</ArticleId>
            <ArticleId IdType="pubmed">22485198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pattingre S., Tassa A., Qu X., Garuti R., Liang X.H., Mizushima N., Packer M., Schneider M.D., Levine B. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2005;122:927&#x2013;939. doi: 10.1016/j.cell.2005.07.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2005.07.002</ArticleId>
            <ArticleId IdType="pubmed">16179260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y., Zheng W., Bian X., Yuan Y., Gu J., Liu X., Liu Z., Bian J. Zearalenone induces apoptosis and cytoprotective autophagy in primary Leydig cells. Toxicol. Lett. 2014;226:182&#x2013;191. doi: 10.1016/j.toxlet.2014.02.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxlet.2014.02.003</ArticleId>
            <ArticleId IdType="pubmed">24530352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J., Zhou Y., Yuan Z., Yi J., Chen J., Wang N., Tian Y. Autophagy and Apoptosis Interact to Modulate T-2 Toxin-Induced Toxicity in Liver Cells. Toxins. 2019;11:45. doi: 10.3390/toxins11010045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins11010045</ArticleId>
            <ArticleId IdType="pmc">PMC6356273</ArticleId>
            <ArticleId IdType="pubmed">30650580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saiki S., Sasazawa Y., Imamichi Y., Kawajiri S., Fujimaki T., Tanida I., Kobayashi H., Sato F., Sato S., Ishikawa K.-I. Caffeine induces apoptosis by enhancement of autophagy via PI3K/Akt/mTOR/p70S6K inhibition. Autophagy. 2011;7:176&#x2013;187. doi: 10.4161/auto.7.2.14074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/auto.7.2.14074</ArticleId>
            <ArticleId IdType="pmc">PMC3039768</ArticleId>
            <ArticleId IdType="pubmed">21081844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y.-C., He S.-M., He Z.-X., Li M., Yang Y., Pang J.-X., Zhang X., Chow K., Zhou Q., Duan W. Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells. Cancer Lett. 2014;344:239&#x2013;259. doi: 10.1016/j.canlet.2013.11.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2013.11.001</ArticleId>
            <ArticleId IdType="pubmed">24280585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu G., Zhang W., Bertram P., Zheng X.F., McLeod H. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int. J. Oncol. 2004;24:893&#x2013;900. doi: 10.3892/ijo.24.4.893.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo.24.4.893</ArticleId>
            <ArticleId IdType="pubmed">15010827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang G.-L., Song J.-L., Ji C.-L., Feng Y.-L., Yu J., Nyachoti C.M., Yang G.-S. Zearalenone exposure enhanced the expression of tumorigenesis genes in donkey granulosa cells via the PTEN/PI3K/AKT signaling pathway. Front. Genet. 2018;9:293. doi: 10.3389/fgene.2018.00293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fgene.2018.00293</ArticleId>
            <ArticleId IdType="pmc">PMC6079390</ArticleId>
            <ArticleId IdType="pubmed">30108608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xing X., Wang J., Xing L.X., Li Y.H., Yan X., Zhang X.H. Involvement of MAPK and PI3K signaling pathway in sterigmatocystin-induced G2 phase arrest in human gastric epithelium cells. Mol. Nutr. Food Res. 2011;55:749&#x2013;760. doi: 10.1002/mnfr.201000344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mnfr.201000344</ArticleId>
            <ArticleId IdType="pubmed">21287681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S.-H., Son K.-M., Kim K.-Y., Yu S.-N., Park S.-G., Kim Y.-W., Nam H.-W., Suh J.-T., Ji J.-H., Ahn S.-C. Deoxypodophyllotoxin induces cytoprotective autophagy against apoptosis via inhibition of PI3K/AKT/mTOR pathway in osteosarcoma U2OS cells. Pharmacol. Rep. 2017;69:878&#x2013;884. doi: 10.1016/j.pharep.2017.04.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pharep.2017.04.007</ArticleId>
            <ArticleId IdType="pubmed">28623712</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31861958</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>01</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>01</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1520-5118</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>68</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jan</Month>
              <Day>08</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of agricultural and food chemistry</Title>
          <ISOAbbreviation>J Agric Food Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Asparanin A from Asparagus officinalis L. Induces G0/G1 Cell Cycle Arrest and Apoptosis in Human Endometrial Carcinoma Ishikawa Cells via Mitochondrial and PI3K/AKT Signaling Pathways.</ArticleTitle>
        <Pagination>
          <StartPage>213</StartPage>
          <EndPage>224</EndPage>
          <MedlinePgn>213-224</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jafc.9b07103</ELocationID>
        <Abstract>
          <AbstractText>Asparanin A (AA), a steroidal saponin from Asparagus officinalis L., has anticancer activity: however, its detailed molecular mechanisms in endometrial cancer (EC) have not been studied so far. We evaluated the anticancer activity and underlying mechanism of AA on EC cell line Ishikawa in vitro and in vivo. AA inhibited the Ishikawa cell proliferation and caused cell morphology alteration and cell cycle arrest in G0/G1 phase. Moreover, it could induce apoptosis through mitochondrial pathway, including the deregulation of Bak/Bcl-xl ratio which led to the generation of ROS, up-regulation of cytochrome c followed by decrease of Δψm, and activation of caspases, besides inhibition of the PI3K/AKT/mTOR pathway. In vivo data showed that administration of AA significantly inhibited the tumor tissue cell proliferation, reduced the tumor growth, and induced the apoptosis occurrence. AA can be a possible functional food ingredient to cure endometrial cancer followed by clinical trials.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Fan</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>School of Food and Biological Engineering , Hefei University of Technology , Hefei 230009 , People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Environmental Science and Engineering , Anhui Normal University , Wuhu 241002 , People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yuan-Yuan</ForeName>
            <Initials>YY</Initials>
            <AffiliationInfo>
              <Affiliation>School of Food and Biological Engineering , Hefei University of Technology , Hefei 230009 , People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Ya-Sai</ForeName>
            <Initials>YS</Initials>
            <Identifier Source="ORCID">0000-0002-1998-7998</Identifier>
            <AffiliationInfo>
              <Affiliation>School of Food and Biological Engineering , Hefei University of Technology , Hefei 230009 , People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Run-Hui</ForeName>
            <Initials>RH</Initials>
            <AffiliationInfo>
              <Affiliation>School of Food and Biological Engineering , Hefei University of Technology , Hefei 230009 , People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thakur</LastName>
            <ForeName>Kiran</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>School of Food and Biological Engineering , Hefei University of Technology , Hefei 230009 , People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jian-Guo</ForeName>
            <Initials>JG</Initials>
            <Identifier Source="ORCID">0000-0001-6020-6148</Identifier>
            <AffiliationInfo>
              <Affiliation>School of Food and Biological Engineering , Hefei University of Technology , Hefei 230009 , People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Zhao-Jun</ForeName>
            <Initials>ZJ</Initials>
            <Identifier Source="ORCID">0000-0003-1729-209X</Identifier>
            <AffiliationInfo>
              <Affiliation>School of Food and Biological Engineering , Hefei University of Technology , Hefei 230009 , People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Agric Food Chem</MedlineTA>
        <NlmUniqueID>0374755</NlmUniqueID>
        <ISSNLinking>0021-8561</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012503">Saponins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C540172">asparanin A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-43-6</RegistryNumber>
          <NameOfSubstance UI="D045304">Cytochromes c</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D027761" MajorTopicYN="N">Asparagus Plant</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045304" MajorTopicYN="N">Cytochromes c</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016889" MajorTopicYN="N">Endometrial Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059585" MajorTopicYN="N">G1 Phase Cell Cycle Checkpoints</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016192" MajorTopicYN="N">Resting Phase, Cell Cycle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012503" MajorTopicYN="N">Saponins</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Ishikawa cell</Keyword>
        <Keyword MajorTopicYN="N">PI3K/AKT</Keyword>
        <Keyword MajorTopicYN="N">asparagus</Keyword>
        <Keyword MajorTopicYN="N">asparanin A</Keyword>
        <Keyword MajorTopicYN="N">mitochondrial pathway</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31861958</ArticleId>
        <ArticleId IdType="doi">10.1021/acs.jafc.9b07103</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31830478</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>01</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>01</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0631</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>241</Volume>
            <PubDate>
              <Year>2020</Year>
              <Month>Jan</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Life sciences</Title>
          <ISOAbbreviation>Life Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>High glucose augments ROS generation regulates mitochondrial dysfunction and apoptosis via stress signalling cascades in keratinocytes.</ArticleTitle>
        <Pagination>
          <StartPage>117148</StartPage>
          <MedlinePgn>117148</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lfs.2019.117148</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0024-3205(19)31076-8</ELocationID>
        <Abstract>
          <AbstractText>Mitochondria are fascinating structures of the cellular compartments that generate energy to run the cells. However, inherent disorders of mitochondria due to diabetes can cause major disruption of metabolism that produces huge amount of reactive oxygen species (ROS). Here we study the elevated level of ROS provoked by high glucose (HG) environment triggered mitochondrial dysfunction, inflammatory response and apoptosis via stress signalling pathway in keratinocytes. Our results demonstrated that elevated glucose level in keratinoctes, increase the accumulations of ROS and decrease in cellular antioxidant capacities. Moreover, excess production of ROS was associated with mitochondrial dysfunction, characterized by loss of mitochondrial membrane potential (ΔΨm), increase in mitochondrial mass, alteration of mitochondrial respiratory complexes, cytochrome c (Cyt c) release, decrease in mitochondrial transcription factor A (TFAM) and increase in mitochondrial DNA (mtDNA) fragmentation. Damaged mtDNA escaped into the cytosol, where it engaged the activation of ERK1/2, PI3K/Akt, tuberin and mTOR via cGAS-STING leading to IRF3 activation. Pre-treatment of pharmacological inhibitors, ERK1/2 or PI3K/Akt suppressed the IRF3 activation. Furthermore, our results demonstrated that activation of IRF3 in HG environment coinciding with increased expression of inflammatory mediators. Excess production of ROS interfered with decreased in cell viability, increased lysosomal content and expression of FoxOs, leading to cell cycle deregulation and apoptosis. Pre-treatment of N-acetyl-l-cysteine (NAC) significantly reduced the HG-induced cell cycle deregulation and apoptosis in keratinocytes. In conclusion, increased oxidative stress underlies the decrease in antioxidant capacities and mitochondrial dysfunction in HG environment correlate with inflammation response and apoptosis via ERK1/2-PI3K/Akt-IRF3 pathway in keratinoctes.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rizwan</LastName>
            <ForeName>Huma</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>School of Biotechnology, Kalinga Institute of Industrial Technology, Bhubaneswar 751024, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pal</LastName>
            <ForeName>Sweta</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>School of Biotechnology, Kalinga Institute of Industrial Technology, Bhubaneswar 751024, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sabnam</LastName>
            <ForeName>Silpa</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>School of Biotechnology, Kalinga Institute of Industrial Technology, Bhubaneswar 751024, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pal</LastName>
            <ForeName>Arttatrana</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>School of Biotechnology, Kalinga Institute of Industrial Technology, Bhubaneswar 751024, India; Department of Zoology, School of Life Sciences, Mahatma Gandhi Central University, Motihari, Bihar 845401, India. Electronic address: arttatranapal@mgcub.ac.in.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Life Sci</MedlineTA>
        <NlmUniqueID>0375521</NlmUniqueID>
        <ISSNLinking>0024-3205</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013549">Sweetening Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IY9XDZ35W2</RegistryNumber>
          <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015603" MajorTopicYN="N">Keratinocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008812" MajorTopicYN="N">Mice, Hairless</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013549" MajorTopicYN="N">Sweetening Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">High glucose</Keyword>
        <Keyword MajorTopicYN="N">IRF3</Keyword>
        <Keyword MajorTopicYN="N">Inflammation</Keyword>
        <Keyword MajorTopicYN="N">cGAS-STING</Keyword>
        <Keyword MajorTopicYN="N">mtDNA damage</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31830478</ArticleId>
        <ArticleId IdType="doi">10.1016/j.lfs.2019.117148</ArticleId>
        <ArticleId IdType="pii">S0024-3205(19)31076-8</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31828466</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-6830</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>40</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cellular and molecular neurobiology</Title>
          <ISOAbbreviation>Cell Mol Neurobiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Berberine attenuated the cytotoxicity induced by t-BHP via inhibiting oxidative stress and mitochondria dysfunction in PC-12 cells.</ArticleTitle>
        <Pagination>
          <StartPage>587</StartPage>
          <EndPage>602</EndPage>
          <MedlinePgn>587-602</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10571-019-00756-7</ELocationID>
        <Abstract>
          <AbstractText>Neurodegenerative diseases all share several common features such as involvement of oxidative damage and mitochondrial dysfunction in pathogenesis. Oxidative stress induced by overproduction of mitochondrial reactive oxygen species (ROS) or impairment of the antioxidant deficiency results in mitochondrial dysfunction and initiation of the cell death cascade. Berberine (BBR), a traditional Chinese medicine, has been reported to exert anti-oxidative stress and anti-apoptosis effect in CNS diseases. However, the mechanism of BBR on regulating mitophagy and protecting mitochondrial function under oxidative stress remains unclear. In present study, we evaluated the beneficial effects of BBR on the tert-butyl hydroperoxide (t-BHP)-induced cytotoxicity. Furthermore, we explored the protective role of BBR in mitochondrial function and mitophagy under oxidative stress in PC-12 cells. Our results demonstrated that BBR effectively inhibited t-BHP-induced apoptosis which is associated with the decreased leakage of lactate dehydrogenase (LDH) and ROS overproduction. Moreover, BBR significantly suppressed cytochrome c expression, upregulated the ratio of Bcl-2/Bax, and ameliorated mitochondrial dysfunction by optimizing mitochondria membrane potential (ΔΨm) status and ATP production. In addition, BBR reduced the expression of autophagy-specific marker LC3, SQTM1/p62, and maintained lysosome normal function which involved the restoration of upstream signaling pathway AKT and mTOR phosphorylation level. Collectively, these findings suggested that BBR protects PC-12 cells from oxidative injury through inhibiting ROS level, mitochondria dysfunction, and mitophagy via PI3K/AKT/mTOR signaling pathways, which suggest a potential therapeutic strategy for oxidative stress and neurotoxic damages.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Zhengmao</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Ting</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Qi</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Ke</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Life Sciences, Wenzhou University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Jianping</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Shaoxing No. 2 Hospital, Shaoxing, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Lei</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopaedics, Shaoxing No. 2 Hospital, Shaoxing, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Zaifeng</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Cixi People's Hospital, Wenzhou Medical Uinversity, Ninbo, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Zhilong</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ye</LastName>
            <ForeName>Luxia</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Kebin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Hongyu</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0003-1946-5468</Identifier>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China. hyzhang@wmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Aiping</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China. hap@wmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>LQ16H090007</GrantID>
            <Agency>Natural Science Foundation of Zhejiang Province</Agency>
          </Grant>
          <Grant>
            <GrantID>LY14H090013</GrantID>
            <Agency>Natural Science Foundation of Zhejiang Province</Agency>
          </Grant>
          <Grant>
            <GrantID>LQ18H090008</GrantID>
            <Agency>Natural Science Foundation of Zhejiang Province</Agency>
          </Grant>
          <Grant>
            <GrantID>LQ18H150003</GrantID>
            <Agency>Natural Science Foundation of Zhejiang Province</Agency>
          </Grant>
          <Grant>
            <GrantID>R18H50001</GrantID>
            <Agency>Natural Science Foundation of Zhejiang Province</Agency>
          </Grant>
          <Grant>
            <GrantID>81501953</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>81572237</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>81772450</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>81722028</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>2018A610309</GrantID>
            <Agency>Natural Science Foundation of Ningbo</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cell Mol Neurobiol</MedlineTA>
        <NlmUniqueID>8200709</NlmUniqueID>
        <ISSNLinking>0272-4340</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002867">Chromones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C526109">LC3 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009025">Morpholines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0I8Y3P32UF</RegistryNumber>
          <NameOfSubstance UI="D001599">Berberine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31M2U1DVID</RegistryNumber>
          <NameOfSubstance UI="C085911">2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-43-6</RegistryNumber>
          <NameOfSubstance UI="D045304">Cytochromes c</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>955VYL842B</RegistryNumber>
          <NameOfSubstance UI="D020122">tert-Butylhydroperoxide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001599" MajorTopicYN="N">Berberine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002867" MajorTopicYN="N">Chromones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045304" MajorTopicYN="N">Cytochromes c</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063306" MajorTopicYN="N">Mitophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009025" MajorTopicYN="N">Morpholines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016716" MajorTopicYN="N">PC12 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020122" MajorTopicYN="N">tert-Butylhydroperoxide</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Berberine (BBR)</Keyword>
        <Keyword MajorTopicYN="N">Mitophagy</Keyword>
        <Keyword MajorTopicYN="N">Neurotoxicity Analysis of variance</Keyword>
        <Keyword MajorTopicYN="N">Oxidative stress</Keyword>
        <Keyword MajorTopicYN="N">PI3K/AKT/mTOR</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31828466</ArticleId>
        <ArticleId IdType="doi">10.1007/s10571-019-00756-7</ArticleId>
        <ArticleId IdType="pii">10.1007/s10571-019-00756-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Antioxid Redox Signal. 2014 Feb 1;20(4):574-88</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23875776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apoptosis. 2008 Apr;13(4):588-99</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18299995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Autophagy. 2013 Nov 1;9(11):1780-800</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24121705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sci Rep. 2017 Sep 12;7(1):11340</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28900305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Exp Med. 2017 Aug 7;214(8):2405-2420</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28626071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Pineal Res. 2018 Apr;64(3):</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29247557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>FASEB J. 2005 Dec;19(14):2040-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16210396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Int J Mol Sci. 2018 Jun 12;19(6):</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29895743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Exp Cell Res. 2015 Jun 10;334(2):194-206</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25889370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sci Signal. 2017 Aug 01;10(490):</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28765513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mol Cell. 2015 Aug 20;59(4):517-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26295958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Pineal Res. 2009 Oct;47(3):238-52</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19664004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Autophagy. 2015 Apr 3;11(4):643-52</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25919711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Exp Neurol. 2018 Feb;300:149-166</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29129468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mol Cells. 2013 Feb;35(2):151-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23329300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Front Neuroendocrinol. 1999 Apr;20(2):97-121</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10328986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell Death Dis. 2017 Jan 19;8(1):e2558</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28102849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Cell Biol. 2019 Feb;21(2):133-142</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30602725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Int J Mol Sci. 2018 Mar 06;19(3):</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29509701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Autophagy. 2019 Sep;15(9):1606-1619</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30859901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biomed Pharmacother. 2019 Nov;119:109445</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31541852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toxicol Lett. 2017 Oct 5;280:29-40</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28802652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trends Pharmacol Sci. 2017 Jul;38(7):592-607</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28551354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neuropharmacology. 2018 Mar 15;131:256-270</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29273519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aging Cell. 2011 Oct;10(5):807-23</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21615675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell Death Differ. 2009 Jul;16(7):1040-52</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19407826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell Mol Life Sci. 2019 Dec;76(23):4783-4794</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31168659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oxid Med Cell Longev. 2019 May 2;2019:7593608</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31191803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Am Soc Nephrol. 2010 Feb;21(2):272-83</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19959713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Redox Biol. 2017 Apr;11:1-11</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27835779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Neurosci Res. 2010 Feb 1;88(2):428-37</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19746425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ann Neurol. 2006 Apr;59(4):700-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16532490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mol Carcinog. 2015 Oct;54(10):1096-109</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24838344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brain. 2008 Aug;131(Pt 8):1969-78</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18187492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Acta Diabetol. 2019 Nov;56(11):1177-1189</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31115753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Biol Chem. 2011 Mar 25;286(12):10814-24</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21252228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biosci Rep. 2019 Jul 23;39(7):</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31273059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Redox Biol. 2017 Apr;11:613-619</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28110218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell Mol Neurobiol. 2015 Jul;35(5):615-21</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25722131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Free Radic Biol Med. 2018 May 20;120:228-238</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29559323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Cell Mol Med. 2018 May;22(5):2727-2738</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29512938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phytother Res. 2011 Jun;25(6):816-20</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21086546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Endocrinol. 2009 Feb;200(2):159-65</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18996945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Autophagy. 2007 May-Jun;3(3):259-62</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17329960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell Death Dis. 2017 Oct 5;8(10):e3081</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28981117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trends Biochem Sci. 2011 Jan;36(1):30-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20728362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Commun. 2018 Jan 17;9(1):256</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29343728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Leukoc Biol. 2018 Jan 22;:</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29357116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neurol Res Int. 2012;2012:542976</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22548167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Physiol Rev. 2019 Jan 1;99(1):853-892</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30540226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Free Radic Biol Med. 2017 Jul;108:819-831</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28478025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Front Pharmacol. 2018 Jul 27;9:782</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30100874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Int J Cardiol. 2013 Aug 10;167(3):936-42</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22465347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antioxid Redox Signal. 2019 Sep 20;31(9):643-663</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30957515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Autophagy. 2010 Apr;6(3):366-77</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20168088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nitric Oxide. 2019 Oct 1;91:23-34</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31323277</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">31454650</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1618-095X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>64</Volume>
            <PubDate>
              <Year>2019</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Phytomedicine : international journal of phytotherapy and phytopharmacology</Title>
          <ISOAbbreviation>Phytomedicine</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Effect of euphorbia factor L1 on oxidative stress, apoptosis, and autophagy in human gastric epithelial cells.</ArticleTitle>
        <Pagination>
          <StartPage>152929</StartPage>
          <MedlinePgn>152929</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.phymed.2019.152929</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0944-7113(19)30098-4</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Euphorbia factor L1 (EFL1), a lathyrane-type diterpenoid from the medicinal herb Euphorbia lathyris L. (Euphorbiaceae), has been reported for many decades to induce gastric irritation, but the underlying mechanisms remain unclear.</AbstractText>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The objective of this study was to investigate EFL1-induced cytotoxicity and the potential mechanisms of action on the human normal gastric epithelial cell GES-1.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">GES-1 cells were treated with EFL1 (12.5-200&#x202f;&#x3bc;M) for different time intervals, and cell survival, LDH release, intracellular reactive oxygen species (ROS), malondialdehyde (MDA) content, and superoxide dismutase (SOD) activity were detected. Mitochondrial membrane potential (MMP) assay, DAPI staining, DNA fragment assay, and annexin V-FITC/PI staining were performed. The interaction between EFL1 and Bcl-2, cytochrome c, caspase-9, caspase-3, PI3K, AKT, and mTOR proteins was simulated by molecular docking. The mRNA and protein expression of apoptosis and autophagy factors were detected by RT-qPCR and Western blotting.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">EFL1 decreased survival, increased LDH leakage, and induced abnormal production of ROS, MDA and SOD in GES-1 cells. Mitochondria-mediated apoptosis was characterized by decreased MMP, condensed nuclei, fragmented DNA, and increased apoptosis rate. EFL1 interacted with proteins via hydrogen bonding. The mRNA, total or phosphorylated protein expression of Bcl-2, mitochondrial cytochrome c, PI3K, AKT, mTOR and p62 were downregulated; in contrast, those of cytoplasmic cytochrome c, cleaved caspase-9, cleaved caspase-3, LC3-ll and Beclin-1 were upregulated.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings indicated that EFL1 decreased the survival of GES-1 cells through EFL1-induced oxidative stress, activation of the mitochondria-mediated apoptosis as well as autophagy via inhibition of the PI3K/AKT/mTOR pathway.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2019 Elsevier GmbH. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>An</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Toxicology, School of Public Health, Peking University, Beijing 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Yuqing</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Toxicology, School of Public Health, Peking University, Beijing 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhong</LastName>
            <ForeName>Qianwen</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Toxicology, School of Public Health, Peking University, Beijing 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Jinlan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Toxicology, School of Public Health, Peking University, Beijing 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Tao</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Toxicology, School of Public Health, Peking University, Beijing 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Jingwei</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Toxicology, School of Public Health, Peking University, Beijing 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Qi</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Toxicology, School of Public Health, Peking University, Beijing 100191, China; Key Laboratory of State Administration of Traditional Chinese Medicine for Compatibility Toxicology, Beijing 100191, China; Beijing Key Laboratory of Toxicological Research and Risk Assessment for Food Safety, Beijing 100191, China. Electronic address: wangqi@bjmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>04</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Phytomedicine</MedlineTA>
        <NlmUniqueID>9438794</NlmUniqueID>
        <ISSNLinking>0944-7113</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004224">Diterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010666">Phenylpropionates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C559819">euphorbia factor L1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C530347">lathyrane</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004224" MajorTopicYN="N">Diterpenes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004847" MajorTopicYN="N">Epithelial Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D028481" MajorTopicYN="N">Euphorbia</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010666" MajorTopicYN="N">Phenylpropionates</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">Autophagy</Keyword>
        <Keyword MajorTopicYN="N">Euphorbia factor L1</Keyword>
        <Keyword MajorTopicYN="N">Gastric toxicity</Keyword>
        <Keyword MajorTopicYN="N">Mitochondria</Keyword>
        <Keyword MajorTopicYN="N">Oxidative stress</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31454650</ArticleId>
        <ArticleId IdType="doi">10.1016/j.phymed.2019.152929</ArticleId>
        <ArticleId IdType="pii">S0944-7113(19)30098-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31398899</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>01</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1420-3049</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>24</Volume>
            <Issue>16</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Aug</Month>
              <Day>08</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecules (Basel, Switzerland)</Title>
          <ISOAbbreviation>Molecules</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Involvement of Mitochondrial Dysfunction, Endoplasmic Reticulum Stress, and the PI3K/AKT/mTOR Pathway in Nobiletin-Induced Apoptosis of Human Bladder Cancer Cells.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">2881</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules24162881</ELocationID>
        <Abstract>
          <AbstractText>Nobiletin (NOB) is a polymethoxylated flavonoid isolated from citrus fruit peel that has been shown to possess anti-tumor, antithrombotic, antifungal, anti-inflammatory and anti-atherosclerotic activities. The main purpose of this study was to explore the potential of using NOB to induce apoptosis in human bladder cancer cells and study the underlying mechanism. Using an MTT assay, agarose gel electrophoresis, a wound-healing assay, flow cytometry, and western blot analysis, this study investigated the signaling pathways involved in NOB-induced apoptosis in BFTC human bladder cancer cells. Our results showed that NOB at concentrations of 60, 80, and 100 μM inhibited cell growth by 42%, 62%, and 80%, respectively. Cells treated with 60 μM NOB demonstrated increased DNA fragmentation, and flow cytometry analysis confirmed that the treatment caused late apoptotic cell death. Western blot analysis showed that mitochondrial dysfunction occurred in NOB-treated BFTC cells, leading to cytochrome C release into cytosol, activation of pro-apoptotic proteins (caspase-3, caspase-9, Bad, and Bax), and inhibition of anti-apoptotic proteins (Mcl-1, Bcl-xl, and Bcl-2). NOB-induced apoptosis was also mediated by regulating endoplasmic reticulum stress via the PERK/elF2α/ATF4/CHOP pathway, and downregulating the PI3K/AKT/mTOR pathway. Our results suggested that the cytotoxic and apoptotic effects of NOB on bladder cancer cells are associated with endoplasmic reticulum stress and mitochondrial dysfunction.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Goan</LastName>
            <ForeName>Yih-Gang</ForeName>
            <Initials>YG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Kaohsiung Veterans General Hospital Pingtung Branch, Pingtung 91202, Taiwan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Thoracic Surgery, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung 81362, Taiwan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Nursing, Meiho University, Pingtung 91202, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Wen-Tung</ForeName>
            <Initials>WT</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Food Science and Nutrition, Meiho University, Pingtung 91202, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Chih-I</ForeName>
            <Initials>CI</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nursing, Meiho University, Pingtung 91202, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Neoh</LastName>
            <ForeName>Choo-Aun</ForeName>
            <Initials>CA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Research, Pingtung Christian Hospital, Pingtung 90059, Taiwan. neohca@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Yu-Jen</ForeName>
            <Initials>YJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nursing, Meiho University, Pingtung 91202, Taiwan. wyr924@ms24.hinet.net.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biological Technology, Meiho University, Pingtung 91202, Taiwan. wyr924@ms24.hinet.net.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Yu Jun Biotechnology Co., Ltd., Kaohsiung 81363, Taiwan. wyr924@ms24.hinet.net.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>08</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Molecules</MedlineTA>
        <NlmUniqueID>100964009</NlmUniqueID>
        <ISSNLinking>1420-3049</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047309">Flavones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>D65ILJ7WLY</RegistryNumber>
          <NameOfSubstance UI="C008661">nobiletin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059865" MajorTopicYN="N">Endoplasmic Reticulum Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047309" MajorTopicYN="N">Flavones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001749" MajorTopicYN="N">Urinary Bladder Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">PI3K/AKT/mTOR pathway</Keyword>
        <Keyword MajorTopicYN="N">endoplasmic reticulum stress</Keyword>
        <Keyword MajorTopicYN="N">mitochondrial dysfunction</Keyword>
        <Keyword MajorTopicYN="N">nobiletin</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31398899</ArticleId>
        <ArticleId IdType="pmc">PMC6719163</ArticleId>
        <ArticleId IdType="doi">10.3390/molecules24162881</ArticleId>
        <ArticleId IdType="pii">molecules24162881</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Gotoh A., Nagaya H., Kanno T., Nishizaki T. Antitumor action of alpha(1)-adrenoceptor blockers on human bladder, prostate and renal cancer cells. Pharmacology. 2012;90:242&#x2013;246. doi: 10.1159/000342797.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000342797</ArticleId>
            <ArticleId IdType="pubmed">23007551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J.J. Recent advances in treatment of advanced urothelial carcinoma. Curr. Urol. Rep. 2012;13:147&#x2013;152. doi: 10.1007/s11934-012-0238-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11934-012-0238-0</ArticleId>
            <ArticleId IdType="pmc">PMC4009980</ArticleId>
            <ArticleId IdType="pubmed">22367511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azemar M., Audouin M., Revaux A., Misrai V., Comperat E., Bitker M., Chartier-Kastler E., Richard F., Cussenot O., Roupret M. Primary upper urinary tract tumors and subsequent location in the bladder. Prog. Urol. 2009;19:583&#x2013;588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19800544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dzombeta T., Krajaci&#x107;-Jagarcec G., Tomas D., Kraus O., Ruzi&#x107; B., Kruslin B. Urothelial carcinoma with an inverted growth pattern: A report of 4 cases. Acta Med. Croat. 2010;64:47&#x2013;50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20653125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi B., Zhang K., Zhang J., Chen J., Zhang N., Xu Z. Relationship between patient age and superficial transitional cell carcinoma characteristics. Urology. 2008;71:1186&#x2013;1190. doi: 10.1016/j.urology.2008.01.062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.urology.2008.01.062</ArticleId>
            <ArticleId IdType="pubmed">18372010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eichhorn J.H., Young R.H. Transitional cell carcinoma of the ovary: A morphologic study of 100 cases with emphasis on differential diagnosis. Am. J. Surg. Pathol. 2004;28:453&#x2013;463. doi: 10.1097/00000478-200404000-00004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00000478-200404000-00004</ArticleId>
            <ArticleId IdType="pubmed">15087664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amling C.L. Diagnosis and management of superficial bladder cancer. Curr. Probl. Cancer. 2001;25:219&#x2013;278. doi: 10.1067/mcn.2001.117539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1067/mcn.2001.117539</ArticleId>
            <ArticleId IdType="pubmed">11514784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Babjuk M., Dvor&#xe1;cek J. Diagnosis and therapy of superficial tumors of the urinary bladder. Cas. Lek. Cesk. 2002;141:723&#x2013;728.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12650028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z., Lu T., Du L., Hu Z., Zhuang Q., Li Y., Wang C.Y., Zhu H., Ye Z. Plasmacytoid urothelial carcinoma of the urinary bladder: A clinical pathological study and literature review. Int. J. Clin. Exp. Pathol. 2012;5:601&#x2013;608.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3430099</ArticleId>
            <ArticleId IdType="pubmed">22949945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ichigo S., Takagi H., Matsunami K., Murase T., Ikeda T., Imai A. Transitional cell carcinoma of the ovary (review) Oncol. Lett. 2012;3:3&#x2013;6. doi: 10.3892/ol.2011.453.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2011.453</ArticleId>
            <ArticleId IdType="pmc">PMC3362466</ArticleId>
            <ArticleId IdType="pubmed">22740845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu C.I., Wang R.Y., Lin J.J., Su J.H., Chiu C.C., Chen J.C., Chen J.Y., Wu Y.J. Proteomic profiling of the 11-dehydrosinulariolide-treated oral carcinoma cells ca9-22: Effects on the cell apoptosis through mitochondrial-related and er stress pathway. J. Proteomics. 2012;75:5578&#x2013;5589. doi: 10.1016/j.jprot.2012.07.037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jprot.2012.07.037</ArticleId>
            <ArticleId IdType="pubmed">22885288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Denicourt C., Dowdy S.F. Medicine. Targeting apoptotic pathways in cancer cells. Science. 2004;305:1411&#x2013;1413. doi: 10.1126/science.1102974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1102974</ArticleId>
            <ArticleId IdType="pubmed">15353788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao C.T., Chang J.T., Wang H.M., Ng S.H., Hsueh C., Lee L.Y., Lin C.H., Chen I.H., Huang S.F., Cheng A.J., et al. Analysis of risk factors of predictive local tumor control in oral cavity cancer. Ann. Surg. Oncol. 2008;15:915&#x2013;922. doi: 10.1245/s10434-007-9761-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1245/s10434-007-9761-5</ArticleId>
            <ArticleId IdType="pubmed">18165878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amarante-Mendes G.P., Naekyung Kim C., Liu L., Huang Y., Perkins C.L., Green D.R., Bhalla K. Bcr-abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3. Blood. 1998;91:1700&#x2013;1705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9473236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicholson D.W., Thornberry N.A. Life and death decisions. Science. 2003;299:214&#x2013;215. doi: 10.1126/science.1081274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1081274</ArticleId>
            <ArticleId IdType="pubmed">12522239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morgensztern D., McLeod H.L. Pi3k/akt/mtor pathway as a target for cancer therapy. Anticancer Drugs. 2005;16:797&#x2013;803. doi: 10.1097/01.cad.0000173476.67239.3b.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.cad.0000173476.67239.3b</ArticleId>
            <ArticleId IdType="pubmed">16096426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LoPiccolo J., Blumenthal G.M., Bernstein W.B., Dennis P.A. Targeting the pi3k/akt/mtor pathway: Effective combinations and clinical considerations. Drug Resist. Updat. 2008;11:32&#x2013;50. doi: 10.1016/j.drup.2007.11.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drup.2007.11.003</ArticleId>
            <ArticleId IdType="pmc">PMC2442829</ArticleId>
            <ArticleId IdType="pubmed">18166498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cirillo P., Conte S., Cimmino G., Pellegrino G., Ziviello F., Barra G., Sasso F.C., Borgia F., De Palma R., Trimarco B. Nobiletin inhibits oxidized-ldl mediated expression of tissue factor in human endothelial cells through inhibition of nf-&#x3ba;b. Biochem. Pharmacol. 2017;128:26&#x2013;33. doi: 10.1016/j.bcp.2016.12.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2016.12.016</ArticleId>
            <ArticleId IdType="pubmed">28017776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goh J.X.H., Tan L.T.H., Goh J.K., Chan K.G., Pusparajah P., Lee L.H., Goh B.H. Nobiletin and derivatives: Functional compounds from citrus fruit peel for colon cancer chemoprevention. Cancers. 2019;11:867. doi: 10.3390/cancers11060867.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11060867</ArticleId>
            <ArticleId IdType="pmc">PMC6627117</ArticleId>
            <ArticleId IdType="pubmed">31234411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guney Eskiler G., Deveci A.O., Bilir C., Kaleli S. Synergistic effects of nobiletin and sorafenib combination on metastatic prostate cancer cells. Nutr. Cancer. 2019:1&#x2013;14. doi: 10.1080/01635581.2019.1601237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/01635581.2019.1601237</ArticleId>
            <ArticleId IdType="pubmed">31037974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin Z., Wu D., Huang L., Jiang C., Pan T., Kang X., Pan J. Nobiletin inhibits il-1&#x3b2;-induced inflammation in chondrocytes via suppression of nf-kb signaling and attenuates osteoarthritis in mice. Front. Pharmacol. 2019;10:570. doi: 10.3389/fphar.2019.00570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2019.00570</ArticleId>
            <ArticleId IdType="pmc">PMC6554687</ArticleId>
            <ArticleId IdType="pubmed">31214026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshimizu N., Otani Y., Saikawa Y., Kubota T., Yoshida M., Furukawa T., Kumai K., Kameyama K., Fujii M., Yano M. Anti-tumour effects of nobiletin, a citrus flavonoid, on gastric cancer include: Antiproliferative effects, induction of apoptosis and cell cycle deregulation. Aliment. Pharmacol. Ther. 2004;20:95&#x2013;101. doi: 10.1111/j.1365-2036.2004.02082.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2036.2004.02082.x</ArticleId>
            <ArticleId IdType="pubmed">15298613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagase H., Yamakuni T., Matsuzaki K., Maruyama Y., Kasahara J., Hinohara Y., Kondo S., Mimaki Y., Sashida Y., Tank A.W., et al. Mechanism of neurotrophic action of nobiletin in pc12d cells. Biochemistry. 2005;44:13683&#x2013;13691. doi: 10.1021/bi050643x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi050643x</ArticleId>
            <ArticleId IdType="pubmed">16229458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsuzaki K., Miyazaki K., Sakai S., Yawo H., Nakata N., Moriguchi S., Fukunaga K., Yokosuka A., Sashida Y., Mimaki Y., et al. Nobiletin, a citrus flavonoid with neurotrophic action, augments protein kinase a-mediated phosphorylation of the ampa receptor subunit, glur1, and the postsynaptic receptor response to glutamate in murine hippocampus. Eur. J. Pharmacol. 2008;578:194&#x2013;200. doi: 10.1016/j.ejphar.2007.09.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejphar.2007.09.028</ArticleId>
            <ArticleId IdType="pubmed">17976577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakajima A., Yamakuni T., Haraguchi M., Omae N., Song S.Y., Kato C., Nakagawasai O., Tadano T., Yokosuka A., Mimaki Y., et al. Nobiletin, a citrus flavonoid that improves memory impairment, rescues bulbectomy-induced cholinergic neurodegeneration in mice. J. Pharmacol. Sci. 2007;105:122&#x2013;126. doi: 10.1254/jphs.SC0070155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1254/jphs.SC0070155</ArticleId>
            <ArticleId IdType="pubmed">17895593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onozuka H., Nakajima A., Matsuzaki K., Shin R.W., Ogino K., Saigusa D., Tetsu N., Yokosuka A., Sashida Y., Mimaki Y., et al. Nobiletin, a citrus flavonoid, improves memory impairment and abeta pathology in a transgenic mouse model of alzheimer&#x2019;s disease. J. Pharmacol. Exp. Ther. 2008;326:739&#x2013;744. doi: 10.1124/jpet.108.140293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/jpet.108.140293</ArticleId>
            <ArticleId IdType="pubmed">18544674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawaii S., Tomono Y., Katase E., Ogawa K., Yano M. Antiproliferative activity of flavonoids on several cancer cell lines. Biosci. Biotechnol. Biochem. 1999;63:896&#x2013;899. doi: 10.1271/bbb.63.896.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1271/bbb.63.896</ArticleId>
            <ArticleId IdType="pubmed">10380632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato T., Koike L., Miyata Y., Hirata M., Mimaki Y., Sashida Y., Yano M., Ito A. Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinases-1 and -9 in human fibrosarcoma ht-1080 cells. Cancer Res. 2002;62:1025&#x2013;1029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11861377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishiwa J., Sato T., Mimaki Y., Sashida Y., Yano M., Ito A. A citrus flavonoid, nobiletin, suppresses production and gene expression of matrix metalloproteinase 9/gelatinase b in rabbit synovial fibroblasts. J. Rheumatol. 2000;27:20&#x2013;25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10648013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minagawa A., Otani Y., Kubota T., Wada N., Furukawa T., Kumai K., Kameyama K., Okada Y., Fujii M., Yano M., et al. The citrus flavonoid, nobiletin, inhibits peritoneal dissemination of human gastric carcinoma in scid mice. Jpn. J. Cancer Res. 2001;92:1322&#x2013;1328. doi: 10.1111/j.1349-7006.2001.tb02156.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1349-7006.2001.tb02156.x</ArticleId>
            <ArticleId IdType="pmc">PMC5926678</ArticleId>
            <ArticleId IdType="pubmed">11749698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian T., Nan K.J., Guo H., Wang W.J., Ruan Z.P., Wang S.H., Liang X., Lu C.X. Pten inhibits the migration and invasion of hepg2 cells by coordinately decreasing mmp expression via the pi3k/akt pathway. Oncol. Rep. 2010;23:1593&#x2013;1600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20428814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawaii S., Tomono Y., Katase E., Ogawa K., Yano M. Effect of citrus flavonoids on hl-60 cell differentiation. Anticancer Res. 1999;19:1261&#x2013;1269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10368686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohnishi H., Asamoto M., Tujimura K., Hokaiwado N., Takahashi S., Ogawa K., Kuribayashi M., Ogiso T., Okuyama H., Shirai T. Inhibition of cell proliferation by nobiletin, a dietary phytochemical, associated with apoptosis and characteristic gene expression, but lack of effect on early rat hepatocarcinogenesis in vivo. Cancer Sci. 2004;95:936&#x2013;942. doi: 10.1111/j.1349-7006.2004.tb03180.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1349-7006.2004.tb03180.x</ArticleId>
            <ArticleId IdType="pubmed">15596041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manthey J.A., Guthrie N. Antiproliferative activities of citrus flavonoids against six human cancer cell lines. J. Agric. Food Chem. 2002;50:5837&#x2013;5843. doi: 10.1021/jf020121d.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jf020121d</ArticleId>
            <ArticleId IdType="pubmed">12358447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng Q., Hirose Y., Yoshimi N., Murakami A., Koshimizu K., Ohigashi H., Sakata K., Matsumoto Y., Sayama Y., Mori H. Further investigation of the modifying effect of various chemopreventive agents on apoptosis and cell proliferation in human colon cancer cells. J. Cancer Res. Clin. Oncol. 2002;128:539&#x2013;546. doi: 10.1007/s00432-002-0373-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00432-002-0373-y</ArticleId>
            <ArticleId IdType="pubmed">12384797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopez L., Villavicencio M.A., Albores A., Martinez M., de la Garza J., Melendez-Zajgla J., Maldonado V. Cupressus lusitanica (cupressaceae) leaf extract induces apoptosis in cancer cells. J. Ethnopharmacol. 2002;80:115&#x2013;120. doi: 10.1016/S0378-8741(01)00417-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0378-8741(01)00417-2</ArticleId>
            <ArticleId IdType="pubmed">12007700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Slee E.A., Martin S.J. Regulation of caspase activation in apoptosis: Implications for transformation and drug resistance. Cytotechnology. 1998;27:309&#x2013;320. doi: 10.1023/A:1008014215581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/A:1008014215581</ArticleId>
            <ArticleId IdType="pmc">PMC3449564</ArticleId>
            <ArticleId IdType="pubmed">19002801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimizu S., Tsujimoto Y. Proapoptotic bh3-only bcl-2 family members induce cytochrome c release, but not mitochondrial membrane potential loss, and do not directly modulate voltage-dependent anion channel activity. Proc. Natl. Acad. Sci. USA. 2000;97:577&#x2013;582. doi: 10.1073/pnas.97.2.577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.97.2.577</ArticleId>
            <ArticleId IdType="pmc">PMC15372</ArticleId>
            <ArticleId IdType="pubmed">10639121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wajant H. The fas signaling pathway: More than a paradigm. Science. 2002;296:1635&#x2013;1636. doi: 10.1126/science.1071553.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1071553</ArticleId>
            <ArticleId IdType="pubmed">12040174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Green D.R., Reed J.C. Mitochondria and apoptosis. Science. 1998;281:1309&#x2013;1312. doi: 10.1126/science.281.5381.1309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.281.5381.1309</ArticleId>
            <ArticleId IdType="pubmed">9721092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rao R.V., Ellerby H., Bredesen D.E. Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ. 2004;11:372&#x2013;380. doi: 10.1038/sj.cdd.4401378.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.cdd.4401378</ArticleId>
            <ArticleId IdType="pubmed">14765132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim I., Xu W., Reed J.C. Cell death and endoplasmic reticulum stress: Disease relevance and therapeutic opportunities. Nat. Rev. Drug Discov. 2008;7:1013&#x2013;1030. doi: 10.1038/nrd2755.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd2755</ArticleId>
            <ArticleId IdType="pubmed">19043451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu C., Bailly-Maitre B., Reed J.C. Endoplasmic reticulum stress: Cell life and death decisions. J. Clin. Investig. 2005;115:2656&#x2013;2664. doi: 10.1172/JCI26373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI26373</ArticleId>
            <ArticleId IdType="pmc">PMC1236697</ArticleId>
            <ArticleId IdType="pubmed">16200199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boyce M., Yuan J. Cellular response to endoplasmic reticulum stress: A matter of life or death. Cell Death Differ. 2006;13:363&#x2013;373. doi: 10.1038/sj.cdd.4401817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.cdd.4401817</ArticleId>
            <ArticleId IdType="pubmed">16397583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kouroku Y., Fujita E., Tanida I., Ueno T., Isoai A., Kumagai H., Ogawa S., Kaufman R., Kominami E., Momoi T. Er stress (perk/eif2&#x3b1; phosphorylation) mediates the polyglutamine-induced lc3 conversion, an essential step for autophagy formation. Cell Death Differ. 2007;14:230&#x2013;239. doi: 10.1038/sj.cdd.4401984.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.cdd.4401984</ArticleId>
            <ArticleId IdType="pubmed">16794605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oyadomari S., Mori M. Roles of chop/gadd153 in endoplasmic reticulum stress. Cell Death Differ. 2004;11:381. doi: 10.1038/sj.cdd.4401373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.cdd.4401373</ArticleId>
            <ArticleId IdType="pubmed">14685163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ron D., Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 2007;8:519&#x2013;529. doi: 10.1038/nrm2199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm2199</ArticleId>
            <ArticleId IdType="pubmed">17565364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bollo M., Paredes R.M., Holstein D., Zheleznova N., Camacho P., Lechleiter J.D. Calcineurin interacts with perk and dephosphorylates calnexin to relieve er stress in mammals and frogs. PLoS ONE. 2010;5:e11925. doi: 10.1371/journal.pone.0011925.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0011925</ArticleId>
            <ArticleId IdType="pmc">PMC2916823</ArticleId>
            <ArticleId IdType="pubmed">20700529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muller C., Bandemer J., Vindis C., Camar&#xe9; C., Mucher E., Gu&#xe9;raud F., Larroque-Cardoso P., Bernis C., Auge N., Salvayre R. Protein disulfide isomerase modification and inhibition contribute to er stress and apoptosis induced by oxidized low density lipoproteins. Antioxid. Redox Signal. 2013;18:731&#x2013;742. doi: 10.1089/ars.2012.4577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2012.4577</ArticleId>
            <ArticleId IdType="pubmed">23083489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teske B.F., Wek S.A., Bunpo P., Cundiff J.K., McClintick J.N., Anthony T.G., Wek R.C. The eif2 kinase perk and the integrated stress response facilitate activation of atf6 during endoplasmic reticulum stress. Mol. Biol. Cell. 2011;22:4390&#x2013;4405. doi: 10.1091/mbc.e11-06-0510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1091/mbc.e11-06-0510</ArticleId>
            <ArticleId IdType="pmc">PMC3216664</ArticleId>
            <ArticleId IdType="pubmed">21917591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan F.L.S., Ooi A., Huang D., Wong J.C., Qian C.N., Chao C., Ooi L., Tan Y.M., Chung A., Cheow P.C. P38delta/mapk13 as a diagnostic marker for cholangiocarcinoma and its involvement in cell motility and invasion. Int. J. Cancer. 2010;126:2353&#x2013;2361. doi: 10.1002/ijc.24944.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.24944</ArticleId>
            <ArticleId IdType="pubmed">19816939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsai J.P., Hsiao P.C., Yang S.F., Hsieh S.C., Bau D.T., Ling C.L., Pai C.L., Hsieh Y.H. Licochalcone a suppresses migration and invasion of human hepatocellular carcinoma cells through downregulation of mkk4/jnk via nf-&#x3ba;b mediated urokinase plasminogen activator expression. PLoS ONE. 2014;9:e86537. doi: 10.1371/journal.pone.0086537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0086537</ArticleId>
            <ArticleId IdType="pmc">PMC3899273</ArticleId>
            <ArticleId IdType="pubmed">24466137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu B., Shi S., Ma Y.G., Fan F., Yao Z.Z. Lysophosphatidic acid enhances human hepatocellular carcinoma cell migration, invasion and adhesion through p38 mapk pathway. Hepatogastroenterology. 2012;59:785&#x2013;789.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22020916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zucchini-Pascal N., Peyre L., Rahmani R. Crosstalk between beta-catenin and snail in the induction of epithelial to mesenchymal transition in hepatocarcinoma: Role of the erk1/2 pathway. Int. J. Mol. Sci. 2013;14:20768&#x2013;20792. doi: 10.3390/ijms141020768.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms141020768</ArticleId>
            <ArticleId IdType="pmc">PMC3821642</ArticleId>
            <ArticleId IdType="pubmed">24135872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X.Y., Zhang X.H., Peng L., Liu Z., Yang Y.X., He Z.X., Dang H.W., Zhou S.F. Bardoxolone methyl (cddo-me or rta402) induces cell cycle arrest, apoptosis and autophagy via pi3k/akt/mtor and p38 mapk/erk1/2 signaling pathways in k562 cells. Am. J. Transl. Res. 2017;9:4652&#x2013;4672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5666072</ArticleId>
            <ArticleId IdType="pubmed">29118925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ke K., Lou T. Microrna-10a suppresses breast cancer progression via pi3k/akt/mtor pathway. Oncol. Lett. 2017;14:5994&#x2013;6000. doi: 10.3892/ol.2017.6930.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2017.6930</ArticleId>
            <ArticleId IdType="pmc">PMC5661611</ArticleId>
            <ArticleId IdType="pubmed">29113237</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31377293</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0003</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>139</Volume>
            <PubDate>
              <Year>2019</Year>
              <Month>Oct</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of biological macromolecules</Title>
          <ISOAbbreviation>Int J Biol Macromol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A polysaccharide from Huaier ameliorates cisplatin nephrotoxicity by decreasing oxidative stress and apoptosis via PI3K/AKT signaling.</ArticleTitle>
        <Pagination>
          <StartPage>932</StartPage>
          <EndPage>943</EndPage>
          <MedlinePgn>932-943</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijbiomac.2019.07.219</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0141-8130(19)32878-8</ELocationID>
        <Abstract>
          <AbstractText>Cisplatin (CP), a common chemotherapy drug used in treatment of malignant tumors. Due to various side effects such as nephrotoxicity (kidney damage), it's efficiency and therapeutic application are limited. This study focuses on finding a suitable drug that would attenuate the side effects like kidney damage, caused by CP. Huaier polysaccharide (HP-1), an extraction of Trametes robiniophila Murr, with a molecular weight of 3 × 10[4] Da. Previous studies have shown that HP-1, exhibits anti-tumor potential and immunomodulatory effects. We hypothesized that HP-1 has the effect of attenuating the nephrotoxicity caused by CP chemotherapy and protecting renal function. Through our experiments, we observed that HP-1 can attenuate the level of oxidative stress, inflammation and mitochondrial dysfunction, thereby reducing kidney damage. In vitro, we observed that HP-1 significantly inhibits CP-induced renal tubular cell apoptosis and cell cycle arrest. In addition, HP-1 also affects the expression level of the protein by regulating the PI3K/Akt/mTOR signaling pathway and thus attenuates the side effects induced by cisplatin. Therefore, HP-1 may be a potential drug for preventing CP-induced renal damage.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2019. Published by Elsevier B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fang</LastName>
            <ForeName>Liang</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Qilu Hospital, Shandong University, Jinan 250012, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yongzhen</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Qilu Hospital, Shandong University, Jinan 250012, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Qi</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>The second people's Hospital of Huangdao District, Qingdao 266400, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zang</LastName>
            <ForeName>Yuanwei</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Qilu Hospital, Shandong University, Jinan 250012, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Zeyan</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Qilu Hospital, Shandong University, Jinan 250012, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Duan</LastName>
            <ForeName>Zhichen</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Qilu Hospital, Shandong University, Jinan 250012, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ren</LastName>
            <ForeName>Juchao</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Qilu Hospital, Shandong University, Jinan 250012, China. Electronic address: rjchao1983@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Zhonghua</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Qilu Hospital, Shandong University, Jinan 250012, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>08</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Int J Biol Macromol</MedlineTA>
        <NlmUniqueID>7909578</NlmUniqueID>
        <ISSNLinking>0141-8130</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D045424">Complex Mixtures</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011134">Polysaccharides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000621679">huaier</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q20Q21Q62J</RegistryNumber>
          <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045424" MajorTopicYN="N">Complex Mixtures</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011134" MajorTopicYN="N">Polysaccharides</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055454" MajorTopicYN="N">Trametes</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cisplatin</Keyword>
        <Keyword MajorTopicYN="N">Huaier polysaccharide (HP-1)</Keyword>
        <Keyword MajorTopicYN="N">Kidney damage</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31377293</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ijbiomac.2019.07.219</ArticleId>
        <ArticleId IdType="pii">S0141-8130(19)32878-8</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31077779</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>01</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>01</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-7573</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>239</Volume>
            <PubDate>
              <Year>2019</Year>
              <Month>Jul</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of ethnopharmacology</Title>
          <ISOAbbreviation>J Ethnopharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.</ArticleTitle>
        <Pagination>
          <StartPage>111928</StartPage>
          <MedlinePgn>111928</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jep.2019.111928</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0378-8741(19)30833-5</ELocationID>
        <Abstract>
          <AbstractText Label="ETHNOPHARMACOLOGICAL RELEVANCE" NlmCategory="BACKGROUND">The Chinese herbal medicine Fuzheng Kang-Ai (FZKA) decoction obtained from Guangdong Kangmei Pharmaceutical Company, which contains 12 components with different types of constituents, has been used as part of the adjuvant treatment of lung cancer for decades. We previously showed that FZKA decoction enhances the growth inhibition of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)-resistant non-small cell lung cancer (NSCLC) cells by suppressing glycoprotein mucin 1 (MUC1) expression. However, the molecular mechanism underlying the therapeutic potential, particularly in sensitizing or/and enhancing the anti-lung cancer effect of EGFR-TKIs, remains unclear.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Cell viability was measured using 3-(4, 5-diMEThylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) and 5-ethynyl -2'-deoxyuridine (EdU) assays. Western blot analysis was performed to examine the protein expressions of DNA methyltransferase 1 (DNMT1), specificity protein 1 (SP1), and MET, an oncogene encoding for a trans-membrane tyrosine kinase receptor activated by the hepatocyte growth factor (HGF). The expression of MET mRNA was measured by quantitative real-time PCR (qRT-PCR). Exogenous expression of DNMT1 and SP1, and MET were carried out by transient transfection assays. The promoter activity of MET was tested using Dual-luciferase reporter assays. A nude mouse xenografted tumor model further evaluated the effect of the combination of FZKA decoction and erlotinib in vivo.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The combination of FZKA and erlotinib produced an even greater inhibition of NSCLC cell growth. FZKA decreased the expressions of DNMT1, SP1, and MET (c-MET) proteins, and the combination of FZKA and erlotinib demonstrated enhanced responses. Interestingly, there was a mutual regulation of DNMT1 and SP1. In addition, exogenously expressed DNMT1 and SP1 blocked the FZKA-inhibited c-MET expression. Moreover, excessive expressed MET neutralized FZKA-inhibited growth of NSCLC cells. FZKA decreased the mRNA and promoter activity of c-MET, which was not observed in cells with ectopic expressed DNMT1 gene. Similar findings were observed in vivo.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">FZKA decreases MET gene expression through the repression and mutual regulation of DNMT1 and SP1 in vitro and in vivo. This leads to inhibit the growth of human lung cancer cells. The combination of FZKA and EGFR-TKI erlotinib exhibits synergy in this process. The regulatory loops among the DNMT1, SP1 and MET converge in the overall effects of FZKA and EGFR-TKI erlotinib. This in vitro and in vivo study clarifies an additional novel molecular mechanism underlying the anti-lung cancer effects in response to the combination of FZKA and erlotinib in gefitinib-resistant NSCLC cells.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2019 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Fang</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Tumor Biology, The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510120, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>YueYang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Tumor Biology, The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510120, China; Department of Medical Oncology, The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510120, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xiong</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Central Laboratory, The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510120, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Qing</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Tumor Biology, The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510120, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>JingJing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Tumor Biology, The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510120, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>WanYin</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510120, China. Electronic address: wwanyin@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hann</LastName>
            <ForeName>Swei Sunny</ForeName>
            <Initials>SS</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Tumor Biology, The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510120, China; Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510120, China. Electronic address: hann2012@outlook.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>05</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>J Ethnopharmacol</MedlineTA>
        <NlmUniqueID>7903310</NlmUniqueID>
        <ISSNLinking>0378-8741</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016329">Sp1 Transcription Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000606530">fuzheng kang'ai</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>DA87705X9K</RegistryNumber>
          <NameOfSubstance UI="D000069347">Erlotinib Hydrochloride</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.1.1.37</RegistryNumber>
          <NameOfSubstance UI="D000076123">DNA (Cytosine-5-)-Methyltransferase 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.1.1.37</RegistryNumber>
          <NameOfSubstance UI="C000619381">Dnmt1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D019859">Proto-Oncogene Proteins c-met</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000076123" MajorTopicYN="N">DNA (Cytosine-5-)-Methyltransferase 1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069347" MajorTopicYN="N">Erlotinib Hydrochloride</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019859" MajorTopicYN="N">Proto-Oncogene Proteins c-met</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016329" MajorTopicYN="N">Sp1 Transcription Factor</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">DNMT1</Keyword>
        <Keyword MajorTopicYN="N">FZKA decoction</Keyword>
        <Keyword MajorTopicYN="N">Gefitinib</Keyword>
        <Keyword MajorTopicYN="N">MET (c-MET)</Keyword>
        <Keyword MajorTopicYN="N">NSCLC</Keyword>
        <Keyword MajorTopicYN="N">SP1</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31077779</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jep.2019.111928</ArticleId>
        <ArticleId IdType="pii">S0378-8741(19)30833-5</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31033054</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2184</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>52</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cell proliferation</Title>
          <ISOAbbreviation>Cell Prolif</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inhibition of PI3K/mTOR increased the sensitivity of hepatocellular carcinoma cells to cisplatin via interference with mitochondrial-lysosomal crosstalk.</ArticleTitle>
        <Pagination>
          <StartPage>e12609</StartPage>
          <MedlinePgn>e12609</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e12609</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/cpr.12609</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The genotoxicity of cisplatin towards nuclear DNA is not sufficient to explain the cisplatin resistance of hepatocellular carcinoma (HCC) cells; cisplatin interacts with many organelles, which can influence the sensitivity. Here, we explored the role of mitochondrial-lysosomal crosstalk in the cisplatin resistance of HCC cells.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Huh7 and HepG2 cells were subjected to different treatments. Flow cytometry was conducted to detect mitochondrial reactive oxygen species, mitochondrial mass, lysosomal function, mitochondrial membrane potential and apoptosis. Western blotting was performed to evaluate protein levels. The oxygen consumption rate was measured to evaluate mitochondrial function.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Cisplatin activated mitophagy and lysosomal biogenesis, resulting in crosstalk between mitochondria and lysosomes and cisplatin resistance in HCC cells. Furthermore, a combination of cisplatin with the phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor PKI-402 induced lysosomal membrane permeabilization. This effect changed the role of the lysosome from a protective one to that of a cell death promoter, completely destroying the mitochondrial-lysosomal crosstalk and significantly enhancing the sensitivity of HCC cells to cisplatin.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This is the first evidence of the importance of mitochondrial-lysosomal crosstalk in the cisplatin resistance of HCC cells and of the destruction of this crosstalk by a PI3K/mTOR inhibitor to increase the sensitivity of HCC cells to cisplatin. This mechanism could be developed as a novel target for treatment of HCC in the future.</AbstractText>
          <CopyrightInformation>&#xa9; 2019 The Authors. Cell Proliferation Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sheng</LastName>
            <ForeName>Jiyao</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Jilin University, Changchun, Jilin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Luyan</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Liankun</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xuewen</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Jilin University, Changchun, Jilin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cui</LastName>
            <ForeName>Ranji</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0002-1129-3772</Identifier>
            <AffiliationInfo>
              <Affiliation>Jilin Provincial Key Laboratory on Molecular and Chemical Genetic, The Second Hospital of Jilin University, Changchun, Jilin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Lizhong</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Jilin Provincial Key Laboratory on Molecular and Chemical Genetic, The Second Hospital of Jilin University, Changchun, Jilin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>2017F009</GrantID>
            <Agency>Project of Hepatobiliary and Pancreatic Disease Translational Medicine Platform Construction</Agency>
          </Grant>
          <Grant>
            <Agency>Finance Department of Jilin Province</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>04</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cell Prolif</MedlineTA>
        <NlmUniqueID>9105195</NlmUniqueID>
        <ISSNLinking>0960-7722</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C550550">PKI 402</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010671">Phenylurea Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q20Q21Q62J</RegistryNumber>
          <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056945" MajorTopicYN="N">Hep G2 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063154" MajorTopicYN="N">Mitochondrial Dynamics</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063306" MajorTopicYN="N">Mitophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010671" MajorTopicYN="N">Phenylurea Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081082" MajorTopicYN="Y">Phosphoinositide-3 Kinase Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">chemotherapy resistance</Keyword>
        <Keyword MajorTopicYN="N">hepatocellular carcinoma</Keyword>
        <Keyword MajorTopicYN="N">lysosomal biogenesis</Keyword>
        <Keyword MajorTopicYN="N">mitochondrial-lysosomal crosstalk</Keyword>
        <Keyword MajorTopicYN="N">mitophagy</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31033054</ArticleId>
        <ArticleId IdType="pmc">PMC6536453</ArticleId>
        <ArticleId IdType="doi">10.1111/cpr.12609</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open&#x2010;label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013;31:3501&#x2010;3508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23980077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llovet JM, Real MI, Monta&#xf1;a X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734&#x2010;1739.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12049862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429&#x2010;442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12540794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64:106&#x2010;116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26765068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439&#x2010;474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2900561</ArticleId>
            <ArticleId IdType="pubmed">20827404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lo GH. Updated management of hepatocellular carcinoma. Hepatology. 2011;54:1113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21520202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verslype C, Rosmorduc O, Rougier P. Hepatocellular carcinoma: ESMO&#x2010;ESDO clinical practice guidelines for diagnosis, treatment and follow&#x2010;up. Ann Oncol. 2012;23(Suppl 7):vii41&#x2010;vii48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22997453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>EASL&#x2010;EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908&#x2010;943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22424438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kudo M, Matsui O, Izumi N, et al. JSH consensus&#x2010;based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer. 2014;3:458&#x2010;468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4531423</ArticleId>
            <ArticleId IdType="pubmed">26280007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin&#x2010;induced cell death always produced by apoptosis? Mol Pharmacol. 2001;59:657&#x2010;663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11259608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cullen KJ, Yang Z, Schumaker L, Guo Z. Mitochondria as a critical target of the chemotherapeutic agent cisplatin in head and neck cancer. J Bioenerg Biomembr. 2007;39:43&#x2010;50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17318397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chauhan SS, Liang XJ, Su AW, et al. Reduced endocytosis and altered lysosome function in cisplatin&#x2010;resistant cell lines. Br J Cancer. 2003;88:1327&#x2010;1334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2747565</ArticleId>
            <ArticleId IdType="pubmed">12698203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qu X, Sheng J, Shen L, et al. Autophagy inhibitor chloroquine increases sensitivity to cisplatin in QBC939 cholangiocarcinoma cells by mitochondrial ROS. PLoS One. 2017;12:e0173712.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5354635</ArticleId>
            <ArticleId IdType="pubmed">28301876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan J, Zhou Y, Chen DaiXing, et al. Effects of mitochondrial translocation of telomerase on drug resistance in hepatocellular carcinoma cells. J Cancer. 2015;6:151&#x2010;159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4280398</ArticleId>
            <ArticleId IdType="pubmed">25561980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu S, Zhang T, Du J. Ursolic acid sensitizes cisplatin&#x2010;resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway. Drug Des Devel Ther. 2016;10:3471&#x2010;3481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5087784</ArticleId>
            <ArticleId IdType="pubmed">27822011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kotiadis VN, Duchen MR, Osellame LD. Mitochondrial quality control and communications with the nucleus are important in maintaining mitochondrial function and cell health. Biochim Biophys Acta. 2014;1840:1254&#x2010;1265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3970188</ArticleId>
            <ArticleId IdType="pubmed">24211250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tell G, Vascotto C, Tiribelli C. Alterations in the redox state and liver damage: hints from the EASL Basic School of Hepatology. J Hepatol. 2013;58:365&#x2010;374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23023012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santandreu FM, Roca P, Oliver J. Uncoupling protein&#x2010;2 knockdown mediates the cytotoxic effects of cisplatin. Free Radic Biol Med. 2010;49:658&#x2010;666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20595066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brooks C, Cho S&#x2010;G, Wang C&#x2010;Y, Yang T, Dong Z. Fragmented mitochondria are sensitized to Bax insertion and activation during apoptosis. Am J Physiol Cell Physiol. 2011;300:C447&#x2010;C455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3063970</ArticleId>
            <ArticleId IdType="pubmed">21160028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han X&#x2010;J, Yang Z&#x2010;J, Jiang L&#x2010;P, et al. Mitochondrial dynamics regulates hypoxia&#x2010;induced migration and antineoplastic activity of cisplatin in breast cancer cells. Int J Oncol. 2015;46:691&#x2010;700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25434519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan S, Liu B, Sun L, et al. Mitochondrial fission determines cisplatin sensitivity in tongue squamous cell carcinoma through the BRCA1&#x2013;miR&#x2010;593&#x2010;5p&#x2013;MFF axis. Oncotarget. 2015;6:14885&#x2010;14904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4558123</ArticleId>
            <ArticleId IdType="pubmed">25912308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li B, Wang W, Li Z, et al. MicroRNA&#x2010;148a&#x2010;3p enhances cisplatin cytotoxicity in gastric cancer through mitochondrial fission induction and cyto&#x2010;protective autophagy suppression. Cancer Lett. 2017;410:212&#x2010;227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5675767</ArticleId>
            <ArticleId IdType="pubmed">28965855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer F, Hamann A, Osiewacz HD. Mitochondrial quality control: an integrated network of pathways. Trends Biochem Sci. 2012;37:284&#x2010;292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22410198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi Y&#x2010;M, Kim H&#x2010;K, Shim W, et al. Mechanism of cisplatin&#x2010;induced cytotoxicity is correlated to impaired metabolism due to mitochondrial ROS generation. PLoS ONE. 2015;10:e0135083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4527592</ArticleId>
            <ArticleId IdType="pubmed">26247588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, Vitale I, Michels J, et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 2014;5:e1257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4047912</ArticleId>
            <ArticleId IdType="pubmed">24874729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JS, Lee JH, Jeong WW, et al. Reactive oxygen species&#x2010;dependent EndoG release mediates cisplatin&#x2010;induced caspase&#x2010;independent apoptosis in human head and neck squamous carcinoma cells. Int J Cancer. 2008;122:672&#x2010;680.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17955488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheng J, Qin H, Zhang K, Li B, Zhang X. Targeting autophagy in chemotherapy&#x2010;resistant of hepatocellular carcinoma. Am J Cancer Res. 2018;8:354&#x2010;365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5883089</ArticleId>
            <ArticleId IdType="pubmed">29636994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Wang J, Wong YK, et al. Docetaxel enhances lysosomal function through TFEB activation. Cell Death Dis. 2018;9:614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5966422</ArticleId>
            <ArticleId IdType="pubmed">29795139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, Bravo&#x2010;San Pedro JM, Kroemer G. Organelle&#x2010;specific initiation of cell death. Nat Cell Biol. 2014;16:728&#x2010;736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25082195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Repnik U, Hafner Cesen M, Turk B. Lysosomal membrane permeabilization in cell death: concepts and challenges. Mitochondrion. 2014;19(Pt A):49&#x2010;57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24984038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marques C, Oliveira C, Alves S, et al. Acetate&#x2010;induced apoptosis in colorectal carcinoma cells involves lysosomal membrane permeabilization and cathepsin D release. Cell Death Dis. 2013;4:e507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3734821</ArticleId>
            <ArticleId IdType="pubmed">23429293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang H, Li RP, Liang P, Zhou YL, Wang GW. miR&#x2010;125a inhibits the migration and invasion of liver cancer cells via suppression of the PI3K/AKT/mTOR signaling pathway. Oncol Lett. 2015;10:681&#x2010;686.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4509408</ArticleId>
            <ArticleId IdType="pubmed">26622553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kirstein MM, Boukouris AE, Pothiraju D, et al. Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3&#x2010;kinase inhibitor BEZ235 and the PI3&#x2010;kinase inhibitor BKM120 in hepatocellular carcinoma. Liver Int. 2013;33:780&#x2010;793.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23489999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu X, Wang Z, Chen M, Chen X, Liang W. The anti&#x2010;osteosarcoma cell activity by a mTORC1/2 dual inhibitor RES&#x2010;529. Biochem Biophys Res Commun. 2018;497:499&#x2010;505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29432734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen YQ, Guerra&#x2010;Librero A, Fernandez&#x2010;Gil BI, et al. Combination of melatonin and rapamycin for head and neck cancer therapy: suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation. J Pineal Res. 2018;64:e12461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29247557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ali D, Mohammad DK, Mujahed H, et al. Anti&#x2010;leukaemic effects induced by APR&#x2010;246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells. Br J Haematol. 2016;174:117&#x2010;126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26991755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shrivastava S, Jeengar MK, Reddy VS, Reddy GB, Naidu VG. Anticancer effect of celastrol on human triple negative breast cancer: possible involvement of oxidative stress, mitochondrial dysfunction, apoptosis and PI3K/Akt pathways. Exp Mol Pathol. 2015;98:313&#x2010;327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25818165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madge LA, Li JH, Choi J, Pober JS. Inhibition of phosphatidylinositol 3&#x2010;kinase sensitizes vascular endothelial cells to cytokine&#x2010;initiated cathepsin&#x2010;dependent apoptosis. J Biol Chem. 2003;278:21295&#x2010;21306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12663669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seitz C, Hugle M, Cristofanon S, Tchoghandjian A, Fulda S. The dual PI3K/mTOR inhibitor NVP&#x2010;BEZ235 and chloroquine synergize to trigger apoptosis via mitochondrial&#x2010;lysosomal cross&#x2010;talk. Int J Cancer. 2013;132:2682&#x2010;2693.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23151917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang F, Yan G, Li Y, et al. Astragalus polysaccharide attenuated iron overload&#x2010;induced dysfunction of mesenchymal stem cells via suppressing mitochondrial ROS. Cell Physiol Biochem. 2016;39:1369&#x2010;1379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27607448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417:1&#x2010;13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2605959</ArticleId>
            <ArticleId IdType="pubmed">19061483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhuang N, Li L, Chen S, Wang T. PINK1&#x2010;dependent phosphorylation of PINK1 and Parkin is essential for mitochondrial quality control. Cell Death Dis. 2016;7:e2501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5261015</ArticleId>
            <ArticleId IdType="pubmed">27906179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol. 2011;12:9&#x2010;14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4780047</ArticleId>
            <ArticleId IdType="pubmed">21179058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>V&#xe1;zquez CL, Colombo MI.Chapter 6 Assays to assess autophagy induction and fusion of autophagic vacuoles with a degradative compartment, using monodansylcadaverine (MDC) and DQ&#x2010;BSA In: Klionsky DJ. (ed.), Methods in Enzymology, Vol 452. Cambridge, MA: Academic Press; 2009:85&#x2010;95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19200877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Settembre C, Di Malta sC, Polito Va, et al. TFEB links autophagy to lysosomal biogenesis. Science. 2011;332:1429&#x2010;1433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3638014</ArticleId>
            <ArticleId IdType="pubmed">21617040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villanueva Paz M, Cot&#xe1;n D, Garrido&#x2010;Maraver J, et al. Targeting autophagy and mitophagy for mitochondrial diseases treatment. Expert Opin Ther Targets. 2016;20:487&#x2010;500.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26523761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y, Guo Y, Jiang Y, Zhu X, Liu Y, Zhang X. Mitophagy regulates macrophage phenotype in diabetic nephropathy rats. Biochem Biophys Res Commun. 2017;494:42&#x2010;50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29061302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Q, Zhang T, Wang J, et al. Rapamycin attenuates mitochondrial dysfunction via activation of mitophagy in experimental ischemic stroke. Biochem Biophys Res Commun. 2014;444:182&#x2010;188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24440703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boya P, Gonzalez&#x2010;Polo R&#x2010;A, Poncet D, et al. Mitochondrial membrane permeabilization is a critical step of lysosome&#x2010;initiated apoptosis induced by hydroxychloroquine. Oncogene. 2003;22:3927&#x2010;3936.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12813466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lemasters JJ. Dying a thousand deaths: redundant pathways from different organelles to apoptosis and necrosis. Gastroenterology. 2005;129:351&#x2010;360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16012960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Z, Schumaker LM, Egorin MJ, Zuhowski EG, Guo Z, Cullen KJ. Cisplatin preferentially binds mitochondrial DNA and voltage&#x2010;dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin Cancer Res. 2006;12:5817&#x2010;5825.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17020989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olivero OA, Semino C, Kassim A, Lopez&#x2010;Larraza DM, Poirier MC. Preferential binding of cisplatin to mitochondrial DNA of Chinese hamster ovary cells. Mutat Res. 1995;346:221&#x2010;230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7753115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baker MJ, Tatsuta T, Langer T. Quality control of mitochondrial proteostasis. Cold Spring Harb Perspect Biol. 2011;3:85&#x2010;95.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhou J, Li G, Zheng Yi, et al. A novel autophagy/mitophagy inhibitor liensinine sensitizes breast cancer cells to chemotherapy through DNM1L&#x2010;mediated mitochondrial fission. Autophagy. 2015;11:1259&#x2010;1279.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4590597</ArticleId>
            <ArticleId IdType="pubmed">26114658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Cheng X, Yu Lu, et al. MCOLN1 is a ROS sensor in lysosomes that regulates autophagy. Nat Commun. 2016;7:12109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4931332</ArticleId>
            <ArticleId IdType="pubmed">27357649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nezich CL, Wang C, Fogel AI, Youle RJ. MiT/TFE transcription factors are activated during mitophagy downstream of Parkin and Atg5. J Cell Biol. 2015;210:435&#x2010;450.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4523611</ArticleId>
            <ArticleId IdType="pubmed">26240184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma X, Liu H, Murphy JT, et al. Regulation of the transcription factor EB&#x2010;PGC1alpha axis by beclin&#x2010;1 controls mitochondrial quality and cardiomyocyte death under stress. Mol Cell Biol. 2015;35:956&#x2010;976.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4333088</ArticleId>
            <ArticleId IdType="pubmed">25561470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boya P, Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene. 2008;27:6434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18955971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang D&#x2010;M, Liu J&#x2010;S, Deng L&#x2010;J, et al. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/AKT/mTOR pathway. Carcinogenesis. 2013;34:1331&#x2010;1342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23393227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Enzenmuller S, Gonzalez P, Debatin KM, Fulda S. Chloroquine overcomes resistance of lung carcinoma cells to the dual PI3K/mTOR inhibitor PI103 by lysosome&#x2010;mediated apoptosis. Anticancer Drugs. 2013;24:14&#x2010;19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23111416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Enzenmuller S, Gonzalez P, Karpel&#x2010;Massler G, Debatin KM, Fulda S. GDC&#x2010;0941 enhances the lysosomal compartment via TFEB and primes glioblastoma cells to lysosomal membrane permeabilization and cell death. Cancer Lett. 2013;329:27&#x2010;36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23000516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serrano&#x2010;Puebla A, Boya P. Lysosomal membrane permeabilization as a cell death mechanism in cancer cells. Biochem Soc Trans. 2018;46:207&#x2010;215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29472365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cirman T, Ore&#x161;i&#x107; K, Mazovec GD, et al. Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papain&#x2010;like lysosomal cathepsins. J Biol Chem. 2004;279:3578&#x2010;3587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14581476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roczniak&#x2010;Ferguson A, Petit CS, Froehlich F, et al. The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci Signal. 2012;5:ra42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3437338</ArticleId>
            <ArticleId IdType="pubmed">22692423</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30989669</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>01</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2042-7158</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>71</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of pharmacy and pharmacology</Title>
          <ISOAbbreviation>J Pharm Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Chlorogenic acid inhibits proliferation and induces apoptosis in A498 human kidney cancer cells via inactivating PI3K/Akt/mTOR signalling pathway.</ArticleTitle>
        <Pagination>
          <StartPage>1100</StartPage>
          <EndPage>1109</EndPage>
          <MedlinePgn>1100-1109</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/jphp.13095</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Kidney cancer is a highly lethal cancer, of which the most common type is renal cell carcinoma (RCC). The targeted drugs used in treating RCC clinically have a lot of side effects. Therefore, it is urgent to find out effective agents with little toxic effects.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">The antiproliferation effect of chlorogenic acid (CA) was performed using the CCK-8 assay. Then, we adopted colony formation assay, Annexin V/PI staining assay and JC-1 mitochondrial membrane potential assay to explore the mechanism of anticancer effect of CA. We also conducted qPCR and Western blot to determine the pathway involved.</AbstractText>
          <AbstractText Label="KEY FINDINGS" NlmCategory="RESULTS">We identified that CA selectively suppressed proliferation of human RCC cell line A498 but not the human embryonic kidney cell HEK293. Mechanistic studies showed that CA significantly induced apoptosis, as indicated by activation of caspase protein and increased ratio of pro-apoptotic protein Bax to anti-apoptotic protein Bcl-2 (P&#xa0;&lt;&#xa0;0.05). Furthermore, we found that PI3K/Akt/mTOR signalling pathway is involved in the inhibitory effect of CA on A498 cells. Activation of this pathway increased proliferation and decreased apoptosis of A498 cells, exhibiting antagonism function against CA.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our research firstly reports the efficacy of CA against RCC cells and elucidates the underlying molecular mechanisms. These findings indicate that CA is a potential agent for treating RCC.</AbstractText>
          <CopyrightInformation>&#xa9; 2019 Royal Pharmaceutical Society.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xiaokang</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0002-4325-9907</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Shenzhen Longhua District Central Hospital, Shenzhen, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Jianghong</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Shenzhen Longhua District Central Hospital, Shenzhen, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Zhanxiong</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Shenzhen Longhua District Central Hospital, Shenzhen, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rao</LastName>
            <ForeName>Jiaoyu</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Gengrui</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Shenzhen Longhua District Central Hospital, Shenzhen, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Kaiyuan</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Shenzhen Longhua District Central Hospital, Shenzhen, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Wenyan</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Shenzhen Longhua District Central Hospital, Shenzhen, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yin</LastName>
            <ForeName>Zijun</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The First Affiliated Hospital, Jinan University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>2017032</GrantID>
            <Agency>Medical Research Council</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>20182131</GrantID>
            <Agency>Research Project of Traditional Chinese Medicine Bureau of Guangdong Province</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>04</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Pharm Pharmacol</MedlineTA>
        <NlmUniqueID>0376363</NlmUniqueID>
        <ISSNLinking>0022-3573</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000595707">BCL2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>318ADP12RI</RegistryNumber>
          <NameOfSubstance UI="D002726">Chlorogenic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D020169">Caspases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002726" MajorTopicYN="N">Chlorogenic Acid</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019253" MajorTopicYN="N">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">apoptosis</Keyword>
        <Keyword MajorTopicYN="N">cell proliferation</Keyword>
        <Keyword MajorTopicYN="N">chlorogenic acid</Keyword>
        <Keyword MajorTopicYN="N">renal cell carcinoma</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30989669</ArticleId>
        <ArticleId IdType="doi">10.1111/jphp.13095</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30910577</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>08</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>08</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-7573</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>237</Volume>
            <PubDate>
              <Year>2019</Year>
              <Month>Jun</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of ethnopharmacology</Title>
          <ISOAbbreviation>J Ethnopharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Reciprocal interaction of HOTAIR and SP1 together enhance the ability of Xiaoji decoction and gefitinib to inhibit EP4 expression.</ArticleTitle>
        <Pagination>
          <StartPage>128</StartPage>
          <EndPage>140</EndPage>
          <MedlinePgn>128-140</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jep.2019.03.027</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0378-8741(19)30543-4</ELocationID>
        <Abstract>
          <AbstractText Label="ETHNOPHARMACOLOGICAL RELEVANCE" NlmCategory="BACKGROUND">The Chinese herbal prescription Xiaoji decoction (XJD) has long been used for cancer treatment. However, the molecular mechanisms underlying the effects of this medicine, particularly to enhance the efficiency of EGFR-TKI in the treatment of lung cancer have not been well elucidated.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Cell viability and cell cycle distribution were detected by MTT assay and flow cytometry, respectively. The phosphorylation of ERK1/2 and protein levels of SP1 and EP4 were determined by Western blot. The expression of the HOX transcript antisense RNA (HOTAIR) was measured by qRT-PCR. Transient transfection experiments were used to overexpress the HOTAIR, SP1 and EP4 genes. The interaction between HOTAIR and SP1 were further examined via RNA immunoprecipitation (RIP) assay. A tumor xenograft model was used to confirm the in vitro findings.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">We showed that XJD inhibited growth and induced cell arrest of human non-small cell lung cancer (NSCLC) cells. We also found that XJD increased the phosphorylation of ERK1/2 and inhibited levels of HOTAIR and SP1, EP4 proteins, which were blocked by inhibitor of MEK/ERK. There was reciprocal interaction between HOTAIR and SP1. Silencing of HOTAIR reduced EP4 protein levels and repressed the growth of NSCLC cells, while overexpression of HOTAIR and SP1 overcame XJD-reduced EP4 protein expression. Additionally, excessive expressed EP4 reversed the effect of XJD on cell growth. Importantly, there was synergy of XJD with another cancer treatment drug, EGFR-TKI gefitinib, in this process. We also found that XJD inhibited tumor growth in a xenograft nude mice model.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results show that XJD inhibits NSCLC cell growth via ERK1/2-mediated reciprocal repression of HOTAIR and SP1 protein expression, followed by reduced EP4 gene expression. XJD and gefitinib exhibit synergy in this process. The in vitro and in vivo study provides a novel mechanism by which XJD enhances the growth inhibitory effect of gefitinib in gefitinib-resistant NSCLC cells.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2019 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Jingjing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Tumor Biology, The Second Clinical Collage of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510120, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Qing</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Tumor Biology, The Second Clinical Collage of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510120, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ren</LastName>
            <ForeName>Xiaolin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Tumor Biology, The Second Clinical Collage of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510120, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Fang</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Tumor Biology, The Second Clinical Collage of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510120, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>ChunXia</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical Collage of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510120, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chai</LastName>
            <ForeName>XiaoSu</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical Collage of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510120, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Liuning</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical Collage of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510120, China. Electronic address: liliuning97@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hann</LastName>
            <ForeName>Swei Sunny</ForeName>
            <Initials>SS</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Tumor Biology, The Second Clinical Collage of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510120, China; Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, The Second Clinical Collage of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510120, China. Electronic address: hann2012@outlook.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>03</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>J Ethnopharmacol</MedlineTA>
        <NlmUniqueID>7903310</NlmUniqueID>
        <ISSNLinking>0378-8741</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C561566">HOTAIR long untranslated RNA, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D062085">RNA, Long Noncoding</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D058309">Receptors, Prostaglandin E, EP4 Subtype</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016329">Sp1 Transcription Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C108209">Sp1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8XXD6IS03Y</RegistryNumber>
          <NameOfSubstance UI="C000597954">xiaoji</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S65743JHBS</RegistryNumber>
          <NameOfSubstance UI="D000077156">Gefitinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="Y">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004365" MajorTopicYN="Y">Drugs, Chinese Herbal</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077156" MajorTopicYN="Y">Gefitinib</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="Y">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062085" MajorTopicYN="N">RNA, Long Noncoding</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058309" MajorTopicYN="N">Receptors, Prostaglandin E, EP4 Subtype</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016329" MajorTopicYN="N">Sp1 Transcription Factor</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">EP4</Keyword>
        <Keyword MajorTopicYN="N">ERK1/2</Keyword>
        <Keyword MajorTopicYN="N">Gefitinib</Keyword>
        <Keyword MajorTopicYN="N">HOTAIR</Keyword>
        <Keyword MajorTopicYN="N">NSCLC</Keyword>
        <Keyword MajorTopicYN="N">SP1</Keyword>
        <Keyword MajorTopicYN="N">Xiaoji decoction</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30910577</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jep.2019.03.027</ArticleId>
        <ArticleId IdType="pii">S0378-8741(19)30543-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30797236</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>03</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">0717-6287</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>52</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Feb</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biological research</Title>
          <ISOAbbreviation>Biol Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Vitexin induces apoptosis through mitochondrial pathway and PI3K/Akt/mTOR signaling in human non-small cell lung cancer A549 cells.</ArticleTitle>
        <Pagination>
          <StartPage>7</StartPage>
          <MedlinePgn>7</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">7</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s40659-019-0214-y</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Currently, the prognosis of patients with non-small cell lung cancer (NSCLC) remains dismal; hence, it is critical to identify effective anti-NSCLC agents with limited side effects. This study aimed to evaluate the therapeutic potential of flavonoid compound vitexin in human NSCLC cells and the underlying mechanisms.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The experimental results indicated that vitexin reduced the viability of A549 cells in a dose-dependent manner with nearly no toxicity against normal human bronchial epithelial 16HBE cells. Vitexin also dose-dependently increased A549 cell apoptosis, accompanied by the decreased Bcl-2/Bax ratio and the increased expression of cleaved caspase-3. Moreover, the in vivo anticancer activity of vitexin was further determined in nude mice bearing A549 cells. In addition, vitexin induced the release of cytochrome c from the mitochondria to the cytosol and the loss of mitochondrial membrane potential. Vitexin also significantly reduced the levels of p-PI3K, p-Akt and p-mTOR, and the pro-apoptotic effect of vitexin on A549 cells was partly blocked by SC79, an Akt activator.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Accordingly, we believed that vitexin could be used as a potential therapeutic agent for the treatment of NSCLC in the future.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Xiaoli</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Integrated Chinese and Western Medicine, Affiliated Cancer Hospital of Zhengzhou University &amp; Henan Cancer Hospital, No. 127 Dongming Road, Zhengzhou City, 450008, Henan Province, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Qingfeng</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Integrated Chinese and Western Medicine, Affiliated Cancer Hospital of Zhengzhou University &amp; Henan Cancer Hospital, No. 127 Dongming Road, Zhengzhou City, 450008, Henan Province, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Huaimin</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Integrated Chinese and Western Medicine, Affiliated Cancer Hospital of Zhengzhou University &amp; Henan Cancer Hospital, No. 127 Dongming Road, Zhengzhou City, 450008, Henan Province, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Suxia</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Integrated Chinese and Western Medicine, Affiliated Cancer Hospital of Zhengzhou University &amp; Henan Cancer Hospital, No. 127 Dongming Road, Zhengzhou City, 450008, Henan Province, People's Republic of China. luosxrm@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>02</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Biol Res</MedlineTA>
        <NlmUniqueID>9308271</NlmUniqueID>
        <ISSNLinking>0716-9760</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7V515PI7F6</RegistryNumber>
          <NameOfSubstance UI="D047310">Apigenin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9VP70K75OK</RegistryNumber>
          <NameOfSubstance UI="C032731">vitexin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000072283" MajorTopicYN="N">A549 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047310" MajorTopicYN="N">Apigenin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Mitochondrial dysfunction</Keyword>
        <Keyword MajorTopicYN="N">Non-small cell lung cancer</Keyword>
        <Keyword MajorTopicYN="N">PI3K/Akt/mTOR signaling</Keyword>
        <Keyword MajorTopicYN="N">Vitexin</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30797236</ArticleId>
        <ArticleId IdType="pmc">PMC6387544</ArticleId>
        <ArticleId IdType="doi">10.1186/s40659-019-0214-y</ArticleId>
        <ArticleId IdType="pii">10.1186/s40659-019-0214-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China. CA Cancer J Clin. 2016;66(2):115&#x2013;132. doi: 10.3322/caac.21338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21338</ArticleId>
            <ArticleId IdType="pubmed">26808342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet. 2000;355(9202):479&#x2013;485. doi: 10.1016/S0140-6736(00)82038-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(00)82038-3</ArticleId>
            <ArticleId IdType="pubmed">10841143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gettinger S, Lynch T. A decade of advances in treatment for advanced non-small cell lung cancer. Clin Chest Med. 2011;32(4):839&#x2013;851. doi: 10.1016/j.ccm.2011.08.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccm.2011.08.017</ArticleId>
            <ArticleId IdType="pubmed">22054890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, Peng W, Qin R, Zhou H. Crataegus pinnatifida: chemical constituents, pharmacology, and potential applications. Molecules. 2014;19(2):1685&#x2013;1712. doi: 10.3390/molecules19021685.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/molecules19021685</ArticleId>
            <ArticleId IdType="pmc">PMC6271784</ArticleId>
            <ArticleId IdType="pubmed">24487567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee CY, Chien YS, Chiu TH, Huang WW, Lu CC, Chiang JH, et al. Apoptosis triggered by vitexin in U937 human leukemia cells via a mitochondrial signaling pathway. Oncol Rep. 2012;28(5):1883&#x2013;1888. doi: 10.3892/or.2012.2000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2012.2000</ArticleId>
            <ArticleId IdType="pubmed">22941432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He JD, Wang Z, Li SP, Xu YJ, Yu Y, Ding YJ, et al. Vitexin suppresses autophagy to induce apoptosis in hepatocellular carcinoma via activation of the JNK signaling pathway. Oncotarget. 2016;7(51):84520&#x2013;84532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5356678</ArticleId>
            <ArticleId IdType="pubmed">27588401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang G, Li D, Chen H, Zhang J, Jin X. Vitexin induces G2/Mphase arrest and apoptosis via Akt/mTOR signaling pathway in human glioblastoma cells. Mol Med Rep. 2018;17(3):4599&#x2013;4604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29328424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Racher AJ, Looby D, Griffiths JB. Use of lactate dehydrogenase release to assess changes in culture viability. Cytotechnology. 1990;3(3):301&#x2013;307. doi: 10.1007/BF00365494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00365494</ArticleId>
            <ArticleId IdType="pubmed">1366664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cossarizza A, Salvioli S. Flow cytometric analysis of mitochondrial membrane potential using JC-1. Current protocols in cytometry. 2001;Chapter 9: Unit 9 14. (Epub 2008/09/05).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18770751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Z, Wang Z, Liu X, Wang D. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer. Anticancer Drugs. 2015;26(1):1&#x2013;14. doi: 10.1097/CAD.0000000000000172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CAD.0000000000000172</ArticleId>
            <ArticleId IdType="pubmed">25304988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eaton KD, Martins RG. Maintenance chemotherapy in non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8(7):815&#x2013;821. doi: 10.6004/jnccn.2010.0058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.6004/jnccn.2010.0058</ArticleId>
            <ArticleId IdType="pubmed">20679540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>An F, Wang S, Tian Q, Zhu D. Effects of orientin and vitexin from Trollius chinensis on the growth and apoptosis of esophageal cancer EC-109 cells. Oncol Lett. 2015;10(4):2627&#x2013;2633. doi: 10.3892/ol.2015.3618.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2015.3618</ArticleId>
            <ArticleId IdType="pmc">PMC4580036</ArticleId>
            <ArticleId IdType="pubmed">26622901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Portugal J, Bataller M, Mansilla S. Cell death pathways in response to antitumor therapy. Tumori. 2009;95(4):409&#x2013;421. doi: 10.1177/030089160909500401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/030089160909500401</ArticleId>
            <ArticleId IdType="pubmed">19856649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9(1):47&#x2013;59. doi: 10.1038/nrm2308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm2308</ArticleId>
            <ArticleId IdType="pubmed">18097445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science. 2004;305(5684):626&#x2013;629. doi: 10.1126/science.1099320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1099320</ArticleId>
            <ArticleId IdType="pubmed">15286356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pal I, Mandal M. PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin. 2012;33(12):1441&#x2013;1458. doi: 10.1038/aps.2012.72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/aps.2012.72</ArticleId>
            <ArticleId IdType="pmc">PMC4001841</ArticleId>
            <ArticleId IdType="pubmed">22983389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol. 2010;7(4):209&#x2013;219. doi: 10.1038/nrclinonc.2010.21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2010.21</ArticleId>
            <ArticleId IdType="pubmed">20234352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papadimitrakopoulou V. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J Thorac Oncol. 2012;7(8):1315&#x2013;1326. doi: 10.1097/JTO.0b013e31825493eb.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/JTO.0b013e31825493eb</ArticleId>
            <ArticleId IdType="pubmed">22648207</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30629288</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>08</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>08</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-4644</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>120</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of cellular biochemistry</Title>
          <ISOAbbreviation>J Cell Biochem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Brusatol inhibits amyloid-β-induced neurotoxicity in U-251 cells via regulating the Nrf2/HO-1 pathway.</ArticleTitle>
        <Pagination>
          <StartPage>10556</StartPage>
          <EndPage>10563</EndPage>
          <MedlinePgn>10556-10563</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/jcb.28341</ELocationID>
        <Abstract>
          <AbstractText>Amyloid-β (Aβ) has been reported to cause oxidative damage of neurons leading to neurotoxicity in a variety of diseases and cancers. As an anticancer drug, brusatol (BR) has been shown to have potent cytotoxic effects on various cancer cell lines. In this study, the effect and mechanism of BR on Aβ-induced neurotoxicity was investigated in U-251 glioma cells. Using the MTT assay, the results suggest that BR ameliorated cell injury induced by Aβ in U-251 cells. After running Hoechst and Western blot assays, BR prevented cell apoptosis induced by Aβ in U-251 cells. In addition, BR inhibited the increased reactive oxygen species and mitochondrial membrane potential levels induced by Aβ in U-251 cells using the DCFH-DA and Rh123 method. Furthermore, BR induced the Nrf2/HO-1 pathway by inhibiting the PI3K/AKT/mTOR pathway to inhibit neurotoxicity elicited by Aβ. These results suggest that brustasol is a valuable potential antitumor drug available for chemotherapy.</AbstractText>
          <CopyrightInformation>&#xa9; 2019 Wiley Periodicals, Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, ZouCheng Branch of Affiliated Hospital of Jining Medical University, Jining, Shandong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>HuaWen</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, ZouCheng Branch of Affiliated Hospital of Jining Medical University, Jining, Shandong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>YueQi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, WeiFang People's Hospital, WeiFang, Shandong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Peng</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, LiaoCheng Third People's Hospital, LiaoCheng, Shandong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <Identifier Source="ORCID">0000-0003-0502-1583</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, ZouCheng Branch of Affiliated Hospital of Jining Medical University, Jining, Shandong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>01</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Cell Biochem</MedlineTA>
        <NlmUniqueID>8205768</NlmUniqueID>
        <ISSNLinking>0730-2312</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C495635">NFE2L2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D036702">Quassins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>14907-98-3</RegistryNumber>
          <NameOfSubstance UI="C020237">brusatol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.14.18</RegistryNumber>
          <NameOfSubstance UI="C496541">HMOX1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.14.18</RegistryNumber>
          <NameOfSubstance UI="D051547">Heme Oxygenase-1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051547" MajorTopicYN="N">Heme Oxygenase-1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D036702" MajorTopicYN="N">Quassins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Nrf2/HO-1 pathway</Keyword>
        <Keyword MajorTopicYN="N">U-251 cells</Keyword>
        <Keyword MajorTopicYN="N">amyloid-&#x3b2; (A&#x3b2;)</Keyword>
        <Keyword MajorTopicYN="N">brusatol (BR)</Keyword>
        <Keyword MajorTopicYN="N">neurotoxicity</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30629288</ArticleId>
        <ArticleId IdType="doi">10.1002/jcb.28341</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30610794</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>08</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1107-0625</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>23</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2018</Year>
              <Season>Nov-Dec</Season>
            </PubDate>
          </JournalIssue>
          <Title>Journal of B.U.ON. : official journal of the Balkan Union of Oncology</Title>
          <ISOAbbreviation>J BUON</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Arglabin is a plant sesquiterpene lactone that exerts potent anticancer effects on human oral squamous cancer cells via mitochondrial apoptosis and downregulation of the mTOR/PI3K/Akt signaling pathway to inhibit tumor growth in vivo.</ArticleTitle>
        <Pagination>
          <StartPage>1679</StartPage>
          <EndPage>1685</EndPage>
          <MedlinePgn>1679-1685</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="PURPOSE">To evaluate the anticancer effects and the underlying mechanism of arglabin on oral squamous cell carcinoma (OSCC) cells.</AbstractText>
          <AbstractText Label="METHODS">4',6-Diamidino-2-phenylindole dihydrochloride (DAPI) and annexin V/propidium iodide (PI) staining were performed to evaluate apoptosis. Reactive oxygen species (ROS) levels and mitochondrial membrane potential (MMP) were examined by flow cytometry. Protein expression was assessed by western blot analysis. To examine the anticancer activity of arglabin in vivo, subcutaneous xenografts in nude mice were evaluated.</AbstractText>
          <AbstractText Label="RESULTS">Arglabin exhibited an IC50 of 10 &#xb5;M in OSCC cells and induced apoptosis by inhibiting MMP and enhancing intracellular ROS levels. DAPI and annexin V/PI staining indicated apoptosis of OSCC cells induced by arglabin. Arglabin also downregulated the expression of key proteins in the mTOR/PI3K/Akt signaling pathway. In vivo evaluation showed that arglabin reduced the average tumor volumes and growth of xenografted tumors, indicative of its anticancer activity.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Arglabin showed selective in vitro and in vivo anticancer activities against OSCC cells and is therefore a potential therapeutic agent for the management of OSCC.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Wenpeng</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Molecular and Functional Imaging, Jinan University, Guangzhou, Guangdong, China, 510630.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lai</LastName>
            <ForeName>Renfa</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Qiang</ForeName>
            <Initials>Q</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Yiman</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Lu</ForeName>
            <Initials>L</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Cyprus</Country>
        <MedlineTA>J BUON</MedlineTA>
        <NlmUniqueID>100883428</NlmUniqueID>
        <ISSNLinking>1107-0625</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012717">Sesquiterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D045789">Sesquiterpenes, Guaiane</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>84692-91-1</RegistryNumber>
          <NameOfSubstance UI="C083346">arglabin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546843">mTOR protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="C514862">Akt1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009062" MajorTopicYN="N">Mouth Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081082" MajorTopicYN="N">Phosphoinositide-3 Kinase Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012717" MajorTopicYN="N">Sesquiterpenes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045789" MajorTopicYN="N">Sesquiterpenes, Guaiane</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>1</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30610794</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30496631</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-8081</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>45</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>BioFactors (Oxford, England)</Title>
          <ISOAbbreviation>Biofactors</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Rhein reverses doxorubicin resistance in SMMC-7721 liver cancer cells by inhibiting energy metabolism and inducing mitochondrial permeability transition pore opening.</ArticleTitle>
        <Pagination>
          <StartPage>85</StartPage>
          <EndPage>96</EndPage>
          <MedlinePgn>85-96</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/biof.1462</ELocationID>
        <Abstract>
          <AbstractText>Rhein, a monomeric anthraquinone obtained from the plant herb species Polygonum multiflorum and P. cuspidatum, has been proposed to have anticancer activity. This activity has been suggested to be associated with mitochondrial injury due to the induction of mitochondrial permeability transition pore (mPTP) opening. In this study, the effects of 5-80 μM rhein on cell viability, half-maximal inhibitory concentration (IC50 value), resistance index, and apoptosis were assessed in the liver cancer cell lines SMMC-7721 and SMMC-7721/DOX (doxorubicin-resistant cells). Rhein (10-80 μM) significantly reduced the viability of both cell lines; 20 μM rhein significantly increased sensitivity to DOX and increased apoptosis in SMMC-7721 cells, but reversed resistance to DOX by 7.24-fold in SMMC-7721/DOX cells. Treatment with rhein increased accumulation of DOX in SMMC-7721/DOX cells, inhibited mitochondrial energy metabolism, decreased cellular ATP, and ADP levels, and altered the ratio of ATP to ADP. These effects may result from the binding of rhein with voltage-dependent ion channels (VDACs), adenine nucleotide translocase (ANT), and cyclophilin D, affecting their function and leading to the inhibition of ATP transport by VDACs and ANT. ATP synthesis was greatly reduced and mitochondrial inner membrane potential decreased. Together, these results indicate that rhein could reverse drug resistance in SMMC-7721/DOX cells by inhibiting energy metabolism and inducing mPTP opening. © 2018 BioFactors, 45(1):85-96, 2019.</AbstractText>
          <CopyrightInformation>&#xa9; 2018 International Union of Biochemistry and Molecular Biology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0001-9380-8620</Identifier>
            <AffiliationInfo>
              <Affiliation>Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cao</LastName>
            <ForeName>Kexin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ni</LastName>
            <ForeName>Zihui</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Shaodong</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Weidong</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Engineering Center of State Ministry of Education for Standardization of Chinese Medicine Processing, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Xiao</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Engineering Center of State Ministry of Education for Standardization of Chinese Medicine Processing, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Zhipeng</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Engineering Center of State Ministry of Education for Standardization of Chinese Medicine Processing, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>PPZY2015A070</GrantID>
            <Agency>the Top-notch Academic Programs Project of Jiangsu Higher Education Institutions</Agency>
          </Grant>
          <Grant>
            <GrantID>18KJA360009</GrantID>
            <Agency>the Key Project of Natural Science Research in Colleges and Universities in Jiangsu Province</Agency>
          </Grant>
          <Grant>
            <GrantID>8150330881873287</GrantID>
            <Agency>the National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>18KJA360009</GrantID>
            <Agency>Key Project of Natural Science Research in Colleges and Universities in Jiangsu Province</Agency>
          </Grant>
          <Grant>
            <GrantID>PPZY2015A070</GrantID>
            <Agency>Top-notch Academic Programs Project of Jiangsu Higher Education Institutions</Agency>
          </Grant>
          <Grant>
            <GrantID>81873287</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
          <Grant>
            <GrantID>81503308</GrantID>
            <Agency>National Natural Science Foundation of China</Agency>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Biofactors</MedlineTA>
        <NlmUniqueID>8807441</NlmUniqueID>
        <ISSNLinking>0951-6433</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000880">Anthraquinones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000903">Antibiotics, Antineoplastic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D033681">Mitochondrial Membrane Transport Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000083162">Mitochondrial Permeability Transition Pore</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050994">Voltage-Dependent Anion Channels</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>80168379AG</RegistryNumber>
          <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8L70Q75FXE</RegistryNumber>
          <NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9068-80-8</RegistryNumber>
          <NameOfSubstance UI="D000226">Mitochondrial ADP, ATP Translocases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 5.2.1.-</RegistryNumber>
          <NameOfSubstance UI="D021983">Cyclophilins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 5.2.1.8</RegistryNumber>
          <NameOfSubstance UI="C114456">PPID protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YM64C2P6UX</RegistryNumber>
          <NameOfSubstance UI="C020491">rhein</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000880" MajorTopicYN="N">Anthraquinones</DescriptorName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000903" MajorTopicYN="N">Antibiotics, Antineoplastic</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D021983" MajorTopicYN="N">Cyclophilins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045468" MajorTopicYN="N">Fallopia japonica</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068676" MajorTopicYN="N">Fallopia multiflora</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022781" MajorTopicYN="N">Hepatocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000226" MajorTopicYN="N">Mitochondrial ADP, ATP Translocases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D033681" MajorTopicYN="N">Mitochondrial Membrane Transport Proteins</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000083162" MajorTopicYN="N">Mitochondrial Permeability Transition Pore</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050994" MajorTopicYN="N">Voltage-Dependent Anion Channels</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Rhein</Keyword>
        <Keyword MajorTopicYN="N">drug resistance</Keyword>
        <Keyword MajorTopicYN="N">energy metabolism</Keyword>
        <Keyword MajorTopicYN="N">liver cancer cells</Keyword>
        <Keyword MajorTopicYN="N">mPTP opening</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>8</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30496631</ArticleId>
        <ArticleId IdType="doi">10.1002/biof.1462</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30469147</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>04</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1439-0221</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>85</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Planta medica</Title>
          <ISOAbbreviation>Planta Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Baicalin Induces Apoptotic Death of Human Chondrosarcoma Cells through Mitochondrial Dysfunction and Downregulation of the PI3K/Akt/mTOR Pathway.</ArticleTitle>
        <Pagination>
          <StartPage>360</StartPage>
          <EndPage>369</EndPage>
          <MedlinePgn>360-369</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1055/a-0791-1049</ELocationID>
        <Abstract>
          <AbstractText>The aim of the present study was to investigate the cytotoxic and antitumour effects of baicalin in human chondrosarcoma both in vivo and in vitro. We examined the effects of baicalin on the growth and apoptosis of human chondrosarcoma cells. Baicalin inhibited the growth of SW1353 and CH2879 cells in a dose- and time-dependent manner, but did not inhibit the growth of normal chondrocytes. Baicalin reduced tumour growth and induced apoptotic death in SW1353-transplanted nude mice without reducing their body weight. Further studies showed that baicalin reduced the mitochondrial membrane potential, upregulated the expression of Bax and cytoplasmic cytochrome c, downregulated the expression of Bcl-2 and mitochondrial cytochromes, and activated caspase-3 and caspase-9. Baicalin inhibited the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin pathway by decreasing the expression of phosphorylated phosphoinositide 3-kinase, phosphorylated protein kinase B, and phosphorylated mammalian target of rapamycin both in vivo and in vitro. Moreover, the mice that received SC79 and baicalin exhibited a greater tumour size compared with the mice that received baicalin. The mice that received LY294002 and baicalin showed a smaller tumour size compared with the mice that received baicalin. In the in vitro study, SC79 and LY294002 affected the baicalin-induced cytotoxic effects on chondrosarcoma cells in the same manner. Our data suggest baicalin has therapeutic efficacy in human chondrosarcoma through the induction of apoptosis and inhibition of the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin pathway. Baicalin can be considered a potential therapeutic agent for treating chondrosarcomas.</AbstractText>
          <CopyrightInformation>Georg Thieme Verlag KG Stuttgart &#xb7; New York.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Minyu</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Spine Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ying</LastName>
            <ForeName>Jinwei</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Spine Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Chaowei</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Spine Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Spine Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Kelun</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Spine Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Spine Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Teng</LastName>
            <ForeName>Honglin</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Spine Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Planta Med</MedlineTA>
        <NlmUniqueID>0066751</NlmUniqueID>
        <ISSNLinking>0032-0943</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002867">Chromones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009025">Morpholines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31M2U1DVID</RegistryNumber>
          <NameOfSubstance UI="C085911">2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>347Q89U4M5</RegistryNumber>
          <NameOfSubstance UI="C038044">baicalin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002813" MajorTopicYN="N">Chondrosarcoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002867" MajorTopicYN="N">Chromones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005419" MajorTopicYN="N">Flavonoids</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019686" MajorTopicYN="N">Lamiaceae</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008516" MajorTopicYN="N">Medicine, Chinese Traditional</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009025" MajorTopicYN="N">Morpholines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081082" MajorTopicYN="Y">Phosphoinositide-3 Kinase Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare that there are no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30469147</ArticleId>
        <ArticleId IdType="doi">10.1055/a-0791-1049</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30358211</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>09</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1107-0625</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>23</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2018</Year>
              <Season>Jul-Aug</Season>
            </PubDate>
          </JournalIssue>
          <Title>Journal of B.U.ON. : official journal of the Balkan Union of Oncology</Title>
          <ISOAbbreviation>J BUON</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Royleanone diterpenoid exhibits potent anticancer effects in LNCaP human prostate carcinoma cells by inducing mitochondrial mediated apoptosis, cell cycle arrest, suppression of cell migration and downregulation of mTOR/PI3K/AKT signalling pathway.</ArticleTitle>
        <Pagination>
          <StartPage>1055</StartPage>
          <EndPage>1060</EndPage>
          <MedlinePgn>1055-1060</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="PURPOSE">Prostate cancer is a deadly malignancy and is responsible for significant cancer-related mortality in men. The incidence of prostate cancer is continuously increasing across the globe and the existing treatment options for this disease are limited and associated with a lot of side effects. Therefore there is an urgent need to identify novel and efficient therapeutic agents for the management of prostate cancer. In the current study we evaluated the anticancer activity of royleanone diterpenoid against prostate cancer LNCaP cell line.</AbstractText>
          <AbstractText Label="METHODS">The anticancer activity of royleanone was determined by CCK8 assay. Apoptosis was detected by acridine orange and ethidium bromide as well as by annexin V/ propidium iodide (PI) staining. Mitochondrial membrane potential (MMP) and cell cycle analysis were investigated by flow cytometry and protein expression by western blotting.</AbstractText>
          <AbstractText Label="RESULTS">The results showed that royleanone exerts potent anticancer activity on LNCaP prostate cancer cells with an IC50 of 12.5 &#x3bc;M at 48 hrs of incubation. The anticancer activity of royleanone was due to induction of cell cycle arrest and mitochondrial-mediated apoptosis. Moreover, royleanone could also suppress the cell migration potential and inhibited the mTOR/ PI3/AKT signalling pathway in LNCaP prostate cancer cells.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Taken together, we propose that royleanone could prove to be an important anticancer lead molecule for the treatment and overall management of prostate cancer, provided further in vivo studies are carried out.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Xiaoming</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, the First Hospital of Jiaxing, the first affiliated hospital of Jiaxing College, Jiaxing 314001, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Yi</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Gaoyue</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Jianhui</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hou</LastName>
            <ForeName>Yansong</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gu</LastName>
            <ForeName>Yanqin</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Hao</ForeName>
            <Initials>H</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Cyprus</Country>
        <MedlineTA>J BUON</MedlineTA>
        <NlmUniqueID>100883428</NlmUniqueID>
        <ISSNLinking>1107-0625</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D045784">Abietanes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>901618Q8AX</RegistryNumber>
          <NameOfSubstance UI="C103399">royleanone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D045784" MajorTopicYN="N">Abietanes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059447" MajorTopicYN="N">Cell Cycle Checkpoints</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30358211</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30229997</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>06</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-4644</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>120</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of cellular biochemistry</Title>
          <ISOAbbreviation>J Cell Biochem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Oridonin-induced mitochondria-dependent apoptosis in esophageal cancer cells by inhibiting PI3K/AKT/mTOR and Ras/Raf pathways.</ArticleTitle>
        <Pagination>
          <StartPage>3736</StartPage>
          <EndPage>3746</EndPage>
          <MedlinePgn>3736-3746</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/jcb.27654</ELocationID>
        <Abstract>
          <AbstractText>Oridonin, an active diterpenoid isolated from Rabdosia rubescens, has been reported for its antitumor activity on several cancers. However, its effect on human esophageal cancer remains unclear. In this study, we demonstrated that oridonin could inhibit the growth of human esophageal cancer cells both in vitro and in vivo. Oridonin not only suppressed the proliferation, but also induced cell cycle arrest and mitochondrial-mediated apoptosis in KYSE-30, KYSE-150, and EC9706 cells with dose-dependent manner. Further mechanism studies revealed that oridonin led cell cycle arrest in esophageal cancer cells via downregulating cell cycle-related proteins, such as cyclin B1 and CDK2, while upregulating p53 and p21. Oridonin also increased proapoptotic protein Bax and reduced antiapoptotic protein Bcl-2, as well as the increased expression of cleaved caspase-3, -8, and -9. In addition, oridonin treatment could significantly inhibit the PI3K/Akt/mTOR and Ras/Raf signaling pathway. In vivo results further demonstrated that oridonin treatment markedly inhibited tumor growth in the esophageal cancer xenograft mice model. Taken together, these results suggest that oridonin may be a potential anticancer agent for the treatment of esophageal cancer.</AbstractText>
          <CopyrightInformation>&#xa9; 2018 Wiley Periodicals, Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Jin-Huan</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Quality Research in Chinese Medicines, Department of Chinese Medicine, Macau University of Science and Technology, Macau, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pi</LastName>
            <ForeName>Jiang</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory for Tropical Diseases Control of the Ministry of Education, Department of Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, University of Illinois, Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jin</LastName>
            <ForeName>Hua</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, University of Illinois, Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cai</LastName>
            <ForeName>Ji-Ye</ForeName>
            <Initials>JY</Initials>
            <Identifier Source="ORCID">0000-0002-4791-3320</Identifier>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Quality Research in Chinese Medicines, Department of Chinese Medicine, Macau University of Science and Technology, Macau, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Jinan University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>09</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Cell Biochem</MedlineTA>
        <NlmUniqueID>8205768</NlmUniqueID>
        <ISSNLinking>0730-2312</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C494826">BAX protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000595707">BCL2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C534699">CCNB1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D056744">Cyclin B1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050759">Cyclin-Dependent Kinase Inhibitor p21</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D045786">Diterpenes, Kaurane</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051028">bcl-2-Associated X Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0APJ98UCLQ</RegistryNumber>
          <NameOfSubstance UI="C011959">oridonin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.22</RegistryNumber>
          <NameOfSubstance UI="C495894">CDK2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.22</RegistryNumber>
          <NameOfSubstance UI="D051357">Cyclin-Dependent Kinase 2</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056744" MajorTopicYN="N">Cyclin B1</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051357" MajorTopicYN="N">Cyclin-Dependent Kinase 2</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050759" MajorTopicYN="N">Cyclin-Dependent Kinase Inhibitor p21</DescriptorName>
          <QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045786" MajorTopicYN="N">Diterpenes, Kaurane</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004938" MajorTopicYN="N">Esophageal Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019253" MajorTopicYN="N">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName>
          <QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051028" MajorTopicYN="N">bcl-2-Associated X Protein</DescriptorName>
          <QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">PI3K/AKT/mTOR pathway</Keyword>
        <Keyword MajorTopicYN="N">apoptosis</Keyword>
        <Keyword MajorTopicYN="N">esophageal cancer</Keyword>
        <Keyword MajorTopicYN="N">oridonin</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>8</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30229997</ArticleId>
        <ArticleId IdType="doi">10.1002/jcb.27654</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30042494</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>09</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-5403</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>25</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cell death and differentiation</Title>
          <ISOAbbreviation>Cell Death Differ</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Mitochondrial ROS-derived PTEN oxidation activates PI3K pathway for mTOR-induced myogenic autophagy.</ArticleTitle>
        <Pagination>
          <StartPage>1921</StartPage>
          <EndPage>1937</EndPage>
          <MedlinePgn>1921-1937</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41418-018-0165-9</ELocationID>
        <Abstract>
          <AbstractText>Muscle differentiation is a crucial process controlling muscle development and homeostasis. Mitochondrial reactive oxygen species (mtROS) rapidly increase and function as critical cell signaling intermediates during the muscle differentiation. However, it has not yet been elucidated how they control myogenic signaling. Autophagy, a lysosome-mediated degradation pathway, is importantly recognized as intracellular remodeling mechanism of cellular organelles during muscle differentiation. Here, we demonstrated that the mtROS stimulated phosphatidylinositol 3 kinase/AKT/mammalian target of rapamycin (mTOR) cascade, and the activated mTORC1 subsequently induced autophagic signaling via phosphorylation of uncoordinated-51-like kinase 1 (ULK1) at serine 317 and upregulation of Atg proteins to prompt muscle differentiation. Treatment with MitoQ or rapamycin impaired both phosphorylation of ULK1 and expression of Atg proteins. Therefore, we propose a novel regulatory paradigm in which mtROS are required to initiate autophagic reconstruction of cellular organization through mTOR activation in muscle differentiation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Jin-Hwan</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Tae Gyu</ForeName>
            <Initials>TG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Park</LastName>
            <ForeName>Seolhui</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Science, Graduate School, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yun</LastName>
            <ForeName>Hyeong Rok</ForeName>
            <Initials>HR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Science, Graduate School, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nguyen</LastName>
            <ForeName>Ngoc Ngo Yen</ForeName>
            <Initials>NNY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Science, Graduate School, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jo</LastName>
            <ForeName>Yong Hwa</ForeName>
            <Initials>YH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jang</LastName>
            <ForeName>Miran</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Jieun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Joungmok</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>MRC Mitochondrial Biology Unit, Hills Road, Cambridge, CB2 0XY, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kang</LastName>
            <ForeName>Insug</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Science, Graduate School, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ha</LastName>
            <ForeName>Joohun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Science, Graduate School, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Murphy</LastName>
            <ForeName>Michael P</ForeName>
            <Initials>MP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oral Biochemistry and Molecular Biology, School of Dentistry, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Dean G</ForeName>
            <Initials>DG</Initials>
            <Identifier Source="ORCID">0000-0001-5029-1174</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, 14263, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Sung Soo</ForeName>
            <Initials>SS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea. sgskim@khu.ac.kr.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Science, Graduate School, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea. sgskim@khu.ac.kr.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>MC_UU_00015/3</GrantID>
            <Acronym>MRC_</Acronym>
            <Agency>Medical Research Council</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>07</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cell Death Differ</MedlineTA>
        <NlmUniqueID>9437445</NlmUniqueID>
        <ISSNLinking>1350-9047</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009943">Organophosphorus Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1339-63-5</RegistryNumber>
          <NameOfSubstance UI="D014451">Ubiquinone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>47BYS17IY0</RegistryNumber>
          <NameOfSubstance UI="C429014">mitoquinone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.15.1.1</RegistryNumber>
          <NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.15.1.1</RegistryNumber>
          <NameOfSubstance UI="C431683">superoxide dismutase 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546843">mTOR protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D000071189">Autophagy-Related Protein-1 Homolog</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="C112444">Ulk1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.3.67</RegistryNumber>
          <NameOfSubstance UI="D051059">PTEN Phosphohydrolase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.3.67</RegistryNumber>
          <NameOfSubstance UI="C487757">Pten protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>W36ZG6FT64</RegistryNumber>
          <NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="Y">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071189" MajorTopicYN="N">Autophagy-Related Protein-1 Homolog</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009943" MajorTopicYN="N">Organophosphorus Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051059" MajorTopicYN="N">PTEN Phosphohydrolase</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014451" MajorTopicYN="N">Ubiquinone</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30042494</ArticleId>
        <ArticleId IdType="pmc">PMC6219511</ArticleId>
        <ArticleId IdType="doi">10.1038/s41418-018-0165-9</ArticleId>
        <ArticleId IdType="pii">10.1038/s41418-018-0165-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bassel-Duby R, Olson EN. Signaling pathways in skeletal muscle remodeling. Annu Rev Biochem. 2006;75:19&#x2013;37. doi: 10.1146/annurev.biochem.75.103004.142622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.biochem.75.103004.142622</ArticleId>
            <ArticleId IdType="pubmed">16756483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Florini JR, Ewton DZ, Coolican SA. Growth hormone and the insulin-like growth factor system in myogenesis. Endocr Rev. 1996;17:481&#x2013;517.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8897022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10:143&#x2013;53. doi: 10.1038/nrclinonc.2013.10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2013.10</ArticleId>
            <ArticleId IdType="pubmed">23400000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem. 2001;276:48627&#x2013;30. doi: 10.1074/jbc.C100556200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.C100556200</ArticleId>
            <ArticleId IdType="pubmed">11707428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Das S, Dixon JE, Cho W. Membrane-binding and activation mechanism of PTEN. Proc Natl Acad Sci USA. 2003;100:7491&#x2013;6. doi: 10.1073/pnas.0932835100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0932835100</ArticleId>
            <ArticleId IdType="pmc">PMC164614</ArticleId>
            <ArticleId IdType="pubmed">12808147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwon J, Lee SR, Yang KS, Ahn Y, Kim YJ, Stadtman ER, et al. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci USA. 2004;101:16419&#x2013;24. doi: 10.1073/pnas.0407396101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0407396101</ArticleId>
            <ArticleId IdType="pmc">PMC534546</ArticleId>
            <ArticleId IdType="pubmed">15534200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang KH, Lemke G, Kim JW. The PI3K-PTEN tug-of-war, oxidative stress and retinal degeneration. Trends Mol Med. 2009;15:191&#x2013;8. doi: 10.1016/j.molmed.2009.03.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molmed.2009.03.005</ArticleId>
            <ArticleId IdType="pmc">PMC2993245</ArticleId>
            <ArticleId IdType="pubmed">19380252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274&#x2013;93. doi: 10.1016/j.cell.2012.03.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.017</ArticleId>
            <ArticleId IdType="pmc">PMC3331679</ArticleId>
            <ArticleId IdType="pubmed">22500797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braun T, Gautel M. Transcriptional mechanisms regulating skeletal muscle differentiation, growth and homeostasis. Nat Rev Mol Cell Biol. 2011;12:349&#x2013;61. doi: 10.1038/nrm3118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm3118</ArticleId>
            <ArticleId IdType="pubmed">21602905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol. 2009;10:307&#x2013;18. doi: 10.1038/nrm2672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm2672</ArticleId>
            <ArticleId IdType="pubmed">19339977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakatogawa H, Suzuki K, Kamada Y, Ohsumi Y. Dynamics and diversity in autophagy mechanisms: lessons from yeast. Nat Rev Mol Cell Biol. 2009;10:458&#x2013;67. doi: 10.1038/nrm2708.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm2708</ArticleId>
            <ArticleId IdType="pubmed">19491929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098&#x2013;101. doi: 10.1126/science.1106148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1106148</ArticleId>
            <ArticleId IdType="pubmed">15718470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim YC, Guan KL. mTOR: a pharmacologic target for autophagy regulation. J Clin Invest. 2015;125:25&#x2013;32. doi: 10.1172/JCI73939.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI73939</ArticleId>
            <ArticleId IdType="pmc">PMC4382265</ArticleId>
            <ArticleId IdType="pubmed">25654547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13:132&#x2013;41. doi: 10.1038/ncb2152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb2152</ArticleId>
            <ArticleId IdType="pmc">PMC3987946</ArticleId>
            <ArticleId IdType="pubmed">21258367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ravikumar B, Sarkar S, Davies JE, Futter M, Garcia-Arencibia M, Green-Thompson ZW, et al. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev. 2010;90:1383&#x2013;435. doi: 10.1152/physrev.00030.2009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/physrev.00030.2009</ArticleId>
            <ArticleId IdType="pubmed">20959619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janku F, McConkey DJ, Hong DS, Kurzrock R. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol. 2011;8:528&#x2013;39. doi: 10.1038/nrclinonc.2011.71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2011.71</ArticleId>
            <ArticleId IdType="pubmed">21587219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krauss S, Zhang CY, Lowell BB. The mitochondrial uncoupling-protein homologues. Nat Rev Mol Cell Biol. 2005;6:248&#x2013;61. doi: 10.1038/nrm1592.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm1592</ArticleId>
            <ArticleId IdType="pubmed">15738989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417:1&#x2013;13. doi: 10.1042/BJ20081386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BJ20081386</ArticleId>
            <ArticleId IdType="pmc">PMC2605959</ArticleId>
            <ArticleId IdType="pubmed">19061483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee S, Tak E, Lee J, Rashid MA, Murphy MP, Ha J, et al. Mitochondrial H2O2 generated from electron transport chain complex I stimulates muscle differentiation. Cell Res. 2011;21:817&#x2013;34. doi: 10.1038/cr.2011.55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cr.2011.55</ArticleId>
            <ArticleId IdType="pmc">PMC3203677</ArticleId>
            <ArticleId IdType="pubmed">21445095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tormos KV, Anso E, Hamanaka RB, Eisenbart J, Joseph J, Kalyanaraman B, et al. Mitochondrial complex III ROS regulate adipocyte differentiation. Cell Metab. 2011;14:537&#x2013;44. doi: 10.1016/j.cmet.2011.08.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2011.08.007</ArticleId>
            <ArticleId IdType="pmc">PMC3190168</ArticleId>
            <ArticleId IdType="pubmed">21982713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamanaka RB, Glasauer A, Hoover P, Yang S, Blatt H, Mullen AR, et al. Mitochondrial reactive oxygen species promote epidermal differentiation and hair follicle development. Sci Signal. 2013;6:ra8. doi: 10.1126/scisignal.2003638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.2003638</ArticleId>
            <ArticleId IdType="pmc">PMC4017376</ArticleId>
            <ArticleId IdType="pubmed">23386745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Del Prete A, Zaccagnino P, Di Paola M, Saltarella M, Oliveros Celis C, Nico B, et al. Role of mitochondria and reactive oxygen species in dendritic cell differentiation and functions. Free Radic Biol Med. 2008;44:1443&#x2013;51. doi: 10.1016/j.freeradbiomed.2007.12.037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2007.12.037</ArticleId>
            <ArticleId IdType="pubmed">18242195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khacho M, Clark A, Svoboda DS, Azzi J, MacLaurin JG, Meghaizel C, et al. Mitochondrial dynamics impacts stem cell identity and fate decisions by regulating a nuclear transcriptional program. Cell Stem Cell. 2016;19:232&#x2013;47. doi: 10.1016/j.stem.2016.04.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.stem.2016.04.015</ArticleId>
            <ArticleId IdType="pubmed">27237737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rhee SG. Cell signaling. H2O2, a necessary evil for cell signaling. Science. 2006;312:1882&#x2013;3. doi: 10.1126/science.1130481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1130481</ArticleId>
            <ArticleId IdType="pubmed">16809515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, DuBois JL, Hedman B, Hodgson KO, Stack TD. Catalytic galactose oxidase models: biomimetic Cu(II)-phenoxyl-radical reactivity. Science. 1998;279:537&#x2013;40. doi: 10.1126/science.279.5350.537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.279.5350.537</ArticleId>
            <ArticleId IdType="pubmed">9438841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalyanaraman B, Darley-Usmar V, Davies KJ, Dennery PA, Forman HJ, Grisham MB, et al. Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations. Free Radic Biol Med. 2012;52:1&#x2013;6. doi: 10.1016/j.freeradbiomed.2011.09.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2011.09.030</ArticleId>
            <ArticleId IdType="pmc">PMC3911769</ArticleId>
            <ArticleId IdType="pubmed">22027063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Connor KM, Subbaram S, Regan KJ, Nelson KK, Mazurkiewicz JE, Bartholomew PJ, et al. Mitochondrial H2O2 regulates the angiogenic phenotype via PTEN oxidation. J Biol Chem. 2005;280:16916&#x2013;24. doi: 10.1074/jbc.M410690200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M410690200</ArticleId>
            <ArticleId IdType="pubmed">15701646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu KL, Wu CA, Wu CW, Chan SH, Chang AY, Chan JY. Redox-sensitive oxidation and phosphorylation of PTEN contribute to enhanced activation of PI3K/Akt signaling in rostral ventrolateral medulla and neurogenic hypertension in spontaneously hypertensive rats. Antioxid Redox Signal. 2013;18:36&#x2013;50. doi: 10.1089/ars.2011.4457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2011.4457</ArticleId>
            <ArticleId IdType="pmc">PMC3503464</ArticleId>
            <ArticleId IdType="pubmed">22746319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crespo FL, Sobrado VR, Gomez L, Cervera AM, McCreath KJ. Mitochondrial reactive oxygen species mediate cardiomyocyte formation from embryonic stem cells in high glucose. Stem Cells. 2010;28:1132&#x2013;42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20506541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoon MS. mTOR as a key regulator in maintaining skeletal muscle mass. Front Physiol. 2017;8:788. doi: 10.3389/fphys.2017.00788.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphys.2017.00788</ArticleId>
            <ArticleId IdType="pmc">PMC5650960</ArticleId>
            <ArticleId IdType="pubmed">29089899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sandri M. Autophagy in skeletal muscle. FEBS Lett. 2010;584:1411&#x2013;6. doi: 10.1016/j.febslet.2010.01.056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2010.01.056</ArticleId>
            <ArticleId IdType="pubmed">20132819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez-Lopez N, Athonvarangkul D, Sahu S, Coletto L, Zong H, Bastie CC, et al. Autophagy in Myf5+ progenitors regulates energy and glucose homeostasis through control of brown fat and skeletal muscle development. EMBO Rep. 2013;14:795&#x2013;803. doi: 10.1038/embor.2013.111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/embor.2013.111</ArticleId>
            <ArticleId IdType="pmc">PMC3790054</ArticleId>
            <ArticleId IdType="pubmed">23907538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forgac M. Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nat Rev Mol Cell Biol. 2007;8:917&#x2013;29. doi: 10.1038/nrm2272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm2272</ArticleId>
            <ArticleId IdType="pubmed">17912264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fortini P, Ferretti C, Iorio E, Cagnin M, Garribba L, Pietraforte D, et al. The fine tuning of metabolism, autophagy and differentiation during in vitro myogenesis. Cell Death Dis. 2016;7:e2168. doi: 10.1038/cddis.2016.50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2016.50</ArticleId>
            <ArticleId IdType="pmc">PMC4823951</ArticleId>
            <ArticleId IdType="pubmed">27031965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J, Guan KL. Regulation of the autophagy initiating kinase ULK1 by nutrients: roles of mTORC1 and AMPK. Cell Cycle. 2011;10:1337&#x2013;8. doi: 10.4161/cc.10.9.15291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cc.10.9.15291</ArticleId>
            <ArticleId IdType="pubmed">21403467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Z, Wang H, Lee IH, Modi S, Wang X, Du J, et al. PTEN inhibition improves muscle regeneration in mice fed a high-fat diet. Diabetes. 2010;59:1312&#x2013;20. doi: 10.2337/db09-1155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/db09-1155</ArticleId>
            <ArticleId IdType="pmc">PMC2874691</ArticleId>
            <ArticleId IdType="pubmed">20200318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vasilaki A, Jackson MJ. Role of reactive oxygen species in the defective regeneration seen in aging muscle. Free Radic Biol Med. 2013;65:317&#x2013;23. doi: 10.1016/j.freeradbiomed.2013.07.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.07.008</ArticleId>
            <ArticleId IdType="pmc">PMC3859734</ArticleId>
            <ArticleId IdType="pubmed">23851030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ownby CL, Fletcher JE, Colberg TR. Cardiotoxin 1 from cobra (Naja naja atra) venom causes necrosis of skeletal muscle in vivo. Toxicon. 1993;31:697&#x2013;709. doi: 10.1016/0041-0101(93)90376-T.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0041-0101(93)90376-T</ArticleId>
            <ArticleId IdType="pubmed">8342169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J, Choi KJ, Lim MJ, Hong F, Choi TG, Tak E, et al. Proto-oncogenic H-Ras, K-Ras, and N-Ras are involved in muscle differentiation via phosphatidylinositol 3-kinase. Cell Res. 2010;20:919&#x2013;34. doi: 10.1038/cr.2010.92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cr.2010.92</ArticleId>
            <ArticleId IdType="pubmed">20603646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Remels AH, Langen RC, Schrauwen P, Schaart G, Schols AM, Gosker HR. Regulation of mitochondrial biogenesis during myogenesis. Mol Cell Endocrinol. 2010;315:113&#x2013;20. doi: 10.1016/j.mce.2009.09.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mce.2009.09.029</ArticleId>
            <ArticleId IdType="pubmed">19804813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malinska D, Kudin AP, Bejtka M, Kunz WS. Changes in mitochondrial reactive oxygen species synthesis during differentiation of skeletal muscle cells. Mitochondrion. 2012;12:144&#x2013;8. doi: 10.1016/j.mito.2011.06.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mito.2011.06.015</ArticleId>
            <ArticleId IdType="pubmed">21782978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13:283&#x2013;96. doi: 10.1038/nrm3330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm3330</ArticleId>
            <ArticleId IdType="pubmed">22473468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>White ES, Atrasz RG, Hu B, Phan SH, Stambolic V, Mak TW, et al. Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10) Am J Respir Crit Care Med. 2006;173:112&#x2013;21. doi: 10.1164/rccm.200507-1058OC.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.200507-1058OC</ArticleId>
            <ArticleId IdType="pmc">PMC1434700</ArticleId>
            <ArticleId IdType="pubmed">16179636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yue F, Bi P, Wang C, Li J, Liu X, Kuang S. Conditional loss of Pten in myogenic progenitors leads to postnatal skeletal muscle hypertrophy but age-dependent exhaustion of satellite cells. Cell Rep. 2016;17:2340&#x2013;53. doi: 10.1016/j.celrep.2016.11.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2016.11.002</ArticleId>
            <ArticleId IdType="pmc">PMC5181649</ArticleId>
            <ArticleId IdType="pubmed">27880908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Erbay E, Chen J. The mammalian target of rapamycin regulates C2C12 myogenesis via a kinase-independent mechanism. J Biol Chem. 2001;276:36079&#x2013;82. doi: 10.1074/jbc.C100406200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.C100406200</ArticleId>
            <ArticleId IdType="pubmed">11500483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y, Ge Y, Drnevich J, Zhao Y, Band M, Chen J. Mammalian target of rapamycin regulates miRNA-1 and follistatin in skeletal myogenesis. J Cell Biol. 2010;189:1157&#x2013;69. doi: 10.1083/jcb.200912093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.200912093</ArticleId>
            <ArticleId IdType="pmc">PMC2894448</ArticleId>
            <ArticleId IdType="pubmed">20566686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohanna M, Sobering AK, Lapointe T, Lorenzo L, Praud C, Petroulakis E, et al. Atrophy of S6K1(&#x2212;/&#x2212;) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat Cell Biol. 2005;7:286&#x2013;94. doi: 10.1038/ncb1231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb1231</ArticleId>
            <ArticleId IdType="pubmed">15723049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shu L, Houghton PJ. The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts. Mol Cell Biol. 2009;29:4691&#x2013;4700. doi: 10.1128/MCB.00764-09.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.00764-09</ArticleId>
            <ArticleId IdType="pmc">PMC2725723</ArticleId>
            <ArticleId IdType="pubmed">19564418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaafar R, Zeiller C, Pirola L, Di Grazia A, Naro F, Vidal H, et al. Phospholipase D regulates myogenic differentiation through the activation of both mTORC1 and mTORC2 complexes. J Biol Chem. 2011;286:22609&#x2013;21. doi: 10.1074/jbc.M110.203885.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M110.203885</ArticleId>
            <ArticleId IdType="pmc">PMC3121405</ArticleId>
            <ArticleId IdType="pubmed">21525000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizushima N, Levine B. Autophagy in mammalian development and differentiation. Nat Cell Biol. 2010;12:823&#x2013;30. doi: 10.1038/ncb0910-823.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb0910-823</ArticleId>
            <ArticleId IdType="pmc">PMC3127249</ArticleId>
            <ArticleId IdType="pubmed">20811354</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30003754</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>08</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1107-0625</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>23</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2018</Year>
              <Season>May-Jun</Season>
            </PubDate>
          </JournalIssue>
          <Title>Journal of B.U.ON. : official journal of the Balkan Union of Oncology</Title>
          <ISOAbbreviation>J BUON</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Galangin induced antitumor effects in human kidney tumor cells mediated via mitochondrial mediated apoptosis, inhibition of cell migration and invasion and targeting PI3K/ AKT/mTOR signalling pathway.</ArticleTitle>
        <Pagination>
          <StartPage>795</StartPage>
          <EndPage>799</EndPage>
          <MedlinePgn>795-799</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="PURPOSE">Galangin is an important flavonoid that has been reported to be of immense pharmacological importance. It has been shown to have a number of bioactivities which range from anticancer to antimicrobial. In this study the effects of Galangin were studied on the proliferation of the A498 kidney cancer cells.</AbstractText>
          <AbstractText Label="METHODS">The antiproliferative effects were tested by MTT assay. Apoptosis was checked by subjecting the A498 cell to DAPI and annexin V/PI double staining. The effect on the cell migration and invasion was assessed by Boyden chamber assays. The expression of the apoptosis-related proteins was examined by western blot analysis.</AbstractText>
          <AbstractText Label="RESULTS">Galangin inhibited the proliferation of the kidney cancer A498 cells. The IC50 of Galangin against the A498 cancer cells was 15 &#x3bc;M. The anticancer effects of Galangin were due to induction of apoptosis in the A498 cancer cells as indicated by DAPI and annexin V/PI staining. Furthermore, Galangin could increase the expression of Bax, Cyt-c and decrease the expression of Bcl-2. Galangin could also inhibit the migration and invasion of the kidney cancer cells and also suppress the expression of some of the important proteins of the PI3K/AKT/mTOR signalling pathway.</AbstractText>
          <AbstractText Label="CONCLUSION">In conclusion, Galangin could prove a useful new molecule in the treatment of kidney carcinoma.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Yun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Nanjing Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, 210002, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rao</LastName>
            <ForeName>Qiu</ForeName>
            <Initials>Q</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xinhua</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Xiaojun</ForeName>
            <Initials>X</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Cyprus</Country>
        <MedlineTA>J BUON</MedlineTA>
        <NlmUniqueID>100883428</NlmUniqueID>
        <ISSNLinking>1107-0625</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>142FWE6ECS</RegistryNumber>
          <NameOfSubstance UI="C037032">galangin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005419" MajorTopicYN="N">Flavonoids</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007680" MajorTopicYN="N">Kidney Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019253" MajorTopicYN="N">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30003754</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30003730</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>09</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1107-0625</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>23</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2018</Year>
              <Season>May-Jun</Season>
            </PubDate>
          </JournalIssue>
          <Title>Journal of B.U.ON. : official journal of the Balkan Union of Oncology</Title>
          <ISOAbbreviation>J BUON</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Lupeol triterpene exhibits potent antitumor effects in A427 human lung carcinoma cells via mitochondrial mediated apoptosis, ROS generation, loss of mitochondrial membrane potential and downregulation of m-TOR/PI3Ksol;AKT signalling pathway.</ArticleTitle>
        <Pagination>
          <StartPage>635</StartPage>
          <EndPage>640</EndPage>
          <MedlinePgn>635-640</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="PURPOSE">Lung cancer is one among the most commonly diagnosed malignancies in developed countries with highest rates of morbidity and mortality. The treatment options for lung cancer are limited and have side effects. Hence, researches are being directed at the exploration and evaluation of new molecules showing anticancer activity. In this study we investigated the anticancer effects of lupeol on the lung cancer A427 cancer cells and normal MRC-5 cells.</AbstractText>
          <AbstractText Label="METHODS">Growth inhibitory effects were checked by MTT assay. Apoptosis was detected by DAPI and annexin V/PI staining. Reactive oxygen species (ROS) and mitochondrial membrane potential (MMP) were estimated by flow cytometry. Protein expression analysis was performed by western blotting.</AbstractText>
          <AbstractText Label="RESULTS">The results showed that lupeol inhibited the growth of A427 lung cancer cells as observed by MTT and colony formation assay. The antiproliferative effects were due to induction of apoptosis as indicated by DAPI and annexin V/PI staining. This was further confirmed by Bax and Bcl-2 expression. Moreover, lupeol triggered generation of ROS and decrease of MMP. Lupeol could also inhibit the mTOR/ PI3K/AKT signalling pathway. Taken together, lupeol could prove beneficial in the treatment of lung cancer.</AbstractText>
          <AbstractText Label="CONCLUSIONS">In brief, the present study indicated that lupeol induced potent and selective cytotoxic effects and these effects were mediated via apoptosis, ROS generation, loss of MMP and inhibition of mTOR/PI3K/AKT signalling pathway.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Respiratory and Critical Care Discipline, Central Hospital Affiliated to Shenyang Medical College, Shenyang , Liaoning,110024, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xiang</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xia</LastName>
            <ForeName>Shuyue</ForeName>
            <Initials>S</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Cyprus</Country>
        <MedlineTA>J BUON</MedlineTA>
        <NlmUniqueID>100883428</NlmUniqueID>
        <ISSNLinking>1107-0625</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053978">Pentacyclic Triterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>O268W13H3O</RegistryNumber>
          <NameOfSubstance UI="C010480">lupeol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053978" MajorTopicYN="N">Pentacyclic Triterpenes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>9</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30003730</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29990575</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-6351</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>120</Volume>
            <PubDate>
              <Year>2018</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association</Title>
          <ISOAbbreviation>Food Chem Toxicol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Molecular mechanism and inhibitory targets of dioscin in HepG2 cells.</ArticleTitle>
        <Pagination>
          <StartPage>143</StartPage>
          <EndPage>154</EndPage>
          <MedlinePgn>143-154</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.fct.2018.07.016</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0278-6915(18)30454-X</ELocationID>
        <Abstract>
          <AbstractText>Dioscin has been known for its anti-cancer activity; however, its detailed molecular mechanisms have not been studied so far. Herein, we evaluated the anti-cancer activity of dioscin for proliferation inhibition and apoptosis in HepG2 cancer cells. Initially, dioscin was purified and identified from Polygonatum sibiricum by HPLC, MS, and NMR analysis, respectively. Dioscin inhibited the cell multiplication at IC50 of 8.34 μM, altered the cell morphology, arrested the cell cycle in G2/M phase and led to considerable programmed cell death. Furthermore, it has efficiently promoted the mitochondrial pathway and death receptor pathway. The inhibition of Caspase-8 and Caspase-9 proteins in these pathways abolished the dioscin induced apoptosis significantly; while dioscin inhibited the PI3K/Akt/mTOR pathway. Moreover, dioscin exposure led to enhanced intracellular ROS generation and the mRNA expression of JNK gene which emphasized their involvement in the apoptosis process in HepG2 cells.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Ying-Shuo</ForeName>
            <Initials>YS</Initials>
            <AffiliationInfo>
              <Affiliation>School of Food Science and Engineering, Hefei University of Technology, Hefei, 230009, People's Republic of China; Xuancheng Campus, Hefei University of Technology, Xuancheng, 242000, People's Republic of China. Electronic address: ying_shuo_zhang@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Yi-Long</ForeName>
            <Initials>YL</Initials>
            <AffiliationInfo>
              <Affiliation>School of Food Science and Engineering, Hefei University of Technology, Hefei, 230009, People's Republic of China; Xuancheng Campus, Hefei University of Technology, Xuancheng, 242000, People's Republic of China. Electronic address: yilong.ma@hfut.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thakur</LastName>
            <ForeName>Kiran</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>School of Food Science and Engineering, Hefei University of Technology, Hefei, 230009, People's Republic of China. Electronic address: kumarikiran@hfut.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hussain</LastName>
            <ForeName>Sayed Sajid</ForeName>
            <Initials>SS</Initials>
            <AffiliationInfo>
              <Affiliation>School of Food Science and Engineering, Hefei University of Technology, Hefei, 230009, People's Republic of China. Electronic address: sajid_biotech1214@yahoo.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Food Science and Engineering, Hefei University of Technology, Hefei, 230009, People's Republic of China. Electronic address: hfutwangjun@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Qi</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>School of Food Science and Engineering, Hefei University of Technology, Hefei, 230009, People's Republic of China. Electronic address: 18256906617@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jian-Guo</ForeName>
            <Initials>JG</Initials>
            <AffiliationInfo>
              <Affiliation>School of Food Science and Engineering, Hefei University of Technology, Hefei, 230009, People's Republic of China. Electronic address: zhangjianguo@hfut.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Zhao-Jun</ForeName>
            <Initials>ZJ</Initials>
            <AffiliationInfo>
              <Affiliation>School of Food Science and Engineering, Hefei University of Technology, Hefei, 230009, People's Republic of China. Electronic address: zjwei@hfut.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>07</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Food Chem Toxicol</MedlineTA>
        <NlmUniqueID>8207483</NlmUniqueID>
        <ISSNLinking>0278-6915</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016588">Anticarcinogenic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053218">Receptors, Death Domain</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>3B95U4OLWV</RegistryNumber>
          <NameOfSubstance UI="C019357">dioscin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>K49P2K8WLX</RegistryNumber>
          <NameOfSubstance UI="D004144">Diosgenin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D016588" MajorTopicYN="N">Anticarcinogenic Agents</DescriptorName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002455" MajorTopicYN="N">Cell Division</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004144" MajorTopicYN="N">Diosgenin</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016195" MajorTopicYN="N">G2 Phase</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018816" MajorTopicYN="N">Genes, cdc</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056945" MajorTopicYN="N">Hep G2 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D031384" MajorTopicYN="N">Polygonatum</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053218" MajorTopicYN="N">Receptors, Death Domain</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">Cell cycle</Keyword>
        <Keyword MajorTopicYN="N">Dioscin</Keyword>
        <Keyword MajorTopicYN="N">Molecular mechanism</Keyword>
        <Keyword MajorTopicYN="N">Polygonatum sibiricum</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29990575</ArticleId>
        <ArticleId IdType="doi">10.1016/j.fct.2018.07.016</ArticleId>
        <ArticleId IdType="pii">S0278-6915(18)30454-X</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29567101</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>04</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-7786</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>286</Volume>
            <PubDate>
              <Year>2018</Year>
              <Month>Apr</Month>
              <Day>25</Day>
            </PubDate>
          </JournalIssue>
          <Title>Chemico-biological interactions</Title>
          <ISOAbbreviation>Chem Biol Interact</ISOAbbreviation>
        </Journal>
        <ArticleTitle>NaHS restores mitochondrial function and inhibits autophagy by activating the PI3K/Akt/mTOR signalling pathway to improve functional recovery after traumatic brain injury.</ArticleTitle>
        <Pagination>
          <StartPage>96</StartPage>
          <EndPage>105</EndPage>
          <MedlinePgn>96-105</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cbi.2018.02.028</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0009-2797(17)31347-9</ELocationID>
        <Abstract>
          <AbstractText>Traumatic brain injury (TBI) is one of the most serious public health problems in the world. TBI causes neurological deficits by triggering secondary injuries. Hydrogen sulfide (H2S), a gaseous mediator, has been reported to exert neuroprotective effects in central nervous system diseases, such as TBI. However, the molecular mechanisms involved in this effect are still unclear. The present study was designed to explore the ability of NaHS, a H2S donor, to provide neuroprotection in a mouse model of TBI and to discover the associated molecular mechanisms of these protective effects. Here, we found that administration of NaHS not only maintained the integrity of the blood brain barrier (BBB), protected neurons from apoptosis, and promoted remyelination and axonal reparation but also protected mitochondrial function. In addition, we found that autophagy was inhibited after treatment with NaHS following TBI, an effect that was induced by activation of the PI3K/AKT/mTOR signalling pathway. Our study indicated that H2S treatment is beneficial for TBI, pointing to H2S as a potential therapeutic target for treating TBI.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2018. Published by Elsevier B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Kebin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Biotechnology and Pharmaceutical Engineering, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Fangfang</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Emergency, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou 325027, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Ke</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Life Sciences, Wenzhou University, Wenzhou 325035, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Zhengmao</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Biotechnology and Pharmaceutical Engineering, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Xiaojie</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Cixi People's Hospital, Wenzhou Medical University, Ningbo 315300, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Qi</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Biotechnology and Pharmaceutical Engineering, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Ting</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Biotechnology and Pharmaceutical Engineering, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Fenzan</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Science and Education Division, Cixi People's Hospital, Wenzhou Medical University, Ningbo 315300, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Xinlong</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Cixi People's Hospital, Wenzhou Medical University, Ningbo 315300, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Jian</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Biotechnology and Pharmaceutical Engineering, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Daqing</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Emergency, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou 325027, Zhejiang, China. Electronic address: cdq@wzhealth.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Hongyu</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Biotechnology and Pharmaceutical Engineering, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China; Experimental Research Centre, Dongyang People's Hospital, Wenzhou Medical University, Jinhua 322100, Zhejiang, China. Electronic address: hyzhang@wmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>03</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>Chem Biol Interact</MedlineTA>
        <NlmUniqueID>0227276</NlmUniqueID>
        <ISSNLinking>0009-2797</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013440">Sulfides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>FWU2KQ177W</RegistryNumber>
          <NameOfSubstance UI="C025451">sodium bisulfide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000070642" MajorTopicYN="N">Brain Injuries, Traumatic</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013440" MajorTopicYN="N">Sulfides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Autophagy</Keyword>
        <Keyword MajorTopicYN="N">Blood brain barrier</Keyword>
        <Keyword MajorTopicYN="N">Hydrogen sulfide</Keyword>
        <Keyword MajorTopicYN="N">Traumatic brain injury</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29567101</ArticleId>
        <ArticleId IdType="doi">10.1016/j.cbi.2018.02.028</ArticleId>
        <ArticleId IdType="pii">S0009-2797(17)31347-9</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29559471</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1538-7445</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>78</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Jun</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer research</Title>
          <ISOAbbreviation>Cancer Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.</ArticleTitle>
        <Pagination>
          <StartPage>3075</StartPage>
          <EndPage>3086</EndPage>
          <MedlinePgn>3075-3086</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1158/0008-5472.CAN-17-3024</ELocationID>
        <Abstract>
          <AbstractText>Inhibitors targeting BCL-2 apoptotic proteins have significant potential for the treatment of acute myeloid leukemia (AML); however, complete responses are observed in only 20% of patients, suggesting that targeting BCL-2 alone is insufficient to yield durable responses. Here, we assessed the efficacy of coadministration of the PI3K/mTOR inhibitor GDC-0980 or the p110β-sparing PI3K inhibitor taselisib with the selective BCL-2 antagonist venetoclax in AML cells. Tetracycline-inducible downregulation of BCL-2 significantly sensitized MV4-11 and MOLM-13 AML cells to PI3K inhibition. Venetoclax/GDC-0980 coadministration induced rapid and pronounced BAX mitochondrial translocation, cytochrome c release, and apoptosis in various AML cell lines in association with AKT/mTOR inactivation and MCL-1 downregulation; ectopic expression of MCL-1 significantly protected cells from this regimen. Combined treatment was also effective against primary AML blasts from 17 patients, including those bearing various genetic abnormalities. Venetoclax/GDC-0980 markedly induced apoptosis in primitive CD34[+]/38[-]/123[+] AML cell populations but not in normal hematopoietic progenitor CD34[+] cells. The regimen was also active against AML cells displaying intrinsic or acquired venetoclax resistance or tumor microenvironment-associated resistance. Either combinatorial treatment markedly reduced AML growth and prolonged survival in a systemic AML xenograft mouse model and diminished AML growth in two patient-derived xenograft models. Venetoclax/GDC-0980 activity was partially diminished in BAK[-/-] cells and failed to induce apoptosis in BAX[-/-] and BAX[-/-]BAK[-/-] cells, whereas BIM[-/-] cells were fully sensitive. Similar results were observed with venetoclax alone in in vitro and in vivo systemic xenograft models. Collectively, these studies demonstrate that venetoclax/GDC-0980 exhibits potent anti-AML activity primarily through BAX and, to a lesser extent, BAK. These findings argue that dual BCL-2 and PI3K inhibition warrants further evaluation in AML.Significance: Combined treatment with clinically relevant PI3K and BCL-2 inhibitors may prove effective in the treatment of acute myeloid leukemia. Cancer Res; 78(11); 3075-86. ©2018 AACR.</AbstractText>
          <CopyrightInformation>&#xa9;2018 American Association for Cancer Research.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rahmani</LastName>
            <ForeName>Mohamed</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Virginia Commonwealth University and the Massey Cancer Center, Virginia. steven.grant@vcuhealth.org mrahmani@sharjah.ac.ae.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>College of Medicine, Sharjah Institute for Medical Research, University of Sharjah, Sharjah, UAE.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nkwocha</LastName>
            <ForeName>Jewel</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Virginia Commonwealth University and the Massey Cancer Center, Virginia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hawkins</LastName>
            <ForeName>Elisa</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Virginia Commonwealth University and the Massey Cancer Center, Virginia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pei</LastName>
            <ForeName>Xinyan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Virginia Commonwealth University and the Massey Cancer Center, Virginia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Parker</LastName>
            <ForeName>Rebecca E</ForeName>
            <Initials>RE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Virginia Commonwealth University and the Massey Cancer Center, Virginia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kmieciak</LastName>
            <ForeName>Maciej</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Virginia Commonwealth University and the Massey Cancer Center, Virginia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leverson</LastName>
            <ForeName>Joel D</ForeName>
            <Initials>JD</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie, North Chicago, Illinois.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sampath</LastName>
            <ForeName>Deepak</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Genentech, South San Francisco, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ferreira-Gonzalez</LastName>
            <ForeName>Andrea</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Virginia Commonwealth University and the Massey Cancer Center, Richmond, Virginia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grant</LastName>
            <ForeName>Steven</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Virginia Commonwealth University and the Massey Cancer Center, Virginia. steven.grant@vcuhealth.org mrahmani@sharjah.ac.ae.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, Virginia Commonwealth University and the Massey Cancer Center, Richmond, Virginia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Virginia Commonwealth University and the Massey Cancer Center, Richmond, Virginia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Human and Molecular Genetics, Virginia Commonwealth University, the Virginia Institute for Molecular Medicine and the Massey Cancer Center, Richmond, Virginia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 CA016059</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA167708</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA205607</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>UH2 TR001373</GrantID>
            <Acronym>TR</Acronym>
            <Agency>NCATS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>03</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cancer Res</MedlineTA>
        <NlmUniqueID>2984705R</NlmUniqueID>
        <ISSNLinking>0008-5472</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C569670">1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C494826">BAX protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000595707">BCL2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019086">Bridged Bicyclo Compounds, Heterocyclic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051028">bcl-2-Associated X Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.-</RegistryNumber>
          <NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>N54AIC43PW</RegistryNumber>
          <NameOfSubstance UI="C579720">venetoclax</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019086" MajorTopicYN="N">Bridged Bicyclo Compounds, Heterocyclic</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064593" MajorTopicYN="N">Heterografts</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015470" MajorTopicYN="N">Leukemia, Myeloid, Acute</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016688" MajorTopicYN="N">Mice, Inbred NOD</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019253" MajorTopicYN="N">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020298" MajorTopicYN="N">U937 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051028" MajorTopicYN="N">bcl-2-Associated X Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Conflict of interest disclosures: J.L, and D.S are employees of AbbVie and Genentech respectively. All other authors have no conflict of interest to disclose.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>10</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>1</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29559471</ArticleId>
        <ArticleId IdType="mid">NIHMS954404</ArticleId>
        <ArticleId IdType="pmc">PMC5984704</ArticleId>
        <ArticleId IdType="doi">10.1158/0008-5472.CAN-17-3024</ArticleId>
        <ArticleId IdType="pii">0008-5472.CAN-17-3024</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Delbridge AR, Strasser A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ. 2015;22:1071&#x2013;80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4572872</ArticleId>
            <ArticleId IdType="pubmed">25952548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677&#x2013;81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15902208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park C-M, Bruncko M, Adickes J, Bauch J, Ding H, Kunzer A, et al. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem. 2008;51:6902&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18841882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson WH, O&#x2019;Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11:1149&#x2013;59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3025495</ArticleId>
            <ArticleId IdType="pubmed">21094089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011;29:909&#x2013;16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4668282</ArticleId>
            <ArticleId IdType="pubmed">21282543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30:488&#x2013;96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4979082</ArticleId>
            <ArticleId IdType="pubmed">22184378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128:1173&#x2013;86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17382885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Debrincat MA, Pleines I, Lebois M, Lane RM, Holmes ML, Corbin J, et al. BCL-2 is dispensable for thrombopoiesis and platelet survival. Cell Death Dis. 2015;6:e1721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4650559</ArticleId>
            <ArticleId IdType="pubmed">25880088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature medicine. 2013;19:202&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23291630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vandenberg CJ, Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood. 2013;121:2285&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3606065</ArticleId>
            <ArticleId IdType="pubmed">23341542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768&#x2013;78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27178240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niu X, Wang G, Wang Y, Caldwell JT, Edwards H, Xie C, et al. Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199. Leukemia. 2014;28:1557&#x2013;60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4090260</ArticleId>
            <ArticleId IdType="pubmed">24531733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nature medicine. 2015;21:178&#x2013;84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4406275</ArticleId>
            <ArticleId IdType="pubmed">25599133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer discovery. 2014;4:362&#x2013;75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3975047</ArticleId>
            <ArticleId IdType="pubmed">24346116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer discovery. 2016;6:1106&#x2013;17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5436271</ArticleId>
            <ArticleId IdType="pubmed">27520294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deeks ED. Venetoclax: First Global Approval. Drugs. 2016;76:979&#x2013;87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27260335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bose P, Vachhani P, Cortes JE. Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Curr Treat Options Oncol. 2017;18:17. doi: 10.1007/s11864-017-0456-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11864-017-0456-2</ArticleId>
            <ArticleId IdType="pubmed">28286924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10:375&#x2013;88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17097560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahmani M, Aust MM, Attkisson E, Williams DC, Jr, Ferreira-Gonzalez A, Grant S. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Cancer Res. 2013;73:1340&#x2013;51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3578060</ArticleId>
            <ArticleId IdType="pubmed">23243017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. MolCell. 2006;21:749&#x2013;60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16543145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mills JR, Hippo Y, Robert F, Chen SM, Malina A, Lin CJ, et al. mTORC1 promotes survival through translational control of Mcl-1. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:10853&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2504845</ArticleId>
            <ArticleId IdType="pubmed">18664580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahmani M, Aust MM, Hawkins E, Parker RE, Ross M, Kmieciak M, et al. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation. Haematologica. 2015;100:1553&#x2013;63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4666331</ArticleId>
            <ArticleId IdType="pubmed">26452980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005;19:1294&#x2013;305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1142553</ArticleId>
            <ArticleId IdType="pubmed">15901672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ndubaku CO, Heffron TP, Staben ST, Baumgardner M, Blaquiere N, Bradley E, et al. Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2&#x2013;4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a beta-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. J Med Chem. 2013;56:4597&#x2013;610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23662903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahmani M, Mayo M, Dash R, Sokhi UK, Dmitriev IP, Sarkar D, et al. Melanoma differentiation associated gene-7/interleukin-24 potently induces apoptosis in human myeloid leukemia cells through a process regulated by endoplasmic reticulum stress. Mol Pharmacol. 2010;78:1096&#x2013;104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2993469</ArticleId>
            <ArticleId IdType="pubmed">20858700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY 43&#x2013;9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. JBiolChem. 2005;280:35217&#x2013;27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16109713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahmani M, Aust MM, Benson EC, Wallace L, Friedberg J, Grant S. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014;20:4849&#x2013;60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4166554</ArticleId>
            <ArticleId IdType="pubmed">25070836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahmani M, Anderson A, Habibi JR, Crabtree TR, Mayo M, Harada H, et al. The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. Blood. 2009;114:4507&#x2013;16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2777129</ArticleId>
            <ArticleId IdType="pubmed">19773546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. AdvEnzyme Regul. 1984;22:27&#x2013;55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6382953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016;374:311&#x2013;22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7107002</ArticleId>
            <ArticleId IdType="pubmed">26639348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hauswirth AW, Florian S, Printz D, Sotlar K, Krauth MT, Fritsch G, et al. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. Eur J Clin Invest. 2007;37:73&#x2013;82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17181570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J, et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax) Cell Death Dis. 2015;6:e1590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4669759</ArticleId>
            <ArticleId IdType="pubmed">25590800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Guo H, Duan H, Yang Y, Meng J, Liu J, et al. Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis. Sci Rep. 2015;5:16228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4633653</ArticleId>
            <ArticleId IdType="pubmed">26538086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen P, Huang H, Wu J, Lu R, Wu Y, Jiang X, et al. Bone marrow stromal cells protect acute myeloid leukemia cells from anti-CD44 therapy partly through regulating PI3K/Akt-p27(Kip1) axis. Mol Carcinog. 2015;54:1678&#x2013;85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25408361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature. 2010;463:103&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20023629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, McCubrey JA. The emerging role of the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin signaling network in cancer stem cell biology. Cancers (Basel) 2010;2:1576&#x2013;96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3837323</ArticleId>
            <ArticleId IdType="pubmed">24281174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sandhofer N, Metzeler KH, Rothenberg M, Herold T, Tiedt S, Groiss V, et al. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. Leukemia. 2015;29:828&#x2013;38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25322685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, et al. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev. 2003 Jun 15;17(12):1475&#x2013;86. Epub2003Jun3 2003;17:1475&#x2013;86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC196078</ArticleId>
            <ArticleId IdType="pubmed">12783855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phillips DC, Xiao Y, Lam LT, Litvinovich E, Roberts-Rapp L, Souers AJ, et al. Loss in MCL-1 function sensitizes non-Hodgkin&#x2019;s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199) Blood cancer journal. 2015;5:e368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4670945</ArticleId>
            <ArticleId IdType="pubmed">26565405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bate-Eya LT, den Hartog IJ, van der Ploeg I, Schild L, Koster J, Santo EE, et al. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition. Oncotarget. 2016;7:27946&#x2013;58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5053701</ArticleId>
            <ArticleId IdType="pubmed">27056887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morales AA, Kurtoglu M, Matulis SM, Liu J, Siefker D, Gutman DM, et al. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. Blood. 2011;118:1329&#x2013;39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3152498</ArticleId>
            <ArticleId IdType="pubmed">21659544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Punnoose EA, Leverson JD, Peale F, Boghaert ER, Belmont LD, Tan N, et al. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. Mol Cancer Ther. 2016;15:1132&#x2013;44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26939706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nature reviews Molecular cell biology. 2010;11:621&#x2013;32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20683470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fresquet V, Rieger M, Carolis C, Garcia-Barchino MJ, Martinez-Climent JA. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood. 2014;123:4111&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24786774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gong JN, Khong T, Segal D, Yao Y, Riffkin CD, Garnier JM, et al. Hierarchy for targeting pro-survival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. Blood. 2016</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27465916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Correia C, Lee SH, Meng XW, Vincelette ND, Knorr KL, Ding H, et al. Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. Biochim Biophys Acta. 2015;1853:1658&#x2013;71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4429517</ArticleId>
            <ArticleId IdType="pubmed">25827952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Huang K, O&#x2019;Neill KL, Pang X, Luo X. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53. Cell Death Dis. 2016;7:e2266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5143395</ArticleId>
            <ArticleId IdType="pubmed">27310874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O&#x2019;Neill KL, Huang K, Zhang J, Chen Y, Luo X. Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane. Genes Dev. 2016;30:973&#x2013;88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4840302</ArticleId>
            <ArticleId IdType="pubmed">27056669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kazi A, Sun J, Doi K, Sung SS, Takahashi Y, Yin H, et al. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner. The Journal of biological chemistry. 2011;286:9382&#x2013;92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3059047</ArticleId>
            <ArticleId IdType="pubmed">21148306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riether C, Schurch CM, Ochsenbein AF. Regulation of hematopoietic and leukemic stem cells by the immune system. Cell Death Differ. 2015;22:187&#x2013;98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4291501</ArticleId>
            <ArticleId IdType="pubmed">24992931</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29458146</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>09</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>12</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-7573</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>217</Volume>
            <PubDate>
              <Year>2018</Year>
              <Month>May</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of ethnopharmacology</Title>
          <ISOAbbreviation>J Ethnopharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Enhanced anticancer effects of Scutellaria barbata D. Don in combination with traditional Chinese medicine components on non-small cell lung cancer cells.</ArticleTitle>
        <Pagination>
          <StartPage>140</StartPage>
          <EndPage>151</EndPage>
          <MedlinePgn>140-151</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jep.2018.02.020</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0378-8741(17)34012-6</ELocationID>
        <Abstract>
          <AbstractText Label="ETHNOPHARMACOLOGICAL RELEVANCE" NlmCategory="BACKGROUND">Experience-based herbal medicine as a complementary to modern western medicine has triggered an array of studies in quest of novel anticancer drugs. Scutellaria barbata D. Don (SB) is commonly used to treat different types of cancers, but its molecular mechanism of action is not clearly understood. In this study, we attempted to elucidate the mode of action of a traditional Chinese medicine prescription with a total of 14 components, named Lian-Jia-San-Jie-Fang (LJSJF, in Chinese), where SB works as the "principle" against non-small cell lung cancer (NSCLC) cells.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Four different NSCLC cell lines (A549, H460, H1650, and H1975) were used. Cytotoxicity, in vitro tumorigenicity, gene expression, and protein expression were analyzed by MTT assay, soft agar assay, real-time PCR, and Western blots, respectively.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 14 components in LJSJF, SB was the only one to possess cytotoxic effects at its pharmacologically relevant doses. Additionally, we observed synergistically dose-dependent cytotoxic effects of SB in combination with other LJSJF components. After SB or LJSJF treatment, significant reductions in colony number and/or size were observed in A549 and H460; a notable dose-dependent decrease in EGFR was observed in A549, H460, and H1650; significant downregulation in EGFR and its downstream signaling targets mTOR and p38MAPK were also observed in A549 and H460; and p53 and p21 were significantly increased while survivin, cyclin D1, and MDM2 were significantly decreased in A549. Additionally, p53, p21, and Mettl7b were decreased, but p73 was increased in H460. Neither EGFR nor p53 was changed in H1975. Therefore, SB or LJSJF may induce cytotoxic effects by regulating multiple and/or distinct apoptotic pathways in different NSCLC cells.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">LJSJF exerts more pronounced cytotoxic effects against NSCLC cells than SB does by synergistically regulating the underlining molecular mechanisms including EGFR and/or p53 signaling pathways.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2018 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Qian</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Environmental Toxicology, The Institute of Environmental and Human Health, Texas Tech University, Lubbock, Texas 79416, United States; Department of Respiratory Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210029, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Acharya</LastName>
            <ForeName>Narayan</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Environmental Toxicology, The Institute of Environmental and Human Health, Texas Tech University, Lubbock, Texas 79416, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Zhongwei</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Environmental Toxicology, The Institute of Environmental and Human Health, Texas Tech University, Lubbock, Texas 79416, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Xianmei</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210029, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cromie</LastName>
            <ForeName>Meghan</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Environmental Toxicology, The Institute of Environmental and Human Health, Texas Tech University, Lubbock, Texas 79416, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Jia</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210029, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Weimin</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Environmental Toxicology, The Institute of Environmental and Human Health, Texas Tech University, Lubbock, Texas 79416, United States. Electronic address: weimin.gao@ttu.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>02</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>J Ethnopharmacol</MedlineTA>
        <NlmUniqueID>7903310</NlmUniqueID>
        <ISSNLinking>0378-8741</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C524947">Scutellaria barbata extract</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C495901">TP53 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000072283" MajorTopicYN="N">A549 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008517" MajorTopicYN="N">Phytotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010946" MajorTopicYN="N">Plants, Medicinal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D031363" MajorTopicYN="Y">Scutellaria</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">EGFR</Keyword>
        <Keyword MajorTopicYN="N">NSCLC</Keyword>
        <Keyword MajorTopicYN="N">Scutellaria barbata D. Don</Keyword>
        <Keyword MajorTopicYN="N">TCM</Keyword>
        <Keyword MajorTopicYN="N">p53</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29458146</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jep.2018.02.020</ArticleId>
        <ArticleId IdType="pii">S0378-8741(17)34012-6</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29289836</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>08</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1950-6007</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>98</Volume>
            <PubDate>
              <Year>2018</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</Title>
          <ISOAbbreviation>Biomed Pharmacother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Brevilin A induces apoptosis and autophagy of colon adenocarcinoma cell CT26 via mitochondrial pathway and PI3K/AKT/mTOR inactivation.</ArticleTitle>
        <Pagination>
          <StartPage>619</StartPage>
          <EndPage>625</EndPage>
          <MedlinePgn>619-625</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopha.2017.12.057</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0753-3322(17)34685-1</ELocationID>
        <Abstract>
          <AbstractText>Brevilin A is a sesquiterpene lactone isolated from Centipeda minima and possesses inhibitory effects on proliferation of various tumor cells. In this study, Brevilin A inhibitory effect on proliferation and its molecular mechanism of action were investigated both in vivo and in vitro in colon adenocarcinoma CT26 cells. The results indicated that the inhibitory effect of Brevilin A in CT26 proliferation was dose-dependent and this effect was due to apoptosis. Furthermore, Brevilin A increased ROS levels, decreased mitochondrial membrane potential (MMP) and induced apoptosis of CT26 cell in a dose-dependent manner. Apoptosis induced by Brevilin A was higher than that induced by adriamycin under the same dose. Cleaved-caspase-8, cleaved-caspase-9 and cleaved-caspase-3 were up-regulated after Brevilin A treatment, together with an increase of Bax protein expression, while Bcl-2 was reduced. Further investigation revealed that Brevilin A inhibited the phosphorylation of PI3K, AKT and mTOR and promoted the expressions of autophagy-related proteins LC3-II, Beclin1 and Atg5 and consequent formation of autophagosomes, whereas 3-methyladenine (3-MA), a type III PI3K inhibitor, inhibited autophagosomes formation induced by Brevilin A. In vivo investigation suggested that Brevilin A significantly inhibited the growth of CT26 tumor compared to adriamycin and concurrently promoted the expressions of LC3-II and cleaved-caspase-3 in tumor tissues. Our results demonstrated that the anti-tumor activity of Brevilin A was mainly achieved by the induction of cell apoptosis and autophagy, suggesting a promising potential as antitumor drug against colon adenocarcinoma.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2017 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>You</LastName>
            <ForeName>Pengtao</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Resources and Chemistry of Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, Hubei 430065, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Hezhen</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Hubei University of Chinese Medicine, Wuhan, Hubei 430065, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>Meng</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Resources and Chemistry of Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, Hubei 430065, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Jingling</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Resources and Chemistry of Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, Hubei 430065, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Fangping</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Resources and Chemistry of Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, Hubei 430065, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Yanfang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Resources and Chemistry of Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, Hubei 430065, PR China; Collaborative Innovation Center of Traditional Chinese Medicine of New Products for Geriatrics Hubei Province, Hubei University of Chinese Medicine, Wuhan, Hubei 430065, PR China. Electronic address: yyf0204@hbtcm.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>France</Country>
        <MedlineTA>Biomed Pharmacother</MedlineTA>
        <NlmUniqueID>8213295</NlmUniqueID>
        <ISSNLinking>0753-3322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003437">Crotonates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012717">Sesquiterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C585263">brevilin A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D020169">Caspases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000072283" MajorTopicYN="N">A549 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003110" MajorTopicYN="N">Colonic Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003437" MajorTopicYN="N">Crotonates</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056945" MajorTopicYN="N">Hep G2 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012717" MajorTopicYN="N">Sesquiterpenes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">Autophagy</Keyword>
        <Keyword MajorTopicYN="N">Brevilin A</Keyword>
        <Keyword MajorTopicYN="N">CT26</Keyword>
        <Keyword MajorTopicYN="N">Mechanism</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>9</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>8</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29289836</ArticleId>
        <ArticleId IdType="doi">10.1016/j.biopha.2017.12.057</ArticleId>
        <ArticleId IdType="pii">S0753-3322(17)34685-1</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29208466</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>02</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>02</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1090-2104</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>495</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Jan</Month>
              <Day>08</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biochemical and biophysical research communications</Title>
          <ISOAbbreviation>Biochem Biophys Res Commun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Chetomin induces apoptosis in human triple-negative breast cancer cells by promoting calcium overload and mitochondrial dysfunction.</ArticleTitle>
        <Pagination>
          <StartPage>1915</StartPage>
          <EndPage>1921</EndPage>
          <MedlinePgn>1915-1921</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2017.11.199</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0006-291X(17)32376-8</ELocationID>
        <Abstract>
          <AbstractText>Human triple-negative breast cancer (TNBC) is poorly diagnosed and unresponsive to conventional hormone therapy. Chetomin (CHET), a fungal metabolite synthesized by Chaetomium cochliodes, has been reported as a promising anticancer and antiangiogenic agent but the complete molecular mechanism of its anticancer potential remains to be elucidated. In our study, we explored the anti-neoplastic action of CHET on TNBC cells. Cytotoxicity studies were performed in human TNBC cells viz. MDA-MB-231 and MDA-MB-468 cells by Sulforhodamine B assay. It exhibited antiproliferative response and induced apoptosis in both the cell types. Cell cycle analysis revealed that it increases the sub G0/G1 phase cell population. Modulation of mitochondrial membrane potential, activation of caspase 3/7 and a remarkable increase in the expression of cleaved PARP and increased chromatin condensation was observed after CHET treatment in MDA-MB-231 and MDA-MB-468 cells. Additionally, an elevated level of intracellular Ca[2+] played an important role in CHET mediated cell death response. Calcium overload in mitochondria led to release of cytochrome c which in turn triggered caspase-3 mediated cell death. Inhibition of calcium signalling using BAPTA-AM reduced apoptosis confirming the involvement of calcium signalling in CHET induced cell death. Chetomin also inhibited PI3K/mTOR cell survival pathway in human TNBC cells. The overall findings suggest that Chetomin inhibited the growth of human TNBC cells by caspase-dependent apoptosis and modulation of PI3K/mTOR signalling and could be used as a novel chemotherapeutic agent for the treatment of human TNBC in future.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dewangan</LastName>
            <ForeName>Jayant</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Genotoxicity Lab, Division of Toxicology and Experimental Medicine, CSIR-Central Drug Research Institute, Lucknow, 226031, Uttar Pradesh, India. Electronic address: jayantdewangan@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Srivastava</LastName>
            <ForeName>Sonal</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Genotoxicity Lab, Division of Toxicology and Experimental Medicine, CSIR-Central Drug Research Institute, Lucknow, 226031, Uttar Pradesh, India. Electronic address: sonal.srivastava24@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mishra</LastName>
            <ForeName>Sakshi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Genotoxicity Lab, Division of Toxicology and Experimental Medicine, CSIR-Central Drug Research Institute, Lucknow, 226031, Uttar Pradesh, India. Electronic address: drsakshimishra@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pandey</LastName>
            <ForeName>Prabhash Kumar</ForeName>
            <Initials>PK</Initials>
            <AffiliationInfo>
              <Affiliation>Genotoxicity Lab, Division of Toxicology and Experimental Medicine, CSIR-Central Drug Research Institute, Lucknow, 226031, Uttar Pradesh, India. Electronic address: pandey.prabhash21@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Divakar</LastName>
            <ForeName>Aman</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Genotoxicity Lab, Division of Toxicology and Experimental Medicine, CSIR-Central Drug Research Institute, Lucknow, 226031, Uttar Pradesh, India. Electronic address: amandivakar@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rath</LastName>
            <ForeName>Srikanta Kumar</ForeName>
            <Initials>SK</Initials>
            <AffiliationInfo>
              <Affiliation>Genotoxicity Lab, Division of Toxicology and Experimental Medicine, CSIR-Central Drug Research Institute, Lucknow, 226031, Uttar Pradesh, India. Electronic address: skrath@cdri.res.in.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Biochem Biophys Res Commun</MedlineTA>
        <NlmUniqueID>0372516</NlmUniqueID>
        <ISSNLinking>0006-291X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004220">Disulfides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D026121">Indole Alkaloids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1403-36-7</RegistryNumber>
          <NameOfSubstance UI="C001598">chetomin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SY7Q814VUP</RegistryNumber>
          <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004220" MajorTopicYN="N">Disulfides</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D026121" MajorTopicYN="N">Indole Alkaloids</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">BAPTA-AM</Keyword>
        <Keyword MajorTopicYN="N">Calcium</Keyword>
        <Keyword MajorTopicYN="N">Chetomin</Keyword>
        <Keyword MajorTopicYN="N">Triple-negative breast cancer</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29208466</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bbrc.2017.11.199</ArticleId>
        <ArticleId IdType="pii">S0006-291X(17)32376-8</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29154879</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>08</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0003</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>109</Volume>
            <PubDate>
              <Year>2018</Year>
              <Month>Apr</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of biological macromolecules</Title>
          <ISOAbbreviation>Int J Biol Macromol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Perillyl alcohol alleviates amyloid-β peptides-induced mitochondrial dysfunction and cytotoxicity in SH-SY5Y cells.</ArticleTitle>
        <Pagination>
          <StartPage>1029</StartPage>
          <EndPage>1038</EndPage>
          <MedlinePgn>1029-1038</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijbiomac.2017.11.082</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0141-8130(17)32840-4</ELocationID>
        <Abstract>
          <AbstractText>Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common type of dementia in elderly (&gt;65years of age). Excessive extra cellular deposits of amyloid beta (Aβ) are a pathological feature of AD. Aβ can cause cell death through oxidative damage; recent studies have implicated opening of mPTP as a detrimental event in AD-related mitochondrial dysfunctions. Over the past few years, natural compounds with antioxidant properties have shown promise for intervention in AD.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2017 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zafeer</LastName>
            <ForeName>Mohammad Faraz</ForeName>
            <Initials>MF</Initials>
            <AffiliationInfo>
              <Affiliation>Interdisciplinary Brain Research Centre, Faculty Of Medicine, Aligarh Muslim University, Aligarh, U.P, India. Electronic address: faraz.zafeer@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Firdaus</LastName>
            <ForeName>Fakiha</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Interdisciplinary Brain Research Centre, Faculty Of Medicine, Aligarh Muslim University, Aligarh, U.P, India; Department Of Zoology, Faculty Of Life Sciences, Aligarh Muslim University, Aligarh, U.P, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ahmad</LastName>
            <ForeName>Faraz</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, U.P, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ullah</LastName>
            <ForeName>Rizwan</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department Of Zoology, Faculty Of Life Sciences, Aligarh Muslim University, Aligarh, U.P, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Anis</LastName>
            <ForeName>Ehraz</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Interdisciplinary Brain Research Centre, Faculty Of Medicine, Aligarh Muslim University, Aligarh, U.P, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Waseem</LastName>
            <ForeName>Mohd</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Elementology and Toxicology, Jamia Hamdard (Hamdard University), Hamdard Nagar, New Delhi, 110062, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ali</LastName>
            <ForeName>Asif</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Interdisciplinary Brain Research Centre, Faculty Of Medicine, Aligarh Muslim University, Aligarh, U.P, India; Department of Biochemistry, JN Medical College, Faculty of Medicine, Aligarh Muslim University, Aligarh, 202002, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hossain</LastName>
            <ForeName>Mohammad Mobarak</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Interdisciplinary Brain Research Centre, Faculty Of Medicine, Aligarh Muslim University, Aligarh, U.P, India.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Int J Biol Macromol</MedlineTA>
        <NlmUniqueID>7909578</NlmUniqueID>
        <ISSNLinking>0141-8130</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D033681">Mitochondrial Membrane Transport Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000083162">Mitochondrial Permeability Transition Pore</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D039821">Monoterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>319R5C7293</RegistryNumber>
          <NameOfSubstance UI="C032208">perillyl alcohol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-43-6</RegistryNumber>
          <NameOfSubstance UI="D045304">Cytochromes c</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045304" MajorTopicYN="N">Cytochromes c</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053938" MajorTopicYN="N">DNA Fragmentation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015640" MajorTopicYN="N">Ion Channel Gating</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D033681" MajorTopicYN="N">Mitochondrial Membrane Transport Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000083162" MajorTopicYN="N">Mitochondrial Permeability Transition Pore</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D039821" MajorTopicYN="N">Monoterpenes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>7</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2017</Year>
          <Month>10</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>8</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29154879</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ijbiomac.2017.11.082</ArticleId>
        <ArticleId IdType="pii">S0141-8130(17)32840-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29138276</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>12</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1549-5477</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>31</Volume>
            <Issue>20</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Oct</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Genes &amp; development</Title>
          <ISOAbbreviation>Genes Dev</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade.</ArticleTitle>
        <Pagination>
          <StartPage>2067</StartPage>
          <EndPage>2084</EndPage>
          <MedlinePgn>2067-2084</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1101/gad.305292.117</ELocationID>
        <Abstract>
          <AbstractText>There is limited knowledge about the metabolic reprogramming induced by cancer therapies and how this contributes to therapeutic resistance. Here we show that although inhibition of PI3K-AKT-mTOR signaling markedly decreased glycolysis and restrained tumor growth, these signaling and metabolic restrictions triggered autophagy, which supplied the metabolites required for the maintenance of mitochondrial respiration and redox homeostasis. Specifically, we found that survival of cancer cells was critically dependent on phospholipase A2 (PLA2) to mobilize lysophospholipids and free fatty acids to sustain fatty acid oxidation and oxidative phosphorylation. Consistent with this, we observed significantly increased lipid droplets, with subsequent mobilization to mitochondria. These changes were abrogated in cells deficient for the essential autophagy gene ATG5 Accordingly, inhibition of PLA2 significantly decreased lipid droplets, decreased oxidative phosphorylation, and increased apoptosis. Together, these results describe how treatment-induced autophagy provides nutrients for cancer cell survival and identifies novel cotreatment strategies to override this survival advantage.</AbstractText>
          <CopyrightInformation>&#xa9; 2017 Lue et al.; Published by Cold Spring Harbor Laboratory Press.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lue</LastName>
            <ForeName>Hui-Wen</ForeName>
            <Initials>HW</Initials>
            <AffiliationInfo>
              <Affiliation>Knight Comprehensive Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Podolak</LastName>
            <ForeName>Jennifer</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Knight Comprehensive Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kolahi</LastName>
            <ForeName>Kevin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Knight Cardiovascular Institute, Oregon Health and Science University, Portland, Oregon 97239, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Larry</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, New Jersey 08903, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rao</LastName>
            <ForeName>Soumya</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Knight Comprehensive Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Garg</LastName>
            <ForeName>Devin</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Knight Comprehensive Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xue</LastName>
            <ForeName>Chang-Hui</ForeName>
            <Initials>CH</Initials>
            <AffiliationInfo>
              <Affiliation>Knight Comprehensive Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rantala</LastName>
            <ForeName>Juha K</ForeName>
            <Initials>JK</Initials>
            <AffiliationInfo>
              <Affiliation>Knight Comprehensive Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tyner</LastName>
            <ForeName>Jeffrey W</ForeName>
            <Initials>JW</Initials>
            <AffiliationInfo>
              <Affiliation>Knight Comprehensive Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thornburg</LastName>
            <ForeName>Kent L</ForeName>
            <Initials>KL</Initials>
            <AffiliationInfo>
              <Affiliation>Knight Cardiovascular Institute, Oregon Health and Science University, Portland, Oregon 97239, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martinez-Acevedo</LastName>
            <ForeName>Ann</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Oregon Health and Science University, Portland, Oregon 97239, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Jen-Jane</ForeName>
            <Initials>JJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Oregon Health and Science University, Portland, Oregon 97239, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Amling</LastName>
            <ForeName>Christopher L</ForeName>
            <Initials>CL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Oregon Health and Science University, Portland, Oregon 97239, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Truillet</LastName>
            <ForeName>Charles</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, University of California at San Francisco School of Medicine, San Francisco, California 94107, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Louie</LastName>
            <ForeName>Sharon M</ForeName>
            <Initials>SM</Initials>
            <AffiliationInfo>
              <Affiliation>University of California at Berkeley, Berkeley, California 94720, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Anderson</LastName>
            <ForeName>Kimberly E</ForeName>
            <Initials>KE</Initials>
            <AffiliationInfo>
              <Affiliation>University of California at Berkeley, Berkeley, California 94720, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Evans</LastName>
            <ForeName>Michael J</ForeName>
            <Initials>MJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, University of California at San Francisco School of Medicine, San Francisco, California 94107, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>O'Donnell</LastName>
            <ForeName>Valerie B</ForeName>
            <Initials>VB</Initials>
            <AffiliationInfo>
              <Affiliation>Systems Immunity Research Institute, Cardiff University, Cardiff CF14 4XN, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nomura</LastName>
            <ForeName>Daniel K</ForeName>
            <Initials>DK</Initials>
            <AffiliationInfo>
              <Affiliation>University of California at Berkeley, Berkeley, California 94720, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Drake</LastName>
            <ForeName>Justin M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, New Jersey 08903, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ritz</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biology, Reed College, Portland, Oregon 97202, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thomas</LastName>
            <ForeName>George V</ForeName>
            <Initials>GV</Initials>
            <Identifier Source="ORCID">0000-0001-7416-8840</Identifier>
            <AffiliationInfo>
              <Affiliation>Knight Comprehensive Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathology and Laboratory Medicine, Oregon Health and Science University, Portland, Oregon 97239, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA176671</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 GM008339</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R00 CA172695</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA169172</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA069533</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Genes Dev</MedlineTA>
        <NlmUniqueID>8711660</NlmUniqueID>
        <ISSNLinking>0890-9369</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006575">Heterocyclic Compounds, 3-Ring</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C548887">MK 2206</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D064801">Phospholipase A2 Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010743">Phospholipids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6O01GMS00P</RegistryNumber>
          <NameOfSubstance UI="C546012">N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019069" MajorTopicYN="N">Cell Respiration</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006575" MajorTopicYN="N">Heterocyclic Compounds, 3-Ring</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066292" MajorTopicYN="N">Lipid Droplets</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081082" MajorTopicYN="N">Phosphoinositide-3 Kinase Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064801" MajorTopicYN="N">Phospholipase A2 Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010743" MajorTopicYN="N">Phospholipids</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">autophagy</Keyword>
        <Keyword MajorTopicYN="N">cancer</Keyword>
        <Keyword MajorTopicYN="N">metabolism</Keyword>
        <Keyword MajorTopicYN="N">phospholipid</Keyword>
        <Keyword MajorTopicYN="N">resistance</Keyword>
        <Keyword MajorTopicYN="N">signaling</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>7</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>10</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29138276</ArticleId>
        <ArticleId IdType="pmc">PMC5733498</ArticleId>
        <ArticleId IdType="doi">10.1101/gad.305292.117</ArticleId>
        <ArticleId IdType="pii">gad.305292.117</ArticleId>
        <ArticleId IdType="medline">8711660</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W, DiPaola RS, Lotze MT, White E. 2011. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 17: 654&#x2013;666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3075808</ArticleId>
            <ArticleId IdType="pubmed">21325294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B, Ferro S, Gasteiger E, Huang H, Lopez R, Magrane M, et al. 2004. UniProt: the Universal Protein knowledgebase. Nucleic Acids Res 32: D115&#x2013;D119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC308865</ArticleId>
            <ArticleId IdType="pubmed">14681372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cabodevilla AG, Sanchez-Caballero L, Nintou E, Boiadjieva VG, Picatoste F, Gubern A, Claro E. 2013. Cell survival during complete nutrient deprivation depends on lipid droplet-fueled &#x3b2;-oxidation of fatty acids. J Biol Chem 288: 27777&#x2013;27788.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3784694</ArticleId>
            <ArticleId IdType="pubmed">23940052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Camarda R, Zhou AY, Kohnz RA, Balakrishnan S, Mahieu C, Anderton B, Eyob H, Kajimura S, Tward A, Krings G, et al. 2016. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med 22: 427&#x2013;432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4892846</ArticleId>
            <ArticleId IdType="pubmed">26950360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cecconi F, Levine B. 2008. The role of autophagy in mammalian development: cell makeover rather than cell death. Dev Cell 15: 344&#x2013;357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2688784</ArticleId>
            <ArticleId IdType="pubmed">18804433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. 2008. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452: 181&#x2013;186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18337815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung S, Arrell DK, Faustino RS, Terzic A, Dzeja PP. 2010. Glycolytic network restructuring integral to the energetics of embryonic stem cell cardiac differentiation. J Mol Cell Cardiol 48: 725&#x2013;734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2837789</ArticleId>
            <ArticleId IdType="pubmed">20045004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox J, Mann M. 2008. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26: 1367&#x2013;1372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19029910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M. 2011. Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res 10: 1794&#x2013;1805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21254760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dangelmaier C, Manne BK, Liverani E, Jin J, Bray P, Kunapuli SP. 2014. PDK1 selectively phosphorylates Thr(308) on Akt and contributes to human platelet functional responses. Thromb Haemost 111: 508&#x2013;517.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4079046</ArticleId>
            <ArticleId IdType="pubmed">24352480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Debnath J. 2008. Detachment-induced autophagy during anoikis and lumen formation in epithelial acini. Autophagy 4: 351&#x2013;353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18196957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dibble CC, Asara JM, Manning BD. 2009. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol 29: 5657&#x2013;5670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2772744</ArticleId>
            <ArticleId IdType="pubmed">19720745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drake JM, Graham NA, Stoyanova T, Sedghi A, Goldstein AS, Cai H, Smith DA, Zhang H, Komisopoulou E, Huang J, et al. 2012. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci 109: 1643&#x2013;1648.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3277127</ArticleId>
            <ArticleId IdType="pubmed">22307624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drake JM, Paull EO, Graham NA, Lee JK, Smith BA, Titz B, Stoyanova T, Faltermeier CM, Uzunangelov V, Carlin DE, et al. 2016. Phosphoproteome integration reveals patient-specific networks in prostate cancer. Cell 166: 1041&#x2013;1054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4985183</ArticleId>
            <ArticleId IdType="pubmed">27499020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, et al. 2010. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 39: 171&#x2013;183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2946786</ArticleId>
            <ArticleId IdType="pubmed">20670887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eaton S. 2002. Control of mitochondrial &#x3b2;-oxidation flux. Prog Lipid Res 41: 197&#x2013;239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11814524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eisen MB, Spellman PT, Brown PO, Botstein D. 1998. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci 95: 14863&#x2013;14868.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC24541</ArticleId>
            <ArticleId IdType="pubmed">9843981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Engelman JA, Luo J, Cantley LC. 2006. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606&#x2013;619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16847462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finn PF, Dice JF. 2006. Proteolytic and lipolytic responses to starvation. Nutrition 22: 830&#x2013;844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16815497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fruman DA, Rommel C. 2014. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13: 140&#x2013;156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3994981</ArticleId>
            <ArticleId IdType="pubmed">24481312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fung C, Lock R, Gao S, Salas E, Debnath J. 2008. Induction of autophagy during extracellular matrix detachment promotes cell survival. Mol Biol Cell 19: 797&#x2013;806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2262959</ArticleId>
            <ArticleId IdType="pubmed">18094039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, Codogno P, Debnath J, Gewirtz DA, Karantza V, et al. 2015. Autophagy in malignant transformation and cancer progression. EMBO J 34: 856&#x2013;880.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4388596</ArticleId>
            <ArticleId IdType="pubmed">25712477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldberg SB, Supko JG, Neal JW, Muzikansky A, Digumarthy S, Fidias P, Temel JS, Heist RS, Shaw AT, McCarthy PO, et al. 2012. A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. J Thorac Oncol 7: 1602&#x2013;1608.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3791327</ArticleId>
            <ArticleId IdType="pubmed">22878749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ. 2008. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30: 214&#x2013;226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2674027</ArticleId>
            <ArticleId IdType="pubmed">18439900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E. 2015. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res 43: D512&#x2013;D520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4383998</ArticleId>
            <ArticleId IdType="pubmed">25514926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu H, Juvekar A, Lyssiotis CA, Lien EC, Albeck JG, Oh D, Varma G, Hung YP, Ullas S, Lauring J, et al. 2016. Phosphoinositide 3-kinase regulates glycolysis through mobilization of aldolase from the actin cytoskeleton. Cell 164: 433&#x2013;446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4898774</ArticleId>
            <ArticleId IdType="pubmed">26824656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang da W, Sherman BT, Lempicki RA. 2009a. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1&#x2013;13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2615629</ArticleId>
            <ArticleId IdType="pubmed">19033363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang da W, Sherman BT, Lempicki RA. 2009b. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44&#x2013;57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19131956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K, Zhu T, Guan KL. 2003. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577&#x2013;590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14651849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeon SM, Chandel NS, Hay N. 2012. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 485: 661&#x2013;665.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3607316</ArticleId>
            <ArticleId IdType="pubmed">22660331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joachim J, Jiang M, McKnight NC, Howell M, Tooze SA. 2015. High-throughput screening approaches to identify regulators of mammalian autophagy. Methods 75: 96&#x2013;104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25688674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Julien LA, Carriere A, Moreau J, Roux PP. 2010. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol 30: 908&#x2013;921.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2815569</ArticleId>
            <ArticleId IdType="pubmed">19995915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerner J, Hoppel C. 2000. Fatty acid import into mitochondria. Biochim Biophys Acta 1486: 1&#x2013;17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10856709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim LC, Cook RS, Chen J. 2017. mTORC1 and mTORC2 in cancer and the tumor microenvironment. Oncogene 36: 2191&#x2013;2201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5393956</ArticleId>
            <ArticleId IdType="pubmed">27748764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, et al. 2016. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12: 1&#x2013;222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4835977</ArticleId>
            <ArticleId IdType="pubmed">26799652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laplante M, Sabatini DM. 2012. mTOR signaling in growth control and disease. Cell 149: 274&#x2013;293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3331679</ArticleId>
            <ArticleId IdType="pubmed">22500797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leonard JT, Rowley JS, Eide CA, Traer E, Hayes-Lattin B, Loriaux M, Spurgeon SE, Druker BJ, Tyner JW, Chang BH. 2016. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Sci Transl Med 8: 354ra114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27582059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long JZ, Cisar JS, Milliken D, Niessen S, Wang C, Trauger SA, Siuzdak G, Cravatt BF. 2011. Metabolomics annotates ABHD3 as a physiologic regulator of medium-chain phospholipids. Nat Chem Biol 7: 763&#x2013;765.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3201731</ArticleId>
            <ArticleId IdType="pubmed">21926997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Louie SM, Grossman EA, Crawford LA, Ding L, Camarda R, Huffman TR, Miyamoto DK, Goga A, Weerapana E, Nomura DK. 2016. GSTP1 is a driver of triple-negative breast cancer cell metabolism and pathogenicity. Cell Chem Biol 23: 567&#x2013;578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4876719</ArticleId>
            <ArticleId IdType="pubmed">27185638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manning BD, Cantley LC. 2007. AKT/PKB signaling: navigating downstream. Cell 129: 1261&#x2013;1274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2756685</ArticleId>
            <ArticleId IdType="pubmed">17604717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. 2002. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10: 151&#x2013;162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12150915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, et al. 2013. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 368: 1781&#x2013;1790.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3730275</ArticleId>
            <ArticleId IdType="pubmed">23656643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maxson JE, Abel ML, Wang J, Deng X, Reckel S, Luty SB, Sun H, Gorenstein J, Hughes SB, Bottomly D, et al. 2016. Identification and characterization of tyrosine kinase nonreceptor 2 mutations in leukemia through integration of kinase inhibitor screening and genomic analysis. Cancer Res 76: 127&#x2013;138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4703549</ArticleId>
            <ArticleId IdType="pubmed">26677978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizushima N, Yamamoto A, Hatano M, Kobayashi Y, Kabeya Y, Suzuki K, Tokuhisa T, Ohsumi Y, Yoshimori T. 2001. Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells. J Cell Biol 152: 657&#x2013;668.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2195787</ArticleId>
            <ArticleId IdType="pubmed">11266458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moritz A, Li Y, Guo A, Villen J, Wang Y, MacNeill J, Kornhauser J, Sprott K, Zhou J, Possemato A, et al. 2010. Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases. Sci Signal 3: ra64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3137639</ArticleId>
            <ArticleId IdType="pubmed">20736484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murakami M, Taketomi Y, Miki Y, Sato H, Hirabayashi T, Yamamoto K. 2011. Recent progress in phospholipase A(2) research: from cells to animals to humans. Prog Lipid Res 50: 152&#x2013;192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21185866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel AB, Vellore NA, Deininger MW. 2016. New strategies in myeloproliferative neoplasms: the evolving genetic and therapeutic landscape. Clin Cancer Res 22: 1037&#x2013;1047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4826348</ArticleId>
            <ArticleId IdType="pubmed">26933174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, Jones RG, Choi Y. 2009. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460: 103&#x2013;107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2803086</ArticleId>
            <ArticleId IdType="pubmed">19494812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rambold AS, Cohen S, Lippincott-Schwartz J. 2015. Fatty acid trafficking in starved cells: regulation by lipid droplet lipolysis, autophagy, mitochondrial fusion dynamics. Dev Cell 32: 678&#x2013;692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4375018</ArticleId>
            <ArticleId IdType="pubmed">25752962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rebecca VW, Amaravadi RK. 2016. Emerging strategies to effectively target autophagy in cancer. Oncogene 35: 1&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4838040</ArticleId>
            <ArticleId IdType="pubmed">25893285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, Mikkelson T, Wang D, Chang YC, Hu J, et al. 2014. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 10: 1359&#x2013;1368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4203513</ArticleId>
            <ArticleId IdType="pubmed">24991840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenson RS, Hislop C, Elliott M, Stasiv Y, Goulder M, Waters D. 2010. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J Am Coll Cardiol 56: 1079&#x2013;1088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20863951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J. 2004. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci 101: 13489&#x2013;13494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC518784</ArticleId>
            <ArticleId IdType="pubmed">15342917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ, Zhang H, Zha XM, Polakiewicz RD, Comb MJ. 2005. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23: 94&#x2013;101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15592455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saldanha AJ. 2004. Java Treeview&#x2014;extensible visualization of microarray data. Bioinformatics 20: 3246&#x2013;3248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15180930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, Clarke PA, Raynaud FI, Levy G, Ware JA, et al. 2015. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res 21: 77&#x2013;86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4287394</ArticleId>
            <ArticleId IdType="pubmed">25370471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sehgal AR, Konig H, Johnson DE, Tang D, Amaravadi RK, Boyiadzis M, Lotze MT. 2015. You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia. Leukemia 29: 517&#x2013;525.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4825874</ArticleId>
            <ArticleId IdType="pubmed">25541151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shanware NP, Bray K, Abraham RT. 2013. The PI3K, metabolic, autophagy networks: interactive partners in cellular health and disease. Annu Rev Pharmacol Toxicol 53: 89&#x2013;106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23294306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, Tanaka K, Cuervo AM, Czaja MJ. 2009. Autophagy regulates lipid metabolism. Nature 458: 1131&#x2013;1135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2676208</ArticleId>
            <ArticleId IdType="pubmed">19339967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Slatter DA, Aldrovandi M, O'Connor A, Allen SM, Brasher CJ, Murphy RC, Mecklemann S, Ravi S, Darley-Usmar V, O'Donnell VB. 2016. Mapping the human platelet lipidome reveals cytosolic phospholipase A2 as a regulator of mitochondrial bioenergetics during activation. Cell Metab 23: 930&#x2013;944.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4873619</ArticleId>
            <ArticleId IdType="pubmed">27133131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sztalryd C, Kimmel AR. 2014. Perilipins: lipid droplet coat proteins adapted for tissue-specific energy storage and utilization, and lipid cytoprotection. Biochimie 96: 96&#x2013;101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4507817</ArticleId>
            <ArticleId IdType="pubmed">24036367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanida I, Minematsu-Ikeguchi N, Ueno T, Kominami E. 2005. Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. Autophagy 1: 84&#x2013;91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16874052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thiam AR, Farese RV Jr, Walther TC. 2013. The biophysics and cell biology of lipid droplets. Nat Rev Mol Cell Biol 14: 775&#x2013;786.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4526153</ArticleId>
            <ArticleId IdType="pubmed">24220094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toska E, Baselga J. 2016. Pharmacology in the era of targeted therapies: the case of PI3K inhibitors. Clin Cancer Res 22: 2099&#x2013;2101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4946572</ArticleId>
            <ArticleId IdType="pubmed">26957555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Towers CG, Thorburn A. 2016. Therapeutic targeting of autophagy. EBioMedicine 14: 15&#x2013;23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5161418</ArticleId>
            <ArticleId IdType="pubmed">28029600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turcotte S, Chan DA, Sutphin PD, Hay MP, Denny WA, Giaccia AJ. 2008. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell 14: 90&#x2013;102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2819422</ArticleId>
            <ArticleId IdType="pubmed">18598947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Unger RH, Clark GO, Scherer PE, Orci L. 2010. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta 1801: 209&#x2013;214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19948243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, et al. 2015. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372: 426&#x2013;435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4358820</ArticleId>
            <ArticleId IdType="pubmed">25629741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, et al. 2012. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366: 799&#x2013;807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4822164</ArticleId>
            <ArticleId IdType="pubmed">22375971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winton EF, Kota V. 2017. Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia. Future Oncol 13: 395&#x2013;407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27785927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, et al. 2011. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29: 4688&#x2013;4695.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22025163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yecies JL, Manning BD. 2011. Transcriptional control of cellular metabolism by mTOR signaling. Cancer Res 71: 2815&#x2013;2820.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3693464</ArticleId>
            <ArticleId IdType="pubmed">21487041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhuang G, Yu K, Jiang Z, Chung A, Yao J, Ha C, Toy K, Soriano R, Haley B, Blackwood E, et al. 2013. Phosphoproteomic analysis implicates the mTORC2&#x2013;FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinases. Sci Signal 6: ra25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23592840</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29129468</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>10</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1090-2430</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>300</Volume>
            <PubDate>
              <Year>2018</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Experimental neurology</Title>
          <ISOAbbreviation>Exp Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inhibition of Rac1 ameliorates neuronal oxidative stress damage via reducing Bcl-2/Rac1 complex formation in mitochondria through PI3K/Akt/mTOR pathway.</ArticleTitle>
        <Pagination>
          <StartPage>149</StartPage>
          <EndPage>166</EndPage>
          <MedlinePgn>149-166</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.expneurol.2017.10.030</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0014-4886(17)30290-X</ELocationID>
        <Abstract>
          <AbstractText>Although the neuroprotective effects of Rac1 inhibition have been reported in various cerebral ischemic models, the molecular mechanisms of action have not yet been fully elucidated. In this study, we investigated whether the inhibition of Rac1 provided neuroprotection in a diabetic rat model of focal cerebral ischemia and hyperglycemia-exposed PC-12 cells. Intracerebroventricular administration of lentivirus expressing the Rac1 small hairpin RNA (shRNA) and specific Rac1 inhibitor NSC23766 not only decreased the infarct volumes and improved neurologic deficits with a correlated significant activation of mitochondrial DNA specific proteins, such as OGG1 and POLG, but also elevated Bcl-2 S70 phosphorylation in mitochondria. Furthermore, the levels of p-PI3K, p-Akt and p-mTOR increased, while 8-OHdG, ROS production and Bcl-2/Rac1 complex formation in mitochondria reduced in both Rac1-shRNA- and NSC23766-treated rats. Moreover, to confirm our in vivo observations, inhibition of Rac1 activity by NSC23766 suppressed the interactions between Bcl-2 and Rac1 in the mitochondria of PC-12 cells cultured in high glucose conditions and protected PC-12 cells from high glucose-induced neurotoxicity. More importantly, these beneficial effects of Rac1 inhibition were abolished by PI3K inhibitor LY294002. In contrast to NSC23766 treatment, LY294002 had little effect on the decrement of p-PTEN level. Taken together, these findings revealed novel neuroprotective roles of Rac1 inhibition against cerebral ischemic reperfusion injury in vivo and high glucose-induced neurotoxicity in PC-12 cells in vitro, by reducing Bcl-2/Rac1 complex formation in mitochondria through the activation of PI3K/Akt/mTOR survival pathway.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Yundan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology, Affiliated Xiangya Hospital of Central South University, Changsha 410078, Hunan Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Na</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology, Affiliated Xiangya Hospital of Central South University, Changsha 410078, Hunan Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xia</LastName>
            <ForeName>Pingping</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology, Affiliated Xiangya Hospital of Central South University, Changsha 410078, Hunan Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>E</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology, Affiliated Xiangya Hospital of Central South University, Changsha 410078, Hunan Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Qulian</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology, Affiliated Xiangya Hospital of Central South University, Changsha 410078, Hunan Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ye</LastName>
            <ForeName>Zhi</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology, Affiliated Xiangya Hospital of Central South University, Changsha 410078, Hunan Province, China. Electronic address: yezhi523@csu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Exp Neurol</MedlineTA>
        <NlmUniqueID>0370712</NlmUniqueID>
        <ISSNLinking>0014-4886</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000617196">Bcl2 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546845">mTOR protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.1.-</RegistryNumber>
          <NameOfSubstance UI="C499134">Rac1 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.5.2</RegistryNumber>
          <NameOfSubstance UI="D020830">rac1 GTP-Binding Protein</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007276" MajorTopicYN="N">Injections, Intraventricular</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016716" MajorTopicYN="N">PC12 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019253" MajorTopicYN="N">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020830" MajorTopicYN="N">rac1 GTP-Binding Protein</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cerebral ischemia</Keyword>
        <Keyword MajorTopicYN="N">Hyperglycemia</Keyword>
        <Keyword MajorTopicYN="N">Neuroprotection</Keyword>
        <Keyword MajorTopicYN="N">Oxidative stress</Keyword>
        <Keyword MajorTopicYN="N">Phosphatidylinositol 3-kinase (PI3K)</Keyword>
        <Keyword MajorTopicYN="N">Rac1</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>5</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2017</Year>
          <Month>10</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>10</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>10</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29129468</ArticleId>
        <ArticleId IdType="doi">10.1016/j.expneurol.2017.10.030</ArticleId>
        <ArticleId IdType="pii">S0014-4886(17)30290-X</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28919254</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>06</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-9754</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>110</Volume>
            <PubDate>
              <Year>2017</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neurochemistry international</Title>
          <ISOAbbreviation>Neurochem Int</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Palmitic acid stimulates energy metabolism and inhibits insulin/PI3K/AKT signaling in differentiated human neuroblastoma cells: The role of mTOR activation and mitochondrial ROS production.</ArticleTitle>
        <Pagination>
          <StartPage>75</StartPage>
          <EndPage>83</EndPage>
          <MedlinePgn>75-83</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuint.2017.09.008</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0197-0186(17)30378-9</ELocationID>
        <Abstract>
          <AbstractText>The high consumption of saturated lipids has been largely associated with the increasing prevalence of metabolic diseases. In particular, saturated fatty acids such as palmitic acid (PA) have been implicated in the development of insulin resistance in peripheral tissues. However, how neurons develop insulin resistance in response to lipid overload is not fully understood. Here, we used cultured rat cortical neurons and differentiated human neuroblastoma cells to demonstrate that PA blocks insulin-induced metabolic activation, inhibits the activation of the insulin/PI3K/Akt pathway and activates mTOR kinase downstream of Akt. Despite the fact that fatty acids are not normally used as a significant source of fuel by neural cells, we also found that short-term neuronal exposure to PA reduces the NAD[+]/NADH ratio, indicating that PA modifies the neuronal energy balance. Finally, inhibiting mitochondrial ROS production with mitoTEMPO prevented the deleterious effect of PA on insulin signaling. This work provides novel evidence of the mechanisms behind saturated fatty acid-induced insulin resistance and its metabolic consequences on neuronal cells.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2017 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Calvo-Ochoa</LastName>
            <ForeName>Erika</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, AP 70-228, 04510, México DF, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sánchez-Alegría</LastName>
            <ForeName>Karina</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, AP 70-228, 04510, México DF, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gómez-Inclán</LastName>
            <ForeName>Cecilia</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, AP 70-228, 04510, México DF, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ferrera</LastName>
            <ForeName>Patricia</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, AP 70-228, 04510, México DF, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arias</LastName>
            <ForeName>Clorinda</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, AP 70-228, 04510, México DF, Mexico. Electronic address: carias@unam.mx.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>09</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Neurochem Int</MedlineTA>
        <NlmUniqueID>8006959</NlmUniqueID>
        <ISSNLinking>0197-0186</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007329">Insulin Antagonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2V16EO95H1</RegistryNumber>
          <NameOfSubstance UI="D019308">Palmitic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007329" MajorTopicYN="N">Insulin Antagonists</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019308" MajorTopicYN="N">Palmitic Acid</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081082" MajorTopicYN="N">Phosphoinositide-3 Kinase Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cortical neurons</Keyword>
        <Keyword MajorTopicYN="N">Energy metabolism</Keyword>
        <Keyword MajorTopicYN="N">Human neuroblastoma cells</Keyword>
        <Keyword MajorTopicYN="N">Insulin resistance</Keyword>
        <Keyword MajorTopicYN="N">Mitochondrial ROS</Keyword>
        <Keyword MajorTopicYN="N">Palmitic acid</Keyword>
        <Keyword MajorTopicYN="N">mTOR</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2017</Year>
          <Month>8</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>9</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>9</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>9</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28919254</ArticleId>
        <ArticleId IdType="doi">10.1016/j.neuint.2017.09.008</ArticleId>
        <ArticleId IdType="pii">S0197-0186(17)30378-9</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28645610</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>08</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>12</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1090-2104</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>490</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Aug</Month>
              <Day>26</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biochemical and biophysical research communications</Title>
          <ISOAbbreviation>Biochem Biophys Res Commun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inhibition of mitochondrial translation effectively sensitizes renal cell carcinoma to chemotherapy.</ArticleTitle>
        <Pagination>
          <StartPage>767</StartPage>
          <EndPage>773</EndPage>
          <MedlinePgn>767-773</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2017.06.115</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0006-291X(17)31246-9</ELocationID>
        <Abstract>
          <AbstractText>The functional importance of mitochondrial protein translation has been recently documented in the context of various cancers but not renal cell carcinoma (RCC). In lines with these efforts, our work demonstrates that mitochondrial translation inhibition by tigecycline or depletion of EF-Tu mitochondrial translation factor effectively targets RCC and significantly sensitizes RCC response to chemotherapy. We show that antibiotic tigecycline inhibits multiple biological functions of RCC, including growth, colony formation and survival. It also significantly enhances in vitro and in vivo efficacy of paclitaxel in RCC. Tigecycline preferentially inhibits translation of mitochondrial DNA-encoded proteins, activities of mitochondrial respiratory complexes that contain mitochondrially encoded subunits. As a consequence of mitochondrial respiratory chain inhibition, decreased mitochondrial respiration is observed in RCC cells exposed to tigecycline. In contrast, tigecycline is ineffective in RCC ρ0 cells that lack mitochondrial DNA and subsequent mitochondrial respiration, further confirm mitochondrial translation inhibition as the mechanism of tigecycline's action in RCC. Importantly, genetic inhibition of mitochondrial translation by EF-Tu knockdown reproduced the inhibitory effects of tigecycline. Finally, we show the association between mitochondrial translation inhibition and suppression of PI3K/Akt/mTOR signaling pathway. Our work used pharmacological and genetic strategies to demonstrate the important roles of mitochondrial translation in RCC and emphasize the therapeutic value of sensitizing RCC to chemotherapy.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Bo</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, The First People's Hospital of Jiangxia District Wuhan City, Wuhan 430200, China. Electronic address: Drskywang@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ao</LastName>
            <ForeName>Jinsong</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, The First People's Hospital of Jiangxia District Wuhan City, Wuhan 430200, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Dan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, The First People's Hospital of Jiangxia District Wuhan City, Wuhan 430200, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rao</LastName>
            <ForeName>Ting</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Wuhan University Renmin Hospital, Wuhan 430060, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ruan</LastName>
            <ForeName>Yuan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Wuhan University Renmin Hospital, Wuhan 430060, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yao</LastName>
            <ForeName>Xiaobin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Wuhan University Renmin Hospital, Wuhan 430060, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>06</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Biochem Biophys Res Commun</MedlineTA>
        <NlmUniqueID>0372516</NlmUniqueID>
        <ISSNLinking>0006-291X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004272">DNA, Mitochondrial</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>70JE2N95KR</RegistryNumber>
          <NameOfSubstance UI="D000078304">Tigecycline</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.1.-</RegistryNumber>
          <NameOfSubstance UI="D010444">Peptide Elongation Factor Tu</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>FYY3R43WGO</RegistryNumber>
          <NameOfSubstance UI="D008911">Minocycline</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>P88XT4IS4D</RegistryNumber>
          <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002292" MajorTopicYN="N">Carcinoma, Renal Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004272" MajorTopicYN="N">DNA, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007680" MajorTopicYN="N">Kidney Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008911" MajorTopicYN="N">Minocycline</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010444" MajorTopicYN="N">Peptide Elongation Factor Tu</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014176" MajorTopicYN="N">Protein Biosynthesis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000078304" MajorTopicYN="N">Tigecycline</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Chemotherapy</Keyword>
        <Keyword MajorTopicYN="N">EF-Tu</Keyword>
        <Keyword MajorTopicYN="N">Mitochondrial translation</Keyword>
        <Keyword MajorTopicYN="N">RCC</Keyword>
        <Keyword MajorTopicYN="N">Tigecycline</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>8</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28645610</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bbrc.2017.06.115</ArticleId>
        <ArticleId IdType="pii">S0006-291X(17)31246-9</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28490807</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>12</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2045-2322</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>7</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>May</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Scientific reports</Title>
          <ISOAbbreviation>Sci Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Zeylenone, a naturally occurring cyclohexene oxide, inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR and MAPK/ERK pathways.</ArticleTitle>
        <Pagination>
          <StartPage>1669</StartPage>
          <MedlinePgn>1669</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">1669</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-017-01804-2</ELocationID>
        <Abstract>
          <AbstractText>There is a strong rationale to therapeutically target the PI3K/Akt/mTOR and MAPK/ERK pathways in cervical carcinoma since they are highly deregulated in this disease. Previous study by our group have demonstrated that Zeylenone (Zey) exhibited strong suppressive activity on PI3K/AKT/mTOR and MAPK/ERK signaling, providing a foundation to investigate its antitumor activity in cervical carcinoma. Herein, the present study aimed to investigate suppressive effect of Zey on HeLa and CaSki cells, and further explore the underlying mechanisms. Cells were treated with Zey for indicated time, followed by measuring its effects on cell viability, colony formation, cell cycle, cell apoptosis, and signal pathways. In vivo antitumor activity of Zey was then assessed with nude xenografts. We found that Zey substantially suppressed cell proliferation, induced cell cycle arrest, and increased cell apoptosis, accompanied by increased production of ROS, decreased mitochondrial membrane potential, activated caspase apoptotic cascade, and attenuated PI3K/Akt/mTOR and MAPK/ERK pathways. Additionally, in vivo experiments showed that Zey exerted good antitumor efficacy against HeLa bearing mice models via decreasing levels of p-PI3K and p-ERK. Collectively, these data clearly demonstrated the antitumor activity of Zey in cervical carcinoma cells, which is most likely via the regulation of PI3K/Akt/mTOR and MAPK/ERK pathways.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Leilei</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100193, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huo</LastName>
            <ForeName>Xiaowei</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100193, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liao</LastName>
            <ForeName>Yonghong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100193, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Feifei</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100193, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100193, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cao</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100193, China. lcao@implad.ac.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>05</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Sci Rep</MedlineTA>
        <NlmUniqueID>101563288</NlmUniqueID>
        <ISSNLinking>2045-2322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003510">Cyclohexanes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053138">Cyclohexenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004273">DNA, Neoplasm</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004146">Dioxanes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C516240">zeylenone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1XYE04C550</RegistryNumber>
          <NameOfSubstance UI="C007193">cyclohexene oxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D020169">Caspases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059447" MajorTopicYN="N">Cell Cycle Checkpoints</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003510" MajorTopicYN="N">Cyclohexanes</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053138" MajorTopicYN="N">Cyclohexenes</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004273" MajorTopicYN="N">DNA, Neoplasm</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004146" MajorTopicYN="N">Dioxanes</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014410" MajorTopicYN="N">Tumor Stem Cell Assay</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>3</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>5</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>5</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28490807</ArticleId>
        <ArticleId IdType="pmc">PMC5431878</ArticleId>
        <ArticleId IdType="doi">10.1038/s41598-017-01804-2</ArticleId>
        <ArticleId IdType="pii">10.1038/s41598-017-01804-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Hasanpourghadi M, et al. Targeting of tubulin polymerization and induction of mitotic blockage by Methyl 2-(5-fluoro-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-carboxylate (MBIC) in human cervical cancer HeLa cell. J Exp Clin Cancer Res. 2016;35:58. doi: 10.1186/s13046-016-0332-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-016-0332-0</ArticleId>
            <ArticleId IdType="pmc">PMC4815073</ArticleId>
            <ArticleId IdType="pubmed">27030360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gomez-Lomeli P, et al. Increase of IFN-gamma and TNF-alpha production in CD107a&#x2009;+&#x2009;NK-92 cells co-cultured with cervical cancer cell lines pre-treated with the HO-1 inhibitor. Cancer Cell Int. 2014;14:100. doi: 10.1186/s12935-014-0100-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12935-014-0100-1</ArticleId>
            <ArticleId IdType="pmc">PMC4190300</ArticleId>
            <ArticleId IdType="pubmed">25302050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Movva S, Rodriguez L, Arias-Pulido H, Verschraegen C. Novel chemotherapy approaches for cervical cancer. Cancer. 2009;115:3166&#x2013;3180. doi: 10.1002/cncr.24364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.24364</ArticleId>
            <ArticleId IdType="pubmed">19452541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minorics R, et al. A molecular understanding of D-homoestrone-induced G2/M cell cycle arrest in HeLa human cervical carcinoma cells. J Cell Mol Med. 2015;19:2365&#x2013;2374. doi: 10.1111/jcmm.12587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcmm.12587</ArticleId>
            <ArticleId IdType="pmc">PMC4594678</ArticleId>
            <ArticleId IdType="pubmed">26228523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho H, et al. Apoptosis inhibitor-5 overexpression is associated with tumor progression and poor prognosis in patients with cervical cancer. BMC Cancer. 2014;14:545. doi: 10.1186/1471-2407-14-545.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-14-545</ArticleId>
            <ArticleId IdType="pmc">PMC4125689</ArticleId>
            <ArticleId IdType="pubmed">25070070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chemoradiotherapy for Cervical Cancer Meta-Analysis, C. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol26, 5802&#x2013;5812 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2645100</ArticleId>
            <ArticleId IdType="pubmed">19001332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walboomers JM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12&#x2013;19. doi: 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F</ArticleId>
            <ArticleId IdType="pubmed">10451482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franko-Tobin LG, et al. Notch1-mediated tumor suppression in cervical cancer with the involvement of SST signaling and its application in enhanced SSTR-targeted therapeutics. Oncologist. 2012;17:220&#x2013;232. doi: 10.1634/theoncologist.2011-0269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2011-0269</ArticleId>
            <ArticleId IdType="pmc">PMC3286171</ArticleId>
            <ArticleId IdType="pubmed">22291092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramdass B, et al. Coexpression of Notch1 and NF-kappaB signaling pathway components in human cervical cancer progression. Gynecol Oncol. 2007;104:352&#x2013;361. doi: 10.1016/j.ygyno.2006.08.054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2006.08.054</ArticleId>
            <ArticleId IdType="pubmed">17098279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perez-Plasencia C, Duenas-Gonzalez A, Alatorre-Tavera B. Second hit in cervical carcinogenesis process: involvement of wnt/beta catenin pathway. Int Arch Med. 2008;1:10. doi: 10.1186/1755-7682-1-10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1755-7682-1-10</ArticleId>
            <ArticleId IdType="pmc">PMC2491599</ArticleId>
            <ArticleId IdType="pubmed">18606007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsai JP, et al. Licochalcone A induces autophagy through PI3K/Akt/mTOR inactivation and autophagy suppression enhances Licochalcone A-induced apoptosis of human cervical cancer cells. Oncotarget. 2015;6:28851&#x2013;28866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4745696</ArticleId>
            <ArticleId IdType="pubmed">26311737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steelman LS, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 2011;3:192&#x2013;222. doi: 10.18632/aging.100296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/aging.100296</ArticleId>
            <ArticleId IdType="pmc">PMC3091517</ArticleId>
            <ArticleId IdType="pubmed">21422497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCubrey JA, et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia. 2008;22:708&#x2013;722. doi: 10.1038/leu.2008.27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/leu.2008.27</ArticleId>
            <ArticleId IdType="pubmed">18337766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martelli AM, et al. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochim Biophys Act. 2010;1803:991&#x2013;1002. doi: 10.1016/j.bbamcr.2010.04.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamcr.2010.04.005</ArticleId>
            <ArticleId IdType="pubmed">20399811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y, Adjei AA. The clinical development of MEK inhibitors. Nat Rev Clin Oncol. 2014;11:385&#x2013;400. doi: 10.1038/nrclinonc.2014.83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2014.83</ArticleId>
            <ArticleId IdType="pubmed">24840079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao HF, Wang J, Jiang HR, Chen ZP, To SS. PI3K p110beta isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition. J Exp Clin Cancer Res. 2016;35:78. doi: 10.1186/s13046-016-0356-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-016-0356-5</ArticleId>
            <ArticleId IdType="pmc">PMC4866398</ArticleId>
            <ArticleId IdType="pubmed">27176481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serra V, et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 2011;30:2547&#x2013;2557. doi: 10.1038/onc.2010.626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2010.626</ArticleId>
            <ArticleId IdType="pmc">PMC3107390</ArticleId>
            <ArticleId IdType="pubmed">21278786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mirzoeva OK, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 2009;69:565&#x2013;572. doi: 10.1158/0008-5472.CAN-08-3389.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-08-3389</ArticleId>
            <ArticleId IdType="pmc">PMC2737189</ArticleId>
            <ArticleId IdType="pubmed">19147570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoeflich KP, et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res. 2009;15:4649&#x2013;4664. doi: 10.1158/1078-0432.CCR-09-0317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-09-0317</ArticleId>
            <ArticleId IdType="pubmed">19567590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holt SV, et al. Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055) Cancer Res. 2012;72:1804&#x2013;1813. doi: 10.1158/0008-5472.CAN-11-1780.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-1780</ArticleId>
            <ArticleId IdType="pubmed">22271687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, et al. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res. 2008;14:5124&#x2013;5130. doi: 10.1158/1078-0432.CCR-07-4774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-07-4774</ArticleId>
            <ArticleId IdType="pubmed">18698030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saini KS, et al. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev. 2013;39:935&#x2013;946. doi: 10.1016/j.ctrv.2013.03.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctrv.2013.03.009</ArticleId>
            <ArticleId IdType="pubmed">23643661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, et al. Quantitative analysis of differential protein expression in cervical carcinoma cells after zeylenone treatment by stable isotope labeling with amino acids in cell culture. J Proteomics. 2015;126:279&#x2013;287. doi: 10.1016/j.jprot.2015.06.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jprot.2015.06.012</ArticleId>
            <ArticleId IdType="pubmed">26130516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yadav V, et al. Gatifloxacin induces S and G2-phase cell cycle arrest in pancreatic cancer cells via p21/p27/p53. Plos One. 2012;7:e47796. doi: 10.1371/journal.pone.0047796.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0047796</ArticleId>
            <ArticleId IdType="pmc">PMC3485023</ArticleId>
            <ArticleId IdType="pubmed">23133524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicol&#xe1;s FJ, Hill CS. Attenuation of the TGF-|[beta]|-Smad signaling pathway in pancreatic tumor cells confers resistance to TGF-|[beta]|-induced growth arrest. Oncogene. 2003;22:3698&#x2013;3711. doi: 10.1038/sj.onc.1206420.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1206420</ArticleId>
            <ArticleId IdType="pubmed">12802277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamed SS, Straubinger RM, Jusko WJ. Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells. Cancer Chemoth Pharm. 2013;2:553&#x2013;563. doi: 10.1007/s00280-013-2226-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00280-013-2226-6</ArticleId>
            <ArticleId IdType="pmc">PMC3777243</ArticleId>
            <ArticleId IdType="pubmed">23835677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008;9:231&#x2013;241. doi: 10.1038/nrm2312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm2312</ArticleId>
            <ArticleId IdType="pubmed">18073771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nica AF, et al. Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK. Cell Cycle. 2008;7:3362&#x2013;3370. doi: 10.4161/cc.7.21.6894.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cc.7.21.6894</ArticleId>
            <ArticleId IdType="pmc">PMC4072224</ArticleId>
            <ArticleId IdType="pubmed">18948750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaufmann SH, Hengartner MO. Programmed cell death: alive and well in the new millennium. Trends Cell Biol. 2001;11:526&#x2013;534. doi: 10.1016/S0962-8924(01)02173-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0962-8924(01)02173-0</ArticleId>
            <ArticleId IdType="pubmed">11719060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Will M, et al. Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov. 2014;4:334&#x2013;347. doi: 10.1158/2159-8290.CD-13-0611.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-13-0611</ArticleId>
            <ArticleId IdType="pmc">PMC4049524</ArticleId>
            <ArticleId IdType="pubmed">24436048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997;278:687&#x2013;689. doi: 10.1126/science.278.5338.687.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.278.5338.687</ArticleId>
            <ArticleId IdType="pubmed">9381178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fletcher JI, Huang DC. Controlling the cell death mediators Bax and Bak: puzzles and conundrums. Cell Cycle. 2008;7:39&#x2013;44. doi: 10.4161/cc.7.1.5178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cc.7.1.5178</ArticleId>
            <ArticleId IdType="pubmed">18196961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steelman LS, et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia. 2008;22:686&#x2013;707. doi: 10.1038/leu.2008.26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/leu.2008.26</ArticleId>
            <ArticleId IdType="pubmed">18337767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buitenhuis M, Coffer PJ. The role of the PI3K-PKB signaling module in regulation of hematopoiesis. Cell Cycle. 2009;8:560&#x2013;566. doi: 10.4161/cc.8.4.7654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cc.8.4.7654</ArticleId>
            <ArticleId IdType="pubmed">19197152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCubrey JA, et al. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol. 2011;226:2762&#x2013;2781. doi: 10.1002/jcp.22647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.22647</ArticleId>
            <ArticleId IdType="pubmed">21302297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez E, McGraw TE. The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle. 2009;8:2502&#x2013;2508. doi: 10.4161/cc.8.16.9335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cc.8.16.9335</ArticleId>
            <ArticleId IdType="pmc">PMC2997486</ArticleId>
            <ArticleId IdType="pubmed">19597332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aksamitiene E, Kiyatkin A, Kholodenko BN. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem Soc Trans. 2012;40:139&#x2013;146. doi: 10.1042/BST20110609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BST20110609</ArticleId>
            <ArticleId IdType="pubmed">22260680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chappell WH, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget. 2011;2:135&#x2013;164. doi: 10.18632/oncotarget.240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.240</ArticleId>
            <ArticleId IdType="pmc">PMC3260807</ArticleId>
            <ArticleId IdType="pubmed">21411864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCubrey JA, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget. 2012;3:1068&#x2013;1111. doi: 10.18632/oncotarget.659.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.659</ArticleId>
            <ArticleId IdType="pmc">PMC3717945</ArticleId>
            <ArticleId IdType="pubmed">23085539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimizu T, et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res. 2012;18:2316&#x2013;2325. doi: 10.1158/1078-0432.CCR-11-2381.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-11-2381</ArticleId>
            <ArticleId IdType="pubmed">22261800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Britten CD. PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemother Pharmacol. 2013;71:1395&#x2013;1409. doi: 10.1007/s00280-013-2121-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00280-013-2121-1</ArticleId>
            <ArticleId IdType="pubmed">23443307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu X, Han R, Quan LH, Liu CY, Liao YH. Stabilization and sustained release of zeylenone, a soft cytotoxic drug, within polymeric micelles for local antitumor drug delivery. Int J Pharm. 2013;450:331&#x2013;337. doi: 10.1016/j.ijpharm.2013.04.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2013.04.007</ArticleId>
            <ArticleId IdType="pubmed">23587966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yunlan L, Juan Z, Qingshan L. Antitumor activity of di-n-butyl-(2,6-difluorobenzohydroxamato)tin(IV) against human gastric carcinoma SGC-7901 cells via G2/M cell cycle arrest and cell apoptosis. PLoS One. 2014;9:e90793. doi: 10.1371/journal.pone.0090793.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0090793</ArticleId>
            <ArticleId IdType="pmc">PMC3958342</ArticleId>
            <ArticleId IdType="pubmed">24643073</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27901493</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>03</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>12</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1949-2553</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Jan</Month>
              <Day>03</Day>
            </PubDate>
          </JournalIssue>
          <Title>Oncotarget</Title>
          <ISOAbbreviation>Oncotarget</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Has aidi injection the attenuation and synergistic efficacy to gemcitabine and cisplatin in non-small cell lung cancer? A meta-analysis of 36 randomized controlled trials.</ArticleTitle>
        <Pagination>
          <StartPage>1329</StartPage>
          <EndPage>1342</EndPage>
          <MedlinePgn>1329-1342</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.13617</ELocationID>
        <Abstract>
          <AbstractText>Gemcitabine and cisplatin is the first line chemotherapy for non-small cell lung cancer with high toxicity. Aidi injection is a cantharidin and astragalu-based Chinese herbs injection in China. Has Aidi injection attenuation and synergistic efficacy to GP in NSCLC? There is lack of strong evidence to prove it. To further reveal it, we systematically evaluated all related studies. We collected all studies about Aidi injection plus GP for NSCLC in Medline, Embase, Web of Science, CNKI, VIP, Wanfang Database, CBM, CCRCT, Chi-CTR, and US-clinical trials (established to June 2015). We evaluated their quality according to the Cochrane evaluation handbook of randomized controlled trials (5.1.0), extracted data following the PICO principles and synthesized the data by Meta analysis. Thirty six RCTs with 2582 NSCLC patients were included, with general methodological quality in most trials. The RR values and their 95% CI of Meta-analysis for ORR, DCR and QOL were as following: 1.28 (1.17, 1.39), 1.11(1.07, 1.15) and 1.81 (1.61, 2.03). The merged RD values and their 95% CI of Meta-analysis for myelosuppression, neutropenia, thrombocytopenia, neurotoxicity and nausea and vomiting were as following: -0.23(-0.29, -0.17), -0.17(-0.22, -0.11), -0.13(-0.18, -0.08), -0.06(-0.17, 0.05) and -0.15(-0.21, -0.10). To compare with GP alone, all differences were statistically significant. The available evidence indicates that Aidi injection plus GP can significantly increase the clinical efficacy and improve the QOL of patients with NSCLC. Aidi injection can reduce myelosuppression, neutropenia, thrombocytopenia neurotoxicity and nausea/vomiting. These indirectly reveal that Aidi injection has the attenuation and synergistic efficacy to GP chemotherapy in NSCLC.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Zheng</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Evidence-Based Medicine Center, MOE Virtual Research Center of Evidence-based Medicine at Zunyi Medical College, Affiliated Hospital of Zunyi Medical College, Zunyi 563003, Guizhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Medicine (Center for Evidence-Based and Translational Medicine of Major Infectious Diseases), Affiliated Hospital of Zunyi Medical College, Zunyi 563003, Guizhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Chengqiong</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Evidence-Based Medicine Center, MOE Virtual Research Center of Evidence-based Medicine at Zunyi Medical College, Affiliated Hospital of Zunyi Medical College, Zunyi 563003, Guizhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Medicine (Center for Evidence-Based and Translational Medicine of Major Infectious Diseases), Affiliated Hospital of Zunyi Medical College, Zunyi 563003, Guizhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Ling</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Evidence-Based Medicine Center, MOE Virtual Research Center of Evidence-based Medicine at Zunyi Medical College, Affiliated Hospital of Zunyi Medical College, Zunyi 563003, Guizhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Medicine (Center for Evidence-Based and Translational Medicine of Major Infectious Diseases), Affiliated Hospital of Zunyi Medical College, Zunyi 563003, Guizhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Xuemei</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Grade 2012 Students, Department of Public Health, Zunyi Medical College. Zunyi 563002, Guizhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Lianhong</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Grade 2012 Students, Department of Public Health, Zunyi Medical College. Zunyi 563002, Guizhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Nana</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Evidence-Based Medicine Center, MOE Virtual Research Center of Evidence-based Medicine at Zunyi Medical College, Affiliated Hospital of Zunyi Medical College, Zunyi 563003, Guizhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory Medicine (Center for Evidence-Based and Translational Medicine of Major Infectious Diseases), Affiliated Hospital of Zunyi Medical College, Zunyi 563003, Guizhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Evidence-Based Medicine Center, MOE Virtual Research Center of Evidence-based Medicine at Zunyi Medical College, Affiliated Hospital of Zunyi Medical College, Zunyi 563003, Guizhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, First People's Hospital of Zunyi City and Third Affiliated Hospital of Zunyi Medical College, Zunyi 563002, Guizhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gong</LastName>
            <ForeName>Qihai</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>School of pharmacy, Zunyi Medical College, Zunyi 563003, Guizhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Fushan</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>School of pharmacy, Zunyi Medical College, Zunyi 563003, Guizhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Jihong</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Affiliated Hospital of Zunyi Medical College, Zunyi 563000, Guizhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xiaofei</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Parasites, Zunyi Medical College, Zunyi 563003, Guizhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Oncotarget</MedlineTA>
        <NlmUniqueID>101532965</NlmUniqueID>
        <ISSNLinking>1949-2553</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C517300">aidi herbal drug</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0W860991D6</RegistryNumber>
          <NameOfSubstance UI="D003841">Deoxycytidine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q20Q21Q62J</RegistryNumber>
          <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000093542">Gemcitabine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003841" MajorTopicYN="N">Deoxycytidine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007267" MajorTopicYN="N">Injections</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000093542" MajorTopicYN="N">Gemcitabine</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">aidi injection</Keyword>
        <Keyword MajorTopicYN="N">gemcitabine and cisplatin (GP)</Keyword>
        <Keyword MajorTopicYN="N">meta-analysis</Keyword>
        <Keyword MajorTopicYN="N">non-small cell lung cancer (NSCLC)</Keyword>
        <Keyword MajorTopicYN="N">randomized controlled trial</Keyword>
      </KeywordList>
      <CoiStatement>CONFLICTS OF INTERESTS. The authors have no conflicts of interest to declare.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>7</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>11</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>12</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>12</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27901493</ArticleId>
        <ArticleId IdType="pmc">PMC5352058</ArticleId>
        <ArticleId IdType="doi">10.18632/oncotarget.13617</ArticleId>
        <ArticleId IdType="pii">13617</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Tsao AS, Scagliotti GV, Bunn PA, Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, et al. Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016;11:613&#x2013;638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27013409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol. 1993;11:1866&#x2013;1872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8410111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsia TC, Tu CY, Fang HY, Liang JA, Li CC, Chien CR. Cost and effectiveness of image-guided radiotherapy for non-operated localized lung cancer: a population-based propensity score-matched analysis. J Thorac Dis. 2015;7:1643&#x2013;1649.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4598523</ArticleId>
            <ArticleId IdType="pubmed">26543613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anagnostou VK, Brahmer JR. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. Clin Cancer Res. 2015;21:976&#x2013;984.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25733707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janne PA, Paz-Ares L, Oh Y, Eschbach C, Hirsh V, Enas N, Brail L, von Pawel J. Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer. J Thorac Oncol. 2014;9:126&#x2013;131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24346102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, Ciuleanu T, Cucevic B, Gyurkovits K, Ulsperger E, Jassem J, Grgic M, Saip P, Szilasi M, Wiltschke C, Wagnerova M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer. 2006:52155&#x2013;163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16569462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) Ann Oncol. 2010;21:1804&#x2013;1809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2924992</ArticleId>
            <ArticleId IdType="pubmed">20150572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wachters FM, Van Putten JW, Kramer H, Erjavec Z, Eppinga P, Strijbos JH, de Leede GP, Boezen HM, de Vries EG, Groen HJ. First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial. Br J Cancer. 2003;89:1192&#x2013;1199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2394313</ArticleId>
            <ArticleId IdType="pubmed">14520444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee NS, Byun JH, Bae SB, Kim CK, Lee KT, Park SK, Won JH, Hong DS, Park HS. Combination of gemcitabine and cisplatin as first-line therapy in advanced non-small-cell lung cancer. Cancer Res Treat. 2004;36:173&#x2013;177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2855082</ArticleId>
            <ArticleId IdType="pubmed">20396540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsia TC, Lin JH, Hsu SC, Tang NY, Lu HF, Wu SH, Lin JG, Chung JG. Cantharidin induces DNA damage and inhibits DNA repair-associated protein levels in NCI-H460 human lung cancer cells. Environ Toxicol. 2015;30:1135&#x2013;1143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24639390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou X, Shi H, Jiang G, Zhou Y, Xu J. Antitumor activities of ginseng polysaccharide in C57BL/6 mice with Lewis lung carcinoma. Tumour Biol. 2014;35:12561&#x2013;12566.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25204674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suh SO, Kroh M, Kim NR, Joh YG, Cho MY. Effects of red ginseng upon postoperative immunity and survival in patients with stage III gastric cancer. Am J Chin Med. 2002:30483&#x2013;494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12568276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim HS, Lim JM, Kim JY, Kim Y, Park S, Sohn J. Panaxydol, a component of Panax ginseng, induces apoptosis in cancer cells through EGFR activation and ER stress and inhibits tumor growth in mouse models. Int J Cancer. 2016;138:1432&#x2013;1441.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26421996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L. Aidi injection combined with gemcitabine hydrochloride and cisplatin for advanced non small cell lung cancer: A clinical study. Journal of Practical Medicine. 2009;25:2929&#x2013;2930.</Citation>
        </Reference>
        <Reference>
          <Citation>Ding P, Ge H, Li M, Zhu M. Aidi injection combined with gemcitabine hydrochloride and cisplatin for advanced non small cell lung cancer: A clinical study. Journal of Clinical Pulmonary Medicine. 2011;16:1802&#x2013;1803.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu Y, Zhao Y. Aidi injection combined with GP for advanced non-small cell lung cancer: A clinical study. China Practical Journal of Medicine. 2014;41:67&#x2013;69.</Citation>
        </Reference>
        <Reference>
          <Citation>Zou Y, Li J, Luo X. Aidi injection combined with GP chemotherapy for advanced lung cancer: A clinical study. Hubei J Traditional Chinese Medicine. 2006;28:33&#x2013;34.</Citation>
        </Reference>
        <Reference>
          <Citation>Feng X, Li X, Cui E. Aidi injection combined with GP for non small cell lung cancer: A clinical study of 68 cases. Journal of Oncology. 2008;14:892&#x2013;893.</Citation>
        </Reference>
        <Reference>
          <Citation>Sun G, Liu J, Wang T, Zhu J. Aidi injection combined with gemcitabine and cisplatin for advanced non small cell lung cancer: A clinical study of 33 cases. Fujian Medical Journal. 2008;30:134&#x2013;134.</Citation>
        </Reference>
        <Reference>
          <Citation>Yang Q, Chen W, Huang J, Chen X. Aidi injection combined with chemotherapy in the treatment of advanced lung cancer. Guangming J Chinese Medicine. 2008;23:1760&#x2013;1761.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhao H, Zhao Y, Su H, Wang C. Aidi injection combined with gemcitabine hydrochloride and cisplatin for advanced non small cell lung cancer: A clinical study. Chinese J Misdiagnostics. 2008;8:5873&#x2013;5874.</Citation>
        </Reference>
        <Reference>
          <Citation>Lv D, Guo Q, Qiu Y. Aidi injection combined with gemcitabine and cisplatin for advanced non small cell lung cancer: A clinical study of 30 cases. Jiangxi J Traditional Chinese Medicine. 2009;40:47&#x2013;48.</Citation>
        </Reference>
        <Reference>
          <Citation>Song Z, Liu X, Zhang H, Shang Y, Xu Y. Aidi injection combined with gemcitabine hydrochloride and cisplatin for advanced non small cell lung cancer: A clinical study. Medical Research and Education. 2009;26:36&#x2013;37.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Y. Aidi injection combined with chemotherapy in the treatment of elderly patients with advanced non-small cell lung cancer: A clinical study. Chinese Primary Health Care. 2009;23:101&#x2013;102.</Citation>
        </Reference>
        <Reference>
          <Citation>Wen K, Li J, Peng D. Aidi injection combined with gemcitabine hydrochloride and cisplatin for advanced non small cell lung cancer: A clinical study. Chinese J Basic Medicine in Traditional Chinese Medicine. 2009;15:716&#x2013;717.</Citation>
        </Reference>
        <Reference>
          <Citation>Hong Y, Wang J, Jiao Z. Aidi injection combined with gemcitabine hydrochloride and cisplatin for advanced non small cell lung cancer: A clinical study. Chinese J Clinical Oncology and Rehabilitation. 2010;17:247&#x2013;249.</Citation>
        </Reference>
        <Reference>
          <Citation>Hou A, Zhang L. Aidi injection combined with gemcitabine and cisplatin for advanced non small cell lung cancer: A clinical study of 78 cases. World Health Digest. 2010;07:285&#x2013;286.</Citation>
        </Reference>
        <Reference>
          <Citation>Li Z, Liu X, Yuan L. Aidi injection combined with gemcitabine hydrochloride and cisplatin for advanced non small cell lung cancer: A clinical study. Journal Community Medicine. 2010;08:23&#x2013;24.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu Y, Liu Y, Zhang T. Aidi injection combined with chemotherapy for advanced non-small cell lung cancer: A short-term curative effect study. National Medical Frontiers of China. 2010;05:46&#x2013;46.</Citation>
        </Reference>
        <Reference>
          <Citation>Shi X, Yu A, Yang Y, Jin X, Dai L, Zhang T, Wang M, Wang Z, Pan W. Aidi injection combined with chemotherapy for advanced non-small cell lung cancer: A clinical study. Zhejiang J Integrated Traditional Chinese and Western Medicine. 2010;20:747&#x2013;748.</Citation>
        </Reference>
        <Reference>
          <Citation>Fan S, Peng L, Qi X. Aidi injection combined with chemotherapy for advanced non-small cell lung cancer: A clinical study. Zhejiang J Integrated Traditional Chinese and Western Medicine. 2011;21:232&#x2013;233.</Citation>
        </Reference>
        <Reference>
          <Citation>He W, Wu L, Yu C, Song Y. Aidi injection combined with gemcitabine hydrochloride and cisplatin for advanced non small cell lung cancer: A clinical study. Journal of Logistics University of Capf. 2011;20:296&#x2013;297. 326.</Citation>
        </Reference>
        <Reference>
          <Citation>Jiang S, Mao X, Hong J. Aidi injection combined with chemotherapy for advanced non small cell lung cancer: A clinical study of 32 cases. Zhejiang J Integrated Traditional Chinese and Western Medicine. 2011;21:24&#x2013;26.</Citation>
        </Reference>
        <Reference>
          <Citation>Lu Z, Xu L, Yu J, Wang D. Aidi injection combined with chemotherapy for advanced non-small cell lung cancer: A clinical study. China Modern Medicine. 2011;18:72&#x2013;73.</Citation>
        </Reference>
        <Reference>
          <Citation>Wu Q, He X. Aidi injection combined with chemotherapy for advanced non-small cell lung cancer: A clinical study. China J Chinese Materia Medica. 2011;36:3364&#x2013;3365.</Citation>
        </Reference>
        <Reference>
          <Citation>Fu L. Aidi injection combined with GP in the treatment of elderly patients with advanced non-small cell lung cancer: A clinical study. Guide of China Medicine. 2012:466.</Citation>
        </Reference>
        <Reference>
          <Citation>Pei W. Efficacy of Aidi Injection combined with GP regimen in patients with advanced non-small cell lung cancer and the impact on expression of serum VEGF. China Medical Herald. 2012;09:99&#x2013;100.</Citation>
        </Reference>
        <Reference>
          <Citation>Sun J, Xu P, Shi D, Cao B. Evaluation on clinical efficacy of Aidi injection combined with GP chemotherapy in treatment of advanced non-small cell lung cancer in elder patients. Journal of Jilin University(Medicine Edition) 2012;38:151&#x2013;154.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang J. Clinical study of Aidi injection combined with GP chemotherapy on treatment of non-small cell lung cancer. Journal of Clinical Pulmonary Medicine. 2012;17:312&#x2013;313.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Y, Peng L. Clinical study on Aidi injection combined GP for treating advanced non-small cell lung cancer. Chinese Community Doctors. 2012;14:231&#x2013;232.</Citation>
        </Reference>
        <Reference>
          <Citation>Xu Y, Zhang Y, Lu B. Clinical study on Aidi injection combined chemotherapy for treating middle and late stage lung cancer. China Pharmaceuticals. 2012;21:56&#x2013;57.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang Y. Aidi injection combined with GP for non small cell lung cancer: A clinical study. Modern Journal of Integrated Traditional Chinese and Western Medicine. 2012;21:2095&#x2013;2096.</Citation>
        </Reference>
        <Reference>
          <Citation>Cai H, Zou H, Chai Y, Zhu H. Clinical study of Aidi injection and GP chemotherapy to improve the quality of life in patients with non-small cell lung cancer. Medicine and Pharmacy of Yunnan. 2013:365&#x2013;365.</Citation>
        </Reference>
        <Reference>
          <Citation>Ju S, Li C, Xu Y. Aidi injection combined with GP in the treatment of elderly patients with advanced non-small cell lung cancer: A clinical study. Strait Pharmaceutical Journal. 2013;25:206&#x2013;207.</Citation>
        </Reference>
        <Reference>
          <Citation>Lai L. Aidi injection combined with GP in the treatment of elderly patients with advanced non-small cell lung cancer: A clinical study. Modern Journal of Integrated Traditional Chinese and Western Medicine. 2013:7&#x2013;258.</Citation>
        </Reference>
        <Reference>
          <Citation>Xu H, Yang T, Zhou M. Clinical evaluation of Aidi injection combined with chemotherapy for advanced non-small cell lung cancer. International Journal of Respiration. 2013;33:765&#x2013;767.</Citation>
        </Reference>
        <Reference>
          <Citation>Li J, Yang G. Clinical evaluation of Aidi injection combined with GP for advanced non-small cell lung cancer. Heilongjiang Medical Journal. 2014;38:447&#x2013;448.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu Z, Zhang C. Aidi injection combined with GP for advanced non-small cell lung cancer:A randomized and paralleled study. Journal of Practical Traditional Chinese Internal Medicine. 2014;28:65&#x2013;67.</Citation>
        </Reference>
        <Reference>
          <Citation>Wen H. Clinical evaluation of TCM combined with Western Medicine for elderly patients with advanced non-small cell lung cancer. Modern Journal of Integrated Traditional Chinese and Western Medicine. 2014;23:2325&#x2013;2326.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Q, He X, Tian J, Wang X, Ru P, Ruan Z, Yang K. A meta analysis of Aidi Injection plus taxotere and cisplatin in the treatment of non-small cell lung Cancer. Chin J Lung Cancer. 2010;13:1027&#x2013;1034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6000489</ArticleId>
            <ArticleId IdType="pubmed">21081042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li XW, Li NL, Zhao LY, Li YQ. Experiment on expression of nm23-1 gene in lung cancer mice affected by cantharidin. Chinese Journal of Clinical Rehabilitation. 2005;9:96&#x2013;98.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang W, Zhao H, Yan Y, Wang X, Zong Z, Liu Y. Apoptosis induced by cantharidin in human pulmonary carcinoma cells A549 and its molecular mechanisms. Chinese Journal of Oncology. 2005;27:330&#x2013;334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16117893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim YM, Ku MJ, Son YJ, Yun JM, Kim SH, Lee SY. Anti-metastatic effect of cantharidin in A549 human lung cancer cells. Arch Pharm Res. 2013;36:479&#x2013;484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23435912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang S, Mao X, Hong J. Aidi injection combining chemotherapy in the treatment of advanced non-small cell lung cancer: a clinical observation of 32 cases. Zhejiang J ITCWM. 2011;21:24&#x2013;26.</Citation>
        </Reference>
        <Reference>
          <Citation>Li J, Wang J, Zhu Y, Lu B, Wang K, Wang Z, Wang J. Clinical observation of Aidi injection combined with chemotherapy in treatment of advanced non small cell lung cancer. Hainan Med J. 2014;25:3444&#x2013;3447.</Citation>
        </Reference>
        <Reference>
          <Citation>Wu S, Xu S. Clinical observation on the effect of Aidi injection in the treatment of advanced NSCLC. Chin J Medicinal Guide. 2013;15:116&#x2013;117.</Citation>
        </Reference>
        <Reference>
          <Citation>Cichello SA, Yao Q, Dowell A, Leury B, He XQ. Proliferative and Inhibitory Activity of Siberian ginseng (Eleutherococcus senticosus) Extract on Cancer Cell Lines; A-549, XWLC-05, HCT-116, CNE and Beas-2b. Asian Pac J Cancer Prev. 2015;16:4781&#x2013;4786.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26107240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang HC, Tseng YH, Wu HR, Chu FH, Kuo YH, Wang SY. Anti-proliferation effect on human breast cancer cells via inhibition of pRb phosphorylation by taiwanin E isolated from Eleutherococcus trifoliatus. Nat Prod Commun. 2014;9:1303&#x2013;1306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25918798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu DT, Lepe-Zuniga J, Wong WL, LaPushin R, Mavligit GM. Fractionated extract of Astragalus membranaceus, a Chinese medicinal herb, potentiates LAK cell cytotoxicity generated by a low dose of recombinant interleukin-2. J Clin Lab Immunol. 1988;26:183&#x2013;187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3264344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu DT, Wong WL, Mavligit GM. Immunotherapy with Chinese medicinal herbs. II. Reversal of cyclophosphamide-induced immune suppression by administration of fractionated Astragalus membranaceus in vivo. J Clin Lab Immunol. 1988;25:125&#x2013;129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3260961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kormosh N, Laktionov K, Antoshechkina M. Effect of a combination of extract from several plants on cell-mediated and humoral immunity of patients with advanced ovarian cancer. Phytother Res. 2006;20:424&#x2013;425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16619374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shao BM, Xu W, Dai H, Tu P, Li Z, Gao XM. A study on the immune receptors for polysaccharides from the roots of Astragalus membranaceus, a Chinese medicinal herb. Biochem Biophys Res Commun. 2004;320:1103&#x2013;1111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15249203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207&#x2013;214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7459811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu B, Xu L, Chen M. Aidi injection combined with paclitaxel plus cisplatin for advanced non small cell lung cancer: a meta-analysis. Zhejiang J Integrated Traditional Chinese and Western Medicine. 2009;19:446&#x2013;447.</Citation>
        </Reference>
        <Reference>
          <Citation>Yang J, Ding M. Eddie combined with gemcitabine and cisplatin for advanced non-Small cell lung cancer:Meta-Analysis. Chinese General Practice. 2012;15:2794&#x2013;2798.</Citation>
        </Reference>
        <Reference>
          <Citation>Miller SC, Ti L, Shan JJ. The sustained influence of short term exposure to a proprietary extract of North American ginseng on the hemopoietic cells of the bone marrow, spleen and blood of adult and juvenile mice. Phytother Res. 2012;26:675&#x2013;681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21997998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raghavendran HR, Sathyanath R, Shin J, Kim HK, Han JM, Cho J, Son CG. Panax ginseng modulates cytokines in bone marrow toxicity and myelopoiesis: ginsenoside Rg1 partially supports myelopoiesis. PLoS One. 2012;7:e33733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3327696</ArticleId>
            <ArticleId IdType="pubmed">22523542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kopalli SR, Cha KM, Jeong MS, Lee SH, Sung JH, Seo SK, Kim SK. Pectinase-treated Panax ginseng ameliorates hydrogen peroxide-induced oxidative stress in GC-2 sperm cells and modulates testicular gene expression in aged rats. J Ginseng Res. 2016;40:185&#x2013;195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4845052</ArticleId>
            <ArticleId IdType="pubmed">27158240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lam P, Cheung F, Tan HY, Wang N, Yuen MF, Feng Y. Hepatoprotective Effects of Chinese Medicinal Herbs: A Focus on Anti-Inflammatory and Anti-Oxidative Activities. Int J Mol Sci. 2016:17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4848921</ArticleId>
            <ArticleId IdType="pubmed">27043533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang YF, Lu L, Zhu DJ, Wang M, Yin Y, Chen DX, Wei LB. Effects of Astragalus Polysaccharides on Dysfunction of Mitochondrial Dynamics Induced by Oxidative Stress. Oxid Med Cell Longev. 2016;2016:9573291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4737051</ArticleId>
            <ArticleId IdType="pubmed">26881048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shahzad M, Small DM, Morais C, Wojcikowski K, Shabbir A, Gobe GC. Protection against oxidative stress-induced apoptosis in kidney epithelium by Angelica and Astragalus. J Ethnopharmacol. 2016;179:412&#x2013;419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26719285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higgins JPTGS. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. http://www.handbookcochraneorg/ [updated March 2011]. Available at.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27612557</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>07</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2017</Year>
        <Month>10</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-7980</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>382</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Nov</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer letters</Title>
          <ISOAbbreviation>Cancer Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inhibition of Aurora kinases induces apoptosis and autophagy via AURKB/p70S6K/RPL15 axis in human leukemia cells.</ArticleTitle>
        <Pagination>
          <StartPage>215</StartPage>
          <EndPage>230</EndPage>
          <MedlinePgn>215-230</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2016.08.016</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0304-3835(16)30491-8</ELocationID>
        <Abstract>
          <AbstractText>Leukemia is a common malignancy of blood cells with poor prognosis in many patients. Aurora kinases, a family of serine/threonine kinases, play a key role in regulating cell division and mitosis and are linked to tumorigenesis, metastasis, and poor prognosis in many human cancers including leukemia and lymphoma. Danusertib (Danu) is a pan-inhibitor of Aurora kinases with few data available in leukemia therapy. This study aimed to identify new molecular targets for Aurora kinase inhibition in human leukemia cells using quantitative proteomic analysis followed by verification experiments. There were at least 2932 proteins responding to Danu treatment, including AURKB, p70S6K, and RPL15, and 603 functional proteins and 245 canonical signaling pathways were involved in regulating cell proliferation, metabolism, apoptosis, and autophagy. The proteomic data suggested that Danu-regulated RPL15 signaling might contribute to the cancer cell killing effect. Our verification experiments confirmed that Danu negatively regulated AURKB/p70S6K/RPL15 axis with the involvement of PI3K/Akt/mTOR, AMPK, and p38 MAPK signaling pathways, leading to the induction of apoptosis and autophagy in human leukemia cells. Further studies are warranted to verify the feasibility via targeting AURKB/p70S6K/RPL15 axis for leukemia therapy.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2016 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Si-Jia</ForeName>
            <Initials>SJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China; Guizhou Provincial Key Laboratory for Regenerative Medicine, Stem Cell and Tissue Engineering Research Center &amp; Sino-US Joint Laboratory for Medical Sciences, Laboratory Animal Center, Guiyang Medical University, Guiyang 550004, China; Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL 33612, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shu</LastName>
            <ForeName>Li-Ping</ForeName>
            <Initials>LP</Initials>
            <AffiliationInfo>
              <Affiliation>Guizhou Provincial Key Laboratory for Regenerative Medicine, Stem Cell and Tissue Engineering Research Center &amp; Sino-US Joint Laboratory for Medical Sciences, Laboratory Animal Center, Guiyang Medical University, Guiyang 550004, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Zhi-Wei</ForeName>
            <Initials>ZW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL 33612, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Tianxin</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, University of Utah and Salt Lake Veterans Affairs Medical Center, Salt Lake City, Utah, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Duan</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Deakin University, Waurn Ponds, Victoria 3217, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xueji</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Research Center for Bioengineering and Sensing Technology, University of Science and Technology Beijing, Beijing 100083, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Zhi-Xu</ForeName>
            <Initials>ZX</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China; Guizhou Provincial Key Laboratory for Regenerative Medicine, Stem Cell and Tissue Engineering Research Center &amp; Sino-US Joint Laboratory for Medical Sciences, Laboratory Animal Center, Guiyang Medical University, Guiyang 550004, China. Electronic address: hzx@gmc.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Shu-Feng</ForeName>
            <Initials>SF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL 33612, USA; Department of Bioengineering and Biotechnology, College of Chemical Engineering, Huaqiao University, Xiamen, Fujian 361021, China. Electronic address: shufengzhou2006@hotmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>09</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>Cancer Lett</MedlineTA>
        <NlmUniqueID>7600053</NlmUniqueID>
        <ISSNLinking>0304-3835</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012269">Ribosomal Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C043649">ribosomal protein L15</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="C576921">AURKB protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D064107">Aurora Kinase B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D038762">Ribosomal Protein S6 Kinases, 70-kDa</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>M3X659D0FY</RegistryNumber>
          <NameOfSubstance UI="C523797">danusertib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064107" MajorTopicYN="N">Aurora Kinase B</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059565" MajorTopicYN="N">G2 Phase Cell Cycle Checkpoints</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018922" MajorTopicYN="N">HL-60 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020014" MajorTopicYN="N">K562 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007938" MajorTopicYN="N">Leukemia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D038762" MajorTopicYN="N">Ribosomal Protein S6 Kinases, 70-kDa</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012269" MajorTopicYN="N">Ribosomal Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">AURKB/RPL15/p70S6K axis</Keyword>
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">Aurora kinase</Keyword>
        <Keyword MajorTopicYN="N">Autophagy</Keyword>
        <Keyword MajorTopicYN="N">Danusertib</Keyword>
        <Keyword MajorTopicYN="N">Leukemia</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>5</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>7</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>8</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>7</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>9</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27612557</ArticleId>
        <ArticleId IdType="doi">10.1016/j.canlet.2016.08.016</ArticleId>
        <ArticleId IdType="pii">S0304-3835(16)30491-8</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27744450</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>02</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1421-9778</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>39</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2016</Year>
            </PubDate>
          </JournalIssue>
          <Title>Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology</Title>
          <ISOAbbreviation>Cell Physiol Biochem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Combination of Hydroxyl Acetylated Curcumin and Ultrasound Induces Macrophage Autophagy with Anti-Apoptotic and Anti-Lipid Aggregation Effects.</ArticleTitle>
        <Pagination>
          <StartPage>1746</StartPage>
          <EndPage>1760</EndPage>
          <MedlinePgn>1746-1760</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">Sonodynamic therapy (SDT) is considered a new approach for the treatment of atherosclerosis. We previously confirmed that hydroxyl acetylated curcumin (HAC) was a sonosensitizer. In this study, we investigated the mechanism of THP-1 macrophage apoptosis and autophagy induced by HAC mediated SDT (HAC-SDT).</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Cell viability was measured using a CCK-8 assay. Laser scanning confocal microscopy was used to measure the levels of intracellular reactive oxygen species (ROS), sub-cellular HAC localization, BAX and cytochrome C translocation, LC3 expression, monodansylcadaverine staining and Dil-labeled oxidized low density lipoprotein (Dil-ox-LDL) uptake. Flow cytometry was used to analyze apoptosis and autophagy via Annexin V/propidium iodide and acridine orange staining, respectively. The expression levels of apoptosis- and autophagy-related proteins were detected by Western blot. Oil red O was used to measure intracellular lipid accumulation.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified HAC (5.0 &#x3bc;g/mL) located in lysosomes, endoplasmic reticulum, Golgi apparatus and mitochondria after 4 h of incubation. Compared with other sonosensitizers (e.g., curcumin and emodin), HAC had a more obvious sonodynamic effect on macrophages. Furthermore, the mitochondrial-caspase pathway was confirmed to play a crucial role in the HAC-SDT-induced apoptosis; BAX translocated from the cytosol to the mitochondria during HAC-SDT. Subsequently, mitochondrial cytochrome C was released into the cytosol, activating the caspase cascade in a time-dependent manner. Furthermore, HAC-SDT could induce PI3K/AKT/mTOR pathway dependent autophagy, accompanied by a decrease in the lipid uptake of THP-1 macrophages. This mechanism was demonstrated by the formation of acidic vesicular organelles, the conversion of LC3 I to LC3 II, the expression of related proteins, and the attenuation of both Dil-ox-LDL and oil red O staining. Moreover, pre-treatment with the autophagy inhibitor 3-methyladenine enhanced the HAC-SDT-induced apoptosis. Additionally, HAC-SDT-induced autophagy and apoptosis were both blocked by ROS scavenger N-acetyl-l-cysteine.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results suggested that autophagy not only played an inhibitory role in the process of apoptosis but also could effectively attenuate lipid aggregation in THP-1 macrophages during HAC-SDT. As important intracellular mediators, the ROS generated by HAC-SDT also played a crucial role in initiating apoptosis and autophagy.</AbstractText>
          <CopyrightInformation>&#xa9; 2016 The Author(s) Published by S. Karger AG, Basel.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Longbin</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathophysiology, Key Laboratory of Cardiovascular Pathophysiology, Harbin Medical University, Harbin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xuesong</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kou</LastName>
            <ForeName>Jiayuan</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhong</LastName>
            <ForeName>Zhaoyu</ForeName>
            <Initials>Z</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Yueqing</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Zhongni</ForeName>
            <Initials>Z</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Ye</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Liming</ForeName>
            <Initials>L</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Cell Physiol Biochem</MedlineTA>
        <NlmUniqueID>9113221</NlmUniqueID>
        <ISSNLinking>1015-8987</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C494826">BAX protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008055">Lipids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008077">Lipoproteins, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C477012">MAP1LC3A protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051028">bcl-2-Associated X Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C099252">oxidized low density lipoprotein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-43-6</RegistryNumber>
          <NameOfSubstance UI="D045304">Cytochromes c</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IT942ZTH98</RegistryNumber>
          <NameOfSubstance UI="D003474">Curcumin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003474" MajorTopicYN="N">Curcumin</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045304" MajorTopicYN="N">Cytochromes c</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
          <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006056" MajorTopicYN="N">Golgi Apparatus</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
          <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006900" MajorTopicYN="N">Hydroxylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008077" MajorTopicYN="N">Lipoproteins, LDL</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
          <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
          <QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069453" MajorTopicYN="N">Ultrasonic Waves</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051028" MajorTopicYN="N">bcl-2-Associated X Protein</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>8</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>2</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27744450</ArticleId>
        <ArticleId IdType="doi">10.1159/000447875</ArticleId>
        <ArticleId IdType="pii">000447875</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27591861</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>02</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-1335</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>142</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of cancer research and clinical oncology</Title>
          <ISOAbbreviation>J Cancer Res Clin Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Epothilone B induces apoptosis and enhances apoptotic effects of ABT-737 on human cancer cells via PI3K/AKT/mTOR pathway.</ArticleTitle>
        <Pagination>
          <StartPage>2281</StartPage>
          <EndPage>2289</EndPage>
          <MedlinePgn>2281-9</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00432-016-2236-y</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Epothilone B and its derivatives are tested in multiple clinical trials. Epothilone B induces neurotoxic effect in clinical trials; however, low-dose epothilone B regimen can promote neuroprotection and neurogenesis. Thus, the study of new combination chemotherapy regimen incorporating low-dose epothilone B with other chemotherapeutic agents might help to develop epothilone B-based approaches to cancer treatment and avoid the neurotoxicity of epothilone B.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Cell proliferation was assessed by SRB cell viability assay. Apoptosis was analyzed by propidium iodide (PI) staining. Mitochondrial membrane depolarization was evaluated using JC-1 staining. The expression of proteins was detected by western blotting.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">In this study, we demonstrated that the combination of ABT-737 and low-dose epothilone B showed synergistic anti-proliferation effects on human cancer cells. In addition, epothilone B&#xa0;+&#xa0;ABT-737 synergy was through mitochondria-mediated apoptosis pathway. Furthermore, combination treatment markedly induced the activation of caspase-3 and the cleavage of PARP. The activation of PI3K/Akt/mTOR pathway is associated with resistance to epothilone B. Our data showed that epothilone B plus ABT-737 resulted in a blockade of the PI3K/AKT/mTOR signaling pathway.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data indicate that ABT-737 may be a pertinent sensitizer to epothilone B, and the strategy of combining epothilone B with ABT-737 appears to be an attractive option for overcoming the resistance and neurotoxicity of epothilone B.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yang-Ling</ForeName>
            <Initials>YL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Pharmacology, Hangzhou First People's Hospital, Nanjing Medical University, No. 261 Huansha Road, Hangzhou, 310006, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Jiao</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Xiu</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Zhejiang University City College, No. 51 Huzhou Street, Hangzhou, 310015, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Yi-Ni</ForeName>
            <Initials>YN</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Zhejiang University City College, No. 51 Huzhou Street, Hangzhou, 310015, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yan</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Pharmacology, Hangzhou First People's Hospital, Nanjing Medical University, No. 261 Huansha Road, Hangzhou, 310006, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Qing-Yu</ForeName>
            <Initials>QY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Pharmacology, Hangzhou First People's Hospital, Nanjing Medical University, No. 261 Huansha Road, Hangzhou, 310006, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Fei</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Pharmacology, Hangzhou First People's Hospital, Nanjing Medical University, No. 261 Huansha Road, Hangzhou, 310006, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Neng-Ming</ForeName>
            <Initials>NM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Pharmacology, Hangzhou First People's Hospital, Nanjing Medical University, No. 261 Huansha Road, Hangzhou, 310006, Zhejiang, China. lnm1013@163.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hangzhou Translational Medicine Research Center, Hangzhou First People's Hospital, Nanjing Medical University, No. 261 Huansha Road, Hangzhou, 310006, Zhejiang, China. lnm1013@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Chong</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Zhejiang University City College, No. 51 Huzhou Street, Hangzhou, 310015, Zhejiang, China. zhangchong@zucc.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>09</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>J Cancer Res Clin Oncol</MedlineTA>
        <NlmUniqueID>7902060</NlmUniqueID>
        <ISSNLinking>0171-5216</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C501332">ABT-737</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001713">Biphenyl Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D034261">Epothilones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009596">Nitrophenols</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>UEC0H0URSE</RegistryNumber>
          <NameOfSubstance UI="C093788">epothilone B</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001713" MajorTopicYN="N">Biphenyl Compounds</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034261" MajorTopicYN="N">Epothilones</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009596" MajorTopicYN="N">Nitrophenols</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ABT-737</Keyword>
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">Epothilone B</Keyword>
        <Keyword MajorTopicYN="N">Neurotoxicity</Keyword>
        <Keyword MajorTopicYN="N">PI3K/Akt/mTOR</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>8</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>8</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>9</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>9</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>2</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27591861</ArticleId>
        <ArticleId IdType="doi">10.1007/s00432-016-2236-y</ArticleId>
        <ArticleId IdType="pii">10.1007/s00432-016-2236-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Cancer Invest. 2015 Jul;33(6):213-24</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25919223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Cancer Res Clin Oncol. 2010 Mar;136(3):437-45</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19727814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell. 2014 May 8;157(4):897-909</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24813612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Pain Symptom Manage. 2011 Dec;42(6):931-40</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21621965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Cell Mol Med. 2015 Feb;19(2):408-17</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25388762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adv Enzyme Regul. 1984;22:27-55</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6382953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cytokine Growth Factor Rev. 2008 Jun-Aug;19(3-4):325-31</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18495520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Science. 2015 Apr 17;348(6232):347-52</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25765066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Natl Cancer Inst. 2015 Feb 17;107(4):null</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25694444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mol Cancer Ther. 2014 Jan;13(1):260-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24252851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Res. 2013 Feb 15;73(4):1340-51</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23243017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Breast Cancer. 2015 Oct;15(5):325-31</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25913905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncogene. 2001 Jun 28;20(29):3806-13</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11439344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drug Resist Updat. 2008 Feb-Apr;11(1-2):32-50</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18166498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sci Rep. 2015 Oct 08;5:14881</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26445909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncotarget. 2016 Sep 13;7(37):60169-60180</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27507059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leuk Res. 2012 Mar;36(3):342-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22137317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer. 2015 Dec 1;121(23):4165-72</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26308485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mol Cancer Ther. 2014 Feb;13(2):275-84</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24435445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gynecol Oncol. 2010 Nov;119(2):345-50</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20674962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Int J Hepatol. 2013;2013:103830</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23509629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 1995 Apr 13;332(15):1004-14</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7885406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onco Targets Ther. 2015 Aug 20;8:2187-98</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26316786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncogene. 2004 Jul 29;23(34):5781-91</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15208671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gynecol Oncol. 2015 Apr;137(1):173-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25677064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Environ Toxicol Pharmacol. 2015 Mar;39(2):700-12</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25721485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Treat Rev. 2006 May;32(3):166-79</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16527420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer. 2013 Jul 15;119(14):2582-92</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23585021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Pharmacol Exp Ther. 2012 Jun;341(3):859-72</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22393246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Res. 1995 Jun 1;55(11):2325-33</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7757983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2009 Feb 15;15(4):1126-32</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19228717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mol Cancer Ther. 2001 Nov;1(1):3-10</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12467233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neurobiol Dis. 2009 Aug;35(2):270-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19464369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncogene. 2006 Aug 7;25(34):4798-811</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16892092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Cancer Res Clin Oncol. 2004 Jan;130(1):8-14</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14605879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Am J Cancer Res. 2013 Aug 14;3(4):390-401</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23977448</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27472346</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>06</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1660-3397</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>14</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Jul</Month>
              <Day>27</Day>
            </PubDate>
          </JournalIssue>
          <Title>Marine drugs</Title>
          <ISOAbbreviation>Mar Drugs</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Sinularin Induces Apoptosis through Mitochondria Dysfunction and Inactivation of the pI3K/Akt/mTOR Pathway in Gastric Carcinoma Cells.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">142</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/md14080142</ELocationID>
        <Abstract>
          <AbstractText>Sinularin is an active compound isolated from the cultured soft coral Sinularia flexibilis. In this study, we investigated the effects of sinularin on two human gastric cancer cell lines, AGS and NCI-N87. Our results demonstrated that sinularin suppressed the proliferation of gastric cancer cells in a dose-dependent manner and induced apoptosis. In addition, the loss of mitochondrial membrane potential, the release of cytochrome C, the activation of Bax, Bad and caspase-3/9, and the suppression of p-Bad, Bcl-xL and Bcl-2 were observed in the cells treated with sinularin. This finding suggests that sinularin-induced apoptosis is associated with mitochondria-mediated apoptosis and occurs through caspase-dependent pathways. Furthermore, sinularin inhibited the phosphoinositol 3-kinase/Akt/mechanistic target of the rapamycin signaling pathway. Taken together, our results show that sinularin-induced apoptosis is mediated by activation of the caspase cascade and mitochondrial dysfunction. Our findings suggest that sinularin merits further evaluation as a chemotherapeutic agent for human gastric cancer.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Yu-Jen</ForeName>
            <Initials>YJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Food Science and Nutrition, Meiho University, Pingtung 91202, Taiwan. x00002180@meiho.edu.tw.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Beauty Science, Meiho University, Pingtung 91202, Taiwan. x00002180@meiho.edu.tw.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wong</LastName>
            <ForeName>Bing-Sang</ForeName>
            <Initials>BS</Initials>
            <AffiliationInfo>
              <Affiliation>Antai Medical Care Cooperation Antai Tian-Sheng Memorial Hospital, Pingtung 92842, Taiwan. a094162@mail.tsmh.org.tw.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yea</LastName>
            <ForeName>Shu-Hao</ForeName>
            <Initials>SH</Initials>
            <AffiliationInfo>
              <Affiliation>Yu Jun Biotechnology Co., Ltd., Kaoshiun 91202, Taiwan. a714825936@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Chi-I</ForeName>
            <Initials>CI</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nursing, Meiho University, Pingtung 91202, Taiwan. x00002177@meiho.edu.tw.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weng</LastName>
            <ForeName>Shun-Hsiang</ForeName>
            <Initials>SH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Food Science and Nutrition, Meiho University, Pingtung 91202, Taiwan. x00009520@meiho.edu.tw.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>07</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Mar Drugs</MedlineTA>
        <NlmUniqueID>101213729</NlmUniqueID>
        <ISSNLinking>1660-3397</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004224">Diterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006575">Heterocyclic Compounds, 3-Ring</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C574383">sinularin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="C494918">AKT1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="C505407">CASP3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="C506433">CASP9 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D053453">Caspase 9</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D037421" MajorTopicYN="N">Anthozoa</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053453" MajorTopicYN="N">Caspase 9</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004224" MajorTopicYN="N">Diterpenes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006575" MajorTopicYN="N">Heterocyclic Compounds, 3-Ring</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013274" MajorTopicYN="N">Stomach Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">apoptosis</Keyword>
        <Keyword MajorTopicYN="N">gastric cancer</Keyword>
        <Keyword MajorTopicYN="N">mitochondrial dysfunction</Keyword>
        <Keyword MajorTopicYN="N">sinularin</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>3</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>7</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>7</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>7</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>7</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27472346</ArticleId>
        <ArticleId IdType="pmc">PMC4999903</ArticleId>
        <ArticleId IdType="doi">10.3390/md14080142</ArticleId>
        <ArticleId IdType="pii">md14080142</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Gonzalez C.A., Sala N., Rokkas T. Gastric cancer: Epidemiologic aspects. Helicobacter. 2013;18:34&#x2013;38. doi: 10.1111/hel.12082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/hel.12082</ArticleId>
            <ArticleId IdType="pubmed">24011243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orditura M., Galizia G., Sforza V., Gambardella V., Fabozzi A., Laterza M.M., Andreozzi F., Ventriglia J., Savastano B., Mabilia A., et al. Treatment of gastric cancer. World J. Gastroenterol. WJG. 2014;20:1635&#x2013;1649. doi: 10.3748/wjg.v20.i7.1635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v20.i7.1635</ArticleId>
            <ArticleId IdType="pmc">PMC3930964</ArticleId>
            <ArticleId IdType="pubmed">24587643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Street A., Macdonald A., Crowder K., Harris M. The Hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade. J. Biol. Chem. 2004;279:12232&#x2013;12241. doi: 10.1074/jbc.M312245200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M312245200</ArticleId>
            <ArticleId IdType="pubmed">14709551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bader A.G., Kang S.Y., Zhao L., Vogt P.K. Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer. 2005;5:921&#x2013;929. doi: 10.1038/nrc1753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1753</ArticleId>
            <ArticleId IdType="pubmed">16341083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cantley L.C. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655&#x2013;1657. doi: 10.1126/science.296.5573.1655.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.296.5573.1655</ArticleId>
            <ArticleId IdType="pubmed">12040186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maehama T., Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 1998;273:13375&#x2013;13378. doi: 10.1074/jbc.273.22.13375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.273.22.13375</ArticleId>
            <ArticleId IdType="pubmed">9593664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Myers M.P., Pass I., Batty I.H., van der Kaay J., Stolarov J.P., Hemmings B.A., Wigler M.H., Downes C.P., Tonks N.K. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl. Acad. Sci. USA. 1998;95:13513&#x2013;13518. doi: 10.1073/pnas.95.23.13513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.95.23.13513</ArticleId>
            <ArticleId IdType="pmc">PMC24850</ArticleId>
            <ArticleId IdType="pubmed">9811831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ali I.U., Schriml L.M., Dean M. Mutational spectra of PTEN/MMAC1 gene: A tumor suppressor with lipid phosphatase activity. J. Natl. Cancer Inst. 1999;91:1922&#x2013;1932. doi: 10.1093/jnci/91.22.1922.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/91.22.1922</ArticleId>
            <ArticleId IdType="pubmed">10564676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bachman K.E., Argani P., Samuels Y., Silliman N., Ptak J., Szabo S., Konishi H., Karakas B., Blair B.G., Lin C., et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 2004;3:772&#x2013;775. doi: 10.4161/cbt.3.8.994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cbt.3.8.994</ArticleId>
            <ArticleId IdType="pubmed">15254419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin J.J., Su J.H., Tsai C.C., Chen Y.J., Liao M.H., Wu Y.J. 11-epi-sinulariolide acetate reduces cell migration and invasion of human hepatocellular carcinoma by reducing the activation of ERK1/2, p38MAPK and Fak/Pi3k/Akt/mTOR signaling pathways. Mar. Drugs. 2014;12:4783&#x2013;4798. doi: 10.3390/md12094783.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/md12094783</ArticleId>
            <ArticleId IdType="pmc">PMC4178498</ArticleId>
            <ArticleId IdType="pubmed">25222667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su C.C., Chen J.Y., Din Z.H., Su J.H., Yang Z.Y., Chen Y.J., Wang R.Y., Wu Y.J. 13-acetoxysarcocrassolide induces apoptosis on human gastric carcinoma cells through mitochondria-related apoptotic pathways: p38/JNK activation and PI3K/AKT suppression. Mar. Drugs. 2014;12:5295&#x2013;5315. doi: 10.3390/md12105295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/md12105295</ArticleId>
            <ArticleId IdType="pmc">PMC4210900</ArticleId>
            <ArticleId IdType="pubmed">25342459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu C.I., Chen C.C., Chen J.C., Su J.H., Huang H.H., Chen J.Y., Wu Y.J. Proteomic analysis of anti-tumor effects of 11-dehydrosinulariolide on cal-27 cells. Mar. Drugs. 2011;9:1254&#x2013;1272. doi: 10.3390/md9071254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/md9071254</ArticleId>
            <ArticleId IdType="pmc">PMC3148502</ArticleId>
            <ArticleId IdType="pubmed">21822415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin Y.F., Kuo C.Y., Wen Z.H., Lin Y.Y., Wang W.H., Su J.H., Sheu J.H., Sung P.J. Flexibilisquinone, a new anti-inflammatory quinone from the cultured soft coral Sinularia flexibilis. Molecules. 2013;18:8160&#x2013;8167. doi: 10.3390/molecules18078160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/molecules18078160</ArticleId>
            <ArticleId IdType="pmc">PMC6269975</ArticleId>
            <ArticleId IdType="pubmed">23846756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su T.R., Lin J.J., Chiu C.C., Chen J.Y., Su J.H., Cheng Z.J., Hwang W.I., Huang H.H., Wu Y.J. Proteomic investigation of anti-tumor activities exerted by sinularin against a2058 melanoma cells. Electrophoresis. 2012;33:1139&#x2013;1152. doi: 10.1002/elps.201100462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/elps.201100462</ArticleId>
            <ArticleId IdType="pubmed">22539317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma J., Shi M., Li G., Wang N., Wei J., Wang T., Ma J., Wang Y. Regulation of id1 expression by epigallocatechin-3-gallate and its effect on the proliferation and apoptosis of poorly differentiated ags gastric cancer cells. Int. J. Oncol. 2013;43:1052&#x2013;1058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3829801</ArticleId>
            <ArticleId IdType="pubmed">23900621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park J.G., Frucht H., LaRocca R.V., Bliss D.P., Jr., Kurita Y., Chen T.R., Henslee J.G., Trepel J.B., Jensen R.T., Johnson B.E., et al. Characteristics of cell lines established from human gastric carcinoma. Cancer Res. 1990;50:2773&#x2013;2780.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2158397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Denicourt C., Dowdy S.F. Targeting apoptotic pathways in cancer cells. Science. 2004;305:1411&#x2013;1413. doi: 10.1126/science.1102974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1102974</ArticleId>
            <ArticleId IdType="pubmed">15353788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matthews G.M., Newbold A., Johnstone R.W. Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity. Adv. Cancer Res. 2012;116:165&#x2013;197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23088871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wajant H. The fas signaling pathway: More than a paradigm. Science. 2002;296:1635&#x2013;1636. doi: 10.1126/science.1071553.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1071553</ArticleId>
            <ArticleId IdType="pubmed">12040174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimizu H., Banno Y., Sumi N., Naganawa T., Kitajima Y., Nozawa Y. Activation of p38 mitogen-activated protein kinase and caspases in UVB-induced apoptosis of human keratinocyte HaCaT cells. J. Investig. Dermatol. 1999;112:769&#x2013;774. doi: 10.1046/j.1523-1747.1999.00582.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1523-1747.1999.00582.x</ArticleId>
            <ArticleId IdType="pubmed">10233770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez-Girones D.M., Moncunill-Massaguer C., Iglesias-Serret D., Cosialls A.M., Perez-Perarnau A., Palmeri C.M., Rubio-Patino C., Villunger A., Pons G., Gil J. AICAR induces Bax/Bak-dependent apoptosis through upregulation of the BH3-only proteins Bim and Noxa in mouse embryonic fibroblasts. Apoptosis Int. J. Program. Cell Death. 2013;18:1008&#x2013;1016. doi: 10.1007/s10495-013-0850-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10495-013-0850-6</ArticleId>
            <ArticleId IdType="pubmed">23605481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaparou M., Choumerianou D., Perdikogianni C., Martimianaki G., Kalmanti M., Stiakaki E. Enhanced levels of the apoptotic BAX/BCL-2 ratio in children with acute lymphoblastic leukemia and high-risk features. Genet. Mol. Biol. 2013;36:7&#x2013;11. doi: 10.1590/S1415-47572013005000003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1590/S1415-47572013005000003</ArticleId>
            <ArticleId IdType="pmc">PMC3615527</ArticleId>
            <ArticleId IdType="pubmed">23569402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicholson D.W., Thornberry N.A. Apoptosis. Life and death decisions. Science. 2003;299:214&#x2013;215. doi: 10.1126/science.1081274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1081274</ArticleId>
            <ArticleId IdType="pubmed">12522239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coulthard L.R., White D.E., Jones D.L., McDermott M.F., Burchill S.A. P38mapk: Stress responses from molecular mechanisms to therapeutics. Trends Mol. Med. 2009;15:369&#x2013;379. doi: 10.1016/j.molmed.2009.06.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molmed.2009.06.005</ArticleId>
            <ArticleId IdType="pmc">PMC3016890</ArticleId>
            <ArticleId IdType="pubmed">19665431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yanase S., Yasuda K., Ishii N. Adaptive responses to oxidative damage in three mutants of Caenorhabditis elegans (age-1, mev-1 and daf-16) that affect life span. Mech. Ageing Dev. 2002;123:1579&#x2013;1587. doi: 10.1016/S0047-6374(02)00093-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0047-6374(02)00093-3</ArticleId>
            <ArticleId IdType="pubmed">12470895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 2005;8:179&#x2013;183. doi: 10.1016/j.ccr.2005.08.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2005.08.008</ArticleId>
            <ArticleId IdType="pubmed">16169463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lawlor M.A., Alessi D.R. PKB/Akt: A key mediator of cell proliferation, survival and insulin responses? J. Cell Sci. 2001;114:2903&#x2013;2910.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11686294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan T.O., Rittenhouse S.E., Tsichlis P.N. Akt/PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositide-dependent phosphorylation. Annu. Rev. Biochem. 1999;68:965&#x2013;1014. doi: 10.1146/annurev.biochem.68.1.965.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.biochem.68.1.965</ArticleId>
            <ArticleId IdType="pubmed">10872470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fletcher J.I., Huang D.C. Controlling the cell death mediators bax and bak: Puzzles and conundrums. Cell Cycle. 2008;7:39&#x2013;44. doi: 10.4161/cc.7.1.5178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cc.7.1.5178</ArticleId>
            <ArticleId IdType="pubmed">18196961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manning B.D., Tee A.R., Logsdon M.N., Blenis J., Cantley L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-Kinase/Akt pathway. Mol. Cell. 2002;10:151&#x2013;162. doi: 10.1016/S1097-2765(02)00568-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1097-2765(02)00568-3</ArticleId>
            <ArticleId IdType="pubmed">12150915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y., Gao X., Saucedo L.J., Ru B., Edgar B.A., Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol. 2003;5:578&#x2013;581. doi: 10.1038/ncb999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb999</ArticleId>
            <ArticleId IdType="pubmed">12771962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J.T., Lehmann B.D., Terrian D.M., Chappell W.H., Stivala F., Libra M., Martelli A.M., Steelman L.S., McCubrey J.A. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle. 2008;7:1745&#x2013;1762. doi: 10.4161/cc.7.12.6166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cc.7.12.6166</ArticleId>
            <ArticleId IdType="pmc">PMC2593475</ArticleId>
            <ArticleId IdType="pubmed">18594202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forde J.E., Dale T.C. Glycogen synthase kinase 3: A key regulator of cellular fate. Cell. Mol. Life Sci. CMLS. 2007;64:1930&#x2013;1944. doi: 10.1007/s00018-007-7045-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-007-7045-7</ArticleId>
            <ArticleId IdType="pubmed">17530463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franke T.F., Hornik C.P., Segev L., Shostak G.A., Sugimoto C. PI3K/Akt and apoptosis: Size matters. Oncogene. 2003;22:8983&#x2013;8998. doi: 10.1038/sj.onc.1207115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1207115</ArticleId>
            <ArticleId IdType="pubmed">14663477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127:469&#x2013;480. doi: 10.1016/j.cell.2006.10.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2006.10.018</ArticleId>
            <ArticleId IdType="pubmed">17081971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mulholland D.J., Dedhar S., Wu H., Nelson C.C. Pten and gsk3beta: Key regulators of progression to androgen-independent prostate cancer. Oncogene. 2006;25:329&#x2013;337. doi: 10.1038/sj.onc.1209020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1209020</ArticleId>
            <ArticleId IdType="pubmed">16421604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian T., Nan K.J., Guo H., Wang W.J., Ruan Z.P., Wang S.H., Liang X., Lu C.X. PTEN inhibits the migration and invasion of HepG2 cells by coordinately decreasing MMP expression via the PI3K/Akt pathway. Oncol. Rep. 2010;23:1593&#x2013;1600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20428814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M.E. Akt phosphorylation of bad couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231&#x2013;241. doi: 10.1016/S0092-8674(00)80405-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0092-8674(00)80405-5</ArticleId>
            <ArticleId IdType="pubmed">9346240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gingras A.C., Kennedy S.G., O&#x2019;Leary M.A., Sonenberg N., Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(Pkb) signaling pathway. Genes Dev. 1998;12:502&#x2013;513. doi: 10.1101/gad.12.4.502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.12.4.502</ArticleId>
            <ArticleId IdType="pmc">PMC316523</ArticleId>
            <ArticleId IdType="pubmed">9472019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gingras A.C., Raught B., Sonenberg N. mTOR signaling to translation. Curr. Top. Microbiol. Immunol. 2004;279:169&#x2013;197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14560958</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27391155</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>02</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1949-2553</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>7</Volume>
            <Issue>34</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Aug</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>Oncotarget</Title>
          <ISOAbbreviation>Oncotarget</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Induction of apoptosis and autophagy via mitochondria- and PI3K/Akt/mTOR-mediated pathways by E. adenophorum in hepatocytes of saanen goat.</ArticleTitle>
        <Pagination>
          <StartPage>54537</StartPage>
          <EndPage>54548</EndPage>
          <MedlinePgn>54537-54548</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.10402</ELocationID>
        <Abstract>
          <AbstractText>E. adenophorum has reported to cause hepatotoxicity. But, the precise effects of E. adenophorum on hepatocytes is unclear. Saanen goats were fed on E. adenophorum to detect the cytotoxicity effects of E. adenophorum on hepatocytes. Our study has shown that the typical apoptotic features, the increasing apoptotic hepatocytes and activated caspase-9, -3 and the subsequent cleavage of PARP indicated the potent pro-apoptotic effects of E. adenophorum. Moreover, the translocation of Bax and Cyt c between mitochondria and cytosol triggering the forming of apoptosome proved that the mitochondria-mediated apoptosis was triggered by E. adenophorum. Furthermore, E. adenophorum increased the MDC-positive autophagic vacuoles and the subcellular localization of punctate LC3, the ratio of LC3-II/LC3-I and the protein levels of Beclin 1, but decreased that of P62, indicating the potent pro-autophagic effects of E. adenophorum. In addition, E. adenophorum significantly inhibited the protein leves of p-PI3K, p-Akt and p-mTORC1, but increased PTEN and p-AMPK. Also, the p-mTORC2 and p-Akt Ser473 were inhibited, indicating that the supression of mTORC2/Akt pathway could induce the autophagy of hepatocytes. The autophagy-realted results indicated that the inhibition of PI3K/Akt/mTORC1- and mTORC2/Akt-mediated pathways contributed to the pro-autophagic activity of E. adenophorum. These findings provide new insights to understand the mechanisms involved in E. adenophorum-caused hepatotoxicity of Saanen goat.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Yajun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Sichuan Province, Wenjiang 611130, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mo</LastName>
            <ForeName>Quan</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Sichuan Province, Wenjiang 611130, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Biao</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Sichuan Province, Wenjiang 611130, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qiao</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Sichuan Province, Wenjiang 611130, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Ruiguang</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Sichuan Province, Wenjiang 611130, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zuo</LastName>
            <ForeName>Zhicai</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Sichuan Province, Wenjiang 611130, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>Junliang</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Sichuan Province, Wenjiang 611130, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nong</LastName>
            <ForeName>Xiang</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>College of Life Science, Leshan Normal University, Le'shan, 614000, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Guangneng</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Sichuan Province, Wenjiang 611130, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Resource Biology and Biotechnology in Western China, School of Life Science, Northwest University, Xi'an 710069, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Yahui</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Resource Biology and Biotechnology in Western China, School of Life Science, Northwest University, Xi'an 710069, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Yanchun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Sichuan Province, Wenjiang 611130, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Oncotarget</MedlineTA>
        <NlmUniqueID>101532965</NlmUniqueID>
        <ISSNLinking>1949-2553</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D036603" MajorTopicYN="Y">Ageratina</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006041" MajorTopicYN="N">Goats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022781" MajorTopicYN="N">Hepatocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081082" MajorTopicYN="Y">Phosphoinositide-3 Kinase Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">E. adenophorum</Keyword>
        <Keyword MajorTopicYN="N">apoptosis</Keyword>
        <Keyword MajorTopicYN="N">autophagy</Keyword>
        <Keyword MajorTopicYN="N">hepatocytes</Keyword>
        <Keyword MajorTopicYN="N">mitochondrial and PI3K/Akt/mTOR pathway</Keyword>
      </KeywordList>
      <CoiStatement>CONFLICTS OF INTEREST. The authors declare that they have no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>1</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>6</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>7</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>7</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27391155</ArticleId>
        <ArticleId IdType="pmc">PMC5342361</ArticleId>
        <ArticleId IdType="doi">10.18632/oncotarget.10402</ArticleId>
        <ArticleId IdType="pii">10402</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lu P, Sang W, Ma K. Progress and prospects in research of an exotic invasive species, Eupatorium adenophorum. Acta Phytoecological Sinica. 2005;29:1029&#x2013;1037.</Citation>
        </Reference>
        <Reference>
          <Citation>Lei Y, Wang W, Feng Y, Zheng Y, Gong H. Synergistic interactions of CO2 enrichment and nitrogen deposition promote growth and ecophysiological advantages of invading Eupatorium adenophorum in Southwest China. Planta. 2012;236:1205&#x2013;1213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22684510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song Q, Fu Y, Tang J, Feng Z, Yang C. Allelopathic potential of Eupatorium adenophorum. Acta Phytoecologica sinica. 2000;24:362&#x2013;365.</Citation>
        </Reference>
        <Reference>
          <Citation>Oelrichs PB, Calanasan CA, Macleod JK, Seawright AA, Ng JC. Isolation of a compound from Eupatorium adenophorum (Spreng.)[Ageratina adenophora (Spreng.)] causing hepatotoxicity in mice. Natural toxins. 1995;3:350&#x2013;354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8581319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng Y, Lei Y, Wang R, Callaway RM, Valiente-Banuet A, Li Y, Zheng Y. Evolutionary tradeoffs for nitrogen allocation to photosynthesis versus cell walls in an invasive plant. Proceedings of the National Academy of Sciences. 2009;106:1853&#x2013;1856.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2644127</ArticleId>
            <ArticleId IdType="pubmed">19171910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nong X, Ren YJ, Wang JH, Xie Y, Fang CL, Yang DY. Clinical efficacy of botanical extracts from Eupatorium adenophorum against the Sarcoptes scabiei (Sarcoptidae: Sarcoptes) in Rabbits. Veterinary parasitology. 2013;195:157&#x2013;164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23518619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seddiek SA, Khater HF, El-Shorbagy MM, Ali AM. The acaricidal efficacy of aqueous neem extract and ivermectin against Sarcoptes scabiei var. cuniculi in experimentally infested rabbits. Parasitology Research. 2013;112:2319&#x2013;2330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23572045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao F, Hu Y, Tan H, Wu L, Wang Y, Huang Y, Mo Q, Wei Y. Acaricidal activity of 9-oxo-10, 11-dehydroageraphorone extracted from Eupatorium adenophorum in vitro. Experimental parasitology. 2014;140:8&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24631419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kundu A, Saha S, Walia S, Ahluwalia V, Kaur C. Antioxidant potential of essential oil and cadinene sesquiterpenes of Eupatorium adenophorum. Toxicological &amp; Environmental Chemistry. 2013;95:127&#x2013;137.</Citation>
        </Reference>
        <Reference>
          <Citation>Liao F, Hu Y, Wu L, Tan H, Mo Q, Luo B, He Y, Deng J, Wei Y. The Antitumor Activity in Vitro by 9-oxo-10, 11-dehydroageraphorone Extracted from Eupatorium adenophorum. Asian Journal of Chemistry. 2014;26:7321&#x2013;7323.</Citation>
        </Reference>
        <Reference>
          <Citation>Chakravarty AK, Mazumder T, Chatterjee SN. Anti-inflammatory potential of ethanolic leaf extract of Eupatorium adenophorum Spreng. Through Alteration in Production of TNF-&#x3b1;, ROS and expression of certain genes. Evidence-Based Complementary and Alternative Medicine. 2011 doi: 10.1093/ecam/neq033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecam/neq033</ArticleId>
            <ArticleId IdType="pmc">PMC3145355</ArticleId>
            <ArticleId IdType="pubmed">21808653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh Y, Mukhopadhayay SM, Ayub Ali, Tolenkhomba TC, Ayub Shah MA. Short-term toxicity studies of Eupatorium adenophorum in Swiss albino mice. Int J Res Phytochem Pharmacol. 2011;1:165&#x2013;171.</Citation>
        </Reference>
        <Reference>
          <Citation>Katoch R, Sharma OP, Dawra RK, Kurade NP. Hepatotoxicity of Eupatorium adenophorum to rats. Toxicon. 2000;38:309&#x2013;314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10665812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaushal V, Dawra R, Sharma O, Kurade N. Hepatotoxicity in rat induced by partially purified toxins from Eupatorium adenophorum (Ageratina adenophora) Toxicon. 2001;39:615&#x2013;619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11072039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhardwaj R, Singh A, Sharma OP, Dawra RK, Kurade NP, Mahato SB. Hepatotoxicity and cholestasis in rats induced by the sesquiterpene, 9-oxo-10, 11-dehydroageraphorone, isolated from Eupatorium adenophorum. Journal of biochemical and molecular toxicology. 2001;15:279&#x2013;286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11835625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pal&#xe1;-Pa&#xfa;l J, P&#xe9;rez-Alonso MJ, Velasco-Negueruela A, Sanz J. Analysis by gas chromatography-mass spectrometry of the volatile components of Ageratina adenophora Spreng., growing in the Canary Islands. Journal of Chromatography A. 2002;947:327&#x2013;331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11883666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bordoloi MJ, Shukla VS, Sharma RP. Absolute stereochemistry of the insect antifeedant cadinene from Eupatorium adenophorum. Tetrahedron Letters. 1985;26:509&#x2013;510.</Citation>
        </Reference>
        <Reference>
          <Citation>O'sullivan B. Investigations into crofton weed (Eupatorium adenophorum) toxicity in horses. Australian veterinary journal. 1985;62:30&#x2013;32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4039926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manara L. Isotopic methods and activation analysis. In: Bacq ZM, Capek R, Paoletti R, Renson J, editors. Fundamentals of Biochemical Pharmacology. Pergamon Press; Oxford: 1971.</Citation>
        </Reference>
        <Reference>
          <Citation>Ravikumar B, Sarkar SDavies JE, Futter M, Garcia AM, Green Thompson ZW, Jimenez SM, Korolchuk VI, Lichtenberg M, Luo S, Massey DC. Regulation of Mammalian Autophagy in Physiology and Pathophysiology. Physiological Reviews. 2010;90:1383&#x2013;1435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20959619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fulda S, Debatin KM. Targeting apoptosis pathways in cancer therapy. Current cancer drug targets. 2004;4:569&#x2013;576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15578914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henson PM, Hume DA. Apoptotic cell removal in development and tissue homeostasis. Trends in immunology. 2006;27:244&#x2013;250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16584921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishigami N, Shinozuka J, Katayama KI, Nakayama H, Doi K. Apoptosis in mouse fetuses from dams exposed to T-2 toxin at different days of gestation. Experimental and Toxicologic Pathology. 2001;52:493&#x2013;501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11256751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA. 2005;55:178&#x2013;194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15890640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Yuan J. Caspases in apoptosis and beyond. Oncogene. 2008;27:6194&#x2013;6206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18931687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kantari C, Walczak H. Caspase-8 and bid: caught in the act between death receptors and mitochondria. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2011;1813:558&#x2013;563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21295084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science. 2000;290:1717&#x2013;1721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2732363</ArticleId>
            <ArticleId IdType="pubmed">11099404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2011;1813:1978&#x2013;1986.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21440011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Copp J, Manning GT. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Research. 2009;69:1821&#x2013;1827.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2652681</ArticleId>
            <ArticleId IdType="pubmed">19244117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rabinowitz JD, Eileen W. Autophagy and metabolism. Science. 2010;330:1344&#x2013;1348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3010857</ArticleId>
            <ArticleId IdType="pubmed">21127245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verma A, Yadav B, Sampath K. Possible use of Spreng (Eupatorium adenophorum) in animal feeding. Indian journal of animal nutrition. 1987;4:189&#x2013;192.</Citation>
        </Reference>
        <Reference>
          <Citation>Annick N, Lionel L, Carine M. Autophagy as a mediator of chemotherapy-induced cell death in cancer. Biochemical Pharmacology. 2011;82:427&#x2013;434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21704023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizushima N. Methods for monitoring autophagy. International Journal of Biochemistry &amp; Cell Biology. 2004;36:2491&#x2013;2502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15325587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jessica M, Charis E. When overgrowth bumps into cancer: the PTEN-opathies. American Journal of Medical Genetics Part C Seminars in Medical Genetics. 2013;163C:114&#x2013;121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23613428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nissim H, Nahum S. Upstream and downstream of mTOR. Genes &amp; Development. 2004;18:1926&#x2013;1945.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15314020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen S, Han Q, Wang X, Yang M, Zhang Z, Li P, Chen A, Hu C, Li S. IBP-mediated suppression of autophagy promotes growth and metastasis of breast cancer cells via activating mTORC2/Akt/FOXO3a signaling pathway. Cell Death &amp; Disease. 2013;4:e842.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3824689</ArticleId>
            <ArticleId IdType="pubmed">24113176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J&#xe4;nicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. Journal of Biological Chemistry. 1998;273:9357&#x2013;9360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9545256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharpe JC, Arnoult D, Youle RJ. Control of mitochondrial permeability by Bcl-2 family members. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2004;1644:107&#x2013;113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14996495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo S, Rubinsztein DC. Apoptosis blocks Beclin 1-dependent autophagosome synthesis: an effect rescued by Bcl-xL. Cell Death &amp; Differentiation. 2010;17:268&#x2013;277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2894406</ArticleId>
            <ArticleId IdType="pubmed">19713971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, Vicencio JM, Kepp O, Tasdemir E, Maiuri MC, Kroemer G. To die or not to die: that is the autophagic question. Current Molecular Medicine. 2008;8:78&#x2013;91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18336289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klionsky DJ, Eskelinen EL, Deretic V. Autophagosomes, phagosomes, autolysosomes, phagolysosomes, autophagolysosomes&#x2026; wait, I'm confused. Autophagy. 2014;10:549&#x2013;551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4091142</ArticleId>
            <ArticleId IdType="pubmed">24657946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Will M, Qin AC, Toy W, Yao Z, Rodrikoutmezguine V, Schneider C, Huang X, Monian P, Jiang X, De SE. Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discovery. 2014;4:334&#x2013;347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4049524</ArticleId>
            <ArticleId IdType="pubmed">24436048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eisenberg-Lerner A, Bialik S, Simon HU, Kimchi A. Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death &amp; Differentiation. 2009;16:966&#x2013;975.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19325568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He MX, He YW. A role for c-FLIP(L) in the regulation of apoptosis, autophagy, and necroptosis in T lymphocytes. Cell Death &amp; Differentiation. 2013;20:188&#x2013;197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3554340</ArticleId>
            <ArticleId IdType="pubmed">23175183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sahoo A, Singh B, Sharma O. Evaluation of feeding value of Eupatorium adenophorum in combination with mulberry leaves. Livestock Science. 2011;136:175&#x2013;183.</Citation>
        </Reference>
        <Reference>
          <Citation>Iqbal M, Philbin VJ, Smith AL. Expression patterns of chicken Toll-like receptor mRNA in tissues, immune cell subsets and cell lines. Veterinary immunology and immunopathology. 2005;104:117&#x2013;127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15661337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2&#x2212;&#x394;&#x394;CT Method. methods. 2001;25:402&#x2013;408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11846609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Z, Xu X, Huang Y, Ding L, Wang Z, Yu G, Xu D, Li W, Tong D. Swainsonine Activates Mitochondria-mediated Apoptotic Pathway in Human Lung Cancer A549 Cells and Retards the Growth of Lung Cancer Xenografts. International journal of biological sciences. 2012;8:394&#x2013;405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3291856</ArticleId>
            <ArticleId IdType="pubmed">22393311</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27050525</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>12</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2211-1247</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>15</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Apr</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell reports</Title>
          <ISOAbbreviation>Cell Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>ERRα-Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer.</ArticleTitle>
        <Pagination>
          <StartPage>323</StartPage>
          <EndPage>335</EndPage>
          <MedlinePgn>323-35</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2016.03.026</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S2211-1247(16)30282-0</ELocationID>
        <Abstract>
          <AbstractText>Imaging studies in animals and in humans have indicated that the oxygenation and nutritional status of solid tumors is dynamic. Furthermore, the extremely low level of glucose within tumors, while reflecting its rapid uptake and metabolism, also suggests that cancer cells must rely on other energy sources in some circumstances. Here, we find that some breast cancer cells can switch to utilizing lactate as a primary source of energy, allowing them to survive glucose deprivation for extended periods, and that this activity confers resistance to PI3K/mTOR inhibitors. The nuclear receptor, estrogen-related receptor alpha (ERRα), was shown to regulate the expression of genes required for lactate utilization, and isotopomer analysis revealed that genetic or pharmacological inhibition of ERRα activity compromised lactate oxidation. Importantly, ERRα antagonists increased the in vitro and in vivo efficacy of PI3K/mTOR inhibitors, highlighting the potential clinical utility of this drug combination.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2016 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Park</LastName>
            <ForeName>Sunghee</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chang</LastName>
            <ForeName>Ching-Yi</ForeName>
            <Initials>CY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Safi</LastName>
            <ForeName>Rachid</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Xiaojing</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baldi</LastName>
            <ForeName>Robert</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jasper</LastName>
            <ForeName>Jeff S</ForeName>
            <Initials>JS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Anderson</LastName>
            <ForeName>Grace R</ForeName>
            <Initials>GR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Tingyu</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rathmell</LastName>
            <ForeName>Jeffrey C</ForeName>
            <Initials>JC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dewhirst</LastName>
            <ForeName>Mark W</ForeName>
            <Initials>MW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, Duke University School of Medicine, Durham, NC 27710, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wood</LastName>
            <ForeName>Kris C</ForeName>
            <Initials>KC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Locasale</LastName>
            <ForeName>Jason W</ForeName>
            <Initials>JW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McDonnell</LastName>
            <ForeName>Donald P</ForeName>
            <Initials>DP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA. Electronic address: donald.mcdonnell@duke.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA193256</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01CA193256</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA174643</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R00CA168997</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01DK105550</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 DK105550</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R00 CA168997</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>UL1TR001117</GrantID>
            <Acronym>TR</Acronym>
            <Agency>NCATS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01CA174643</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>UL1 TR001117</GrantID>
            <Acronym>TR</Acronym>
            <Agency>NCATS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>K12 HD043446</GrantID>
            <Acronym>HD</Acronym>
            <Agency>NICHD NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>03</Month>
          <Day>31</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cell Rep</MedlineTA>
        <NlmUniqueID>101573691</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C098744">ERRalpha estrogen-related receptor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007773">Lactates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071248">Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011804">Quinolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0RH81L854J</RegistryNumber>
          <NameOfSubstance UI="D005973">Glutamine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IY9XDZ35W2</RegistryNumber>
          <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>RUJ6Z9Y0DT</RegistryNumber>
          <NameOfSubstance UI="C531198">dactolisib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019069" MajorTopicYN="N">Cell Respiration</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019610" MajorTopicYN="N">Cytoprotection</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="Y">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName>
          <QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005973" MajorTopicYN="N">Glutamine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007773" MajorTopicYN="N">Lactates</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016688" MajorTopicYN="N">Mice, Inbred NOD</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071248" MajorTopicYN="N">Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081082" MajorTopicYN="N">Phosphoinositide-3 Kinase Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011804" MajorTopicYN="N">Quinolines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>11</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>1</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>3</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>4</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>4</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>12</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27050525</ArticleId>
        <ArticleId IdType="mid">NIHMS768238</ArticleId>
        <ArticleId IdType="pmc">PMC4833658</ArticleId>
        <ArticleId IdType="doi">10.1016/j.celrep.2016.03.026</ArticleId>
        <ArticleId IdType="pii">S2211-1247(16)30282-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bendell JC, Kurkjian C, Infante JR, Bauer TM, Burris HA, Greco FA, Shih KC, Thompson DS, Lane CM, Finney LH, Jones SF., 3rd A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors. Invest New Drugs. 2015;33:463&#x2013;471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25707361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boidot R, Vegran F, Meulle A, Le Breton A, Dessy C, Sonveaux P, Lizard-Nacol S, Feron O. Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors. Cancer Res. 2012;72:939&#x2013;948.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22184616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burris H, Rodon J, Sharma S, Herbst RS, Tabernero J, Infante JR, Silva A, Demanse D, Hackl W, Baselga J. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. J Clin Oncol. 2010;28</Citation>
        </Reference>
        <Reference>
          <Citation>Chandel NS, Budinger GR, Schumacker PT. Molecular oxygen modulates cytochrome c oxidase function. J Biol Chem. 1996;271:18672&#x2013;18677.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8702521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang CY, Kazmin D, Jasper JS, Kunder R, Zuercher WJ, McDonnell DP. The metabolic regulator ERRalpha, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer. Cancer Cell. 2011;20:500&#x2013;510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3199323</ArticleId>
            <ArticleId IdType="pubmed">22014575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Charest-Marcotte A, Dufour CR, Wilson BJ, Tremblay AM, Eichner LJ, Arlow DH, Mootha VK, Giguere V. The homeobox protein Prox1 is a negative modulator of ERR{alpha}/PGC-1{alpha} bioenergetic functions. Genes Dev. 2010;24:537&#x2013;542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2841331</ArticleId>
            <ArticleId IdType="pubmed">20194433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J, Lee HJ, Wu X, Huo L, Kim SJ, Xu L, Wang Y, He J, Bollu LR, Gao G, et al. Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain. Cancer Res. 2015;75:554&#x2013;565.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4315743</ArticleId>
            <ArticleId IdType="pubmed">25511375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dang CV, Hamaker M, Sun P, Le A, Gao P. Therapeutic targeting of cancer cell metabolism. J Mol Med (Berl) 2011;89:205&#x2013;212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3345191</ArticleId>
            <ArticleId IdType="pubmed">21301795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11&#x2013;20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18177721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med. 2011;9:33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3224599</ArticleId>
            <ArticleId IdType="pubmed">21470407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab. 2014;20:953&#x2013;966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25456737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujimoto J, Alam SM, Jahan I, Sato E, Sakaguchi H, Tamaya T. Clinical implication of estrogen-related receptor (ERR) expression in ovarian cancers. J Steroid Biochem Mol Biol. 2007;104:301&#x2013;304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17509876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaillard S, Grasfeder LL, Haeffele CL, Lobenhofer EK, Chu TM, Wolfinger R, Kazmin D, Koves TR, Muoio DM, Chang CY, McDonnell DP. Receptor-selective coactivators as tools to define the biology of specific receptor-coactivator pairs. Mol Cell. 2006;24:797&#x2013;803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17157261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gallagher CN, Carpenter KL, Grice P, Howe DJ, Mason A, Timofeev I, Menon DK, Kirkpatrick PJ, Pickard JD, Sutherland GR, Hutchinson PJ. The human brain utilizes lactate via the tricarboxylic acid cycle: a 13C&#x2013;labelled microdialysis and high-resolution nuclear magnetic resonance study. Brain. 2009;132:2839&#x2013;2849.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19700417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo JY, White E. Autophagy is required for mitochondrial function, lipid metabolism, growth, and fate of KRAS(G12D)-driven lung tumors. Autophagy. 2013;9:1636&#x2013;1638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5424446</ArticleId>
            <ArticleId IdType="pubmed">23959381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, Frederick DT, Hurley AD, Nellore A, Kung AL, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell. 2013;23:302&#x2013;315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3635826</ArticleId>
            <ArticleId IdType="pubmed">23477830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, Kinoshita T, Saito N, Ochiai A, Tomita M, et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 2009;69:4918&#x2013;4925.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19458066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho PC, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R, Tsui YC, Cui G, Micevic G, Perales JC, et al. Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. Cell. 2015;162:1217&#x2013;1228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4567953</ArticleId>
            <ArticleId IdType="pubmed">26321681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huss JM, Imahashi K, Dufour CR, Weinheimer CJ, Courtois M, Kovacs A, Giguere V, Murphy E, Kelly DP. The nuclear receptor ERRalpha is required for the bioenergetic and functional adaptation to cardiac pressure overload. Cell Metab. 2007;6:25&#x2013;37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17618854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kennedy KM, Scarbrough PM, Ribeiro A, Richardson R, Yuan H, Sonveaux P, Landon CD, Chi JT, Pizzo S, Schroeder T, Dewhirst MW. Catabolism of exogenous lactate reveals it as a legitimate metabolic substrate in breast cancer. PLoS One. 2013;8:e75154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3771963</ArticleId>
            <ArticleId IdType="pubmed">24069390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koppenol WH, Bounds PL, Dang CV. Otto Warburg&#x2019;s contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11:325&#x2013;337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21508971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lam SS, Mak AS, Yam JW, Cheung AN, Ngan HY, Wong AS. Targeting estrogen-related receptor alpha inhibits epithelial-to-mesenchymal transition and stem cell properties of ovarian cancer cells. Mol Ther. 2014;22:743&#x2013;751.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3982489</ArticleId>
            <ArticleId IdType="pubmed">24419103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leithner K, Hrzenjak A, Trotzmuller M, Moustafa T, Kofeler HC, Wohlkoenig C, Stacher E, Lindenmann J, Harris AL, Olschewski A, Olschewski H. PCK2 activation mediates an adaptive response to glucose depletion in lung cancer. Oncogene. 2015;34:1044&#x2013;1050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24632615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim JH, Luo C, Vazquez F, Puigserver P. Targeting mitochondrial oxidative metabolism in melanoma causes metabolic compensation through glucose and glutamine utilization. Cancer Res. 2014;74:3535&#x2013;3545.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24812272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liou GY, Storz P. Reactive oxygen species in cancer. Free Radic Res. 2010;44:479&#x2013;496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3880197</ArticleId>
            <ArticleId IdType="pubmed">20370557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X, Ser Z, Locasale JW. Development and quantitative evaluation of a high-resolution metabolomics technology. Anal Chem. 2014;86:2175&#x2013;2184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3983012</ArticleId>
            <ArticleId IdType="pubmed">24410464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patch RJ, Searle LL, Kim AJ, De D, Zhu X, Askari HB, O&#x2019;Neill JC, Abad MC, Rentzeperis D, Liu J, et al. Identification of diaryl ether-based ligands for estrogen-related receptor alpha as potential antidiabetic agents. J Med Chem. 2011;54:788&#x2013;808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21218783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle. 2009;8:3984&#x2013;4001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19923890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pfeiffer T, Schuster S, Bonhoeffer S. Cooperation and competition in the evolution of ATP-producing pathways. Science. 2001;292:504&#x2013;507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11283355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Philp A, Macdonald AL, Watt PW. Lactate--a signal coordinating cell and systemic function. J Exp Biol. 2005;208:4561&#x2013;4575.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16326938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roland CL, Arumugam T, Deng D, Liu SH, Philip B, Gomez S, Burns WR, Ramachandran V, Wang H, Cruz-Monserrate Z, Logsdon CD. Cell surface lactate receptor GPR81 is crucial for cancer cell survival. Cancer Res. 2014;74:5301&#x2013;5310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4167222</ArticleId>
            <ArticleId IdType="pubmed">24928781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rumsey WL, Schlosser C, Nuutinen EM, Robiolio M, Wilson DF. Cellular energetics and the oxygen dependence of respiration in cardiac myocytes isolated from adult rat. J Biol Chem. 1990;265:15392&#x2013;15402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2394731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schell JC, Olson KA, Jiang L, Hawkins AJ, Van Vranken JG, Xie J, Egnatchik RA, Earl EG, DeBerardinis RJ, Rutter J. A role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growth. Mol Cell. 2014;56:400&#x2013;413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4268416</ArticleId>
            <ArticleId IdType="pubmed">25458841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schroeder T, Yuan H, Viglianti BL, Peltz C, Asopa S, Vujaskovic Z, Dewhirst MW. Spatial heterogeneity and oxygen dependence of glucose consumption in R3230Ac and fibrosarcomas of the Fischer 344 rat. Cancer Res. 2005;65:5163&#x2013;5171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15958560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 2008;118:3930&#x2013;3942.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2582933</ArticleId>
            <ArticleId IdType="pubmed">19033663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki T, Miki Y, Moriya T, Shimada N, Ishida T, Hirakawa H, Ohuchi N, Sasano H. Estrogen-related receptor alpha in human breast carcinoma as a potent prognostic factor. Cancer Res. 2004;64:4670&#x2013;4676.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15231680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev. 2007;26:299&#x2013;310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17415526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urasaki Y, Heath L, Xu CW. Coupling of glucose deprivation with impaired histone H2B monoubiquitination in tumors. PLoS One. 2012;7:e36775.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3353945</ArticleId>
            <ArticleId IdType="pubmed">22615809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vellinga TT, Borovski T, de Boer VC, Fatrai S, van Schelven S, Trumpi K, Verheem A, Snoeren N, Emmink BL, Koster J, et al. SIRT1/PGC1alpha-Dependent Increase in Oxidative Phosphorylation Supports Chemotherapy Resistance of Colon Cancer. Clin Cancer Res. 2015;21:2870&#x2013;2879.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25779952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viale A, Corti D, Draetta GF. Tumors and Mitochondrial Respiration: A Neglected Connection. Cancer Res. 2015</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26374463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sanchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014;514:628&#x2013;632.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4376130</ArticleId>
            <ArticleId IdType="pubmed">25119024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walenta S, Chau TV, Schroeder T, Lehr HA, Kunz-Schughart LA, Fuerst A, Mueller-Klieser W. Metabolic classification of human rectal adenocarcinomas: a novel guideline for clinical oncologists? J Cancer Res Clin Oncol. 2003;129:321&#x2013;326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12827509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warburg O, Wind F, Negelein E. The Metabolism of Tumors in the Body. J Gen Physiol. 1927;8:519&#x2013;530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2140820</ArticleId>
            <ArticleId IdType="pubmed">19872213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinberg SE, Chandel NS. Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol. 2015;11:9&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4340667</ArticleId>
            <ArticleId IdType="pubmed">25517383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, Glasauer A, Dufour E, Mutlu GM, Budigner GS, Chandel NS. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife. 2014;3:e02242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4017650</ArticleId>
            <ArticleId IdType="pubmed">24843020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willy PJ, Murray IR, Qian J, Busch BB, Stevens WC, Martin R, Mohan R, Zhou S, Ordentlich P, Wei P, Jr, et al. Regulation of PPARgamma coactivator 1alpha (PGC-1alpha) signaling by an estrogen-related receptor alpha (ERRalpha) ligand. Proc Natl Acad Sci U S A. 2004;101:8912&#x2013;8917.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC428446</ArticleId>
            <ArticleId IdType="pubmed">15184675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB, Thompson CB. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A. 2008;105:18782&#x2013;18787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2596212</ArticleId>
            <ArticleId IdType="pubmed">19033189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zu XL, Guppy M. Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun. 2004;313:459&#x2013;465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14697210</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26902121</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>08</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1090-2104</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>471</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Mar</Month>
              <Day>18</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biochemical and biophysical research communications</Title>
          <ISOAbbreviation>Biochem Biophys Res Commun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Repositioning of antibiotic levofloxacin as a mitochondrial biogenesis inhibitor to target breast cancer.</ArticleTitle>
        <Pagination>
          <StartPage>639</StartPage>
          <EndPage>645</EndPage>
          <MedlinePgn>639-45</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2016.02.072</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0006-291X(16)30261-3</ELocationID>
        <Abstract>
          <AbstractText>Targeting mitochondrial biogenesis has become a potential therapeutic strategy in cancer due to their unique metabolic dependencies. In this study, we show that levofloxacin, a FDA-approved antibiotic, is an attractive candidate for breast cancer treatment. This is achieved by the inhibition of proliferation and induction of apoptosis in a panel of breast cancer cell lines while sparing normal breast cells. It also acts synergistically with conventional chemo drug in two independent in vivo breast xenograft mouse models. Importantly, levofloxacin inhibits mitochondrial biogenesis as shown by the decreased level of mitochondrial respiration, membrane potential and ATP. In addition, the anti-proliferative and pro-apoptotic effects of levofloxacin are reversed by acetyl-L-Carnitine (ALCAR, a mitochondrial fuel), confirming that levofloxacin's action in breast cancer cells is through inhibition of mitochondrial biogenesis. A consequence of mitochondrial biogenesis inhibition by levofloxacin in breast cancer cells is the deactivation of PI3K/Akt/mTOR and MAPK/ERK pathways. We further demonstrate that breast cancer cells have increased mitochondrial biogenesis than normal breast cells, and this explains their different sensitivity to levofloxacin. Our work suggest that levofloxacin is a useful addition to breast cancer treatment. Our work also establish the essential role of mitochondrial biogenesis on the activation of PI3K/Akt/mTOR and MAPK/ERK pathways in breast cancer cells.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2016 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Min</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Galactophore Department, JingZhou Central Hospital, JingZhou, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Ruishu</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Forensic Surgery Department, JingZhou Traditional Chinese Medicine Hospital, JingZhou, People's Republic of China. Electronic address: liruishu2016@yahoo.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Juan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Endocrinology Department, JingZhou Central Hospital, JingZhou, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>02</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Biochem Biophys Res Commun</MedlineTA>
        <NlmUniqueID>0372516</NlmUniqueID>
        <ISSNLinking>0006-291X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6GNT3Y5LMF</RegistryNumber>
          <NameOfSubstance UI="D064704">Levofloxacin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>U3P01618RT</RegistryNumber>
          <NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058492" MajorTopicYN="Y">Drug Repositioning</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064704" MajorTopicYN="N">Levofloxacin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053858" MajorTopicYN="N">Metabolic Networks and Pathways</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001678" MajorTopicYN="Y">Organelle Biogenesis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Breast cancer</Keyword>
        <Keyword MajorTopicYN="N">Levofloxacin</Keyword>
        <Keyword MajorTopicYN="N">MAPK/ERK</Keyword>
        <Keyword MajorTopicYN="N">Mitochondrial biogenesis</Keyword>
        <Keyword MajorTopicYN="N">PI3K/Akt/mTOR</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>2</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>2</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>8</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26902121</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bbrc.2016.02.072</ArticleId>
        <ArticleId IdType="pii">S0006-291X(16)30261-3</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26792585</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>10</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1559-0259</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>17</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cardiovascular toxicology</Title>
          <ISOAbbreviation>Cardiovasc Toxicol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>17-Methoxyl-7-Hydroxy-Benzene-Furanchalcone Ameliorates Myocardial Ischemia/Reperfusion Injury in Rat by Inhibiting Apoptosis and Autophagy Via the PI3K-Akt Signal Pathway.</ArticleTitle>
        <Pagination>
          <StartPage>79</StartPage>
          <EndPage>87</EndPage>
          <MedlinePgn>79-87</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12012-016-9358-y</ELocationID>
        <Abstract>
          <AbstractText>17-Methoxyl-7-hydroxy-benzene-furanchalcone (MHBFC), a monomer isolated from the root of Millettia pulchra (Benth.) Kurz var. Laxior (Dunn) Z. Wei (Papilionaceae), has been demonstrated to exhibit protective effects on myocardial ischemia/reperfusion (I/R) injury in rats. However, the mechanisms for the effect are not completely clear. In the present study, we tested whether MHBFC could reduce I/R-induced apoptosis and overautophagy via the PI3K-Akt pathway. The rat I/R model was established by ligating the left anterior descending coronary artery for 30 min and then followed by reperfusion for 2 h. MHBFC (10 mg/kg, intravenously) was administered alone or along with LY294002 (PI3K inhibitor, 0.3 mg/kg, intravenously) 5 min before the onset of reperfusion. We found that MHBFC postconditioning prevented I/R-induced release of creatine kinase-MB and tumor necrosis factor-α, inhibited the opening of mitochondrial permeability transition pore, and promoted nitric oxide production. Additionally, MHBFC caused a significant increase in PI3K, phosphorylation of Akt, mammalian target of rapamycin, and endothelial nitric oxide synthase, and a decrease in the expression of cleaved caspase-3, Beclin1, and conversion of microtubule-associated protein 1 light chain 3. However, the above functions of MHBFC were blocked by LY294002. These observations indicate that MHBFC plays a protective role against myocardial I/R injury by inhibiting apoptosis and excessive autophagy, which might be related to the activation of the PI3K-Akt signal pathway.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xuan</LastName>
            <ForeName>Feifei</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Guangxi Medical University, 22, Shuangyong Road, Nanning, 530021, Guangxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jian</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Guilin Medical University, Huan Cheng North 2nd Road, Guilin, 541004, Guangxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Xing</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Guangxi Medical University, 22, Shuangyong Road, Nanning, 530021, Guangxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Jianchun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Guangxi Medical University, 22, Shuangyong Road, Nanning, 530021, Guangxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiao</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Guangxi Medical University, 22, Shuangyong Road, Nanning, 530021, Guangxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Wansu</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Guangxi Medical University, 22, Shuangyong Road, Nanning, 530021, Guangxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Juman</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Guangxi Medical University, 22, Shuangyong Road, Nanning, 530021, Guangxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Zhi</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Guangxi Medical University, 22, Shuangyong Road, Nanning, 530021, Guangxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Renbin</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Guangxi Medical University, 22, Shuangyong Road, Nanning, 530021, Guangxi, China. huangrenbin518@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cardiovasc Toxicol</MedlineTA>
        <NlmUniqueID>101135818</NlmUniqueID>
        <ISSNLinking>1530-7905</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C578356">17-methoxyl-7-hydroxy-benzene-furanchalcone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047188">Chalcones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D033681">Mitochondrial Membrane Transport Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000083162">Mitochondrial Permeability Transition Pore</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31C4KY9ESH</RegistryNumber>
          <NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.13.39</RegistryNumber>
          <NameOfSubstance UI="D052250">Nitric Oxide Synthase Type III</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.13.39</RegistryNumber>
          <NameOfSubstance UI="C496316">Nos3 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546845">mTOR protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.137</RegistryNumber>
          <NameOfSubstance UI="D058539">Phosphatidylinositol 3-Kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.3.2</RegistryNumber>
          <NameOfSubstance UI="D052279">Creatine Kinase, MB Form</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047188" MajorTopicYN="N">Chalcones</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D052279" MajorTopicYN="N">Creatine Kinase, MB Form</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019610" MajorTopicYN="N">Cytoprotection</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008929" MajorTopicYN="N">Mitochondria, Heart</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D033681" MajorTopicYN="N">Mitochondrial Membrane Transport Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000083162" MajorTopicYN="N">Mitochondrial Permeability Transition Pore</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015428" MajorTopicYN="N">Myocardial Reperfusion Injury</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032383" MajorTopicYN="N">Myocytes, Cardiac</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D052250" MajorTopicYN="N">Nitric Oxide Synthase Type III</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058539" MajorTopicYN="N">Phosphatidylinositol 3-Kinase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081082" MajorTopicYN="N">Phosphoinositide-3 Kinase Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">Autophagy</Keyword>
        <Keyword MajorTopicYN="N">Ischemia/reperfusion</Keyword>
        <Keyword MajorTopicYN="N">MHBFC</Keyword>
        <Keyword MajorTopicYN="N">PI3K&#x2013;Akt</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>1</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>10</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26792585</ArticleId>
        <ArticleId IdType="doi">10.1007/s12012-016-9358-y</ArticleId>
        <ArticleId IdType="pii">10.1007/s12012-016-9358-y</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26686468</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>12</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2016</Year>
        <Month>12</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-4596</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>91</Volume>
            <PubDate>
              <Year>2016</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Free radical biology &amp; medicine</Title>
          <ISOAbbreviation>Free Radic Biol Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Enhanced targeting of mitochondrial peroxide defense by the combined use of thiosemicarbazones and inhibitors of thioredoxin reductase.</ArticleTitle>
        <Pagination>
          <StartPage>81</StartPage>
          <EndPage>92</EndPage>
          <MedlinePgn>81-92</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.freeradbiomed.2015.12.008</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0891-5849(15)01150-8</ELocationID>
        <Abstract>
          <AbstractText>Peroxiredoxin-3 (Prx3) accounts for about 90% of mitochondrial peroxidase activity, and its marked upregulation in many cancers is important for cell survival. Prx3 oxidation can critically alter peroxide signaling and defense and can be a seminal event in promoting cell death. Here it is shown that this mechanism can be exploited pharmacologically by combinations of clinically available drugs that compromise Prx3 function in different ways. Clinically relevant levels of the thiosemicarbazone iron chelators triapine (Tp) and 2,2'-Dipyridyl-N,N-dimethylsemicarbazone (Dp44mT) promote selective oxidation of mitochondrial Prx3, but not cytosolic Prx1, in multiple human lung and ovarian cancer lines. Decreased cell survival closely correlates with Prx3 oxidation. However, Prx3 oxidation is not merely an indicator of cell death as cytotoxic concentrations of cisplatin do not cause Prx3 oxidation. The siRNA-mediated suppression of either Prx3 or thioredoxin-2, which supports Prx3, enhances Tp's cytotoxicity. Tp-mediated Prx3 oxidation is driven by enhanced peroxide generation, but not by nitric oxide. Many tumors overexpress thioredoxin reductase (TrxR) which supports Prx activity. Direct inhibitors of TrxR (e.g. auranofin, cisplatin) markedly enhanced Tp's cytotoxicity, and auranofin enhanced Prx3 oxidation by low dose Tp. Together, these results support an important role for Prx3 oxidation in the cytotoxicity of Tp, and demonstrate that TrxR inhibitors can significantly enhance Tp's cytotoxicity. Thiosemicarbazone-based regimens could prove effective for targeting Prx3 in a variety of cancers.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Myers</LastName>
            <ForeName>Charles R</ForeName>
            <Initials>CR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Free Radical Research Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA. Electronic address: cmyers@mcw.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Free Radic Biol Med</MedlineTA>
        <NlmUniqueID>8709159</NlmUniqueID>
        <ISSNLinking>0891-5849</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013882">Thiosemicarbazones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C539263">di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>143621-35-6</RegistryNumber>
          <NameOfSubstance UI="C078157">3-aminopyridine-2-carboxaldehyde thiosemicarbazone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.15</RegistryNumber>
          <NameOfSubstance UI="C516115">PRDX3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.11.1.15</RegistryNumber>
          <NameOfSubstance UI="D061105">Peroxiredoxin III</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.8.1.9</RegistryNumber>
          <NameOfSubstance UI="D013880">Thioredoxin-Disulfide Reductase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004354" MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061105" MajorTopicYN="N">Peroxiredoxin III</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013880" MajorTopicYN="N">Thioredoxin-Disulfide Reductase</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013882" MajorTopicYN="N">Thiosemicarbazones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Auranofin</Keyword>
        <Keyword MajorTopicYN="N">Cisplatin</Keyword>
        <Keyword MajorTopicYN="N">Peroxiredoxin-3</Keyword>
        <Keyword MajorTopicYN="N">Thioredoxin reductase</Keyword>
        <Keyword MajorTopicYN="N">Thiosemicarbazones</Keyword>
        <Keyword MajorTopicYN="N">Triapine</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>6</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26686468</ArticleId>
        <ArticleId IdType="doi">10.1016/j.freeradbiomed.2015.12.008</ArticleId>
        <ArticleId IdType="pii">S0891-5849(15)01150-8</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26580601</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>08</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2015</Year>
              <Month>Nov</Month>
              <Day>13</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Danusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells.</ArticleTitle>
        <Pagination>
          <StartPage>27228</StartPage>
          <EndPage>27251</EndPage>
          <MedlinePgn>27228-51</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms161126018</ELocationID>
        <Abstract>
          <AbstractText>Ovarian carcinoma (OC) is one of the most common gynecological malignancies, with a poor prognosis for patients at advanced stage. Danusertib (Danu) is a pan-inhibitor of the Aurora kinases with unclear anticancer effect and underlying mechanisms in OC treatment. This study aimed to examine the cancer cell killing effect and explore the possible mechanisms with a focus on proliferation, cell cycle progression, apoptosis, autophagy, and epithelial to mesenchymal transition (EMT) in human OC cell lines C13 and A2780cp. The results showed that Danu remarkably inhibited cell proliferation, induced apoptosis and autophagy, and suppressed EMT in both cell lines. Danu arrested cells in G2/M phase and led to an accumulation of polyploidy through the regulation of the expression key cell cycle modulators. Danu induced mitochondria-dependent apoptosis and autophagy in dose and time-dependent manners. Danu suppressed PI3K/Akt/mTOR signaling pathway, evident from the marked reduction in the phosphorylation of PI3K/Akt/mTOR, contributing to the autophagy inducing effect of Danu in both cell lines. In addition, Danu inhibited EMT. In aggregate, Danu exerts potent inducing effect on cell cycle arrest, apoptosis, and autophagy, but exhibits a marked inhibitory effect on EMT. PI3K/Akt/mTOR signaling pathway contributes, partially, to the cancer cell killing effect of Danu in C13 and A2780cp cells.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zi</LastName>
            <ForeName>Dan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China. danzi@health.usf.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL 33612, USA. danzi@health.usf.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Zhi-Wei</ForeName>
            <Initials>ZW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL 33612, USA. zzhou1@health.usf.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Ying-Jie</ForeName>
            <Initials>YJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China. yyjgmc@outlook.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Gynecologic Oncology Surgery, Affiliated Cancer Hospital of Guizhou Medical University, Guiyang 550002, China. yyjgmc@outlook.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Lin</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China. hlgmc@outlook.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Zun-Lun</ForeName>
            <Initials>ZL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China. zzlgmc@outlook.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Shu-Ming</ForeName>
            <Initials>SM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Xiaolan Hospital, Southern Medical University, Zhongshan 528415, China. smhxlh@outlook.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Zhi-Xu</ForeName>
            <Initials>ZX</Initials>
            <AffiliationInfo>
              <Affiliation>Guizhou Provincial Key Laboratory for Regenerative Medicine, Stem Cell and Tissue Engineering Research Center &amp; Sino-US Joint Laboratory for Medical Sciences, Guizhou Medical University, Guiyang 550004, China. hzx@gmc.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Shu-Feng</ForeName>
            <Initials>SF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL 33612, USA. szhou@health.usf.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>11</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>M3X659D0FY</RegistryNumber>
          <NameOfSubstance UI="C523797">danusertib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059447" MajorTopicYN="N">Cell Cycle Checkpoints</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">apoptosis</Keyword>
        <Keyword MajorTopicYN="N">autophagy</Keyword>
        <Keyword MajorTopicYN="N">cell cycle</Keyword>
        <Keyword MajorTopicYN="N">danusertib</Keyword>
        <Keyword MajorTopicYN="N">epithelial to mesenchymal transition</Keyword>
        <Keyword MajorTopicYN="N">ovarian cancer</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>8</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2015</Year>
          <Month>11</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>11</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>11</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>11</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>8</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26580601</ArticleId>
        <ArticleId IdType="pmc">PMC4661876</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms161126018</ArticleId>
        <ArticleId IdType="pii">ijms161126018</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. GLOBOCAN; Lyon, France: 2013.</Citation>
        </Reference>
        <Reference>
          <Citation>Howlader N., Noone A.M., Krapcho M., Garshell J., Miller D., Altekruse S.F., Kosary C.L., Yu M., Ruhl J., Tatalovich Z., et al., editors. SEER Cancer Statistics Review, 1975&#x2013;2012. National Cancer Institute; Bethesda, MD, USA: 2015.</Citation>
        </Reference>
        <Reference>
          <Citation>Group . United States Cancer Statistics: 1999&#x2013;2011 Incidence and Mortality Web-based Report. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; Atlanta, Georgia: 2014.</Citation>
        </Reference>
        <Reference>
          <Citation>Lowe K.A., Chia V.M., Taylor A., O&#x2019;Malley C., Kelsh M., Mohamed M., Mowat F.S., Goff B. An international assessment of ovarian cancer incidence and mortality. Gynecol. Oncol. 2013;130:107&#x2013;114. doi: 10.1016/j.ygyno.2013.03.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2013.03.026</ArticleId>
            <ArticleId IdType="pubmed">23558050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jayson G.C., Kohn E.C., Kitchener H.C., Ledermann J.A. Ovarian cancer. Lancet. 2014;384:1376&#x2013;1388. doi: 10.1016/S0140-6736(13)62146-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(13)62146-7</ArticleId>
            <ArticleId IdType="pubmed">24767708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis A., Tinker A.V., Friedlander M. &#x201c;Platinum resistant&#x201d; ovarian cancer: What is it, who to treat and how to measure benefit? Gynecol. Oncol. 2014;133:624&#x2013;631. doi: 10.1016/j.ygyno.2014.02.038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2014.02.038</ArticleId>
            <ArticleId IdType="pubmed">24607285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nigg E.A. Mitotic kinases as regulators of cell division and its checkpoints. Nature reviews. Mol. Cell. Biol. 2001;2:21&#x2013;32. doi: 10.1038/35048096.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35048096</ArticleId>
            <ArticleId IdType="pubmed">11413462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu J., Bian M., Jiang Q., Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol. Cancer Res. 2007;5:1&#x2013;10. doi: 10.1158/1541-7786.MCR-06-0208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-06-0208</ArticleId>
            <ArticleId IdType="pubmed">17259342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keen N., Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer. 2004;4:927&#x2013;936. doi: 10.1038/nrc1502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1502</ArticleId>
            <ArticleId IdType="pubmed">15573114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swanton C. Cell-cycle targeted therapies. Lancet. Oncol. 2004;5:27&#x2013;36. doi: 10.1016/S1470-2045(03)01321-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(03)01321-4</ArticleId>
            <ArticleId IdType="pubmed">14700606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kollareddy M., Zheleva D., Dzubak P., Brahmkshatriya P.S., Lepsik M., Hajduch M. Aurora kinase inhibitors: Progress towards the clinic. Investig. New Drugs. 2012;30:2411&#x2013;2432. doi: 10.1007/s10637-012-9798-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10637-012-9798-6</ArticleId>
            <ArticleId IdType="pmc">PMC3484309</ArticleId>
            <ArticleId IdType="pubmed">22350019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lok W., Klein R.Q., Saif M.W. Aurora kinase inhibitors as anti-cancer therapy. Anti-Cancer Drugs. 2010;21:339&#x2013;350. doi: 10.1097/CAD.0b013e3283350dd1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CAD.0b013e3283350dd1</ArticleId>
            <ArticleId IdType="pubmed">20016367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carpinelli P., Ceruti R., Giorgini M.L., Cappella P., Gianellini L., Croci V., Degrassi A., Texido G., Rocchetti M., Vianello P., et al. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol. Cancer Ther. 2007;6:3158&#x2013;3168. doi: 10.1158/1535-7163.MCT-07-0444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-07-0444</ArticleId>
            <ArticleId IdType="pubmed">18089710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meulenbeld H.J., Mathijssen R.H., Verweij J., de Wit R., de Jonge M.J. Danusertib, an aurora kinase inhibitor. Expert Opin. Investig. Drugs. 2012;21:383&#x2013;393. doi: 10.1517/13543784.2012.652303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/13543784.2012.652303</ArticleId>
            <ArticleId IdType="pubmed">22242557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gontarewicz A., Brummendorf T.H. Danusertib (formerly PHA-739358)&#x2014;A novel combined pan-aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor. Small Mol. Oncol. 2010;184:199&#x2013;214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20072840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schoffski P., Besse B., Gauler T., de Jonge M.J., Scambia G., Santoro A., Davite C., Jannuzzo M.G., Petroccione A., Delord J.P. Efficacy and safety of biweekly intravenous administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: A multi-tumour, multi-institutional phase II study. Ann. Oncol. 2015;26:598&#x2013;607.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25488684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan C.X., Zhou Z.W., Yang Y.X., He Z.X., Zhang X., Wang D., Yang T., Pan S.Y., Chen X.W., Zhou S.F. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells. Drug Des. Dev. Ther. 2015;9:1293&#x2013;1318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4354435</ArticleId>
            <ArticleId IdType="pubmed">25767376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J.P., Yang Y.X., Liu Q.L., Zhou Z.W., Pan S.T., He Z.X., Zhang X., Yang T., Pan S.Y., Duan W., et al. The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells. Drug Des. Dev. Ther. 2015;9:1027&#x2013;1062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4338784</ArticleId>
            <ArticleId IdType="pubmed">25733818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu X., Moscinski L.C. Cdc2: A monopotent or pluripotent CDK? Cell Prolif. 2011;44:205&#x2013;211. doi: 10.1111/j.1365-2184.2011.00753.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2184.2011.00753.x</ArticleId>
            <ArticleId IdType="pmc">PMC6496858</ArticleId>
            <ArticleId IdType="pubmed">21535261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warfel N.A., El-Deiry W.S. p21WAF1 and tumourigenesis: 20 years after. Curr. Opin. Oncol. 2013;25:52&#x2013;58. doi: 10.1097/CCO.0b013e32835b639e.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CCO.0b013e32835b639e</ArticleId>
            <ArticleId IdType="pubmed">23159848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christensen M.E., Jansen E.S., Sanchez W., Waterhouse N.J. Flow cytometry based assays for the measurement of apoptosis-associated mitochondrial membrane depolarisation and cytochrome c release. Methods. 2013;61:138&#x2013;145. doi: 10.1016/j.ymeth.2013.03.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ymeth.2013.03.020</ArticleId>
            <ArticleId IdType="pubmed">23545197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132:27&#x2013;42. doi: 10.1016/j.cell.2007.12.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2007.12.018</ArticleId>
            <ArticleId IdType="pmc">PMC2696814</ArticleId>
            <ArticleId IdType="pubmed">18191218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manning B.D., Cantley L.C. AKT/PKB signaling: Navigating downstream. Cell. 2007;129:1261&#x2013;1274. doi: 10.1016/j.cell.2007.06.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2007.06.009</ArticleId>
            <ArticleId IdType="pmc">PMC2756685</ArticleId>
            <ArticleId IdType="pubmed">17604717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamouille S., Xu J., Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 2014;15:178&#x2013;196. doi: 10.1038/nrm3758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm3758</ArticleId>
            <ArticleId IdType="pmc">PMC4240281</ArticleId>
            <ArticleId IdType="pubmed">24556840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agarwal R., Kaye S.B. Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer. 2003;3:502&#x2013;516. doi: 10.1038/nrc1123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1123</ArticleId>
            <ArticleId IdType="pubmed">12835670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naora H., Montell D.J. Ovarian cancer metastasis: Integrating insights from disparate model organisms. Nat. Rev. Cancer. 2005;5:355&#x2013;366. doi: 10.1038/nrc1611.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc1611</ArticleId>
            <ArticleId IdType="pubmed">15864277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hennessy B.T., Coleman R.L., Markman M. Ovarian cancer. Lancet. 2009;374:1371&#x2013;1382. doi: 10.1016/S0140-6736(09)61338-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(09)61338-6</ArticleId>
            <ArticleId IdType="pubmed">19793610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ledermann J.A., Raja F.A., Fotopoulou C., Gonzalez-Martin A., Colombo N., Sessa C., Group E.G.W. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013;24:24&#x2013;32. doi: 10.1093/annonc/mdt333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdt333</ArticleId>
            <ArticleId IdType="pubmed">24078660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609&#x2013;615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3163504</ArticleId>
            <ArticleId IdType="pubmed">21720365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiedemeyer W.R., Beach J.A., Karlan B.Y. Reversing platinum resistance in high-grade serous ovarian carcinoma: Targeting BRCA and the homologous recombination system. Front. Oncol. 2014;4:34. doi: 10.3389/fonc.2014.00034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2014.00034</ArticleId>
            <ArticleId IdType="pmc">PMC3939430</ArticleId>
            <ArticleId IdType="pubmed">24624361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., Scott C.L., Meier W., Shapira-Frommer R., Safra T., et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852&#x2013;861. doi: 10.1016/S1470-2045(14)70228-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(14)70228-1</ArticleId>
            <ArticleId IdType="pubmed">24882434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raja F.A., Chopra N., Ledermann J.A. Optimal first-line treatment in ovarian cancer. Ann. Oncol. 2012;23:118&#x2013;127. doi: 10.1093/annonc/mds315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mds315</ArticleId>
            <ArticleId IdType="pubmed">22987945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markman M. Maintenance chemotherapy in the management of epithelial ovarian cancer. Cancer Metastasis Rev. 2015;34:11&#x2013;17. doi: 10.1007/s10555-014-9537-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10555-014-9537-x</ArticleId>
            <ArticleId IdType="pubmed">25566684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bayliss R., Sardon T., Vernos I., Conti E. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol. Cell. 2003;12:851&#x2013;862. doi: 10.1016/S1097-2765(03)00392-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1097-2765(03)00392-7</ArticleId>
            <ArticleId IdType="pubmed">14580337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crosio C., Fimia G.M., Loury R., Kimura M., Okano Y., Zhou H., Sen S., Allis C.D., Sassone-Corsi P. Mitotic phosphorylation of histone H3: Spatio-temporal regulation by mammalian Aurora kinases. Mol. Cell. Biol. 2002;22:874&#x2013;885. doi: 10.1128/MCB.22.3.874-885.2002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.22.3.874-885.2002</ArticleId>
            <ArticleId IdType="pmc">PMC133550</ArticleId>
            <ArticleId IdType="pubmed">11784863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ducat D., Zheng Y. Aurora kinases in spindle assembly and chromosome segregation. Exp. Cell Res. 2004;301:60&#x2013;67. doi: 10.1016/j.yexcr.2004.08.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexcr.2004.08.016</ArticleId>
            <ArticleId IdType="pubmed">15501446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gautschi O., Heighway J., Mack P.C., Purnell P.R., Lara P.N., Jr., Gandara D.R. Aurora kinases as anticancer drug targets. Clin. Cancer Res. 2008;14:1639&#x2013;1648. doi: 10.1158/1078-0432.CCR-07-2179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-07-2179</ArticleId>
            <ArticleId IdType="pubmed">18347165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katayama H., Brinkley W.R., Sen S. The Aurora kinases: Role in cell transformation and tumorigenesis. Cancer Metastasis Rev. 2003;22:451&#x2013;464. doi: 10.1023/A:1023789416385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/A:1023789416385</ArticleId>
            <ArticleId IdType="pubmed">12884918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benten D., Keller G., Quaas A., Schrader J., Gontarewicz A., Balabanov S., Braig M., Wege H., Moll J., Lohse A.W., et al. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia. 2009;11:934&#x2013;944. doi: 10.1593/neo.09664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1593/neo.09664</ArticleId>
            <ArticleId IdType="pmc">PMC2735802</ArticleId>
            <ArticleId IdType="pubmed">19724687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie L., Kassner M., Munoz R.M., Que Q.Q., Kiefer J., Zhao Y., Mousses S., Yin H.H., von Hoff D.D., Han H. Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors. Biochem. Pharmacol. 2012;83:452&#x2013;461. doi: 10.1016/j.bcp.2011.11.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2011.11.005</ArticleId>
            <ArticleId IdType="pmc">PMC3265162</ArticleId>
            <ArticleId IdType="pubmed">22100984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abbas T., Dutta A. p21 in cancer: Intricate networks and multiple activities. Nat. Rev. Cancer. 2009;9:400&#x2013;414. doi: 10.1038/nrc2657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2657</ArticleId>
            <ArticleId IdType="pmc">PMC2722839</ArticleId>
            <ArticleId IdType="pubmed">19440234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aylon Y., Oren M. Living with p53, dying of p53. Cell. 2007;130:597&#x2013;600. doi: 10.1016/j.cell.2007.08.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2007.08.005</ArticleId>
            <ArticleId IdType="pubmed">17719538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang D., Lotze M.T., Kang R., Zeh H.J. Apoptosis promotes early tumorigenesis. Oncogene. 2011;30:1851&#x2013;1854. doi: 10.1038/onc.2010.573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2010.573</ArticleId>
            <ArticleId IdType="pubmed">21151175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashkenazi A. Targeting the extrinsic apoptotic pathway in cancer: Lessons learned and future directions. J. Clin. Investing. 2015;125:487&#x2013;489. doi: 10.1172/JCI80420.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI80420</ArticleId>
            <ArticleId IdType="pmc">PMC4319431</ArticleId>
            <ArticleId IdType="pubmed">25642709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor R.C., Cullen S.P., Martin S.J. Apoptosis: Controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol. 2008;9:231&#x2013;241. doi: 10.1038/nrm2312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm2312</ArticleId>
            <ArticleId IdType="pubmed">18073771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eskelinen E.L. The dual role of autophagy in cancer. Curr. Opin. Pharmacol. 2011;11:294&#x2013;300. doi: 10.1016/j.coph.2011.03.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.coph.2011.03.009</ArticleId>
            <ArticleId IdType="pubmed">21498118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klionsky D.J., Emr S.D. Autophagy as a regulated pathway of cellular degradation. Science. 2000;290:1717&#x2013;1721. doi: 10.1126/science.290.5497.1717.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.290.5497.1717</ArticleId>
            <ArticleId IdType="pmc">PMC2732363</ArticleId>
            <ArticleId IdType="pubmed">11099404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Denton D., Nicolson S., Kumar S. Cell death by autophagy: Facts and apparent artefacts. Cell Death Differ. 2012;19:87&#x2013;95. doi: 10.1038/cdd.2011.146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2011.146</ArticleId>
            <ArticleId IdType="pmc">PMC3252836</ArticleId>
            <ArticleId IdType="pubmed">22052193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Do T.V., Xiao F., Bickel L.E., Klein-Szanto A.J., Pathak H.B., Hua X., Howe C., O&#x2019;Brien S.W., Maglaty M., Ecsedy J.A., et al. Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion. Oncogene. 2014;33:539&#x2013;549. doi: 10.1038/onc.2012.632.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2012.632</ArticleId>
            <ArticleId IdType="pmc">PMC3640671</ArticleId>
            <ArticleId IdType="pubmed">23334327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodon J., Dienstmann R., Serra V., Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. 2013;10:143&#x2013;153. doi: 10.1038/nrclinonc.2013.10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2013.10</ArticleId>
            <ArticleId IdType="pubmed">23400000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polivka J., Jr., Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol. Ther. 2014;142:164&#x2013;175. doi: 10.1016/j.pharmthera.2013.12.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pharmthera.2013.12.004</ArticleId>
            <ArticleId IdType="pubmed">24333502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benjamin D., Colombi M., Moroni C., Hall M.N. Rapamycin passes the torch: A new generation of mTOR inhibitors. Nat. Rev. Drug Discov. 2011;10:868&#x2013;880. doi: 10.1038/nrd3531.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd3531</ArticleId>
            <ArticleId IdType="pubmed">22037041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Z., Yan S., Attayan N., Ramalingam S., Thiele C.J. Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma. Clin. Cancer Res. 2012;18:3603&#x2013;3615. doi: 10.1158/1078-0432.CCR-11-3321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-11-3321</ArticleId>
            <ArticleId IdType="pmc">PMC6693338</ArticleId>
            <ArticleId IdType="pubmed">22550167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petrich A.M., Leshchenko V., Kuo P.Y., Xia B., Thirukonda V.K., Ulahannan N., Gordon S., Fazzari M.J., Ye B.H., Sparano J.A., et al. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma. Clin. Cancer Res. 2012;18:2534&#x2013;2544. doi: 10.1158/1078-0432.CCR-11-1407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-11-1407</ArticleId>
            <ArticleId IdType="pmc">PMC3889476</ArticleId>
            <ArticleId IdType="pubmed">22338016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu S., Li S., Guo Z., Luo J., Ellis M.J., Ma C.X. Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models. Mol. Cancer Ther. 2013;12:1665&#x2013;1675. doi: 10.1158/1535-7163.MCT-13-0159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-13-0159</ArticleId>
            <ArticleId IdType="pmc">PMC3742690</ArticleId>
            <ArticleId IdType="pubmed">23689832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang J., Weinberg R.A. Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev. Cell. 2008;14:818&#x2013;829. doi: 10.1016/j.devcel.2008.05.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.devcel.2008.05.009</ArticleId>
            <ArticleId IdType="pubmed">18539112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704&#x2013;715. doi: 10.1016/j.cell.2008.03.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2008.03.027</ArticleId>
            <ArticleId IdType="pmc">PMC2728032</ArticleId>
            <ArticleId IdType="pubmed">18485877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta P.B., Fillmore C.M., Jiang G., Shapira S.D., Tao K., Kuperwasser C., Lander E.S. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 2011;146:633&#x2013;644. doi: 10.1016/j.cell.2011.07.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2011.07.026</ArticleId>
            <ArticleId IdType="pubmed">21854987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beavon I.R. The E-cadherin-catenin complex in tumour metastasis: Structure, function and regulation. Eur. Cancer. 2000;36:1607&#x2013;1620. doi: 10.1016/S0959-8049(00)00158-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0959-8049(00)00158-1</ArticleId>
            <ArticleId IdType="pubmed">10959047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu C.Y., Lin H.H., Tang M.J., Wang Y.K. Vimentin contributes to epithelial-mesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation. Oncotarget. 2015;6:15966&#x2013;15983. doi: 10.18632/oncotarget.3862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.3862</ArticleId>
            <ArticleId IdType="pmc">PMC4599250</ArticleId>
            <ArticleId IdType="pubmed">25965826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cannito S., Novo E., di Bonzo L.V., Busletta C., Colombatto S., Parola M. Epithelial-mesenchymal transition: From molecular mechanisms, redox regulation to implications in human health and disease. Antioxid. Redox Signal. 2010;12:1383&#x2013;1430. doi: 10.1089/ars.2009.2737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2009.2737</ArticleId>
            <ArticleId IdType="pubmed">19903090</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26549689</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>09</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-8057</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>420</Volume>
            <PubDate>
              <Year>2016</Year>
              <Month>Jan</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecular and cellular endocrinology</Title>
          <ISOAbbreviation>Mol Cell Endocrinol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Effects of orexin A on glucose metabolism in human hepatocellular carcinoma in vitro via PI3K/Akt/mTOR-dependent and -independent mechanism.</ArticleTitle>
        <Pagination>
          <StartPage>208</StartPage>
          <EndPage>216</EndPage>
          <MedlinePgn>208-16</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mce.2015.11.002</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0303-7207(15)30128-3</ELocationID>
        <Abstract>
          <AbstractText>Orexins are hypothalamic neuropeptides that regulate food intake, energy homeostasis, reward system and sleep/wakefulness states. The purpose of this study was to investigate the effects of orexin A on glucose metabolism in human hepatocellular carcinoma cell line, Hep3B, and determine the possible mechanisms. Hep3B cells were incubated with different concentrations of orexin A (10(-9)-10(-7) M) in vitro in the presence or absence of the orexin receptor 1 (OX1R) inhibitor (SB334867), Akt inhibitor (PF-04691502) and mammalian target of rapamycin (mTOR) inhibitor (temsirolimus). Subsequently, OX1R protein expression, glucose transporter 1 (GLUT1) expression, glucose uptake, the mRNA expression of lactate dehydrogenase (LDHA), pyruvate dehydrogenase kinase 1 (PDK1) and pyruvate dehydrogenase B (PDHB), lactate generation and mitochondrial pyruvate dehydrogenase (PDH) enzyme activity were measured. The activity of phosphoinositide 3-kinase (PI3K)/Akt/mTOR signaling was also determined. OX1R was expressed in hepatoma tissues and Hep3B cells. Stimulation of the Hep3B cells with orexin A resulted in a dose-dependent increase of GLUT1 expression and glucose uptake, which was associated with the activation of PI3K/Akt/mTOR pathway. Further, orexin A increased PDHB expression and PDH enzyme activity, decreased LDHA, PDK1 mRNA levels and lactate generation independent of PI3K/Akt/mTOR pathway. Our results demonstrated that orexin A directed the cellular metabolism towards mitochondrial glucose oxidation rather than glycolysis. These findings provide functional evidence of the metabolic actions of orexin A in hepatocellular carcinoma cells.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2015 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yuanyuan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, First Affiliated Hospital, China Medical University, Shenyang, Liaoning, 110001, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Yuyan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, First Affiliated Hospital, China Medical University, Shenyang, Liaoning, 110001, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Lei</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedic Surgery, First Affiliated Hospital, China Medical University, Shenyang, Liaoning, 110001, PR China. Electronic address: g572@sina.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>11</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>Mol Cell Endocrinol</MedlineTA>
        <NlmUniqueID>7500844</NlmUniqueID>
        <ISSNLinking>0303-7207</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051272">Glucose Transporter Type 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D064446">Orexin Receptors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000068797">Orexins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.1.1.27</RegistryNumber>
          <NameOfSubstance UI="D007770">L-Lactate Dehydrogenase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IY9XDZ35W2</RegistryNumber>
          <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002952" MajorTopicYN="N">Citric Acid Cycle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051272" MajorTopicYN="N">Glucose Transporter Type 1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006019" MajorTopicYN="N">Glycolysis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007770" MajorTopicYN="N">L-Lactate Dehydrogenase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064688" MajorTopicYN="N">Metabolic Flux Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064446" MajorTopicYN="N">Orexin Receptors</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068797" MajorTopicYN="N">Orexins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010085" MajorTopicYN="N">Oxidative Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Akt</Keyword>
        <Keyword MajorTopicYN="N">Glucose metabolism</Keyword>
        <Keyword MajorTopicYN="N">Hepatocellular carcinoma</Keyword>
        <Keyword MajorTopicYN="N">Orexin A</Keyword>
        <Keyword MajorTopicYN="N">Orexin receptor 1</Keyword>
        <Keyword MajorTopicYN="N">mTOR</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>8</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2015</Year>
          <Month>10</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>11</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>11</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>11</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26549689</ArticleId>
        <ArticleId IdType="doi">10.1016/j.mce.2015.11.002</ArticleId>
        <ArticleId IdType="pii">S0303-7207(15)30128-3</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26545383</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>12</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1532-2807</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Pathology oncology research : POR</Title>
          <ISOAbbreviation>Pathol Oncol Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>L744,832 and Everolimus Induce Cytotoxic and Cytostatic Effects in Non-Hodgkin Lymphoma Cells.</ArticleTitle>
        <Pagination>
          <StartPage>301</StartPage>
          <EndPage>309</EndPage>
          <MedlinePgn>301-9</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12253-015-9998-4</ELocationID>
        <Abstract>
          <AbstractText>Non-Hodgkin Lymphoma (NHL) constitutes a very heterogeneous group of diseases with different aggressiveness. Diffuse large B-cell lymphoma (DLBCL) and Burkitt's lymphoma (BL) are two clinically aggressive lymphomas from the germinal center, very heterogeneous and with different genetic signatures. Several intracellular pathways are involved in lymphomagenesis, being BCR/PI3K/AKT/mTOR and RAS/RAF pathways the most frequently ones. In this context the therapeutic potential of a mTOR inhibitor--everolimus--and a RAS/RAF pathway inhibitor--L744,832--was evaluated in two NHL cell lines. Farage and Raji cells were cultured in the absence and presence of several concentrations of everolimus and L744,832 in monotherapy and in combination with each other, as well as in association with the conventional chemotherapy drug vincristine. Our results show that everolimus and L744,832 induce antiproliferative and cytotoxic effect in a time-, dose-, and cell line-dependent manner, inducing cell death mainly by apoptosis. A potentiation effect was observed when the drugs were used in combination. In conclusion, the results suggest that everolimus and L744,832, alone or in combination, could provide therapeutic benefits in these subtypes of NHL.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mendes</LastName>
            <ForeName>José</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>University Clinic of Hematology and Applied Molecular Biology, Faculty of Medicine University of Coimbra - FMUC, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gonçalves</LastName>
            <ForeName>Ana Cristina</ForeName>
            <Initials>AC</Initials>
            <AffiliationInfo>
              <Affiliation>University Clinic of Hematology and Applied Molecular Biology, Faculty of Medicine University of Coimbra - FMUC, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Investigation on Environment Genetic and Oncobiology - CIMAGO, FMUC, Coimbra, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Neuroscience and Cell Biology - CNC.IBILI, University of Coimbra, Coimbra, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alves</LastName>
            <ForeName>Raquel</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>University Clinic of Hematology and Applied Molecular Biology, Faculty of Medicine University of Coimbra - FMUC, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Investigation on Environment Genetic and Oncobiology - CIMAGO, FMUC, Coimbra, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Neuroscience and Cell Biology - CNC.IBILI, University of Coimbra, Coimbra, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jorge</LastName>
            <ForeName>Joana</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>University Clinic of Hematology and Applied Molecular Biology, Faculty of Medicine University of Coimbra - FMUC, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Investigation on Environment Genetic and Oncobiology - CIMAGO, FMUC, Coimbra, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pires</LastName>
            <ForeName>Ana</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>University Clinic of Hematology and Applied Molecular Biology, Faculty of Medicine University of Coimbra - FMUC, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Investigation on Environment Genetic and Oncobiology - CIMAGO, FMUC, Coimbra, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ribeiro</LastName>
            <ForeName>Ana</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>University Clinic of Hematology and Applied Molecular Biology, Faculty of Medicine University of Coimbra - FMUC, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sarmento-Ribeiro</LastName>
            <ForeName>Ana Bela</ForeName>
            <Initials>AB</Initials>
            <AffiliationInfo>
              <Affiliation>University Clinic of Hematology and Applied Molecular Biology, Faculty of Medicine University of Coimbra - FMUC, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal. absarmento@fmed.uc.pt.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Investigation on Environment Genetic and Oncobiology - CIMAGO, FMUC, Coimbra, Portugal. absarmento@fmed.uc.pt.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Neuroscience and Cell Biology - CNC.IBILI, University of Coimbra, Coimbra, Portugal. absarmento@fmed.uc.pt.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Clinical Hematology Department, Centro Hospitalar Universitário de Coimbra (CHUC), Coimbra, Portugal. absarmento@fmed.uc.pt.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>11</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Pathol Oncol Res</MedlineTA>
        <NlmUniqueID>9706087</NlmUniqueID>
        <ISSNLinking>1219-4956</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054697">Cytostatic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9HW64Q8G6G</RegistryNumber>
          <NameOfSubstance UI="D000068338">Everolimus</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.5.1.29</RegistryNumber>
          <NameOfSubstance UI="D051231">Farnesyltranstransferase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054697" MajorTopicYN="N">Cytostatic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068338" MajorTopicYN="N">Everolimus</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051231" MajorTopicYN="N">Farnesyltranstransferase</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008228" MajorTopicYN="N">Lymphoma, Non-Hodgkin</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">Burkitt&#x2019;s lymphoma</Keyword>
        <Keyword MajorTopicYN="N">Diffuse Large B-cell Lymphoma</Keyword>
        <Keyword MajorTopicYN="N">Everolimus</Keyword>
        <Keyword MajorTopicYN="N">L744,832</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>2</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>10</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>11</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>11</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>12</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26545383</ArticleId>
        <ArticleId IdType="doi">10.1007/s12253-015-9998-4</ArticleId>
        <ArticleId IdType="pii">10.1007/s12253-015-9998-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Semin Cancer Biol. 2009 Dec;19(6):351-65</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19619654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell Cycle. 2005 Nov;4(11):1540-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16205124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Cell Biol. 1990 May;110(5):1489-99</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2335559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>FEBS Lett. 1997 Sep 1;414(1):65-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9305733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Oncol. 2009 Jan 10;27(2):193-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19047305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Br J Cancer. 2004 Oct 18;91(8):1420-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15365568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anticancer Res. 2012 Mar;32(3):831-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22399601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood Rev. 2009 Jan;23(1):11-23</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18620786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood Cells Mol Dis. 2015 Oct;55(3):255-65</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26227856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet. 2012 Sep 1;380(9844):848-57</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22835603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncogene. 2006 Oct 16;25(48):6436-46</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17041628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood. 2004 Dec 15;104(13):4181-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15304393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Cell Physiol. 2000 Mar;182(3):311-22</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10653597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hematology Am Soc Hematol Educ Program. 2002;:241-62</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12446426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Semin Cancer Biol. 2013 Dec;23(6):410-21</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24060900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Res. 2003 Sep 15;63(18):5656-68</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14522880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncologist. 2005 Sep;10 (8):565-78</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16177281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell Res. 2007 Aug;17(8):666-81</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17680028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Lymphoma Myeloma. 2009;9 Suppl 3:S231-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19778846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet Oncol. 2004 Jun;5(6):341-53</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15172354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2010 Apr 15;362(15):1417-29</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20393178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neoplasia. 2000 May-Jun;2(3):261-72</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10935512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet Oncol. 2010 Nov;11(11):1074-85</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21051020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pharmacol Ther. 2014 May;142(2):164-75</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24333502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stem Cells. 2006 May;24(5):1174-84</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16410383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Semin Diagn Pathol. 2011 May;28(2):167-77</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21842702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood. 2005 Sep 15;106(6):1911-23</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15802530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2010 Mar 1;16(5):1368-72</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20179227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nature. 2004 Mar 18;428(6980):332-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15029198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hematology Am Soc Hematol Educ Program. 2006;:178-84</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17124058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Target Oncol. 2011 Mar;6(1):53-61</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21499765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2000 Jun;6(6):2318-25</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10873082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Cell. 2012 Aug 14;22(2):167-79</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22897848</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26403635</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>08</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2045-2322</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>5</Volume>
            <PubDate>
              <Year>2015</Year>
              <Month>Sep</Month>
              <Day>25</Day>
            </PubDate>
          </JournalIssue>
          <Title>Scientific reports</Title>
          <ISOAbbreviation>Sci Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations.</ArticleTitle>
        <Pagination>
          <StartPage>13891</StartPage>
          <MedlinePgn>13891</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">13891</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/srep13891</ELocationID>
        <Abstract>
          <AbstractText>Drug resistance in Plasmodium parasites is a constant threat. Novel therapeutics, especially new drug combinations, must be identified at a faster rate. In response to the urgent need for new antimalarial drug combinations we screened a large collection of approved and investigational drugs, tested 13,910 drug pairs, and identified many promising antimalarial drug combinations. The activity of known antimalarial drug regimens was confirmed and a myriad of new classes of positively interacting drug pairings were discovered. Network and clustering analyses reinforced established mechanistic relationships for known drug combinations and identified several novel mechanistic hypotheses. From eleven screens comprising &gt;4,600 combinations per parasite strain (including duplicates) we further investigated interactions between approved antimalarials, calcium homeostasis modulators, and inhibitors of phosphatidylinositide 3-kinases (PI3K) and the mammalian target of rapamycin (mTOR). These studies highlight important targets and pathways and provide promising leads for clinically actionable antimalarial therapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mott</LastName>
            <ForeName>Bryan T</ForeName>
            <Initials>BT</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eastman</LastName>
            <ForeName>Richard T</ForeName>
            <Initials>RT</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guha</LastName>
            <ForeName>Rajarshi</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sherlach</LastName>
            <ForeName>Katy S</ForeName>
            <Initials>KS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Georgetown University, 37th and O St., NW, Washington, DC.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Siriwardana</LastName>
            <ForeName>Amila</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Georgetown University, 37th and O St., NW, Washington, DC.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shinn</LastName>
            <ForeName>Paul</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McKnight</LastName>
            <ForeName>Crystal</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Michael</LastName>
            <ForeName>Sam</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lacerda-Queiroz</LastName>
            <ForeName>Norinne</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Paresma R</ForeName>
            <Initials>PR</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Khine</LastName>
            <ForeName>Pwint</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Hongmao</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kasbekar</LastName>
            <ForeName>Monica</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aghdam</LastName>
            <ForeName>Nima</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Georgetown University, 37th and O St., NW, Washington, DC.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fontaine</LastName>
            <ForeName>Shaun D</ForeName>
            <Initials>SD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Chemistry, Small Molecule Discovery Center, University of California, San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Dongbo</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mierzwa</LastName>
            <ForeName>Tim</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mathews-Griner</LastName>
            <ForeName>Lesley A</ForeName>
            <Initials>LA</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ferrer</LastName>
            <ForeName>Marc</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Renslo</LastName>
            <ForeName>Adam R</ForeName>
            <Initials>AR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Chemistry, Small Molecule Discovery Center, University of California, San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Inglese</LastName>
            <ForeName>James</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>National Human Genome Research Institute, National Institutes of Health, Bethesda, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yuan</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Roepe</LastName>
            <ForeName>Paul D</ForeName>
            <Initials>PD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Georgetown University, 37th and O St., NW, Washington, DC.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, Cellular and Molecular Biology and Center for Infectious Diseases, Georgetown University, 37th and O St., NW, Washington, DC.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Su</LastName>
            <ForeName>Xin-Zhuan</ForeName>
            <Initials>XZ</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thomas</LastName>
            <ForeName>Craig J</ForeName>
            <Initials>CJ</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 AI105106</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U54CA143930</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <Agency>Intramural NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U54 CA143930</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AI111962</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>09</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Sci Rep</MedlineTA>
        <NlmUniqueID>101563288</NlmUniqueID>
        <ISSNLinking>2045-2322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SY7Q814VUP</RegistryNumber>
          <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004336" MajorTopicYN="N">Drug Antagonism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057166" MajorTopicYN="Y">High-Throughput Screening Assays</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008288" MajorTopicYN="N">Malaria</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000469" MajorTopicYN="N">parasitology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D021261" MajorTopicYN="Y">Parasitic Sensitivity Tests</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010588" MajorTopicYN="N">Phagosomes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081082" MajorTopicYN="N">Phosphoinositide-3 Kinase Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010961" MajorTopicYN="N">Plasmodium</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>4</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>8</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>9</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>9</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>8</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26403635</ArticleId>
        <ArticleId IdType="pmc">PMC4585899</ArticleId>
        <ArticleId IdType="doi">10.1038/srep13891</ArticleId>
        <ArticleId IdType="pii">srep13891</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>WHO. Guidelines for the treatment of malaria. World Health Organization: Geneva, Switzerland (2010).</Citation>
        </Reference>
        <Reference>
          <Citation>Nzila A. et al. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob. Agents Chemother. 44, 991&#x2013;996 (2000).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC89803</ArticleId>
            <ArticleId IdType="pubmed">10722502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuhn S., Gill M. J. &amp; Kain K. C. Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveller to west Africa. Am. J. Trop. Med. Hyg. 72, 407&#x2013;409 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15827276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sidhu A. B. S. et al. Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J. Infect. Dis. 194, 528&#x2013;535 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2978021</ArticleId>
            <ArticleId IdType="pubmed">16845638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan J. et al. Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. Science 33, 724&#x2013;729 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3396183</ArticleId>
            <ArticleId IdType="pubmed">21817045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sidhu A. B. S., Valderramos S. G. &amp; Fidock D. A. pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol. Microbiol. 57, 913&#x2013;926 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16091034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wongsrichanalai C. Artemisinin resistance or artemisinin-based combination therapy resistance? Lancet Infect. Dis. 13, 114&#x2013;115 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23347632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dondorp A. M. et al. Artemisinin resistance in Plasmodium falciparum malaria. New Eng. J. Med. 361, 455&#x2013;467 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3495232</ArticleId>
            <ArticleId IdType="pubmed">19641202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miotto O. et al. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat. Genet. 45, 648&#x2013;655 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3807790</ArticleId>
            <ArticleId IdType="pubmed">23624527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guiguemde W. A. et al. Chemical genetics of Plasmodium falciparum. Nature 465, 311&#x2013;315 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2874979</ArticleId>
            <ArticleId IdType="pubmed">20485428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rottmann M. et al. Spiroindolones, a potent compound class for the treatment of malaria. Science 329, 1175&#x2013;1180 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3050001</ArticleId>
            <ArticleId IdType="pubmed">20813948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H. et al. Validation of the Proteasome as a Therapeutic Target in Plasmodium Using an Epoxyketone Inhibitor with Parasite-Specific Toxicity. Chem. Biol. 19, 1535&#x2013;1545 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3529830</ArticleId>
            <ArticleId IdType="pubmed">23142757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>S Ramdhave A., Patel D., Ramya I., Nandave , M. &amp; S Kharkar , P. Targeting Heat Shock Protein 90 for Malaria. Mini-Rev. Med. Chem. 13, 1903&#x2013;1920 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24070209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weisman J. L. et al. Searching for new antimalarial therapeutics amongst known drugs. Chem. Biol. Drug. Des. 67, 409&#x2013;416 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1592519</ArticleId>
            <ArticleId IdType="pubmed">16882315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griner L. A. M. et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell&#x2013;like diffuse large B-cell lymphoma cells. Proc. Nat. Acad. Sci. 111, 2349&#x2013;2354 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3926026</ArticleId>
            <ArticleId IdType="pubmed">24469833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cokol M. et al. Systematic exploration of synergistic drug pairs. Mol. Syst. Biol. 7 1&#x2013;9 (2011).</Citation>
        </Reference>
        <Reference>
          <Citation>Alin M. H., Bj&#xf6;rkman A. &amp; Wernsdorfer W. Synergism of benflumetol and artemether in Plasmodium falciparum. Am. J. Trop. Med. Hyg. 61, 439&#x2013;445 (1999).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10497987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lukens A. K. et al. Diversity-oriented synthesis probe targets Plasmodium falciparum cytochrome b ubiquinone reduction site and synergies with oxidation site inhibitors. J. Infect. Dis. 11, 1097&#x2013;1103 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4354981</ArticleId>
            <ArticleId IdType="pubmed">25336726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia C. Calcium homeostasis and signaling in the blood-stage malaria parasite. Parasitol. Today 15, 488&#x2013;491 (1999).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10557149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cruz L. N. et al. Extracellular ATP triggers proteolysis and cytosolic Ca2+ rise in Plasmodium berghei and Plasmodium yoelii malaria parasites. Malar. J. 11, 69 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3358241</ArticleId>
            <ArticleId IdType="pubmed">22420332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lakshmanan V. et al. A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO J 24, 2294&#x2013;2305 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1173140</ArticleId>
            <ArticleId IdType="pubmed">15944738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin R. E. et al. Chloroquine transport via the malaria parasite&#x2019;s chloroquine resistance transporter. Science 325, 1680&#x2013;1682 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19779197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krogstad D. J. et al. Efflux of chloroquine from Plasmodium falciparum: mechanism of chloroquine resistance. Science 238, 1283&#x2013;1285 (1987).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3317830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baro N.K., Callaghan P. S. &amp; Roepe P. D. Function of resistance conferring Plasmodium falciparum chloroquine resistance transporter isoforms Biochemistry 52, 4242&#x2013;4249 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3703759</ArticleId>
            <ArticleId IdType="pubmed">23688277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Summers R. L. et al. Diverse mutational pathways converge on saturable chloroquine transport via the malaria parasite&#x2019;s chloroquine resistance transporter. Proc. Nat. Acad. Sci. 111, E1759&#x2013;E1767 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4035986</ArticleId>
            <ArticleId IdType="pubmed">24728833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cavanaugh A., Huang Y. &amp; Breitwieser G. E. Behind the curtain: cellular mechanisms for allosteric modulation of calcium-sensing receptors. Br. J. Pharmacol. 165, 1670&#x2013;1677 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3372821</ArticleId>
            <ArticleId IdType="pubmed">21470201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klonis N. et al. Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc. Nat. Acad. Sci. 108, 11405&#x2013;11410 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3136263</ArticleId>
            <ArticleId IdType="pubmed">21709259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Becker K. et al. Oxidative stress in malaria parasite-infected erythrocytes: host&#x2013;parasite interactions. Int. J. Parasitol. 34, 163&#x2013;189 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15037104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feissner R. F., Skalska J., Gaum W. E. &amp; Sheu S.-S. Crosstalk signaling between mitochondrial Ca2+ and ROS. Front. Biosci. 14, 1197 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2683671</ArticleId>
            <ArticleId IdType="pubmed">19273125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaviria D. et al. A Process Similar to Autophagy is Associated with Cytocidal Chloroquine Resistance in Plasmodium falciparum. PLoS One 8, e79059 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3835802</ArticleId>
            <ArticleId IdType="pubmed">24278114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hain A. U. &amp; Bosch J. Autophagy in Plasmodium, a multifunctional pathway? Comput. Struc. Biotech. J. 8, e201308002 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3962217</ArticleId>
            <ArticleId IdType="pubmed">24688742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomlins A. M. et al. Plasmodium falciparum Atg8 implicated in both autophagy and apicoplast formation. Autophagy 9, 9&#x2013;8 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24025672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanson K. K. et al. Torins are potent antimalarials that block replenishment of Plasmodium liver stage parasitophorous vacuole membrane proteins. Proc. Nat. Acad. Sci. 110, E2838&#x2013;E2847 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3725106</ArticleId>
            <ArticleId IdType="pubmed">23836641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun W. et al. Chemical signatures and new drug targets for gametocytocidal drug development. Sci. Rep. 4, 3743 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3894558</ArticleId>
            <ArticleId IdType="pubmed">24434750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vaid A., Ranjan R., Smythe W. A., Hoppe H. C. &amp; Sharma P. PfPI3K, a phosphatidylinositol-3 kinase from Plasmodium falciparum, is exported to the host erythrocyte and is involved in hemoglobin trafficking. Blood 115, 2500&#x2013;2507 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2918364</ArticleId>
            <ArticleId IdType="pubmed">20093402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitamura K. et al. Autophagy-related Atg8 localizes to the apicoplast of the human malaria parasite Plasmodium falciparum. PLoS One 7, e42977 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3416769</ArticleId>
            <ArticleId IdType="pubmed">22900071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ager A. L. Rodent malaria models. 231-232 (Springer-Verlag, 1984).</Citation>
        </Reference>
        <Reference>
          <Citation>Gorka A. P., Jacobs L. M. &amp; Roepe P. D. Cytostatic versus cytocidal profiling of quinoline drug combinations via modified fixed-ratio isobologram analysis. Malaria J. 12, 332 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3874740</ArticleId>
            <ArticleId IdType="pubmed">24044530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smilkstein M., Sriwilaijaroen N., Kelly J. X., Wilairat P. &amp; Riscoe M. Simple and inexpensive fluorecence-based technique for high-throughput antimalarial drug screening. Antimicrob. Agents Chemother. 48, 1803&#x2013;1806 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC400546</ArticleId>
            <ArticleId IdType="pubmed">15105138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett T. N. et al. Novel, rapid, and inexpensive cell-based quantification of antimalarial drug efficacy. Antimicrob. Agents Chemother. 48, 1807&#x2013;1810 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC400551</ArticleId>
            <ArticleId IdType="pubmed">15105139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelly J. X. et al. Discovery of dual function acridones as a new antimalarial chemotype. Nature 459, 270&#x2013;273 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8158239</ArticleId>
            <ArticleId IdType="pubmed">19357645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mott B. T. et al. Synthesis and antimalarial efficacy of two-carbon-linked, artemisinin-derived trioxane dimers in combination with known antimalarial drugs. J. Med. Chem. 56, 2630&#x2013;2641 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3630999</ArticleId>
            <ArticleId IdType="pubmed">23425037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Powles M. A. et al. MK-4815, a potential new oral agent for treatment of malaria. Antimicrob. Agents Chemother. 56, 2414&#x2013;2419 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3346645</ArticleId>
            <ArticleId IdType="pubmed">22314528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chou T.-C. &amp; Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enz. Regul. 22, 27&#x2013;55 (1984).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6382953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chou T.-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharm. Rev. 58, 621&#x2013;681 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16968952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chou T.-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440&#x2013;446 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20068163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prim R. C. Shortest connection networks and some generalizations. Bell Labs Tech. J. 36, 1389&#x2013;1401 (1957).</Citation>
        </Reference>
        <Reference>
          <Citation>Bennett T. N. et al. Drug resistance-associated pFCRT mutations confer decreased Plasmodium falciparum digestive vacuolar pH. Mol. Biochem. Parasitol. 133, 99&#x2013;144 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14668017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Desjardins R. E., Canfield C., Haynes J. &amp; Chulay J. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. 16, 710&#x2013;718 (1979).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC352941</ArticleId>
            <ArticleId IdType="pubmed">394674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paguio M. F., Bogle K. L. &amp; Roepe P. D. Plasmodium falciparum resistance to cytocidal versus cytostatic effects of chloroquine. Mol. Biochem. Parasitol. 178, 1&#x2013;6 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3101316</ArticleId>
            <ArticleId IdType="pubmed">21470564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gligorijevic B., Bennett T., McAllister R., Urbach J. S. &amp; Roepe P. D. Spinning disk confocal microscopy of live, intraerythrocytic malarial parasites. 2. Altered vacuolar volume regulation in drug resistant malaria. Biochemistry 45, 12411&#x2013;12423 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17029397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peters W. Chemotherapy and drug resistance in malaria. 2nd edn, (Academic Press, 1987).</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26325371</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>07</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1949-2553</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>6</Volume>
            <Issue>28</Issue>
            <PubDate>
              <Year>2015</Year>
              <Month>Sep</Month>
              <Day>22</Day>
            </PubDate>
          </JournalIssue>
          <Title>Oncotarget</Title>
          <ISOAbbreviation>Oncotarget</ISOAbbreviation>
        </Journal>
        <ArticleTitle>RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.</ArticleTitle>
        <Pagination>
          <StartPage>25281</StartPage>
          <EndPage>25294</EndPage>
          <MedlinePgn>25281-94</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.4634</ELocationID>
        <Abstract>
          <AbstractText>Ovarian cancer remains the leading cause of death in gynecologic malignancies partially because of resistance to chemotherapy. In the present study, we show that RY-2f, a chemically synthesized isoflavone analog, inhibited ovarian cancer cell proliferation, blocked cell cycle in G2/M phase and induced cellular apoptosis through up-regulation of p21, cyclin B1, Bax, Bad and cleaved-PARP, and suppression of cyclin A, CDK2 and Bcl-2. We also show that RY-2f could increase the chemotherapeutic efficacy of cisplatin as tested by cell proliferation and colony formation assays, indicating a synergistic effect of RY-2f and cisplatin. Mechanistic study revealed that RY-2f exerted the anti-tumor activities mainly through suppression of the PI3K/AKT/mTOR signaling. Finally, in vivo studies showed that RY-2f blocked the A2780-induced xenograft tumor growth without detectable toxicity in the animals at the therapeutic doses, and whereas RY-2f re-sensitized the cisplatin resistant cell line A2780/CDDP induced xenograft tumor to cisplatin treatment. Thus, RY-2f may be developed as a potential therapeutic agent to treat ovarian cancer.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Mingming</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Fudan University Shanghai Cancer Center; and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qi</LastName>
            <ForeName>Zihao</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Fudan University Shanghai Cancer Center; and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Bingzhi</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ren</LastName>
            <ForeName>Yi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Hanbin</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Gong</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Fudan University Shanghai Cancer Center; and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Central Laboratory, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai 200240, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Qian</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Oncotarget</MedlineTA>
        <NlmUniqueID>101532965</NlmUniqueID>
        <ISSNLinking>1949-2553</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001578">Benzopyrans</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006835">Hydrazones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007529">Isoflavones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000609206">N'-(7-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-4H-chromen-4-ylidene)acetohydrazide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.137</RegistryNumber>
          <NameOfSubstance UI="D058539">Phosphatidylinositol 3-Kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q20Q21Q62J</RegistryNumber>
          <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001578" MajorTopicYN="N">Benzopyrans</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059565" MajorTopicYN="N">G2 Phase Cell Cycle Checkpoints</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006835" MajorTopicYN="N">Hydrazones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007529" MajorTopicYN="N">Isoflavones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058539" MajorTopicYN="N">Phosphatidylinositol 3-Kinase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">PI3K/AKT inhibition</Keyword>
        <Keyword MajorTopicYN="N">anti-cancer agent</Keyword>
        <Keyword MajorTopicYN="N">cytotoxicity</Keyword>
        <Keyword MajorTopicYN="N">isoflavone analog</Keyword>
        <Keyword MajorTopicYN="N">ovarian cancer</Keyword>
      </KeywordList>
      <CoiStatement>CONFLICTS OF INTEREST. No potential conflicts of interests were disclosed.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>1</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>7</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>9</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>9</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>7</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26325371</ArticleId>
        <ArticleId IdType="pmc">PMC4694831</ArticleId>
        <ArticleId IdType="doi">10.18632/oncotarget.4634</ArticleId>
        <ArticleId IdType="pii">4634</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11&#x2013;30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23335087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mai PL, Wentzensen N, Greene MH. Challenges related to developing serum-based biomarkers for early ovarian cancer detection. Cancer Prev Res (Phila) 2011;4:303&#x2013;306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3077065</ArticleId>
            <ArticleId IdType="pubmed">21372029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist. 2002;7:20&#x2013;28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12324630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bast RC, Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9:415&#x2013;428.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2814299</ArticleId>
            <ArticleId IdType="pubmed">19461667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markman M. Pharmaceutical management of ovarian cancer : current status. Drugs. 2008;68:771&#x2013;789.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18416585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perego P, Gatti L, Righetti SC, Beretta GL, Carenini N, Corna E, Dal Bo L, Tinelli S, Colangelo D, Leone R, Apostoli P, Lombardi L, Beggiolin G, Piazzoni L, Zunino F. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells. Int J Cancer. 2003;105:617&#x2013;624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12740909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papadimitrakopoulou V. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J Thorac Oncol. 2012;7:1315&#x2013;1326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22648207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolin EM. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors. Cancer Lett. 2013;335:1&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23419523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazzoletti M, Broggini M. PI3K/AKT/mTOR inhibitors in ovarian cancer. Curr Med Chem. 2010;17:4433&#x2013;4447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21062259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol. 2014;4:64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3995050</ArticleId>
            <ArticleId IdType="pubmed">24782981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64:7678&#x2013;7681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15520168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ, Shih Ie M. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 2009;174:1597&#x2013;1601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2671248</ArticleId>
            <ArticleId IdType="pubmed">19349352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng Q, Xia C, Fang J, Rojanasakul Y, Jiang BH. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal. 2006;18:2262&#x2013;2271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16839745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI, Boyd J. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res. 2005;11:2875&#x2013;2878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15837735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Marco C, Rinaldo N, Bruni P, Malzoni C, Zullo F, Fabiani F, Losito S, Scrima M, Marino FZ, Franco R, Quintiero A, Agosti V, Viglietto G. Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma. PLoS One. 2013;8:e55362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3567053</ArticleId>
            <ArticleId IdType="pubmed">23408974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee S, Choi EJ, Jin C, Kim DH. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol. 2005;97:26&#x2013;34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15790433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kolasa IK, Rembiszewska A, Felisiak A, Ziolkowska-Seta I, Murawska M, Moes J, Timorek A, Dansonka-Mieszkowska A, Kupryjanczyk J. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol Ther. 2009;8:21&#x2013;26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19029838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carden CP, Stewart A, Thavasu P, Kipps E, Pope L, Crespo M, Miranda S, Attard G, Garrett MD, Clarke PA, Workman P, de Bono JS, Gore M, Kaye SB, Banerji U. The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. Mol Cancer Ther. 2012;11:1609&#x2013;1617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4630857</ArticleId>
            <ArticleId IdType="pubmed">22556379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H, Zeng J, Shen K. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer. Arch Gynecol Obstet. 2014;290:1067&#x2013;1078.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25086744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Westin SN, Herzog TJ, Coleman RL. Investigational agents in development for the treatment of ovarian cancer. Invest New Drugs. 2013;31:213&#x2013;229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4103697</ArticleId>
            <ArticleId IdType="pubmed">22661305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Kong D, Bao B, Ahmad A, Sarkar FH. Induction of cancer cell death by isoflavone: the role of multiple signaling pathways. Nutrients. 2011;3:877&#x2013;896.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3244210</ArticleId>
            <ArticleId IdType="pubmed">22200028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahmoud AM, Yang W, Bosland MC. Soy isoflavones and prostate cancer: a review of molecular mechanisms. J Steroid Biochem Mol Biol. 2014;140:116&#x2013;132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3962012</ArticleId>
            <ArticleId IdType="pubmed">24373791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Chen H. Genistein, an epigenome modifier during cancer prevention. Epigenetics. 2011;6:888&#x2013;891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21610327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein A, He X, Roche M, Mallett A, Duska L, Supko JG, Seiden MV. Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy. Gynecol Oncol. 2006;100:205&#x2013;209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16171852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paxton RJ, Garcia-Prieto C, Berglund M, Hernandez M, Hajek RA, Handy B, Brown J, Jones LA. A randomized parallel-group dietary study for stages II-IV ovarian cancer survivors. Gynecol Oncol. 2012;124:410&#x2013;416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3278555</ArticleId>
            <ArticleId IdType="pubmed">22119991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee AH, Su D, Pasalich M, Tang L, Binns CW, Qiu L. Soy and isoflavone intake associated with reduced risk of ovarian cancer in southern Chinese women. Nutr Res. 2014;34:302&#x2013;307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24774066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakauchi F, Khan MM, Mori M, Kubo T, Fujino Y, Suzuki S, Tokudome S, Tamakoshi A. Dietary habits and risk of ovarian cancer death in a large-scale cohort study (JACC study) in Japan. Nutr Cancer. 2007;57:138&#x2013;145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17571946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gossner G, Choi M, Tan L, Fogoros S, Griffith KA, Kuenker M, Liu JR. Genistein-induced apoptosis and autophagocytosis in ovarian cancer cells. Gynecol Oncol. 2007;105:23&#x2013;30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17234261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee JY, Kim HS, Song YS. Genistein as a Potential Anticancer Agent against Ovarian Cancer. J Tradit Complement Med. 2012;2:96&#x2013;104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3942921</ArticleId>
            <ArticleId IdType="pubmed">24716121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adjakly M, Ngollo M, Boiteux JP, Bignon YJ, Guy L, Bernard-Gallon D. Genistein and daidzein: different molecular effects on prostate cancer. Anticancer Res. 2013;33:39&#x2013;44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23267126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu MM, Chen XY, Huang YQ, Feng P, Guo YL, Yang G, Chen Y. Hybrids of phenylsulfonylfuroxan and coumarin as potent antitumor agents. J Med Chem. 2014;57:9343&#x2013;9356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25350923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1:2315&#x2013;2319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17406473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arafa el SA, Zhu Q, Barakat BM, Wani G, Zhao Q, El-Mahdy MA, Wani AA. Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. Cancer Res. 2009;69:8910&#x2013;8917.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3319094</ArticleId>
            <ArticleId IdType="pubmed">19903849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmad A, Biersack B, Li Y, Kong D, Bao B, Schobert R, Padhye SB, Sarkar FH. Deregulation of PI3K/Akt/mTOR signaling pathways by isoflavones and its implication in cancer treatment. Anticancer Agents Med Chem. 2013;13:1014&#x2013;1024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23272911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalai T, Kuppusamy ML, Balog M, Selvendiran K, Rivera BK, Kuppusamy P, Hideg K. Synthesis of N-substituted 3,5-bis(arylidene)-4-piperidones with high antitumor and antioxidant activity. J Med Chem. 2011;54:5414&#x2013;5421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21702507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cragg GM, Grothaus PG, Newman DJ. Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009;109:3012&#x2013;3043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19422222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta. 2013;1830:3670&#x2013;3695.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3672862</ArticleId>
            <ArticleId IdType="pubmed">23428572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oakes V, Wang W, Harrington B, Lee WJ, Beamish H, Chia KM, Pinder A, Goto H, Inagaki M, Pavey S, Gabrielli B. Cyclin A/Cdk2 regulates Cdh1 and claspin during late S/G2 phase of the cell cycle. Cell Cycle. 2014;13:3302&#x2013;3311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4615124</ArticleId>
            <ArticleId IdType="pubmed">25485510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evdokiou A, Raggatt LJ, Atkins GJ, Findlay DM. Calcitonin receptor-mediated growth suppression of HEK-293 cells is accompanied by induction of p21WAF1/CIP1 and G2/M arrest. Mol Endocrinol. 1999;13:1738&#x2013;1750.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10517675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi YH, Zhang L, Lee WH, Park KY. Genistein-induced G2/M arrest is associated with the inhibition of cyclin B1 and the induction of p21 in human breast carcinoma cells. Int J Oncol. 1998;13:391&#x2013;396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9664138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Souza CP, Ellem KA, Gabrielli BG. Centrosomal and cytoplasmic Cdc2/cyclin B1 activation precedes nuclear mitotic events. Exp Cell Res. 2000;257:11&#x2013;21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10854050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishidate T, Elewa A, Kim S, Mello CC, Shirayama M. Divide and differentiate: CDK/Cyclins and the art of development. Cell Cycle. 2014;13:1384&#x2013;1391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4050136</ArticleId>
            <ArticleId IdType="pubmed">24675894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song JD, Lee SK, Kim KM, Park SE, Park SJ, Kim KH, Ahn SC, Park YC. Molecular mechanism of diallyl disulfide in cell cycle arrest and apoptosis in HCT-116 colon cancer cells. J Biochem Mol Toxicol. 2009;23:71&#x2013;79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19202565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Estaquier J, Vallette F, Vayssiere JL, Mignotte B. The mitochondrial pathways of apoptosis. Advances in experimental medicine and biology. 2012;942:157&#x2013;183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22399422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol. 1993;4:327&#x2013;332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8142617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ali AY, Farrand L, Kim JY, Byun S, Suh JY, Lee HJ, Tsang BK. Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. Ann N Y Acad Sci. 2012;1271:58&#x2013;67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3499654</ArticleId>
            <ArticleId IdType="pubmed">23050965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis A, Tinker AV, Friedlander M. &#x201c;Platinum resistant&#x201d; ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol. 2014;133:624&#x2013;631.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24607285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selvendiran K, Tong L, Vishwanath S, Bratasz A, Trigg NJ, Kutala VK, Hideg K, Kuppusamy P. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J Biol Chem. 2007;282:28609&#x2013;28618.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4610350</ArticleId>
            <ArticleId IdType="pubmed">17684018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polivka J, Jr, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Therapeut. 2014;142:164&#x2013;175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24333502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coutte L, Dreyer C, Sablin MP, Faivre S, Raymond E. [PI3K-AKT-mTOR pathway and cancer] Bull Cancer. 2012;99:173&#x2013;180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21742593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:121&#x2013;130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22239433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hresko RC, Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem. 2005;280:40406&#x2013;40416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16221682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci. 2002;27:462&#x2013;467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12217521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle. 2003;2:339&#x2013;345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12851486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol. 2004;15:177&#x2013;182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15209377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan X, Yin J, Yao H, Mao N, Yang Y, Pan L. Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer. Cancer Res. 2010;70:1616&#x2013;1624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20103635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kohn AD, Summers SA, Birnbaum MJ, Roth RA. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem. 1996;271:31372&#x2013;31378.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8940145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Meerloo J, Kaspers GJ, Cloos J. Cell sensitivity assays: the MTT assay. Methods Mol Biol. 2011;731:237&#x2013;245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21516412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, Hou J, Lu L, Qi Z, Sun J, Gao W, Meng J, Wang Y, Sun H, Gu H, Xin Y, Guo X, Yang G. Small ribosomal protein subunit S7 suppresses ovarian tumorigenesis through regulation of the PI3K/AKT and MAPK pathways. PLoS One. 2013;8:e79117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3823983</ArticleId>
            <ArticleId IdType="pubmed">24244431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim TW, Lee JH, He L, Boyd DA, Hardwick JM, Hung CF, Wu TC. Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res. 2005;65:309&#x2013;316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15665308</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26124089</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>10</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1091-6490</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>112</Volume>
            <Issue>28</Issue>
            <PubDate>
              <Year>2015</Year>
              <Month>Jul</Month>
              <Day>14</Day>
            </PubDate>
          </JournalIssue>
          <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
          <ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation>
        </Journal>
        <ArticleTitle>PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion.</ArticleTitle>
        <Pagination>
          <StartPage>8638</StartPage>
          <EndPage>8643</EndPage>
          <MedlinePgn>8638-43</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1500722112</ELocationID>
        <Abstract>
          <AbstractText>Molecular therapies are hallmarks of "personalized" medicine, but how tumors adapt to these agents is not well-understood. Here we show that small-molecule inhibitors of phosphatidylinositol 3-kinase (PI3K) currently in the clinic induce global transcriptional reprogramming in tumors, with activation of growth factor receptors, (re)phosphorylation of Akt and mammalian target of rapamycin (mTOR), and increased tumor cell motility and invasion. This response involves redistribution of energetically active mitochondria to the cortical cytoskeleton, where they support membrane dynamics, turnover of focal adhesion complexes, and random cell motility. Blocking oxidative phosphorylation prevents adaptive mitochondrial trafficking, impairs membrane dynamics, and suppresses tumor cell invasion. Therefore, "spatiotemporal" mitochondrial respiration adaptively induced by PI3K therapy fuels tumor cell invasion, and may provide an important antimetastatic target.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Caino</LastName>
            <ForeName>M Cecilia</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>Prostate Cancer Discovery and Development Program, The Wistar Institute, Philadelphia, PA 19104; Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104;</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ghosh</LastName>
            <ForeName>Jagadish C</ForeName>
            <Initials>JC</Initials>
            <AffiliationInfo>
              <Affiliation>Prostate Cancer Discovery and Development Program, The Wistar Institute, Philadelphia, PA 19104; Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104;</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chae</LastName>
            <ForeName>Young Chan</ForeName>
            <Initials>YC</Initials>
            <AffiliationInfo>
              <Affiliation>Prostate Cancer Discovery and Development Program, The Wistar Institute, Philadelphia, PA 19104; Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104;</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vaira</LastName>
            <ForeName>Valentina</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi," Milan 20122, Italy; Division of Pathology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, Milan 20122, Italy;</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rivadeneira</LastName>
            <ForeName>Dayana B</ForeName>
            <Initials>DB</Initials>
            <AffiliationInfo>
              <Affiliation>Prostate Cancer Discovery and Development Program, The Wistar Institute, Philadelphia, PA 19104; Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104;</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Faversani</LastName>
            <ForeName>Alice</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pathology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, Milan 20122, Italy;</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rampini</LastName>
            <ForeName>Paolo</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Neurosurgery, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan 20122, Italy;</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kossenkov</LastName>
            <ForeName>Andrew V</ForeName>
            <Initials>AV</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Systems and Computational Biology, The Wistar Institute, Philadelphia, PA 19104;</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aird</LastName>
            <ForeName>Katherine M</ForeName>
            <Initials>KM</Initials>
            <AffiliationInfo>
              <Affiliation>Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, PA 19104;</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Rugang</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, PA 19104;</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Webster</LastName>
            <ForeName>Marie R</ForeName>
            <Initials>MR</Initials>
            <AffiliationInfo>
              <Affiliation>Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104;</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weeraratna</LastName>
            <ForeName>Ashani T</ForeName>
            <Initials>AT</Initials>
            <AffiliationInfo>
              <Affiliation>Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104;</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bosari</LastName>
            <ForeName>Silvano</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pathology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, Milan 20122, Italy; Department of Pathophysiology and Organ Transplant, University of Milan, Milan 20122, Italy;</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Languino</LastName>
            <ForeName>Lucia R</ForeName>
            <Initials>LR</Initials>
            <AffiliationInfo>
              <Affiliation>Prostate Cancer Discovery and Development Program, The Wistar Institute, Philadelphia, PA 19104; Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Altieri</LastName>
            <ForeName>Dario C</ForeName>
            <Initials>DC</Initials>
            <AffiliationInfo>
              <Affiliation>Prostate Cancer Discovery and Development Program, The Wistar Institute, Philadelphia, PA 19104; Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104; daltieri@wistar.org.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA078810</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>F32 CA177018</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA089720</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 CA140043</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA010815</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA78810</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA190027</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 CA114046</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA174746</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01CA140043</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA190027</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA010815</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA160331</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 CA009171</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>06</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
        <NlmUniqueID>7505876</NlmUniqueID>
        <ISSNLinking>0027-8424</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003599" MajorTopicYN="N">Cytoskeleton</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009361" MajorTopicYN="Y">Neoplasm Invasiveness</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081082" MajorTopicYN="Y">Phosphoinositide-3 Kinase Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">PI3K</Keyword>
        <Keyword MajorTopicYN="N">cell invasion</Keyword>
        <Keyword MajorTopicYN="N">cytoskeleton</Keyword>
        <Keyword MajorTopicYN="N">mitochondria</Keyword>
        <Keyword MajorTopicYN="N">molecular therapy</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>7</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>7</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>10</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26124089</ArticleId>
        <ArticleId IdType="pmc">PMC4507184</ArticleId>
        <ArticleId IdType="doi">10.1073/pnas.1500722112</ArticleId>
        <ArticleId IdType="pii">1500722112</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7(8):606&#x2013;619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16847462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manning BD, Cantley LC. AKT/PKB signaling: Navigating downstream. Cell. 2007;129(7):1261&#x2013;1274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2756685</ArticleId>
            <ArticleId IdType="pubmed">17604717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489&#x2013;501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12094235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: Lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10(3):143&#x2013;153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23400000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fruman DA, Rommel C. PI3K and cancer: Lessons, challenges and opportunities. Nat Rev Drug Discov. 2014;13(2):140&#x2013;156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3994981</ArticleId>
            <ArticleId IdType="pubmed">24481312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J&#xe4;nne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov. 2009;8(9):709&#x2013;723.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19629074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen AA, et al. Dynamic proteomics of individual cancer cells in response to a drug. Science. 2008;322(5907):1511&#x2013;1516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19023046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakrabarty A, S&#xe1;nchez V, Kuba MG, Rinehart C, Arteaga CL. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci USA. 2012;109(8):2718&#x2013;2723.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3286932</ArticleId>
            <ArticleId IdType="pubmed">21368164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghosh JC, et al. Adaptive mitochondrial reprogramming and resistance to PI3K therapy. J Natl Cancer Inst. 2015;107(3):dju502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4565533</ArticleId>
            <ArticleId IdType="pubmed">25650317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ward PS, Thompson CB. Metabolic reprogramming: A cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21(3):297&#x2013;308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3311998</ArticleId>
            <ArticleId IdType="pubmed">22439925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallace DC. Mitochondria and cancer. Nat Rev Cancer. 2012;12(10):685&#x2013;698.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4371788</ArticleId>
            <ArticleId IdType="pubmed">23001348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frezza C, et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature. 2011;477(7363):225&#x2013;228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21849978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vaira V, et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci USA. 2010;107(18):8352&#x2013;8356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2889536</ArticleId>
            <ArticleId IdType="pubmed">20404174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roussos ET, Condeelis JS, Patsialou A. Chemotaxis in cancer. Nat Rev Cancer. 2011;11(8):573&#x2013;587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4030706</ArticleId>
            <ArticleId IdType="pubmed">21779009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hinz B, Alt W, Johnen C, Herzog V, Kaiser H-W. Quantifying lamella dynamics of cultured cells by SACED, a new computer-assisted motion analysis. Exp Cell Res. 1999;251(1):234&#x2013;243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10438589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petrie RJ, Doyle AD, Yamada KM. Random versus directionally persistent cell migration. Nat Rev Mol Cell Biol. 2009;10(8):538&#x2013;549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2752299</ArticleId>
            <ArticleId IdType="pubmed">19603038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. Science. 2012;337(6098):1062&#x2013;1065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4762028</ArticleId>
            <ArticleId IdType="pubmed">22936770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: Mechanistic findings and clinical applications. Nat Rev Cancer. 2014;14(9):598&#x2013;610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4365862</ArticleId>
            <ArticleId IdType="pubmed">25098269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chae YC, et al. Landscape of the mitochondrial Hsp90 metabolome in tumours. Nat Commun. 2013;4:2139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3732457</ArticleId>
            <ArticleId IdType="pubmed">23842546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janiszewska M, et al. Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev. 2012;26(17):1926&#x2013;1944.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3435496</ArticleId>
            <ArticleId IdType="pubmed">22899010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viale A, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014;514(7524):628&#x2013;632.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4376130</ArticleId>
            <ArticleId IdType="pubmed">25119024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haq R, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1&#x3b1; and MITF. Cancer Cell. 2013;23(3):302&#x2013;315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3635826</ArticleId>
            <ArticleId IdType="pubmed">23477830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LeBleu VS, et al. PGC-1&#x3b1; mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 2014;16(10):992&#x2013;1003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4369153</ArticleId>
            <ArticleId IdType="pubmed">25241037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shiraishi T, et al. 2015. Glycolysis is the primary bioenergetic pathway for cell motility and cytoskeletal remodeling in human prostate and breast cancer cells. Oncotarget 6(1):130&#x2013;143.</Citation>
        </Reference>
        <Reference>
          <Citation>Porporato PE, et al. A mitochondrial switch promotes tumor metastasis. Cell Reports. 2014;8(3):754&#x2013;766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25066121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olgun A, Akman S. Mitochondrial DNA-deficient models and aging. Ann N Y Acad Sci. 2007;1100:241&#x2013;245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17460185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Bock K, et al. Role of PFKFB3-driven glycolysis in vessel sprouting. Cell. 2013;154(3):651&#x2013;663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23911327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee CW, Peng HB. Mitochondrial clustering at the vertebrate neuromuscular junction during presynaptic differentiation. J Neurobiol. 2006;66(6):522&#x2013;536.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16555236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saxton WM, Hollenbeck PJ. The axonal transport of mitochondria. J Cell Sci. 2012;125(Pt 9):2095&#x2013;2104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3656622</ArticleId>
            <ArticleId IdType="pubmed">22619228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birsa N, Norkett R, Higgs N, Lopez-Domenech G, Kittler JT. Mitochondrial trafficking in neurons and the role of the Miro family of GTPase proteins. Biochem Soc Trans. 2013;41(6):1525&#x2013;1531.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24256248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao J, et al. Mitochondrial dynamics regulates migration and invasion of breast cancer cells. Oncogene. 2013;32(40):4814&#x2013;4824.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3911914</ArticleId>
            <ArticleId IdType="pubmed">23128392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morlino G, et al. Miro-1 links mitochondria and microtubule dynein motors to control lymphocyte migration and polarity. Mol Cell Biol. 2014;34(8):1412&#x2013;1426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3993592</ArticleId>
            <ArticleId IdType="pubmed">24492963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Desai SP, Bhatia SN, Toner M, Irimia D. Mitochondrial localization and the persistent migration of epithelial cancer cells. Biophys J. 2013;104(9):2077&#x2013;2088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3647149</ArticleId>
            <ArticleId IdType="pubmed">23663851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>K&#xf6;lsch V, Charest PG, Firtel RA. The regulation of cell motility and chemotaxis by phospholipid signaling. J Cell Sci. 2008;121(Pt 5):551&#x2013;559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2671295</ArticleId>
            <ArticleId IdType="pubmed">18287584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiger MC, et al. Spontaneous phosphoinositide 3-kinase signaling dynamics drive spreading and random migration of fibroblasts. J Cell Sci. 2009;122(Pt 3):313&#x2013;323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2724728</ArticleId>
            <ArticleId IdType="pubmed">19126672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kraynov VS, et al. Localized Rac activation dynamics visualized in living cells. Science. 2000;290(5490):333&#x2013;337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11030651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fabry B, Klemm AH, Kienle S, Sch&#xe4;ffer TE, Goldmann WH. Focal adhesion kinase stabilizes the cytoskeleton. Biophys J. 2011;101(9):2131&#x2013;2138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3207160</ArticleId>
            <ArticleId IdType="pubmed">22067150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pennacchietti S, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003;3(4):347&#x2013;361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12726861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11):891&#x2013;899.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15516961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ebos JM, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15(3):232&#x2013;239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4540346</ArticleId>
            <ArticleId IdType="pubmed">19249681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>P&#xe0;ez-Ribes M, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15(3):220&#x2013;231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2874829</ArticleId>
            <ArticleId IdType="pubmed">19249680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caino MC, et al. Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. J Clin Invest. 2013;123(7):2907&#x2013;2920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3998961</ArticleId>
            <ArticleId IdType="pubmed">23921130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang BH, et al. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J Clin Invest. 2009;119(3):454&#x2013;464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2648691</ArticleId>
            <ArticleId IdType="pubmed">19229106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ortensi B, et al. Rai is a new regulator of neural progenitor migration and glioblastoma invasion. Stem Cells. 2012;30(5):817&#x2013;832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22311806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vaira V, et al. miR-296 regulation of a cell polarity-cell plasticity module controls tumor progression. Oncogene. 2012;31(1):27&#x2013;38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3252463</ArticleId>
            <ArticleId IdType="pubmed">21643016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-&#x394;&#x394;CT method. Methods. 2001;25(4):402&#x2013;408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11846609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995;57(1):289&#x2013;300.</Citation>
        </Reference>
        <Reference>
          <Citation>Louis DN, et al. The 2007 WHO classification of tumors of the central nervous system. Acta Neurophatol. 2007;114(2):97&#x2013;109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1929165</ArticleId>
            <ArticleId IdType="pubmed">17618441</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26116776</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>09</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1090-2104</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>464</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2015</Year>
              <Month>Aug</Month>
              <Day>14</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biochemical and biophysical research communications</Title>
          <ISOAbbreviation>Biochem Biophys Res Commun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>ABT-737 sensitizes curcumin-induced anti-melanoma cell activity through facilitating mPTP death pathway.</ArticleTitle>
        <Pagination>
          <StartPage>286</StartPage>
          <EndPage>291</EndPage>
          <MedlinePgn>286-91</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2015.06.144</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0006-291X(15)30198-4</ELocationID>
        <Abstract>
          <AbstractText>In the current study, we studied the potential role of ABT-737, a novel Bcl-2 inhibitor, on curcumin-induced anti-melanoma cell activity in vitro. The associated mechanisms were also investigated. We demonstrated that ABT-737 significantly sensitized curcumin-induced activity against melanoma cells (WM-115 and B16 lines), resulting in substantial cell death and apoptosis with co-administration. At the molecular level, curcumin and ABT-737 synergistically induced mitochondrial permeability transition pore (mPTP) opening in melanoma cells, the latter was evidenced by mitochondrial membrane potential (MPP) reduction and mitochondrial complexation between cyclophilin-D (CyPD) and adenine nucleotide translocator 1 (ANT-1). Significantly, mPTP blockers, including cyclosporin A and sanglifehrin A, remarkably inhibited curcumin and ABT-737 co-administration-induced cytotoxicity against melanoma cells. Meanwhile, siRNA-mediated knockdown of CyPD or ANT-1, the two key components of mPTP, alleviated WM-116 cell death by the co-treatment. Collectively, we show that ABT-737 sensitizes curcumin-induced anti-melanoma cell activity probably through facilitating mPTP death pathway. ABT-737 could be further investigated as a potential curcumin adjuvant in melanoma and other cancer treatment.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Teng</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Shandong Ji-ning No.1 People's Hospital, Ji-ning City, Shandong Province, 272011, PR China. Electronic address: tengyu33@yahoo.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Chao</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Shandong Ji-ning No.1 People's Hospital, Ji-ning City, Shandong Province, 272011, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thoracic Surgery, Shandong Ji-ning No.1 People's Hospital, Ji-ning City, Shandong Province, 272011, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Blood Transfusion, Shandong Ji-ning No.1 People's Hospital, Ji-ning City, Shandong Province, 272011, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Tian-Hang</ForeName>
            <Initials>TH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Shandong Ji-ning No.1 People's Hospital, Ji-ning City, Shandong Province, 272011, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meng</LastName>
            <ForeName>Jin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Shandong Ji-ning No.1 People's Hospital, Ji-ning City, Shandong Province, 272011, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Xianhua</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Shandong Ji-ning No.1 People's Hospital, Ji-ning City, Shandong Province, 272011, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>06</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Biochem Biophys Res Commun</MedlineTA>
        <NlmUniqueID>0372516</NlmUniqueID>
        <ISSNLinking>0006-291X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C501332">ABT-737</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D033741">Adenine Nucleotide Translocator 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000595707">BCL2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001713">Biphenyl Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081406">Cyclophilin D</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007783">Lactones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D033681">Mitochondrial Membrane Transport Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000083162">Mitochondrial Permeability Transition Pore</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009596">Nitrophenols</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000631446">PPIF protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013141">Spiro Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C121329">sanglifehrin A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>114100-40-2</RegistryNumber>
          <NameOfSubstance UI="C052617">Bcl2 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>83HN0GTJ6D</RegistryNumber>
          <NameOfSubstance UI="D016572">Cyclosporine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 5.2.1.-</RegistryNumber>
          <NameOfSubstance UI="D021983">Cyclophilins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IT942ZTH98</RegistryNumber>
          <NameOfSubstance UI="D003474">Curcumin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D033741" MajorTopicYN="N">Adenine Nucleotide Translocator 1</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001713" MajorTopicYN="N">Biphenyl Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003474" MajorTopicYN="N">Curcumin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081406" MajorTopicYN="N">Cyclophilin D</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D021983" MajorTopicYN="N">Cyclophilins</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016572" MajorTopicYN="N">Cyclosporine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007783" MajorTopicYN="N">Lactones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008546" MajorTopicYN="N">Melanoma, Experimental</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D033681" MajorTopicYN="N">Mitochondrial Membrane Transport Proteins</DescriptorName>
          <QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000083162" MajorTopicYN="N">Mitochondrial Permeability Transition Pore</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009596" MajorTopicYN="N">Nitrophenols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019253" MajorTopicYN="N">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013141" MajorTopicYN="N">Spiro Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ABT-737</Keyword>
        <Keyword MajorTopicYN="N">Cell death and chemo-sensitization</Keyword>
        <Keyword MajorTopicYN="N">Curcumin</Keyword>
        <Keyword MajorTopicYN="N">Melanoma</Keyword>
        <Keyword MajorTopicYN="N">Mitochondrial permeability transition pore (mPTP)</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>6</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>6</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>6</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>6</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26116776</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bbrc.2015.06.144</ArticleId>
        <ArticleId IdType="pii">S0006-291X(15)30198-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26010875</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>10</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1471-4159</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>134</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2015</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of neurochemistry</Title>
          <ISOAbbreviation>J Neurochem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The mitochondrial uncoupler DNP triggers brain cell mTOR signaling network reprogramming and CREB pathway up-regulation.</ArticleTitle>
        <Pagination>
          <StartPage>677</StartPage>
          <EndPage>692</EndPage>
          <MedlinePgn>677-92</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/jnc.13176</ELocationID>
        <Abstract>
          <AbstractText>Mitochondrial metabolism is highly responsive to nutrient availability and ongoing activity in neuronal circuits. The molecular mechanisms by which brain cells respond to an increase in cellular energy expenditure are largely unknown. Mild mitochondrial uncoupling enhances cellular energy expenditure in mitochondria and can be induced with 2,4-dinitrophenol (DNP), a proton ionophore previously used for weight loss. We found that DNP treatment reduces mitochondrial membrane potential, increases intracellular Ca(2+) levels and reduces oxidative stress in cerebral cortical neurons. Gene expression profiling of the cerebral cortex of DNP-treated mice revealed reprogramming of signaling cascades that included suppression of the mammalian target of rapamycin (mTOR) and insulin--PI3K - MAPK pathways, and up-regulation of tuberous sclerosis complex 2, a negative regulator of mTOR. Genes encoding proteins involved in autophagy processes were up-regulated in response to DNP. CREB (cAMP-response element-binding protein) signaling, Arc and brain-derived neurotrophic factor, which play important roles in synaptic plasticity and adaptive cellular stress responses, were up-regulated in response to DNP, and DNP-treated mice exhibited improved performance in a test of learning and memory. Immunoblot analysis verified that key DNP-induced changes in gene expression resulted in corresponding changes at the protein level. Our findings suggest that mild mitochondrial uncoupling triggers an integrated signaling response in brain cells characterized by reprogramming of mTOR and insulin signaling, and up-regulation of pathways involved in adaptive stress responses, molecular waste disposal, and synaptic plasticity. Physiological bioenergetic challenges such as exercise and fasting can enhance neuroplasticity and protect neurons against injury and neurodegeneration. Here, we show that the mitochondrial uncoupling agent 2,4-dinitrophenol (DNP) elicits adaptive signaling responses in the cerebral cortex involving activation of Ca(2+) -CREB and autophagy pathways, and inhibition of mTOR and insulin signaling pathways. The molecular reprogramming induced by DNP, which is similar to that of exercise and fasting, is associated with improved learning and memory, suggesting potential therapeutic applications for DNP.</AbstractText>
          <CopyrightInformation>&#xa9; 2015 International Society for Neurochemistry.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Dong</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, Baltimore, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yongqing</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Gene Expression and Genomics Unit, National Institute on Aging Intramural Research Program, Baltimore, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gharavi</LastName>
            <ForeName>Robert</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, Baltimore, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Park</LastName>
            <ForeName>Hee Ra</ForeName>
            <Initials>HR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, College of Pharmacy, Molecular Inflammation Research Center for Aging Intervention, Pusan National University, Busan, Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Jaewon</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, College of Pharmacy, Molecular Inflammation Research Center for Aging Intervention, Pusan National University, Busan, Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Siddiqui</LastName>
            <ForeName>Sana</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, Baltimore, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Telljohann</LastName>
            <ForeName>Richard</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, Baltimore, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nassar</LastName>
            <ForeName>Matthew R</ForeName>
            <Initials>MR</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, Baltimore, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cutler</LastName>
            <ForeName>Roy G</ForeName>
            <Initials>RG</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, Baltimore, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Becker</LastName>
            <ForeName>Kevin G</ForeName>
            <Initials>KG</Initials>
            <AffiliationInfo>
              <Affiliation>Gene Expression and Genomics Unit, National Institute on Aging Intramural Research Program, Baltimore, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mattson</LastName>
            <ForeName>Mark P</ForeName>
            <Initials>MP</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, Baltimore, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>ZIA AG000312-13</GrantID>
            <Agency>Intramural NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>ZIA AG000314-13</GrantID>
            <Agency>Intramural NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>ZIA AG000312-14</GrantID>
            <Agency>Intramural NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>ZIA AG000317-14</GrantID>
            <Agency>Intramural NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>ZIA AG000317-13</GrantID>
            <Agency>Intramural NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>ZIA AG000314-14</GrantID>
            <Agency>Intramural NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>06</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Neurochem</MedlineTA>
        <NlmUniqueID>2985190R</NlmUniqueID>
        <ISSNLinking>0022-3042</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C492004">Creb1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017362">Cyclic AMP Response Element-Binding Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014475">Uncoupling Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546843">mTOR protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q13SKS21MN</RegistryNumber>
          <NameOfSubstance UI="D019297">2,4-Dinitrophenol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D019297" MajorTopicYN="N">2,4-Dinitrophenol</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017362" MajorTopicYN="N">Cyclic AMP Response Element-Binding Protein</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014475" MajorTopicYN="N">Uncoupling Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">2,4-dinitrophenol</Keyword>
        <Keyword MajorTopicYN="N">BDNF</Keyword>
        <Keyword MajorTopicYN="N">CREB</Keyword>
        <Keyword MajorTopicYN="N">autophagy</Keyword>
        <Keyword MajorTopicYN="N">insulin signaling</Keyword>
        <Keyword MajorTopicYN="N">mTOR</Keyword>
      </KeywordList>
      <CoiStatement>Conflicts of interests. The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2014</Year>
          <Month>11</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>10</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26010875</ArticleId>
        <ArticleId IdType="mid">NIHMS702253</ArticleId>
        <ArticleId IdType="pmc">PMC4516713</ArticleId>
        <ArticleId IdType="doi">10.1111/jnc.13176</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Altarejos JY, Montminy M. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol. 2011;12:141&#x2013;151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4324555</ArticleId>
            <ArticleId IdType="pubmed">21346730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrews ZB, Diano S, Horvath TL. Mitochondrial uncoupling proteins in the CNS: in support of function and survival. Nat Rev Neurosci. 2005;6:829&#x2013;40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16224498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arancibia S, Rage F, Givaloi L, Tapia-Arancibia L. Neurotrophins in neuroendocrine control: brain derived-neurotrophic factor (BDNF) and somatostatin involvement in the stress response and reproductive physiology. Ann Rev Biomed Sciences. 2003;5:5&#x2013;28.</Citation>
        </Reference>
        <Reference>
          <Citation>Arumugam TV, Phillips TM, Cheng A, Morrell CH, Mattson MP, Wan R. Age and energy intake interact to modify cell stress pathways and stroke outcome. Ann Neurol. 2010;67:41&#x2013;52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2844782</ArticleId>
            <ArticleId IdType="pubmed">20186857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baird TD, Wek RC. Eukaryotic initiation factor 2 phosphorylation and translational control in metabolism American Society for Nutrition. Adv Nutr. 2012;3:307&#x2013;321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3649462</ArticleId>
            <ArticleId IdType="pubmed">22585904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benito E, Barco A. CREB&#x2019;s control of intrinsic and synaptic plasticity: implications for CREB-dependent memory models. Trends Neurosci. 2010;33:230&#x2013;240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20223527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bl&#xfc;her M, Kahn BB, Kahn CR. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science. 2003;299:572&#x2013;574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12543978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brand MD. Uncoupling to survive? The role of mitochondrial inefficiency in ageing. Experiment Gerontol. 2000;35:811&#x2013;820.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11053672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a) Molecu Cellul Biol. 2001;21:952&#x2013;965.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC86685</ArticleId>
            <ArticleId IdType="pubmed">11154281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burkhalter J, Fiumelli H, Allaman I, Chatton JY, Martin JL. Brain-derived neurotrophic factor stimulates energy metabolism in developing cortical neurons. J Neurosci. 2003;23:8212&#x2013;8220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6740684</ArticleId>
            <ArticleId IdType="pubmed">12967982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caldeira da Silva CC, Cerqueira FM, Barbosa LF, Medeiros MH, Kowaltowski AJ. Mild mitochondrial uncoupling in mice affects energy metabolism, redox balance and longevity. Aging Cell. 2008;7:552&#x2013;60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18505478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carlon S, Girelli S, Scopa C, Buonocore G, Longgin M, Balduini W. Activation of autophagy and Akt/CREB signaling play an equivalent role in the neuroprotective effect of rapamycin in neonatal hypoxia-ischemia. Autophagy. 2010;6:366&#x2013;377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20168088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan CB, Harper ME. Uncoupling proteins: role in insulin resistance and insulin insufficiency. Curr Diabetes Rev. 2006;2:271&#x2013;283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3060851</ArticleId>
            <ArticleId IdType="pubmed">18220632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan SL, Li D, Kyriazis G, Bagsiyao P, Ouyang X, Mattson MP. Mitochondrial uncoupling protein-4 regulates calcium homeostasis and sensitivity to store-depletion-induced apoptosis in neural cells. J Biol Chem. 2006;281:37391&#x2013;37403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17035241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheadle C, Vawter MP, Freed WJ, Becker KG. Analysis of microarray data using Z score transformation. J Mol Diagn. 2003;5:73&#x2013;81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1907322</ArticleId>
            <ArticleId IdType="pubmed">12707371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen DY, Bambah-Mukku D, Pollonini G, Alberini CM. Glucocorticoid receptors recruit the CaMKII&#x3b1;-BDNF-CREB pathways to mediate memory consolidation. Nat Neurosci. 2012;15:1707&#x2013;1714.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3509234</ArticleId>
            <ArticleId IdType="pubmed">23160045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiang HU, Terlecky SR, Plant CP, Fred Dice J. A Role for a 70-kilodaton heat shock protein in lysosomal degradation of intracellular proteins. Science. 1989;346:382&#x2013;385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2799391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colman E. Dinitrophenol and obesity: an early twentieth-century regulatory dilemma. Regul Toxicol Pharmacol. 2007;48:115&#x2013;117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17475379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng A, Wan R, Yang JL, Kamimura N, Son TG, Ouyang X, Luo Y, Okun E, Mattson MP. Involvement of PGC-1&#x3b1; in the formation and maintenance of neuronal dendritic spines. Nat Commun. 2012;3:1250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4091730</ArticleId>
            <ArticleId IdType="pubmed">23212379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng Z, Tseng Y, White MF. Insulin signaling meets mitochondria in metabolism. Trends Endocrinol Metab. 2010;21:589&#x2013;598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3994704</ArticleId>
            <ArticleId IdType="pubmed">20638297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Culmsee C, Monnig J, Kemp BE, Mattson MP. AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation. J Mol Neurosci. 2001;17:45&#x2013;58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11665862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol. 2002;52:448&#x2013;457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12325074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>da Costa RF, Martinez AM, Ferreira ST. 2,4-Dinitrophenol blocks neurodegeneration and preserves sciatic nerve function after trauma. J Neurotrauma. 2010;27:829&#x2013;841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20143955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dibble CC, Manning BD. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol. 2013;15:555&#x2013;564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3743096</ArticleId>
            <ArticleId IdType="pubmed">23728461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Echtay KS. Mitochondrial uncoupling proteins&#x2013;what is their physiological role? Free Radic Biol Med. 2007;43:1351&#x2013;1371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17936181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Enerb&#xe4;ck S, Jacobsson A, Simpson EM, Guerra C, Yamashita H, Harper ME, Kozak LP. Mice lacking mitochondrial uncoupling protein are cold-sensitive but not obese. Nature. 1997;387:90&#x2013;94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9139827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Martinez JM, Alessi DR. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1) Biochem J. 2008;416:375&#x2013;385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18925875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gellerich FN, Gizatullina Z, Gainutdinov T, Muth K, Seppet E, Orynbayeva Z, Vielhaber S. The control of brain mitochondrial energization by cytosolic calcium: the mitochondrial gas pedal. IUBMB Life. 2013;65:180&#x2013;190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23401251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldgof M, Cuiying Xiao C, Chanturiya T, Jou W, Gavrilova O, Marc L, Reitman ML. The Chemical uncoupler 2,4-dinitrophenol (DNP) protects against diet-induced obesity and improves energy. J Biol Chem. 2014;289:19341&#x2013;19350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4094046</ArticleId>
            <ArticleId IdType="pubmed">24872412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griffioen KJ, Rothman SM, Ladenheim B, Wan R, Vranis N, Hutchison E, Okun E, Cadet JL, Mattson MP. Dietary energy intake modifies brainstem autonomic dysfunction caused by mutant &#x3b1;-synuclein. Neurobiol Aging. 2013;34:928&#x2013;935.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3498580</ArticleId>
            <ArticleId IdType="pubmed">22883907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guertin DA, Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, Sabatini DM. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKC&#x3b1;, but not S6K1. Dev Cell. 2006;11:859&#x2013;871.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17141160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halagappa VK, Guo Z, Pearson M, Matsuoka Y, Cutler RG, Laferla FM, Mattson MP. Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer&#x2019;s disease. Neurobiol Dis. 2007;26:212&#x2013;220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17306982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Ann Rev Genet. 2009;43:67&#x2013;93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2831538</ArticleId>
            <ArticleId IdType="pubmed">19653858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang J, Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochemical Society Transactions. 2009;37:217&#x2013;222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2778026</ArticleId>
            <ArticleId IdType="pubmed">19143635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Develop. 2003;17:1829&#x2013;1834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC196227</ArticleId>
            <ArticleId IdType="pubmed">12869586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K, Guan KL. Complexity of the TOR signaling network. Trends Cell Biol. 2006;16:206&#x2013;212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16516475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K, Kim J, Guan KL. AMPK and mTOR in cellular energy homeostasis and drug targets. Ann Rev Pharmacol Toxicol. 2012;52:381&#x2013;400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22017684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacinto E, Loewith R, Schmidt A, Lin S, R&#xfc;egg MA, Hall A, Hall MN. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004;6:1122&#x2013;1128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15467718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jamart C, Naslain D, Gilson H, Francaux M. Higher activation of autophagy in skeletal muscle of mice during endurance exercise in the fasted state. Am J Physiol Endocrinol Metab. 2013;305:E964&#x2013;974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23964069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson SC, Rabinovitch PS, Kaeberlein M. MTOR is a key modulator of ageing and age-related disease. Nature. 2013;493:338&#x2013;345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3687363</ArticleId>
            <ArticleId IdType="pubmed">23325216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung AH, Ro S, Cao J, Otto NM, Kim DH. mTOR regulation of autophagy. FEBS Let. 2010;584:1287&#x2013;1295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2846630</ArticleId>
            <ArticleId IdType="pubmed">20083114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000;19:5720&#x2013;5728.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC305793</ArticleId>
            <ArticleId IdType="pubmed">11060023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaiser JA. Studies on the toxicity of disophenol (26-diiodo-4-nitrophenol (2,6-diiodo-4-nitrophenol) to dogs and rodents plus some comparisons with 2,4-dinitrophenol. Ther Ggw. 1964;103:232&#x2013;44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14129994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kihara A, Kabeya Y, Ohsumi Y, Yoshimori T. Beclin-phosphatidylinositol 3-kinase complex functions at the trans-Golgi network. EMBO Rep. 2001;2:330&#x2013;335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1083858</ArticleId>
            <ArticleId IdType="pubmed">11306555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korde AS, Pettigrew LC, Craddock SD, Maragos WF. The mitochondrial uncoupler 2,4-dinitrophenol attenuates tissue damage and improves mitochondrial homeostasis following transient focal cerebral ischemia. J Neurochem. 2005;94:1676&#x2013;1684.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16045446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274&#x2013;293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3331679</ArticleId>
            <ArticleId IdType="pubmed">22500797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larsen MH, Mikkelsen JD, Hay-schmid A, Sandi C. Regulation of brain-derived neurotrophic factor (BDNF) in the chronic unpredictable stress rat model and the effects of chronic antidepressant treatment. J Psychiat Res. 2010;44:808&#x2013;816.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20172535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee B, Cao R, Choi YS, Cho HY, Rhee AD, Hah CK, Hoyt KR, Obrietan K. The CREB/CRE transcriptional pathway: protection against oxidative stress-mediated neuronal cell death. J Neurochem. 2009;108:1251&#x2013;1265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2884273</ArticleId>
            <ArticleId IdType="pubmed">19141071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee Y, Lee HY, Hanna RA, Gustafsson &#xc5;B. Mitochondrial autophagy by Bnip3 involves Drp1-mediated mitochondrial fission and recruitment of Parkin in cardiac myocytes. Am J Physiol Heart Circ Physiol. 2011;301:H1924&#x2013;H1931.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3213962</ArticleId>
            <ArticleId IdType="pubmed">21890690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, Levine B. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 1999;402:672&#x2013;676.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10604474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liesa M, Shirihai OS. Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. Cell Metab. 2013;17:491&#x2013;506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5967396</ArticleId>
            <ArticleId IdType="pubmed">23562075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu D, Chan SL, de Souza-Pinto NC, Slevin JR, Wersto RP, Zhan M, Mustafa K, de Cabo R, Mattson MP. Mitochondrial UCP4 mediates an adaptive shift in energy metabolism and increases the resistance of neurons to metabolic and oxidative stress. Neuromol Med. 2006;8:389&#x2013;414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16775390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu D, Pitta M, Mattson MP. Preventing NAD+ depletion protects neurons against excitotoxicity: bioenergetic effects of mild mitochondrial uncoupling and caloric restriction. Ann N Y Acad Sci. 2008;1147:275&#x2013;282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2645538</ArticleId>
            <ArticleId IdType="pubmed">19076449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu D, Pitta M, Lee JH, Ray B, Lahiri DK, Furukawa K, Mughal M, Jiang H, Villarreal J, Cutler RG, Greig NH, Mattson MP. The KATP channel activator diazoxide ameliorates amyloid-b and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer&#x2019;s disease. J Alzheimers Dis. 2010;22:443&#x2013;457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2988870</ArticleId>
            <ArticleId IdType="pubmed">20847430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu D, Gharavi R, Pitta M, Gleichmann M, Mattson MP. Nicotinamide prevents NAD+ depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD+ consumption by SIRT1 may endanger energetically compromised neurons. Neuromol Med. 2009;11:28&#x2013;42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2677622</ArticleId>
            <ArticleId IdType="pubmed">19288225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P, Hall MN. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell. 2002;10:457&#x2013;468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12408816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson&#x2019;s disease. J Neurosci. 2010;30:1166&#x2013;1175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2880868</ArticleId>
            <ArticleId IdType="pubmed">20089925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Majumder S, Caccamo A, Medina DX, Benavide AD, Javors MA, Kraig E, Strong R, Richardson A, Oddo S. Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1&#x3b2; and enhancing NMDA signaling. Aging Cell. 2012;11:326&#x2013;335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3306461</ArticleId>
            <ArticleId IdType="pubmed">22212527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Piccolo PD, Burden SJ, Sandri C, Zhao J, Goldberg AL, Schiaffino S, Sandri M. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metabol. 2007;6:458&#x2013;471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18054315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manzoni C, Lewis PA. Dysfunction of the autophagy/lysosomal degradation pathway is a shared feature of the genetic synucleinopathies. FASEB J. 2013;27:3424&#x2013;3429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4194632</ArticleId>
            <ArticleId IdType="pubmed">23682122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maragos WF, Korde AS. Mitochondrial uncoupling as a potential therapeutic target in acute central nervous system injury. J Neurochem. 2004;91:257&#x2013;262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15447659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marosi K, Mattson MP. BDNF mediates adaptive brain and body responses to energetic challenges. Trends Endocrinol Metab. 2014;25:89&#x2013;98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3915771</ArticleId>
            <ArticleId IdType="pubmed">24361004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, Iwanami A, Liu F, Villa GR, Gu Y, Campos C, Zhu S, Yang H, Yong WH, Cloughesy TF, Mellinghoff IK, Cavenee WK, Shaw RJ, Mischel PS. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab. 2013;18:726&#x2013;39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3840163</ArticleId>
            <ArticleId IdType="pubmed">24140020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mattson MP, Barger SW, Begley JG, Mark RJ. Calcium, free radicals, and excitotoxic neuronal death in primary cell culture. Methods Cell Biol. 1995;46:187&#x2013;216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7541884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mattson MP. Perspective: Does brown fat protect against diseases of aging? Ageing Res Rev. 2010;9:69&#x2013;76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2818667</ArticleId>
            <ArticleId IdType="pubmed">19969105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mattson MP. Energy intake and exercise as determinants of brain health and vulnerability to injury and disease. Cell Metab. 2012;16:706&#x2013;722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3518570</ArticleId>
            <ArticleId IdType="pubmed">23168220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mehta SL, Li PA. Neuroprotective role of mitochondrial uncoupling protein 2 in cerebral stroke. J Cereb Blood Flow Metab. 2009;29:1069&#x2013;1078.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19240738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meller R, Simon RP. Tolerance to Ischemia &#x2013; an increasingly complex biology. Transl Stroke Res. 2013;4:40&#x2013;50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3596882</ArticleId>
            <ArticleId IdType="pubmed">23504451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mercken EM, Crosby SD, Lamming DW, Jebailey L, Krzysik-Walker S, Villareal DT, Capri M, Franceschi C, Zhang Y, Becker K, Sabatini DM, de Cabo R, Fontana L. Calorie restriction in humans inhibits the PI3K/AKT pathway and induces a younger transcription profile. Aging Cell. 2013;12:645&#x2013;51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3714316</ArticleId>
            <ArticleId IdType="pubmed">23601134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mookerjee SA, Divakaruni AS, Jastroch M, Brand MD. Mitochondrial uncoupling and lifespan. Mech Ageing Dev. 2010;13:463&#x2013;472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2924931</ArticleId>
            <ArticleId IdType="pubmed">20363244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakagawa T, Ono-Kishino M, Sugaru E, Yamanaka M, Taiji M, Noguchi H. Brain-derived neurotrophic factor (BDNF) regulates glucose and energy metabolism in diabetic mice. Diabetes Metab Res Rev. 2002;18:185&#x2013;191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12112936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakatogawa H, Ichimura Y, Ohsumi Y. Atg8, a ubiquitin-like protein required for autophagosome formation, mediates membrane tethering and hemifusion. Cell. 2007;130:165&#x2013;178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17632063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nixon RA, Yang DS. Autophagy failure in Alzheimer&#x2019;s disease&#x2013;locating the primary defect. Neurobiol Dis. 2011;43:38&#x2013;45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3096679</ArticleId>
            <ArticleId IdType="pubmed">21296668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pandya JD, Pauly JR, Nukala VN, Sebastian AH, Day KM, Korde AS, Maragos WF, Hall ED, Sullivan PG. Post-injury administration of mitochondrial uncouplers increases tissue sparing and improves behavioral outcome following traumatic brain injury in rodents. J Neurotrauma. 2007;24:798&#x2013;811.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17518535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perry RJ, Kim T, Zhang XM, Lee HY, Pesta D, Popov VB, Zhang D, Rahimi Y, Jurczak MJ, Cline GW, Spiegel DA, Shulman GL. Reversal of hypertriglyceridemia, fatty liver disease and insulin resistance by a liver-targeted mitochondrial uncoupler. Cell Metab. 2013;18:740&#x2013;748.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4104686</ArticleId>
            <ArticleId IdType="pubmed">24206666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramsden DB, Ho PW, Ho JW, Liu HF, So DH, Tse HM, Chan KH, Ho SL. Human neuronal uncoupling proteins 4 and 5 (UCP4 and UCP5): structural properties, regulation, and physiological role in protection against oxidative stress and mitochondrial dysfunction. Brain Behav. 2012;2:468&#x2013;478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3432969</ArticleId>
            <ArticleId IdType="pubmed">22950050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, Scaravilli F, Easton DF, Duden R, O&#x2019;Kane CJ, Rubinsztein DC. Inhibition of mTOR induces autophagy and reduces toxicity of the Huntington&#x2019;s disease mutation in drosophila and mouse models. Nat Genet. 2004;36:585&#x2013;595.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15146184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Russell RC, Fang C, Guan KL. An emerging role for TOR signaling in mammalian tissue and stem cell physiology. Develop. 2011;138:3343&#x2013;56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3143559</ArticleId>
            <ArticleId IdType="pubmed">21791526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah OJ, Wan Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol. 2004;14:1650&#x2013;1656.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15380067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sahin P, McCaig C, Jeevahan J, Murra JT, Hainsworth AH. The cell survival kinase SGK1 and its targets FOXO3a and NDRG1 in aged human brain. Neuropathol Appl Neurobiol. 2013;39:623&#x2013;633.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23363009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakamoto K, Karelina K, Obrietan K. CREB: a multifaceted regulator of neuronal plasticity and protection. J Neurochem. 2011;116:1&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3575743</ArticleId>
            <ArticleId IdType="pubmed">21044077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salminen A, Kaarniranta K. AMP-activated protein kinase (AMPK) controls the aging process via an integrated signaling network. Ageing Res Rev. 2012;11:230&#x2013;241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22186033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Searcy JL, Phelps JT, Pancani T, Kadish I, Popovic J, Anderson KL, Beckett TL, Murphy MP, Chen KC, Blalock EM, Landfield PW, Porter NM, Thibault O. Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer&#x2019;s disease. J Alzheimers Dis. 2012;30:943&#x2013;961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3378773</ArticleId>
            <ArticleId IdType="pubmed">22495349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sebollela A, Freitas-Corr&#xea;a L, Oliveira FF, Mendes CT, Wasilewska-Sampai AP, Camacho-Pereir J, Galina A, Brentani H, Passetti F, De Felice FG, Dias-Neto E, Ferreira ST. Expression profile of rat hippocampal neurons treated with the neuroprotective compound 2,4-dinitrophenol: up-regulation of cAMP signaling genes. Neurotox Res. 2010;18:112&#x2013;23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19949915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shatzow S, U. S. Environmental Protection Agency EPA 440/5-80-063. Ambient water quality criteria for nitrophenols. 1980:C37.</Citation>
        </Reference>
        <Reference>
          <Citation>Singh R, Cuervo AM. Autophagy in the cellular energetic balance. Cell Metab. 2011;13:495&#x2013;504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3099265</ArticleId>
            <ArticleId IdType="pubmed">21531332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spilman P, Podlutskaya N, Hart MJ, Debnat J, Gorostiza O, Bredese D, Richardson A, Strong R, Galvan V. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer&#x2019;s disease. PLoS One. 2010;5:e9979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2848616</ArticleId>
            <ArticleId IdType="pubmed">20376313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Starkov AA, Fiskum G. Regulation of brain mitochondrial H2O2 production by membrane potential and NAD(P)H redox state. J Neurochem. 2003;86:1101&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12911618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Starkov AA. Protein-mediated energy-dissipating pathways in mitochondria. Chemico-Biol Interact. 2006;161:57&#x2013;68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16584718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stenzel-Poore MP, Stevens SL, Xiong Z, Lessov NS, Harrington CA, Mori M, Meller R, Rosenzweig HL, Tobar E, Shaw TE, Chu X, Simon RP. Effect of ischaemic preconditioning on genomic response to cerebral ischaemia: similarity to neuroprotective strategies in hibernation and hypoxia-tolerant states. Lancet. 2003;362:1028&#x2013;1037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14522533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stranahan AM, Lee K, Becker KG, Zhang Y, Maudsley S, Martin B, Cutler RG, Mattson MP. Hippocampal gene expression patterns underlying the enhancement of memory by running in aged mice. Neurobiol Aging. 2010;31:1937&#x2013;1949.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2889222</ArticleId>
            <ArticleId IdType="pubmed">19070401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki A, Fukushima H, Mukawa T, Toyoda H, Wu LJ, Zhao MG, Xu H, Shang Y, Endoh K, Iwamoto T, Mamiya N, Okano E, Hasegawa S, Mercaldo V, Zhang Y, Maeda R, Ohta M, Josselyn SA, Zhuo M, Kida S. Upregulation of CREB-mediated transcription enhances both short- and long-term memory. J Neurosci. 2011;31:8786&#x2013;8802.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6622960</ArticleId>
            <ArticleId IdType="pubmed">21677163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tain LS, Mortiboys H, Tao RN, Ziviani E, Bandmann O, Whitworth AJ. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat Neurosci. 2009;12:1129&#x2013;1135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2745154</ArticleId>
            <ArticleId IdType="pubmed">19684592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tong L, Shen H, Perreau VM, Balazs R, Cotman CW. Effects of exercise on gene-expression profile in the rat hippocampus. Neurobiol Dis. 2001;8:1046&#x2013;1056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11741400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tseng YH, Cypess AM, Ronal KC. Cellular bioenergetics as a target for obesity therapy. Nat Rev Drug Discov. 2010;9:465&#x2013;482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2880836</ArticleId>
            <ArticleId IdType="pubmed">20514071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vidal-Puig AJ. Uncoupling expectations. Nat Genet. 2000;26:387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11101825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wasilewska-Sampaio AP, Silveira MS, Holub O, Goecking R, Gomes FC, Neto VM, Linden R, Ferreira ST, De Felice FG. Neuritogenesis and neuronal differentiation promoted by 2,4-dinitrophenol, a novel anti-amyloidogenic compound. FASEB J. 2005;19:1627&#x2013;36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16195371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wullachleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471&#x2013;484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16469695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang JL, Tadokoro T, Keijzers G, Mattson MP, Bohr VA. Neurons efficiently repair glutamate-induced oxidative DNA damage by a process involving CREB-mediated up-regulation of apurinic endonuclease 1. J Biol Chem. 2010;285:28191&#x2013;28199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2934684</ArticleId>
            <ArticleId IdType="pubmed">20573957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang JL, Lin YT, Chuang PC, Bohr VA, Mattson MP. BDNF and exercise enhance neuronal DNA repair by stimulating CREB-mediated production of apurinic/apyrimidinic endonuclease 1. Neuromolecular Med. 2014;16:161&#x2013;74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3948322</ArticleId>
            <ArticleId IdType="pubmed">24114393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youle R, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol. 2011;12:9&#x2013;14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4780047</ArticleId>
            <ArticleId IdType="pubmed">21179058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshida S, Hong S, Suzuki T, Nada S, Mannan AM, Wang J, Okada M, Guan KL, Inoki K. Redox regulates mammalian target of rapamycin complex 1 (mTORC1) activity by modulating the TSC1/TSC2-Rheb GTPase pathway. J Biol Chem. 2011;286:32651&#x2013;60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3173157</ArticleId>
            <ArticleId IdType="pubmed">21784859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu L, McPhee CK, Zheng L, Mardones GA, Rong Y, Peng J, Mi N, Zhao Y, Liu Z, Wan F, Hailey DW, Oorschot V, Klumperman J, Baehrecke EH, Lenardo MJ. Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature. 2010;465:942&#x2013;946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2920749</ArticleId>
            <ArticleId IdType="pubmed">20526321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang F, Wu Y, Jia J. Exercise preconditioning and brain ischemic tolerance. Neuroscience. 2011;177:170&#x2013;176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21241780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, Vazquez F, Carpenter CL, Kwiatkowski DJ. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest. 2003;112:1223&#x2013;1233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC213485</ArticleId>
            <ArticleId IdType="pubmed">14561707</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26007644</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0712</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>762</Volume>
            <PubDate>
              <Year>2015</Year>
              <Month>Sep</Month>
              <Day>05</Day>
            </PubDate>
          </JournalIssue>
          <Title>European journal of pharmacology</Title>
          <ISOAbbreviation>Eur J Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Coenzyme Q10 remarkably improves the bio-energetic function of rat liver mitochondria treated with statins.</ArticleTitle>
        <Pagination>
          <StartPage>270</StartPage>
          <EndPage>274</EndPage>
          <MedlinePgn>270-4</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejphar.2015.05.041</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0014-2999(15)30037-6</ELocationID>
        <Abstract>
          <AbstractText>CoQ10 shares a biosynthetic pathway with cholesterol therefore it can be a potential target of the widely available lipid-lowering agents such as statins. Statins are the most widely prescribed cholesterol-lowering drugs with the ability to inhibit HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase. Preclinical and clinical safety data have shown that statins do not cause serious adverse effects in humans. However, their long-term administration is associated with a variety of myopatic complaints. The aim of this study was to investigate whether CoQ10 supplementation of animals under high fat diet (HFD) treated with statins is able to bypass the mitochondrial metabolic defects or not? Animals were divided into 7 groups and fed with either regular (RD) or HFD during experiments. The first group considered as regular control and fed with a RD. Groups 2-7 including HFD control, CoQ10 (10mg/kg), simvastatin (30mg/kg), atorvastatin (30mg/kg), simvastatin+CoQ10 or atorvastatin+CoQ10 treated orally for 30 days and fed with HFD. At the end of treatments, the animals were killed and blood samples were collected for biochemical examinations. The rat liver mitochondria were isolated and several mitochondrial indices including succinate dehydrogenase activity (SDA), ATP levels, mitochondrial membrane potential (MMP) and mitochondrial permeability transition pore (MPP) were determined. We found that triglyceride (Tg), cholesterol (Chol) and low-density lipoprotein (LDL) were augmented with HFD compared to RD and treatment with statins remarkably lowered the Tg, Chol and LDL levels. Mitochondrial parameters including, SDA, ATP levels, MMP and MPP were reduced with statin treatment and improved by co-administration with CoQ10.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2015 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mohammadi-Bardbori</LastName>
            <ForeName>Afshin</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Fars 71345-1583, Shiraz, Iran. Electronic address: toxicology@sums.ac.ir.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Najibi</LastName>
            <ForeName>Asma</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Fars 71345-1583, Shiraz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Amirzadegan</LastName>
            <ForeName>Najmeh</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Fars 71345-1583, Shiraz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gharibi</LastName>
            <ForeName>Raziyeh</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Fars 71345-1583, Shiraz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dashti</LastName>
            <ForeName>Ayat</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Fars 71345-1583, Shiraz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Omidi</LastName>
            <ForeName>Mahmoud</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Fars 71345-1583, Shiraz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saeedi</LastName>
            <ForeName>Arastoo</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Fars 71345-1583, Shiraz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ghafarian-Bahreman</LastName>
            <ForeName>Ali</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Fars 71345-1583, Shiraz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Niknahad</LastName>
            <ForeName>Hossein</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Fars 71345-1583, Shiraz, Iran; Pharmaceutical Science Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>05</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Eur J Pharmacol</MedlineTA>
        <NlmUniqueID>1254354</NlmUniqueID>
        <ISSNLinking>0014-2999</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D033681">Mitochondrial Membrane Transport Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000083162">Mitochondrial Permeability Transition Pore</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1339-63-5</RegistryNumber>
          <NameOfSubstance UI="D014451">Ubiquinone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8L70Q75FXE</RegistryNumber>
          <NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EJ27X76M46</RegistryNumber>
          <NameOfSubstance UI="C024989">coenzyme Q10</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001774" MajorTopicYN="N">Blood Chemical Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059305" MajorTopicYN="N">Diet, High-Fat</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008930" MajorTopicYN="N">Mitochondria, Liver</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D033681" MajorTopicYN="N">Mitochondrial Membrane Transport Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000083162" MajorTopicYN="N">Mitochondrial Permeability Transition Pore</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014451" MajorTopicYN="N">Ubiquinone</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Atorvastatin</Keyword>
        <Keyword MajorTopicYN="N">Coenzyme Q10</Keyword>
        <Keyword MajorTopicYN="N">HFD (high fat diet)</Keyword>
        <Keyword MajorTopicYN="N">HMG-CoA reductase inhibitors</Keyword>
        <Keyword MajorTopicYN="N">Mitotoxicity</Keyword>
        <Keyword MajorTopicYN="N">Simvastatin</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>3</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>5</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26007644</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ejphar.2015.05.041</ArticleId>
        <ArticleId IdType="pii">S0014-2999(15)30037-6</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25998538</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-6240</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>1620</Volume>
            <PubDate>
              <Year>2015</Year>
              <Month>Sep</Month>
              <Day>16</Day>
            </PubDate>
          </JournalIssue>
          <Title>Brain research</Title>
          <ISOAbbreviation>Brain Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Extracellular α-crystallin protects astrocytes from cell death through activation of MAPK, PI3K/Akt signaling pathway and blockade of ROS release from mitochondria.</ArticleTitle>
        <Pagination>
          <StartPage>17</StartPage>
          <EndPage>28</EndPage>
          <MedlinePgn>17-28</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.brainres.2015.05.011</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0006-8993(15)00396-0</ELocationID>
        <Abstract>
          <AbstractText>α-Crystallin with two isoforms, αA-crystallin (HSPB4) and αB-crystallin (HSPB5), is found in eye lens, spleen, lung, kidney, cornea, skin, but also in brain. Several studies revealed roles of αA/αB-crystallin in regulating cell viability and protection in the central nervous system. We previously demonstrated that α-crystallin serves as an intracellular protectant in astrocytes. Compared to well-studied intracellular functions of α-crystallin, there is limited proof for the role of α-crystallin as extracellular protectant. In order to clarify protective effects of extracellular αA/αB-crystallin, we exposed astrocytes to the toxic agents, staurosporine or C2-ceramide, or serum-starvation in the presence of αA/αB-crystallin. Extracellular αA/αB-crystallin protected astrocytes from staurosporine- and C2-ceramide-induced cell death. In addition, extracellular αB-crystallin/HSPB5 effectively promoted astrocytes viability through phosphatidylinositol 3 kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) and extracellular signal-regulated kinase 1/2 (ERK1/2), p38 mitogen-activated protein kinases (p38) and c-Jun N-terminal kinases (JNK) signaling pathways under serum-deprivation. Furthermore, αB-crystallin/HSPB5 decreases the staurosporine-mediated cleavage of caspase 3 through PI3K/Akt signaling preventing apoptosis of astrocytes. Thus, the current study indicates that extracellular αA/αB-crystallin protects astrocytes exposed to various harmful stimuli. Furthermore, application of αB-crystallin/HSPB5 to isolated rat brain mitochondria inhibits ROS generation induced by complex III inhibition with Antimycin A.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2015 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Zhihui</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Institut für Neurobiochemie (Institut für Inflammation und Neurodegeneration), Otto-von-Guericke-Universität Magdeburg, Medizinische Fakultät, Leipziger Straße 44, Magdeburg 39120, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Rongyu</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Institut für Neurobiochemie (Institut für Inflammation und Neurodegeneration), Otto-von-Guericke-Universität Magdeburg, Medizinische Fakultät, Leipziger Straße 44, Magdeburg 39120, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stricker</LastName>
            <ForeName>Rolf</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Institut für Neurobiochemie (Institut für Inflammation und Neurodegeneration), Otto-von-Guericke-Universität Magdeburg, Medizinische Fakultät, Leipziger Straße 44, Magdeburg 39120, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Reiser</LastName>
            <ForeName>Georg</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Institut für Neurobiochemie (Institut für Inflammation und Neurodegeneration), Otto-von-Guericke-Universität Magdeburg, Medizinische Fakultät, Leipziger Straße 44, Magdeburg 39120, Germany. Electronic address: georg.reiser@med.ovgu.de.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>05</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Brain Res</MedlineTA>
        <NlmUniqueID>0045503</NlmUniqueID>
        <ISSNLinking>0006-8993</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C064769">N-acetylsphingosine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D038201">alpha-Crystallins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>642-15-9</RegistryNumber>
          <NameOfSubstance UI="D000968">Antimycin A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546845">mTOR protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>H88EPA0A3N</RegistryNumber>
          <NameOfSubstance UI="D019311">Staurosporine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>NGZ37HRE42</RegistryNumber>
          <NameOfSubstance UI="D013110">Sphingosine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000968" MajorTopicYN="N">Antimycin A</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005110" MajorTopicYN="N">Extracellular Space</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013110" MajorTopicYN="N">Sphingosine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019311" MajorTopicYN="N">Staurosporine</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D038201" MajorTopicYN="N">alpha-Crystallins</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">Astrocytes</Keyword>
        <Keyword MajorTopicYN="N">Neuroprotection</Keyword>
        <Keyword MajorTopicYN="N">Reactive oxygen species</Keyword>
        <Keyword MajorTopicYN="N">Small heat shock proteins HSPB4 and HSPB5</Keyword>
        <Keyword MajorTopicYN="N">&#x3b1;-Crystallin</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2014</Year>
          <Month>8</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25998538</ArticleId>
        <ArticleId IdType="doi">10.1016/j.brainres.2015.05.011</ArticleId>
        <ArticleId IdType="pii">S0006-8993(15)00396-0</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25981922</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>08</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>12</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1618-095X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2015</Year>
              <Month>May</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Phytomedicine : international journal of phytotherapy and phytopharmacology</Title>
          <ISOAbbreviation>Phytomedicine</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Marsdenia tenacissima extract enhances gefitinib efficacy in non-small cell lung cancer xenografts.</ArticleTitle>
        <Pagination>
          <StartPage>560</StartPage>
          <EndPage>567</EndPage>
          <MedlinePgn>560-7</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.phymed.2015.03.001</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0944-7113(15)00067-7</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The stem of Marsdenia tenacissima (Roxb.) Wight et Arn. has long been used as a medicine to treat cancer in China. Our previous in vitro results showed that Marsdenia tenacissima extract (MTE) overcomes gefitinib resistance in non-small cell lung cancer (NSCLC) cells. However, it is unknown whether MTE could enhance gefitinib efficacy in vivo. The present study was intended to investigate the in vivo anti-tumour activity of MTE combined with gefitinib.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Human NSCLC H460 (K-ras mutation) or H1975 cells (EGFR T790M mutation) were subcutaneously inoculated into nude mice. Tumour volume and body weight were measured regularly. Resected tumours were weighed after the animals were sacrificed. Immunoblotting or immunohistochemistry was used to assess the cellular proliferation and apoptosis in xenograft tumour tissue. Expression of the EGFR downstream pathways and c-Met were measured with western blot analysis to explore possible mechanisms.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">MTE (5, 10, 20 g/kg) dose-dependently reduced tumour growth and induced cell apoptosis. MTE suppressed EGFR related signals, and 20 g/kg was the most effective dose. Low-dose MTE (5 g/kg) significantly enhanced gefitinib efficacy in resistant H460 and H1975 xenografts. The combination inhibited tumour proliferation and induced cell apoptosis in both resistant NSCLC xenografts. Constitutive activation of the PI3K/Akt and MEK/ERK pathways is related to EGFR-TKI resistance. Accordingly, phosphorylation of PI3K/Akt/mTOR and ERK1/2 was suppressed after combination treatment. Simultaneously, cross-talked c-Met and EGFR were also prominently lowered in the presence of MTE combined with gefitinib.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The present results suggest that the combination of MTE and gefitinib may be a promising therapeutic approach to enhance gefitinib efficacy in resistant NSCLC.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2015 Elsevier GmbH. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Shu-Yan</ForeName>
            <Initials>SY</Initials>
            <AffiliationInfo>
              <Affiliation>Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital &amp; Institute, Beijing 100142, PR China; Department of Integration of Chinese and Western Medicine, Peking University School of Oncology, Beijing 100142, PR China. Electronic address: shuyanhan@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital &amp; Institute, Beijing 100142, PR China; Department of Cell Biology, Peking University Cancer Hospital &amp; Institute, Beijing 100142, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Hong</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital &amp; Institute, Beijing 100142, PR China; Department of Integration of Chinese and Western Medicine, Peking University School of Oncology, Beijing 100142, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Ning</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital &amp; Institute, Beijing 100142, PR China; Department of Integration of Chinese and Western Medicine, Peking University School of Oncology, Beijing 100142, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Fei</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital &amp; Institute, Beijing 100142, PR China; Department of Integration of Chinese and Western Medicine, Peking University School of Oncology, Beijing 100142, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>An</LastName>
            <ForeName>Guo</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital &amp; Institute, Beijing 100142, PR China; Laboratory Animal Unit, Peking University Cancer Hospital &amp; Institute, Beijing 100142, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Ping-Ping</ForeName>
            <Initials>PP</Initials>
            <AffiliationInfo>
              <Affiliation>Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital &amp; Institute, Beijing 100142, PR China; Department of Integration of Chinese and Western Medicine, Peking University School of Oncology, Beijing 100142, PR China. Electronic address: lppma123@sina.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>03</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Phytomedicine</MedlineTA>
        <NlmUniqueID>9438794</NlmUniqueID>
        <ISSNLinking>0944-7113</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S65743JHBS</RegistryNumber>
          <NameOfSubstance UI="D000077156">Gefitinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077156" MajorTopicYN="N">Gefitinib</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D031101" MajorTopicYN="N">Marsdenia</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011799" MajorTopicYN="N">Quinazolines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Gefitinib resistance</Keyword>
        <Keyword MajorTopicYN="N">H1975</Keyword>
        <Keyword MajorTopicYN="N">H460</Keyword>
        <Keyword MajorTopicYN="N">Marsdenia tenacissima extract</Keyword>
        <Keyword MajorTopicYN="N">NSCLC xenografts</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2014</Year>
          <Month>10</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2015</Year>
          <Month>2</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>3</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>8</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25981922</ArticleId>
        <ArticleId IdType="doi">10.1016/j.phymed.2015.03.001</ArticleId>
        <ArticleId IdType="pii">S0944-7113(15)00067-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25961538</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>03</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2768-6698</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2015</Year>
              <Month>Jun</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in bioscience (Landmark edition)</Title>
          <ISOAbbreviation>Front Biosci (Landmark Ed)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>L-arginine improves DNA synthesis in LPS-challenged enterocytes.</ArticleTitle>
        <Pagination>
          <StartPage>989</StartPage>
          <EndPage>1003</EndPage>
          <MedlinePgn>989-1003</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The neonatal small intestine is susceptible to damage by endotoxin, and this cytotoxicity may involve intracellular generation of reactive oxygen species (ROS), resulting in DNA damage and mitochondrial dysfunction. L-Arginine (Arg) confers a cytoprotective effect on lipopolysaccharide (LPS)-treated enterocytes through activation of the mammalian target of the rapamycin (mTOR) signaling pathway. Arg improves DNA synthesis and mitochondrial bioenergetics, which may also be responsible for beneficial effects of Arg on intestinal mucosal cells. In support of this notion, results of recent studies indicate that elevated Arg concentrations enhances DNA synthesis, cell-cycle progression, and mitochondrial bioenergetics in LPS-treated intestinal epithelial cells through mechanisms involving activation of the PI3K-Akt pathway. These findings provide a biochemical basis for dietary Arg supplementation to improve the regeneration and repair of the small-intestinal mucosa in both animals and humans.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tan</LastName>
            <ForeName>Bi'e</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Observation and Experiment Station of Animal Nutrition and Feed Science in South-Central China, Ministry of Agriculture; Hunan Provincial Engineering Research Center for Healthy Livestock and Poultry Production, Key Laboratory of Agro-ecological Processes, bietan@isa.ac.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Hao</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiong</LastName>
            <ForeName>Xia</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Guangran</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yin</LastName>
            <ForeName>Yulong</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Bo</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hou</LastName>
            <ForeName>Yongqing</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Guoyao</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Animal Science, Texas A&amp;M University.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>06</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Singapore</Country>
        <MedlineTA>Front Biosci (Landmark Ed)</MedlineTA>
        <NlmUniqueID>101612996</NlmUniqueID>
        <ISSNLinking>2768-6698</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-49-2</RegistryNumber>
          <NameOfSubstance UI="D004247">DNA</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>94ZLA3W45F</RegistryNumber>
          <NameOfSubstance UI="D001120">Arginine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001120" MajorTopicYN="N">Arginine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020895" MajorTopicYN="N">Enterocytes</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>3</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25961538</ArticleId>
        <ArticleId IdType="doi">10.2741/4352</ArticleId>
        <ArticleId IdType="pii">4352</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25926716</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>02</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1177-8881</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>9</Volume>
            <PubDate>
              <Year>2015</Year>
            </PubDate>
          </JournalIssue>
          <Title>Drug design, development and therapy</Title>
          <ISOAbbreviation>Drug Des Devel Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Schisandrin B inhibits cell growth and induces cellular apoptosis and autophagy in mouse hepatocytes and macrophages: implications for its hepatotoxicity.</ArticleTitle>
        <Pagination>
          <StartPage>2001</StartPage>
          <EndPage>2027</EndPage>
          <MedlinePgn>2001-27</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2147/DDDT.S77071</ELocationID>
        <Abstract>
          <AbstractText>A number of drugs and herbal compounds have been documented to cause hepatoxicity. Schisandrin B (Sch B) is an active dibenzocyclooctadiene isolated from Schisandrae fructus, with a wide array of pharmacological activities. However, the potential hepatotoxicity of Sch B is a major safety concern, and the underlying mechanism for Sch B-induced liver toxic effects is not fully elucidated. In the present study, we aimed to investigate the liver toxic effects and the molecular mechanisms of Sch B in mouse liver and macrophage cells. The results have shown that Sch B exhibits potent grow inhibitory, proapoptotic, and proautophagic effects in AML-12 and RAW 264.7 cells. Sch B markedly arrested cells in G1 phase in both cell lines, accompanied by the down-regulation of cyclin dependent kinase 2 (CDK2) and cyclin D1 and up-regulation of p27 Kip1 and checkpoint kinase 1. Furthermore, Sch B markedly increased the apoptosis of AML-12 and RAW 264.7 cells with a decrease in the expression of B-cell lymphoma-extra-large and (Bcl-xl) B-cell lymphoma 2 (Bcl-2), but an increase in the expression of B-cell lymphoma 2-associated X protein (Bax). Sch B promoted the cleavage of caspase 3 and poly-adenosine diphosphate-ribose polymerase (PARP) in both cell lines. Additionally, Sch B significantly induced autophagy of AML-12 and RAW 264.7 cells. Sch B inhibited the activation of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling pathway, as indicated by their altered phosphorylation, contributing to the proautophagic effect of Sch B. Taken together, our findings show that the inducing effects of Sch B on cell cycle arrest, apoptosis, and autophagy may contribute to its liver toxic effects, which might provide a clue for the investigation of the molecular toxic targets and underlying mechanisms for Sch B-induced hepatotoxicity in herbal consumers. More studies are warranted to fully delineate the underlying mechanisms, efficacy, and safety of Sch B for clinical use.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, People's Republic of China ; Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Zhi-Wei</ForeName>
            <Initials>ZW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jin</LastName>
            <ForeName>Hua</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Chengbin</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Zhi-Xu</ForeName>
            <Initials>ZX</Initials>
            <AffiliationInfo>
              <Affiliation>Guizhou Provincial Key Laboratory for Regenerative Medicine, Stem Cell and Tissue Engineering Research Center and Sino-US Joint Laboratory for Medical Sciences, Guiyang Medical University, Guiyang, Guizhou, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Zhi-Ling</ForeName>
            <Initials>ZL</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ko</LastName>
            <ForeName>Kam-Ming</ForeName>
            <Initials>KM</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Life Science, Hong Kong University of Science and Technology, Hong Kong, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Tianxin</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, University of Utah and Salt Lake Veterans Affairs Medical Center, Salt Lake City, UT, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xueji</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Research Center for Bioengineering and Sensing Technology, University of Science and Technology Beijing, Beijing, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Si-Yuan</ForeName>
            <Initials>SY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Shu-Feng</ForeName>
            <Initials>SF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>04</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>New Zealand</Country>
        <MedlineTA>Drug Des Devel Ther</MedlineTA>
        <NlmUniqueID>101475745</NlmUniqueID>
        <ISSNLinking>1177-8881</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D034242">Cyclooctanes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017705">Lignans</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011083">Polycyclic Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>02XA4X3KZW</RegistryNumber>
          <NameOfSubstance UI="C015499">schizandrin B</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002455" MajorTopicYN="N">Cell Division</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056486" MajorTopicYN="N">Chemical and Drug Induced Liver Injury</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034242" MajorTopicYN="N">Cyclooctanes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016193" MajorTopicYN="N">G1 Phase</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022781" MajorTopicYN="N">Hepatocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017705" MajorTopicYN="N">Lignans</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008930" MajorTopicYN="N">Mitochondria, Liver</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011083" MajorTopicYN="N">Polycyclic Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016196" MajorTopicYN="N">S Phase</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">AML-12 cell</Keyword>
        <Keyword MajorTopicYN="N">Bcl-2</Keyword>
        <Keyword MajorTopicYN="N">RAW 264.7 cell</Keyword>
        <Keyword MajorTopicYN="N">herbal medicine</Keyword>
        <Keyword MajorTopicYN="N">liver toxicity</Keyword>
        <Keyword MajorTopicYN="N">mTOR</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>5</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>2</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25926716</ArticleId>
        <ArticleId IdType="pmc">PMC4403607</ArticleId>
        <ArticleId IdType="doi">10.2147/DDDT.S77071</ArticleId>
        <ArticleId IdType="pii">dddt-9-2001</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354(7):731&#x2013;739.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16481640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stedman C. Herbal hepatotoxicity. Semin Liver Dis. 2002;22(2):195&#x2013;206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12016550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grant LM, Rockey DC. Drug-induced liver injury. Curr Opin Gastroenterol. 2012;28(3):198&#x2013;202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22450893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology. 2006;43(3):618&#x2013;631.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16496329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peters TS. Do preclinical testing strategies help predict human hepatotoxic potentials? Toxicol Pathol. 2005;33(1):146&#x2013;154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15805066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suk KT, Kim DJ. Drug-induced liver injury: present and future. Clin Mol Hepatol. 2012;18(3):249&#x2013;257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3467427</ArticleId>
            <ArticleId IdType="pubmed">23091804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ostapowicz G, Fontana RJ, Schiodt FV, et al. U.S. Acute Liver Failure Study Group Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137(12):947&#x2013;954.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12484709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao P, Wang C, Liu W, et al. Causes and outcomes of acute liver failure in China. PLoS One. 2013;8(11):e80991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3838343</ArticleId>
            <ArticleId IdType="pubmed">24278360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf. 2007;30(4):277&#x2013;294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17408305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol. 2007;47:513&#x2013;539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16879083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med. 2008;23(6):854&#x2013;859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2517879</ArticleId>
            <ArticleId IdType="pubmed">18415652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dunnick JK, Nyska A. The toxicity and pathology of selected dietary herbal medicines. Toxicol Pathol. 2013;41(2):374&#x2013;386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23262639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teschke R, Wolff A, Frenzel C, Schulze J, Eickhoff A. Herbal hepatotoxicity: a tabular compilation of reported cases. Liver Int. 2012;32(10):1543&#x2013;1556.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22928722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Navarro VJ, Barnhart H, Bonkovsky HL, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology. 2014;60(4):1399&#x2013;1408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4293199</ArticleId>
            <ArticleId IdType="pubmed">25043597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y, Yang L, Liao Z, He X, Guo H. Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21,789 patients. Eur J Gastroenterol Hepatol. 2013;25(7):825&#x2013;829.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23510965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saper RB, Phillips RS, Sehgal A, et al. Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet. JAMA. 2008;300(8):915&#x2013;923.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2755247</ArticleId>
            <ArticleId IdType="pubmed">18728265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stickel F, Droz S, Patsenker E, B&#xf6;gli-Stuber K, Aebi B, Leib SL. Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis. J Hepatol. 2009;50(1):111&#x2013;117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19010564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009;69(13):1777&#x2013;1798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19719333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu M, Yeung RY, Lin KF, Li RC. Improvement of phase I drug metabolism with Schisandra chinensis against CCl4 hepatotoxicity in a rat model. Planta Med. 2000;66(6):521&#x2013;525.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10985077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang O, Cheng Q, Liu J, et al. Hepatoprotective effect of Schisandra chinensis (Turcz.) Baill. lignans and its formula with Rubus idaeus on chronic alcohol-induced liver injury in mice. Food Funct. 2014;5(11):3018&#x2013;3025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25255087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Pan SY, Zhou SF, et al. Time and dose relationships between schisandrin B- and Schisandrae fructus oil-induced hepatotoxicity and the associated elevations in hepatic and serum triglyceride levels in mice. Drug Des Devel Ther. 2014;8:1429&#x2013;1439.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4179757</ArticleId>
            <ArticleId IdType="pubmed">25278745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan SY, Jia H, Zhang Y, et al. Novel mouse model of combined hyperlipidemia associated with steatosis and liver injury by a single-dose intragastric administration of schisandrin B/cholesterol/bile salts mixture. J Pharmacol Sci. 2013;123(2):110&#x2013;119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24096833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan SY, Dong H, Han YF, Li WY, Zhao XY, Ko KM. A novel experimental model of acute hypertriglyceridemia induced by schisandrin B. Eur J Pharmacol. 2006;537(1&#x2013;3):200&#x2013;204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16624278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smejkal K, Slapetov&#xe1; T, Krmen&#x10d;&#xed;k P, et al. Evaluation of cytotoxic activity of Schisandra chinensis lignans. Planta Med. 2010;76(15):1672&#x2013;1677.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20458670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chyau CC, Ker YB, Chang CH, et al. Schisandra chinensis peptidoglycan-assisted transmembrane transport of lignans uniquely altered the pharmacokinetic and pharmacodynamic mechanisms in human HepG2 cell model. PLoS One. 2014;9(1):e85165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3903492</ArticleId>
            <ArticleId IdType="pubmed">24475039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiang SS, Wang XA, Li HF, et al. Schisandrin B induces apoptosis and cell cycle arrest of gallbladder cancer cells. Molecules. 2014;19(9):13235&#x2013;13250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6271519</ArticleId>
            <ArticleId IdType="pubmed">25165862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ip SP, Poon MK, Wu SS, et al. Effect of schisandrin B on hepatic glutathione antioxidant system in mice: protection against carbon tetrachloride toxicity. Planta Med. 1995;61(5):398&#x2013;401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7480197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li YC, He SM, He ZM, et al. Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells. Cancer Lett. 2014;344(2):239&#x2013;259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24280585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murray MM, Bui T, Smith M, et al. Staurosporine is chemoprotective by inducing G1 arrest in a Chk1- and pRb-dependent manner. Carcinogenesis. 2013;34(10):2244&#x2013;2252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3786379</ArticleId>
            <ArticleId IdType="pubmed">23722650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shibutani ST, de la Cruz AF, Tran V, et al. Intrinsic negative cell cycle regulation provided by PIP box- and Cul4Cdt2-mediated destruction of E2f1 during S phase. Dev Cell. 2008;15(6):890&#x2013;900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2644461</ArticleId>
            <ArticleId IdType="pubmed">19081076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. 2009;43:67&#x2013;93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2831538</ArticleId>
            <ArticleId IdType="pubmed">19653858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boya P, Reggiori F, Codogno P. Emerging regulation and functions of autophagy. Nat Cell Biol. 2013;15(7):713&#x2013;720.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7097732</ArticleId>
            <ArticleId IdType="pubmed">23817233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103&#x2013;141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23333322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou SF, Xue CC, Yu XQ, Wang G. Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. Curr Drug Metab. 2007;8(6):526&#x2013;553.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17691916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis. 2002;6(3):755&#x2013;774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12362579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaplowitz N. Drug-induced liver injury. Clin Infect Dis. 2004;38(Suppl 2):S44&#x2013;S48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14986274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>G&#xf3;mez-Lech&#xf3;n MJ, Ponsoda X, Bort R, Castell JV. The use of cultured hepatocytes to investigate the metabolism of drugs and mechanisms of drug hepatotoxicity. Altern Lab Anim. 2001;29(3):225&#x2013;231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11387019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thakur V, Pritchard MT, McMullen MY, Nagy LE. Adiponectin normalizes LPS-stimulated TNF-&#x3b1; production by rat Kupffer cells after chronic ethanol feeding. Am J Physiol Gastrointest Liver Physiol. 2006;290(5):G998&#x2013;G1007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1975781</ArticleId>
            <ArticleId IdType="pubmed">16410364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandal P, Roychowdhury S, Park PH, Pratt BT, Roger T, Nagy LE. Adiponectin and heme oxygenase-1 suppress TLR4/MyD88-independent signaling in rat Kupffer cells and in mice after chronic ethanol exposure. J Immunol. 2010;185(8):4928&#x2013;4937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5085268</ArticleId>
            <ArticleId IdType="pubmed">20861358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen Z, Ajmo JM, Rogers CQ, et al. Role of SIRT1 in regulation of LPS- or two ethanol metabolite-induced TNF-&#x3b1; production in cultured macrophage cell lines. Am J Physiol Gastrointest Liver Physiol. 2009;296(5):G1047&#x2013;G1053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2696216</ArticleId>
            <ArticleId IdType="pubmed">19299582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407(6805):770&#x2013;776.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11048727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bertoli C, Skotheim JM, de Bruin RA. Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol. 2013;14(8):518&#x2013;528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4569015</ArticleId>
            <ArticleId IdType="pubmed">23877564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masamha CP, Benbrook DM. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res. 2009;69(16):6565&#x2013;6572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19638577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi YJ, Saez B, Anders L, et al. D-cyclins repress apoptosis in hematopoietic cells by controlling death receptor Fas and its ligand FasL. Dev Cell. 2014;30(3):255&#x2013;267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4134362</ArticleId>
            <ArticleId IdType="pubmed">25087893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo Y, Hurwitz J, Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature. 1995;375(6527):159&#x2013;161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7753174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003;36(3):131&#x2013;149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6496723</ArticleId>
            <ArticleId IdType="pubmed">12814430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carreira S, Goodall J, Aksan I, et al. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature. 2005;433(7027):764&#x2013;769.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15716956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol. 2003;13(2):65&#x2013;70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12559756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O&#x2019;Connell MJ, Walworth NC, Carr AM. The G2-phase DNA-damage checkpoint. Trends Cell Biol. 2000;10(7):296&#x2013;303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10856933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>S&#xf8;rensen CS, Hansen LT, Dziegielewski J, et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol. 2005;7(2):195&#x2013;201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15665856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reinhardt HC, Yaffe MB. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol. 2009;21(2):245&#x2013;255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2699687</ArticleId>
            <ArticleId IdType="pubmed">19230643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495&#x2013;516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2117903</ArticleId>
            <ArticleId IdType="pubmed">17562483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C, Youle RJ. The role of mitochondria in apoptosis. Annu Rev Genet. 2009;43:95&#x2013;118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4762029</ArticleId>
            <ArticleId IdType="pubmed">19659442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang X, Wang X. Cytochrome C-mediated apoptosis. Annu Rev Biochem. 2004;73:87&#x2013;106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15189137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li L, Lu Q, Shen Y, Hu X. Schisandrin B enhances doxorubicin-induced apoptosis of cancer cells but not normal cells. Biochem Pharmacol. 2006;71(5):584&#x2013;595.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16405922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizushima N. Autophagy: process and function. Genes Dev. 2007;21(22):2861&#x2013;2873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18006683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Codogno P. Shining light on autophagy. Nat Rev Mol Cell Biol. 2014;15(3):153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24496390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung CH, Ro SH, Cao J, Otto NM, Kim DH. mTOR regulation of autophagy. FEBS Lett. 2010;584(7):1287&#x2013;1295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2846630</ArticleId>
            <ArticleId IdType="pubmed">20083114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li M, Khambu B, Zhang H, et al. Suppression of lysosome function induces autophagy via a feedback down-regulation of MTOR complex 1 (MTORC1) activity. J Biol Chem. 2013;288(50):35769&#x2013;35780.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3861628</ArticleId>
            <ArticleId IdType="pubmed">24174532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009;122(Pt 20):3589&#x2013;3594.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2758797</ArticleId>
            <ArticleId IdType="pubmed">19812304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shang L, Wang X. AMPK and mTOR coordinate the regulation of Ulk1 and mammalian autophagy initiation. Autophagy. 2011;7(8):924&#x2013;926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21521945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan HX, Russell RC, Guan KL. Regulation of PIK3C3/VPS34 complexes by MTOR in nutrient stress-induced autophagy. Autophagy. 2013;9(12):1983&#x2013;1995.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4028342</ArticleId>
            <ArticleId IdType="pubmed">24013218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene. 2008;27(41):5527&#x2013;5541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18794886</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25909282</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>02</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2045-2322</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>5</Volume>
            <PubDate>
              <Year>2015</Year>
              <Month>Apr</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>Scientific reports</Title>
          <ISOAbbreviation>Sci Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Synergistic protection of N-acetylcysteine and ascorbic acid 2-phosphate on human mesenchymal stem cells against mitoptosis, necroptosis and apoptosis.</ArticleTitle>
        <Pagination>
          <StartPage>9819</StartPage>
          <MedlinePgn>9819</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">9819</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/srep09819</ELocationID>
        <Abstract>
          <AbstractText>Human mesenchymal stem cells (hMSCs) contribute to ischemic tissue repair, regeneration, and possess ability to self-renew. However, poor viability of transplanted hMSCs within ischemic tissues has limited its therapeutic efficiency. Therefore, it is urgent to explore new method to improve the viability of the grafted cells. By using a systematic analysis, we reveal the mechanism of synergistic protection of N-acetylcysteine (NAC) and ascorbic acid 2-phosphate (AAP) on hMSCs that were under H2O2-induced oxidative stress. The combined treatment of NAC and AAP (NAC/AAP) reduces reactive oxygen species (ROS) generation, stabilizes mitochondrial membrane potential and decreases mitochondrial fission/fragmentation due to oxidative stress. Mitochondrial fission/fragmentation is a major prologue of mitoptosis. NAC/AAP prevents apoptotic cell death via decreasing the activation of BAX, increasing the expression of BCL2, and reducing cytochrome c release from mitochondria that might lead to the activation of caspase cascade. Stabilization of mitochondria also prevents the release of AIF, and its nuclear translocation which may activate necroptosis via H2AX pathway. The decreasing of mitoptosis is further studied by MicroP image analysis, and is associated with decreased activation of Drp1. In conclusion, NAC/AAP protects mitochondria from H2O2-induced oxidative stress and rescues hMSCs from mitoptosis, necroptosis and apoptosis.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Chia-Jung</ForeName>
            <Initials>CJ</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Li-Yi</ForeName>
            <Initials>LY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Research, Buddhist Tzu Chi General Hospital, Hualien, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pang</LastName>
            <ForeName>Cheng-Yoong</ForeName>
            <Initials>CY</Initials>
            <AffiliationInfo>
              <Affiliation>1] Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan [2] Department of Medical Research, Buddhist Tzu Chi General Hospital, Hualien, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>04</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Sci Rep</MedlineTA>
        <NlmUniqueID>101563288</NlmUniqueID>
        <ISSNLinking>2045-2322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C494829">AIFM1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051033">Apoptosis Inducing Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C468783">H2AX protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006657">Histones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020011">Protective Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051028">bcl-2-Associated X Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>23313-12-4</RegistryNumber>
          <NameOfSubstance UI="C011669">ascorbate-2-phosphate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-43-6</RegistryNumber>
          <NameOfSubstance UI="D045304">Cytochromes c</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BBX060AN9V</RegistryNumber>
          <NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.1.-</RegistryNumber>
          <NameOfSubstance UI="D020558">GTP Phosphohydrolases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.5.5</RegistryNumber>
          <NameOfSubstance UI="C110768">DNM1L protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.5.5</RegistryNumber>
          <NameOfSubstance UI="D034281">Dynamins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PQ6CK8PD0R</RegistryNumber>
          <NameOfSubstance UI="D001205">Ascorbic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>WYQ7N0BPYC</RegistryNumber>
          <NameOfSubstance UI="D000111">Acetylcysteine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000111" MajorTopicYN="N">Acetylcysteine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051033" MajorTopicYN="N">Apoptosis Inducing Factor</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001205" MajorTopicYN="N">Ascorbic Acid</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045304" MajorTopicYN="N">Cytochromes c</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034281" MajorTopicYN="N">Dynamins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020558" MajorTopicYN="N">GTP Phosphohydrolases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006657" MajorTopicYN="N">Histones</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059630" MajorTopicYN="N">Mesenchymal Stem Cells</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009336" MajorTopicYN="N">Necrosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020011" MajorTopicYN="N">Protective Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019253" MajorTopicYN="N">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051028" MajorTopicYN="N">bcl-2-Associated X Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>1</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>3</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>4</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>4</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>3</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25909282</ArticleId>
        <ArticleId IdType="pmc">PMC4408980</ArticleId>
        <ArticleId IdType="doi">10.1038/srep09819</ArticleId>
        <ArticleId IdType="pii">srep09819</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Herrmann R. P., Sturm M. J. Adult human mesenchymal stromal cells and the treatment of graft versus host disease. Stem Cells Cloning 7, 45&#x2013;52 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3945047</ArticleId>
            <ArticleId IdType="pubmed">24627644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S., Qu X., Zhao R. C. Clinical applications of mesenchymal stem cells. J. Hematol. Oncol. 5, 19 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3416655</ArticleId>
            <ArticleId IdType="pubmed">22546280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittenger M. F. , et al. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143&#x2013;147 (1999).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10102814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kern S., Eichler H., Stoeve J., Kluter H., Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 24, 1294&#x2013;1301 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16410387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toma C., Wagner W. R., Bowry S., Schwartz A., Villanueva F. Fate of culture&#x2013;expanded mesenchymal stem cells in the microvasculature: in vivo observations of cell kinetics. Circ. Res. 104, 398&#x2013;402 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3700384</ArticleId>
            <ArticleId IdType="pubmed">19096027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu X. Y., Lerman A., Lerman L. O. Concise review: mesenchymal stem cell treatment for ischemic kidney disease. Stem Cells 31, 1731&#x2013;1736 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3795813</ArticleId>
            <ArticleId IdType="pubmed">23766020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Souidi N., Stolk M., Seifert M. Ischemia&#x2013;reperfusion injury: beneficial effects of mesenchymal stromal cells. Curr. Opin. Organ. Transplant. 18, 34&#x2013;43 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23254704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen C. T., Shih Y. R., Kuo T. K., Lee O. K., Wei Y. H. Coordinated changes of mitochondrial biogenesis and antioxidant enzymes during osteogenic differentiation of human mesenchymal stem cells. Stem Cells 26, 960&#x2013;968 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18218821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanda Y., Hinata T., Kang S. W., Watanabe Y. Reactive oxygen species mediate adipocyte differentiation in mesenchymal stem cells. Life Sci. 89, 250&#x2013;258 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21722651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chapple I. L. Reactive oxygen species and antioxidants in inflammatory diseases. J. Clin. Periodontol. 24, 287&#x2013;296 (1997).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9178107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ott M., Gogvadze V., Orrenius S., Zhivotovsky B. Mitochondria, oxidative stress and cell death. Apoptosis 12, 913&#x2013;922 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17453160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou J. , et al. Autophagy prevents irradiation injury and maintains stemness through decreasing ROS generation in mesenchymal stem cells. Cell Death Dis. 4, e844 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3824648</ArticleId>
            <ArticleId IdType="pubmed">24113178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCully J. D., Wakiyama H., Hsieh Y. J., Jones M., Levitsky S. Differential contribution of necrosis and apoptosis in myocardial ischemia&#x2013;reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 286, H1923&#x2013;1935 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14715509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iliodromitis E. K., Lazou A., Kremastinos D. T. Ischemic preconditioning: protection against myocardial necrosis and apoptosis. Vasc. Health Risk Manag. 3, 629&#x2013;637 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2291307</ArticleId>
            <ArticleId IdType="pubmed">18078014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sart S., Ma T., Li Y. Preconditioning stem cells for in vivo delivery. Biores. Open. Access 3, 137&#x2013;149 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4120806</ArticleId>
            <ArticleId IdType="pubmed">25126478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takamizawa S., et al. Effects of ascorbic acid and ascorbic acid 2-phosphate, a long-acting vitamin C derivative, on the proliferation and differentiation of human osteoblast-like cells. Cell. Biol. Int. 28, 255&#x2013;265 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15109981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu J., Tu Y. K., Tang Y. B., Cheng N. C. Stemness and transdifferentiation of adipose-derived stem cells using L-ascorbic acid 2-phosphate-induced cell sheet formation. Biomaterials 35, 3516&#x2013;3526 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24462360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Millea P. J. N-acetylcysteine: multiple clinical applications. Am. Fam. Physician 80, 265&#x2013;269 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19621836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li S., Deng Y., Feng J., Ye W. Oxidative preconditioning promotes bone marrow mesenchymal stem cells migration and prevents apoptosis. Cell. Biol. Int. 33, 411&#x2013;418 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19356708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin I., Muraglia A., Campanile G., Cancedda R., Quarto R. Fibroblast growth factor-2 supports ex vivo expansion and maintenance of osteogenic precursors from human bone marrow. Endocrinology 138, 4456&#x2013;4462 (1997).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9322963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun L. Y. , et al. Antioxidants cause rapid expansion of human adipose-derived mesenchymal stem cells via CDK and CDK inhibitor regulation. J. Biomed. Sci. 20, 53 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3751058</ArticleId>
            <ArticleId IdType="pubmed">23915242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsai C. C. , et al. Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST. Blood 117, 459&#x2013;469 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20952688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Green D. R., Reed J. C. Mitochondria and apoptosis. Science 281, 1309&#x2013;1312 (1998).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9721092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vandenabeele P., Galluzzi L., Vanden Berghe T., Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat. Rev. Mol. Cell. Biol. 11, 700&#x2013;714 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20823910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linkermann A., Green D. R. Necroptosis. N. Engl. J. Med. 370, 455&#x2013;465 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4035222</ArticleId>
            <ArticleId IdType="pubmed">24476434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reed J. C., Kroemer G. Mechanisms of mitochondrial membrane permeabilization. Cell Death Differ 7, 1145 (2000).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11175250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Artus C. , et al. AIF promotes chromatinolysis and caspase-independent programmed necrosis by interacting with histone H2AX. EMBO J. 29, 1585&#x2013;1599 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2876946</ArticleId>
            <ArticleId IdType="pubmed">20360685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baritaud M. , et al. AIF-mediated caspase-independent necroptosis requires ATM and DNA-PK-induced histone H2AX Ser139 phosphorylation. Cell Death Dis. 3, e390 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3461360</ArticleId>
            <ArticleId IdType="pubmed">22972376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vermes I., Haanen C., Steffens-Nakken H., Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods. 184, 39&#x2013;51 (1995).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7622868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nikoletopoulou V., Markaki M., Palikaras K., Tavernarakis N. Crosstalk between apoptosis, necrosis and autophagy. Biochim. Biophys. Acta. 1833, 3448&#x2013;3459 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23770045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng J. Y. , et al. Automatic morphological subtyping reveals new roles of caspases in mitochondrial dynamics. PLoS Comput. Biol. 7, e1002212 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3188504</ArticleId>
            <ArticleId IdType="pubmed">21998575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jangamreddy J. R., Los M. J. Mitoptosis, a novel mitochondrial death mechanism leading predominantly to activation of autophagy. Hepat. Mon. 12, e6159 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3475017</ArticleId>
            <ArticleId IdType="pubmed">23087751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Estaquier J., Arnoult D. Inhibiting Drp1-mediated mitochondrial fission selectively prevents the release of cytochrome c during apoptosis. Cell Death Differ. 14, 1086&#x2013;1094 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17332775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi K. M. , et al. Effect of ascorbic acid on bone marrow-derived mesenchymal stem cell proliferation and differentiation. J. Biosci. Bioeng. 105, 586&#x2013;594 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18640597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Langenbach F., Handschel J. Effects of dexamethasone, ascorbic acid and beta-glycerophosphate on the osteogenic differentiation of stem cells in vitro. Stem Cell Res. Ther. 4, 117 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3854789</ArticleId>
            <ArticleId IdType="pubmed">24073831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao N. , et al. Ascorbic acid enhances the cardiac differentiation of induced pluripotent stem cells through promoting the proliferation of cardiac progenitor cells. Cell Res. 22, 219&#x2013;236 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3351910</ArticleId>
            <ArticleId IdType="pubmed">22143566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang F. W. , et al. Protective effect of melatonin on bone marrow mesenchymal stem cells against hydrogen peroxide-induced apoptosis in vitro. J. Cell Biochem. 114, 2346&#x2013;2355 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23824714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yagi H., Tan J., Tuan R. S. Polyphenols suppress hydrogen peroxide-induced oxidative stress in human bone-marrow derived mesenchymal stem cells. J. Cell Biochem. 114, 1163&#x2013;1173 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23192437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen H. Y. , et al. The protective effect of 17beta-estradiol against hydrogen peroxide-induced apoptosis on mesenchymal stem cell. Biomed. Pharmacother. 66, 57&#x2013;63 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22281292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richter C. Oxidative stress, mitochondria, and apoptosis. Restor. Neurol. Neurosci. 12, 59&#x2013;62 (1998).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12671298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vanden Berghe T. , et al. Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration features. Cell Death Differ. 17, 922&#x2013;930 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20010783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tinari A., Garofalo T., Sorice M., Esposti M. D., Malorni W. Mitoptosis: different pathways for mitochondrial execution. Autophagy 3, 282&#x2013;284 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17329965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen W. H. , et al. Dual-targeting pro-apoptotic peptide for programmed cancer cell death via specific mitochondria damage. Sci. Rep. 3, 3468 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3863817</ArticleId>
            <ArticleId IdType="pubmed">24336626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Los M. , et al. Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling. Mol. Biol. Cell. 13, 978&#x2013;988 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC99613</ArticleId>
            <ArticleId IdType="pubmed">11907276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lonskaya I., et al. Regulation of poly(ADP-ribose) polymerase-1 by DNA structure-specific binding. J. Biol. Chem. 280, 17076&#x2013;17083 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15737996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zaniolo K., Desnoyers S., Leclerc S., Guerin S. L. Regulation of poly(ADP-ribose) polymerase-1 (PARP-1) gene expression through the post-translational modification of Sp1: a nuclear target protein of PARP-1. BMC Mol. Biol. 8, 96 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2175517</ArticleId>
            <ArticleId IdType="pubmed">17961220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Virag L., Robaszkiewicz A., Rodriguez-Vargas J. M., Oliver F. J. Poly(ADP-ribose) signaling in cell death. Mol. Aspects Med. 34, 1153&#x2013;1167 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23416893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cabon L. , et al. BID regulates AIF-mediated caspase-independent necroptosis by promoting BAX activation. Cell Death Differ. 19, 245&#x2013;256 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3263500</ArticleId>
            <ArticleId IdType="pubmed">21738214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haince J. F., Rouleau M., Hendzel M. J., Masson J. Y., Poirier G. G. Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy. Trends Mol. Med. 11, 456&#x2013;463 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16154385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonner W. M. , et al. GammaH2AX and cancer. Nat. Rev. Cancer 8, 957&#x2013;967 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3094856</ArticleId>
            <ArticleId IdType="pubmed">19005492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z., Jiang H., Chen S., Du F., Wang X. The mitochondrial phosphatase PGAM5 functions at the convergence point of multiple necrotic death pathways. Cell 148, 228&#x2013;243 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22265414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Z., Han V., Han J. New components of the necroptotic pathway. Protein Cell 3, 811&#x2013;817 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4875459</ArticleId>
            <ArticleId IdType="pubmed">23073834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chou T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621&#x2013;681 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16968952</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25834399</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>08</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1177-8881</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>9</Volume>
            <PubDate>
              <Year>2015</Year>
            </PubDate>
          </JournalIssue>
          <Title>Drug design, development and therapy</Title>
          <ISOAbbreviation>Drug Des Devel Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Induction of apoptosis and autophagy via sirtuin1- and PI3K/Akt/mTOR-mediated pathways by plumbagin in human prostate cancer cells.</ArticleTitle>
        <Pagination>
          <StartPage>1511</StartPage>
          <EndPage>1554</EndPage>
          <MedlinePgn>1511-54</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2147/DDDT.S75976</ELocationID>
        <Abstract>
          <AbstractText>Plumbagin (PLB) has been shown to have anticancer activities in animal models, but the role of PLB in prostate cancer treatment is unclear. This study aimed to investigate the effects of PLB on apoptosis and autophagy and the underlying mechanisms in human prostate cancer cell lines PC-3 and DU145. Our study has shown that PLB had potent pro-apoptotic and pro-autophagic effects on PC-3 and DU145 cells. PLB induced mitochondria-mediated apoptosis and autophagy in concentration- and time-dependent manners in both PC-3 and DU145 cells. PLB induced inhibition of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) and p38 mitogen-activated protein kinase (MAPK) pathways and activation of 5'-AMP-dependent kinase (AMPK) as indicated by their altered phosphorylation, contributing to the pro-autophagic activity of PLB. Modulation of autophagy altered basal and PLB-induced apoptosis in both cell lines. Furthermore, PLB downregulated sirtuin 1 (Sirt1), and inhibition of Sirt1 enhanced autophagy, whereas the induction of Sirt1 abolished PLB-induced autophagy in PC-3 and DU145 cells. In addition, PLB downregulated pre-B cell colony-enhancing factor/visfatin, and the inhibition of pre-B cell colony-enhancing factor/visfatin significantly enhanced basal and PLB-induced apoptosis and autophagy in both cell lines. Moreover, reduction of intracellular reactive oxygen species (ROS) level attenuated the apoptosis- and autophagy-inducing effects of PLB on both PC-3 and DU145 cells. These findings indicate that PLB promotes apoptosis and autophagy in prostate cancer cells via Sirt1- and PI3K/Akt/mTOR-mediated pathways with contribution from AMPK-, p38 MAPK-, visfatin-, and ROS-associated pathways.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Zhi-Wei</ForeName>
            <Initials>ZW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA ; Guizhou Provincial Key Laboratory for Regenerative Medicine, Stem Cell and Tissue Engineering Research Center and Sino-US Joint Laboratory for Medical Sciences, Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xing-Xiao</ForeName>
            <Initials>XX</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Zhi-Xu</ForeName>
            <Initials>ZX</Initials>
            <AffiliationInfo>
              <Affiliation>Guizhou Provincial Key Laboratory for Regenerative Medicine, Stem Cell and Tissue Engineering Research Center and Sino-US Joint Laboratory for Medical Sciences, Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Shu-Ting</ForeName>
            <Initials>ST</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA ; Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Yinxue</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Colorectal Surgery, General Hospital of Ningxia Medical University, Yinchuan City, Ningxia, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xueji</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Research Center for Bioengineering and Sensing Technology, University of Science and Technology Beijing, Beijing, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chow</LastName>
            <ForeName>Kevin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Tianxin</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, University of Utah and Salt Lake Veterans Affairs Medical Center, Salt Lake City, UT, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qiu</LastName>
            <ForeName>Jia-Xuan</ForeName>
            <Initials>JX</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Qingyu</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tan</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Behavioral Neurosciences, Silver Child Development Center, Rashid Laboratory for Developmental Neurobiology, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Dong</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Shu-Feng</ForeName>
            <Initials>SF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA ; Guizhou Provincial Key Laboratory for Regenerative Medicine, Stem Cell and Tissue Engineering Research Center and Sino-US Joint Laboratory for Medical Sciences, Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016441">Retracted Publication</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>03</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>New Zealand</Country>
        <MedlineTA>Drug Des Devel Ther</MedlineTA>
        <NlmUniqueID>101475745</NlmUniqueID>
        <ISSNLinking>1177-8881</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009285">Naphthoquinones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.5.1.-</RegistryNumber>
          <NameOfSubstance UI="D056564">Sirtuin 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YAS4TBQ4OQ</RegistryNumber>
          <NameOfSubstance UI="C014758">plumbagin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="RetractionIn">
          <RefSource>Drug Des Devel Ther. 2022 Jul 29;16:2437-2438</RefSource>
          <PMID Version="1">35937567</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004354" MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009285" MajorTopicYN="N">Naphthoquinones</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056564" MajorTopicYN="N">Sirtuin 1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">AMPK</Keyword>
        <Keyword MajorTopicYN="N">DU145</Keyword>
        <Keyword MajorTopicYN="N">PC-3</Keyword>
        <Keyword MajorTopicYN="N">ROS</Keyword>
        <Keyword MajorTopicYN="N">visfatin</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>4</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>4</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25834399</ArticleId>
        <ArticleId IdType="pmc">PMC4366042</ArticleId>
        <ArticleId IdType="doi">10.2147/DDDT.S75976</ArticleId>
        <ArticleId IdType="pii">dddt-9-1511</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11&#x2013;30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23335087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmed HU. Prostate cancer: time for active surveillance of intermediate-risk disease? Nat Rev Urol. 2013;10(1):6&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23147924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>American Cancer Society . Global Cancer Facts and Figures. Atlanta: American Cancer Society; 2011.</Citation>
        </Reference>
        <Reference>
          <Citation>U.S., Cancer Statistics Working Group, United States cancer statistics: 1999&#x2013;2011 incidence and mortality web-based report. Centers for Disease Control and Prevention and National Cancer Institute; Atlanta, GA: 2014.</Citation>
        </Reference>
        <Reference>
          <Citation>Cancer mortality statistics: Cancer mortality for common cancers. London: Cancer Research UK; [Accessed November 6, 2014]. [updated September 15, 2014]. Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/mortality/cancerdeaths/uk-cancer-mortality-statistics-for-common-cancers#Ten.</Citation>
        </Reference>
        <Reference>
          <Citation>Saylor PJ. Prostate cancer: the androgen receptor remains front and centre. Nat Rev Clin Oncol. 2013;10(3):126&#x2013;128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23381000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen S, Niu Y, Lee SO, Chang C. Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death. Cancer Treat Rev. 2014;40(1):31&#x2013;40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3833078</ArticleId>
            <ArticleId IdType="pubmed">23993415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giatromanolaki A, Sivridis E, Mendrinos S, Koutsopoulos AV, Koukourakis MI. Autophagy proteins in prostate cancer: relation with anaerobic metabolism and Gleason score. Urol Oncol. 2014;32(1):e11&#x2013;e18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23787295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008;9(3):231&#x2013;241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18073771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science. 2000;290(5497):1717&#x2013;1721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2732363</ArticleId>
            <ArticleId IdType="pubmed">11099404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Denton D, Nicolson S, Kumar S. Cell death by autophagy: facts and apparent artefacts. Cell Death Differ. 2012;19(1):87&#x2013;95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3252836</ArticleId>
            <ArticleId IdType="pubmed">22052193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Preyat N, Leo O. Sirtuin deacylases: a molecular link between metabolism and immunity. J Leukoc Biol. 2013;93(5):669&#x2013;680.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23325925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Padhye S, Dandawate P, Yusufi M, Ahmad A, Sarkar FH. Perspectives on medicinal properties of plumbagin and its analogs. Med Res Rev. 2012;32(6):1131&#x2013;1158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23059762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Subramaniya BR, Srinivasan G, Sadullah SS, et al. Apoptosis inducing effect of plumbagin on colonic cancer cells depends on expression of COX-2. PLoS One. 2011;6(4):e18695.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3084694</ArticleId>
            <ArticleId IdType="pubmed">21559086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nazeem S, Azmi AS, Hanif S, et al. Plumbagin induces cell death through a copper-redox cycle mechanism in human cancer cells. Mutagenesis. 2009;24(5):413&#x2013;418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19505895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu KH, Lu DP. Plumbagin induces ROS-mediated apoptosis in human promyelocytic leukemia cells in vivo. Leuk Res. 2010;34(5):658&#x2013;665.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19748668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun J, McKallip RJ. Plumbagin treatment leads to apoptosis in human K562 leukemia cells through increased ROS and elevated TRAIL receptor expression. Leuk Res. 2011;35(10):1402&#x2013;1408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3163832</ArticleId>
            <ArticleId IdType="pubmed">21741707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shieh JM, Chiang TA, Chang WT, et al. Plumbagin inhibits TPA-induced MMP-2 and u-PA expressions by reducing binding activities of NF-&#x3ba;B and AP-1 via ERK signaling pathway in A549 human lung cancer cells. Mol Cell Biochem. 2010;335(1&#x2013;2):181&#x2013;193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19768635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li YC, He SM, He ZX, et al. Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells. Cancer Lett. 2014;344(2):239&#x2013;259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24280585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha S, Pal K, Elkhanany A, et al. Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo. Int J Cancer. 2013;132(5):1201&#x2013;1212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3496826</ArticleId>
            <ArticleId IdType="pubmed">22806981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Checker R, Gambhir L, Sharma D, Kumar M, Sandur SK. Plumbagin induces apoptosis in lymphoma cells via oxidative stress mediated glutathionylation and inhibition of mitogen-activated protein kinase phosphatases (MKP1/2) Cancer Lett. 2015;357(1):265&#x2013;278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25444924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aziz MH, Dreckschmidt NE, Verma AK. Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res. 2008;68(21):9024&#x2013;9032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2584362</ArticleId>
            <ArticleId IdType="pubmed">18974148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Powolny AA, Singh SV. Plumbagin-induced apoptosis in human prostate cancer cells is associated with modulation of cellular redox status and generation of reactive oxygen species. Pharm Res. 2008;25(9):2171&#x2013;2180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18213451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abedinpour P, Baron VT, Chrastina A, Welsh J, Borgstrom P. The combination of plumbagin with androgen withdrawal causes profound regression of prostate tumors in vivo. Prostate. 2013;73(5):489&#x2013;499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22996809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiu JX, Zhou ZW, He ZX, et al. Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial to mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells. Drug Des Devel Ther. 2015;9:349&#x2013;417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4294653</ArticleId>
            <ArticleId IdType="pubmed">25609920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alimirah F, Chen J, Basrawala Z, Xin H, Choubey D. DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation. FEBS Lett. 2006;580(9):2294&#x2013;2300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16580667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ouyang DY, Xu LH, He XH, et al. Autophagy is differentially induced in prostate cancer LNCaP, DU145 and PC-3 cells via distinct splicing profiles of ATG5. Autophagy. 2013;9(1):20&#x2013;32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3542215</ArticleId>
            <ArticleId IdType="pubmed">23075929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Estaquier J, Vallette F, Vayssiere JL, Mignotte B. The mitochondrial pathways of apoptosis. Adv Exp Med Biol. 2012;942:157&#x2013;183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22399422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91(4):479&#x2013;489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9390557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296(5573):1655&#x2013;1657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12040186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dunlop EA, Tee AR. The kinase triad, AMPK, mTORC1 and ULK1, maintains energy and nutrient homoeostasis. Biochem Soc Trans. 2013;41(4):939&#x2013;943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23863160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13(2):132&#x2013;141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3987946</ArticleId>
            <ArticleId IdType="pubmed">21258367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arthur JS, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol. 2013;13(9):679&#x2013;692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23954936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koul HK, Pal M, Koul S. Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer. 2013;4(9&#x2013;10):342&#x2013;359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3863344</ArticleId>
            <ArticleId IdType="pubmed">24349632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta. 2011;1813(11):1978&#x2013;1986.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21440011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rabinowitz JD, White E. Autophagy and metabolism. Science. 2010;330(6009):1344&#x2013;1348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3010857</ArticleId>
            <ArticleId IdType="pubmed">21127245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mester J, Eng C. When overgrowth bumps into cancer: the PTEN-opathies. Am J Med Genet C Semin Med Genet. 2013;163C(2):114&#x2013;121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23613428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 2011;18(4):571&#x2013;580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3131912</ArticleId>
            <ArticleId IdType="pubmed">21311563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maiuri MC, Criollo A, Kroemer G. Crosstalk between apoptosis and autophagy within the Beclin 1 interactome. EMBO J. 2010;29(3):515&#x2013;516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2830702</ArticleId>
            <ArticleId IdType="pubmed">20125189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kabeya Y, Mizushima N, Ueno T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000;19(21):5720&#x2013;5728.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC305793</ArticleId>
            <ArticleId IdType="pubmed">11060023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng F, Tang BL. Sirtuins&#x2019; modulation of autophagy. J Cell Physiol. 2013;228(12):2262&#x2013;2270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23696314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montecucco F, Cea M, Bauer I, et al. Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience. Curr Drug Targets. 2013;14(6):637&#x2013;643.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23531116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cea M, Cagnetta A, Fulciniti M, et al. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood. 2012;120(17):3519&#x2013;3529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3482862</ArticleId>
            <ArticleId IdType="pubmed">22955917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou W, Liu X, Yue P, et al. c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28- oate in human lung cancer cells. Cancer Res. 2004;64(20):7570&#x2013;7578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15492284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao X, Liu Y, Deeb D, et al. ROS mediate proapoptotic and antisurvival activity of oleanane triterpenoid CDDO-Me in ovarian cancer cells. Anticancer Res. 2013;33(1):215&#x2013;221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3711076</ArticleId>
            <ArticleId IdType="pubmed">23267148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jutooru I, Chadalapaka G, Abdelrahim M, et al. Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a. Mol Pharmacol. 2010;78(2):226&#x2013;236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2917860</ArticleId>
            <ArticleId IdType="pubmed">20488920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang CC, Chiang YM, Sung SC, Hsu YL, Chang JK, Kuo PL. Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells. Cancer Lett. 2008;259(1):82&#x2013;98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18023967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsu YL, Cho CY, Kuo PL, Huang YT, Lin CC. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo. J Pharmacol Exp Ther. 2006;318(2):484&#x2013;494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16632641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang SJ, Chang SC, Wen HC, Chen CY, Liao JF, Chang CH. Plumbagin activates ERK1/2 and Akt via superoxide, Src and PI3-kinase in 3T3-L1 cells. Eur J Pharmacol. 2010;638(1&#x2013;3):21&#x2013;28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20420821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y, Yu L. Autophagic lysosome reformation. Exp Cell Res. 2013;319(2):142&#x2013;146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22999865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10(3):143&#x2013;153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23400000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zielinski RR, Eigl BJ, Chi KN. Targeting the apoptosis pathway in prostate cancer. Cancer J. 2013;19(1):79&#x2013;89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23337761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuo PL, Hsu YL, Cho CY. Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Mol Cancer Ther. 2006;5(12):3209&#x2013;3221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17172425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menon MB, Kotlyarov A, Gaestel M. SB202190-induced cell type-specific vacuole formation and defective autophagy do not depend on p38 MAP kinase inhibition. PLoS One. 2011;6(8):e23054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3154272</ArticleId>
            <ArticleId IdType="pubmed">21853067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee IH, Cao L, Mostoslavsky R, et al. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci U S A. 2008;105(9):3374&#x2013;3379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2265142</ArticleId>
            <ArticleId IdType="pubmed">18296641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skokowa J, Lan D, Thakur BK, et al. NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD+-sirtuin-1-dependent pathway. Nat Med. 2009;15(2):151&#x2013;158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19182797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 2003;63(21):7436&#x2013;7442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14612543</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25818165</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>07</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1096-0945</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>98</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2015</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Experimental and molecular pathology</Title>
          <ISOAbbreviation>Exp Mol Pathol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Anticancer effect of celastrol on human triple negative breast cancer: possible involvement of oxidative stress, mitochondrial dysfunction, apoptosis and PI3K/Akt pathways.</ArticleTitle>
        <Pagination>
          <StartPage>313</StartPage>
          <EndPage>327</EndPage>
          <MedlinePgn>313-27</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.yexmp.2015.03.031</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0014-4800(15)00066-0</ELocationID>
        <Abstract>
          <AbstractText>Signaling via the phosphatidylinositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) is crucial for divergent physiological processes including transcription, translation, cell-cycle progression and apoptosis. The aim of work was to elucidate the anti-cancer effect of celastrol and the signal transduction pathways involved. Cytotoxic effect of celastrol was assessed by MTT assay on human triple negative breast cancer cells (TNBCs) and compared with that of MCF-7. Apoptosis induction was determined by AO/EtBr staining, mitochondrial membrane potential by JC-1, Annexin binding assays and modulation of apoptotic proteins and its effect on PI3K/Akt/mTOR pathway by western blotting. Celastrol induced apoptosis in TNBC cells, were supported by DNA fragmentation, caspase-3 activation and PARP cleavage. Meanwhile, celastrol triggered reactive oxygen species production with collapse of mitochondrial membrane potential, down-regulation of Bcl-2 and up-regulation of Bax expression. Celastrol effectively decreased PI3K 110α/85α enzyme activity, phosphorylation of Akt(ser473) and p70S6K1 and 4E-BP1. Although insulin treatment increased the phosphorylation of Akt(ser473), p70S6K1, 4E-BP1, celastrol abolished the insulin mediated phosphorylation. It clearly indicates that celastrol acts through PI3k/Akt/mTOR axis. We also found that celastrol inhibited the Akt/GSK3β and Akt/NFkB survival pathway. PI3K/Akt/mTOR inhibitor, PF-04691502 and mTOR inhibitor rapamycin enhanced the apoptosis-inducing effect of celastrol. These data demonstrated that celastrol induces apoptosis in TNBC cells and indicated that apoptosis might be mediated through mitochondrial dysfunction and PI3K/Akt signaling pathway.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2015 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shrivastava</LastName>
            <ForeName>Shweta</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology &amp; Toxicology, National Institute of Pharmaceutical Education &amp; Research (NIPER-Hyderabad), Balanagar, Hyderabad, Telangana 500037, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jeengar</LastName>
            <ForeName>Manish Kumar</ForeName>
            <Initials>MK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology &amp; Toxicology, National Institute of Pharmaceutical Education &amp; Research (NIPER-Hyderabad), Balanagar, Hyderabad, Telangana 500037, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Reddy</LastName>
            <ForeName>V Sudhakar</ForeName>
            <Initials>VS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, National Institute of Nutrition, Tarnaka, Hyderabad, Telangana, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Reddy</LastName>
            <ForeName>G Bhanuprakash</ForeName>
            <Initials>GB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, National Institute of Nutrition, Tarnaka, Hyderabad, Telangana, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Naidu</LastName>
            <ForeName>V G M</ForeName>
            <Initials>VG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology &amp; Toxicology, National Institute of Pharmaceutical Education &amp; Research (NIPER-Hyderabad), Balanagar, Hyderabad, Telangana 500037, India. Electronic address: vgmnaidu@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>03</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Exp Mol Pathol</MedlineTA>
        <NlmUniqueID>0370711</NlmUniqueID>
        <ISSNLinking>0014-4800</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053978">Pentacyclic Triterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014315">Triterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>L8GG98663L</RegistryNumber>
          <NameOfSubstance UI="C050414">celastrol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053978" MajorTopicYN="N">Pentacyclic Triterpenes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014315" MajorTopicYN="N">Triterpenes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">Celastrol</Keyword>
        <Keyword MajorTopicYN="N">Mitochondrial dysfunction</Keyword>
        <Keyword MajorTopicYN="N">Oxidative stress</Keyword>
        <Keyword MajorTopicYN="N">PI3K/Akt</Keyword>
        <Keyword MajorTopicYN="N">TNBC</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>2</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>3</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>3</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>3</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>7</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25818165</ArticleId>
        <ArticleId IdType="doi">10.1016/j.yexmp.2015.03.031</ArticleId>
        <ArticleId IdType="pii">S0014-4800(15)00066-0</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25792811</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>08</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1177-8881</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>9</Volume>
            <PubDate>
              <Year>2015</Year>
            </PubDate>
          </JournalIssue>
          <Title>Drug design, development and therapy</Title>
          <ISOAbbreviation>Drug Des Devel Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.</ArticleTitle>
        <Pagination>
          <StartPage>1555</StartPage>
          <EndPage>1584</EndPage>
          <MedlinePgn>1555-84</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2147/DDDT.S74197</ELocationID>
        <Abstract>
          <AbstractText>Osteosarcoma (OS) is the most common malignant bone tumor occurring mostly in children and adolescents between 10 and 20 years of age with poor response to current therapeutics. Alisertib (ALS, MLN8237) is a selective Aurora kinase A inhibitor that displays anticancer effects on several types of cancer. However, the role of ALS in the treatment of OS remains unknown. This study aimed to investigate the effects of ALS on the cell growth, apoptosis, autophagy, and epithelial to mesenchymal transition (EMT) and the underlying mechanisms in two human OS cell lines U-2 OS and MG-63. The results showed that ALS had potent growth inhibitory, pro-apoptotic, pro-autophagic, and EMT inhibitory effects on U-2 OS and MG-63 cells. ALS remarkably induced G2/M arrest and down-regulated the expression levels of cyclin-dependent kinases 1 and 2 and cyclin B1 in both U-2 OS and MG-63 cells. ALS markedly induced mitochondria-mediated apoptosis with a significant increase in the expression of key pro-apoptotic proteins and a decrease in main anti-apoptotic proteins. Furthermore, ALS promoted autophagic cell death via the inhibition of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) and p38 mitogen-activated protein kinase (p38 MAPK) signaling pathways, and activation of 5'-AMP-dependent kinase (AMPK) signaling pathway. Inducers or inhibitors of apoptosis or autophagy simultaneously altered ALS-induced apoptotic and autophagic death in both U-2 OS and MG-63 cells, suggesting a crosstalk between these two primary modes of programmed cell death. Moreover, ALS suppressed EMT-like phenotypes with a marked increase in the expression of E-cadherin but a decrease in N-cadherin in U-2 OS and MG-63 cells. ALS treatment also induced reactive oxygen species (ROS) generation but inhibited the expression levels of sirtuin 1 and nuclear factor-erythroid-2-related factor 2 (Nrf2) in both cell lines. Taken together, these findings show that ALS promotes apoptosis and autophagy but inhibits EMT via PI3K/Akt/mTOR, p38 MAPK, and AMPK signaling pathways with involvement of ROS- and sirtuin 1-associated pathways in U-2 OS and MG-63 cells. ALS is a promising anticancer agent in OS treatment and further studies are needed to confirm its efficacy and safety in OS chemotherapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Niu</LastName>
            <ForeName>Ning-Kui</ForeName>
            <Initials>NK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Spinal Surgery, General Hospital of Ningxia Medical University, Yinchuan, People's Republic of China ; Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA ; Department of Orthopedics, General Hospital of Tianjin Medical University, Tianjin, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zi-Li</ForeName>
            <Initials>ZL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Spinal Surgery, General Hospital of Ningxia Medical University, Yinchuan, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Shu-Ting</ForeName>
            <Initials>ST</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA ; Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ding</LastName>
            <ForeName>Hui-Qiang</ForeName>
            <Initials>HQ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Spinal Surgery, General Hospital of Ningxia Medical University, Yinchuan, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Au</LastName>
            <ForeName>Giang H T</ForeName>
            <Initials>GH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Zhi-Xu</ForeName>
            <Initials>ZX</Initials>
            <AffiliationInfo>
              <Affiliation>Guizhou Provincial Key Laboratory for Regenerative Medicine, Stem Cell and Tissue Engineering Research Center and Sino-US Joint Laboratory for Medical Sciences, Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Zhi-Wei</ForeName>
            <Initials>ZW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA ; Guizhou Provincial Key Laboratory for Regenerative Medicine, Stem Cell and Tissue Engineering Research Center and Sino-US Joint Laboratory for Medical Sciences, Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Guozhi</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry, Medical Center, Rush University, Chicago, IL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Yin-Xue</ForeName>
            <Initials>YX</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Colorectal Surgery, General Hospital of Ningxia Medical University, Yinchuan, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xueji</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Research Center for Bioengineering and Sensing Technology, University of Science and Technology Beijing, Beijing, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Tianxin</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, University of Utah and Salt Lake Veterans Affairs Medical Center, Salt Lake City, UT, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Xiao-Wu</ForeName>
            <Initials>XW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, The First People's Hospital of Shunde affiliated to Southern Medical University, Foshan, Guangdong, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qiu</LastName>
            <ForeName>Jia-Xuan</ForeName>
            <Initials>JX</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Shu-Feng</ForeName>
            <Initials>SF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>03</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>New Zealand</Country>
        <MedlineTA>Drug Des Devel Ther</MedlineTA>
        <NlmUniqueID>101475745</NlmUniqueID>
        <ISSNLinking>1177-8881</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001381">Azepines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C550258">MLN 8237</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001381" MajorTopicYN="N">Azepines</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004354" MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020928" MajorTopicYN="N">Mitogen-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081082" MajorTopicYN="N">Phosphoinositide-3 Kinase Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ALS</Keyword>
        <Keyword MajorTopicYN="N">EMT</Keyword>
        <Keyword MajorTopicYN="N">PI3K/Akt/mTOR pathway</Keyword>
        <Keyword MajorTopicYN="N">apoptosis</Keyword>
        <Keyword MajorTopicYN="N">autophagy</Keyword>
        <Keyword MajorTopicYN="N">osteosarcoma</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>3</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>3</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>8</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25792811</ArticleId>
        <ArticleId IdType="pmc">PMC4362906</ArticleId>
        <ArticleId IdType="doi">10.2147/DDDT.S74197</ArticleId>
        <ArticleId IdType="pii">dddt-9-1555</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Marulanda GA, Henderson ER, Johnson DA, Letson GD, Cheong D. Orthopedic surgery options for the treatment of primary osteosarcoma. Cancer Control. 2008;15(1):13&#x2013;20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18094657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115(7):1531&#x2013;1543.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2813207</ArticleId>
            <ArticleId IdType="pubmed">19197972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010;21(Suppl 7):vii320&#x2013;5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20943636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. In: Jaffe, Bruland OS, Bielack S, editors. Pediatric and Adolescent Osteosarcoma. Springer; 2010. pp. 3&#x2013;13.</Citation>
        </Reference>
        <Reference>
          <Citation>Ta HT, Dass CR, Choong PF, Dunstan DE. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 2009;28(1&#x2013;2):247&#x2013;263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19214708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bielack S, Carrle D, Casali PG, ESMO Guidelines Working Group Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl 4):137&#x2013;139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19454435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang G, Yuan J, Li K. EMT transcription factors: implication in osteosarcoma. Med Oncol. 2013;30(4):697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23975634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gill J, Ahluwalia MK, Geller D, Gorlick R. New targets and approaches in osteosarcoma. Pharmacol Ther. 2013;137(1):89&#x2013;99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22983152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaabane W, User SD, El-Gazzah M, et al. Autophagy, apoptosis, mitoptosis and necrosis: interdependence between those pathways and effects on cancer. Arch Immunol Ther Exp (Warsz) 2013;61(1):43&#x2013;58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23229678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su M, Mei Y, Sinha S. Role of the crosstalk between autophagy and apoptosis in cancer. J Oncol. 2013;2013:102735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3687500</ArticleId>
            <ArticleId IdType="pubmed">23840208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie X, White EP, Mehnert JM. Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma. PLoS One. 2013;8(1):e55096.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3559441</ArticleId>
            <ArticleId IdType="pubmed">23383069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou Z, Yuan Z, Zhang Q, et al. Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells. Autophagy. 2012;8(12):1798&#x2013;1810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3541289</ArticleId>
            <ArticleId IdType="pubmed">23026799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fimia GM, Piacentini M. Regulation of autophagy in mammals and its interplay with apoptosis. Cell Mol Life Sci. 2010;67(10):1581&#x2013;1588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20165902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marquez RT, Xu L. Bcl-2: Beclin 1 complex: multiple, mechanisms regulating autophagy/apoptosis toggle switch. Am J Cancer Res. 2012;2(2):214&#x2013;221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3304572</ArticleId>
            <ArticleId IdType="pubmed">22485198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Erlich S, Mizrachy L, Segev O, et al. Differential interactions between Beclin 1 and bcl-2 family members. Autophagy. 2007;3(6):561&#x2013;568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17643073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan A, Wang L, Xu S, Xu J. Aurora-A kinase inhibitor scaffolds and binding modes. Drug Discov Today. 2011;16(5&#x2013;6):260&#x2013;269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21147253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitzen JJ, de Jonge MJ, Verweij J. Aurora kinase inhibitors. Crit Rev Oncol Hematol. 2010;73(2):99&#x2013;110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19369091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedberg JW, Mahadevan D, Cebula E, et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014;32(1):44&#x2013;50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3867644</ArticleId>
            <ArticleId IdType="pubmed">24043741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta. 2008;1786(1):60&#x2013;72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18662747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kruse JP, Gu W. Modes of p53 regulation. Cell. 2009;137(4):609&#x2013;622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3737742</ArticleId>
            <ArticleId IdType="pubmed">19450511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tasdemir E, Maiuri MC, Galluzzi L, et al. Regulation of autophagy by cytoplasmic p53. Nat Cell Biol. 2008;10(6):676&#x2013;687.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2676564</ArticleId>
            <ArticleId IdType="pubmed">18454141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maiuri MC, Galluzzi L, Morselli E, Kepp O, Malik SA, Kroemer G. Autophagy regulation by p53. Curr Opin Cell Biol. 2010;22(2):181&#x2013;185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20044243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maris JM, Morton CL, Gorlick R, et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP) Pediatr Blood Cancer. 2010;55(1):26&#x2013;34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2874079</ArticleId>
            <ArticleId IdType="pubmed">20108338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan CX, Zhou ZW, Yang YX, et al. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells. Drug Des Devel Ther. 2015;9:487&#x2013;508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4298344</ArticleId>
            <ArticleId IdType="pubmed">25609923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding YH, Zhou ZW, Ha CF, et al. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells. Drug Des Devel Ther. 2015;9:425&#x2013;464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4296919</ArticleId>
            <ArticleId IdType="pubmed">25624750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsai JH, Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 2013;27(20):2192&#x2013;2206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3814640</ArticleId>
            <ArticleId IdType="pubmed">24142872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol. 2012;13(4):225&#x2013;238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4872805</ArticleId>
            <ArticleId IdType="pubmed">22395773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byles V, Zhu L, Lovaas JD, et al. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene. 2012;31(43):4619&#x2013;4629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4157820</ArticleId>
            <ArticleId IdType="pubmed">22249256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296(5573):1655&#x2013;1657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12040186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu X, Moscinski LC. Cdc2: a monopotent or pluripotent CDK? Cell Prolif. 2011;44(3):205&#x2013;211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6496858</ArticleId>
            <ArticleId IdType="pubmed">21535261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warfel NA, El-Deiry WS. p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol. 2013;25(1):52&#x2013;58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23159848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Estaquier J, Vallette F, Vayssiere J-L, Mignotte B. The mitochondrial pathways of apoptosis. Adv Exp Med Biol. 2012;942:157&#x2013;183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22399422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91(4):479&#x2013;489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9390557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klionsky DJ, Emr SD. Cell biology &#x2013; Autophagy as a regulated pathway of cellular degradation. Science. 2000;290(5497):1717&#x2013;1721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2732363</ArticleId>
            <ArticleId IdType="pubmed">11099404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arthur JS, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol. 2013;13(9):679&#x2013;692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23954936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koul HK, Pal M, Koul S. Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer. 2013;4(9&#x2013;10):342&#x2013;359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3863344</ArticleId>
            <ArticleId IdType="pubmed">24349632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Tang N, Hadden TJ, Rishi AK. Rishi, Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta. 2011;1813(11):1978&#x2013;1986.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21440011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rabinowitz JD, White E. Autophagy and metabolism. Science. 2010;330(6009):1344&#x2013;1348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3010857</ArticleId>
            <ArticleId IdType="pubmed">21127245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mester J, Eng C. When overgrowth bumps into cancer: the PTEN-opathies. Am J Med Genet C Semin Med Genet. 2013;163C(2):114&#x2013;121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23613428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cannito S, Novo E, di Bonzo LV, Busletta C, Colombatto S, Parola M. Epithelial-mesenchymal transition: from molecular mechanisms, redox regulation to implications in human health and disease. Antioxid Redox Signal. 2010;12(12):1383&#x2013;1430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19903090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng F, Tang BL. Sirtuins&#x2019; modulation of autophagy. J Cell Physiol. 2013;228(12):2262&#x2013;2270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23696314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bellot GL, Liu D, Pervaiz S. ROS, autophagy, mitochondria and cancer: Ras, the hidden master? Mitochondrion. 2013;13(3):155&#x2013;162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22750269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dodson M, Darley-Usmar V, Zhang J. Cellular metabolic and autophagic pathways: traffic control by redox signaling. Free Radic Biol Med. 2013;63:207&#x2013;221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3729625</ArticleId>
            <ArticleId IdType="pubmed">23702245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaminskyy VO, Zhivotovsky B. Free radicals in cross talk between autophagy and apoptosis. Antioxid Redox Signal. 2014;21(1):86&#x2013;102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24359220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki T, Motohashi H, Yamamoto M. Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol Sci. 2013;34(6):340&#x2013;346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23664668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 2013;53:401&#x2013;426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4680839</ArticleId>
            <ArticleId IdType="pubmed">23294312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol. 2007;47:89&#x2013;116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16968214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Denton D, Nicolson S, Kumar S. Cell death by autophagy: facts and apparent artefacts. Cell Death Differ. 2012;19(1):87&#x2013;95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3252836</ArticleId>
            <ArticleId IdType="pubmed">22052193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y, Yu L. Autophagic lysosome reformation. Exp Cell Res. 2013;319(2):142&#x2013;146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22999865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10(3):143&#x2013;153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23400000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest. 2001;19(3):292&#x2013;315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11338887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117(7):927&#x2013;939.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15210113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin K, Margolis B. ZOning out tight junctions. Cell. 2006;126(4):647&#x2013;649.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16923383</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25769821</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>12</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2015</Year>
        <Month>03</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1096-1208</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>81</Volume>
            <PubDate>
              <Year>2015</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Microbial pathogenesis</Title>
          <ISOAbbreviation>Microb Pathog</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Deciphering the protein interaction in adhesion of Francisella tularensis subsp. holarctica to the endothelial cells.</ArticleTitle>
        <Pagination>
          <StartPage>6</StartPage>
          <EndPage>15</EndPage>
          <MedlinePgn>6-15</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.micpath.2015.03.007</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0882-4010(15)00034-0</ELocationID>
        <Abstract>
          <AbstractText>Extracellular form of Francisella is able to cross various cell barriers and invade multiple organs, such as skin, liver, lung and central nervous system. Transient adhesion of Francisella to endothelial cells may trigger the process of translocation. In this report, we showed that Francisella tularensis subsp. holarctica (Fth) is able to adhere to the endothelial cells, while ICAM-1 may serve as an adhesion molecule for Fth. Pull down and affinity ligand binding assays indicated that the PilE4 could be the probable ligand for ICAM-1. Further deciphering of this ligand:receptor interaction revealed that PilE4 interacts with Ig-like C2-type 1 domain of ICAM-1. To corroborate the role of PilE4 and ICAM-1 interaction in adhesion of extracellular form of Fth to endothelial cells, ICAM-1 was blocked with monoclonal anti-ICAM-1 antibody prior to the incubation with Fth and numbers of adherent bacteria were counted. Blocking of the ICAM-1 significantly reduced (500-fold, P &lt; 0.05) number of adherent Fth compared to unblocked cells. PilE4:ICAM-1 interaction unfolded here may provide a new perspective on molecules involved in the adhesion of extracellular form of Francisella to endothelial cells and probably its translocation across endothelial barriers.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2015 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bencurova</LastName>
            <ForeName>Elena</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Biomedical Microbiology and Immunology, Department of Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in Kosice, 041 81 Kosice, Slovakia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kovac</LastName>
            <ForeName>Andrej</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Neuroimmunology, Slovak Academy of Sciences, 845 10 Bratislava, Slovakia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pulzova</LastName>
            <ForeName>Lucia</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Biomedical Microbiology and Immunology, Department of Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in Kosice, 041 81 Kosice, Slovakia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gyuranecz</LastName>
            <ForeName>Miklós</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Veterinary Medical Research, Centre for Agricultural Research, Hungarian Academy of Sciences, H-1581 Budapest, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mlynarcik</LastName>
            <ForeName>Patrik</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Biomedical Microbiology and Immunology, Department of Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in Kosice, 041 81 Kosice, Slovakia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mucha</LastName>
            <ForeName>Rastislav</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Neuroimmunology, Slovak Academy of Sciences, 845 10 Bratislava, Slovakia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vlachakis</LastName>
            <ForeName>Dimitrios</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Bioinformatics &amp; Medical Informatics Team, Biomedical Research Foundation, Academy of Athens, Athens 11527, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kossida</LastName>
            <ForeName>Sophia</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Bioinformatics &amp; Medical Informatics Team, Biomedical Research Foundation, Academy of Athens, Athens 11527, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Flachbartova</LastName>
            <ForeName>Zuzana</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Biomedical Microbiology and Immunology, Department of Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in Kosice, 041 81 Kosice, Slovakia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bhide</LastName>
            <ForeName>Mangesh</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Biomedical Microbiology and Immunology, Department of Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in Kosice, 041 81 Kosice, Slovakia; Institute of Neuroimmunology, Slovak Academy of Sciences, 845 10 Bratislava, Slovakia. Electronic address: bhidemangesh@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>03</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Microb Pathog</MedlineTA>
        <NlmUniqueID>8606191</NlmUniqueID>
        <ISSNLinking>0882-4010</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>126547-89-5</RegistryNumber>
          <NameOfSubstance UI="D018799">Intercellular Adhesion Molecule-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>147680-16-8</RegistryNumber>
          <NameOfSubstance UI="D036781">Fimbriae Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001422" MajorTopicYN="Y">Bacterial Adhesion</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName>
          <QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D036781" MajorTopicYN="N">Fimbriae Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005604" MajorTopicYN="N">Francisella tularensis</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054884" MajorTopicYN="Y">Host-Pathogen Interactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018799" MajorTopicYN="N">Intercellular Adhesion Molecule-1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Endothelial cells</Keyword>
        <Keyword MajorTopicYN="N">Francisella</Keyword>
        <Keyword MajorTopicYN="N">ICAM-1</Keyword>
        <Keyword MajorTopicYN="N">Type IV pili</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2014</Year>
          <Month>8</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2015</Year>
          <Month>2</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>3</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>3</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>3</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25769821</ArticleId>
        <ArticleId IdType="doi">10.1016/j.micpath.2015.03.007</ArticleId>
        <ArticleId IdType="pii">S0882-4010(15)00034-0</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25378496</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1098-5514</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>89</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2015</Year>
              <Month>Jan</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of virology</Title>
          <ISOAbbreviation>J Virol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>White spot syndrome virus protein kinase 1 defeats the host cell's iron-withholding defense mechanism by interacting with host ferritin.</ArticleTitle>
        <Pagination>
          <StartPage>1083</StartPage>
          <EndPage>1093</EndPage>
          <MedlinePgn>1083-93</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.02318-14</ELocationID>
        <Abstract>
          <AbstractText Label="UNLABELLED">Iron is an essential nutrient for nearly all living organisms, including both hosts and invaders. Proteins such as ferritin regulate the iron levels in a cell, and in the event of a pathogenic invasion, the host can use an iron-withholding mechanism to restrict the availability of this essential nutrient to the invading pathogens. However, pathogens use various strategies to overcome this host defense. In this study, we demonstrated that white spot syndrome virus (WSSV) protein kinase 1 (PK1) interacted with shrimp ferritin in the yeast two-hybrid system. A pulldown assay and 27-MHz quartz crystal microbalance (QCM) analysis confirmed the interaction between PK1 and both ferritin and apoferritin. PK1 did not promote the release of iron ions from ferritin, but it prevented apoferritin from binding ferrous ions. When PK1 was overexpressed in Sf9 cells, the cellular labile iron pool (LIP) levels were elevated significantly. Immunoprecipitation and atomic absorption spectrophotometry (AAS) further showed that the number of iron ions bound by ferritin decreased significantly at 24 h post-WSSV infection. Taken together, these results suggest that PK1 prevents apoferritin from iron loading, and thus stabilizes the cellular LIP levels, and that WSSV uses this novel mechanism to counteract the host cell's iron-withholding defense mechanism.</AbstractText>
          <AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">We show here that white spot syndrome virus (WSSV) ensures the availability of iron by using a previously unreported mechanism to defeat the host cell's iron-withholding defense mechanism. This defense is often implemented by ferritin, which can bind up to 4,500 iron atoms and acts to sequester free iron within the cell. WSSV's novel counterstrategy is mediated by a direct protein-protein interaction between viral protein kinase 1 (PK1) and host ferritin. PK1 interacts with both ferritin and apoferritin, suppresses apoferritin's ability to sequester free iron ions, and maintains the intracellular labile iron pool (LIP), and thus the availability of free iron is increased within cells.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2015, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Shin-Jen</ForeName>
            <Initials>SJ</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Bioinformatics and Biosignal Transduction, College of Bioscience and Biotechnology, National Cheng Kung University, Tainan, Taiwan Department of Life Science, College of Life Science, National Taiwan University, Taipei, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Der-Yen</ForeName>
            <Initials>DY</Initials>
            <AffiliationInfo>
              <Affiliation>Technology Commons, College of Life Science, National Taiwan University, Taipei, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Hao-Ching</ForeName>
            <Initials>HC</Initials>
            <AffiliationInfo>
              <Affiliation>Graduate Institute of Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kang</LastName>
            <ForeName>Shih-Ting</ForeName>
            <Initials>ST</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Bioinformatics and Biosignal Transduction, College of Bioscience and Biotechnology, National Cheng Kung University, Tainan, Taiwan Department of Life Science, College of Life Science, National Taiwan University, Taipei, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hwang</LastName>
            <ForeName>Pung-Pung</ForeName>
            <Initials>PP</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kou</LastName>
            <ForeName>Guang-Hsiung</ForeName>
            <Initials>GH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Life Science, College of Life Science, National Taiwan University, Taipei, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Ming-Fen</ForeName>
            <Initials>MF</Initials>
            <AffiliationInfo>
              <Affiliation>Graduate Institute of Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chang</LastName>
            <ForeName>Geen-Dong</ForeName>
            <Initials>GD</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Biochemical Sciences, College of Life Science, National Taiwan University, Taipei, Taiwan gdchang@ntu.edu.tw gracelow@mail.ncku.edu.tw.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lo</LastName>
            <ForeName>Chu-Fang</ForeName>
            <Initials>CF</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Bioinformatics and Biosignal Transduction, College of Bioscience and Biotechnology, National Cheng Kung University, Tainan, Taiwan Department of Life Science, College of Life Science, National Taiwan University, Taipei, Taiwan gdchang@ntu.edu.tw gracelow@mail.ncku.edu.tw.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>11</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Virol</MedlineTA>
        <NlmUniqueID>0113724</NlmUniqueID>
        <ISSNLinking>0022-538X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-73-2</RegistryNumber>
          <NameOfSubstance UI="D005293">Ferritins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.-</RegistryNumber>
          <NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002498" MajorTopicYN="N">Centrifugation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003674" MajorTopicYN="N">Defense Mechanisms</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005293" MajorTopicYN="N">Ferritins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054884" MajorTopicYN="Y">Host-Pathogen Interactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D025941" MajorTopicYN="N">Protein Interaction Mapping</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058525" MajorTopicYN="N">Quartz Crystal Microbalance Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020798" MajorTopicYN="N">Two-Hybrid System Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046848" MajorTopicYN="N">White spot syndrome virus 1</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>11</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>11</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>4</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25378496</ArticleId>
        <ArticleId IdType="pmc">PMC4300627</ArticleId>
        <ArticleId IdType="doi">10.1128/JVI.02318-14</ArticleId>
        <ArticleId IdType="pii">JVI.02318-14</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Balla G, Jacob HS, Balla J, Rosenberg M, Nath K, Apple F, Eaton JW, Vercellotti GM. 1992. Ferritin: a cytoprotective antioxidant stratagem of endothelium. J Biol Chem 267:18148&#x2013;18153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1517245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Epsztejn S, Glickstein H, Picard V, Slotki IN, Breuer W, Beaumont C, Cabantchik ZI. 1999. H-ferritin subunit overexpression in erythroid cells reduces the oxidative stress response and induces multidrug resistance properties. Blood 94:3593&#x2013;3603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10552971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theil EC. 1987. Ferritin: structure, gene regulation, and cellular function in animals, plants, and microorganisms. Annu Rev Biochem 56:289&#x2013;315. doi:10.1146/annurev.bi.56.070187.001445.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.bi.56.070187.001445</ArticleId>
            <ArticleId IdType="pubmed">3304136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinberg ED, Miklossy J. 2008. Iron withholding: a defense against disease. J Alzheimers Dis 13:451&#x2013;463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18487852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larson JA, Howie HL, So M. 2004. Neisseria meningitidis accelerates ferritin degradation in host epithelial cells to yield an essential iron source. Mol Microbiol 53:807&#x2013;820. doi:10.1111/j.1365-2958.2004.04169.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2958.2004.04169.x</ArticleId>
            <ArticleId IdType="pubmed">15255894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Segond D, Abi Khalil E, Buisson C, Daou N, Kallassy M, Lereclus D, Arosio P, Bou-Abdallah F, Nielsen Le Roux C. 2014. Iron acquisition in Bacillus cereus: the roles of IlsA and bacillibactin in exogenous ferritin iron mobilization. PLoS Pathog 10:e1003935. doi:10.1371/journal.ppat.1003935.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1003935</ArticleId>
            <ArticleId IdType="pmc">PMC3923779</ArticleId>
            <ArticleId IdType="pubmed">24550730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinberg ED. 1999. Iron loading and disease surveillance. Emerg Infect Dis 5:346&#x2013;352. doi:10.3201/eid0503.990305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3201/eid0503.990305</ArticleId>
            <ArticleId IdType="pmc">PMC2640766</ArticleId>
            <ArticleId IdType="pubmed">10341171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whitby PW, Vanwagoner TM, Springer JM, Morton DJ, Seale TW, Stull TL. 2006. Burkholderia cenocepacia utilizes ferritin as an iron source. J Med Microbiol 55:661&#x2013;668. doi:10.1099/jmm.0.46199-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1099/jmm.0.46199-0</ArticleId>
            <ArticleId IdType="pubmed">16687582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ben-Arieh SV, Zimerman B, Smorodinsky NI, Yaacubovicz M, Schechter C, Bacik I, Gibbs J, Bennink JR, Yewdell JW, Coligan JE, Firat H, Lemonnier F, Ehrlich R. 2001. Human cytomegalovirus protein US2 interferes with the expression of human HFE, a nonclassical class I major histocompatibility complex molecule that regulates iron homeostasis. J Virol 75:10557&#x2013;10562. doi:10.1128/JVI.75.21.10557-10562.2001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.75.21.10557-10562.2001</ArticleId>
            <ArticleId IdType="pmc">PMC114637</ArticleId>
            <ArticleId IdType="pubmed">11581431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vahdati-Ben Arieh S, Laham N, Schechter C, Yewdell JW, Coligan JE, Ehrlich R. 2003. A single viral protein HCMV US2 affects antigen presentation and intracellular iron homeostasis by degradation of classical HLA class I and HFE molecules. Blood 101:2858&#x2013;2864. doi:10.1182/blood-2002-07-2158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2002-07-2158</ArticleId>
            <ArticleId IdType="pubmed">12456502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsuji Y, Akebi N, Lam TK, Nakabeppu Y, Torti SV, Torti FM. 1995. FER-1, an enhancer of the ferritin H gene and a target of E1A-mediated transcriptional repression. Mol Cell Biol 15:5152&#x2013;5164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC230762</ArticleId>
            <ArticleId IdType="pubmed">7651432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bevilacqua MA, Faniello MC, Quaresima B, Tiano MT, Giuliano P, Feliciello A, Avvedimento VE, Cimino F, Costanzo F. 1997. A common mechanism underlying the E1A repression and the cAMP stimulation of the H ferritin transcription. J Biol Chem 272:20736&#x2013;20741. doi:10.1074/jbc.272.33.20736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.272.33.20736</ArticleId>
            <ArticleId IdType="pubmed">9252395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan D, He N, Yang Z, Liu H, Xu X. 2005. Differential gene expression profile in hepatopancreas of WSSV-resistant shrimp (Penaeus japonicus) by suppression subtractive hybridization. Dev Comp Immunol 29:103&#x2013;112. doi:10.1016/j.dci.2004.07.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.dci.2004.07.001</ArticleId>
            <ArticleId IdType="pubmed">15450750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Li F, Wang Z, Zhang X, Zhou Q, Xiang J. 2006. Cloning, expression and identification of ferritin from Chinese shrimp, Fenneropenaeus chinensis. J Biotechnol 125:173&#x2013;184. doi:10.1016/j.jbiotec.2006.03.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jbiotec.2006.03.010</ArticleId>
            <ArticleId IdType="pubmed">16621097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clavero-Salas A, Sotelo-Mundo RR, Gollas-Galv&#xe1;n T, Hern&#xe1;ndez-L&#xf3;pez J, Peregrino-Uriarte AB, Muhlia-Almaz&#xe1;n A, Yepiz-Plascencia G. 2007. Transcriptome analysis of gills from the white shrimp Litopenaeus vannamei infected with white spot syndrome virus. Fish Shellfish Immunol 23:459&#x2013;472. doi:10.1016/j.fsi.2007.01.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fsi.2007.01.010</ArticleId>
            <ArticleId IdType="pubmed">17337210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pongsomboon S, Tang S, Boonda S, Aoki T, Hirono I, Yasuike M, Tassanakajon A. 2008. Differentially expressed genes in Penaeus monodon hemocytes following infection with yellow head virus. BMB Rep 41:670&#x2013;677. doi:10.5483/BMBRep.2008.41.9.670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5483/BMBRep.2008.41.9.670</ArticleId>
            <ArticleId IdType="pubmed">18823592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruan YH, Kuo CM, Lo CF, Lee MH, Lian JL, Hsieh SL. 2010. Ferritin administration effectively enhances immunity, physiological responses, and survival of Pacific white shrimp (Litopenaeus vannamei) challenged with white spot syndrome virus. Fish Shellfish Immunol 28:542&#x2013;548. doi:10.1016/j.fsi.2009.12.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fsi.2009.12.013</ArticleId>
            <ArticleId IdType="pubmed">20045064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu WJ, Yu HT, Peng SE, Chang YS, Pien HW, Lin CJ, Huang CJ, Tsai MF, Huang CJ, Wang CH, Lin JY, Lo CF, Kou GH. 2001. Cloning, characterization, and phylogenetic analysis of a shrimp white spot syndrome virus gene that encodes a protein kinase. Virology 289:362&#x2013;377. doi:10.1006/viro.2001.1091.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/viro.2001.1091</ArticleId>
            <ArticleId IdType="pubmed">11689058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Hulten MC, Vlak JM. 2001. Identification and phylogeny of a protein kinase gene of white spot syndrome virus. Virus Genes 22:201&#x2013;207. doi:10.1023/A:1008127709325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/A:1008127709325</ArticleId>
            <ArticleId IdType="pubmed">11324757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Hulten MC, Witteveldt J, Peters S, Kloosterboer N, Tarchini R, Fiers M, Sandbrink H, Lankhorst RK, Vlak JM. 2001. The white spot syndrome virus DNA genome sequence. Virology 28:7&#x2013;22. doi:10.1006/viro.2001.1002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/viro.2001.1002</ArticleId>
            <ArticleId IdType="pubmed">11448154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim CS, Kosuke Z, Nam YK, Kim SK, Kim KH. 2007. Protection of shrimp (Penaeus chinensis) against white spot syndrome virus (WSSV) challenge by double-stranded RNA. Fish Shellfish Immunol 23:242&#x2013;246. doi:10.1016/j.fsi.2006.10.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fsi.2006.10.012</ArticleId>
            <ArticleId IdType="pubmed">17175172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsieh SL, Chiu YC, Kuo CM. 2006. Molecular cloning and tissue distribution of ferritin in Pacific white shrimp (Litopenaeus vannamei). Fish Shellfish Immunol 21:279&#x2013;283. doi:10.1016/j.fsi.2005.12.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fsi.2005.12.003</ArticleId>
            <ArticleId IdType="pubmed">16546402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sangsuriya P, Huang JY, Chu YF, Phiwsaiya K, Leekitcharoenphon P, Meemetta W, Senapin S, Huang WP, Withyachumnarnkul B, Flegel TW, Lo CF. 2014. Construction and application of a protein interaction map for white spot syndrome virus (WSSV). Mol Cell Proteomics 13:269&#x2013;282. doi:10.1074/mcp.M113.029199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/mcp.M113.029199</ArticleId>
            <ArticleId IdType="pmc">PMC3879619</ArticleId>
            <ArticleId IdType="pubmed">24217020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leu JH, Kuo YC, Kou GH, Lo CF. 2008. Molecular cloning and characterization of an inhibitor of apoptosis protein (IAP) from the tiger shrimp, Penaeus monodon. Dev Comp Immunol 32:121&#x2013;133. doi:10.1016/j.dci.2007.05.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.dci.2007.05.005</ArticleId>
            <ArticleId IdType="pubmed">17628672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esp&#xf3;sito BP, Epsztejn S, Breuer W, Cabantchik ZI. 2002. A review of fluorescence methods for assessing labile iron in cells and biological fluids. Anal Biochem 304:1&#x2013;18. doi:10.1006/abio.2002.5611.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/abio.2002.5611</ArticleId>
            <ArticleId IdType="pubmed">11969183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Breuer W, Epsztejn S, Millgram P, Cabantchik IZ. 1995. Transport of iron and other transition metals into cells as revealed by a fluorescent probe. Am J Physiol 268:1354&#x2013;1361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7611353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen IT, Aoki T, Huang YT, Hirono I, Chen TC, Huang JY, Chang GD, Lo CF, Wang HC. 2011. White spot syndrome virus induces metabolic changes resembling the Warburg effect in shrimp hemocytes in the early stage of infection. J Virol 85:12919&#x2013;12928. doi:10.1128/JVI.05385-11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.05385-11</ArticleId>
            <ArticleId IdType="pmc">PMC3233138</ArticleId>
            <ArticleId IdType="pubmed">21976644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aziz N, Munro HN. 1987. Iron regulates ferritin mRNA translation through a segment of its 5&#x2032; untranslated region. Proc Natl Acad Sci U S A 84:8478&#x2013;8482. doi:10.1073/pnas.84.23.8478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.84.23.8478</ArticleId>
            <ArticleId IdType="pmc">PMC299567</ArticleId>
            <ArticleId IdType="pubmed">3479802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hentze MW, Rouault TA, Caughman SW, Dancis A, Harford JB, Klausner RD. 1987. A cis-acting element is necessary and sufficient for translational regulation of human ferritin expression in response to iron. Proc Natl Acad Sci U S A 84:6730&#x2013;6734. doi:10.1073/pnas.84.19.6730.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.84.19.6730</ArticleId>
            <ArticleId IdType="pmc">PMC299157</ArticleId>
            <ArticleId IdType="pubmed">3477805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eisenstein RS. 2000. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu Rev Nutr 20:627&#x2013;662. doi:10.1146/annurev.nutr.20.1.627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.nutr.20.1.627</ArticleId>
            <ArticleId IdType="pubmed">10940348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fraga CG. 2005. Relevance, essentiality and toxicity of trace elements in human health. Mol Aspects Med 26:235&#x2013;244. doi:10.1016/j.mam.2005.07.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mam.2005.07.013</ArticleId>
            <ArticleId IdType="pubmed">16125765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hatefi Y. 1985. The mitochondrial electron transport and oxidative phosphorylation system. Annu Rev Biochem 54:1015&#x2013;1069. doi:10.1146/annurev.bi.54.070185.005055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.bi.54.070185.005055</ArticleId>
            <ArticleId IdType="pubmed">2862839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jordan A, Reichard P. 1998. Ribonucleotide reductases. Annu Rev Biochem 67:71&#x2013;98. doi:10.1146/annurev.biochem.67.1.71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.biochem.67.1.71</ArticleId>
            <ArticleId IdType="pubmed">9759483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pang H, Bartlam M, Zeng Q, Miyatake H, Hisano T, Miki K, Wong LL, Gao GF, Rao Z. 2004. Crystal structure of human pirin: an iron-binding nuclear protein and transcription cofactor. J Biol Chem 279:1491&#x2013;1498. doi:10.1074/jbc.M310022200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M310022200</ArticleId>
            <ArticleId IdType="pubmed">14573596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rudolf J, Makrantoni V, Ingledew WJ, Stark MJ, White MF. 2006. The DNA repair helicases XPD and FancJ have essential iron-sulfur domains. Mol Cell 23:801&#x2013;808. doi:10.1016/j.molcel.2006.07.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2006.07.019</ArticleId>
            <ArticleId IdType="pubmed">16973432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klinge S, Hirst J, Maman JD, Krude T, Pellegrini L. 2007. An iron-sulfur domain of the eukaryotic primase is essential for RNA primer synthesis. Nat Struct Mol Biol 14:875&#x2013;877. doi:10.1038/nsmb1288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nsmb1288</ArticleId>
            <ArticleId IdType="pmc">PMC2268749</ArticleId>
            <ArticleId IdType="pubmed">17704817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack R, Porter JB. 1996. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem 271:20291&#x2013;20299. doi:10.1074/jbc.271.34.20291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.271.34.20291</ArticleId>
            <ArticleId IdType="pubmed">8702762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamarche N, Matton G, Massie B, Fontecave M, Atta M, Dumas F, Gaudreau P, Langelier Y. 1996. Production of the R2 subunit of ribonucleotide reductase from herpes simplex virus with prokaryotic and eukaryotic expression systems: higher activity of R2 produced by eukaryotic cells related to higher iron-binding capacity. Biochem J 320:129&#x2013;135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1217907</ArticleId>
            <ArticleId IdType="pubmed">8947477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chabes A, Domkin V, Larsson G, Liu A, Graslund A, Wijmenga S, Thelander L. 2000. Yeast ribonucleotide reductase has a heterodimeric iron-radical-containing subunit. Proc Natl Acad Sci U S A 97:2474&#x2013;2479. doi:10.1073/pnas.97.6.2474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.97.6.2474</ArticleId>
            <ArticleId IdType="pmc">PMC15953</ArticleId>
            <ArticleId IdType="pubmed">10716984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai Y, Gold B, Vishwanatha JK, Rhode SL. 1994. Mimosine inhibits viral DNA synthesis through ribonucleotide reductase. Virology 205:210&#x2013;216. doi:10.1006/viro.1994.1636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/viro.1994.1636</ArticleId>
            <ArticleId IdType="pubmed">7975217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romeo AM, Christen L, Niles EG, Kosman DJ. 2001. Intracellular chelation of iron by bipyridyl inhibits DNA virus replication: ribonucleotide reductase maturation as a probe of intracellular iron pools. J Biol Chem 276:24301&#x2013;24308. doi:10.1074/jbc.M010806200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M010806200</ArticleId>
            <ArticleId IdType="pubmed">11301321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laghaei R, Evans DG, Coalson RD. 2013. Metal binding sites of human H-chain ferritin and iron transport mechanism to the ferroxidase sites: a molecular dynamics simulation study. Proteins 81:1042&#x2013;1050. doi:10.1002/prot.24251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/prot.24251</ArticleId>
            <ArticleId IdType="pubmed">23344859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Durand JP, Goudard F, Pieri J, Escoubas JM, Schreiber N, Cadoret JP. 2004. Crassostrea gigas ferritin: cDNA sequence analysis for two heavy chain type subunits and protein purification. Gene 338:187&#x2013;195. doi:10.1016/j.gene.2004.04.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gene.2004.04.027</ArticleId>
            <ArticleId IdType="pubmed">15315822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong F, Zhang X, Culver B, Chew HG Jr, Kelley RO, Ren J. 2005. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci (Lond) 109:277&#x2013;286. doi:10.1042/CS20040278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/CS20040278</ArticleId>
            <ArticleId IdType="pubmed">15877545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halliwell B, Gutteridge JM. 1990. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 186:1&#x2013;85. doi:10.1016/0076-6879(90)86093-B.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0076-6879(90)86093-B</ArticleId>
            <ArticleId IdType="pubmed">2172697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ihara K, Maeguchi K, Young CT, Theil EC. 1984. Cell-specific properties of red cell and liver ferritin from bullfrog tadpoles probed by phosphorylation in vitro. J Biol Chem 259:278&#x2013;283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6608521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rama-Kumar T. 1998. Ph.D. thesis University of Hyderabad, Hyderabad, India.</Citation>
        </Reference>
        <Reference>
          <Citation>Weaver J, Pollack S. 1989. Low-Mr iron isolated from guinea pig reticulocytes as AMP-Fe and ATP-Fe complexes. Biochem J 261:787&#x2013;792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1138900</ArticleId>
            <ArticleId IdType="pubmed">2803243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konopka K, Mareschal JC, Crichton RR. 1981. Iron transfer from transferrin to ferritin mediated by polyphosphate compounds. Biochim Biophys Acta 677:417&#x2013;423. doi:10.1016/0304-4165(81)90255-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0304-4165(81)90255-5</ArticleId>
            <ArticleId IdType="pubmed">6271255</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25128467</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>08</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-4596</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>76</Volume>
            <PubDate>
              <Year>2014</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Free radical biology &amp; medicine</Title>
          <ISOAbbreviation>Free Radic Biol Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>FoxO proteins' nuclear retention and BH3-only protein Bim induction evoke mitochondrial dysfunction-mediated apoptosis in berberine-treated HepG2 cells.</ArticleTitle>
        <Pagination>
          <StartPage>185</StartPage>
          <EndPage>199</EndPage>
          <MedlinePgn>185-99</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.freeradbiomed.2014.07.039</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0891-5849(14)00356-6</ELocationID>
        <Abstract>
          <AbstractText>Mammalian forkhead-box family members belonging to the 'O' category (FoxO) manipulate a plethora of genes modulating a wide array of cellular functions including cell cycle regulation, apoptosis, DNA damage repair, and energy metabolism. FoxO overexpression and nuclear accumulation have been reported to show correlation with hindered tumor growth in vitro and size in vivo, while FoxO's downregulation via phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway has been linked with tumor promotion. In this study, we have explored for the first time intervention of berberine, a plant-derived isoquinoline alkaloid, with FoxO family proteins in hepatoma cells. We observed that berberine significantly upregulated the mRNA expression of both FoxO1 and FoxO3a. Their phosphorylation-mediated cytoplasmic sequestration followed by degradation was prevented by berberine-induced downmodulation of the PI3K/Akt/mTOR pathway which promoted FoxO nuclear retention. PTEN, a tumor suppressor gene and negative regulator of the PI3K/Akt axis, was upregulated while phosphorylation of its Ser380 residue (possible mechanism of PTEN degradation) was significantly decreased in treated HepG2 cells. Exposure to berberine induced a significant increase in transcriptional activity of FoxO, as shown by GFP reporter assay. FoxO transcription factors effectively heightened BH3-only protein Bim expression, which in turn, being a direct activator of proapoptotic protein Bax, altered Bax/Bcl-2 ratio, culminating into mitochondrial dysfunction, caspases activation, and DNA fragmentation. The pivotal role of Bim in berberine-mediated cytotoxicity was further corroborated by knockdown experiments where Bim-silencing partially restored HepG2 cell viability during berberine exposure. In addition, a correlation between oxidative overload and FoxO's nuclear accumulation via JNK activation was evident as berberine treatment led to a pronounced increase in JNK phosphorylation together with enhanced ROS generation, lipid peroxidation, decreased activities of superoxide dismutase and catalase, and diminished glutathione levels. Thus, our findings suggest that the antiproliferative effect of berberine may in part be due to mitochondria-mediated apoptosis with Bim acting as a pivotal downstream factor of FoxO-induced transcriptional activation.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shukla</LastName>
            <ForeName>Shatrunajay</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Herbal Research Section, CSIR-Indian Institute of Toxicology Research, Post Box No. 80, Mahatma Gandhi Marg, Lucknow 226001, India; Department of Medical Elementology and Toxicology, Jamia Hamdard (Hamdard University), Hamdard Nagar, New Delhi 110062, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rizvi</LastName>
            <ForeName>Fatima</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Herbal Research Section, CSIR-Indian Institute of Toxicology Research, Post Box No. 80, Mahatma Gandhi Marg, Lucknow 226001, India; Academy of Scientific and Innovative Research, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Raisuddin</LastName>
            <ForeName>Sheikh</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Elementology and Toxicology, Jamia Hamdard (Hamdard University), Hamdard Nagar, New Delhi 110062, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kakkar</LastName>
            <ForeName>Poonam</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Herbal Research Section, CSIR-Indian Institute of Toxicology Research, Post Box No. 80, Mahatma Gandhi Marg, Lucknow 226001, India; Academy of Scientific and Innovative Research, India. Electronic address: kakkarp59@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>08</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Free Radic Biol Med</MedlineTA>
        <NlmUniqueID>8709159</NlmUniqueID>
        <ISSNLinking>0891-5849</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000606775">BCL2L11 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000072224">Bcl-2-Like Protein 11</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C085126">FOXO1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C499517">FOXO3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071161">Forkhead Box Protein O1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071316">Forkhead Box Protein O3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051858">Forkhead Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0I8Y3P32UF</RegistryNumber>
          <NameOfSubstance UI="D001599">Berberine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D020169">Caspases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072224" MajorTopicYN="N">Bcl-2-Like Protein 11</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001599" MajorTopicYN="N">Berberine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071161" MajorTopicYN="N">Forkhead Box Protein O1</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071316" MajorTopicYN="N">Forkhead Box Protein O3</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051858" MajorTopicYN="N">Forkhead Transcription Factors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007124" MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">Berberine</Keyword>
        <Keyword MajorTopicYN="N">Bim</Keyword>
        <Keyword MajorTopicYN="N">FoxO1</Keyword>
        <Keyword MajorTopicYN="N">FoxO3a</Keyword>
        <Keyword MajorTopicYN="N">HepG2</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2014</Year>
          <Month>7</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2014</Year>
          <Month>7</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>8</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>8</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2015</Year>
          <Month>8</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25128467</ArticleId>
        <ArticleId IdType="doi">10.1016/j.freeradbiomed.2014.07.039</ArticleId>
        <ArticleId IdType="pii">S0891-5849(14)00356-6</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">24741074</PMID>
      <DateCompleted>
        <Year>2014</Year>
        <Month>08</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1521-0103</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>350</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of pharmacology and experimental therapeutics</Title>
          <ISOAbbreviation>J Pharmacol Exp Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inhibition of phosphatidylinositol 3-kinase/AKT signaling by NVP-BKM120 promotes ABT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells.</ArticleTitle>
        <Pagination>
          <StartPage>22</StartPage>
          <EndPage>35</EndPage>
          <MedlinePgn>22-35</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1124/jpet.114.212910</ELocationID>
        <Abstract>
          <AbstractText>Identification of therapeutic strategies that might enhance the efficacy of B-cell lymphoma-2 (Bcl-2) inhibitor ABT-737 [N-{4-[4-(4-chloro-biphenyl-2-ylmethyl)-piperazin-1-yl]-benzoyl}-4-(3-dimethylamino-1-phenylsulfanylmethyl-propylamino)-3-nitro-benzenesulfonamide] is of great interest in many cancers, including glioma. Our recent study suggested that Akt is a crucial mediator of apoptosis sensitivity in response to ABT-737 in glioma cell lines. Inhibitors of phosphatidylinositol 3-kinase (PI3K)/Akt are currently being assessed clinically in patients with glioma. Because PI3K/Akt inhibition would be expected to have many proapoptotic effects, we hypothesized that there may be unique synergy between PI3K inhibitors and Bcl-2 homology 3 mimetics. Toward this end, we assessed the combination of the PI3K/Akt inhibitor NVP-BKM120 [5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine] and the Bcl-2 family inhibitor ABT-737 in established and primary cultured glioma cells. We found that the combined treatment with these agents led to a significant activation of caspase-8 and -3, PARP, and cell death, irrespective of PTEN status. The enhanced lethality observed with this combination also appears dependent on the loss of mitochondrial membrane potential and release of cytochrome c, smac/DIABLO, and apoptosis-inducing factor to the cytosol. Further study revealed that the upregulation of Noxa, truncation of Bid, and activation of Bax and Bak caused by these inhibitors were the key factors for the synergy. In addition, we demonstrated the release of proapoptotic proteins Bim and Bak from Mcl-1. We found defects in chromosome segregation leading to multinuclear cells and loss of colony-forming ability, suggesting the potential use of NVP-BKM120 as a promising agent to improve the anticancer activities of ABT-737.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2014 by The American Society for Pharmacology and Experimental Therapeutics.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Jane</LastName>
            <ForeName>Esther P</ForeName>
            <Initials>EP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurologic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (E.P.J., D.R.P., K.A.F., I.F.P.); University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania (E.P.J., D.R.P., A.M., K.A.F., I.F.P.); and University of Pittsburgh Brain Tumor Center, Pittsburgh, Pennsylvania (K.A.F., I.F.P.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Premkumar</LastName>
            <ForeName>Daniel R</ForeName>
            <Initials>DR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurologic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (E.P.J., D.R.P., K.A.F., I.F.P.); University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania (E.P.J., D.R.P., A.M., K.A.F., I.F.P.); and University of Pittsburgh Brain Tumor Center, Pittsburgh, Pennsylvania (K.A.F., I.F.P.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morales</LastName>
            <ForeName>Alejandro</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurologic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (E.P.J., D.R.P., K.A.F., I.F.P.); University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania (E.P.J., D.R.P., A.M., K.A.F., I.F.P.); and University of Pittsburgh Brain Tumor Center, Pittsburgh, Pennsylvania (K.A.F., I.F.P.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Foster</LastName>
            <ForeName>Kimberly A</ForeName>
            <Initials>KA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurologic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (E.P.J., D.R.P., K.A.F., I.F.P.); University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania (E.P.J., D.R.P., A.M., K.A.F., I.F.P.); and University of Pittsburgh Brain Tumor Center, Pittsburgh, Pennsylvania (K.A.F., I.F.P.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pollack</LastName>
            <ForeName>Ian F</ForeName>
            <Initials>IF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurologic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (E.P.J., D.R.P., K.A.F., I.F.P.); University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania (E.P.J., D.R.P., A.M., K.A.F., I.F.P.); and University of Pittsburgh Brain Tumor Center, Pittsburgh, Pennsylvania (K.A.F., I.F.P.) ian.pollack@chp.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P01 NS040923</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01-NS40923</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>04</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Pharmacol Exp Ther</MedlineTA>
        <NlmUniqueID>0376362</NlmUniqueID>
        <ISSNLinking>0022-3565</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C501332">ABT-737</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000631">Aminopyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051033">Apoptosis Inducing Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C494772">BAK1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000606775">BCL2L11 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000072224">Bcl-2-Like Protein 11</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001713">Biphenyl Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C412403">DIABLO protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009025">Morpholines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C571178">NVP-BKM120</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009596">Nitrophenols</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C498702">PMAIP1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050998">bcl-2 Homologous Antagonist-Killer Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051028">bcl-2-Associated X Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-43-6</RegistryNumber>
          <NameOfSubstance UI="D045304">Cytochromes c</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.4.2.30</RegistryNumber>
          <NameOfSubstance UI="D011065">Poly(ADP-ribose) Polymerases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D053181">Caspase 8</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D020169">Caspases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000631" MajorTopicYN="N">Aminopyridines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051033" MajorTopicYN="N">Apoptosis Inducing Factor</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072224" MajorTopicYN="N">Bcl-2-Like Protein 11</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001713" MajorTopicYN="N">Biphenyl Compounds</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053181" MajorTopicYN="N">Caspase 8</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020090" MajorTopicYN="N">Chromosome Segregation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045304" MajorTopicYN="N">Cytochromes c</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004249" MajorTopicYN="N">DNA Damage</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005909" MajorTopicYN="N">Glioblastoma</DescriptorName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009025" MajorTopicYN="N">Morpholines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009596" MajorTopicYN="N">Nitrophenols</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081082" MajorTopicYN="Y">Phosphoinositide-3 Kinase Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011065" MajorTopicYN="N">Poly(ADP-ribose) Polymerases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061251" MajorTopicYN="N">Primary Cell Culture</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019253" MajorTopicYN="N">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050998" MajorTopicYN="N">bcl-2 Homologous Antagonist-Killer Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051028" MajorTopicYN="N">bcl-2-Associated X Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>8</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24741074</ArticleId>
        <ArticleId IdType="pmc">PMC4056270</ArticleId>
        <ArticleId IdType="doi">10.1124/jpet.114.212910</ArticleId>
        <ArticleId IdType="pii">jpet.114.212910</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, et al. (2012) Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 30:282&#x2013;290</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22162589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, Letai A. (2006) Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9:351&#x2013;365</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16697956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, Huang DC. (2005) Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17:393&#x2013;403</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15694340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen S, Dai Y, Harada H, Dent P, Grant S. (2007) Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 67:782&#x2013;791</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17234790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cristofanon S, Fulda S. (2012) ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells. Cell Death Dis 3:e432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3542599</ArticleId>
            <ArticleId IdType="pubmed">23190604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeAngelis LM. (2001) Brain tumors. N Engl J Med 344:114&#x2013;123</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11150363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Debien E, Hervouet E, Gautier F, Juin P, Vallette FM, Cartron PF. (2011) ABT-737 and/or folate reverse the PDGF-induced alterations in the mitochondrial apoptotic pathway in low-grade glioma patients. Clin Epigenetics 2:369&#x2013;381</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3156333</ArticleId>
            <ArticleId IdType="pubmed">21949549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. (2007) Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 117:112&#x2013;121</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1716201</ArticleId>
            <ArticleId IdType="pubmed">17200714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gil-Parrado S, Fern&#xe1;ndez-Montalv&#xe1;n A, Assfalg-Machleidt I, Popp O, Bestvater F, Holloschi A, Knoch TA, Auerswald EA, Welsh K, Reed JC, et al. (2002) Ionomycin-activated calpain triggers apoptosis. A probable role for Bcl-2 family members. J Biol Chem 277:27217&#x2013;27226</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12000759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goping IS, Gross A, Lavoie JN, Nguyen M, Jemmerson R, Roth K, Korsmeyer SJ, Shore GC. (1998) Regulated targeting of BAX to mitochondria. J Cell Biol 143:207&#x2013;215</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2132805</ArticleId>
            <ArticleId IdType="pubmed">9763432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O&#x2019;Brien R, Khaw SL, Vikstrom IB, Roberts AW, Lock RB. (2010) The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol 77:483&#x2013;494</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20038611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jane EP, Premkumar DR, DiDomenico JD, Hu B, Cheng SY, Pollack IF. (2013) YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context. Mol Cancer Ther 12:326&#x2013;338</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3596447</ArticleId>
            <ArticleId IdType="pubmed">23325792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jane EP, Premkumar DR, Pollack IF. (2006) Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J Pharmacol Exp Ther 319:1070&#x2013;1080</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16959960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jane EP, Premkumar DR, Pollack IF. (2011) Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-kappaB signaling pathway. Mol Cancer Ther 10:198&#x2013;208</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3075591</ArticleId>
            <ArticleId IdType="pubmed">21220502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitchens CA, McDonald PR, Shun TY, Pollack IF, Lazo JS. (2011) Identification of chemosensitivity nodes for vinblastine through small interfering RNA high-throughput screens. J Pharmacol Exp Ther 339:851&#x2013;858</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3226368</ArticleId>
            <ArticleId IdType="pubmed">21880871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, et al. (2006) Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10:375&#x2013;388</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17097560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ, Schlesinger PH. (2000) Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 7:1166&#x2013;1173</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11175253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koul D, Fu J, Shen R, LaFortune TA, Wang S, Tiao N, Kim YW, Liu JL, Ramnarian D, Yuan Y, et al. (2012) Antitumor activity of NVP-BKM120&#x2014;a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res 18:184&#x2013;195</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3785365</ArticleId>
            <ArticleId IdType="pubmed">22065080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H, Zhu H, Xu CJ, Yuan J. (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491&#x2013;501</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9727492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lovell JF, Billen LP, Bindner S, Shamas-Din A, Fradin C, Leber B, Andrews DW. (2008) Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. Cell 135:1074&#x2013;1084</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19062087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA. (2001) Malignant glioma: genetics and biology of a grave matter. Genes Dev 15:1311&#x2013;1333</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11390353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, et al. (2012) Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 11:317&#x2013;328</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22188813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinou JC, Green DR. (2001) Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2:63&#x2013;67</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11413467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nencioni A, Wille L, Dal Bello G, Boy D, Cirmena G, Wesselborg S, Belka C, Brossart P, Patrone F, Ballestrero A. (2005) Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells. Clin Cancer Res 11:4259&#x2013;4265</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15930365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677&#x2013;681</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15902208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pollack IF. (1994) Brain tumors in children. N Engl J Med 331:1500&#x2013;1507</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7969301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Premkumar DR, Arnold B, Jane EP, Pollack IF. (2006a) Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells. Mol Carcinog 45:47&#x2013;59</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16267832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Premkumar DR, Arnold B, Pollack IF. (2006b) Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth. Mol Carcinog 45:288&#x2013;301</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16550610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Premkumar DR, Jane EP, Agostino NR, DiDomenico JD, Pollack IF. (2013a) Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage. Mol Carcinog 52:118&#x2013;133</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4068609</ArticleId>
            <ArticleId IdType="pubmed">22086447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Premkumar DR, Jane EP, DiDomenico JD, Vukmer NA, Agostino NR, Pollack IF. (2012) ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines. J Pharmacol Exp Ther 341:859&#x2013;872</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3362891</ArticleId>
            <ArticleId IdType="pubmed">22393246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Premkumar DR, Jane EP, Foster KA, Pollack IF. (2013b) Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway. J Pharmacol Exp Ther 346:201&#x2013;210</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3716309</ArticleId>
            <ArticleId IdType="pubmed">23740602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Premkumar DR, Jane EP, Pollack IF. (2010) Co-administration of NVP-AEW541 and dasatinib induces mitochondrial-mediated apoptosis through Bax activation in malignant human glioma cell lines. Int J Oncol 37:633&#x2013;643</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20664932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qian J, Zou Y, Rahman JS, Lu B, Massion PP. (2009) Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung. Mol Cancer Ther 8:101&#x2013;109</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3110728</ArticleId>
            <ArticleId IdType="pubmed">19139118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren H, Chen M, Yue P, Tao H, Owonikoko TK, Ramalingam SS, Khuri FR, Sun SY. (2012) The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo. Cancer Lett 325:139&#x2013;146</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3433638</ArticleId>
            <ArticleId IdType="pubmed">22781393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. (1998) DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273:5858&#x2013;5868</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9488723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Russo M, Spagnuolo C, Volpe S, Tedesco I, Bilotto S, Russo GL. (2013) ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation. Biochem Pharmacol 85:927&#x2013;936</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23353698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salmena L, Carracedo A, Pandolfi PP. (2008) Tenets of PTEN tumor suppression. Cell 133:403&#x2013;414</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18455982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spender LC, Inman GJ. (2012) Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt&#x2019;s lymphoma cells to BH3 mimetics. Mol Cancer Res 10:347&#x2013;359</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3378513</ArticleId>
            <ArticleId IdType="pubmed">22241218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, B&#xf6;ck BC, Macher-Goeppinger S, Radlwimmer B, Wiestler OD, Herold-Mende C, et al. (2008) Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 27:6646&#x2013;6656</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18663354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tait SW, Green DR. (2010) Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 11:621&#x2013;632</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20683470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thaker NG, McDonald PR, Zhang F, Kitchens CA, Shun TY, Pollack IF, Lazo JS. (2010a) Designing, optimizing, and implementing high-throughput siRNA genomic screening with glioma cells for the discovery of survival genes and novel drug targets. J Neurosci Methods 185:204&#x2013;212</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19782703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thaker NG, Zhang F, McDonald PR, Shun TY, Lazo JS, Pollack IF. (2010b) Functional genomic analysis of glioblastoma multiforme through short interfering RNA screening: a paradigm for therapeutic development. Neurosurg Focus 28:E4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20043719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thaker NG, Zhang F, McDonald PR, Shun TY, Lewen MD, Pollack IF, Lazo JS. (2009) Identification of survival genes in human glioblastoma cells by small interfering RNA screening. Mol Pharmacol 76:1246&#x2013;1255</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2784725</ArticleId>
            <ArticleId IdType="pubmed">19783622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, et al. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389&#x2013;399</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2953559</ArticleId>
            <ArticleId IdType="pubmed">17097561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogler M, Dinsdale D, Dyer MJ, Cohen GM. (2009) Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 16:360&#x2013;367</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18806758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogler M, Dinsdale D, Sun XM, Young KW, Butterworth M, Nicotera P, Dyer MJ, Cohen GM. (2008) A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death Differ 15:820&#x2013;830</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18309326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voss V, Senft C, Lang V, Ronellenfitsch MW, Steinbach JP, Seifert V, K&#xf6;gel D. (2010) The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma. Mol Cancer Res 8:1002&#x2013;1016</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20587533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ. (2001) Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292:727&#x2013;730</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3049805</ArticleId>
            <ArticleId IdType="pubmed">11326099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen PY, Kesari S. (2008) Malignant gliomas in adults. N Engl J Med 359:492&#x2013;507</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18669428</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">24030154</PMID>
      <DateCompleted>
        <Year>2014</Year>
        <Month>03</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2041-4889</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>4</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Sep</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell death &amp; disease</Title>
          <ISOAbbreviation>Cell Death Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis.</ArticleTitle>
        <Pagination>
          <StartPage>e802</StartPage>
          <MedlinePgn>e802</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/cddis.2013.320</ELocationID>
        <Abstract>
          <AbstractText>Evasion of apoptosis, for example, by inhibitor of apoptosis (IAP) proteins, contributes to treatment resistance and poor outcome in acute myeloid leukemia (AML). Here we identify a novel synergistic interaction between the small-molecule second mitochondria-derived activator of caspases (Smac) mimetic BV6, which antagonizes X-linked IAP, cellular IAP (cIAP)1 and cIAP2, and the demethylating agents 5-azacytidine or 5-aza-2'-deoxycytidine (DAC) to induce cell death in AML cells, including apoptosis-resistant cells. Calculation of combination index (CI) confirms that this drug combination is highly synergistic (CI 0.02-0.4). In contrast, BV6 and DAC at equimolar concentrations do not cause synergistic toxicity against normal peripheral blood lymphocytes, pointing to some tumor cell selectivity. Molecular studies reveal that BV6 and DAC cooperate to trigger the activation of caspases, mitochondrial perturbations and DNA fragmentation, consistent with apoptotic cell death. However, the broad-range caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD.fmk) fails to protect against BV6/DAC-induced cell death and even significantly increases the percentage of Annexin-V/propidium iodide double-positive cells. Importantly, BV6/DAC-induced cell death in the presence of zVAD.fmk is significantly reduced by pharmacological inhibition of key components of necroptosis signaling, that is, receptor-interacting protein (RIP) 1 using necrostatin-1 or mixed lineage kinase domain-like protein (MLKL) using necrosulfonamide. This indicates a switch from BV6/DAC-induced cell death from apoptosis to necroptosis upon caspase inhibition. Thus, BV6 cooperates with demethylating agents to induce cell death in AML cells and circumvents apoptosis resistance via a switch to necroptosis as an alternative mode of cell death. The identification of a novel synergism of BV6 and demethylating agents has important implications for the development of new treatment strategies for AML.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Steinhart</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Frankfurt, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Belz</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fulda</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>09</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cell Death Dis</MedlineTA>
        <NlmUniqueID>101524092</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C582180">BV6 peptide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>776B62CQ27</RegistryNumber>
          <NameOfSubstance UI="D000077209">Decitabine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D020169">Caspases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>M801H13NRU</RegistryNumber>
          <NameOfSubstance UI="D001374">Azacitidine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019898" MajorTopicYN="N">Autocrine Communication</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001374" MajorTopicYN="N">Azacitidine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053938" MajorTopicYN="N">DNA Fragmentation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077209" MajorTopicYN="N">Decitabine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015470" MajorTopicYN="N">Leukemia, Myeloid, Acute</DescriptorName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009336" MajorTopicYN="N">Necrosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009842" MajorTopicYN="N">Oligopeptides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019899" MajorTopicYN="N">Paracrine Communication</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>3</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24030154</ArticleId>
        <ArticleId IdType="pmc">PMC3789178</ArticleId>
        <ArticleId IdType="doi">10.1038/cddis.2013.320</ArticleId>
        <ArticleId IdType="pii">cddis2013320</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368:1894&#x2013;1907.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17126723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schimmer AD. Apoptosis in leukemia: from molecular pathways to targeted therapies. Best Pract Res Clin Haematol. 2008;21:5&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18342807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fulda S. Cell death in hematological tumors. Apoptosis. 2009;14:409&#x2013;423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19130230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25:4798&#x2013;4811.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16892092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646&#x2013;674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21376230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012;19:107&#x2013;120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3252826</ArticleId>
            <ArticleId IdType="pubmed">21760595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 2008;19:325&#x2013;331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18495520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007;87:99&#x2013;163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17237344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol. 2010;11:700&#x2013;714.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20823910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun L, Wang H, Wang Z, He S, Chen S, Liao D, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148:213&#x2013;227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22265413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oberst A, Dillon CP, Weinlich R, McCormick LL, Fitzgerald P, Pop C, et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature. 2011;471:363&#x2013;367.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3077893</ArticleId>
            <ArticleId IdType="pubmed">21368763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fulda S, Vucic D, Targeting IAP. proteins for therapeutic intervention in cancer. Nat Rev Drug Discov. 2012;11:109&#x2013;124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22293567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 2006;7:988&#x2013;994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1618369</ArticleId>
            <ArticleId IdType="pubmed">17016456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell. 2008;30:689&#x2013;700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18570872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K, et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem. 2008;283:24295&#x2013;24299.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3259840</ArticleId>
            <ArticleId IdType="pubmed">18621737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res. 2000;6:1796&#x2013;1803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10815900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tamm I, Richter S, Scholz F, Schmelz K, Oltersdorf D, Karawajew L, et al. XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. Hematol J. 2004;5:489&#x2013;495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15570290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hess CJ, Berkhof J, Denkers F, Ossenkoppele GJ, Schouten JP, Oudejans JJ, et al. Activated intrinsic apoptosis pathway is a key related prognostic parameter in acute myeloid leukemia. J Clin Oncol. 2007;25:1209&#x2013;1215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17401010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bullinger L, Rucker FG, Kurz S, Du J, Scholl C, Sander S, et al. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood. 2007;110:1291&#x2013;1300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17485551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luck SC, Russ AC, Botzenhardt U, Paschka P, Schlenk RF, Dohner H, et al. Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups. Leukemia. 2011;25:1728&#x2013;1738.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21701487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007;131:669&#x2013;681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18022362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell. 2007;131:682&#x2013;693.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18022363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell. 2008;133:693&#x2013;703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18485876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fakler M, Loeder S, Vogler M, Schneider K, Jeremias I, Debatin KM, et al. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood. 2009;113:1710&#x2013;1722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19036706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loeder S, Drensek A, Jeremias I, Debatin KM, Fulda S. Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis. Int J Cancer. 2010;126:2216&#x2013;2228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19676052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loeder S, Fakler M, Schoeneberger H, Cristofanon S, Leibacher J, Vanlangenakker N, et al. RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis. Leukemia. 2012;26:1020&#x2013;1029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22173242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ganetsky A. The role of decitabine for the treatment of acute myeloid leukemia. Ann Pharmacother. 2012;46:1511&#x2013;1517.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23115225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fulda S, Meyer E, Friesen C, Susin SA, Kroemer G, Debatin KM. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene. 2001;20:1063&#x2013;1075.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11314043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fulda S, Debatin KM. 5-Aza-2'-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene. 2006;25:5125&#x2013;5133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16607283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J, et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell. 2007;12:445&#x2013;456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3431210</ArticleId>
            <ArticleId IdType="pubmed">17996648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov. 2010;9:447&#x2013;464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20467424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fulda S. Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies. Leukemia. 2012;26:1155&#x2013;1165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22230799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weisberg E, Kung AL, Wright RD, Moreno D, Catley L, Ray A, et al. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Mol Cancer Ther. 2007;6:1951&#x2013;1961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17620426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weisberg E, Ray A, Barrett R, Nelson E, Christie AL, Porter D, et al. Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia. 2010;24:2100&#x2013;2109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4037865</ArticleId>
            <ArticleId IdType="pubmed">20844561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carter BZ, Gronda M, Wang Z, Welsh K, Pinilla C, Andreeff M, et al. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood. 2005;105:4043&#x2013;4050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1895077</ArticleId>
            <ArticleId IdType="pubmed">15687241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Servida F, Lecis D, Scavullo C, Drago C, Seneci P, Carlo-Stella C, et al. Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis. Invest New Drugs. 2011;29:1264&#x2013;1275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20614162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fabre C, Grosjean J, Tailler M, Boehrer S, Ades L, Perfettini JL, et al. A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts. Cell Cycle. 2008;7:2139&#x2013;2145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18641459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valdez BC, Li Y, Murray D, Corn P, Champlin RE, Andersson BS. 5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leuk Res. 2010;34:364&#x2013;372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2823987</ArticleId>
            <ArticleId IdType="pubmed">19732952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laukens B, Jennewein C, Schenk B, Vanlangenakker N, Schier A, Cristofanon S, et al. Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor alpha-induced necroptosis. Neoplasia. 2011;13:971&#x2013;979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3201573</ArticleId>
            <ArticleId IdType="pubmed">22028622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vanlangenakker N, Vanden Berghe T, Bogaert P, Laukens B, Zobel K, Deshayes K, et al. cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death Differ. 2011;18:656&#x2013;665.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3131911</ArticleId>
            <ArticleId IdType="pubmed">21052097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horita H, Frankel AE, Thorburn A. Acute myeloid leukemia-targeted toxin activates both apoptotic and necroptotic death mechanisms. PLoS One. 2008;3:e3909.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2592546</ArticleId>
            <ArticleId IdType="pubmed">19079542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marcucci G, Silverman L, Eller M, Lintz L, Beach CL. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol. 2005;45:597&#x2013;602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15831784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cashen AF, Shah AK, Todt L, Fisher N, DiPersio J. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) Cancer Chemother Pharmacol. 2008;61:759&#x2013;766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17564707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol. 2007;25:3884&#x2013;3891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17679729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fulda S, Strauss G, Meyer E, Debatin KM. Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. Blood. 2000;95:301&#x2013;308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10607716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tchoghandjian A, Jennewein C, Eckhardt I, Rajalingam K, Fulda S. Identification of non-canonical NF-kappaB signaling as a critical mediator of Smac mimetic-stimulated migration and invasion of glioblastoma cells. Cell Death Dis. 2013;4:e564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3615728</ArticleId>
            <ArticleId IdType="pubmed">23538445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chou TC.The median-effect principle and the combination index for quantitation of synergism and antagonismIn: Chou TC (eds).Synergism and Antagonism in Chemotherapy Academic Press: San Diego, USA; 199161&#x2013;102.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23956071</PMID>
      <DateCompleted>
        <Year>2014</Year>
        <Month>07</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1095-8355</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>38</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cell biology international</Title>
          <ISOAbbreviation>Cell Biol Int</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Hypoxia induces adipocyte differentiation of adipose-derived stem cells by triggering reactive oxygen species generation.</ArticleTitle>
        <Pagination>
          <StartPage>32</StartPage>
          <EndPage>40</EndPage>
          <MedlinePgn>32-40</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/cbin.10170</ELocationID>
        <Abstract>
          <AbstractText>Generation of reactive oxygen species (ROS) by NADPH oxidase 4 (Nox4) induces the proliferation and migration of adipose-derived stem cells (ASCs). However, the functional role of mitochondrial ROS (mtROS) generation in ASCs is unknown. Therefore, we have investigated whether hypoxia induces the differentiation of ASCs via ROS generation. We also have tried to identify the cellular mechanisms of ROS generation underlying adipocyte differentiation. Hypoxia (2%) and ROS generators, such as antimycin and rotenone, induced adipocyte differentiation, which was attenuated by an ROS scavenger. Although Nox4 generates ROS and regulates proliferation of ASCs, Nox4 inhibition or Nox4 silencing did not inhibit adipocyte differentiation; indeed fluorescence intensity of mito-SOX increased in hypoxia, and treatment with mito-CP, a mtROS scavenger, significantly reduced hypoxia-induced adipocyte differentiation. Phosphorylation of Akt and mTOR was induced by hypoxia, while inhibition of these molecules prevented adipocyte differentiation. Thus hypoxia induces adipocyte differentiation by mtROS generation, and the PI3K/Akt/mTOR pathway is involved.</AbstractText>
          <CopyrightInformation>&#xa9; 2013 International Federation for Cell Biology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Ji Hye</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Applied Bioscience, CHA University, Seoul, Korea; Stem Cell Research Laboratory, CHA Stem Cell Institute, Seoul, Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Seok-Ho</ForeName>
            <Initials>SH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Seung Yong</ForeName>
            <Initials>SY</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Won-Serk</ForeName>
            <Initials>WS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Sun U</ForeName>
            <Initials>SU</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yi</LastName>
            <ForeName>TacGhee</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jeon</LastName>
            <ForeName>Myung-Shin</ForeName>
            <Initials>MS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chung</LastName>
            <ForeName>Hyung-Min</ForeName>
            <Initials>HM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xia</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sung</LastName>
            <ForeName>Jong-Hyuk</ForeName>
            <Initials>JH</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>09</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cell Biol Int</MedlineTA>
        <NlmUniqueID>9307129</NlmUniqueID>
        <ISSNLinking>1065-6995</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003497">Cyclic N-Oxides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016166">Free Radical Scavengers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009943">Organophosphorus Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C571715">mito-carboxy proxyl</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>03L9OT429T</RegistryNumber>
          <NameOfSubstance UI="D012402">Rotenone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>11118-72-2</RegistryNumber>
          <NameOfSubstance UI="C032456">antimycin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>642-15-9</RegistryNumber>
          <NameOfSubstance UI="D000968">Antimycin A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.6.3.-</RegistryNumber>
          <NameOfSubstance UI="D000074663">NADPH Oxidase 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.6.3.-</RegistryNumber>
          <NameOfSubstance UI="D019255">NADPH Oxidases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.6.3.-</RegistryNumber>
          <NameOfSubstance UI="C498910">NOX4 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000273" MajorTopicYN="N">Adipose Tissue</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000968" MajorTopicYN="N">Antimycin A</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="Y">Cell Differentiation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015687" MajorTopicYN="Y">Cell Hypoxia</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003497" MajorTopicYN="N">Cyclic N-Oxides</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016166" MajorTopicYN="N">Free Radical Scavengers</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074663" MajorTopicYN="N">NADPH Oxidase 4</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019255" MajorTopicYN="N">NADPH Oxidases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009943" MajorTopicYN="N">Organophosphorus Compounds</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012402" MajorTopicYN="N">Rotenone</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">adipocyte differentiation</Keyword>
        <Keyword MajorTopicYN="N">adipose-derived stem cells</Keyword>
        <Keyword MajorTopicYN="N">hypoxia</Keyword>
        <Keyword MajorTopicYN="N">mitochondria</Keyword>
        <Keyword MajorTopicYN="N">reactive oxygen species</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>4</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>7</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23956071</ArticleId>
        <ArticleId IdType="doi">10.1002/cbin.10170</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23892275</PMID>
      <DateCompleted>
        <Year>2014</Year>
        <Month>07</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1745-7254</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>34</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Acta pharmacologica Sinica</Title>
          <ISOAbbreviation>Acta Pharmacol Sin</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Retigeric acid B-induced mitophagy by oxidative stress attenuates cell death against prostate cancer cells in vitro.</ArticleTitle>
        <Pagination>
          <StartPage>1183</StartPage>
          <EndPage>1191</EndPage>
          <MedlinePgn>1183-91</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/aps.2013.68</ELocationID>
        <Abstract>
          <AbstractText Label="AIM" NlmCategory="OBJECTIVE">Retigeric acid B (RAB), a pentacyclic triterpenic acid from Lobaria kurokawae Yoshim, has been found to induce apoptosis in prostate cancer cells. The aim of this study was to investigate the roles of mitochondrial damage-caused mitophagy in RAB-induced prostate cancer cell death in vitro.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Human prostate cancer PC3 and LNCaP cells were tested. Cell viability was analyzed with MTT assay. Cell apoptosis, ROS level and mitochondrial transmembrane potential (mt&#x394;&#x3c8;) were measured with flow cytometry. Autophagy- and apoptosis-related proteins were studied using Western blotting. GFP-LC3B puncta, mitochondrial swelling and mitophagy were examined morphologically. Quantitative RT-PCR was used to measure LC3B mRNA level, and siRNA was used to knock down LC3BII.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">In both PC3 and LNCaP cells, RAB (15 &#x3bc;mol/L) increased ROS accumulation and decreased mt&#x394;&#x3c8; in a time-dependent manner. Furthermore, RAB induced mitochondrial swelling and mitophagy, significantly increased LC3B expression and conversion of LC3BI to LC3BII, and the elimination of mitochondria by LC3BII-containing autophagolysosomes. In addition, RAB suppressed the PI3K/Akt/mTOR pathway activation. Pretreatment of PC3 cells with autophagy inhibitor 3-MA (5 mmol/L) or the lysosomal protease inhibitor CQ (10 &#x3bc;mol/L) significantly increased RAB-induced apoptosis. Similar results were obtained in RAB-treated PC3 cells with LC3B knocked down.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">RAB induces mitochondrial damage and mitophagy that attenuates RAB-induced prostate cancer cell death. Thus, suppression of mitophagy might be a potential strategy for improving the chemotherapeutic effects of RAB.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yong-qing</ForeName>
            <Initials>YQ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry and Molecular Biology, School of Medicine, Shandong University, Ji-nan 250012, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ji</LastName>
            <ForeName>Yuan</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xian-zhe</ForeName>
            <Initials>XZ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Ke-li</ForeName>
            <Initials>KL</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Young</LastName>
            <ForeName>Charles Y F</ForeName>
            <Initials>CY</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lou</LastName>
            <ForeName>Hong-xiang</ForeName>
            <Initials>HX</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yuan</LastName>
            <ForeName>Hui-qing</ForeName>
            <Initials>HQ</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>07</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Acta Pharmacol Sin</MedlineTA>
        <NlmUniqueID>100956087</NlmUniqueID>
        <ISSNLinking>1671-4083</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014315">Triterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C540615">retigeric acid B</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D063306" MajorTopicYN="N">Mitophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014315" MajorTopicYN="N">Triterpenes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>2</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>4</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>7</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23892275</ArticleId>
        <ArticleId IdType="pmc">PMC4003163</ArticleId>
        <ArticleId IdType="doi">10.1038/aps.2013.68</ArticleId>
        <ArticleId IdType="pii">aps201368</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature. 2008;451:1069&#x2013;75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2670399</ArticleId>
            <ArticleId IdType="pubmed">18305538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Z, Klionsky DJ. Eaten alive: a history of macroautophagy. Nat Cell Biol. 2010;12:814&#x2013;22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3616322</ArticleId>
            <ArticleId IdType="pubmed">20811353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanida I, Ueno T, Kominami E. Human light chain 3/MAP1LC3B is cleaved at its carboxyl-terminal Met121 to expose Gly120 for lipidation and targeting to autophagosomal membranes. J Biol Chem. 2004;279:47704&#x2013;10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15355958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell. 2010;40:280&#x2013;93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3127250</ArticleId>
            <ArticleId IdType="pubmed">20965422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clarke R, Cook KL, Hu R, Facey CO, Tavassoly I, Schwartz JL, et al. Endoplasmic reticulum stress, the unfolded protein response, autophagy, and the integrated regulation of breast cancer cell fate. Cancer Res. 2012;72:1321&#x2013;31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3313080</ArticleId>
            <ArticleId IdType="pubmed">22422988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagakubo D, Taira T, Kitaura H, Ikeda M, Tamai K, Iguchi-Ariga SM, et al. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun. 1997;231:509&#x2013;13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9070310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shendelman S, Jonason A, Martinat C, Leete T, Abeliovich A. DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol. 2004;2:e362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC521177</ArticleId>
            <ArticleId IdType="pubmed">15502874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lev N, Ickowicz D, Barhum Y, Lev S, Melamed E, Offen D. DJ-1 protects against dopamine toxicity. J Neural Transm. 2009;116:151&#x2013;60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18974921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cookson MR. Pathways to Parkinsonism. Neuron. 2003;37:7&#x2013;10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12526767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu H, Wang M, Li M, Wang D, Rao Q, Wang Y, et al. Expression and role of DJ-1 in leukemia. Biochem Biophys Res Commun. 2008;375:477&#x2013;83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18722352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>MacKeigan JP, Clements CM, Lich JD, Pope RM, Hod Y, Ting JP. Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIalpha. Cancer Res. 2003;63:6928&#x2013;34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14583493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ismail IA, Kang HS, Lee HJ, Kwon BM, Hong SH. 2&#x2032;-Benzoyloxycinnamaldehyde-mediated DJ-1 upregulation protects MCF-7 cells from mitochondrial damage. Biol Pharm Bull. 2012;35:895&#x2013;902.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22687481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Junn E, Jang WH, Zhao X, Jeong BS, Mouradian MM. Mitochondrial localization of DJ-1 leads to enhanced neuroprotection. J Neurosci Res. 2009;87:123&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2752655</ArticleId>
            <ArticleId IdType="pubmed">18711745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCoy MK, Cookson MR. DJ-1 regulation of mitochondrial function and autophagy through oxidative stress. Autophagy. 2011;7:531&#x2013;2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3127213</ArticleId>
            <ArticleId IdType="pubmed">21317550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 2004;5:213&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1298985</ArticleId>
            <ArticleId IdType="pubmed">14749723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Opipari AW, Tan L, Boitano AE, Sorenson DR, Aurora A, Liu JR. Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res. 2004;64:696&#x2013;703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14744787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Donovan TR, O'Sullivan GC, McKenna SL. Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. Autophagy. 2011;7:509&#x2013;24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3127212</ArticleId>
            <ArticleId IdType="pubmed">21325880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viola G, Bortolozzi R, Hamel E, Moro S, Brun P, Castagliuolo I, et al. MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR pathway and delayed apoptosis in A549 cells. Biochem Pharmacol. 2012;83:16&#x2013;26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3234688</ArticleId>
            <ArticleId IdType="pubmed">21964343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xi G, Hu X, Wu B, Jiang H, Young CY, Pang Y, et al. Autophagy inhibition promotes paclitaxel-induced apoptosis in cancer cells. Cancer Lett. 2011;307:141&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21511395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abedin MJ, Wang D, McDonnell MA, Lehmann U, Kelekar A. Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ. 2007;14:500&#x2013;10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16990848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu YQ, Hu XY, Lu T, Cheng YN, Young CY, Yuan HQ, et al. Retigeric acid B exhibits antitumor activity through suppression of nuclear factor-kappaB signaling in prostate cancer cells in vitro and in vivo. PLoS One. 2012;7:e38000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3362538</ArticleId>
            <ArticleId IdType="pubmed">22666431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu H, Liu YQ, Liu YQ, Xu AH, Young CY, Yuan HQ, et al. A novel anticancer agent, retigeric acid B, displays proliferation inhibition, S phase arrest and apoptosis activation in human prostate cancer cells. Chem Biol Interact. 2010;188:598&#x2013;606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20692244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan H, Young CY, Tian Y, Liu Z, Zhang M, Lou H. Suppression of the androgen receptor function by quercetin through protein-protein interactions of Sp1, c-Jun, and the androgen receptor in human prostate cancer cells. Mol Cell Biochem. 2010;339:253&#x2013;62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20148354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zoratti M, Szabo I. The mitochondrial permeability transition. Biochim Biophys Acta. 1995;1241:139&#x2013;76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7640294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeuchi H, Kondo Y, Fujiwara K, Kanzawa T, Aoki H, Mills GB, et al. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res. 2005;65:3336&#x2013;46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15833867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>VanderWeele DJ, Zhou R, Rudin CM. Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol Cancer Ther. 2004;3:1605&#x2013;13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15634654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh K, Matsuyama S, Drazba JA, Almasan A. Autophagy-dependent senescence in response to DNA damage and chronic apoptotic stress. Autophagy. 2012;8:236&#x2013;51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3336077</ArticleId>
            <ArticleId IdType="pubmed">22240589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrin G, Linares CI, Muntane J. Mitochondrial drug targets in cell death and cancer. Curr Pharm Des. 2011;17:2002&#x2013;16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21718250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li ZY, Yang Y, Ming M, Liu B. Mitochondrial ROS generation for regulation of autophagic pathways in cancer. Biochem Biophys Res Commun. 2011;414:5&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21951851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lemasters JJ, Qian T, Elmore SP, Trost LC, Nishimura Y, Herman B, et al. Confocal microscopy of the mitochondrial permeability transition in necrotic cell killing, apoptosis and autophagy. Biofactors. 1998;8:283&#x2013;5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9914830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lemasters JJ, Nieminen AL, Qian T, Trost LC, Elmore SP, Nishimura Y, et al. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta. 1998;1366:177&#x2013;96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9714796</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23874830</PMID>
      <DateCompleted>
        <Year>2014</Year>
        <Month>02</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Electronic-Print">
        <Journal>
          <ISSN IssnType="Electronic">1932-6203</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>PloS one</Title>
          <ISOAbbreviation>PLoS One</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt.</ArticleTitle>
        <Pagination>
          <StartPage>e68973</StartPage>
          <MedlinePgn>e68973</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e68973</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0068973</ELocationID>
        <Abstract>
          <AbstractText>Hormonal therapy resistance remains a considerable barrier in the treatment of breast cancer. Activation of the Akt-PI3K-mTOR pathway plays an important role in hormonal therapy resistance. Our recent preclinical and clinical studies showed that the addition of a histone deacetylase inhibitor re-sensitized hormonal therapy resistant breast cancer to tamoxifen. As histone deacetylases are key regulators of Akt, we evaluated the effect of combined treatment with the histone deacetylase inhibitor PCI-24781 and tamoxifen on Akt in breast cancer cells. We demonstrate that while both histone deacetylase and estrogen receptor inhibition down regulate AKT mRNA and protein, their concerted effort results in down regulation of AKT activity with induction of cell death. Histone deacetylase inhibition exerts its effect on AKT mRNA through an estrogen receptor-dependent mechanism, primarily down regulating the most abundant isoform AKT1. Although siRNA depletion of AKT modestly induces cell death, when combined with an anti-estrogen, cytotoxicity is significantly enhanced. Thus, histone deacetylase regulation of AKT mRNA is a key mediator of this therapeutic combination and may represent a novel biomarker for predicting response to this regimen.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Thomas</LastName>
            <ForeName>Scott</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thurn</LastName>
            <ForeName>K Ted</ForeName>
            <Initials>KT</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Raha</LastName>
            <ForeName>Paromita</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Stephanie</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Munster</LastName>
            <ForeName>Pamela N</ForeName>
            <Initials>PN</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA152989</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>5 R01 CA152989</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>07</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>PLoS One</MedlineTA>
        <NlmUniqueID>101285081</NlmUniqueID>
        <ISSNLinking>1932-6203</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001572">Benzofurans</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D056572">Histone Deacetylase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006877">Hydroxamic Acids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020845">Selective Estrogen Receptor Modulators</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>094ZI81Y45</RegistryNumber>
          <NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.5.1.98</RegistryNumber>
          <NameOfSubstance UI="D006655">Histone Deacetylases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IYO470654U</RegistryNumber>
          <NameOfSubstance UI="C512352">abexinostat</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001572" MajorTopicYN="N">Benzofurans</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056572" MajorTopicYN="N">Histone Deacetylase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006655" MajorTopicYN="N">Histone Deacetylases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006877" MajorTopicYN="N">Hydroxamic Acids</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020845" MajorTopicYN="N">Selective Estrogen Receptor Modulators</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013629" MajorTopicYN="N">Tamoxifen</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Competing Interests: Pharmacyclics Inc. provided to the authors the compound PCI-24781 and a
modest research grant. However, these provisions have not altered the
authors' adherence to all the PLOS ONE policies on sharing data and
materials.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>4</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23874830</ArticleId>
        <ArticleId IdType="pmc">PMC3711340</ArticleId>
        <ArticleId IdType="doi">10.1371/journal.pone.0068973</ArticleId>
        <ArticleId IdType="pii">PONE-D-13-15657</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics
CA Cancer J Clin
60: 277-300. doi:10.3322/caac.20073. PubMed: 20610543.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.20073</ArticleId>
            <ArticleId IdType="pubmed">20610543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas S, Munster PN (2009) Histone deacetylase inhibitor induced
modulation of anti-estrogen therapy. Cancer
Lett
280: 184-191. doi:10.1016/j.canlet.2008.12.026. PubMed:
19185986.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2008.12.026</ArticleId>
            <ArticleId IdType="pubmed">19185986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB et al. (2011) Invasive breast cancer. J Natl Compr Canc Netw JNCCN 9: 136-222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21310842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raha P, Thomas S, Munster PN (2011) Epigenetic modulation: a novel
therapeutic target for overcoming hormonal therapy
resistance. Epigenomics
3: 451-470. doi:10.2217/epi.11.72. PubMed: 22126205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/epi.11.72</ArticleId>
            <ArticleId IdType="pubmed">22126205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS
et al. (2012) Everolimus in
postmenopausal hormone-receptor-positive advanced breast
cancer. N Engl J Med
366: 520-529. doi:10.1056/NEJMoa1109653. PubMed: 22149876.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1109653</ArticleId>
            <ArticleId IdType="pmc">PMC5705195</ArticleId>
            <ArticleId IdType="pubmed">22149876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bi&#xe7;aku E, Marchion DC, Schmitt ML, M&#xfc;nster PN (2008) Selective inhibition of histone
deacetylase 2 silences progesterone receptor mediated
signaling. Cancer Res
68: 1513-1519. doi:10.1158/0008-5472.CAN-07-2822. PubMed:
18316616.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-07-2822</ArticleId>
            <ArticleId IdType="pubmed">18316616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas S, Thurn KT, Bi&#xe7;aku E, Marchion DC, M&#xfc;nster PN (2011) Addition of a histone deacetylase
inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis,
which is opposed by the induction of autophagy.
Breast Cancer Res Treat
130: 437-447. doi:10.1007/s10549-011-1364-y. PubMed: 21298336.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-011-1364-y</ArticleId>
            <ArticleId IdType="pmc">PMC3760725</ArticleId>
            <ArticleId IdType="pubmed">21298336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hodges-Gallagher L, Valentine CD, Bader SE, Kushner PJ (2006) Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Treat: Breast Cancer Res.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17186358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M
et al. (2011) A phase II study of the
histone deacetylase inhibitor vorinostat combined with tamoxifen for the
treatment of patients with hormone therapy-resistant breast
cancer. Br J Cancer
104: 1828-1835. doi:10.1038/bjc.2011.156. PubMed: 21559012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2011.156</ArticleId>
            <ArticleId IdType="pmc">PMC3111195</ArticleId>
            <ArticleId IdType="pubmed">21559012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J
et al. (2011) Gefitinib or placebo in
combination with tamoxifen in patients with hormone receptor-positive
metastatic breast cancer: a randomized phase II study.
Clin Cancer Res
17: 1147-1159. doi:10.1158/1078-0432.CCR-10-1869. PubMed:
21220480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-10-1869</ArticleId>
            <ArticleId IdType="pmc">PMC3074404</ArticleId>
            <ArticleId IdType="pubmed">21220480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL
et al. (2008) An integrative genomic
and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast
cancer. Cancer Res
68: 6084-6091. doi:10.1158/0008-5472.CAN-07-6854. PubMed:
18676830.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-07-6854</ArticleId>
            <ArticleId IdType="pmc">PMC2680495</ArticleId>
            <ArticleId IdType="pubmed">18676830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL
et al. (2007) A transforming mutation
in the pleckstrin homology domain of AKT1 in cancer.
Nature
448: 439-444. doi:10.1038/nature05933. PubMed: 17611497.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature05933</ArticleId>
            <ArticleId IdType="pubmed">17611497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ
et al. (1995) Molecular alterations of
the AKT2 oncogene in ovarian and breast carcinomas.
Int J Cancer J Int Cancer
64: 280-285. doi:10.1002/ijc.2910640412. PubMed: 7657393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.2910640412</ArticleId>
            <ArticleId IdType="pubmed">7657393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ
et al. (2001) AKT1/PKBalpha kinase is
frequently elevated in human cancers and its constitutive activation is
required for oncogenic transformation in NIH3T3 cells.
Am J Pathol
159: 431-437. doi:10.1016/S0002-9440(10)61714-2. PubMed:
11485901.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-9440(10)61714-2</ArticleId>
            <ArticleId IdType="pmc">PMC1850562</ArticleId>
            <ArticleId IdType="pubmed">11485901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT
pathway in human cancer. Nat Rev Cancer
2: 489-501. doi:10.1038/nrc839. PubMed: 12094235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc839</ArticleId>
            <ArticleId IdType="pubmed">12094235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of
Akt/PKB by the rictor-mTOR complex. Science
307: 1098-1101. doi:10.1126/science.1106148. PubMed: 15718470.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1106148</ArticleId>
            <ArticleId IdType="pubmed">15718470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF
et al. (1998) Protein kinase B kinases
that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation
of protein kinase B. Science
279: 710-714. doi:10.1126/science.279.5351.710. PubMed:
9445477.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.279.5351.710</ArticleId>
            <ArticleId IdType="pubmed">9445477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Datta SR, Dudek H, Tao X, Masters S, Fu H
et al. (1997) Akt phosphorylation of
BAD couples survival signals to the cell-intrinsic death
machinery. Cell
91: 231-241. doi:10.1016/S0092-8674(00)80405-5. PubMed:
9346240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0092-8674(00)80405-5</ArticleId>
            <ArticleId IdType="pubmed">9346240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P
et al. (1999) Akt promotes cell
survival by phosphorylating and inhibiting a Forkhead transcription
factor. Cell
96: 857-868. doi:10.1016/S0092-8674(00)80595-4. PubMed:
10102273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0092-8674(00)80595-4</ArticleId>
            <ArticleId IdType="pubmed">10102273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995) Inhibition of glycogen synthase
kinase-3 by insulin mediated by protein kinase B.
Nature
378: 785-789. doi:10.1038/378785a0. PubMed: 8524413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/378785a0</ArticleId>
            <ArticleId IdType="pubmed">8524413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen CS, Weng SC, Tseng PH, Lin HP (2005) Histone acetylation-independent
effect of histone deacetylase inhibitors on Akt through the reshuffling of
protein phosphatase 1 complexes. J Biol
Chem
280: 38879-38887. doi:10.1074/jbc.M505733200. PubMed: 16186112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M505733200</ArticleId>
            <ArticleId IdType="pubmed">16186112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alao JP, Stavropoulou AV, Lam EW, Coombes RC, Vigushin DM (2006) Histone deacetylase inhibitor,
trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7
breast cancer cells. Mol Cancer
5: 8. doi:10.1186/1476-4598-5-8. PubMed: 16504004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1476-4598-5-8</ArticleId>
            <ArticleId IdType="pmc">PMC1397858</ArticleId>
            <ArticleId IdType="pubmed">16504004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alao JP, Stavropoulou AV, Lam EW, Coombes RC (2006) Role of glycogen synthase kinase 3
beta (GSK3beta) in mediating the cytotoxic effects of the histone
deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer
cells. Mol Cancer
5: 40. doi:10.1186/1476-4598-5-40. PubMed: 17018141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1476-4598-5-40</ArticleId>
            <ArticleId IdType="pmc">PMC1592505</ArticleId>
            <ArticleId IdType="pubmed">17018141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bradley EW, Carpio LR, Westendorf JJ (2013) Histone deacetylase 3 suppression
increases PH domain and leucine-rich repeat phosphatase (Phlpp)1 expression
in chondrocytes to suppress Akt signaling and matrix
secretion. J Biol Chem
288: 9572-9582. doi:10.1074/jbc.M112.423723. PubMed: 23408427.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M112.423723</ArticleId>
            <ArticleId IdType="pmc">PMC3617261</ArticleId>
            <ArticleId IdType="pubmed">23408427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S
et al. (2006) CRA-024781: a novel
synthetic inhibitor of histone deacetylase enzymes with antitumor activity
in vitro and in vivo. Mol Cancer Ther
5: 1309-1317. doi:10.1158/1535-7163.MCT-05-0442. PubMed:
16731764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-05-0442</ArticleId>
            <ArticleId IdType="pubmed">16731764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Undevia SD, Janisch L, Schilsky RL, Loury D, Balasubramanian S et al. (2008) Phase I study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the histone deacetylase inhibitor (HDACi) PCI-24781. J Clin Oncol 26(suppl): abstr 14514</Citation>
        </Reference>
        <Reference>
          <Citation>Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT
et al. (2005) HDAC6 regulates Hsp90
acetylation and chaperone-dependent activation of glucocorticoid
receptor. Mol Cell
18: 601-607. doi:10.1016/j.molcel.2005.04.021. PubMed:
15916966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2005.04.021</ArticleId>
            <ArticleId IdType="pubmed">15916966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P
et al. (2002) Akt forms an
intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is
destabilized by inhibitors of Hsp90 function. J Biol
Chem
277: 39858-39866. doi:10.1074/jbc.M206322200. PubMed: 12176997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M206322200</ArticleId>
            <ArticleId IdType="pubmed">12176997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee RS, House CM, Cristiano BE, Hannan RD, Pearson RB
et al. (2011) Relative Expression
Levels Rather Than Specific Activity Plays the Major Role in Determining In
Vivo AKT Isoform Substrate Specificity. Enzyme
Res, 2011: 2011: 720985. PubMed:
21869924</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3160084</ArticleId>
            <ArticleId IdType="pubmed">21869924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yi X, Wei W, Wang SY, Du ZY, Xu YJ
et al. (2008) Histone deacetylase
inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by
CHIP-mediated ubiquitin pathway and inhibits survival
signaling. Biochem Pharmacol
75: 1697-1705. doi:10.1016/j.bcp.2007.10.035. PubMed: 18342836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2007.10.035</ArticleId>
            <ArticleId IdType="pubmed">18342836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W
et al. (2005) Inhibition of histone
deacetylase 6 acetylates and disrupts the chaperone function of heat shock
protein 90: a novel basis for antileukemia activity of histone deacetylase
inhibitors. J Biol Chem
280: 26729-26734. doi:10.1074/jbc.C500186200. PubMed: 15937340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.C500186200</ArticleId>
            <ArticleId IdType="pubmed">15937340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiskus W, Ren Y, Mohapatra A, Bali P, Mandawat A
et al. (2007) Hydroxamic acid analogue
histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and
transcriptional activity: a result of hyperacetylation and inhibition of
chaperone function of heat shock protein 90. Clin
Cancer Res
13: 4882-4890. doi:10.1158/1078-0432.CCR-06-3093. PubMed:
17699868.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-06-3093</ArticleId>
            <ArticleId IdType="pubmed">17699868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC (2006) Rapid alteration of microRNA levels
by histone deacetylase inhibition. Cancer
Res
66: 1277-1281. doi:10.1158/0008-5472.CAN-05-3632. PubMed:
16452179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-05-3632</ArticleId>
            <ArticleId IdType="pubmed">16452179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wada T, Kikuchi J, Furukawa Y (2012) Histone deacetylase 1 enhances
microRNA processing via deacetylation of DGCR8. EMBO
Rep
13: 142-149. doi:10.1038/embor.2011.247. PubMed: 22222205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/embor.2011.247</ArticleId>
            <ArticleId IdType="pmc">PMC3271337</ArticleId>
            <ArticleId IdType="pubmed">22222205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin RJ, Lin YC, Yu AL (2010) miR-149* induces apoptosis by
inhibiting Akt1 and E2F1 in human cancer cells. Mol
Carcinog
49: 719-727. PubMed: 20623644.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20623644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foley NH, Bray IM, Tivnan A, Bryan K, Murphy DM
et al. (2010) MicroRNA-184 inhibits
neuroblastoma cell survival through targeting the serine/threonine kinase
AKT2. Mol Cancer
9: 83. doi:10.1186/1476-4598-9-83. PubMed: 20409325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1476-4598-9-83</ArticleId>
            <ArticleId IdType="pmc">PMC2864218</ArticleId>
            <ArticleId IdType="pubmed">20409325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Chen Y, Zhao J, Kong F, Zhang Y (2011) miR-203 reverses chemoresistance in
p53-mutated colon cancer cells through downregulation of Akt2
expression. Cancer Lett
304: 52-59. doi:10.1016/j.canlet.2011.02.003. PubMed:
21354697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2011.02.003</ArticleId>
            <ArticleId IdType="pubmed">21354697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Margueron R, Duong V, Castet A, Cavaill&#xe8;s V (2004) Histone deacetylase inhibition and
estrogen signalling in human breast cancer cells.
Biochem Pharmacol
68: 1239-1246. doi:10.1016/j.bcp.2004.04.031. PubMed: 15313422.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2004.04.031</ArticleId>
            <ArticleId IdType="pubmed">15313422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawai H, Li H, Avraham S, Jiang S, Avraham HK (2003) Overexpression of histone deacetylase
HDAC1 modulates breast cancer progression by negative regulation of estrogen
receptor alpha. Int J Cancer
107: 353-358. doi:10.1002/ijc.11403. PubMed: 14506733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.11403</ArticleId>
            <ArticleId IdType="pubmed">14506733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alao JP, Lam EW, Ali S, Buluwela L, Bordogna W
et al. (2004) Histone deacetylase
inhibitor trichostatin A represses estrogen receptor alpha-dependent
transcription and promotes proteasomal degradation of cyclin D1 in human
breast carcinoma cell lines. Clin Cancer
Res
10: 8094-8104. doi:10.1158/1078-0432.CCR-04-1023. PubMed:
15585645.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-04-1023</ArticleId>
            <ArticleId IdType="pubmed">15585645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S
et al. (2006) CRA-024781: a novel
synthetic inhibitor of histone deacetylase enzymes with antitumor activity
in vitro and in vivo. Mol Cancer Ther
5: 1309-1317. doi:10.1158/1535-7163.MCT-05-0442. PubMed:
16731764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-05-0442</ArticleId>
            <ArticleId IdType="pubmed">16731764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahmani M, Reese E, Dai Y, Bauer C, Payne SG
et al. (2005) Coadministration of
histone deacetylase inhibitors and perifosine synergistically induces
apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and
the generation of ceramide and reactive oxygen species.
Cancer Res
65: 2422-2432. doi:10.1158/0008-5472.CAN-04-2440. PubMed:
15781658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-04-2440</ArticleId>
            <ArticleId IdType="pubmed">15781658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozaki K, Kosugi M, Baba N, Fujio K, Sakamoto T
et al. (2010) Blockade of the ERK or
PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase
inhibitors in tumor cells resistant to gefitinib or
imatinib. Biochem Biophys Res Commun
391: 1610-1615. doi:10.1016/j.bbrc.2009.12.086. PubMed: 20026060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2009.12.086</ArticleId>
            <ArticleId IdType="pubmed">20026060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Erlich RB, Kherrouche Z, Rickwood D, Endo-Munoz L, Cameron S
et al. (2012) Preclinical evaluation of
dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and
neck squamous cell carcinoma. Br J Cancer
106: 107-115. doi:10.1038/bjc.2011.495. PubMed: 22116303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2011.495</ArticleId>
            <ArticleId IdType="pmc">PMC3251846</ArticleId>
            <ArticleId IdType="pubmed">22116303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM
et al. (2012) Randomized Phase II Trial
of Everolimus in Combination With Tamoxifen in Patients With Hormone
Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative
Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A
GINECO Study. J Clin Oncol Off J American Society Of
Clinical Oncology, 30:
2718&#x2013;24. PubMed: 22565002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22565002</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23708970</PMID>
      <DateCompleted>
        <Year>2014</Year>
        <Month>03</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1791-2423</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>43</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>International journal of oncology</Title>
          <ISOAbbreviation>Int J Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Magnolol inhibits angiogenesis by regulating ROS-mediated apoptosis and the PI3K/AKT/mTOR signaling pathway in mES/EB-derived endothelial-like cells.</ArticleTitle>
        <Pagination>
          <StartPage>600</StartPage>
          <EndPage>610</EndPage>
          <MedlinePgn>600-10</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3892/ijo.2013.1959</ELocationID>
        <Abstract>
          <AbstractText>Magnolol, a neolignan from the traditional medicinal plant Magnolia obovata, has been shown to possess neuroprotective, anti-inflammatory, anticancer and anti-angiogenic activities. However, the precise mechanism of the anti-angiogenic activity of magnolol remains to be elucidated. In the present study, the anti-angiogenic effect of magnolol was evaluated in mouse embryonic stem (mES)/embryoid body (EB)-derived endothelial-like cells. The endothelial-like cells were obtained by differentiation from mES/EB cells. Magnolol (20 µM) significantly suppressed the transcriptional and translational expression of platelet endothelial cell adhesion molecule (PECAM), an endothelial biomarker, in mES/EB-derived endothelial-like cells. To further understand the molecular mechanism of the suppression of PECAM expression, signaling pathways were analyzed in the mES/EB-derived endothelial-like cells. Magnolol induced the generation of reactive oxygen species (ROS) by mitochondria, a process that was associated with the induction of apoptosis as determined by positive Annexin V staining and the activation of cleaved caspase-3. The involvement of ROS generation by magnolol was confirmed by treatment with an antioxidant, N-acetyl-cysteine (NAC). NAC inhibited the magnolol-mediated induction of ROS generation and suppression of PECAM expression. In addition, magnolol suppressed the activation of MAPKs (ERK, JNK and p38) and the PI3K/AKT/mTOR signaling pathway in mES/EB-derived endothelial-like cells. Taken together, these findings demonstrate for the first time that the anti-angiogenic activity of magnolol may be associated with ROS-mediated apoptosis and the suppression of the PI3K/AKT/mTOR signaling pathway in mES/EB-derived endothelial-like cells.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Gi Dae</ForeName>
            <Initials>GD</Initials>
            <AffiliationInfo>
              <Affiliation>Natural Products Research Institute, College of Pharmacy, Seoul National University, Gwanak-gu, Seoul 151-742, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oh</LastName>
            <ForeName>Jedo</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Park</LastName>
            <ForeName>Hyen-Joo</ForeName>
            <Initials>HJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bae</LastName>
            <ForeName>Kihwan</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Sang Kook</ForeName>
            <Initials>SK</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>05</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Greece</Country>
        <MedlineTA>Int J Oncol</MedlineTA>
        <NlmUniqueID>9306042</NlmUniqueID>
        <ISSNLinking>1019-6439</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001713">Biphenyl Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017705">Lignans</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019408">Platelet Endothelial Cell Adhesion Molecule-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>001E35HGVF</RegistryNumber>
          <NameOfSubstance UI="C005498">magnolol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.13.39</RegistryNumber>
          <NameOfSubstance UI="D019001">Nitric Oxide Synthase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546843">mTOR protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D048049">Extracellular Signal-Regulated MAP Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D048031">JNK Mitogen-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>WYQ7N0BPYC</RegistryNumber>
          <NameOfSubstance UI="D000111">Acetylcysteine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000111" MajorTopicYN="N">Acetylcysteine</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001713" MajorTopicYN="N">Biphenyl Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053595" MajorTopicYN="N">Embryonic Stem Cells</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048049" MajorTopicYN="N">Extracellular Signal-Regulated MAP Kinases</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048031" MajorTopicYN="N">JNK Mitogen-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017705" MajorTopicYN="N">Lignans</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019001" MajorTopicYN="N">Nitric Oxide Synthase</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019408" MajorTopicYN="N">Platelet Endothelial Cell Adhesion Molecule-1</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048051" MajorTopicYN="N">p38 Mitogen-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23708970</ArticleId>
        <ArticleId IdType="doi">10.3892/ijo.2013.1959</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23645590</PMID>
      <DateCompleted>
        <Year>2014</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1538-8514</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Molecular cancer therapeutics</Title>
          <ISOAbbreviation>Mol Cancer Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Aerosol administration of phospho-sulindac inhibits lung tumorigenesis.</ArticleTitle>
        <Pagination>
          <StartPage>1417</StartPage>
          <EndPage>1428</EndPage>
          <MedlinePgn>1417-28</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1158/1535-7163.MCT-13-0006-T</ELocationID>
        <Abstract>
          <AbstractText>Phospho-sulindac is a sulindac derivative with promising anticancer activity in lung cancer, but its limited metabolic stability presents a major challenge for systemic therapy. We reasoned that inhalation delivery of phospho-sulindac might overcome first-pass metabolism and produce high levels of intact drug in lung tumors. Here, we developed a system for aerosolization of phospho-sulindac and evaluated the antitumor efficacy of inhaled phospho-sulindac in an orthotopic model of human non-small cell lung cancer (A549 cells). We found that administration by inhalation delivered high levels of phospho-sulindac to the lungs and minimized its hydrolysis to less active metabolites. Consequently, inhaled phospho-sulindac (6.5 mg/kg) was highly effective in inhibiting lung tumorigenesis (75%; P &lt; 0.01) and significantly improved the survival of mice bearing orthotopic A549 xenografts. Mechanistically, phospho-sulindac suppressed lung tumorigenesis by (i) inhibiting EGF receptor (EGFR) activation, leading to profound inhibition of Raf/MEK/ERK and PI3K/AKT/mTOR survival cascades; (ii) inducing oxidative stress, which provokes the collapse of mitochondrial membrane potential and mitochondria-dependent cell death; and (iii) inducing autophagic cell death. Our data establish that inhalation delivery of phospho-sulindac is an efficacious approach to the control of lung cancer, which merits further evaluation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Ka Wing</ForeName>
            <Initials>KW</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Cancer Prevention, Stony Brook University, Stony Brook, NY 11794, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wong</LastName>
            <ForeName>Chi C</ForeName>
            <Initials>CC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alston</LastName>
            <ForeName>Ninche</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mackenzie</LastName>
            <ForeName>Gerardo G</ForeName>
            <Initials>GG</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Liqun</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ouyang</LastName>
            <ForeName>Nengtai</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Gang</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wiedmann</LastName>
            <ForeName>Timothy</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rigas</LastName>
            <ForeName>Basil</ForeName>
            <Initials>B</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA139454</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R43 CA165448</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01CA139454</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R41CA162683</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>05</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Mol Cancer Ther</MedlineTA>
        <NlmUniqueID>101132535</NlmUniqueID>
        <ISSNLinking>1535-7163</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>184SNS8VUH</RegistryNumber>
          <NameOfSubstance UI="D013467">Sulindac</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.-</RegistryNumber>
          <NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D048490">raf Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002471" MajorTopicYN="N">Cell Transformation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020928" MajorTopicYN="N">Mitogen-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013467" MajorTopicYN="N">Sulindac</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048490" MajorTopicYN="N">raf Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Conflicts of interest: The authors have nothing to disclose except for Basil Rigas, who has an equity position in Medicon Pharmaceuticals, Inc. and Nengtai Ouyang who is an employee for the same.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23645590</ArticleId>
        <ArticleId IdType="mid">NIHMS475441</ArticleId>
        <ArticleId IdType="pmc">PMC3780561</ArticleId>
        <ArticleId IdType="doi">10.1158/1535-7163.MCT-13-0006-T</ArticleId>
        <ArticleId IdType="pii">1535-7163.MCT-13-0006-T</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Siegel R, Ward E, Brawley O, Jemal A. The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212&#x2013;36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21685461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thatcher N, Chang A, Parikh P, Rodrigues PJ, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet. 2005;366:1527&#x2013;37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16257339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris RE, Beebe-Donk J, Schuller HM. Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep. 2002;9:693&#x2013;5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12066194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brasky TM, Baik CS, Slatore CG, Alvarado M, White E. Prediagnostic nonsteroidal anti-inflammatory drug use and lung cancer survival in the VITAL study. J Thorac Oncol. 2012;7:1503&#x2013;12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3445269</ArticleId>
            <ArticleId IdType="pubmed">22982651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duperron C, Castonguay A. Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis. 1997;18:1001&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9163687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castonguay A, Rioux N. Inhibition of lung tumourigenesis by sulindac: comparison of two experimental protocols. Carcinogenesis. 1997;18:491&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9067547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henry D, Lim LL, Garcia Rodriguez LA, Perez GS, Carson JL, Griffin M, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996;312:1563&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2351326</ArticleId>
            <ArticleId IdType="pubmed">8664664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mackenzie GG, Sun Y, Huang L, Xie G, Ouyang N, Gupta RC, et al. Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice. Gastroenterology. 2010;139:1320&#x2013;32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2949489</ArticleId>
            <ArticleId IdType="pubmed">20600034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mackenzie GG, Ouyang N, Xie G, Vrankova K, Huang L, Sun Y, et al. Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice. Cancer Prev Res (Phila) 2011;4:1052&#x2013;60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3131469</ArticleId>
            <ArticleId IdType="pubmed">21464038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang L, Zhu C, Sun Y, Xie G, Mackenzie GG, Qiao G, Komninou D, et al. Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect. Carcinogenesis. 2010;31:1982&#x2013;90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2966552</ArticleId>
            <ArticleId IdType="pubmed">20627873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dahl AR, Grossi IM, Houchens DP, Scovell LJ, Placke ME, Imondi AR, et al. Inhaled isotretinoin (13-cis retinoic acid) is an effective lung cancer chemopreventive agent in A/J mice at low doses: a pilot study. Clin Cancer Res. 2000;6:3015&#x2013;24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10955779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wattenberg LW, Wiedmann TS, Estensen RD, Zimmerman CL, Steele VE, Kelloff GJ. Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res. 1997;57:5489&#x2013;92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9407956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tatsumura T, Koyama S, Tsujimoto M, Kitagawa M, Kagamimori S. Further Study of Nebulization Chemotherapy, a New Chemotherapeutic Method in the Treatment of Lung Carcinomas - Fundamental and Clinical. Brit J Cancer. 1993;68:1146&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1968665</ArticleId>
            <ArticleId IdType="pubmed">8260366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie G, Sun Y, Nie T, Mackenzie GG, Huang L, Kopelovich L, et al. Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models. J Pharmacol Exp Ther. 2011;337:876&#x2013;86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3101013</ArticleId>
            <ArticleId IdType="pubmed">21422165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>She QB, Solit DB, Ye Q, O&#x2019;Reilly KE, Lobo J, Rosen N. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell. 2005;8:287&#x2013;97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3203692</ArticleId>
            <ArticleId IdType="pubmed">16226704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291&#x2013;310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17496923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balsara BR, Pei J, Mitsuuchi Y, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis. 2004;25:2053&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15240509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu WK, Coffelt SB, Cho CH, Wang XJ, Lee CW, Chan FK, et al. The autophagic paradox in cancer therapy. Oncogene. 31:939&#x2013;53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21765470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y, Rowehl LM, Huang L, Mackenzie GG, Vrankova K, Komninou D, et al. Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: an effect controlled by the thioredoxin system. Breast Cancer Res. 2012;14:R20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3496138</ArticleId>
            <ArticleId IdType="pubmed">22293394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhoopathi P, Chetty C, Gujrati M, Dinh DH, Rao JS, Lakka S. Cathepsin B facilitates autophagy-mediated apoptosis in SPARC overexpressed primitive neuroectodermal tumor cells. Cell Death Differ. 2010;17:1529&#x2013;39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3025815</ArticleId>
            <ArticleId IdType="pubmed">20339379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naito A, Carcel-Trullols J, Xie CH, Evans TT, Mizumachi T, Higuchi M. Induction of acquired resistance to antiestrogen by reversible mitochondrial DNA depletion in breast cancer cell line. Int J Cancer. 2008;122:1506&#x2013;11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2293290</ArticleId>
            <ArticleId IdType="pubmed">17990320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie G, Nie T, Mackenzie GG, Sun Y, Huang L, Ouyang N, et al. The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine. Br J Pharmacol. 2012;165:2152&#x2013;66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3413853</ArticleId>
            <ArticleId IdType="pubmed">21955327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doki Y, Murakami K, Yamaura T, Sugiyama S, Misaki T, Saiki I. Mediastinal lymph node metastasis model by orthotopic intrapulmonary implantation of Lewis lung carcinoma cells in mice. Br J Cancer. 1999;79:1121&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2362254</ArticleId>
            <ArticleId IdType="pubmed">10098745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy. 2008;4:151&#x2013;75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2654259</ArticleId>
            <ArticleId IdType="pubmed">18188003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang JH, Chang YC, Maurizi MR. 4-O-carboxymethyl ascochlorin causes ER stress and induced autophagy in human hepatocellular carcinoma cells. J Biol Chem. 2012;287:15661&#x2013;71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3346088</ArticleId>
            <ArticleId IdType="pubmed">22433868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fulzele SV, Chatterjee A, Shaik MS, Jackson T, Singh M. Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model. Pharm Res. 2006;23:2094&#x2013;106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2902545</ArticleId>
            <ArticleId IdType="pubmed">16902813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blasco RB, Francoz S, Santamaria D, Ca&#xf1;amero M, Dubus P, Charron J, et al. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell. 2011;19:652&#x2013;63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4854330</ArticleId>
            <ArticleId IdType="pubmed">21514245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sahin U, Blobel CP. Ectodomain shedding of the EGF-receptor ligand epigen is mediated by ADAM17. FEBS Lett. 2007;581:41&#x2013;4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17169360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, et al. An essential role for ectodomain shedding in mammalian development. Science. 1998;282:1281&#x2013;4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9812885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rigas B, Sun Y. Induction of oxidative stress as a mechanism of action of chemopreventive agents against cancer. Br J Cancer. 2008;98:1157&#x2013;60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2359637</ArticleId>
            <ArticleId IdType="pubmed">18253125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sithanandam G, Smith GT, Masuda A, Takahashi T, Anderson LM, Fornwald LW. Cell cycle activation in lung adenocarcinoma cells by the ErbB3/phosphatidylinositol 3-kinase/Akt pathway. Carcinogenesis. 2003;24:1581&#x2013;92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12896906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soltoff SP, Carraway KL, 3rd, Prigent SA, Gullick WG, Cantley LC. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol. 1994;14:3550&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC358722</ArticleId>
            <ArticleId IdType="pubmed">7515147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Din FV, Valanciute A, Houde VP, Zibrova D, Green KA, Sakamoto K, et al. Aspirin Inhibits mTOR Signaling, Activates AMP-Activated Protein Kinase, and Induces Autophagy in Colorectal Cancer Cells. Gastroenterology. 2012;142:1504&#x2013;15. e3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3682211</ArticleId>
            <ArticleId IdType="pubmed">22406476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanida I, Ueno T, Kominami E. LC3 conjugation system in mammalian autophagy. Int J Biochem Cell Biol. 2004;36:2503&#x2013;18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7129593</ArticleId>
            <ArticleId IdType="pubmed">15325588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang L, Mackenzie GG, Sun Y, Ouyang N, Xie G, Vrankova K, et al. Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds. Cancer Res. 2011;71:7617&#x2013;27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3242900</ArticleId>
            <ArticleId IdType="pubmed">22025561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montuschi P, Barnes PJ, Roberts LJ., 2nd Isoprostanes: markers and mediators of oxidative stress. FASEB J. 2004;18:1791&#x2013;800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15576482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marchi S, Giorgi C, Suski JM, Agnoletto C, Bononi A, Bonora M, et al. Mitochondria-ros crosstalk in the control of cell death and aging. J Signal Transduct. 2012;2012:329635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3235816</ArticleId>
            <ArticleId IdType="pubmed">22175013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong CC, Cheng KW, Xie G, Zhou D, Zhu CH, Constantinides PP, et al. Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity. J Pharmacol Exp Ther. 2012;340:422&#x2013;32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3263964</ArticleId>
            <ArticleId IdType="pubmed">22085648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hosokawa M. Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules. 2008;13:412&#x2013;31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6245361</ArticleId>
            <ArticleId IdType="pubmed">18305428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morton CL, Wierdl M, Oliver L, Ma MK, Danks MK, Stewart CF, et al. Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase. Cancer Res. 2000;60:4206&#x2013;10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10945631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res. 2004;10:4227s&#x2013;32s.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15217963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi S, Boggon TJ, Dayaram T, J&#xe4;nne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786&#x2013;92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15728811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gong HC, Wang S, Mayer G, Chen G, Leesman G, Singh S, et al. Signatures of drug sensitivity in nonsmall cell lung cancer. Int J Proteomics. 2011:215496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3200133</ArticleId>
            <ArticleId IdType="pubmed">22091388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sergina NV, Rausch M, Wang D, Blair J, Hann B, Kevan M, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445:437&#x2013;41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3025857</ArticleId>
            <ArticleId IdType="pubmed">17206155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu Z, Xu S. ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life. 2006;58:621&#x2013;31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17085381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y, Huang L, Mackenzie GG, Rigas B. Oxidative stress mediates through apoptosis the anticancer effect of phospho-nonsteroidal anti-inflammatory drugs: implications for the role of oxidative stress in the action of anticancer agents. J Pharmacol Exp Ther. 2011;338:775&#x2013;83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3164348</ArticleId>
            <ArticleId IdType="pubmed">21646387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011;475:106&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3404470</ArticleId>
            <ArticleId IdType="pubmed">21734707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature. 2008;451:1069&#x2013;75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2670399</ArticleId>
            <ArticleId IdType="pubmed">18305538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levine B. Cell biology: autophagy and cancer. Nature. 2007;446:745&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17429391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shivapurkar N, Reddy J, Chaudhary PM, Gazdar AF. Apoptosis and lung cancer: a review. J Cell Biochem. 2003;88:885&#x2013;98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12616528</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23364915</PMID>
      <DateCompleted>
        <Year>2013</Year>
        <Month>07</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2023</Year>
        <Month>06</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-0215</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>133</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Aug</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of cancer</Title>
          <ISOAbbreviation>Int J Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.</ArticleTitle>
        <Pagination>
          <StartPage>624</StartPage>
          <EndPage>636</EndPage>
          <MedlinePgn>624-36</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/ijc.28070</ELocationID>
        <Abstract>
          <AbstractText>Certain chemotherapeutic regimens trigger cancer cell death while inducing dendritic cell maturation and subsequent immune responses. However, chemotherapy-induced immunogenic cell death (ICD) has thus far been restricted to select agents. In contrast, several chemotherapeutic drugs modulate antitumor immune responses, despite not inducing classic ICD. In addition, in many cases tumor cells do not die after treatment. Here, using docetaxel, one of the most widely used cancer chemotherapeutic agents, as a model, we examined phenotypic and functional consequences of tumor cells that do not die from ICD. Docetaxel treatment of tumor cells did not induce ATP or high-mobility group box 1 (HMGB1) secretion, or cell death. However, calreticulin (CRT) exposure was observed in all cell lines examined after chemotherapy treatment. Killing by carcinoembryonic antigen (CEA), MUC-1, or PSA-specific CD8(+) CTLs was significantly enhanced after docetaxel treatment. This killing was associated with increases in components of antigen-processing machinery, and mediated largely by CRT membrane translocation, as determined by functional knockdown of CRT, PERK, or CRT-blocking peptide. A docetaxel-resistant cell line was selected (MDR-1(+), CD133(+)) by continuous exposure to docetaxel. These cells, while resistant to direct cytostatic effects of docetaxel, were not resistant to the chemomodulatory effects that resulted in enhancement of CTL killing. Here, we provide an operational definition of "immunogenic modulation," where exposure of tumor cells to nonlethal/sublethal doses of chemotherapy alters tumor phenotype to render the tumor more sensitive to CTL killing. These observations are distinct and complementary to ICD and highlight a mechanism whereby chemotherapy can be used in combination with immunotherapy.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2013 UICC.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hodge</LastName>
            <ForeName>James W</ForeName>
            <Initials>JW</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. jh241d@nih.gov</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Garnett</LastName>
            <ForeName>Charlie T</ForeName>
            <Initials>CT</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Farsaci</LastName>
            <ForeName>Benedetto</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Palena</LastName>
            <ForeName>Claudia</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsang</LastName>
            <ForeName>Kwong-Yok</ForeName>
            <Initials>KY</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ferrone</LastName>
            <ForeName>Soldano</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gameiro</LastName>
            <ForeName>Sofia R</ForeName>
            <Initials>SR</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>Y99 CA999999</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>Z99 CA999999</GrantID>
            <Acronym>ImNIH</Acronym>
            <Agency>Intramural NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>ZIA BC010661-08</GrantID>
            <Acronym>ImNIH</Acronym>
            <Agency>Intramural NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>03</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Int J Cancer</MedlineTA>
        <NlmUniqueID>0042124</NlmUniqueID>
        <ISSNLinking>0020-7136</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D037282">Calreticulin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002272">Carcinoembryonic Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D024243">HMGB1 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C060192">MUC1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018396">Mucin-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D043823">Taxoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>15H5577CQD</RegistryNumber>
          <NameOfSubstance UI="D000077143">Docetaxel</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8L70Q75FXE</RegistryNumber>
          <NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="C117035">PERK kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D019892">eIF-2 Kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.77</RegistryNumber>
          <NameOfSubstance UI="D017430">Prostate-Specific Antigen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D037282" MajorTopicYN="N">Calreticulin</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002272" MajorTopicYN="N">Carcinoembryonic Antigen</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003602" MajorTopicYN="Y">Cytotoxicity, Immunologic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003713" MajorTopicYN="N">Dendritic Cells</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077143" MajorTopicYN="N">Docetaxel</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024243" MajorTopicYN="N">HMGB1 Protein</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018396" MajorTopicYN="N">Mucin-1</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017430" MajorTopicYN="N">Prostate-Specific Antigen</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D043823" MajorTopicYN="N">Taxoids</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019892" MajorTopicYN="N">eIF-2 Kinase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>9</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>1</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>2</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>2</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23364915</ArticleId>
        <ArticleId IdType="mid">NIHMS444261</ArticleId>
        <ArticleId IdType="pmc">PMC3663913</ArticleId>
        <ArticleId IdType="doi">10.1002/ijc.28070</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 2004;64:7985&#x2013;94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15520206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res. 2008;14:3536&#x2013;44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2682419</ArticleId>
            <ArticleId IdType="pubmed">18519787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today. 2000;21:455&#x2013;64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10953098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bandoh N, Ogino T, Cho HS, Hur SY, Shen J, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S. Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens. 2005;66:185&#x2013;94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16101829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogino T, Wang X, Ferrone S. Modified flow cytometry and cell-ELISA methodology to detect HLA class I antigen processing machinery components in cytoplasm and endoplasmic reticulum. J Immunol Methods. 2003;278:33&#x2013;44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12957394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muraro R, Wunderlich D, Thor A, Lundy J, Noguchi P, Cunningham R, Schlom J. Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Res. 1985;45:5769&#x2013;80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2413997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsang KY, Palena C, Gulley J, Arlen P, Schlom J. A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. Clin Cancer Res. 2004;10:2139&#x2013;49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15041735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst. 1995;87:982&#x2013;90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7629885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsang KY, Zhu M, Nieroda CA, Correale P, Zaremba S, Hamilton JM, Cole D, Lam C, Schlom J. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. Clin Cancer Res. 1997;3:2439&#x2013;49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9815645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gelbard A, Garnett CT, Abrams SI, Patel V, Gutkind JS, Palena C, Tsang KY, Schlom J, Hodge JW. Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res. 2006;12:1897&#x2013;905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1865094</ArticleId>
            <ArticleId IdType="pubmed">16551875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown I, Shalli K, McDonald SL, Moir SE, Hutcheon AW, Heys SD, Schofield AC. Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells. Breast Cancer Res. 2004;6:R601&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC549179</ArticleId>
            <ArticleId IdType="pubmed">15318941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martins I, Tesniere A, Kepp O, Michaud M, Schlemmer F, Senovilla L, Seror C, Metivier D, Perfettini JL, Zitvogel L, Kroemer G. Chemotherapy induces ATP release from tumor cells. Cell Cycle. 2009;8:3723&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19855167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M, Sukkurwala AQ, Menger L, Zitvogel L, Kroemer G. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev. 2011;30:61&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21249425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Locher C, Conforti R, Aymeric L, Ma Y, Yamazaki T, Rusakiewicz S, Tesniere A, Ghiringhelli F, Apetoh L, Morel Y, Girard JP, Kroemer G, et al. Desirable cell death during anticancer chemotherapy. Ann N Y Acad Sci. 2010;1209:99&#x2013;108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20958322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martins I, Kepp O, Galluzzi L, Senovilla L, Schlemmer F, Adjemian S, Menger L, Michaud M, Zitvogel L, Kroemer G. Surface-exposed calreticulin in the interaction between dying cells and phagocytes. Ann N Y Acad Sci. 2011;1209:77&#x2013;82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20958319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res. 2010;16:3100&#x2013;4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20421432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panis C, Lemos LG, Victorino VJ, Herrera AC, Campos FC, Colado Simao AN, Pinge-Filho P, Cecchini AL, Cecchini R. Immunological effects of taxol and adryamicin in breast cancer patients. Cancer immunology, immunotherapy: CII. 2012;61:481&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21959683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fojo AT, Menefee M. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR) Semin Oncol. 2005;32:S3&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16360716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Komarova NL, Wodarz D. Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci U S A. 2005;102:9714&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1172248</ArticleId>
            <ArticleId IdType="pubmed">15980154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawamoto H, Yuasa T, Kubota Y, Seita M, Sasamoto H, Shahid JM, Hayashi T, Nakahara H, Hassan R, Iwamuro M, Kondo E, Nakaji S, et al. Characteristics of CD133(+) human colon cancer SW620 cells. Cell Transplant. 2010;19:857&#x2013;64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20587144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leibowitz MS, Andrade Filho PA, Ferrone S, Ferris RL. Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. Cancer Immunol Immunother. 2011;60:525&#x2013;35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3426276</ArticleId>
            <ArticleId IdType="pubmed">21207025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopez-Albaitero A, Nayak JV, Ogino T, Machandia A, Gooding W, DeLeo AB, Ferrone S, Ferris RL. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol. 2006;176:3402&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16517708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Setiadi AF, Omilusik K, David MD, Seipp RP, Hartikainen J, Gopaul R, Choi KB, Jefferies WA. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res. 2008;68:9601&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19047136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, Durchschlag M, Joza N, Pierron G, van Endert P, Yuan J, Zitvogel L, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. Embo J. 2009;28:578&#x2013;90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2657583</ArticleId>
            <ArticleId IdType="pubmed">19165151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panaretakis T, Joza N, Modjtahedi N, Tesniere A, Vitale I, Durchschlag M, Fimia GM, Kepp O, Piacentini M, Froehlich KU, van Endert P, Zitvogel L, et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell death and differentiation. 2008;15:1499&#x2013;509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18464797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, Majeti R, Weissman IL. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med. 2010;2:63ra94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4126904</ArticleId>
            <ArticleId IdType="pubmed">21178137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hannani D, Sistigu A, Kepp O, Galluzzi L, Kroemer G, Zitvogel L. Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. Cancer J. 2011;17:351&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21952286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S, Michaud M, Menger L, Gdoura A, Tajeddine N, Tesniere A, Zitvogel L, et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene. 2011;30:1147&#x2013;58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21151176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011;8:151&#x2013;60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21364688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Kroemer G. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2012;1:179&#x2013;88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3376992</ArticleId>
            <ArticleId IdType="pubmed">22720239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gameiro SR, Caballero JA, Higgins JP, Apelian D, Hodge JW. Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer immunology, immunotherapy: CII. 2011;60:1227&#x2013;42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3167076</ArticleId>
            <ArticleId IdType="pubmed">21544650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan OT, Yang LX. The immunological effects of taxanes. Cancer Immunol Immunother. 2000;49:181&#x2013;5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10941900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eckert K, Fuhrmann-Selter T, Maurer HR. Docetaxel enhances the expression of E-cadherin and carcinoembryonic antigen (CEA) on human colon cancer cell lines in vitro. Anticancer Res. 1997;17:7&#x2013;12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9066624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsuzaki I, Suzuki H, Kitamura M, Minamiya Y, Kawai H, Ogawa J. Cisplatin induces fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells. Oncology. 2000;59:336&#x2013;43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11096347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prete SP, Aquino A, Masci G, Orlando L, Giuliani A, De Santis S, De Vecchis L, De Filippi R, Greiner JW, Bonmassar E, Graziani G. Drug-induced changes of carcinoembryonic antigen expression in human cancer cells: effect of 5-fluorouracil. J Pharmacol Exp Ther. 1996;279:1574&#x2013;81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8968385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, Coutant F, Metivier D, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202:1691&#x2013;701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2212968</ArticleId>
            <ArticleId IdType="pubmed">16365148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pradeu T, Carosella ED. On the definition of a criterion of immunogenicity. Proceedings of the National Academy of Sciences of the United States of America. 2006;103:17858&#x2013;61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1693837</ArticleId>
            <ArticleId IdType="pubmed">17101995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minami H, Kawada K, Sasaki Y, Tahara M, Igarashi T, Itoh K, Fujii H, Saeki T, Ozawa K, Sato H. Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Sci. 2009;100:144&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19018756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morse DL, Gray H, Payne CM, Gillies RJ. Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther. 2005;4:1495&#x2013;504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16227398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo B, Lee AS. The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene. 2012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3819728</ArticleId>
            <ArticleId IdType="pubmed">22508478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huerta S, Heinzerling JH, Anguiano-Hernandez YM, Huerta-Yepez S, Lin J, Chen D, Bonavida B, Livingston EH. Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF. J Surg Res. 2007;142:184&#x2013;94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17603079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shtil AA, Turner JG, Durfee J, Dalton WS, Yu H. Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: the role of cytotoxic T lymphocytes. Blood. 1999;93:1831&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10068654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Racanelli V, Leone P, Frassanito MA, Brunetti C, Perosa F, Ferrone S, Dammacco F. Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma. Blood. 2011;115:1185&#x2013;93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2826230</ArticleId>
            <ArticleId IdType="pubmed">20008301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seliger B, Stoehr R, Handke D, Mueller A, Ferrone S, Wullich B, Tannapfel A, Hofstaedter F, Hartmann A. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol Immunother. 2010;59:529&#x2013;40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3426221</ArticleId>
            <ArticleId IdType="pubmed">19820934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu H, Liu C, Flutter B, Tao H, Gao B. Calreticulin maintains the low threshold of peptide required for efficient antigen presentation. Mol Immunol. 2009;46:3198&#x2013;206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19748124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, Rubio N, Firczuk M, Mathieu C, Roebroek AJ, Annaert W, Golab J, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. Embo J. 2012;31:1062&#x2013;79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3298003</ArticleId>
            <ArticleId IdType="pubmed">22252128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li SS, Liu Z, Uzunel M, Sundqvist KG. Endogenous thrombospondin-1 is a cell-surface ligand for regulation of integrin-dependent T-lymphocyte adhesion. Blood. 2006;108:3112&#x2013;20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16835379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang KY, Grosenbach DW, Feldman J, Steinberg SM, Jones E, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res. 2006;12:1260&#x2013;9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1526707</ArticleId>
            <ArticleId IdType="pubmed">16489082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petrylak D. Defining the optimal role of immunotherapy and chemotherapy: advanced prostate cancer patients who recieve sipuleucel-T (PROVENGE) followed by docetaxel derive greatest survivial benefit. 14th Annual Meeting of the Chemotherapy Foundation Symposium; 2006.</Citation>
        </Reference>
        <Reference>
          <Citation>Schlom J, Gulley JL, Arlen PM. Paradigm shifts in cancer vaccine therapy. Exp Biol Med (Maywood) 2008;233:522&#x2013;34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6326176</ArticleId>
            <ArticleId IdType="pubmed">18375829</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23238221</PMID>
      <DateCompleted>
        <Year>2013</Year>
        <Month>07</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1095-8584</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>56</Volume>
            <PubDate>
              <Year>2013</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of molecular and cellular cardiology</Title>
          <ISOAbbreviation>J Mol Cell Cardiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Synergistic protective effect of cyclosporin A and rotenone against hypoxia-reoxygenation in cardiomyocytes.</ArticleTitle>
        <Pagination>
          <StartPage>55</StartPage>
          <EndPage>62</EndPage>
          <MedlinePgn>55-62</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.yjmcc.2012.11.023</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0022-2828(12)00430-0</ELocationID>
        <Abstract>
          <AbstractText>Reperfusion of the heart after an ischemic event leads to the opening of a nonspecific pore in the inner mitochondrial membrane, the mitochondrial permeability transition pore (mPTP). Inhibition of mPTP opening is an effective strategy to prevent cardiomyocyte death. The matrix protein cyclophilin-D (CypD) is the best-known regulator of mPTP opening. In this study we confirmed that preconditioning and postconditioning with CypD inhibitor cyclosporin-A (CsA) reduced cell death after hypoxia-reoxygenation (H/R) in wild-type (WT) cardiomyocytes and HL-1 mouse cardiac cell line as measured by nuclear staining with propidium iodide. The complex I inhibitor rotenone (Rot), alone, had no effect on HL-1 and WT cardiomyocyte death after H/R, but enhanced the native protection of CypD-knocked-out (CypD KO) cardiomyocytes. Reduction of cell death was associated with a delay of mPTP opening challenged by H/R and observed by the calcein loading CoCl(2)-quenching technique. Simultaneous inhibition of complex I and CypD increased in a synergistic manner the calcium retention capacity in permeabilized cardiomyocytes and cardiac mitochondria. These results demonstrated that protection by complex I inhibition was CypD dependent.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Teixeira</LastName>
            <ForeName>Geoffrey</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>INSERM UMR 1060, CarMeN, F-69373, Lyon, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abrial</LastName>
            <ForeName>Maryline</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Portier</LastName>
            <ForeName>Karine</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chiari</LastName>
            <ForeName>Pascal</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Couture-Lepetit</LastName>
            <ForeName>Elisabeth</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tourneur</LastName>
            <ForeName>Yves</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ovize</LastName>
            <ForeName>Michel</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gharib</LastName>
            <ForeName>Abdallah</ForeName>
            <Initials>A</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2012</Year>
          <Month>12</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Mol Cell Cardiol</MedlineTA>
        <NlmUniqueID>0262322</NlmUniqueID>
        <ISSNLinking>0022-2828</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002316">Cardiotonic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081406">Cyclophilin D</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D033681">Mitochondrial Membrane Transport Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000083162">Mitochondrial Permeability Transition Pore</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000631446">PPIF protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>03L9OT429T</RegistryNumber>
          <NameOfSubstance UI="D012402">Rotenone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>83HN0GTJ6D</RegistryNumber>
          <NameOfSubstance UI="D016572">Cyclosporine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 5.2.1.-</RegistryNumber>
          <NameOfSubstance UI="D021983">Cyclophilins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 7.1.1.2</RegistryNumber>
          <NameOfSubstance UI="D042967">Electron Transport Complex I</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002316" MajorTopicYN="N">Cardiotonic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015687" MajorTopicYN="N">Cell Hypoxia</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081406" MajorTopicYN="N">Cyclophilin D</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D021983" MajorTopicYN="N">Cyclophilins</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016572" MajorTopicYN="N">Cyclosporine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042967" MajorTopicYN="N">Electron Transport Complex I</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057507" MajorTopicYN="N">Mice, 129 Strain</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008929" MajorTopicYN="N">Mitochondria, Heart</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D033681" MajorTopicYN="N">Mitochondrial Membrane Transport Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000083162" MajorTopicYN="N">Mitochondrial Permeability Transition Pore</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015428" MajorTopicYN="N">Myocardial Reperfusion Injury</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032383" MajorTopicYN="N">Myocytes, Cardiac</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010101" MajorTopicYN="N">Oxygen Consumption</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010539" MajorTopicYN="N">Permeability</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012402" MajorTopicYN="N">Rotenone</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>9</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2012</Year>
          <Month>11</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2012</Year>
          <Month>11</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2012</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2012</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23238221</ArticleId>
        <ArticleId IdType="doi">10.1016/j.yjmcc.2012.11.023</ArticleId>
        <ArticleId IdType="pii">S0022-2828(12)00430-0</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23159058</PMID>
      <DateCompleted>
        <Year>2013</Year>
        <Month>05</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1934-6069</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2012</Year>
              <Month>Nov</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell host &amp; microbe</Title>
          <ISOAbbreviation>Cell Host Microbe</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Metabolic adaptation to tissue iron overload confers tolerance to malaria.</ArticleTitle>
        <Pagination>
          <StartPage>693</StartPage>
          <EndPage>704</EndPage>
          <MedlinePgn>693-704</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.chom.2012.10.011</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1931-3128(12)00357-5</ELocationID>
        <Abstract>
          <AbstractText>Disease tolerance is a defense strategy that limits the fitness costs of infection irrespectively of pathogen burden. While restricting iron (Fe) availability to pathogens is perceived as a host defense strategy, the resulting tissue Fe overload can be cytotoxic and promote tissue damage to exacerbate disease severity. Examining this interplay during malaria, the disease caused by Plasmodium infection, we find that expression of the Fe sequestering protein ferritin H chain (FtH) in mice, and ferritin in humans, is associated with reduced tissue damage irrespectively of pathogen burden. FtH protection relies on its ferroxidase activity, which prevents labile Fe from sustaining proapoptotic c-Jun N-terminal kinase (JNK) activation. FtH expression is inhibited by JNK activation, promoting tissue Fe overload, tissue damage, and malaria severity. Mimicking FtH's antioxidant effect or inhibiting JNK activation pharmacologically confers therapeutic tolerance to malaria in mice. Thus, FtH provides metabolic adaptation to tissue Fe overload, conferring tolerance to malaria.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2012 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gozzelino</LastName>
            <ForeName>Raffaella</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Instituto Gulbenkian de Ciência, 2780-156 Oeiras, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Andrade</LastName>
            <ForeName>Bruno Bezerril</ForeName>
            <Initials>BB</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Larsen</LastName>
            <ForeName>Rasmus</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luz</LastName>
            <ForeName>Nivea F</ForeName>
            <Initials>NF</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vanoaica</LastName>
            <ForeName>Liviu</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Seixas</LastName>
            <ForeName>Elsa</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Coutinho</LastName>
            <ForeName>Antonio</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cardoso</LastName>
            <ForeName>Sílvia</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rebelo</LastName>
            <ForeName>Sofia</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Poli</LastName>
            <ForeName>Maura</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barral-Netto</LastName>
            <ForeName>Manoel</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Darshan</LastName>
            <ForeName>Deepak</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kühn</LastName>
            <ForeName>Lukas C</ForeName>
            <Initials>LC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Soares</LastName>
            <ForeName>Miguel P</ForeName>
            <Initials>MP</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <Agency>Intramural NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cell Host Microbe</MedlineTA>
        <NlmUniqueID>101302316</NlmUniqueID>
        <ISSNLinking>1931-3128</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-73-2</RegistryNumber>
          <NameOfSubstance UI="D005293">Ferritins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9013-31-4</RegistryNumber>
          <NameOfSubstance UI="D001052">Apoferritins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E1UOL152H7</RegistryNumber>
          <NameOfSubstance UI="D007501">Iron</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.16.3.1</RegistryNumber>
          <NameOfSubstance UI="D002570">Ceruloplasmin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D048031">JNK Mitogen-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001052" MajorTopicYN="N">Apoferritins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002570" MajorTopicYN="N">Ceruloplasmin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019610" MajorTopicYN="N">Cytoprotection</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005293" MajorTopicYN="N">Ferritins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022781" MajorTopicYN="N">Hepatocytes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006790" MajorTopicYN="N">Host-Parasite Interactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019190" MajorTopicYN="N">Iron Overload</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048031" MajorTopicYN="N">JNK Mitogen-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008288" MajorTopicYN="N">Malaria</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000469" MajorTopicYN="Y">parasitology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010962" MajorTopicYN="N">Plasmodium berghei</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016788" MajorTopicYN="N">Plasmodium chabaudi</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010966" MajorTopicYN="N">Plasmodium vivax</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>4</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2012</Year>
          <Month>8</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2012</Year>
          <Month>10</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2012</Year>
          <Month>11</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2012</Year>
          <Month>11</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23159058</ArticleId>
        <ArticleId IdType="doi">10.1016/j.chom.2012.10.011</ArticleId>
        <ArticleId IdType="pii">S1931-3128(12)00357-5</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23151917</PMID>
      <DateCompleted>
        <Year>2013</Year>
        <Month>05</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-0215</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>132</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Jun</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of cancer</Title>
          <ISOAbbreviation>Int J Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The dual PI3K/mTOR inhibitor NVP-BEZ235 and chloroquine synergize to trigger apoptosis via mitochondrial-lysosomal cross-talk.</ArticleTitle>
        <Pagination>
          <StartPage>2682</StartPage>
          <EndPage>2693</EndPage>
          <MedlinePgn>2682-93</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/ijc.27935</ELocationID>
        <Abstract>
          <AbstractText>On the basis of our previous identification of aberrant phosphatidylinositol-3-kinase (PI3K)/Akt signaling as a novel poor prognostic factor in neuroblastoma, we evaluated the dual PI3K/mTOR inhibitor BEZ235 in the present study. Here, BEZ235 acts in concert with the lysosomotropic agent chloroquine (CQ) to trigger apoptosis in neuroblastoma cells in a synergistic manner, as calculated by combination index (CI &lt; 0.5). Surprisingly, inhibition of BEZ235-induced autophagy is unlikely the primary mechanism of this synergism as reported in other cancers, since neither inhibition of autophagosome formation by knockdown of Atg7 or Atg5 nor disruption of the autophagic flux by Bafilomycin A1 (BafA1) enhance BEZ235-induced apoptosis. BEZ235 stimulates enlargement of the lysosomal compartment and generation of reactive oxygen species (ROS), while CQ promotes lysosomal membrane permeabilization (LMP). In combination, BEZ235 and CQ cooperate to trigger LMP, Bax activation, loss of mitochondrial membrane potential (MMP) and caspase-dependent apoptosis. Lysosome-mediated apoptosis occurs in a ROS-dependent manner, as ROS scavengers significantly reduce BEZ235/CQ-induced loss of MMP, LMP and apoptosis. There is a mitochondrial-lysosomal cross-talk, since lysosomal enzyme inhibitors significantly decrease BEZ235- and CQ-induced drop of MMP and apoptosis. In conclusion, BEZ235 and CQ act in concert to trigger LMP and lysosome-mediated apoptosis via a mitochondrial-lysosomal cross-talk. These findings have important implications for the rational development of PI3K/mTOR inhibitor-based combination therapies.</AbstractText>
          <CopyrightInformation>Copyright &#xa9; 2012 UICC.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Seitz</LastName>
            <ForeName>Christian</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Komturstr. 3a, 60528 Frankfurt, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hugle</LastName>
            <ForeName>Manuela</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cristofanon</LastName>
            <ForeName>Silvia</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tchoghandjian</LastName>
            <ForeName>Aurélie</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fulda</LastName>
            <ForeName>Simone</ForeName>
            <Initials>S</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2012</Year>
          <Month>12</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Int J Cancer</MedlineTA>
        <NlmUniqueID>0042124</NlmUniqueID>
        <ISSNLinking>0020-7136</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C494826">BAX protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011804">Quinolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051028">bcl-2-Associated X Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>886U3H6UFF</RegistryNumber>
          <NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>RUJ6Z9Y0DT</RegistryNumber>
          <NameOfSubstance UI="C531198">dactolisib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002463" MajorTopicYN="N">Cell Membrane Permeability</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081082" MajorTopicYN="N">Phosphoinositide-3 Kinase Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011804" MajorTopicYN="N">Quinolines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051028" MajorTopicYN="N">bcl-2-Associated X Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>4</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2012</Year>
          <Month>10</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2012</Year>
          <Month>11</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2012</Year>
          <Month>11</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23151917</ArticleId>
        <ArticleId IdType="doi">10.1002/ijc.27935</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23065091</PMID>
      <DateCompleted>
        <Year>2013</Year>
        <Month>10</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1573-675X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>17</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2012</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Apoptosis : an international journal on programmed cell death</Title>
          <ISOAbbreviation>Apoptosis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Celastrol inhibits growth and induces apoptotic cell death in melanoma cells via the activation ROS-dependent mitochondrial pathway and the suppression of PI3K/AKT signaling.</ArticleTitle>
        <Pagination>
          <StartPage>1275</StartPage>
          <EndPage>1286</EndPage>
          <MedlinePgn>1275-86</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10495-012-0767-5</ELocationID>
        <Abstract>
          <AbstractText>Celastrol has been reported to possess anticancer effects in various cancers; however, the precise mechanism underlying ROS-mediated mitochondria-dependent apoptotic cell death triggered by celastrol treatment in melanoma cells remains unknown. We showed that celastrol effectively induced apoptotic cell death and inhibited tumor growth using tissue culture and in vivo models of B16 melanoma. In addition to apoptotic cell death in B16 cells, several apoptotic events such as PARP cleavage and activation of caspase were confirmed. Pretreatment with caspase inhibitor modestly attenuated the celastrol-induced increase in PARP cleavage and sub-G1 cell population, implying that caspases play a partial role in celastrol-induced apoptosis. Moreover, ROS generation was detected following celastrol treatment. Blocking of ROS accumulation with ROS scavengers resulted in inhibition of celastrol-induced Bcl-2 family-mediated apoptosis, indicating that celastrol-induced apoptosis involves ROS generation as well as an increase in the Bax/Bcl-2 ratio leading to release of cytochrome c and AIF. Importantly, silencing of AIF by transfection of siAIF into cells remarkably attenuated celastrol-induced apoptotic cell death. Moreover, celastrol inhibited the activation of PI3K/AKT/mTOR signaling cascade in B16 cells. Our data reveal that celastrol inhibits growth and induces apoptosis in melanoma cells via the activation of ROS-mediated caspase-dependent and -independent pathways and the suppression of PI3K/AKT signaling.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Ju-Hye</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Food and Nutrition, Sunchon National University, Jungangno, Suncheon, Jeonnam 540-742, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Won</LastName>
            <ForeName>Yeong-Seon</ForeName>
            <Initials>YS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Park</LastName>
            <ForeName>Ki-Hun</ForeName>
            <Initials>KH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Mi-Kyung</ForeName>
            <Initials>MK</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tachibana</LastName>
            <ForeName>Hirofumi</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yamada</LastName>
            <ForeName>Koji</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Seo</LastName>
            <ForeName>Kwon-Il</ForeName>
            <Initials>KI</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Apoptosis</MedlineTA>
        <NlmUniqueID>9712129</NlmUniqueID>
        <ISSNLinking>1360-8185</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053978">Pentacyclic Triterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014315">Triterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>L8GG98663L</RegistryNumber>
          <NameOfSubstance UI="C050414">celastrol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053978" MajorTopicYN="N">Pentacyclic Triterpenes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019253" MajorTopicYN="N">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014315" MajorTopicYN="N">Triterpenes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2012</Year>
          <Month>10</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2012</Year>
          <Month>10</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>10</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23065091</ArticleId>
        <ArticleId IdType="doi">10.1007/s10495-012-0767-5</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">22505595</PMID>
      <DateCompleted>
        <Year>2013</Year>
        <Month>09</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>12</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1552-695X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Integrative cancer therapies</Title>
          <ISOAbbreviation>Integr Cancer Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Lactobacillus casei extract induces apoptosis in gastric cancer by inhibiting NF-κB and mTOR-mediated signaling.</ArticleTitle>
        <Pagination>
          <StartPage>165</StartPage>
          <EndPage>173</EndPage>
          <MedlinePgn>165-73</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1177/1534735412442380</ELocationID>
        <Abstract>
          <AbstractText>Lactobacillus casei extract (LBX) has been reported to prevent gastric cancer, but the underlying mechanism remains unclear. The proliferation and cell death of gastric cancer KATO3 cells were examined after treatment with LBX for various times and at various doses. LBX inhibited the growth of gastric cancer cells and induced apoptosis by inactivating NF-κB promoter activity. Apoptosis induced by LBX, however, is not directly associated with the intrinsic mitochondrial pathway. Immunoblot analysis revealed that LBX decreased the expressions of NF-κB and IκB. The reduced NF-κB levels led to the decreased phosphorylation of mTOR signaling components, such as PI3K, Akt, and (p70)S6 kinase. These results showed for the first time that LBX induced apoptosis in gastric cancer cells by inhibiting NF-κB and mTOR-mediated signaling.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hwang</LastName>
            <ForeName>Jeong Won</ForeName>
            <Initials>JW</Initials>
            <AffiliationInfo>
              <Affiliation>Korea Basic Science Institute, Daejeon, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baek</LastName>
            <ForeName>Young-Mi</ForeName>
            <Initials>YM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Kyeong Eun</ForeName>
            <Initials>KE</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yoo</LastName>
            <ForeName>Hwa-Seung</ForeName>
            <Initials>HS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cho</LastName>
            <ForeName>Chong-Kwan</ForeName>
            <Initials>CK</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Yeon-Weol</ForeName>
            <Initials>YW</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Park</LastName>
            <ForeName>Junsoo</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Eom</LastName>
            <ForeName>Chi-Yong</ForeName>
            <Initials>CY</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Zee-Won</ForeName>
            <Initials>ZW</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Jong-Soon</ForeName>
            <Initials>JS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jang</LastName>
            <ForeName>Ik-Soon</ForeName>
            <Initials>IS</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2012</Year>
          <Month>04</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Integr Cancer Ther</MedlineTA>
        <NlmUniqueID>101128834</NlmUniqueID>
        <ISSNLinking>1534-7354</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001688">Biological Products</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020672">I-kappa B Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D038762">Ribosomal Protein S6 Kinases, 70-kDa</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001688" MajorTopicYN="N">Biological Products</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020672" MajorTopicYN="N">I-kappa B Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007780" MajorTopicYN="N">Lacticaseibacillus casei</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D038762" MajorTopicYN="N">Ribosomal Protein S6 Kinases, 70-kDa</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013274" MajorTopicYN="N">Stomach Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2012</Year>
          <Month>4</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2012</Year>
          <Month>4</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>9</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">22505595</ArticleId>
        <ArticleId IdType="doi">10.1177/1534735412442380</ArticleId>
        <ArticleId IdType="pii">1534735412442380</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">22443280</PMID>
      <DateCompleted>
        <Year>2012</Year>
        <Month>09</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1535-3907</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2012</Year>
              <Month>May</Month>
              <Day>04</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of proteome research</Title>
          <ISOAbbreviation>J Proteome Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ferritin heavy chain is the host factor responsible for HCV-induced inhibition of apoB-100 production and is required for efficient viral infection.</ArticleTitle>
        <Pagination>
          <StartPage>2786</StartPage>
          <EndPage>2797</EndPage>
          <MedlinePgn>2786-97</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/pr201128s</ELocationID>
        <Abstract>
          <AbstractText>Hepatic fat export occurs by apolipoprotein B-100-containing lipoprotein production, whereas impaired production leads to liver steatosis. Hepatitis C virus (HCV) infection is associated to dysregulation of apoB-100 secretion and steatosis; however, the molecular mechanism by which HCV affects the apoB-100 secretion is not understood. Here, combining quantitative proteomics and computational biology, we propose ferritin heavy chain (Fth) as being the cellular determinant of apoB-100 production inhibition. By means of molecular analyses, we found that HCV nonstructural proteins and NS5A appear to be sufficient for inducing Fth up-regulation. Fth in turn was found to inhibit apoB-100 secretion leading to increased intracellular degradation via proteasome. Notably, intracellular Fth down-regulation by siRNA restores apoB-100 secretion. The inverse correlation between ferritin and plasma apoB-100 concentrations was also found in JFH-1 HCV cell culture systems (HCVcc) and HCV-infected patients. Finally, Fth expression was found to be required for robust HCV infection. These observations provide a further molecular explanation for the onset of liver steatosis and allow for hypothesizing on new therapeutic and antiviral strategies.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mancone</LastName>
            <ForeName>Carmine</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>L. Spallanzani National Institute for Infectious Diseases, IRCCS, via Portuense 292, 00149, Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Montaldo</LastName>
            <ForeName>Claudia</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Santangelo</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Di Giacomo</LastName>
            <ForeName>Cristina</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Costa</LastName>
            <ForeName>Viviana</ForeName>
            <Initials>V</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Amicone</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ippolito</LastName>
            <ForeName>Giuseppe</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pucillo</LastName>
            <ForeName>Leopoldo Paolo</ForeName>
            <Initials>LP</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alonzi</LastName>
            <ForeName>Tonino</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tripodi</LastName>
            <ForeName>Marco</ForeName>
            <Initials>M</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2012</Year>
          <Month>04</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Proteome Res</MedlineTA>
        <NlmUniqueID>101128775</NlmUniqueID>
        <ISSNLinking>1535-3893</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053299">Apolipoprotein B-100</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9013-31-4</RegistryNumber>
          <NameOfSubstance UI="D001052">Apoferritins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.7.48</RegistryNumber>
          <NameOfSubstance UI="C087036">NS-5 protein, hepatitis C virus</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.25.1</RegistryNumber>
          <NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001052" MajorTopicYN="N">Apoferritins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053299" MajorTopicYN="N">Apolipoprotein B-100</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005234" MajorTopicYN="N">Fatty Liver</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015967" MajorTopicYN="Y">Gene Expression Regulation, Viral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022781" MajorTopicYN="N">Hepatocytes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007553" MajorTopicYN="N">Isotope Labeling</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060066" MajorTopicYN="N">Protein Interaction Maps</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2012</Year>
          <Month>3</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2012</Year>
          <Month>3</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2012</Year>
          <Month>9</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">22443280</ArticleId>
        <ArticleId IdType="doi">10.1021/pr201128s</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">22139542</PMID>
      <DateCompleted>
        <Year>2012</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">1672-0415</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>17</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2011</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Chinese journal of integrative medicine</Title>
          <ISOAbbreviation>Chin J Integr Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>In vitro and in vivo inhibitory effect of the combination of Wenxia Changfu formula [see text] with cisplatin in non-small cell lung cancer.</ArticleTitle>
        <Pagination>
          <StartPage>908</StartPage>
          <EndPage>916</EndPage>
          <MedlinePgn>908-16</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To observe the effect of the combination of Wenxia Changfu Formula ([see text], WCF) with cisplatin (CDDP) on inhibiting non-small cell lung cancer (NSCLC) in vitro and In Vivo and explore its mechanism from its effect on cell cycle.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In vitro, WCF-containing serum was prepared and the rhubarb b1, emodin, and aconitine were detected qualitatively by high-performance liquid chromatogram (HPLC). A549 cell lines were treated with blank control (dimethyl sulfoxide), normal serum, normal serum with CDDP (1.25, 2.5, and 5.0 &#x3bc;g/mL, respectively), WCF-containing serum plus different doses of CDDP (1.25, 2.5, and 5.0 &#x3bc;g/mL, respectively). The inhibitory effect was detected by 3-(4,5)-dimethylthiazo(-zy1)-3,5-diphenylterazolium bromide (MTT). The cell cycle was detected by flow cytometry. The protein and mRNA expressions of cyclin D1, proliferating cell nuclear antigen (PCNA), retinoblastoma (Rb), and p16 were observed with immunofluorescence and RT-PCR, respectively. In Vivo, nude mice xenograft model was established and grouped into the control, CDDP, WCF, and combination groups. The combination's inhibition of tumor growth and influence on the weight, spleen, and thymus gland were observed.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The inhibitory rate of the combination against A549 cell lines excelled the CDDP alone significantly (P &lt;0.05); the combination showed a synergism inhibitory effect (Q=1.19). Compared with the monotherapy, the combination increased the cell percentage in G(0)/G(1) phase and decreased the cell percentage in S phase significantly (P &lt;0.05); the protein and mRNA expressions of cyclin D1, PCNA, and Rb were significantly reduced; the protein and mRNA expressions of p16 were significantly enhanced. Compared with the monotherapy, the combination inhibited the tumor growth significantly In Vivo and reduced the weight of tumor (P &lt;0.05); compared with the CDDP group, the spleen and thymus gland index of the combination group were enhanced significantly (P &lt;0.05).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The combination of WCF with CDDP significantly inhibited the A549 cell lines proliferation in vitro and the growth of the tumor In Vivo; it inhibited effectively the atrophy of the immune organ caused by chemotherapy. The combination inhibited overproliferation of A549 cell lines by arresting the G(0) /G(1) phase of cell cycle and affecting the protein and mRNA expressions of cell cycle-related proteins, cyclin D1, etc.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ji</LastName>
            <ForeName>Xu-ming</ForeName>
            <Initials>XM</Initials>
            <AffiliationInfo>
              <Affiliation>School of Basic Medical Science, Shandong University of Traditional Chinese Medicine, Jinan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ouyang</LastName>
            <ForeName>Bing</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Heng</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Guo-wei</ForeName>
            <Initials>GW</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Zhi-chun</ForeName>
            <Initials>ZC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Hua-yun</ForeName>
            <Initials>HY</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Chun-yan</ForeName>
            <Initials>CY</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zhong-xia</ForeName>
            <Initials>ZX</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Wen-ping</ForeName>
            <Initials>WP</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2011</Year>
          <Month>12</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>China</Country>
        <MedlineTA>Chin J Integr Med</MedlineTA>
        <NlmUniqueID>101181180</NlmUniqueID>
        <ISSNLinking>1672-0415</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C571442">wenxia changfu</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q20Q21Q62J</RegistryNumber>
          <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013154" MajorTopicYN="N">Spleen</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013950" MajorTopicYN="N">Thymus Gland</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2011</Year>
          <Month>5</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2011</Year>
          <Month>12</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2011</Year>
          <Month>12</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2012</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">22139542</ArticleId>
        <ArticleId IdType="doi">10.1007/s11655-011-0934-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>N Engl J Med. 2006 Dec 14;355(24):2542-50</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17167137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Res. 2003 Feb 15;63(4):742-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12591718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncogene. 1998 Nov 12;17(19):2437-44</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9824154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Int J Epidemiol. 1997 Feb;26(1):14-23</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9126499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2002 Jan 10;346(2):92-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11784875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Med Oncol. 2010 Sep;27(3):985-91</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19806481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Semin Oncol Nurs. 2005 Aug;21(3):177-83</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16092805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncogene. 1998 Jan 22;16(3):311-20</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9467956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Res. 1995 Nov 1;55(21):4818-23</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7585513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18287387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayo Clin Proc. 2008 May;83(5):584-94</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18452692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayo Clin Proc. 2008 Mar;83(3):355-67</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18316005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Exp Clin Cancer Res. 2010 Jul 01;29:87</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20594324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Cancer Res Clin Oncol. 2003 Apr;129(4):199-221</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12707770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Oncol. 1989 Aug;7(8):1087-92</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2547028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhongguo Zhong Xi Yi Jie He Za Zhi. 2009 Jan;29(1):85-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19338161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mol Carcinog. 2007 Sep;46(9):807-17</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17393422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Science. 1994 Feb 25;263(5150):1093</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8108726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Biol Chem. 2000 Jul 28;275(30):22882-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10930425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Breast Cancer Res Treat. 2006 Jan;95(2):185-94</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16319987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2006 Jul;22(4):458-62</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16806008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brain Res. 2002 Apr 5;932(1-2):10-24</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11911857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2008 Sep 25;359(13):1367-80</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18815398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong Yao Cai. 2008 Feb;31(2):261-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18619275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Histochem Cytochem. 1996 Dec;44(12):1363-72</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8985128</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">21649487</PMID>
      <DateCompleted>
        <Year>2011</Year>
        <Month>10</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1525-6014</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>34</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2011</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug and chemical toxicology</Title>
          <ISOAbbreviation>Drug Chem Toxicol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Effect of oral coadministration of artesunate with ferrous sulfate on rat liver mitochondrial membrane permeability transition.</ArticleTitle>
        <Pagination>
          <StartPage>318</StartPage>
          <EndPage>323</EndPage>
          <MedlinePgn>318-23</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3109/01480545.2010.547498</ELocationID>
        <Abstract>
          <AbstractText>The recent resurgence of interest in the study of mitochondria has been fuelled in large part by the recognition that genetic and/or metabolic alterations in this organelle are causative or contributing factors in a variety of human diseases including cancer. This study hypothesizes that co-administration of artesunate and ferrous sulfate could induce apoptosis which can be targeted on cancerous cells in such a manner, thus providing a novel, viable and perhaps inexpensive way of dealing with the cancer scourge. Artesunate and Ferrous sulfate were co-administered to rats at various doses for seven days. At the end of the treatment, the rats were fasted overnight and sacrificed by cervical dislocation. Low ionic strength mitochondria were isolated from hepatic cells of the rats and assayed for protein content; changes in the absorbance of the liver mitochondria; and mitochondrial swelling. Co-administration of artesunate and ferrous sulfate resulted in a significant increase (P&lt;0.05) in pore opening. The difference in pore opening was found to be statistically significant (P&lt;0.05) when the artesunate and ferrous iron-treated groups were compared with the artesunate only treated group. Results from this study show that co-administration of artesunate and ferrous sulfate can cause an opening in the mitochondrial membrane transition pore. A combined dose of ferrous sulfate and artesunate may prove to be a more potent therapy for targeting cancerous cells.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fafowora</LastName>
            <ForeName>Mosebolatan V</ForeName>
            <Initials>MV</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratories for Biomembrane Research and Biotechnology, Biochemistry Department, College of Medicine, University of Ibadan, Ibadan, Nigeria. ladyfafo@yahoo.com</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Atanu</LastName>
            <ForeName>Francis</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sanya</LastName>
            <ForeName>Olayinka</ForeName>
            <Initials>O</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Olorunsogo</LastName>
            <ForeName>Olufunso O</ForeName>
            <Initials>OO</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Erukainure</LastName>
            <ForeName>Ochuko L</ForeName>
            <Initials>OL</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Drug Chem Toxicol</MedlineTA>
        <NlmUniqueID>7801723</NlmUniqueID>
        <ISSNLinking>0148-0545</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D037621">Artemisinins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005296">Ferrous Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D033681">Mitochondrial Membrane Transport Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000083162">Mitochondrial Permeability Transition Pore</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>39R4TAN1VT</RegistryNumber>
          <NameOfSubstance UI="C020748">ferrous sulfate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>60W3249T9M</RegistryNumber>
          <NameOfSubstance UI="D000077332">Artesunate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D037621" MajorTopicYN="N">Artemisinins</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077332" MajorTopicYN="N">Artesunate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005296" MajorTopicYN="N">Ferrous Compounds</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008111" MajorTopicYN="N">Liver Function Tests</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008930" MajorTopicYN="N">Mitochondria, Liver</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D033681" MajorTopicYN="N">Mitochondrial Membrane Transport Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000083162" MajorTopicYN="N">Mitochondrial Permeability Transition Pore</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2011</Year>
          <Month>6</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2011</Year>
          <Month>6</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2011</Year>
          <Month>10</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">21649487</ArticleId>
        <ArticleId IdType="doi">10.3109/01480545.2010.547498</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">21242120</PMID>
      <DateCompleted>
        <Year>2011</Year>
        <Month>09</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>12</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1557-3265</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>17</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2011</Year>
              <Month>Apr</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>
          <ISOAbbreviation>Clin Cancer Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Smac modulates chemosensitivity in head and neck cancer cells through the mitochondrial apoptotic pathway.</ArticleTitle>
        <Pagination>
          <StartPage>2361</StartPage>
          <EndPage>2372</EndPage>
          <MedlinePgn>2361-72</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-10-2262</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Overexpression of inhibitors of apoptosis proteins (IAP) contributes to therapeutic resistance. Second mitochondria-derived activator of caspase (Smac) promotes caspase activation by binding to IAPs upon release from the mitochondria. IAP antagonists, also called SMAC mimetics, are promising anticancer agents modeled after this mechanism. We investigated the role and mechanisms of Smac- and Smac mimetic-mediated chemosensitization in head and neck squamous cell carcinoma (HNSCC) cells.</AbstractText>
          <AbstractText Label="EXPERIMENTAL DESIGN" NlmCategory="METHODS">The effects of SMAC knockdown, SMAC overexpression, and a small molecule Smac mimetic on the chemosensitivities of HNSCC cells were determined. The mechanisms of Smac- and Smac mimetic-mediated chemosensitization were investigated by analyzing growth suppression, the mitochondrial apoptotic pathway, caspase activation, and IAP proteins. The therapeutic responses of HNSCC cells with different levels of Smac were compared in xenograft models.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that Smac mediates apoptosis induced by several classes of therapeutic agents through the mitochondrial pathway. SMAC knockdown led to impaired caspase activation, mitochondrial membrane depolarization, and release of cytochrome c. A small molecule Smac mimetic, at nanomolar concentrations, significantly sensitized HNSCC cells to gemcitabine-induced apoptosis and restored gemcitabine sensitivity in SMAC knockdown cells, through caspase activation, X-linked IAP dissociation, and mitochondria-associated events, but not the TNF-&#x3b1; pathway. Furthermore, Smac levels modulated the therapeutic response of HNSCC cells to gemcitabine in xenograft models.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results establish a critical role of Smac in mediating therapeutic responses of HNSCC cells and provide a strong rationale for combining Smac mimetics with other anticancer agents to treat HNSCC.</AbstractText>
          <CopyrightInformation>&#xa9;2011 AACR.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Quanhong</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>University of Pittsburgh Cancer Institute, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Xingnan</ForeName>
            <Initials>X</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Lin</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Jian</ForeName>
            <Initials>J</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA129829-03</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA121105-04</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA121105</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA129829-02</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA129829</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA121105-05</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA106348-06A2</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA129829</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA129829-01A1</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA106348-05</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA121105-03</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA121105</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA106348</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA106348</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA106348-04</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2011</Year>
          <Month>01</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Clin Cancer Res</MedlineTA>
        <NlmUniqueID>9502500</NlmUniqueID>
        <ISSNLinking>1078-0432</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000964">Antimetabolites, Antineoplastic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C412403">DIABLO protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0W860991D6</RegistryNumber>
          <NameOfSubstance UI="D003841">Deoxycytidine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-43-6</RegistryNumber>
          <NameOfSubstance UI="D045304">Cytochromes c</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000093542">Gemcitabine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000964" MajorTopicYN="N">Antimetabolites, Antineoplastic</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D040761" MajorTopicYN="N">Biomimetic Materials</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045304" MajorTopicYN="N">Cytochromes c</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003841" MajorTopicYN="N">Deoxycytidine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006258" MajorTopicYN="N">Head and Neck Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000093542" MajorTopicYN="N">Gemcitabine</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2011</Year>
          <Month>1</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2011</Year>
          <Month>1</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2011</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">21242120</ArticleId>
        <ArticleId IdType="mid">NIHMS264537</ArticleId>
        <ArticleId IdType="pmc">PMC3079009</ArticleId>
        <ArticleId IdType="doi">10.1158/1078-0432.CCR-10-2262</ArticleId>
        <ArticleId IdType="pii">1078-0432.CCR-10-2262</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225&#x2013;49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19474385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Airoldi M, Cattel L, Cortesina G, et al. Gemcitabine and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. Anticancer Res. 2003;23:2845&#x2013;52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12926122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang Y, Wei YQ, Luo F, et al. Gemcitabine and cisplatin in advanced nasopharyngeal carcinoma: a pilot study. Cancer Invest. 2005;23:123&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15813504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aguilar-Ponce J, Granados-Garcia M, Villavicencio V, et al. Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck. Ann Oncol. 2004;15:301&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14760126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57&#x2013;70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10647931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002;108:153&#x2013;64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11832206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu J, Zhang L. Apoptosis in human cancer cells. Curr Opin Oncol. 2004;16:19&#x2013;24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14685088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ragin CC, Modugno F, Gollin SM. The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res. 2007;86:104&#x2013;14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17251508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu J, Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun. 2005;331:851&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15865941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26:1324&#x2013;37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2930981</ArticleId>
            <ArticleId IdType="pubmed">17322918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trask DK, Wolf GT, Bradford CR, et al. Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. Laryngoscope. 2002;112:638&#x2013;44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12150516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006;24:2666&#x2013;72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16763281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lippert BM, Knauer SK, Fetz V, Mann W, Stauber RH. Dynamic survivin in head and neck cancer: molecular mechanism and therapeutic potential. Int J Cancer. 2007;121:1169&#x2013;74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17617794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salvesen GS, Duckett CS. IAP proteins: blocking the road to death&#x2019;s door. Nat Rev Mol Cell Biol. 2002;3:401&#x2013;10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12042762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Velculescu VE, Madden SL, Zhang L, et al. Analysis of human transcriptomes. Nat Genet. 1999;23:387&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10581018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene. 2008;27:6252&#x2013;75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18931692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102:33&#x2013;42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10929711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okada H, Suh WK, Jin J, et al. Generation and characterization of Smac/DIABLO-deficient mice. Mol Cell Biol. 2002;22:3509&#x2013;17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC133802</ArticleId>
            <ArticleId IdType="pubmed">11971981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bank A, Wang P, Du C, Yu J, Zhang L. SMAC mimetics sensitize nonsteroidal anti-inflammatory drug-induced apoptosis by promoting caspase-3-mediated cytochrome c release. Cancer Res. 2008;68:276&#x2013;84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18172320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oost TK, Sun C, Armstrong RC, et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem. 2004;47:4417&#x2013;26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15317454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science. 2004;305:1471&#x2013;4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15353805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun H, Nikolovska-Coleska Z, Yang CY, et al. Structure-based design of potent, conformationally constrained Smac mimetics. J Am Chem Soc. 2004;126:16686&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15612682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varfolomeev E, Blankenship JW, Wayson SM, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007;131:669&#x2013;81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18022362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vince JE, Wong WW, Khan N, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell. 2007;131:682&#x2013;93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18022363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petersen SL, Wang L, Yalcin-Chin A, et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell. 2007;12:445&#x2013;56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3431210</ArticleId>
            <ArticleId IdType="pubmed">17996648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell. 2008;133:693&#x2013;703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18485876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci U S A. 2003;100:1931&#x2013;6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC149936</ArticleId>
            <ArticleId IdType="pubmed">12574499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Q, Sakaida T, Yue W, Gollin SM, Yu J. Chemosensitization of head and neck cancer cells by PUMA. Mol Cancer Ther. 2007;6:3180&#x2013;8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18089712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ming L, Wang P, Bank A, Yu J, Zhang L. PUMA dissociates Bax and BCL-XL to induce apoptosis in colon cancer cells. J Biol Chem. 2006;281:16034&#x2013;42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16608847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kohli M, Yu J, Seaman C, et al. SMAC/Diablo-dependent apoptosis induced by nonsteroidal antiinflammatory drugs (NSAIDs) in colon cancer cells. Proc Natl Acad Sci U S A. 2004;101:16897&#x2013;902.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC534714</ArticleId>
            <ArticleId IdType="pubmed">15557007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Q, Ming L, Thomas SM, et al. PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells. Oncogene. 2009;18:2348&#x2013;57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2872091</ArticleId>
            <ArticleId IdType="pubmed">19421143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang QH, Du C. Smac/DIABLO selectively reduces the levels of c-IAP1 and c-IAP2 but not that of XIAP and livin in HeLa cells. J Biol Chem. 2004;279:16963&#x2013;70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14960576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rolff J, Dorn C, Merk J, Fichtner I. Response of Patient-Derived Non-Small Cell Lung Cancer Xenografts to Classical and Targeted Therapies Is Not Related to Multidrug Resistance Markers. J Oncol. 2009;2009:814140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2696640</ArticleId>
            <ArticleId IdType="pubmed">19547715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Q, Gong B, Almasan A. Distinct stages of cytochrome c release from mitochondria: evidence for a feedback amplification loop linking caspase activation to mitochondrial dysfunction in genotoxic stress induced apoptosis. Cell Death Differ. 2000;7:227&#x2013;33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1199554</ArticleId>
            <ArticleId IdType="pubmed">10713737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu J, Wang P, Ming L, Wood MA, Zhang L. SMAC/Diablo mediates the proapoptotic function of PUMA by regulating PUMA-induced mitochondrial events. Oncogene. 2007;26:4189&#x2013;98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17237824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu G, Chai J, Suber TL, et al. Structural basis of IAP recognition by Smac/DIABLO. Nature. 2000;408:1008&#x2013;12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11140638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song Z, Yao X, Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem. 2003;278:23130&#x2013;40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12660240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest. 2004;114:1117&#x2013;27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC522254</ArticleId>
            <ArticleId IdType="pubmed">15489959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med. 2002;8:808&#x2013;15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12118245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao J, Jin J, Zhang X, et al. Transfection of Smac sensitizes tumor cells to etoposide-induced apoptosis and eradicates established human hepatoma in vivo. Cancer Gene Ther. 2006;13:420&#x2013;7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16211087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giagkousiklidis S, Vogler M, Westhoff MA, Kasperczyk H, Debatin KM, Fulda S. Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase. Cancer Res. 2005;65:10502&#x2013;13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16288043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costa DB, Halmos B, Kumar A, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 2007;4:1669&#x2013;79. discussion 80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2043012</ArticleId>
            <ArticleId IdType="pubmed">17973572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med. 2007;4:1681&#x2013;89. discussion 90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2043013</ArticleId>
            <ArticleId IdType="pubmed">17973573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gong Y, Somwar R, Politi K, et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med. 2007;4:e294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2001209</ArticleId>
            <ArticleId IdType="pubmed">17927446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu J, Yue W, Wu B, Zhang L. PUMA sensitizes lung cancer cells to chemotherapeutic agents and irradiation. Clin Cancer Res. 2006;12:2928&#x2013;36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16675590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell. 2006;9:45&#x2013;56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16413471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barbieri CE, Barton CE, Pietenpol JA. Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway. J Biol Chem. 2003;278:51408&#x2013;14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14555649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lassus P, Opitz-Araya X, Lazebnik Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science. 2002;297:1352&#x2013;4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12193789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Probst BL, Liu L, Ramesh V, et al. Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-alpha-dependent manner. Cell Death Differ. 2010;17:1645&#x2013;54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3104849</ArticleId>
            <ArticleId IdType="pubmed">20431601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki Y, Imai Y, Nakayama H, Takahashi K, Takio K, Takahashi R. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell. 2001;8:613&#x2013;21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11583623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 2005;5:876&#x2013;85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16239906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Ming L, Yu J. BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist Updat. 2007;10:207&#x2013;17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2265791</ArticleId>
            <ArticleId IdType="pubmed">17921043</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">21048307</PMID>
      <DateCompleted>
        <Year>2011</Year>
        <Month>06</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1347-5215</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>33</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2010</Year>
            </PubDate>
          </JournalIssue>
          <Title>Biological &amp; pharmaceutical bulletin</Title>
          <ISOAbbreviation>Biol Pharm Bull</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Tanshinone IIA induces mitochondria dependent apoptosis in prostate cancer cells in association with an inhibition of phosphoinositide 3-kinase/AKT pathway.</ArticleTitle>
        <Pagination>
          <StartPage>1828</StartPage>
          <EndPage>1834</EndPage>
          <MedlinePgn>1828-34</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Tanshinone IIA (Tan IIA; 14,16-epoxy-20-nor-5(10),6,8,13,15-abietapentaene-11,12-dione), a phytochemical derived from the roots of Salvia miltiorrhiza BUNGE, has been reported to posses anti-angiogenic, anti-oxidant, anti-inflammatory and apoptotic activities. However, the cancer growth inhibitory/cytocidal effects and molecular mechanisms in prostate cancer cells have not been well studied. In the present study, we demonstrate that Tan IIA significantly decreased the viable cell number of LNCaP (phosphate and tensin homolog (PTEN) mutant, high AKT, wild type p53) prostate cancer cells more sensitively than against the PC-3 (PTEN null, high AKT, p53 null) prostate cancer cells. Tan IIA significantly increased TdT-mediated dUTP nick-end labeling (TUNEL) positive index and sub-G1 DNA contents of treated cells, consistent with apoptosis. Tan IIA treatment led to cleavage activation of pro-caspases-9 and 3, but not pro-caspase-8, and cleavage of poly (ADP ribose) polymerase (PARP), a caspase-3 substrate. Additionally, Tan IIA treatment induced cytochrome c release from the mitochondria into the cytosol and reduced mitochondrial membrane potential and suppressed the expression of mitochondria protective Bcl-2 family protein Mcl-1(L). Tan IIA reduced the expression of phosphoinositide 3-kinase (PI3K) p85 subunit, and the phosphorylation of AKT and mammalian target of rapamycin (mTOR) in a concentration-dependent manner. Moreover, the combination of Tan IIA and LY294002, a specific PI3K inhibitor, enhanced PARP cleavage of LNCaP and PC-3, but not in MDA-MB-231 breast cancer cells which do not contain detectable active AKT. The findings suggest that Tan IIA-induced apoptosis involves mitochondria intrinsic caspase activation cascade and an inhibition of the PI3K/AKT survival pathway.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Won</LastName>
            <ForeName>Suk-Hyun</ForeName>
            <Initials>SH</Initials>
            <AffiliationInfo>
              <Affiliation>College of Oriental Medicine, Kyung Hee University, 1 Hoegidong, Dongdaemungu, Seoul 130–701, South Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Hyo-Jeong</ForeName>
            <Initials>HJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jeong</LastName>
            <ForeName>Soo-Jin</ForeName>
            <Initials>SJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Hyo-Jung</ForeName>
            <Initials>HJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Eun-Ok</ForeName>
            <Initials>EO</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jung</LastName>
            <ForeName>Deok-Beom</ForeName>
            <Initials>DB</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shin</LastName>
            <ForeName>Ji-Min</ForeName>
            <Initials>JM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kwon</LastName>
            <ForeName>Tae-Rin</ForeName>
            <Initials>TR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yun</LastName>
            <ForeName>Sun-Mi</ForeName>
            <Initials>SM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Min-Ho</ForeName>
            <Initials>MH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Seung-Hoon</ForeName>
            <Initials>SH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lü</LastName>
            <ForeName>Junxuan</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Sung-Hoon</ForeName>
            <Initials>SH</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Japan</Country>
        <MedlineTA>Biol Pharm Bull</MedlineTA>
        <NlmUniqueID>9311984</NlmUniqueID>
        <ISSNLinking>0918-6158</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D045784">Abietanes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004798">Enzymes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>03UUH3J385</RegistryNumber>
          <NameOfSubstance UI="C021751">tanshinone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-49-2</RegistryNumber>
          <NameOfSubstance UI="D004247">DNA</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.67</RegistryNumber>
          <NameOfSubstance UI="D019870">1-Phosphatidylinositol 4-Kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D020169">Caspases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D019870" MajorTopicYN="N">1-Phosphatidylinositol 4-Kinase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045784" MajorTopicYN="N">Abietanes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004798" MajorTopicYN="N">Enzymes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008517" MajorTopicYN="N">Phytotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018517" MajorTopicYN="N">Plant Roots</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D027561" MajorTopicYN="N">Salvia miltiorrhiza</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2010</Year>
          <Month>11</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2010</Year>
          <Month>11</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2011</Year>
          <Month>6</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">21048307</ArticleId>
        <ArticleId IdType="doi">10.1248/bpb.33.1828</ArticleId>
        <ArticleId IdType="pii">JST.JSTAGE/bpb/33.1828</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">19846588</PMID>
      <DateCompleted>
        <Year>2010</Year>
        <Month>02</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1521-0103</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>332</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2010</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of pharmacology and experimental therapeutics</Title>
          <ISOAbbreviation>J Pharmacol Exp Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inhibition of delayed-type hypersensitivity by Cucurbitacin R through the curbing of lymphocyte proliferation and cytokine expression by means of nuclear factor AT translocation to the nucleus.</ArticleTitle>
        <Pagination>
          <StartPage>352</StartPage>
          <EndPage>363</EndPage>
          <MedlinePgn>352-63</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1124/jpet.109.159327</ELocationID>
        <Abstract>
          <AbstractText>Cucurbitacin R is known to exhibit an anti-inflammatory effect in different experimental models of inflammation. In this article, we outline the effect of cucurbitacin R on T lymphocyte proliferation, cytokine production, and nuclear factor activation, as well as its influence on various experimental models of delayed-type hypersensitivity (DTH) in mice. Cucurbitacin R reduced the proliferation of phytohemagglutinin A-stimulated human T lymphocytes (IC(50), 18 microM), modifying the cell cycle, as well as the production of cytokines [interleukin (IL)-2, IL-4, IL-10, and especially interferon-gamma] and the induction of the principal cyclins implicated in the cell cycle (A(1), B(1), D(2), and E). These effects are brought on by a novel, selective inhibition of nuclear factor AT (NFAT) by cucurbitacin R, with no concomitant effect on other transcription factors such as activator protein-1. In addition, we tested the in vivo effects of cucurbitacin R in three experimental models of DTH, as well as its effects on T lymphocyte proliferation, the cell cycle, cytokines, and cyclins. Although cucurbitacin R was found to reduce the inflammatory response brought on by both oxazolone and dinitrofluorobenzene, its activity was even more pronounced against sheep red blood cell-induced edema in mouse paws, with a clear reduction in the production of IL-1beta, IL-4, and tumor necrosis factor alpha in the inflamed paw. In conclusion, cucurbitacin R has the potential to be a new immunosuppressive agent with antiproliferative effects through the inhibition of the NFAT with anti-inflammatory activity in DTH reactions.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Escandell</LastName>
            <ForeName>José M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Departament de Farmacologia, Facultat de Farmàcia, Universitat de València, Av. Vicent Andrés Estellés s/n, 46100 Burjassot, Valencia, Spain. riosjl@uv.es.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Recio</LastName>
            <ForeName>María-Carmen</ForeName>
            <Initials>MC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giner</LastName>
            <ForeName>Rosa M</ForeName>
            <Initials>RM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Máñez</LastName>
            <ForeName>Salvador</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cerdá-Nicolás</LastName>
            <ForeName>Miguel</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Merfort</LastName>
            <ForeName>Irmgard</ForeName>
            <Initials>I</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ríos</LastName>
            <ForeName>José-Luis</ForeName>
            <Initials>JL</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2009</Year>
          <Month>10</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Pharmacol Exp Ther</MedlineTA>
        <NlmUniqueID>0376362</NlmUniqueID>
        <ISSNLinking>0022-3565</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C505360">CAVIN3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016213">Cyclins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050778">NFATC Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014315">Triterpenes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C517916">cucurbitacin R</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>15646-46-5</RegistryNumber>
          <NameOfSubstance UI="D010081">Oxazolone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>D241E059U6</RegistryNumber>
          <NameOfSubstance UI="D004139">Dinitrofluorobenzene</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016213" MajorTopicYN="N">Cyclins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004139" MajorTopicYN="N">Dinitrofluorobenzene</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004342" MajorTopicYN="N">Drug Hypersensitivity</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004423" MajorTopicYN="N">Ear</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005528" MajorTopicYN="N">Foot</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006968" MajorTopicYN="N">Hypersensitivity, Delayed</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019169" MajorTopicYN="N">Jurkat Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050778" MajorTopicYN="N">NFATC Transcription Factors</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010081" MajorTopicYN="N">Oxazolone</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014315" MajorTopicYN="N">Triterpenes</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2009</Year>
          <Month>10</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2009</Year>
          <Month>10</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2010</Year>
          <Month>2</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">19846588</ArticleId>
        <ArticleId IdType="doi">10.1124/jpet.109.159327</ArticleId>
        <ArticleId IdType="pii">jpet.109.159327</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">19137438</PMID>
      <DateCompleted>
        <Year>2010</Year>
        <Month>06</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-6822</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>25</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2009</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cell biology and toxicology</Title>
          <ISOAbbreviation>Cell Biol Toxicol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Acetaldehyde-induced mitochondrial dysfunction sensitizes hepatocytes to oxidative damage.</ArticleTitle>
        <Pagination>
          <StartPage>599</StartPage>
          <EndPage>609</EndPage>
          <MedlinePgn>599-609</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10565-008-9115-5</ELocationID>
        <Abstract>
          <AbstractText>Acetaldehyde (Ac), the main metabolite of ethanol oxidation, is a very reactive compound involved in alcohol-induced liver damage. In the present work, we studied the effect of Ac in mitochondria functionality. Mitochondria from Wistar rats were isolated and treated with Ac. Ac decreased respiratory control by 50% which was associated with a decrease in adenosine triphosphate content (28.5%). These results suggested that Ac could be inducing changes in cell redox status. We determined protein oxidation, superoxide dismutase (SOD) activity, and glutathione ratio, indicating that Ac induced an enhanced oxidation of proteins and a decrease in SOD activity (90%) and glutathione/oxidized GSH ratio (36%). The data suggested that Ac-induced oxidative stress mediated by mitochondria dysfunction can lead to cell sensitization and to a second oxidative challenge. We pretreated hepatocytes with Ac followed by treatment with antimycin A, and this experiment revealed a noticeable decrease in cell viability, determined by neutral red assay, in comparison with cells treated with Ac alone. Our data demonstrate that Ac impairs mitochondria functionality generating oxidative stress that sensitizes cells to a second damaging signal contributing to the development of alcoholic liver disease.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Farfán Labonne</LastName>
            <ForeName>Blanca Eugenia</ForeName>
            <Initials>BE</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Ciencias de la Salud, División de Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana-Iztapalapa, Avenida San Rafael Atlixco 186, Colonia Vicentina Iztapalapa, Mexico City, 09340, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gutiérrez</LastName>
            <ForeName>Mario</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gómez-Quiroz</LastName>
            <ForeName>Luis Enrique</ForeName>
            <Initials>LE</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Konigsberg Fainstein</LastName>
            <ForeName>Mina</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bucio</LastName>
            <ForeName>Leticia</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Souza</LastName>
            <ForeName>Verónica</ForeName>
            <Initials>V</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Flores</LastName>
            <ForeName>Oscar</ForeName>
            <Initials>O</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ortíz</LastName>
            <ForeName>Victor</ForeName>
            <Initials>V</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hernández</LastName>
            <ForeName>Elizabeth</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kershenobich</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gutiérrez-Ruíz</LastName>
            <ForeName>María Concepción</ForeName>
            <Initials>MC</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2009</Year>
          <Month>01</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Cell Biol Toxicol</MedlineTA>
        <NlmUniqueID>8506639</NlmUniqueID>
        <ISSNLinking>0742-2091</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>642-15-9</RegistryNumber>
          <NameOfSubstance UI="D000968">Antimycin A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8L70Q75FXE</RegistryNumber>
          <NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.15.1.1</RegistryNumber>
          <NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GO1N1ZPR3B</RegistryNumber>
          <NameOfSubstance UI="D000079">Acetaldehyde</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>ULW86O013H</RegistryNumber>
          <NameOfSubstance UI="D019803">Glutathione Disulfide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000079" MajorTopicYN="N">Acetaldehyde</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000968" MajorTopicYN="N">Antimycin A</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019069" MajorTopicYN="N">Cell Respiration</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019803" MajorTopicYN="N">Glutathione Disulfide</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056945" MajorTopicYN="N">Hep G2 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008108" MajorTopicYN="N">Liver Diseases, Alcoholic</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008930" MajorTopicYN="N">Mitochondria, Liver</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2008</Year>
          <Month>8</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2008</Year>
          <Month>12</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2009</Year>
          <Month>1</Month>
          <Day>13</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2009</Year>
          <Month>1</Month>
          <Day>13</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2010</Year>
          <Month>6</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">19137438</ArticleId>
        <ArticleId IdType="doi">10.1007/s10565-008-9115-5</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">18660440</PMID>
      <DateCompleted>
        <Year>2008</Year>
        <Month>10</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">0363-6135</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>295</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2008</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>American journal of physiology. Heart and circulatory physiology</Title>
          <ISOAbbreviation>Am J Physiol Heart Circ Physiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Exogenous zinc protects cardiac cells from reperfusion injury by targeting mitochondrial permeability transition pore through inactivation of glycogen synthase kinase-3beta.</ArticleTitle>
        <Pagination>
          <StartPage>H1227</StartPage>
          <EndPage>H1233</EndPage>
          <MedlinePgn>H1227-H1233</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpheart.00610.2008</ELocationID>
        <Abstract>
          <AbstractText>The purpose of this study was to determine whether exogenous zinc prevents cardiac reperfusion injury by targeting the mitochondrial permeability transition pore (mPTP) via glycogen synthase kinase-3beta (GSK-3beta). The treatment of cardiac H9c2 cells with ZnCl2 (10 microM) in the presence of zinc ionophore pyrithione for 20 min significantly enhanced GSK-3beta phosphorylation at Ser9, indicating that exogenous zinc can inactivate GSK-3beta in H9c2 cells. The effect of zinc on GSK-3beta activity was blocked by the phosphatidylinositol 3-kinase (PI3K) inhibitor LY-294002 but not by the mammalian target of rapamycin (mTOR) inhibitor rapamycin or the PKC inhibitor chelerythrine, implying that PI3K but not mTOR or PKC accounts for the action of zinc. In support of this interpretation, zinc induced a significant increase in Akt but not mTOR phosphorylation. Further experiments found that zinc also increased mitochondrial GSK-3beta phosphorylation. This may indicate an involvement of the mitochondria in the action of zinc. The effect of zinc on mitochondrial GSK-3beta phosphorylation was not altered by the mitochondrial ATP-sensitive K+ channel blocker 5-hydroxydecanoic acid. Zinc applied at reperfusion reduced cell death in cells subjected to simulated ischemia/reperfusion, indicating that zinc can prevent reperfusion injury. However, zinc was not able to exert protection in cells transfected with the constitutively active GSK-3beta (GSK-3beta-S9A-HA) mutant, suggesting that zinc prevents reperfusion injury by inactivating GSK-3beta. Cells transfected with the catalytically inactive GSK-3beta (GSK-3beta-KM-HA) also revealed a significant decrease in cell death, strongly supporting the essential role of GSK-3beta inactivation in cardioprotection. Moreover, zinc prevented oxidant-induced mPTP opening through the inhibition of GSK-3beta. Taken together, these data suggest that zinc prevents reperfusion injury by modulating the mPTP opening through the inactivation of GSK-3beta. The PI3K/Akt signaling pathway is responsible for the inactivation of GSK-3beta by zinc.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chanoit</LastName>
            <ForeName>Guillaume</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anesthesiology, CB #7010, The Univ. of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>SungRyul</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xi</LastName>
            <ForeName>Jinkun</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Min</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>McIntosh</LastName>
            <ForeName>Rachel A</ForeName>
            <Initials>RA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mueller</LastName>
            <ForeName>Robert A</ForeName>
            <Initials>RA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Norfleet</LastName>
            <ForeName>Edward A</ForeName>
            <Initials>EA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Zhelong</ForeName>
            <Initials>Z</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01-HL-08336</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2008</Year>
          <Month>07</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Physiol Heart Circ Physiol</MedlineTA>
        <NlmUniqueID>100901228</NlmUniqueID>
        <ISSNLinking>0363-6135</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002316">Cardiotonic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-49-2</RegistryNumber>
          <NameOfSubstance UI="D004247">DNA</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.26</RegistryNumber>
          <NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>J41CSQ7QDS</RegistryNumber>
          <NameOfSubstance UI="D015032">Zinc</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Am J Physiol Heart Circ Physiol. 2009 Jan;296(1):H233-4; author reply H235</RefSource>
          <PMID Version="1">19116335</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002316" MajorTopicYN="Y">Cardiotonic Agents</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003600" MajorTopicYN="N">Cytosol</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004791" MajorTopicYN="Y">Enzyme Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008929" MajorTopicYN="N">Mitochondria, Heart</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015428" MajorTopicYN="N">Myocardial Reperfusion Injury</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032383" MajorTopicYN="N">Myocytes, Cardiac</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010539" MajorTopicYN="N">Permeability</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010957" MajorTopicYN="N">Plasmids</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015032" MajorTopicYN="N">Zinc</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2008</Year>
          <Month>7</Month>
          <Day>29</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2008</Year>
          <Month>10</Month>
          <Day>17</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2008</Year>
          <Month>7</Month>
          <Day>29</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">18660440</ArticleId>
        <ArticleId IdType="pmc">PMC2544499</ArticleId>
        <ArticleId IdType="doi">10.1152/ajpheart.00610.2008</ArticleId>
        <ArticleId IdType="pii">00610.2008</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>An WL, Bjorkdahl C, Liu R, Cowburn RF, Winblad B, Pei JJ. Mechanism of zinc-induced phosphorylation of p70 S6 kinase and glycogen synthase kinase 3&#x3b2; in SH-SY5Y neuroblastoma cells. J Neurochem 92: 1104&#x2013;1115, 2005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15715661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>An WL, Pei JJ, Nishimura T, Winblad B, Cowburn RF. Zinc-induced anti-apoptotic effects in SH-SY5Y neuroblastoma cells via the extracellular signal-regulated kinase 1/2. Brain Res Mol Brain Res 135: 40&#x2013;47, 2005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15857667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baines CP, Zhang J, Wang GW, Zheng YT, Xiu JX, Cardwell EM, Bolli R, Ping P. Mitochondrial PKCepsilon and MAPK form signaling modules in the murine heart: enhanced mitochondrial PKCepsilon-MAPK interactions and differential MAPK activation in PKCepsilon-induced cardioprotection. Circ Res 90: 390&#x2013;397, 2002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11884367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bao S, Knoell DL. Zinc modulates airway epithelium susceptibility to death receptor-mediated apoptosis. Am J Physiol Lung Cell Mol Physiol 290: L433&#x2013;L441, 2006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16284213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barthel A, Ostrakhovitch EA, Walter PL, Kampk&#xf6;tter A, Klotz LO. Stimulation of phosphoinositide 3-kinase/Akt signaling by copper and zinc ions: mechanisms and consequences. Arch Biochem Biophys 463: 175&#x2013;182, 2007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17509519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basuki W, Hiromura M, Sakurai H. Insulinomimetic Zn complex [Zn(opt)2] enhances insulin signaling pathway in 3T3-L1 adipocytes. J Inorg Biochem 101: 692&#x2013;699, 2007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17316811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berg JM, Shi Y. The galvanization of biology: a growing appreciation for the roles of zinc. Science 271: 1081&#x2013;1085, 1996.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8599083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beyersmann D, Haase H. Functions of zinc in signaling, proliferation and differentiation of mammalian cells. Biometals 14: 331&#x2013;341, 2001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11831463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bijur GN, Jope RS. Glycogen synthase kinase-3&#x3b2; is highly activated in nuclei and mitochondria. Neuroreport 14: 2415&#x2013;2419, 2003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14663202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen MV, Baines CP, Downey JM. Ischemic preconditioning: from adenosine receptor to KATP channel. Annu Rev Physiol 62: 79&#x2013;109, 2000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10845085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2: 769&#x2013;776, 2001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11584304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359: 1&#x2013;16, 2001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1222116</ArticleId>
            <ArticleId IdType="pubmed">11563964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gomez L, Paillard M, Thibault H, Derumeaux G, Ovize M. Inhibition of GSK3&#x3b2; by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation 117: 2761&#x2013;2768, 2008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18490522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 307: 93&#x2013;98, 1995.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1136749</ArticleId>
            <ArticleId IdType="pubmed">7717999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gross ER, Hsu AK, Gross GJ. Opioid-induced cardioprotection occurs via glycogen synthase kinase &#x3b2; inhibition during reperfusion in intact rat hearts. Circ Res 94: 960&#x2013;966, 2004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14976126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion&#x2014;a target for cardioprotection. Cardiovasc Res 61: 372&#x2013;385, 2004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14962470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 55: 534&#x2013;543, 2002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12160950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho JC, Wu S, Kam KW, Sham JS, Wong TM. Effects of pharmacological preconditioning with U50488H on calcium homeostasis in rat ventricular myocytes subjected to metabolic inhibition and anoxia. Br J Pharmacol 137: 739&#x2013;748, 2002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1573565</ArticleId>
            <ArticleId IdType="pubmed">12411403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ilouz R, Kaidanovich O, Gurwitz D, Eldar-Finkelman H. Inhibition of glycogen synthase kinase-3&#x3b2; by bivalent zinc ions: insight into the insulin-mimetic action of zinc. Biochem Biophys Res Commun 295: 102&#x2013;106, 2002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12083774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jang Y, Wang H, Xi J, Mueller RA, Norfleet EA, Xu Z. NO mobilizes intracellular Zn2+ via cGMP/PKG signaling pathway and prevents mitochondrial oxidant damage in cardiomyocytes. Cardiovasc Res 75: 426&#x2013;433, 2007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1986796</ArticleId>
            <ArticleId IdType="pubmed">17570352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jope RS, Johnson GVW. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29: 95&#x2013;102, 2004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15102436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, Ziman BD, Wang S, Ytrehus K, Antos CL, Olson EN, Sollott SJ. Glycogen synthase kinase-3&#x3b2; mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113: 1535&#x2013;1549, 2004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC419483</ArticleId>
            <ArticleId IdType="pubmed">15173880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karagulova G, Yue Y, Moreyra A, Boutjdir M, Korichneva I. Protective role of intracellular zinc in myocardial ischemia/reperfusion is associated with preservation of protein kinase C isoforms. J Pharmacol Exp Ther 321: 517&#x2013;525, 2007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17322024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S, Jung Y, Kim D, Koh H, Chung J. Extracellular zinc activates p70 S6 kinase through the phosphatidylinositol 3-kinase signaling pathway. J Biol Chem 275: 25979&#x2013;25984, 2000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10851233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S, Jung Y, Kim D, Koh H, Chung J. Extracellular zinc activates p70s6 kinase through the phosphatidylinositol 3-kinase signaling pathway. J Biol Chem 275: 25979&#x2013;25984, 2000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10851233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kown MH, Van der Steenhoven T, Blankenberg FG, Hoyt G, Berry GJ, Tait JF, Strauss HW, Robbins RC. Zinc-mediated reduction of apoptosis in cardiac allografts. Circulation 102: III228&#x2013;III232, 2000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11082392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krezel A, Hao Q, Maret W. The zinc/thiolate redox biochemistry of metallothionein and the control of zinc ion fluctuations in cell signaling. Arch Biochem Biophys 463: 188&#x2013;200, 2007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17391643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 60: 619&#x2013;642, 1998.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9558479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lynch CJ, Patson BJ, Goodman SA, Trapolsi D, Kimball SR. Zinc stimulates the activity of the insulin- and nutrient-regulated protein kinase mTOR. Am J Physiol Endocrinol Metab 281: E25&#x2013;E34, 2001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11404220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsushita K, Kitagawa K, Matsuyama T, Ohtsuki T, Taguchi A, Mandai K, Mabuchi T, Yagita Y, Yanagihara T, Matsumoto M. Effect of systemic zinc administration on delayed neuronal death in the gerbil hippocampus. Brain Res 743: 362&#x2013;365, 1996.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9017270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meares GP, Jope RS. Resolution of the nuclear localization mechanism of glycogen synthase kinase-3: functional effects in apoptosis. J Biol Chem 282: 16989&#x2013;17001, 2007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1948884</ArticleId>
            <ArticleId IdType="pubmed">17438332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishihara M, Miura T, Miki T, Tanno M, Yano T, Naitoh K, Ohori K, Hotta H, Terashima Y, Shimamoto K. Modulation of the mitochondrial permeability transition pore complex in GSK-3&#x3b2;-mediated myocardial protection. J Mol Cell Cardiol 43: 564&#x2013;570, 2007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17931653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park SS, Zhao H, Jang Y, Mueller RA, Xu Z. N6-(3-Iodobenzyl)-adenosine-5&#x2032;-N-methylcarboxamide confers cardioprotection at reperfusion by inhibiting mitochondrial permeability transition pore opening via glycogen synthase kinase 3&#x3b2;. J Pharmacol Exp Ther 318: 124&#x2013;131, 2006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16611852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park SS, Zhao H, Mueller R, Xu Z. Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3&#x3b2;. J Mol Cell Cardiol 40: 708&#x2013;716, 2006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16516918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perry DK, Smyth MJ, Stennicke HR, Salvesen GS, Duriez P, Poirier GG, Hannun YA. Zinc is a potent inhibitor of the apoptotic protease, caspase-3. A novel target for zinc in the inhibition of apoptosis. J Biol Chem 272: 18530&#x2013;18533, 1997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9228015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Powell SR, Hall D, Aiuto L, Wapnir RA, Teichberg S, Tortolani AJ. Zinc improves postischemic recovery of isolated rat hearts through inhibition of oxidative stress. Am J Physiol Heart Circ Physiol 266: H2497&#x2013;H2507, 1994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8024011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prost AL, Bloc A, Hussy N, Derand R, Vivaudou M. Zinc is both an intracellular and extracellular regulator of KATP channel function. J Physiol 559: 157&#x2013;167, 2004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1665068</ArticleId>
            <ArticleId IdType="pubmed">15218066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suleiman MS, Halestrap AP, Griffiths EJ. Mitochondria: a target for myocardial protection. Pharmacol Ther 89: 29&#x2013;46, 2001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11316512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas DJ, Caffrey TC. Lipopolysaccharide induces double-stranded DNA fragmentation in mouse thymus: protective effect of zinc pretreatment. Toxicology 68: 327&#x2013;337, 1991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1910215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tong H, Imahashi K, Steenbergen C, Murphy E. Phosphorylation of glycogen synthase kinase-3&#x3b2; during preconditioning through a phosphatidylinositol-3-kinase-dependent pathway is cardioprotective. Circ Res 90: 377&#x2013;379, 2002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11884365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Truong-Tran AQ, Carter J, Ruffin RE, Zalewski PD. The role of zinc in caspase activation and apoptotic cell death. Biometals 14: 315&#x2013;330, 2001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11831462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walter PL, Kampk&#xf6;tter A, Eckers A, Barthel A, Schmoll D, Sies H, Klotz LO. Modulation of FoxO signaling in human hepatoma cells by exposure to copper or zinc ions. Arch Biochem Biophys 454: 107&#x2013;113, 2006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16973122</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">18561330</PMID>
      <DateCompleted>
        <Year>2008</Year>
        <Month>07</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1099-0461</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2008</Year>
              <Season>May-Jun</Season>
            </PubDate>
          </JournalIssue>
          <Title>Journal of biochemical and molecular toxicology</Title>
          <ISOAbbreviation>J Biochem Mol Toxicol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inorganic phosphate stimulates the toxic effects of Tl+ in rat liver mitochondria.</ArticleTitle>
        <Pagination>
          <StartPage>148</StartPage>
          <EndPage>157</EndPage>
          <MedlinePgn>148-57</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/jbt.20215</ELocationID>
        <Abstract>
          <AbstractText>We studied action of inorganic phosphate (P(i)) on toxic effects of Tl+ in isolated rat liver mitochondria. This is a convenient model to study the toxicity of heavy metals. P(i) markedly retarded contraction of energized mitochondria swollen in the TlNO3 medium and even stronger stimulated swelling and state 4 of succinate-energized mitochondria in the TlNO3 medium. A valinomycin-induced decrease of K+-diffusion potential was also accelerated by Tl+ in the presence of P(i). The mitochondrial permeability transition pore in the medium containing Ca2+, TlNO3, and nitrates of univalent cations was distinctly stimulated by P(i). However, P(i) did not affect both the Tl+-stimulated swelling of nonenergized mitochondria in the TlNO3 medium and swelling of energized mitochondria in the Tl acetate medium. Respiration stimulated by 2,4-dinitrophenol and monoamine oxidase activity of energized mitochondria were not affected by Tl+ regardless of the presence of P(i). We suggested that stimulation by P(i) of toxic action of Tl+ in mitochondria and cells could be due to even greater enhancement of uncoupling of mitochondria as shown by an additional increase of swelling and state 4, and in the greater probability of opening of MPTP in the presence of P(i) and Ca2+.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Korotkov</LastName>
            <ForeName>Sergey M</ForeName>
            <Initials>SM</Initials>
            <AffiliationInfo>
              <Affiliation>Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Thorez pr. 44, 194223 St. Petersburg, Russia. korotkov@SK1645.spb.edu</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Emel'yanova</LastName>
            <ForeName>Larisa V</ForeName>
            <Initials>LV</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yagodina</LastName>
            <ForeName>Olga V</ForeName>
            <Initials>OV</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Biochem Mol Toxicol</MedlineTA>
        <NlmUniqueID>9717231</NlmUniqueID>
        <ISSNLinking>1095-6670</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D033681">Mitochondrial Membrane Transport Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000083162">Mitochondrial Permeability Transition Pore</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009942">Organometallic Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010710">Phosphates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>AD84R52XLF</RegistryNumber>
          <NameOfSubstance UI="D013793">Thallium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.4.3.4</RegistryNumber>
          <NameOfSubstance UI="D008995">Monoamine Oxidase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LJQ38DSR12</RegistryNumber>
          <NameOfSubstance UI="C042172">thallium nitrate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q2901889VM</RegistryNumber>
          <NameOfSubstance UI="C026995">thallium acetate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008930" MajorTopicYN="N">Mitochondria, Liver</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D033681" MajorTopicYN="N">Mitochondrial Membrane Transport Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051336" MajorTopicYN="N">Mitochondrial Membranes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000083162" MajorTopicYN="N">Mitochondrial Permeability Transition Pore</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008933" MajorTopicYN="N">Mitochondrial Swelling</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008995" MajorTopicYN="N">Monoamine Oxidase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009942" MajorTopicYN="N">Organometallic Compounds</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010101" MajorTopicYN="N">Oxygen Consumption</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010539" MajorTopicYN="N">Permeability</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010710" MajorTopicYN="N">Phosphates</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013793" MajorTopicYN="N">Thallium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2008</Year>
          <Month>6</Month>
          <Day>19</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2008</Year>
          <Month>7</Month>
          <Day>26</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2008</Year>
          <Month>6</Month>
          <Day>19</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">18561330</ArticleId>
        <ArticleId IdType="doi">10.1002/jbt.20215</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">17971516</PMID>
      <DateCompleted>
        <Year>2008</Year>
        <Month>03</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2010</Year>
        <Month>11</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">0193-1849</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>294</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2008</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>American journal of physiology. Endocrinology and metabolism</Title>
          <ISOAbbreviation>Am J Physiol Endocrinol Metab</ISOAbbreviation>
        </Journal>
        <ArticleTitle>TNF-alpha increases protein content in C2C12 and primary myotubes by enhancing protein translation via the TNF-R1, PI3K, and MEK.</ArticleTitle>
        <Pagination>
          <StartPage>E241</StartPage>
          <EndPage>E250</EndPage>
          <MedlinePgn>E241-50</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Recent evidence supports that TNF-alpha, long considered a catabolic factor, may also have a physiological function in skeletal muscle. The catabolic view, mainly based on correlative studies in human and in vivo animal models, was challenged by experiments with myoblasts, in which TNF-alpha induced differentiation. The biological effects of TNF-alpha in differentiated muscle, however, remain poorly understood. In the present study, we tested whether TNF-alpha has growth-promoting effects in myotubes, and we characterized the mechanisms leading to these effects. Treatment of C(2)C(12) myotubes with TNF-alpha for 24 h increased protein synthesis (PS) and enhanced cellular dehydrogenase activity by 22 and 26%, respectively, without changing cell numbers. These effects were confirmed in myotubes differentiated from primary rat myoblasts. TNF-alpha activated two signaling cascades: 1) ERK1/2 and its target eIF4E and 2) Akt and its downstream effectors GSK-3, p70(S6K), and 4E-BP1. TNF-alpha-induced phosphorylation of Akt, and ERK1/2 was inhibited by an antibody against TNF-alpha receptor 1 (TNF-R1). PD-98059 pretreatment abolished TNF-alpha-induced phosphorylation of ERK1/2 and eIF4E, whereas PS was only partially inhibited. LY-294002 completely abolished TNF-alpha-induced stimulation of PS as well as phosphorylation of Akt and its downstream targets GSK-3, p70(S6K), and 4E-BP1. Rapamycin inhibited TNF-alpha-induced phosphorylation of the mTOR C1 target p70(S6K) without altering TNF-alpha-induced PS and 4E-BP1 phosphorylation. In conclusion, our results provide evidence that TNF-alpha enhances PS in myotubes and that this is based on enhanced protein translation mediated by the TNF-R1 and PI3K-Akt and MEK-ERK signaling cascades.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Plaisance</LastName>
            <ForeName>Isabelle</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Physiology, Department of Biomedicine, University and University Hospital of Basel, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morandi</LastName>
            <ForeName>Christian</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Murigande</LastName>
            <ForeName>Claire</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brink</LastName>
            <ForeName>Marijke</ForeName>
            <Initials>M</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2007</Year>
          <Month>10</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Physiol Endocrinol Metab</MedlineTA>
        <NlmUniqueID>100901226</NlmUniqueID>
        <ISSNLinking>0193-1849</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009124">Muscle Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047888">Receptors, Tumor Necrosis Factor, Type I</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.-</RegistryNumber>
          <NameOfSubstance UI="D010088">Oxidoreductases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.-</RegistryNumber>
          <NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051058">Oncogene Protein v-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008931" MajorTopicYN="N">Mitochondria, Muscle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020928" MajorTopicYN="N">Mitogen-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018485" MajorTopicYN="N">Muscle Fibers, Skeletal</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009124" MajorTopicYN="N">Muscle Proteins</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051058" MajorTopicYN="N">Oncogene Protein v-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010088" MajorTopicYN="N">Oxidoreductases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014176" MajorTopicYN="N">Protein Biosynthesis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047888" MajorTopicYN="N">Receptors, Tumor Necrosis Factor, Type I</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2007</Year>
          <Month>11</Month>
          <Day>1</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2008</Year>
          <Month>3</Month>
          <Day>12</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2007</Year>
          <Month>11</Month>
          <Day>1</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">17971516</ArticleId>
        <ArticleId IdType="doi">10.1152/ajpendo.00129.2007</ArticleId>
        <ArticleId IdType="pii">00129.2007</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">16263381</PMID>
      <DateCompleted>
        <Year>2006</Year>
        <Month>01</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">0045-6535</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>61</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2005</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Chemosphere</Title>
          <ISOAbbreviation>Chemosphere</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Comparative effects of the Roundup and glyphosate on mitochondrial oxidative phosphorylation.</ArticleTitle>
        <Pagination>
          <StartPage>1115</StartPage>
          <EndPage>1122</EndPage>
          <MedlinePgn>1115-22</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The potential toxicity of the herbicide Roundup and its fundamental substance (glyphosate) was tested in bioenergetic functions of isolated rat liver mitochondria. Roundup stimulates succinate-supported respiration twice, with simultaneous collapse of transmembrane electrical potential, while glyphosate used in the same concentrations does not induce any significant effect. Additionally, Roundup depresses state 3 respiration by about 40%, at 15 mM, whereas uncoupled respiration in the presence of FCCP is depressed by about 50%. Depression of uncoupled respiratory activity is mediated through partial inhibition of mitochondrial complexes II and III, but not of complex IV. The phosphorylative system was affected by both a direct and an indirect effect on the F0F1 ATPase activity. The addition of uncoupled concentrations of Roundup to Ca2+-loaded mitochondria treated with Ruthenium Red resulted in non-specific membrane permeabilization, as evidenced by mitochondrial swelling in isosmotic sucrose medium. Therefore, the uncoupling of oxidative phosphorylation is also related to the non-specific membrane permeabilization induced by Roundup. Glyphosate alone does not show any relevant effect on the mitochondrial bioenergetics, in opposition to Roundup formulation products. The differences in the toxicity observed could be either attributed to some products of Roundup or to a synergic effect of glyphosate and formulation products. Bearing in mind that mitochondria is provided with a variety of bioenergetic functions mandatory for the regulation of intracellular aerobic energy production and electrolyte homeostasis, these results question the safety of Roundup on animal health.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Peixoto</LastName>
            <ForeName>Francisco</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Química, Universidade de Trás-os-Montes e Alto Douro, 5001 Vila Real, Portugal. fpeixoto@utad.pt</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2005</Year>
          <Month>04</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Chemosphere</MedlineTA>
        <NlmUniqueID>0320657</NlmUniqueID>
        <ISSNLinking>0045-6535</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006540">Herbicides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4632WW1X5A</RegistryNumber>
          <NameOfSubstance UI="C010974">glyphosate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>61D2G4IYVH</RegistryNumber>
          <NameOfSubstance UI="D000244">Adenosine Diphosphate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.-</RegistryNumber>
          <NameOfSubstance UI="D013384">Succinate Cytochrome c Oxidoreductase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.3.99.1</RegistryNumber>
          <NameOfSubstance UI="D013385">Succinate Dehydrogenase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.9.3.1</RegistryNumber>
          <NameOfSubstance UI="D003576">Electron Transport Complex IV</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.1.-</RegistryNumber>
          <NameOfSubstance UI="D000251">Adenosine Triphosphatases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.3.-</RegistryNumber>
          <NameOfSubstance UI="D025261">Mitochondrial Proton-Translocating ATPases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>TE7660XO1C</RegistryNumber>
          <NameOfSubstance UI="D005998">Glycine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000244" MajorTopicYN="N">Adenosine Diphosphate</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000251" MajorTopicYN="N">Adenosine Triphosphatases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003576" MajorTopicYN="N">Electron Transport Complex IV</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005998" MajorTopicYN="N">Glycine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006540" MajorTopicYN="N">Herbicides</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008564" MajorTopicYN="N">Membrane Potentials</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008930" MajorTopicYN="N">Mitochondria, Liver</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D025261" MajorTopicYN="N">Mitochondrial Proton-Translocating ATPases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008933" MajorTopicYN="N">Mitochondrial Swelling</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010085" MajorTopicYN="N">Oxidative Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013384" MajorTopicYN="N">Succinate Cytochrome c Oxidoreductase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013385" MajorTopicYN="N">Succinate Dehydrogenase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2004</Year>
          <Month>9</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2005</Year>
          <Month>2</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2005</Year>
          <Month>3</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2005</Year>
          <Month>11</Month>
          <Day>3</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2006</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2005</Year>
          <Month>11</Month>
          <Day>3</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">16263381</ArticleId>
        <ArticleId IdType="doi">10.1016/j.chemosphere.2005.03.044</ArticleId>
        <ArticleId IdType="pii">S0045-6535(05)00455-8</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">15634644</PMID>
      <DateCompleted>
        <Year>2005</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>09</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1535-7163</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>3</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2004</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Molecular cancer therapeutics</Title>
          <ISOAbbreviation>Mol Cancer Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.</ArticleTitle>
        <Pagination>
          <StartPage>1513</StartPage>
          <EndPage>1524</EndPage>
          <MedlinePgn>1513-24</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Interactions between the cyclin-dependent kinase inhibitor flavopiridol and the small-molecule Bcl-2 antagonist HA14-1 were examined in human multiple myeloma cells. Whereas individual treatment of U266 myeloma cells with 10 micromol/L HA14-1 or 100 nmol/L flavopiridol had little effect, exposure of cells to flavopiridol (6 hours) followed by HA14-1 (18 hours) resulted in a striking increase in mitochondrial dysfunction (cytochrome c and Smac/DIABLO release; loss of mitochondrial membrane potential), activation of the caspase cascade, apoptosis, and diminished clonogenic survival. Similar findings were noted in other myeloma cell lines (e.g., MM.1S, RPMI8226, and NCI-H929) as well as in those resistant to dexamethasone and cytotoxic agents (e.g., MM.1R, 8226/Dox40, and 8226/LR5). Combined exposure to flavopiridol and HA14-1 was associated with down-regulation of Mcl-1 and Bcl-xL, Bid cleavage, and mitochondrial translocation of Bax. Flavopiridol/HA14-1-treated cells also exhibited a pronounced activation of Jun NH2-terminal kinase, a modest activation of p38 mitogen-activated protein kinase, and down-regulation of cyclin D1. Flavopiridol/HA14-1-induced apoptosis was associated with a marked increase in reactive oxygen species generation; moreover,both events were attenuated by the antioxidant N-acetyl-l-cysteine. Finally, in contrast to dexamethasone, flavopiridol/HA14-1-induced lethality was unaffected by exogenous interleukin-6 or insulin-like growth factor-I. Together, these findings indicate that flavopiridol and the small-molecule Bcl-2 antagonist HA14-1 cooperate to trigger oxidant injury, mitochondrial dysfunction, caspase activation, and apoptosis in human multiple myeloma cells and suggest that this approach may warrant further evaluation as an antimyeloma strategy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pei</LastName>
            <ForeName>Xin-Yan</ForeName>
            <Initials>XY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Virginia Commonwealth University/Medical College of Virginia, Richmond, Virginia 23298, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dai</LastName>
            <ForeName>Yun</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grant</LastName>
            <ForeName>Steven</ForeName>
            <Initials>S</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>CA 100866</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA 93738</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA63753</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Mol Cancer Ther</MedlineTA>
        <NlmUniqueID>101132535</NlmUniqueID>
        <ISSNLinking>1535-7163</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C494811">BCL2L1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051023">BH3 Interacting Domain Death Agonist Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C494814">BID protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001578">Benzopyrans</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C412403">DIABLO protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005609">Free Radicals</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D064549">Myeloid Cell Leukemia Sequence 1 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009570">Nitriles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010880">Piperidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051020">bcl-X Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C456800">ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>136601-57-5</RegistryNumber>
          <NameOfSubstance UI="D019938">Cyclin D1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>45AD6X575G</RegistryNumber>
          <NameOfSubstance UI="C077990">alvocidib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-43-6</RegistryNumber>
          <NameOfSubstance UI="D045304">Cytochromes c</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.22</RegistryNumber>
          <NameOfSubstance UI="D018844">Cyclin-Dependent Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D048031">JNK Mitogen-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051023" MajorTopicYN="N">BH3 Interacting Domain Death Agonist Protein</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001578" MajorTopicYN="N">Benzopyrans</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019938" MajorTopicYN="N">Cyclin D1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018844" MajorTopicYN="N">Cyclin-Dependent Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045304" MajorTopicYN="N">Cytochromes c</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005419" MajorTopicYN="N">Flavonoids</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005609" MajorTopicYN="N">Free Radicals</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048031" MajorTopicYN="N">JNK Mitogen-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008564" MajorTopicYN="N">Membrane Potentials</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009101" MajorTopicYN="N">Multiple Myeloma</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064549" MajorTopicYN="N">Myeloid Cell Leukemia Sequence 1 Protein</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019253" MajorTopicYN="N">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051020" MajorTopicYN="N">bcl-X Protein</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048051" MajorTopicYN="N">p38 Mitogen-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2005</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2005</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2005</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">15634644</ArticleId>
        <ArticleId IdType="pii">3/12/1513</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">15574755</PMID>
      <DateCompleted>
        <Year>2005</Year>
        <Month>01</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0008-5472</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>64</Volume>
            <Issue>23</Issue>
            <PubDate>
              <Year>2004</Year>
              <Month>Dec</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer research</Title>
          <ISOAbbreviation>Cancer Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl)propionic acid, a small molecule isocoumarin, potentiates dexamethasone-induced apoptosis of human multiple myeloma cells.</ArticleTitle>
        <Pagination>
          <StartPage>8512</StartPage>
          <EndPage>8516</EndPage>
          <MedlinePgn>8512-6</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>2-(8-Hydroxy-6-methoxy-1-oxo-1Eta-2-benzopyran-3-yl)propionic acid (NM-3) is a small molecule isocoumarin derivative that has recently entered clinical trials as an orally bioavailable anticancer agent. NM-3 induces lethality of human carcinoma cells by both apoptotic and nonapoptotic mechanisms and potentiates the effects of cytotoxic chemotherapeutic agents. The present studies have evaluated the effects of NM-3 on human multiple myeloma (MM) cells. The results demonstrate that NM-3 potentiates dexamethasone-induced killing of both dexamethasone-sensitive MM1.S and dexamethasone-resistant RPMI8226 and U266 MM cells. We show that NM-3 enhances dexamethasone-induced release of the mitochondrial apoptogenic factors cytochrome c and Smac/DIABLO. The results also demonstrate that NM-3 enhances dexamethasone-induced activation of the intrinsic caspase-9-&gt;caspase-3 apoptotic pathway. In concert with these results, NM-3 potentiates dexamethasone-induced apoptosis of MM1.S cells. Moreover, NM-3 acts synergistically with dexamethasone in inducing apoptosis of the dexamethasone-resistant RPMI8226 and U266 MM cells. These findings indicate that NM-3 may be effective in combination with dexamethasone in the treatment of MM.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Agata</LastName>
            <ForeName>Naoki</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>ILEX Products, Inc., Boston, Massachusetts 02115, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nogi</LastName>
            <ForeName>Hiroko</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Milhollen</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kharbanda</LastName>
            <ForeName>Surender</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kufe</LastName>
            <ForeName>Donald</ForeName>
            <Initials>D</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>CA100707</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA42802</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cancer Res</MedlineTA>
        <NlmUniqueID>2984705R</NlmUniqueID>
        <ISSNLinking>0008-5472</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003374">Coumarins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C412403">DIABLO protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D049934">Isocoumarins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C453300">isocoumarin NM-3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7S5I7G3JQL</RegistryNumber>
          <NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-43-6</RegistryNumber>
          <NameOfSubstance UI="D045304">Cytochromes c</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="C505407">CASP3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="C506433">CASP9 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D053453">Caspase 9</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D020169">Caspases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053453" MajorTopicYN="N">Caspase 9</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003374" MajorTopicYN="N">Coumarins</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045304" MajorTopicYN="N">Cytochromes c</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049934" MajorTopicYN="N">Isocoumarins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009101" MajorTopicYN="N">Multiple Myeloma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2004</Year>
          <Month>12</Month>
          <Day>3</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2005</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2004</Year>
          <Month>12</Month>
          <Day>3</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">15574755</ArticleId>
        <ArticleId IdType="doi">10.1158/0008-5472.CAN-04-2626</ArticleId>
        <ArticleId IdType="pii">64/23/8512</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">15385934</PMID>
      <DateCompleted>
        <Year>2004</Year>
        <Month>12</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2016</Year>
        <Month>11</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0887-6924</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>18</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2004</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Leukemia</Title>
          <ISOAbbreviation>Leukemia</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.</ArticleTitle>
        <Pagination>
          <StartPage>1780</StartPage>
          <EndPage>1788</EndPage>
          <MedlinePgn>1780-8</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Interactions between the cyclin-dependent kinase inhibitor flavopiridol (FP) and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL/Apo2L), were examined in human leukemia cells (U937 and Jurkat). Coexposure of cells to marginally toxic concentrations of TRAIL and FP (24 h) synergistically increased mitochondrial injury (eg, cytochrome c, AIF, Smac/DIABLO release), cytoplasmic depletion of Bax, activation of Bid as well as caspase-8 and -3, PARP cleavage, and apoptosis. Coadministration of TRAIL markedly increased FP-induced apoptosis in leukemic cells ectopically expressing Bcl-2, Bcl-x(L), or a phosphorylation loop-deleted form of Bcl-2 (DeltaBcl-2), whereas lethality was substantially attenuated in cells ectopically expressing CrmA, dominant-negative-FADD, or dominant-negative-caspase-8. TRAIL/FP induced no discernible changes in FLIP, DR4, DR5, Mcl-1, or survivin expression, modest declines in levels of DcR2 and c-IAP, but resulted in the marked transcriptional downregulation of XIAP. Moreover, cells stably expressing an XIAP-antisense construct exhibited a pronounced increase in TRAIL sensitivity comparable to degrees of apoptosis achieved with TRAIL/FP. Conversely, enforced XIAP expression significantly attenuated caspase activation and TRAIL/FP lethality. Together, these findings suggest that simultaneous activation of the intrinsic and extrinsic apoptotic pathways by TRAIL and FP synergistically induces apoptosis in human leukemia cells through a mechanism that involves FP-mediated XIAP downregulation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rosato</LastName>
            <ForeName>R R</ForeName>
            <Initials>RR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dai</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Almenara</LastName>
            <ForeName>J A</ForeName>
            <Initials>JA</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maggio</LastName>
            <ForeName>S C</ForeName>
            <Initials>SC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grant</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>CA100866</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA63753</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA93738</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Leukemia</MedlineTA>
        <NlmUniqueID>8704895</NlmUniqueID>
        <ISSNLinking>0887-6924</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C494829">AIFM1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051033">Apoptosis Inducing Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C494826">BAX protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C494811">BCL2L1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051023">BH3 Interacting Domain Death Agonist Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C494814">BID protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015938">Complement Membrane Attack Complex</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C412403">DIABLO protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005420">Flavoproteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006023">Glycoproteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010880">Piperidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C047610">SC5b-9 protein complex</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053221">TNF-Related Apoptosis-Inducing Ligand</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C505653">TNFSF10 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051636">X-Linked Inhibitor of Apoptosis Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C496866">XIAP protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051028">bcl-2-Associated X Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051020">bcl-X Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>45AD6X575G</RegistryNumber>
          <NameOfSubstance UI="C077990">alvocidib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-36-7</RegistryNumber>
          <NameOfSubstance UI="D003165">Complement System Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9007-43-6</RegistryNumber>
          <NameOfSubstance UI="D045304">Cytochromes c</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.4.2.30</RegistryNumber>
          <NameOfSubstance UI="C499320">PARP1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.4.2.30</RegistryNumber>
          <NameOfSubstance UI="D000071137">Poly (ADP-Ribose) Polymerase-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.4.2.30</RegistryNumber>
          <NameOfSubstance UI="D011065">Poly(ADP-ribose) Polymerases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D020169">Caspases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051033" MajorTopicYN="N">Apoptosis Inducing Factor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051023" MajorTopicYN="N">BH3 Interacting Domain Death Agonist Protein</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015938" MajorTopicYN="N">Complement Membrane Attack Complex</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003165" MajorTopicYN="N">Complement System Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045304" MajorTopicYN="N">Cytochromes c</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005419" MajorTopicYN="N">Flavonoids</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005420" MajorTopicYN="N">Flavoproteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006023" MajorTopicYN="N">Glycoproteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018922" MajorTopicYN="N">HL-60 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019169" MajorTopicYN="N">Jurkat Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007938" MajorTopicYN="N">Leukemia</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009101" MajorTopicYN="N">Multiple Myeloma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071137" MajorTopicYN="N">Poly (ADP-Ribose) Polymerase-1</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011065" MajorTopicYN="N">Poly(ADP-ribose) Polymerases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019253" MajorTopicYN="N">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053221" MajorTopicYN="N">TNF-Related Apoptosis-Inducing Ligand</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020298" MajorTopicYN="N">U937 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051636" MajorTopicYN="N">X-Linked Inhibitor of Apoptosis Protein</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051028" MajorTopicYN="N">bcl-2-Associated X Protein</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051020" MajorTopicYN="N">bcl-X Protein</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2004</Year>
          <Month>9</Month>
          <Day>24</Day>
          <Hour>5</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2004</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2004</Year>
          <Month>9</Month>
          <Day>24</Day>
          <Hour>5</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">15385934</ArticleId>
        <ArticleId IdType="doi">10.1038/sj.leu.2403491</ArticleId>
        <ArticleId IdType="pii">2403491</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">15120628</PMID>
      <DateCompleted>
        <Year>2004</Year>
        <Month>06</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0006-291X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>318</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2004</Year>
              <Month>May</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biochemical and biophysical research communications</Title>
          <ISOAbbreviation>Biochem Biophys Res Commun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Glutamate modulation of human lymphocyte growth: in vitro studies.</ArticleTitle>
        <Pagination>
          <StartPage>496</StartPage>
          <EndPage>502</EndPage>
          <MedlinePgn>496-502</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Peripheral blood mononuclear cell (PBMC) proliferation induced by phytohemagglutinin, or by anti-CD3 alone or plus anti-CD28 monoclonal antibodies (mAb) was inhibited by glutamate (Glu) in a concentration-dependent manner. This inhibition was not reproduced by selective ionotropic Glu receptor agonists, whereas it was potentiated by l-buthionine-(S,R)-sulfoximine, which depletes glutathione (GSH) stores, and counteracted by 2-mercaptoethanol, a preserver of cell thiols. The inhibitory effects of Glu were related to depletion of intracellular GSH stores, since it decreased GSH levels in a concentration-dependent manner. Furthermore, Glu modulated cytokine secretion by anti-CD3 mAb activated PBMC: it increased IFN-gamma (+44.3+/-8.2%) and IL-10 (+31.6+/-9.7%) secretion, whereas that of IL-2, IL-4, IL-5, and TNF-alpha was not affected. These data suggest that high levels of Glu, which can be reached in damaged tissues, modulate lymphocyte responses to activating stimuli by favouring polarization of the T helper effector response.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lombardi</LastName>
            <ForeName>Grazia</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Interdisciplinary Research Center of Autoimmune Diseases, DISCAFF Department, Eastern Piedmont University, Via Bovio 6, 28100 Novara, Italy. lombardi@pharm.unipmn.it</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miglio</LastName>
            <ForeName>Gianluca</ForeName>
            <Initials>G</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dianzani</LastName>
            <ForeName>Chiara</ForeName>
            <Initials>C</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mesturini</LastName>
            <ForeName>Riccardo</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Varsaldi</LastName>
            <ForeName>Federica</ForeName>
            <Initials>F</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chiocchetti</LastName>
            <ForeName>Annalisa</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dianzani</LastName>
            <ForeName>Umberto</ForeName>
            <Initials>U</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fantozzi</LastName>
            <ForeName>Roberto</ForeName>
            <Initials>R</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Biochem Biophys Res Commun</MedlineTA>
        <NlmUniqueID>0372516</NlmUniqueID>
        <ISSNLinking>0006-291X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017252">CD3 Complex</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005971">Glutamates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007378">Interleukins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010835">Phytohemagglutinins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5072-26-4</RegistryNumber>
          <NameOfSubstance UI="D019328">Buthionine Sulfoximine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>60-24-2</RegistryNumber>
          <NameOfSubstance UI="D008623">Mercaptoethanol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>82115-62-6</RegistryNumber>
          <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>GAN16C9B8O</RegistryNumber>
          <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019328" MajorTopicYN="N">Buthionine Sulfoximine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017252" MajorTopicYN="N">CD3 Complex</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002455" MajorTopicYN="N">Cell Division</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005971" MajorTopicYN="N">Glutamates</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007378" MajorTopicYN="N">Interleukins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008623" MajorTopicYN="N">Mercaptoethanol</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010835" MajorTopicYN="N">Phytohemagglutinins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2004</Year>
          <Month>2</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2004</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>5</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2004</Year>
          <Month>6</Month>
          <Day>26</Day>
          <Hour>5</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2004</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>5</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">15120628</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bbrc.2004.04.053</ArticleId>
        <ArticleId IdType="pii">S0006291X04007752</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">14996711</PMID>
      <DateCompleted>
        <Year>2004</Year>
        <Month>03</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0008-5472</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>64</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2004</Year>
              <Month>Mar</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer research</Title>
          <ISOAbbreviation>Cancer Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia-induced cell death.</ArticleTitle>
        <Pagination>
          <StartPage>1575</StartPage>
          <EndPage>1578</EndPage>
          <MedlinePgn>1575-8</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Epidermal growth factor receptor (EGFR) signaling has become an important target for drug development because EGFR signaling enhances tumor cell proliferation, migration, and invasion and inhibits apoptosis. However, the results of clinical trials using EGFR inhibitors in patients with solid tumors have been disappointing. Here, we report a protective effect of the EGFR inhibitors AG1478 and PD153035 against cell death induced by acute hypoxia, which contrasts with their proapoptotic effects under normoxia. Under hypoxic conditions, both agents reduced glucose consumption, delayed ATP depletion, and preserved the mitochondrial membrane potential. Exposure either to hypoxia or the EGFR inhibitors under normoxic conditions resulted in the dephosphorylation of ribosomal protein S6, a player in the energy and nutrient-sensing pathway governed by mammalian target-of-rapamycin (mTOR). Combined inhibition of phosphatidylinositol 3'-kinase (PI3K) and extracellular signal-regulated kinase-1/2 (ERK1/2) mimicked the protective effects of EGFR inhibition on hypoxia-induced cell death and protein S6 dephosphorylation. These results caution that therapies targeting EGFR signaling pathways can protect tumor cells from acute hypoxia.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Steinbach</LastName>
            <ForeName>Joachim P</ForeName>
            <Initials>JP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, School of Medicine, Tübingen, Germany. joachim.steinbach@uni-tuebingen.de</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klumpp</LastName>
            <ForeName>Andrea</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wolburg</LastName>
            <ForeName>Hartwig</ForeName>
            <Initials>H</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weller</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Cancer Res</MedlineTA>
        <NlmUniqueID>2984705R</NlmUniqueID>
        <ISSNLinking>0008-5472</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020032">Tyrphostins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>170449-18-0</RegistryNumber>
          <NameOfSubstance UI="C101044">RTKI cpd</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8L70Q75FXE</RegistryNumber>
          <NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D019950">Mitogen-Activated Protein Kinase 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D048052">Mitogen-Activated Protein Kinase 3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IY9XDZ35W2</RegistryNumber>
          <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015687" MajorTopicYN="Y">Cell Hypoxia</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004261" MajorTopicYN="N">DNA Replication</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005910" MajorTopicYN="N">Glioma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008564" MajorTopicYN="N">Membrane Potentials</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019950" MajorTopicYN="N">Mitogen-Activated Protein Kinase 1</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048052" MajorTopicYN="N">Mitogen-Activated Protein Kinase 3</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020928" MajorTopicYN="N">Mitogen-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081082" MajorTopicYN="N">Phosphoinositide-3 Kinase Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011799" MajorTopicYN="N">Quinazolines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020032" MajorTopicYN="N">Tyrphostins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2004</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>5</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2004</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>5</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2004</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>5</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">14996711</ArticleId>
        <ArticleId IdType="doi">10.1158/0008-5472.can-03-3775</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">14519443</PMID>
      <DateCompleted>
        <Year>2003</Year>
        <Month>10</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>07</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0024-3205</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>73</Volume>
            <Issue>23</Issue>
            <PubDate>
              <Year>2003</Year>
              <Month>Oct</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>Life sciences</Title>
          <ISOAbbreviation>Life Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Effect of arachidonic acid on proliferation, cytokines production and pleiotropic genes expression in Jurkat cells--a comparison with oleic acid.</ArticleTitle>
        <Pagination>
          <StartPage>2939</StartPage>
          <EndPage>2951</EndPage>
          <MedlinePgn>2939-51</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The effects of arachidonic (AA) and oleic acids (OA) on proliferation, cytokine production and pleiotropic genes expression in Jurkat T cells were investigated. The following parameters were evaluated: cytotoxicity assessed by loss of membrane integrity and DNA fragmentation, cell proliferation as measured by [14C]-thymidine incorporation, production of IL-2, IL-4, IL-10, and INF-gamma, and expression of pleiotropic genes as determined by macroarray technique (83 genes in total). AA was more toxic for Jurkat cells than OA. However, the inhibiting effect of OA on Jurkat cells proliferation was more pronounced than that of AA. The reduction in the production of IL-2 and INF-gamma was more intense by OA (50 microM) than by AA (5 microM). The percentage of genes changed by the fatty acids was: 20.5% (17 genes) for AA (5 microM) and only 2.4% (2 genes) for OA (50 microM). AA markedly affected the expression of genes clustered as: signal transduction pathways, transcription factors and related genes, cell cycle, defense and repair, apoptosis, DNA synthesis, cell adhesion, cytoskeleton and related genes. In particular, AA induced marked changes in cell cycle, signal transduction, and anti-apoptosis genes expression. Therefore, the effect of AA on T-lymphocyte function does involve regulation of expression of important genes, whereas oleic acid did not markedly affect gene expression of Jurkat cells.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Verlengia</LastName>
            <ForeName>Rozangela</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Departamento de Fisiologia e Biofísica, Instituto de Ciências Biomédicas, Universidade de São Paulo, Av Prof Lineu Prestes, 1524, 05508-900, Butantã, São Paulo, SP, Brazil. rverleng@usp.br</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gorjão</LastName>
            <ForeName>Renata</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kanunfre</LastName>
            <ForeName>Carla Cristine</ForeName>
            <Initials>CC</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bordin</LastName>
            <ForeName>Silvana</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Lima</LastName>
            <ForeName>Thais Martins</ForeName>
            <Initials>TM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Curi</LastName>
            <ForeName>Rui</ForeName>
            <Initials>R</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Life Sci</MedlineTA>
        <NlmUniqueID>0375521</NlmUniqueID>
        <ISSNLinking>0024-3205</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>27YG812J1I</RegistryNumber>
          <NameOfSubstance UI="D016718">Arachidonic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2UMI9U37CP</RegistryNumber>
          <NameOfSubstance UI="D019301">Oleic Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D016718" MajorTopicYN="N">Arachidonic Acid</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002455" MajorTopicYN="N">Cell Division</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004249" MajorTopicYN="N">DNA Damage</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053938" MajorTopicYN="N">DNA Fragmentation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019169" MajorTopicYN="N">Jurkat Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019301" MajorTopicYN="N">Oleic Acid</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020411" MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2003</Year>
          <Month>10</Month>
          <Day>2</Day>
          <Hour>5</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2003</Year>
          <Month>10</Month>
          <Day>29</Day>
          <Hour>5</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2003</Year>
          <Month>10</Month>
          <Day>2</Day>
          <Hour>5</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">14519443</ArticleId>
        <ArticleId IdType="doi">10.1016/j.lfs.2003.04.003</ArticleId>
        <ArticleId IdType="pii">S0024320503007409</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">11801653</PMID>
      <DateCompleted>
        <Year>2002</Year>
        <Month>02</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0022-1767</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>168</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2002</Year>
              <Month>Feb</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
          <ISOAbbreviation>J Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>1,25-dihydroxyvitamin D3 inhibits IFN-gamma and IL-4 levels during in vitro polarization of primary murine CD4+ T cells.</ArticleTitle>
        <Pagination>
          <StartPage>1181</StartPage>
          <EndPage>1189</EndPage>
          <MedlinePgn>1181-9</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Following their activation, naive CD4+ T cells can differentiate into one of two effector cell subsets, Th1 and Th2. These two subsets have different cytokine secretion patterns and thus mediate separate arms of the immune response. It has been established that the fat-soluble vitamin D(3) metabolite 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) and its nuclear receptor, the vitamin D receptor, play an important role in the immune system primarily through the transcriptional inhibition of cytokine genes that either are required for Th1 differentiation or are products of differentiated Th1 cells. Therefore, we wanted to test directly the ability of 1,25(OH)(2)D(3) to alter the Th differentiation process. Our results indicate that 1,25(OH)(2)D(3) inhibits not only the Th1 cytokine IFN-gamma but also the Th2 cytokine IL-4 in naive CD62 ligand+CD4+ T cells during their in vitro polarization. This effect is most dramatic when the ligand is present from the onset of the differentiation process. If the ligand is added after the polarization has ensued, the inhibition is significantly diminished. In activated (CD62 ligand-CD4+) T cells, 1,25(OH)(2)D(3) is still able to inhibit IFN-gamma but has no effect on IL-4 production. Our results also indicate that inhibition of these two cytokines in naive cells by vitamin D receptor and its ligand is neither a result of a cell cycle block nor an inhibition of Th1 or Th2 transcription factor expression but, rather, at least in the case of Th2 differentiation, an attenuation of IL-4 transcription by the receptor.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Staeva-Vieira</LastName>
            <ForeName>Teodora P</ForeName>
            <Initials>TP</Initials>
            <AffiliationInfo>
              <Affiliation>Immunology and Cell Biology Programs, Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Division, Weill Graduate School of Medical Sciences of Cornell University, New York, NY 10021, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Freedman</LastName>
            <ForeName>Leonard P</ForeName>
            <Initials>LP</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>DK 45460</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Immunol</MedlineTA>
        <NlmUniqueID>2985117R</NlmUniqueID>
        <ISSNLinking>0022-1767</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006131">Growth Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018167">Receptors, Calcitriol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>126880-86-2</RegistryNumber>
          <NameOfSubstance UI="D019041">L-Selectin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>207137-56-2</RegistryNumber>
          <NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>82115-62-6</RegistryNumber>
          <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>FXC9231JVH</RegistryNumber>
          <NameOfSubstance UI="D002117">Calcitriol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002117" MajorTopicYN="N">Calcitriol</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004306" MajorTopicYN="N">Dose-Response Relationship, Immunologic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006131" MajorTopicYN="N">Growth Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007399" MajorTopicYN="N">Interphase</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019169" MajorTopicYN="N">Jurkat Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019041" MajorTopicYN="N">L-Selectin</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018167" MajorTopicYN="N">Receptors, Calcitriol</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016176" MajorTopicYN="N">T-Lymphocyte Subsets</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006377" MajorTopicYN="N">T-Lymphocytes, Helper-Inducer</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018417" MajorTopicYN="N">Th1 Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018418" MajorTopicYN="N">Th2 Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2002</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>10</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2002</Year>
          <Month>2</Month>
          <Day>13</Day>
          <Hour>10</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2002</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>10</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">11801653</ArticleId>
        <ArticleId IdType="doi">10.4049/jimmunol.168.3.1181</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">11390463</PMID>
      <DateCompleted>
        <Year>2001</Year>
        <Month>08</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>05</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0022-1767</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>166</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2001</Year>
              <Month>Jun</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
          <ISOAbbreviation>J Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Sanglifehrin A, a novel cyclophilin-binding compound showing immunosuppressive activity with a new mechanism of action.</ArticleTitle>
        <Pagination>
          <StartPage>7165</StartPage>
          <EndPage>7171</EndPage>
          <MedlinePgn>7165-71</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>We report here on the characterization of the novel immunosuppressant Sanglifehrin A (SFA). SFA is a representative of a class of macrolides produced by actinomycetes that bind to cyclophilin A (CypA), the binding protein of the fungal cyclic peptide cyclosporin A (CsA). SFA interacts with high affinity with the CsA binding side of CypA and inhibits its peptidyl-prolyl isomerase activity. The mode of action of SFA is different from known immunosuppressive drugs. It has no effect on the phosphatase activity of calcineurin, the target of the immunosuppressants CsA and FK506 when complexed to their binding proteins CypA and FK binding protein, respectively. Moreover, its effects are independent of binding of cyclophilin. SFA inhibits alloantigen-stimulated T cell proliferation but acts at a later stage than CsA and FK506. In contrast to these drugs, SFA does not affect IL-2 transcription or secretion. However, it blocks IL-2-dependent proliferation and cytokine production of T cells, in this respect resembling rapamycin. SFA inhibits the proliferation of mitogen-activated B cells, but, unlike rapamycin, it has no effect on CD154/IL-4-induced Ab synthesis. The activity of SFA is also different from that of other known late-acting immunosuppressants, e.g., mycophenolate mofetil or brequinar, as it does not affect de novo purine and pyrimidine biosynthesis. In summary, we have identified a novel immunosuppressant, which represents, in addition to CsA, FK506 and rapamycin, a fourth class of immunophilin-binding metabolites with a new, yet undefined mechanism of action.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zenke</LastName>
            <ForeName>G</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Transplantation Research, Core Technology, and Nervous System Research, Novartis Pharma, Basel, Switzerland. gerhard.zenke@pharma.novartis.com</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Strittmatter</LastName>
            <ForeName>U</ForeName>
            <Initials>U</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fuchs</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Quesniaux</LastName>
            <ForeName>V F</ForeName>
            <Initials>VF</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brinkmann</LastName>
            <ForeName>V</ForeName>
            <Initials>V</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schuler</LastName>
            <ForeName>W</ForeName>
            <Initials>W</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zurini</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Enz</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Billich</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sanglier</LastName>
            <ForeName>J J</ForeName>
            <Initials>JJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fehr</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Immunol</MedlineTA>
        <NlmUniqueID>2985117R</NlmUniqueID>
        <ISSNLinking>0022-1767</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007783">Lactones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013141">Spiro Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C121329">sanglifehrin A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.1.1.205</RegistryNumber>
          <NameOfSubstance UI="D007168">IMP Dehydrogenase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.5.2.3</RegistryNumber>
          <NameOfSubstance UI="D004080">Dihydroorotase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 5.2.1.-</RegistryNumber>
          <NameOfSubstance UI="D021984">Cyclophilin A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 5.2.1.-</RegistryNumber>
          <NameOfSubstance UI="D022061">Tacrolimus Binding Protein 1A</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001854" MajorTopicYN="N">Bone Marrow Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002999" MajorTopicYN="N">Clone Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D021984" MajorTopicYN="N">Cyclophilin A</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004080" MajorTopicYN="N">Dihydroorotase</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007168" MajorTopicYN="N">IMP Dehydrogenase</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019169" MajorTopicYN="N">Jurkat Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007783" MajorTopicYN="N">Lactones</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008808" MajorTopicYN="N">Mice, Inbred CBA</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013141" MajorTopicYN="N">Spiro Compounds</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022061" MajorTopicYN="N">Tacrolimus Binding Protein 1A</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2001</Year>
          <Month>6</Month>
          <Day>8</Day>
          <Hour>10</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2001</Year>
          <Month>8</Month>
          <Day>24</Day>
          <Hour>10</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2001</Year>
          <Month>6</Month>
          <Day>8</Day>
          <Hour>10</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">11390463</ArticleId>
        <ArticleId IdType="doi">10.4049/jimmunol.166.12.7165</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">7759860</PMID>
      <DateCompleted>
        <Year>1995</Year>
        <Month>06</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2014</Year>
        <Month>11</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0022-1767</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>154</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>1995</Year>
              <Month>Jun</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
          <ISOAbbreviation>J Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Antigen recognition by CTL is dependent upon ectoATPase activity.</ArticleTitle>
        <Pagination>
          <StartPage>6227</StartPage>
          <EndPage>6237</EndPage>
          <MedlinePgn>6227-37</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Alloantigen-specific and OVA-specific CD8+ CTL were shown here to express an ectoATPase. These CTL also express an ectoADPase, but do not express detectable levels of an ectoAMPase. CD8+ CTL transported adenosine into their cytoplasm at a rate of 2.3 x 10(-11) mmol/min/10(5) cells. In contrast, adenosine uptake was 34-fold lower when ATP was used as the source of the nucleoside. This was consistent with the lack of ectoAMPase and suggests that the role of ectoATPase is not in the salvage of extracellular nucleotides. 5'-p-(fluorosulfonyl)benzoyl adenosine (5'-FSBA) is an ATP analogue affinity label that irreversibly inhibits CTL ectoATPase. Cells made ectoATPase activity deficient by modification with 5'-FSBA were not susceptible to potential lytic effects of extracellular ATP with less than 20% specific lysis at 20 mM of exogenous ATP. However, cells modified by 5'-FSBA were unable to kill their respective target cells. Complete inhibition of cell-mediated killing was observed with 1 mM 5'-FSBA. CTL modified by 5'-FSBA also failed to secrete TNF-alpha and IFN-gamma after activation by the appropriate Ag. Killing was also inhibited by 5'-adenylylimidodiphosphate (a nonhydrolyzable ATP analogue), but not by ATP, ADP, alpha, beta-methylene ADP (a nonhydrolyzable ADP analogue), AMP, or adenosine. Blockage of CTL activity by 5'-FSBA was not reversed by addition of ADP, suggesting that hydrolysis of ATP is an essential ectoATPase-mediated signal for CTL activation. These results suggest that ectoATPase is essential for Ag recognition and/or effector activities of CTL.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dombrowski</LastName>
            <ForeName>K E</ForeName>
            <Initials>KE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Veterans Affairs Medical Center, Amarillo, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ke</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thompson</LastName>
            <ForeName>L F</ForeName>
            <Initials>LF</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kapp</LastName>
            <ForeName>J A</ForeName>
            <Initials>JA</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>AI-13987</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>AI-18220</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>GM-39699</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Immunol</MedlineTA>
        <NlmUniqueID>2985117R</NlmUniqueID>
        <ISSNLinking>0022-1767</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000345">Affinity Labels</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000941">Antigens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007519">Isoantigens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>78859-42-4</RegistryNumber>
          <NameOfSubstance UI="C010959">5'-(4-fluorosulfonylbenzoyl)adenosine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8L70Q75FXE</RegistryNumber>
          <NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9006-59-1</RegistryNumber>
          <NameOfSubstance UI="D010047">Ovalbumin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.1.-</RegistryNumber>
          <NameOfSubstance UI="D000251">Adenosine Triphosphatases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.1.-</RegistryNumber>
          <NameOfSubstance UI="C027201">ectoATPase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>K72T3FS567</RegistryNumber>
          <NameOfSubstance UI="D000241">Adenosine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000241" MajorTopicYN="N">Adenosine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000251" MajorTopicYN="N">Adenosine Triphosphatases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000345" MajorTopicYN="N">Affinity Labels</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000941" MajorTopicYN="N">Antigens</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002645" MajorTopicYN="N">Chickens</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003602" MajorTopicYN="N">Cytotoxicity, Immunologic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007519" MajorTopicYN="N">Isoantigens</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010047" MajorTopicYN="N">Ovalbumin</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1995</Year>
          <Month>6</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1995</Year>
          <Month>6</Month>
          <Day>15</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1995</Year>
          <Month>6</Month>
          <Day>15</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">7759860</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">2546761</PMID>
      <DateCompleted>
        <Year>1989</Year>
        <Month>09</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0014-2956</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>182</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>1989</Year>
              <Month>Jul</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>European journal of biochemistry</Title>
          <ISOAbbreviation>Eur J Biochem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The ATP/ADP-antiporter is involved in the uncoupling effect of fatty acids on mitochondria.</ArticleTitle>
        <Pagination>
          <StartPage>585</StartPage>
          <EndPage>592</EndPage>
          <MedlinePgn>585-92</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The ATP/ADP-antiporter inhibitors and the substrate ADP suppress the uncoupling effect induced by low (10-20 microM) concentrations of palmitate in mitochondria from skeletal muscle and liver. The inhibitors and ADP are found to (a) inhibit the palmitate-stimulated respiration in the controlled state and (b) increase the membrane potential lowered by palmitate. The degree of efficiency decreases in the order: carboxyatractylate (CAtr) greater than ADP greater than bongkrekic acid, atractylate. GDP is ineffective, Mg.ADP is of much smaller effect, whereas ATP is effective at much higher concentration than is ADP. Inhibitor concentrations, which maximally suppress the palmitate-stimulated respiration, correspond to those needed for arresting the state 3 respiration. The extent of the CAtr-sensitive stimulation of respiration by palmitate has been found to decrease with an increase in palmitate concentration. Stimulation of the controlled respiration by p-trifluoromethoxycarbonylcyanide phenylhydrozone (FCCP) and gramicidin D at any concentrations of these uncouplers is CAtr-insensitive, whereas that caused by a low concentrations of 2,4-dinitrophenol and dodecyl sulfate is inhibited by CAtr. The above effect of palmitate develops immediately after addition of the fatty acid. It is resistant to EGTA as well as to inhibitors of phospholipase (nupercain) and of lipid peroxidation (ionol). Moreover, palmitate accelerates spontaneous release of the respiratory control, developing in rat liver mitochondria under certain conditions. This effect takes several minutes, being sensitive to EGTA, nupercain and ionol. Like the fast uncoupling, this slow effect is inhibited by ADP but CAtr and atractylate are stimulatory rather than inhibitory. In artificial planar phospholipid membrane, palmitate does not increase the membrane conductance, FCCP increases it strongly and dinitrophenol only slightly. In cytochrome oxidase proteoliposomes, FCCP, gramicidin and dinitrophenol (less effectively) lower, whereas palmitate enhances the cytochrome-oxidase-generated membrane potential. In this system, monensin substitutes for palmitate. It is concluded that the ATP/ADP antiporter is somehow involved in the uncoupling effect caused by low concentrations of palmitate and, partially, of dinitrophenol, whereas uncoupling produced by FCCP and gramicidin is due to their action on the phospholipid part of the mitochondrial membrane. A possible mechanism of this effect is discussed.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Andreyev AYu</LastName>
            <AffiliationInfo>
              <Affiliation>A. N. Belozersky Laboratory of Molecular Biology and Bioorganic Chemistry, Moscow State University, USSR.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bondareva</LastName>
            <ForeName>T O</ForeName>
            <Initials>TO</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dedukhova</LastName>
            <ForeName>V I</ForeName>
            <Initials>VI</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mokhova</LastName>
            <ForeName>E N</ForeName>
            <Initials>EN</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Skulachev</LastName>
            <ForeName>V P</ForeName>
            <Initials>VP</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsofina</LastName>
            <ForeName>L M</ForeName>
            <Initials>LM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Volkov</LastName>
            <ForeName>N I</ForeName>
            <Initials>NI</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vygodina</LastName>
            <ForeName>T V</ForeName>
            <Initials>TV</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Eur J Biochem</MedlineTA>
        <NlmUniqueID>0107600</NlmUniqueID>
        <ISSNLinking>0014-2956</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005227">Fatty Acids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010168">Palmitates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014475">Uncoupling Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>370-86-5</RegistryNumber>
          <NameOfSubstance UI="D002259">Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>61D2G4IYVH</RegistryNumber>
          <NameOfSubstance UI="D000244">Adenosine Diphosphate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9068-80-8</RegistryNumber>
          <NameOfSubstance UI="D000226">Mitochondrial ADP, ATP Translocases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.7.-</RegistryNumber>
          <NameOfSubstance UI="D009713">Nucleotidyltransferases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000244" MajorTopicYN="N">Adenosine Diphosphate</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002259" MajorTopicYN="N">Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005227" MajorTopicYN="N">Fatty Acids</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008564" MajorTopicYN="N">Membrane Potentials</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000226" MajorTopicYN="N">Mitochondrial ADP, ATP Translocases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009713" MajorTopicYN="N">Nucleotidyltransferases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010101" MajorTopicYN="N">Oxygen Consumption</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010168" MajorTopicYN="N">Palmitates</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014475" MajorTopicYN="N">Uncoupling Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1989</Year>
          <Month>7</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1989</Year>
          <Month>7</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1989</Year>
          <Month>7</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">2546761</ArticleId>
        <ArticleId IdType="doi">10.1111/j.1432-1033.1989.tb14867.x</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
